<SEC-DOCUMENT>0001628280-23-006037.txt : 20230302
<SEC-HEADER>0001628280-23-006037.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302160111
ACCESSION NUMBER:		0001628280-23-006037
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		78
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cardiff Oncology, Inc.
		CENTRAL INDEX KEY:			0001213037
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				272004382
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35558
		FILM NUMBER:		23698727

	BUSINESS ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-952-7570

	MAIL ADDRESS:	
		STREET 1:		11055 FLINTKOTE AVENUE
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Trovagene, Inc.
		DATE OF NAME CHANGE:	20130304

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TrovaGene Inc.
		DATE OF NAME CHANGE:	20110830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XENOMICS INC
		DATE OF NAME CHANGE:	20040719
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>crdf-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:43395891-7664-4c15-a02f-d7b4811c3213,g:94da96fa-a6f9-430a-8c03-f421ae94b6bc,d:0116a601b82b4da2824bf8e7269bebaf--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/1999/xhtml" xmlns:srt="http://fasb.org/srt/2022" xmlns:crdf="http://www.cardiffoncology.com/20221231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>crdf-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF80LTEtMS0xLTQwMzY4_5273c1d5-1945-4f47-9cb1-cc04e8a6f232">0001213037</ix:nonNumeric><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF85LTEtMS0xLTQwMzY4_b026c205-8993-4cc9-aefb-bd782d4f9330">2022</ix:nonNumeric><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF8xMC0xLTEtMS00MDM2OA_413bea19-7b73-4754-8245-da380010722f">FY</ix:nonNumeric><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF8xMS0xLTEtMS00MDM2OA_c5079820-da30-4657-9ea5-b5cfd38ba2ab">FALSE</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="crdf-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f11541efb704082a265f9324c80eedc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i06ea67f0d3b64fe49af654a24cca7b41_I20230223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i8e8826dc39c04031b505d8c4ed59725d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f96c19e96104c05b51cc23d98344c24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8163d9f52ab94b4aafd5fb22fd53dadf_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1bdcccd341047f39901c6c37adf4d01_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i388253962d4b4b3ab93b1e08702adfdd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b4884c1cff544f0bb9f898e5ddbf8e0_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08542de1deb8454493ed1ff8baf6b427_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia11a41c8cea2407c8bdeb44938a52270_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb897010af224abc95b5952441ea70a0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9c669ee81da4204bcdcb71cf65565a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7978fbf15d3f41dcbf8154394977cca6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief4483220d7c41bea4914cd482792617_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib920a1f02b184e238f9c206b9a064d82_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a8cbdcbd3ba44fbad8ef0797734695d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic0f3d29f09ee44a4bf376bf33507e1fc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0614bca5466e47cebcb947482e4d0305_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5e71be265fa4fa7a538e7d7379fab1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia0f6bc6df8014431a77c99ab2c34a707_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4cde148671c44d794a76ed6b416a19d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i57d61ca588534e27a11812dffb0c09f4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa0fcea09ba4d2384358db55c650345_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1460f61dda948aabd2999ef5dc73481_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i689740219e214ef58af97e73397e9639_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c4b1dd7a85546b99de632aa3cd6850d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i99b6a1cd1dcc4ce799987fb33f9e4c9d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a6e8d2aa5e54a42941fae9f78ca955b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5d69223477441e6ba07ac77a66de571_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief601a71b15a453791b8b9ef7994a50b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3e300c60978432fa06883530ae83613_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9cf7788e55c4739b94fc0cf078e531e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i866498a356ac40ad9fc5fc95f6654ec4_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:CommonStockAndWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>crdf:segment</xbrli:measure></xbrli:unit><xbrli:context id="ic357b095a944414684981c1dc8b89fb7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db42fc039fd45aeaea7b5bc0553089e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6e8c265de294538a1036e72f7c48ee4_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d722eb9049649258eed2c0dc7b7f489_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6db19d7e4c5b45118fb2b4e6b4642581_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa12187761644b8fb660f20d8935e788_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04fc18d316ba46f4b37af84f0a656dae_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfc3ebfa98e941b5bc6b10599b18ba6f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a80f0906358478ab1f82fee730acdf1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaabac25eea454ee4a957bcb868f30e54_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7de3c2329b134630bba5604f67f427b2_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbac0ee763c14b4691866040faab8881_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9cfa801a2fb64cd2a7453b02850a5da8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d7ee18907d4487f8a1215d75d135ee7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb4e0e354837488d92217bd45d8de5d9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib79309171dc9429497e5fe33bfa88be7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">crdf:CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc25c72ae12437eaaac485fab890f66_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id39a83cf8e894d87a841a0c710893a25_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcb3367ce4cc4990a02e061fdb54b181_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i148a84869fe740b3a3078739ed04eb1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3de22f800dcc41fe9ec79feeab414c28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb08599bdf3f4cd491334a0f7a14e458_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e22fef9a7a4228a7799fa9e0bb1735_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i007c30ebe4ca4d128452e15ece8e01d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9081e23b06e6448d9830510d151ca033_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14c3caa3006c4f6ebf14421f944e494e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd60c6be701446a9bbe35fdcd554faf1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9982ed59fd6427f808ced5af06dbdd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc787def7f7467b8134e270f125cecc_D20220101-20270228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2027-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="lease"><xbrli:measure>crdf:lease</xbrli:measure></xbrli:unit><xbrli:context id="i437c6b27648f43149169d43e9d00f190_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2513f13b8a974c7daed93b812f580722_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i967e88231f6e41158f5760ef3badc44a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15da6dbca1f446fabca739e995d15020_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf1325a8adbb464aa4a9459b6c1ebf24_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c031a24f5041998bc94baf5d5e7878_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2bbcf65ab5b4c44852255c9f2d94146_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a7c515d9ae6485d9e93a24cb7826442_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad1bd806a546460c98ffb5ac6f3ac8c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf86537bddcb4f599b70afe570a83e20_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0c78aec3b59415da597680943386c88_D20070701-20070930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2007-07-01</xbrli:startDate><xbrli:endDate>2007-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2742890db242d6bf741c1ee3352f61_D20060317-20060317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2006-03-17</xbrli:startDate><xbrli:endDate>2006-03-17</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfbfb8b01efa4a1299b3d55a92ac99c6_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crdf:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i945e201b0a974dac9a79bbce7e560aac_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6fbb0b602b174b52b951641f74a93e02_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4060629a24449e582b7b1c954cde009_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01b6d2c9f16c4851800bc4d351b41c95_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34bf0c72c7264502a3fd19a93c17fc34_I20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac45431f2954aeea968270d5152763f_D20201201-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba4fe2a0ab954fd996d5aeadefcf0d29_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i537f6a2ef9cb45469a00fe1de5bbadbd_D20220101-20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f68406df2c440b8b525d03472d93a8_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c69ebdd813b43cf9b9e7435a5b93db8_D20221001-20221031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i121f9fb27a22487c9da80cbd21f3696c_D20200615-20200615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-15</xbrli:startDate><xbrli:endDate>2020-06-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i108dcc73776440a2bb02b0906b8fb804_D20210501-20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7370af0295e247098c3f37e012a4710d_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2ae2c2e51104727ab30997d35b6e45b_I20220609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9738a5e163944c6ea598de6c5bd1a81c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3450ae440464e099c7b194d9e93da51_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4075c1548dc7491f83a6970912aca8fa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88d9796297a64fb8928bef8b221160e5_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7653394ffa3343d58c6ca060d5bfc38e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f1151fb051c43a3a54f391052603412_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12ca60f5c6f2431eb4b26a3b8e10d21f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54f3b30b34ae4b56b912ae1b787704d5_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d91a06d3c074593b7c7a0c70ea5c098_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6c27981ae474b778f9da78071df3c6c_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c1532e9351741698480572142e9d643_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2095721442fd459a96884e78016c08c6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i742d83ea624f49ce83073c6574708721_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0303b15e3f184176afecec0057db48a9_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa54b0f02c246f49fa614c49650a57b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i271b9a9812a34766a92109b7e9619679_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad6ba7c42c22486fbe96bea3b5c38401_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92fafe950c8f4417b2b04359b916f56c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0914d051b344922b3bc650fe526e585_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff69cbb07e994ae88562ba51fc89f559_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a07aa7c69da44d09083212536411b77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2569ead797594df6944309ee7f73c65a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39321e212ba6459991b552dacbff98c5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26cfa5a3c7f344f38855d2fe383ea8ca_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5a580a4d19d4faaa1dc83d296793561_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91378a5db9e4460aa7fd228629188cda_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i559bf50fb42d497ebedd77cbd829099a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fda4d776d4441dbbfb4413a40f5e88c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15b0c01e3be148e2b5d184d7b0a95541_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d4fe76ae8674e07a30a62a4550a8659_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31a535f0f5474b53930803ca83868183_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i19fe2e4f93f04be6b765339abdde93a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccb84b1da2524dcca88a14bcd81ef349_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id05871e6ded54574ac496cd98d0e4696_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie85454a3cb3a449e989750c88baec3c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80b5d8a47de34c9eb00dd9153e2778de_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if98e0631384e478d878a491576d94a8a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide57bacb5fcd4817820479a301609b87_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18b7ac7b497e43c5a2626cc79179be2c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb973974a4fc444080d9042fa7203123_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6514853ca989457f9d06c6c616a89977_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifce1d5e58a8f4ea4b1a87da480e31782_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0acf1c3b475f4b8a81a25aee9941f99b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id799229c6920407f97f22581a8fa94e6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee9cd5b6263248798f95445a96022bad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6eeede3e492747df92a9120df4d9cc8e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i101cb968b2e848d79fffd76c16210cef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82958f514bb0410cacf6fa01b1a48f5d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida5f1f7b2ea54929968874ffdbd66397_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieef0de49d2b147eca762ee3c00cc7304_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae038c8a23044d3ebf1fcfa5f900eb65_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d6e1e6167d64ccaa6c44f9ba201432f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ef75d470db04581b85f0f68742c2606_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea2ee687a6f34deb8370b027572ae45d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i291d4bc8966f478cb947f0421e4b1625_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2e4c7108fe54d94a35daa0010043cdb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic637b3f96e40484683e069e269081b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id928b4407f1f45369fc9e7339ca8dc19_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cf29fe2ae264154a0c772eac0487121_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d295ad0fab4be1ab0b93436cbf5e45_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96c3d5ecadf6458bb42cbcca79de87c5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58cd328823a74a059647630be8c9bd53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d946c3997c8417998d8519879aed8e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519eaf766bb74f9d94fda2c533facecd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i57286981e17d447682811b77a9794aaa_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f92ad9ff9224a48ac42201d146a3949_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i39404762c230459fbd8d949512073537_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdda4c739f784510827447c73dcf98f8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i371c8b26e2e74115ab24d25d9f222d61_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40877594c7984b29870c62f1c8d1bdc8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ac4c76631b14de28b082ab760f8c24d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59de1a0bb89f47af947b9f576e513d78_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b28a9f7521d4d68bf4be2df75a35b05_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i41d8e41740a749a489f23559bd330d4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95814041224f4377a9cb681bea4771a2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iede7ddb493894499ac185e6508bb0bec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5863e8943b44c3aae93910dab768c3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7db2823712cb403fb76468ee499dba28_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eb9fb7597594e409dd14b7de369e07d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75170cbe292740eb8905b33cefbb47e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia539fce54f0549ee98e69a7feb86123b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf0a0c7937904a32bf6356ddaa1dff71_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7e5322a521b4cd3abc87556084fd935_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">crdf:TaxYear2021AndPriorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67adec9130714636a68f59baafa0faeb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">crdf:TaxYear2021AndPriorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c1454942fd4f6cb115a433327d89b6_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifab578dbdeed4bdaaf35f05006bb4d2a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2021Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001213037</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00NDAzMA_adfa9e98-dd45-4169-8fb4-e22092848d17 id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00NDAzMA_5a23862e-0f2b-48c4-8d1b-d8a37e2de710" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzU0OTc1NTgxNDI5MQ_1a318d9b-4802-4289-89e7-651eed85f6ed" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTktMS0xLTQwMzY4_7028abee-aacd-49fc-8cbf-ce760a5e3489 id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTE3LTEtMS00MDM2OA_b44d00aa-a7de-4a0f-b422-af1a4d75627b id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTUtMS0xLTQwMzY4_73b7005e-a7c8-4b80-a4e8-2315e826eb30" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816" order="1"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" fromRefs="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTEtMS0xLTQ0MDUw_f2e0fb40-bbae-4a9e-8106-5f0d6024c12d id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTMtMS0xLTQ0MDUw_9e89a259-fea7-4ee7-a671-d7f9833e7bd7" linkRole="http://www.xbrl.org/2003/role/link" toRefs="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90ZXh0cmVnaW9uOjM3NTdiYzExYjJhNjRkMzZhY2RjZThiMjAxYjQ2N2MzXzU0OTc1NTgxNDEyOQ_14e5891d-ac53-44b8-98bd-d418bf65976e" order="1"></ix:relationship></ix:resources></ix:header></div><div id="i0116a601b82b4da2824bf8e7269bebaf_1"></div><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:4pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI2_1fd90097-e270-4445-8abf-cff4196e7a88">10-K</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Mark One)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.148%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.652%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MzlkNTIxNmIxMGM4NDUxYTgzMGEzNGExYTc2OTkxOTkvdGFibGVyYW5nZTozOWQ1MjE2YjEwYzg0NTFhODMwYTM0YTFhNzY5OTE5OV8wLTAtMS0xLTQwMzY4_a0e58ebd-ae7d-40e7-9844-64be4545577a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18xMjg_cba57136-1fdc-47fb-b3b0-fa70fc1cb6ee"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18xMjg_627b0a46-9255-42e0-9597-6071251b4d39">December 31</ix:nonNumeric>, 2022</ix:nonNumeric> </span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.766%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.934%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGMwNjZlZWMwOWMyNGQwZThjMTc5N2QwYmU0MWYyZWQvdGFibGVyYW5nZTowYzA2NmVlYzA5YzI0ZDBlOGMxNzk3ZDBiZTQxZjJlZF8wLTAtMS0xLTQwMzY4_981a6def-06be-443b-8526-058f8a1d0326">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the Transition Period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTMw_a849504f-adc5-4516-856a-e7d26d706f8c">001-35558</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTMz_fbf60868-0f2b-4b73-9ea0-2ca4526f26a4">CARDIFF ONCOLOGY, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;text-decoration:underline">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.787%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.407%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8wLTAtMS0xLTQwMzY4_a85a8a38-0aa1-403f-a769-ed42cd4d73ee">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8wLTItMS0xLTQwMzY4_1d0a94bd-2cd4-404a-8dd1-54f9001c9799">27-2004382</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTQ0MjczOWMyNDNkNDk4ZGIyNzI5MTU1YmJjYmUxZjZfNA_50046be0-c994-4df7-966e-f86cf2bdfede">11055 Flintkote Avenue</ix:nonNumeric>, <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTQ0MjczOWMyNDNkNDk4ZGIyNzI5MTU1YmJjYmUxZjZfOA_01e38c64-2ed9-4fbb-9c55-bc9254469b9d">San Diego</ix:nonNumeric>, <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTQ0MjczOWMyNDNkNDk4ZGIyNzI5MTU1YmJjYmUxZjZfMTI_0426a01f-100f-4e3e-a485-ee548d094994">California</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTItMS0xLTQwMzY4_d2b10e3a-aef7-445b-830d-ccb4a0a151ae">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF80LTAtMS0xLTQwMzY4L3RleHRyZWdpb246ZmM3NmYwNjY5NDI2NDIzN2IzYWJhNDY4NzQ5MTc4OWJfNQ_46aa6fad-e2ae-43d9-af39-673cbc5a3982">858</ix:nonNumeric>) <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF80LTAtMS0xLTQwMzY4L3RleHRyZWdpb246ZmM3NmYwNjY5NDI2NDIzN2IzYWJhNDY4NzQ5MTc4OWJfOQ_03718b12-94f9-4a7e-987d-1bfb7c665c67">952-7570</ix:nonNumeric></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Registrant&#8217;s telephone number, including area code)</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Title&#160;of&#160;each&#160;class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF84LTAtMS0xLTQwMzY4_ca3ab3ac-7124-454d-8ea5-4a166b249a9e">Common Stock, $0.0001 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The NASDAQ Capital Market</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities registered pursuant to Section&#160;12(g)&#160;of the Act: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">None</span></div></td></tr></table></div><div style="margin-bottom:3pt;margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTM0_326a24a9-c5e2-4a45-8782-cfcab2499a30">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check if the registrant is not required to file reports pursuant to Section&#160;13 or Section 15(d)&#160;of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI3_4dea4d52-ab03-4b5e-badb-45eee5359cd4">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160; <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTM1_d3ddb8ee-a42f-496a-9b96-3862ca09a81e">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160; <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTM2_3e40dfc8-ba2c-4d8a-a398-7d97c317def3">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (&#167;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company.&#160;See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</span></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.858%"><tr><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.974%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.994%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.507%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.999%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Large accelerated filer&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGJmMjE5ODZmNjc1NGU1MTg3YTJmMjMxNTk2OGJjNDgvdGFibGVyYW5nZTowYmYyMTk4NmY2NzU0ZTUxODdhMmYyMzE1OTY4YmM0OF8wLTQtMS0xLTQwMzY4L3RleHRyZWdpb246ZTMwYzE2MmYxM2FjNDRkZDkxNjVkNTRlMGQ4M2RkYmFfNA_c5b37331-d404-482d-93c0-3d0dce00af81">Non-accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></div><div style="text-align:center"><span><br/></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company&#160;<ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGJmMjE5ODZmNjc1NGU1MTg3YTJmMjMxNTk2OGJjNDgvdGFibGVyYW5nZTowYmYyMTk4NmY2NzU0ZTUxODdhMmYyMzE1OTY4YmM0OF8wLTYtMS0xLTQwMzY4L3RleHRyZWdpb246ZTE2ODY5YzhjOTY4NDA2MWE3NWMzY2U3M2IxYmI1ODJfMzA_8e683b59-a5a6-49dc-a3ab-b8ff2429a43f">&#9746;</ix:nonNumeric></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGJmMjE5ODZmNjc1NGU1MTg3YTJmMjMxNTk2OGJjNDgvdGFibGVyYW5nZTowYmYyMTk4NmY2NzU0ZTUxODdhMmYyMzE1OTY4YmM0OF8wLTgtMS0xLTQwMzY4L3RleHRyZWdpb246MDg4MzljYjZmMmEwNDE1NWE1ZDdhYjA2M2JlZTljNmRfMjg_25052abd-4307-4975-b601-80119501cc4d">&#9744;</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI4_6e3737de-3441-403d-8ca4-7731d8606ff2">&#9744;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Act).&#160; Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI5_fe0e7853-4523-429f-89d3-0306c3dbb55e">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:2pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of the voting and non-voting common equity held by non-affiliates based on a closing sale price of $2.20 per share, which was the last sale price of the common stock as of June&#160;30, 2022, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was $<ix:nonFraction unitRef="usd" contextRef="i6f11541efb704082a265f9324c80eedc_I20220630" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMDA5_e786c1f4-bc2b-4fb5-960d-5e5e13dc6764">93,819,519</ix:nonFraction>.&#160;</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of&#160;February&#160;23, 2023, <ix:nonFraction unitRef="shares" contextRef="i06ea67f0d3b64fe49af654a24cca7b41_I20230223" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMDI0_2ab35688-ca02-4f94-ae99-b451f55cbdb3">44,677,169</ix:nonFraction> shares of the registrant&#8217;s common stock, $0.0001 par value per share, were issued and outstanding.</span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN181NDk3NTU4MjUyMjk_f3e07583-21eb-408c-acac-348b0ef5fd24" escape="true"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Specified portions of the registrant's proxy statement, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14 A in connection with the registrant's 2023 Annual Meeting of Stockholders (the "Proxy Statement"), are incorporated by reference into Part III of this Annual Report on Form 10-K.  Except with respect to information specifically incorporated by reference in this Annual Report, the Proxy Statement is not deemed to be filed as part hereof.</span></div></ix:nonNumeric><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:4pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:84.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.913%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_13">PART I</a></span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_16">Item 1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_16">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_55">Item 1A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_55">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_55">17</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_70">Item 1B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_70">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_70">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_73">Item 2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_73">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_73">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_76">Item 3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_76">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_76">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_79">Item 4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_79">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_79">39</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_82">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_85">Item 5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_85">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_85">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_97">Item 6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_97">[Reserved]</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_97">40</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_100">Item 7</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_100">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_100">40</a></span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_130">Item 8</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_130">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_130">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_133">Item 9</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_133">Changes In and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_133">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_136">Item 9A</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_136">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_136">43</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_139">Item 9B</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_139">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_2442">Item 9</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_2442">C</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_2442">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_2442">44</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_142">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_145">Item 10</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_145">Directors, Executive Officers, and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_145">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_148">Item 11</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_148">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_148">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_151">Item 12</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_151">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_151">44</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_154">Item 13</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_154">Certain Relationship and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_154">45</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_157">Item 14</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_157">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_157">45</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_235">PART IV</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_235">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_238">Item 15</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_238">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_238">46</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_241">Item 16</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_241">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_241">48</a></span></div></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_244">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_244">49</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve risks and uncertainties. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in the forward-looking statements for many reasons, including the reasons described in our &#8220;Business,&#8221; &#8220;Risk Factors,&#8221; and &#8220;Management Discussion and Analysis of Financial Condition and Result of Operations,&#8221; sections. In some cases, you can identify these forward-looking statements by terms such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;depends,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;ongoing,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of those terms or other similar expressions, although not all forward-looking statements contain those words.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations and business prospects are always subject to risks and uncertainties including, among others:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of regulatory submissions;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to obtain and maintain regulatory approval of our existing product candidate and any other product candidates we may develop, and the labeling under any approval we may obtain;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approvals for clinical trials may be delayed or withheld by regulatory agencies;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pre-clinical and clinical studies will not be successful or confirm earlier results or meet expectations or meet regulatory requirements or meet performance thresholds for commercial success;</span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks relating to the timing and costs of clinical trials, the timing and costs of other expenses;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with obtaining funding from third parties;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">management and employee operations and execution risks;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of key personnel;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks related to market acceptance of products;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property risks;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">assumptions regarding the size of the available market, benefits of our products, product pricing, timing of product launches;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with the uncertainty of future financial results;</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to attract collaborators and partners; and</span></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">risks associated with our reliance on third party organizations. </span></div><div style="padding-left:54pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K represent our views as of the date of filing of this Annual Report on Form 10-K. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this Annual Report on Form 10-K.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to significant risks and uncertainties that make an investment in us speculative and risky. Below we summarize what we believe are the principal risk factors but these risks are not the only ones we face, and you should carefully review and consider the full discussion of our risk factors in the section titled &#8220;Risk Factors&#8221;, together with the other information in this Annual Report on Form 10-K. If any of the following risks actually occurs (or if any of those listed elsewhere in this Annual Report on Form 10-K occur), our business, reputation, financial condition, results of operations, revenue, and future prospects could be seriously harmed. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We will need to raise substantial additional capital to develop and commercialize, our product candidate, onvansertib, and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidate is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our product candidate, if approved for sale, may not gain acceptance among physicians, patients and the medical community, thereby limiting our potential to generate revenues.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">If we materially breach or default under the Nerviano Licensing Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_16"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.  BUSINESS</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. Our goal is to target tumor vulnerabilities with treatment combinations of onvansertib, our oral and highly selective PLK1 inhibitor, and standard of care ("SoC") therapeutics. We are focusing our clinical program in indications such as KRAS/NRAS-mutated metastatic colorectal cancer ("mCRC") and metastatic pancreatic ductal adenocarcinoma ("mPDAC"), as well as in investigator-initiated trials in triple negative breast cancer ("TNBC") and small cell lung cancer ("SCLC"). Our clinical development programs incorporate tumor genomics and biomarker assays to refine assessment of patient response to treatment.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Lead Drug Candidate, Onvansertib</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is an oral, small molecule drug candidate that is highly specific for PLK1 inhibition with a 24-hour half-life.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe the attributes of onvansertib described below, as well as clinical evidence of favorable safety and efficacy, with expected on-target, easy to manage and reversible side effects, may prove beneficial in addressing clinical therapeutic needs across a variety of cancers:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib is highly potent and highly selective against the PLK1 enzyme (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> = 2nM; IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> is the concentration for 50% inhibition), compared to prior PLK1 inhibitors that were pan-inhibitors of several PLK targets.  Low or no activity of onvansertib was observed on a panel of 63 kinases (IC50&gt;500 nM), including the PLK members PLK2 and PLK3 (IC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:1.4pt;vertical-align:baseline">50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&gt;10,000 nM);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Onvansertib has a relatively short drug half-life of 24 hours, allowing for flexible dosing and scheduling which has shown favorable safety and tolerability across multiple clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Onvansertib is orally bioavailable, allowing for relative ease and flexibility of dosing.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies have shown synergistic effects when onvansertib was administered in combination with different cytotoxic agents including microtubule-targeting agents, topoisomerase 1 inhibitors, antimetabolites, alkylating agents, proteasome inhibitors, kinase inhibitors, PARP inhibitors, BCL-2 inhibitors, and androgen biosynthesis inhibitors.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination studies have confirmed the positive results obtained </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and synergistic effects have been observed in xenograft models of onvansertib in combination with irinotecan, 5-fluorouracil ("5-FU"), abiraterone, PARP inhibitors, venetoclax, and paclitaxel, while additive effects in combination with cytarabine or bevacizumab have been demonstrated. Combining onvansertib with standard of care cancer agents provides opportunities for synergy with many cancer therapies.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are five ongoing clinical trials of onvansertib: two trials (TROV-054 and ONSEMBLE) in second line treatment in patients with KRAS-mutated Metastatic Colorectal Cancer ("mCRC"), one trial in second line treatment in patients with Metastatic Pancreatic Ductal Adenocarcinoma ("mPDAC"), and two investigator-initiated trials in patients with unresectable locally advanced or metastatic Triple Negative Breast Cancer ("TNBC") and relapsed Small Cell Lung Cancer ("SCLC").</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1b/2 Clinical Trial in KRAS-mutated mCRC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TROV-054 is a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the second line treatment of patients with KRAS-mutated mCRC, which is being conducted at seven clinical trial sites across the U.S. - USC Norris Comprehensive Cancer Center, The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute and CARTI Cancer Center. This trial completed enrollment in October 2022. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objectives of this trial are to evaluate the Dose-Limiting Toxicities ("DLTs"), maximum tolerated dose ("MTD") and recommended Phase 2 dose ("RP2D") of onvansertib in combination with FOLFIRI and bevacizumab (Phase 1b) and to continue to assess the safety and preliminary efficacy of onvansertib in combination with FOLFIRI and bevacizumab patients with KRAS-mutated mCRC (Phase 2).</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scientific rationale for this clinical trial is based on the two key principles of synthetic lethality and synergy, with the objective of demonstrating a proof-of-concept of clinical benefit within this phase 1b/2 trial. Synthetic lethality refers to a critical vulnerability to tumor cell death by way of PLK1 inhibition within CRC tumor cells harboring KRAS mutations versus KRAS wild-type isogenic cells. Synergy occurs when the combination of multiple drugs results in an unexpected greater activity than an expected additive effect of the individual drugs. Onvansertib in combination with two DNA-damaging agents, irinotecan and 5-FU (two components of FOLFIRI), demonstrated synergy in colorectal cancer cell lines and both combinations have demonstrated significantly greater tumor growth inhibition than either drug alone in CRC in vivo models. We believe this synergy occurs because PLK1 can promote the repair of DNA damage caused by chemotherapeutic agents and by inhibiting PLK1, onvansertib leaves damaged tumor cells unable to repair DNA damage from chemotherapy and then replicate. For more information, please visit NCT03829410 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Data presented on September 12, 2022 provided an update of the ongoing TROV-054 phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Objective response rate ("ORR") across all evaluable patients was 35%, with 17 of 48 evaluable patients achieving an objective response. Responses have been observed across multiple KRAS variants;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median duration of response ("mDoR") across all evaluable patients was 11.7 months (95% confidence interval ("CI"): 8.9 &#8211; not reached);</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Median progression free survival ("mPFS") across all evaluable patients was 9.3 months (95% CI: 7.6 &#8211; 13.5). Historical control trials of different drug combinations, including the standard of care ("SOC") of FOLFIRI with bevacizumab, in similar patient populations have shown ORR and mPFS of 5 &#8211; 13% and ~4.5 &#8211; 5.7 months, respectively.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A subgroup analysis of patients who were bevacizumab na&#239;ve when they entered 2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">nd</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line therapy vs patients who had received prior bevacizumab in 1st line therapy showed that patients who were bevacizumab na&#239;ve (n=13) had an ORR of 69% and mPFS of 13.5 months, which is well above historical controls. In contrast, patients previously treated with bevacizumab (n=35) had an ORR of 23% and mPFS of 7.8 months.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Randomized Clinical Trial in KRAS-mutated mCRC (the ONSEMBLE trial)</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ONSEMBLE trial (CRDF-003), is a Phase 2 open-label, randomized multi-center clinical trial of onvansertib in combination with standard of care FOLFIRI and bevacizumab for the second line treatment of patients with KRAS/NRAS-mutated mCRC. The trial is currently open for enrollment and will be conducted at approximately 40 clinical trial sites across the U.S. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary objective of the ONSEMBLE trial is to evaluate onvansertib&#8217;s safety and efficacy in combination with the standard-of-care FOLFIRI/bevacizumab regimen in patients with second-line KRAS/NRAS-mutated mCRC. The trial is expected to enroll approximately 150 patients who will be randomized 1:1:1 to receive standard of care alone, standard of care plus 20 mg onvansertib, or standard of care plus 30 mg onvansertib, with onvansertib administered on days 1-5 and 15-19 of 28-day treatment cycles. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of the trial is objective response rate. Progression-free survival and duration of response will be key secondary endpoints. The trial was activated during Q4 2022, with topline data anticipated in 2H 2024. For more information, please visit NCT05593328 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Clinical Trial in mPDAC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CRDF-001 is a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan (Onivyde</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), leucovorin, and fluorouracil for second line treatment of patients with mPDAC, which is being conducted at six clinical trial sites across the U.S. &#8211; The Mayo Clinic Cancer Centers (Arizona, Minnesota, and Florida), Kansas University Medical Center, Inova Schar Cancer Institute, and the University of Nebraska Medical Center.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first patient was dosed in June 2021. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The objective of this trial is to assess the safety and preliminary efficacy of onvansertib in combination with nanoliposomal irinotecan (Onyvide</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">), 5-FU and leucovorin as a second-line treatment in patients with mPDAC who have failed 1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> line gemcitabine-based therapy. The trial is expected to enroll approximately 45 patients. For more information, please visit NCT04752696 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preliminary data presented on September 12, 2022 provided an update of the ongoing CRDF-001 phase 2 open label clinical trial in mPDAC:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Preliminary data from 5 evaluable patients showed 1 patient achieving an initial partial response ("PR") and 3 patients achieving stable disease ("SD");</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The 4 patients achieving SD or PR remain on study; the fifth evaluable patient discontinued treatment due to disease progression and an additional 3 patients remain on study awaiting their first post-baseline scan;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Additional data is anticipated in mid 2023.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 1b/2 Investigator-Initiated Clinical Trial in TNBC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single-arm, Phase 1b/2 trial of onvansertib in combination with paclitaxel in patients with unresectable locally advanced or metastatic TNBC is open for enrollment at Dana Farber Cancer Institute ("DFCI"). In Phase 1b, approximately 14-16 patients will be treated with different doses of onvansertib in combination with a fixed dose of paclitaxel to determine the maximum tolerated dose and RP2D of onvansertib. In Phase 2, approximately 34 patients will be treated with the selected onvansertib RP2D in combination with paclitaxel. </span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary endpoint of Phase 2 of the trial is ORR, with PFS included as a secondary endpoint. Preliminary data from the trial are expected in Q4 2023 or Q1 2024. For more information, please visit NCT05383196 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Phase 2 Investigator-Initiated Clinical Trial in SCLC</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A single-arm, two-stage, Phase 2 trial of onvansertib monotherapy in patients with relapsed SCLC is open for enrollment at the University of Pittsburgh Medical Center ("UPMC"). The trial is designed to enroll 15 patients in Stage 1, with the study proceeding to Stage 2 if 2 or more Stage 1 patients achieve an objective response. Stage 2 is designed to enroll an additional 20 patients. The primary endpoint of the trial is ORR, while key secondary endpoints include PFS and overall survival. Preliminary data from the trial are expected in mid-2023. For more information, please visit NCT05450965 at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.clinicialtrials.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_19"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Identifying Biomarkers that Predict Patient Benefit</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our laboratory in San Diego, California, enables us to optimize drug development and patient care. In the clinical development of our lead drug candidate, onvansertib, correlative biomarker analyses are being used to help inform decisions in the evaluation of dose-response and optimal regimen for desired pharmacologic effect and safety.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some biomarkers can be used as a surrogate endpoint for efficacy and/or toxicity, as well as identifying certain patient populations that are more likely to respond to the drug therapy.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">   </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our ongoing clinical trial in KRAS-mutated mCRC, we are quantitatively assessing changes in the KRAS mutational burden with a blood test based on ctDNA. In TROV-054, our phase 1b/2 single arm clinical trial in KRAS-mutated metastatic colorectal cancer, decreases in KRAS Mutant Allelic Frequency ("MAF") in ctDNA after the first cycle of treatment were highly predictive of subsequent radiographic response observed as tumor shrinkage.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_22"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating Segment and Geographic Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment, using one measurement of profitability to manage our business. We do not assess the performance of geographic regions on measures of revenue or comprehensive income or expense. In addition, all of our principal operations, assets and decision-making functions are located in the U.S. We do not produce reports for, or measure the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance of, geographic regions on any asset-based metrics. Therefore, geographic information is not presented for revenues or long-lived assets.</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_25"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Market</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Metastatic Colorectal Cancer</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Colorectal Cancer ("CRC") is a common cause of cancer death in the US. The American Cancer Society's estimates for the number of CRC diagnoses expected in the US in 2023 are 106,970 new cases of colon cancer and 46,050 new cases of rectal cancer, with an estimated 52,550 deaths predicted during 2023. Cancer&#8209;specific mortality of CRC is predominantly due to metastatic disease. Despite significant progress in the treatment of mCRC, the majority of patients with mCRC succumb to the disease. RAS mutations in the CRC population are common, with greater than 50% of tumors from CRC patients harboring a RAS mutation (43% KRAS, 9% NRAS).</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The efficacy of second-line therapy in terms of response and survival prolongation remains limited. Therefore, improving the treatment options and effectiveness of treatment is critical to changing the outcomes for the KRAS-mutated patient population.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Additional Cancer Indications</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain investigators are currently conducting signal-finding clinical trials to explore the treatment opportunity for onvansertib in mPDAC, SCLC and TNBC.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_28"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaborative Relationship</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Pfizer Breakthrough Growth Initiative</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, we entered into a Securities Purchase Agreement (the &#8220;SPA&#8221;) with Pfizer Inc., as part of the Pfizer Breakthrough Growth Initiative, pursuant to which Pfizer purchased 2.4 million shares of our common stock at a purchase price per share of $6.22 for gross proceeds of approximately $15.0 million. In connection with the stock purchase, we and Pfizer entered into an Information Rights Agreement pursuant to which Adam Schayowitz, Ph.D., MBA, Vice President &amp; Medicine Team Group Lead for Breast Cancer, Colorectal Cancer and Melanoma at Pfizer will join our Scientific Advisory Board, and until May 17, 2024 we agreed to provide Pfizer with rights of first access to any pre-clinical or final clinical data and results generated as part of the onvansertib development program at least two business days prior to us providing such data to a third party.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_37"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the protection of our proprietary technologies and products, as well as our ability to maintain patent protection that covers the composition of matter of our product candidates, their methods of use, and other related technologies and inventions, to be a critical element in the success of our business. As of December&#160;31, 2022, our owned and licensed intellectual property included 52 issued patents and 37&#160;pending patent applications in the U.S. and abroad, some of which are related to our legacy patent portfolio.&#160;The pending patent applications include multiple international patent applications filed under the Patent Cooperation Treaty that may be used as the basis for multiple additional patent applications worldwide.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We licensed onvansertib from Nerviano Medical Sciences ("NMS" or "Nerviano") pursuant to a license agreement with NMS dated March 13, 2017 which grants us exclusive, worldwide licenses under a portfolio of three patent families of U.S. and foreign patents covering three broad areas: (1) onvansertib (composition of matter), related compounds and processes for making compounds; pharmaceutical compositions and methods of treating diseases characterized by dysregulated protein kinase activity; (2) salts and pharmaceutical compositions of onvansertib; methods of treating mammals in need of PLK inhibition; and (3) synergistic combinations of onvansertib and one or more of a broad range of antineoplastic agents, and pharmaceutical compositions of those combinations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents of this licensed portfolio will expire between 2027 and 2030. U.S. patents of this licensed patent portfolio will expire in 2030, with patent term extension up to 2035.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 19, 2018, we entered into an Exclusive Patent License Agreement with MIT to a patent family directed to combination therapies including an antiandrogen or androgen antagonist and a polo-like kinase inhibitor (such as onvansertib) for the treatment of cancer. The license agreement covers the rights to develop combination therapies and identified predictive clinical biomarkers across cancer types, expanding potential indications for onvansertib. Under the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement, we have exclusive rights to develop, make, use, and sell combination therapies that include an anti-androgen or androgen antagonist and a PLK inhibitor for the treatment of cancer. The exclusive license agreement is part of our strategy to explore the efficacy of onvansertib in combination with anti-androgen drugs in cancers including prostate, breast, pancreatic, lung and gastrointestinal. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensed MIT patent family includes U.S. Patent Nos. 9,566,280, 10,155,006, and 10,772,898, which will expire in 2035, with patent term extension up to 2040. U.S. Patent No. 9,566,280 encompasses using abiraterone in combination with onvansertib to treat cancer. U.S. Patent Nos. 10,155,006 and 10,772,898 broaden previously issued U.S. Patent No. 9,566,280, by expanding the use of onvansertib to encompass combination therapies with any anti-androgen and androgen antagonist drug, such as Zytiga</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Xtandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Erleada</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the treatment of metastatic and non-metastatic castrate-resistant prostate cancer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our owned intellectual property includes eighteen patent families related to onvansertib. These families include patent applications directed to treating cancer using PLK1 inhibitors and determining efficacy of the treatment, treating benign prostatic hyperplasia using onvansertib, treating prostate cancer using PLK1 inhibitors, determining or predicting efficacies or responsiveness of PLK1 inhibitor treatments based on biomarkers, and treating cancers with combination therapies of PLK1 inhibitors (including combination therapies of PLK1 inhibitors with B-cell lymphoma 2 inhibitors or poly ADP ribose polymerase inhibitors). Any patents issued in these families will expire between 2039 and 2043. One of the patent families includes patent applications directed to selecting and treating cancers with combination therapies of PLK1 inhibitors. MIT and we co-own this family. On November 17, 2021, we amended the Exclusive Patent License Agreement with MIT to include this patent family. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Wherever possible, we seek to protect our inventions by filing U.S. patent applications as well as foreign counterpart applications in select countries. Because patent applications in the U.S. are maintained in secrecy for at least eighteen months after the applications are filed, and since publication of discoveries in the scientific or patent literature often lags behind actual discoveries, we cannot be certain that we were the first to make the inventions covered by each of our issued or pending patent applications, or that we were the first to file for protection of inventions set forth in such patent applications. Our planned or potential products may be covered by third-party patents or other intellectual property rights, in which case continued development and marketing of our products would require a license. Required licenses may not be available to us on commercially acceptable terms, if at all. If we do not obtain these licenses, we could encounter delays in product introductions while we attempt to design around the patents, or we could find that the development, manufacture or sale of products requiring such licenses are not possible.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to patent protection, we also rely on know-how, trade secrets and the careful monitoring of proprietary information, all of which can be difficult to protect. We seek to protect some of our proprietary technologies and processes by entering into confidentiality agreements with our employees, consultants, and contractors. These agreements may be breached, we may not have adequate remedies for any breach and our trade secrets may otherwise become known or be independently discovered by competitors. To the extent that intellectual property owned by others is used by our employees, consultants or contractors, disputes may arise as to the rights in related or resulting know-how and inventions.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_40"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Distribution</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely on third-party manufacturers and distributors to supply and distribute onvansertib used in our clinical studies and nonclinical development programs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_43"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in a highly regulated industry that is subject to significant federal, state, local and foreign regulation. Our present and future business has been, and will continue to be, subject to a variety of laws including, the Federal Food, Drug, and Cosmetic Act (&#8220;FDC Act&#8221;), and the Public Health Service Act, among others.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDC Act and other federal and state statutes and regulations govern the testing, manufacturing, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of our products. As a result of these laws and regulations, product development and product approval processes are very expensive and time-consuming.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">FDA Approval Process</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, pharmaceutical products, including biologics, are subject to extensive regulation by the FDA. The FDC Act and other federal and state statutes and regulations, govern, among other things, the research, development, testing, manufacturing, storage, record keeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as FDA refusal to approve pending New Drug Applications (&#8220;NDAs&#8221;) or Biologics License Applications (&#8220;BLAs&#8221;) warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical product development in the United States typically involves preclinical laboratory and animal tests, the submission to the FDA of an Investigational New Drug Application ("IND"), which must become effective before clinical testing may commence, and adequate and well-controlled clinical trials to establish the safety and effectiveness of the drug or biologic for each indication for which FDA approval is sought. Satisfaction of FDA pre-market approval requirements typically takes many years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical tests include laboratory evaluation as well as animal trials to assess the characteristics and potential pharmacology and toxicity of the product. The conduct of the pre-clinical tests must comply with federal regulations and requirements including good laboratory practices. The results of pre-clinical testing are submitted to the FDA as part of an IND along with other information, including information about product chemistry, manufacturing and controls, and a proposed clinical trial protocol. Long term pre-clinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A 30-day waiting period after the submission of each IND is required prior to the commencement of clinical testing in humans. If the FDA has not objected to the IND within this 30-day period, the clinical trial proposed in the IND may begin. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational drug to healthy volunteers or patients under the supervision of a qualified investigator. Clinical trials must be conducted in compliance with federal regulations and Good Clinical Practices (&#8220;GCP&#8221;) as well as under protocols detailing the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may order the temporary or permanent discontinuation of a clinical trial at any time or impose other sanctions if it believes that the clinical trial is not being conducted in accordance with FDA requirements or presents an unacceptable risk to the clinical trial patients. The clinical trial protocol and informed consent information for patients in clinical trials must also be submitted to an Institutional Review Board (&#8220;IRB&#8221;) for approval. An IRB may also require the clinical trial at the site to be halted, either temporarily or permanently, for failure to comply with the IRB&#8217;s requirements, or may impose other conditions. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials to support NDAs or BLAs, which are applications for marketing approval, are typically conducted in three sequential Phases, but the Phases may overlap. In Phase 1, the initial introduction of the investigational drug candidate into healthy human subjects or patients, the investigational drug is tested to assess metabolism, pharmacokinetics, pharmacological actions, side effects associated with increasing doses and, if possible, early evidence on effectiveness. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2 usually involves trials in a limited patient population, to determine the effectiveness of the investigational drug for a particular indication or indications, dosage tolerance and optimum dosage, and identify common adverse effects and safety risks. In the case of product candidates for severe or life-threatening diseases such as cancer, the initial human testing is often conducted in patients rather than in healthy volunteers. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an investigational drug demonstrates evidence of effectiveness and an acceptable safety profile in Phase 2 evaluations, Phase 3 clinical trials are undertaken to obtain additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the investigational drug and to provide adequate information for its labeling. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After completion of the required clinical testing, an NDA or, in the case of a biologic, a BLA, is prepared and submitted to the FDA. FDA approval of the marketing application is required before marketing of the product may begin in the United States. The marketing application must include the results of all preclinical, clinical and other testing and a compilation of data relating to the product&#8217;s pharmacology, chemistry, manufacture, and controls. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has 60 days from its receipt of an NDA or BLA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review. The FDA has agreed to certain performance goals in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review of marketing applications. Most such applications for non-priority drug products are reviewed within ten months. The review process may be extended by the FDA for three additional months to consider new information submitted during the review or clarification regarding information already provided in the submission. The FDA may also refer applications for novel drug products or drug products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. Before approving a marketing application, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the FDA will inspect the facility or the facilities at which the drug product is manufactured. The FDA will not approve the NDA or, in the case of a biologic, the BLA unless compliance with CGMPs is satisfactory and the marketing application contains data that provide substantial evidence that the product is safe and effective in the indication studied. Manufacturers of biologics also must comply with FDA&#8217;s general biological product standards. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA evaluates the NDA or BLA and the manufacturing facilities, it issues an approval letter or a complete response letter. A complete response letter outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed in a resubmission of the marketing application, the FDA will re-initiate their review. If the FDA is satisfied that the deficiencies have been addressed, the agency will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. It is not unusual for the FDA to issue a complete response letter because it believes that the drug product is not safe enough or effective enough or because it does not believe that the data submitted are reliable or conclusive. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter authorizes commercial marketing of the drug product with specific prescribing information for specific indications. As a condition of approval of the marketing application, the FDA may require substantial post-approval testing and surveillance to monitor the drug product&#8217;s safety or efficacy and may impose other conditions, including labeling restrictions, which can materially affect the product&#8217;s potential market and profitability. Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained, or problems are identified following initial marketing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulatory Requirements </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once a NDA or BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and promotion of therapeutic products, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the internet. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new BLA or BLA supplement, before the change can be implemented. A BLA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the same procedures and actions in reviewing BLA supplements as it does in reviewing BLAs. We cannot be certain that the FDA or any other regulatory agency will grant approval for our product candidate for any other indications or any other product candidate for any indication on a timely basis, if at all. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse event reporting and submission of periodic reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, risk evaluation and mitigation strategies, and surveillance to monitor the effects of an approved product or place conditions on an approval that could restrict the distribution or use of the product. In addition, quality control as well as product manufacturing, packaging, and labeling procedures must continue to conform to CGMPs after approval. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA during which the agency inspects manufacturing facilities to assess compliance with CGMPs. Accordingly, manufacturers must continue to expend time, money, and effort in the areas of production and quality control to maintain compliance with CGMPs. Regulatory authorities may withdraw product approvals or request product recalls if a company fails to comply with regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently discovered. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Foreign Corrupt Practices Act </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Foreign Corrupt Practices Act, to which we are subject, prohibits corporations and individuals from engaging in certain activities to obtain or retain business or to influence a person working in an official capacity. It is illegal to pay, offer to pay or authorize the payment of anything of value to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal and State Fraud and Abuse Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play a primary role in the recommendation and prescription of drug and biologic product candidates which obtain marketing approval. In addition to FDA restrictions on marketing of pharmaceutical products, pharmaceutical manufacturers are exposed, directly, or indirectly, through customers, to broadly applicable fraud and abuse and other healthcare laws and regulations that may affect the business or financial arrangements and relationships through which a pharmaceutical manufacturer can market, sell and distribute drug and biologic products. These laws include, but are not limited to: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Anti-Kickback Statute which prohibits, any person or entity from, among other things, knowingly and willfully offering, paying, soliciting, or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in-kind, to induce or reward either the referring of an individual for, or the purchasing, leasing, ordering, or arranging for the purchase, lease, or order of any healthcare item or service reimbursable, in whole or in part, under Medicare, Medicaid, or any other federally financed healthcare program. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, and formulary managers on the other hand. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchases, or recommendations may be subject to scrutiny if they do not qualify for an exemption or safe harbor. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal false claims and civil monetary penalty laws, including the Federal False Claims Act, which imposes significant penalties and can be enforced by private citizens through civil </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions, prohibits any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to the federal government, or knowingly making, using or causing to be made, a false statement or record material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. Criminal prosecution is also possible for making or presenting a false, fictitious or fraudulent claim to the federal government. Several pharmaceutical and other healthcare companies have been prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Other companies have been prosecuted for causing false claims to be submitted because of the company&#8217;s marketing of the product for unapproved, and thus non-reimbursable, uses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;) which, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statements or representations, or making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of, or payment for, benefits, items or services.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology and Clinical Health Act of 2009 (&#8220;HITECH&#8221;) and its implementing regulations, which impose certain requirements relating to the privacy, security, transmission and breach reporting of individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and healthcare providers and their respective business associates that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act,&#8221; and its implementing regulations, which require certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the United States Department of Health and Human Services (&#8220;HHS&#8221;) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and foreign law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by non-governmental third-party payors, including private insurers.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare providers, and other federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the collection, use, disclosure, and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus requiring additional compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some business activities can be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that business arrangements with third parties comply with applicable healthcare laws and regulations is costly and time consuming. If business operations are found to be in violation of any of the laws described above or any other applicable governmental regulations a pharmaceutical manufacturer may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from governmental funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future earnings, additional reporting obligations and oversight if subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of operations, any of which could adversely affect a pharmaceutical manufacturer&#8217;s ability to operate its business and the results of its operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform in the United States</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect the future results of pharmaceutical manufactures&#8217; operations. In particular, there have been and continue to be a number of initiatives at the federal and state levels that seek to reduce healthcare costs. The Patient Protection and Affordable Care Act (&#8220;PPACA&#8221;) was enacted in March 2010, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical and biotechnology industry are the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act&#8221;;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (&#8220;AMP&#8221;);</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidate, that are inhaled, infused, instilled, implanted or injected;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health program.</span></div><div style="padding-left:54pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Some of the provisions of the PPACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the PPACA. During President Trump's administration, he signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 (&#8220;TCJA&#8221;) includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Congress may consider other legislation to repeal or replace elements of the PPACA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the details regarding the implementation of the PPACA are yet to be determined, and at this time, the full effect that the PPACA would have on a pharmaceutical manufacturer remains unclear. In particular, there is uncertainty surrounding the applicability of the biosimilars provisions under the PPACA. The FDA has issued several guidance documents, but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. The regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way pharmaceutical manufacturers conduct their business and may require changes to current strategies. A biosimilar is a biological product that is highly similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm a pharmaceutical manufacturer&#8217;s business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for certain products or put pressure on product pricing, which could negatively affect a pharmaceutical manufacturer&#8217;s business, results of operations, financial condition and prospects. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics and the reform of the Medicare and Medicaid programs. While no one can predict the full outcome of any such legislation, it may result in decreased reimbursement for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm a pharmaceutical manufacturer&#8217;s ability to generate revenue. Increases in importation </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or re-importation of pharmaceutical products from foreign countries into the United States could put competitive pressure on a pharmaceutical manufacturer&#8217;s ability to profitably price products, which, in turn, could adversely affect business, results of operations, financial condition and prospects. A pharmaceutical manufacturer might elect not to seek approval for or market products in foreign jurisdictions in order to minimize the risk of re-importation, which could also reduce the revenue generated from product sales. It is also possible that other legislative proposals having similar effects will be adopted. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulation in the European Union </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biologics are also subject to extensive regulation outside of the United States. In the European Union, for example, there is a centralized approval procedure that authorizes marketing of a product in all countries of the European Union, which includes most major countries in Europe. If this procedure is not used, approval in one country of the European Union can be used to obtain approval in another country of the European Union under two simplified application processes, the mutual recognition procedure, or the decentralized procedure, both of which rely on the principle of mutual recognition. After receiving regulatory approval through any of the European registration procedures, pricing and reimbursement approvals are also required in most countries. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Regulations </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to numerous federal, state and local laws relating to such matters as safe working conditions, manufacturing practices, environmental protection, fire hazard control, and disposal of hazardous or potentially hazardous substances and biological materials. We may incur significant costs to comply with such laws and regulations now or in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some drugs benefit from additional government incentives.&#160;Orphan drugs&#160;receive special consideration from the FDA in order to encourage pharmaceutical companies to develop treatments for rare diseases. Incentives for the development of orphan drugs include quicker approval time and potential financial assistance, including waiver of the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;). Companies are often permitted to charge substantial prices for orphan drugs, making them more profitable than they would be without government intervention. As a result, the development of orphan drugs continues to grow at a faster rate than the development of traditional pharmaceuticals.</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_46"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Onvansertib is not the first PLK inhibitor that has entered clinical development; however, we believe it currently is the only oral PLK1 inhibitor in active clinical development that delivers highly selective PLK1 inhibition. Onvansertib is also synergistic in combination with numerous chemotherapies and targeted therapeutics and may enhance and/or extend response to treatment across a number of solid tumor cancers and hematologic malignancies. In five clinical trials with over 200 patients, onvansertib was shown to be well-tolerated when dosed as a single agent or in combination with other therapies. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The PLK inhibitor that reached the latest stage of clinical development (Phase 3), is volasertib, a pan-PLK inhibitor developed by Boehringer Ingelheim. Boehringer Ingelheim was developing volasertib plus LDAC for the treatment of AML which did not meet the primary endpoint of ORR (EHA 2016). The data showed an unfavorable overall survival trend with the safety profile of volasertib plus LDAC considered as the main reason. Volasertib's safety profile may have resulted from the fact that its inhibition of PLK1 is not highly selective and it also inhibits PLK2 and PLK3. By contrast, onvansertib is able to deliver much more selective inhibition of PLK1 than volasertib. Onvansertib also has a half-life of 24 hours vs. volasertib's 135 hours and it is orally administered.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One additional PLK1 inhibitor in early-stage clinical development is plogosertib, which is being developed by Cyclacel. Plogosertib has primary selectivity for PLK1 and secondary selectivity for PLK2 and PLK3. </span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_49"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The human capital objectives we focus on in managing our business include attracting, developing, and retaining key personnel. Our employees are critical to the success of our organization and we are committed to supporting our employees&#8217; professional development. We believe our management team has the experience necessary to effectively implement our growth strategy and continue to drive shareholder value. We provide competitive compensation and benefits to attract and retain key personnel, while also providing a safe, inclusive and respectful workplace.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;23, 2023, we had a total of 26 employees, 25 of whom were full-time. Based on self-identification data 50% of our employees identify as women and 38% of our employees identify as a racial or ethnic minority.  None of our employees are covered by a collective bargaining agreement, and we consider our relations with our employees to be good.</span></div><div style="text-indent:27pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_52"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporation Information</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We were originally incorporated under the laws of the State of Florida in April 2002. In January&#160;2010, we re-incorporated under the laws of the State of Delaware and changed our name to Trovagene,&#160;Inc. In May&#160;2012, our common stock was listed on The Nasdaq Capital Market ("Nasdaq") under the ticker symbol TROV. In May 2020 we changed our name to Cardiff Oncology, Inc. and our Nasdaq ticker symbol changed to CRDF. Our corporate website address is www.cardiffoncology.com. Our annual reports on Form 10-K, quarterly reports on Form 10-Q, proxy statements, current reports on Form 8-K and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge at www.cardiffoncology.com as soon as reasonably practicable after electronically filing such reports with the Securities and Exchange Commission. Any information contained on, or that can be accessed through, our website is not incorporated by reference into, nor is it in any way a part of, this Annual Report on Form 10-K. These reports are also available at www.sec.gov. </span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_55"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.  RISK FACTORS</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in our securities involves a high degree of risk. An investor should carefully consider the risks described below as well as other information contained in this Annual Report on Form 10-K and our other reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial may also impair our business operations. If any of the following risks actually occur, our business, financial condition or results of operations could be materially adversely affected, the value of our securities could decline, and investors in our company may lose all or part of their investment.</span></div><div style="text-indent:20.25pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_58"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are a clinical stage company and may never earn a profit.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical stage company and have incurred losses since our formation. As of December&#160;31, 2022, we have an accumulated total deficit of approximately $298.1 million. For the fiscal years ended December&#160;31, 2022 and 2021, we had a net loss attributable to common stockholders of approximately $38.7 million and $28.3 million, respectively. To date, we have experienced negative cash flow from development of our product candidate,&#160;onvansertib. We have generated limited revenue from operations, and we expect to incur substantial net losses for the foreseeable future as we seek to further develop and commercialize&#160;onvansertib. We cannot predict the extent of these future net losses, or when we may attain profitability, if at all. If we are unable to generate significant revenue from&#160;onvansertib or attain profitability, we will not be able to sustain operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with developing and commercializing&#160;onvansertib, we are unable to predict the extent of any future losses or when we will attain profitability, if ever. We may never become profitable and you may never receive a return on an investment in our common stock. An investor in our common stock must carefully consider the substantial challenges, risks and uncertainties inherent in the attempted development and commercialization of&#160;onvansertib. We may never successfully commercialize&#160;onvansertib, and our business may not be successful.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to raise substantial additional capital to develop and commercialize&#160;onvansertib&#160;and our failure to obtain funding when needed may force us to delay, reduce or eliminate our product development programs or collaboration efforts.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our cash, cash equivalents and short-term investments balance was approximately $105.3 million and our working capital was approximately $103.5 million. Due to our recurring losses from operations and the expectation that we will continue to incur losses in the future, we will be required to raise additional capital to complete the development and commercialization of our current product candidate. We have historically relied upon private and public sales of our equity, as well as debt financings to fund our operations. In order to raise additional capital, we may seek to sell additional equity and/or debt securities or obtain a credit facility or other loan, which we may not be able to do on favorable terms, or at all. Our ability to obtain additional financing will be subject to a number of factors, including market conditions, our operating performance and investor sentiment. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of our product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate, restrict our operations or obtain funds by entering into agreements on unfavorable terms. Failure to obtain additional capital at acceptable terms would result in a material and adverse impact on our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate,&#160;onvansertib,&#160;is in the early stages of clinical development and its commercial viability remains subject to current and future preclinical studies, clinical trials, regulatory approvals and the risks generally inherent in the development of a pharmaceutical product candidate. If we are unable to successfully advance or develop our product candidate, our business will be materially harmed.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the near-term, failure to successfully advance the development of our product candidate may have a material adverse effect on us. To date, we have not successfully developed or commercially marketed, distributed or sold any product candidate. The success of our business depends primarily upon our ability to successfully advance the development of our product candidate through preclinical studies and clinical trials, have the product candidate approved for sale by the FDA or regulatory authorities in other countries, and ultimately have the product candidate successfully commercialized by us or a strategic partner. We cannot assure you that the results of our ongoing preclinical studies or clinical trials will support or justify the continued development of our product candidate, or that we will receive approval from the FDA, or similar regulatory authorities in other countries, to advance the development of our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate must satisfy rigorous regulatory standards of safety and efficacy before we can advance or complete its clinical development or it can be approved for sale. To satisfy these standards, we must engage in expensive and lengthy preclinical studies and clinical trials, develop acceptable manufacturing processes, and obtain regulatory approval of our product candidate. Despite these efforts, our product candidate may not:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">offer therapeutic or other medical benefits over existing drugs or other product candidates in development to treat the same patient population;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be proven to be safe and effective in current and future preclinical studies or clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the desired effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be free from undesirable or unexpected effects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">meet applicable regulatory standards;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be capable of being formulated and manufactured in commercially suitable quantities and at an acceptable cost; or</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be successfully commercialized by us or by collaborators.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we demonstrate favorable results in preclinical studies and early-stage clinical trials, we cannot assure you that the results of late-stage clinical trials will be favorable enough to support the continued development of our product candidate. A number of companies in the pharmaceutical and biopharmaceutical industries have experienced significant delays, setbacks and failures in all stages of development, including late-stage clinical trials, even after achieving promising results in preclinical testing or early-stage clinical trials. Accordingly, results from completed preclinical studies and early-stage clinical trials of our product candidate may not be predictive of the results we may obtain in later-stage trials. Furthermore, even if the data collected from preclinical studies and clinical trials involving our product candidate demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of an NDA or a Biologics License Application ("BLA") to obtain regulatory approval from the FDA in the U.S., or other similar regulatory agencies in other jurisdictions, which is required to market and sell the product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate will require significant additional research and development efforts, the commitment of substantial financial resources, and regulatory approvals prior to advancing into further clinical development or being commercialized by us or collaborators. We cannot assure you that our product candidate will successfully progress through the drug development process or will result in commercially viable products. We do not expect our product candidate to be commercialized by us or collaborators for at least several years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate may exhibit undesirable side effects when used alone or in combination with other approved pharmaceutical products or investigational new drugs, which may delay or preclude further development or regulatory approval, or limit their use if approved.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the drug development process, we must continually demonstrate the safety and tolerability of our product candidate to obtain regulatory approval to further advance clinical development or to market it. Even if our product candidate demonstrates biologic activity and clinical efficacy, any unacceptable adverse side effects or toxicities, when administered alone or in the presence of other pharmaceutical products, which can arise at any stage of development, may outweigh potential benefits. In preclinical studies and clinical trials we have conducted to date, our product candidate&#8217;s safety profile is based on studies and trials that have involved a small number of subjects or patients over a limited period of time. We may observe adverse or significant adverse events or drug-drug interactions in future preclinical studies or clinical trial candidates, which could result in the delay or termination of development, prevent regulatory approval, or limit market acceptance if ultimately approved.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the results of preclinical studies or clinical trials for our product candidate, including those that are subject to existing or future license or collaboration agreements, are unfavorable or delayed, we could be delayed or precluded from the further development or commercialization of our product candidate, which could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to further advance the development of, and ultimately receive regulatory approval to sell, our product candidate, we must conduct extensive preclinical studies and clinical trials to demonstrate its safety and efficacy to the satisfaction of the FDA or similar regulatory authorities in other countries, as the case may be. Preclinical studies and clinical trials are expensive, complex, can take many years to complete, and have highly uncertain outcomes. Delays, setbacks, or failures can occur at any time, or in any phase of preclinical or clinical testing, and can result from concerns about safety or toxicity, a lack of demonstrated efficacy or superior efficacy over other similar products that have been approved for sale or are in more advanced stages of development, poor study or trial design, and issues related to the formulation or manufacturing process of the materials used to conduct the trials. The results of prior preclinical studies or clinical trials are not necessarily predictive of the results we may observe in later stage clinical trials. In many cases, product candidates in clinical development may fail to show desired safety and efficacy characteristics despite having favorably demonstrated such characteristics in preclinical studies or earlier stage clinical trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may experience numerous unforeseen events during, or as a result of, preclinical studies and the clinical trial process, which could delay or impede our ability to advance the development of, receive regulatory approval for, or commercialize our product candidate, including, but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">communications with the FDA, or similar regulatory authorities in different countries, regarding the scope or design of a trial or trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory authorities, including an IRB or Ethical Committee (&#8220;EC&#8221;),&#160;not authorizing us to commence or conduct a clinical trial at a prospective trial site;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enrollment in our clinical trials being delayed, or proceeding at a slower pace than we expected, because we have difficulty recruiting patients or participants dropping out of our clinical trials at a higher rate than we anticipated;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third party contractors, upon whom we rely for conducting preclinical studies, clinical trials and manufacturing of our trial materials, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">having to suspend or ultimately terminate our clinical trials if participants are being exposed to unacceptable health or safety risks;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">IRBs, ECs or regulators requiring that we hold, suspend or terminate our preclinical studies and clinical trials for various reasons, including&#160;non-compliance&#160;with regulatory requirements; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of drug material necessary to conduct our preclinical studies or clinical trials being insufficient, inadequate or unavailable.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the data collected from preclinical studies or clinical trials involving our product candidates demonstrate a favorable safety and efficacy profile, such results may not be sufficient to support the submission of a NDA or BLA to obtain regulatory approval from the FDA in the U.S., or other similar foreign regulatory authorities in foreign jurisdictions, which is required to market and sell the product.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third party vendors upon whom we intend to rely on to conduct our preclinical studies or clinical trials do not perform or fail to comply with strict regulations, these studies or trials of our product candidate may be delayed, terminated, or fail, or we could incur significant additional expenses, which could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited resources dedicated to designing, conducting and managing preclinical studies and clinical trials. We intend to rely on third parties, including clinical research organizations, consultants and principal investigators, to assist us in designing, managing, monitoring and conducting our preclinical studies and clinical trials. We intend to rely on these vendors and individuals to perform many facets of the drug development process, including certain preclinical studies, the recruitment of sites and patients for participation in our clinical trials, maintenance of good relations with the clinical sites, and ensuring that these sites are conducting our trials in compliance with the trial protocol, including safety monitoring and applicable regulations. If these third parties fail to perform satisfactorily, or do not adequately fulfill their obligations under the terms of our agreements with them, we may not be able to enter into alternative arrangements without undue delay or additional expenditures, and therefore the preclinical studies and clinical trials of our product candidate may be delayed or prove unsuccessful. Further, the FDA, or other similar foreign regulatory authorities, may inspect some of the clinical sites participating in our clinical trials in the U.S., or our third-party vendors&#8217; sites, to determine if our clinical trials are being conducted according to Good Clinical Practices. If we or the FDA determine that our third-party vendors are not in compliance with, or have not conducted our clinical trials according to, applicable regulations we may be forced to delay, repeat or terminate such clinical trials.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited capacity for recruiting and managing clinical trials, which could impair our timing to initiate or complete clinical trials of our product candidate and materially harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited capacity to recruit and manage the clinical trials necessary to obtain FDA approval or approval by other regulatory authorities. By contrast, larger pharmaceutical and&#160;bio-pharmaceutical&#160;companies often have substantial staff with extensive experience in conducting clinical trials with multiple product candidates across multiple indications. In addition, they may have greater financial resources to compete for the same clinical investigators and patients that we are attempting to recruit for our clinical trials. If potential competitors are successful in completing drug development for their product candidates and obtain approval from the FDA, they could limit the demand for&#160;onvansertib.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result, we may be at a competitive disadvantage that could delay the initiation, recruitment, timing, completion of our clinical trials and obtaining regulatory approvals, if at all, for our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We, and our collaborators, must comply with extensive government regulations in order to advance our product candidate through the development process and ultimately obtain and maintain marketing approval for our products in the U.S. and abroad.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product candidate that we, or our collaborators, are developing requires regulatory approval to advance through clinical development and to ultimately be marketed and sold, and are subject to extensive and rigorous domestic and foreign government regulation. In the U.S., the FDA regulates, among other things, the development, testing, manufacture, safety, efficacy, record-keeping, labeling, storage, approval, advertising, promotion, sale and distribution of pharmaceutical and biopharmaceutical products. Our product candidate is also subject to similar regulation by foreign governments to the extent we seek to develop or market it in those countries. We, or our collaborators, must provide the FDA and foreign regulatory authorities, if applicable, with preclinical and clinical data, as well as data supporting an acceptable manufacturing process, that appropriately demonstrate our product candidate&#8217;s safety and efficacy before it can be approved for the targeted indications. Our product candidate has not been approved for sale in the U.S. or any foreign market, and we cannot predict whether we or our collaborators will obtain regulatory approval for any product candidates we are developing or plan to develop. The regulatory review and approval process can take many years, is dependent upon the type, complexity, novelty of, and medical need for the product candidate, requires the expenditure of substantial resources, and involves post-marketing surveillance and vigilance and ongoing requirements for post-marketing studies or Phase&#160;4 clinical trials. In addition, we or our collaborators may encounter delays in, or fail to gain, regulatory approval for our product candidate based upon additional governmental regulation resulting from future legislative, administrative action or changes in FDA&#8217;s or other similar foreign regulatory authorities&#8217; policy or interpretation during the period of product development. Delays or failures in obtaining regulatory approval to advance our product candidate through clinical development, and ultimately commercialize them, may: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely impact our ability to raise sufficient capital to fund the development of our product candidate; </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affect our ability to further develop or commercialize our product candidate; </span></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminish any competitive advantages that we or our collaborators may have or attain; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adversely affect the receipt of potential milestone payments and royalties from the sale of our products or product revenues.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, any regulatory approvals, if granted, may later be withdrawn. If we or our collaborators fail to comply with applicable regulatory requirements at any time, or if post-approval safety concerns arise, we or our collaborators may be subject to restrictions or a number of actions, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays, suspension or termination of clinical trials related to our products;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by regulatory authorities to review pending applications or supplements to approved applications;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product recalls or seizures;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">suspension of manufacturing;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawals of previously approved marketing applications; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, civil penalties and criminal prosecutions.</span></div><div style="padding-left:54pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, at any time we or our collaborators may voluntarily suspend or terminate the preclinical or clinical development of a product candidate, or withdraw any approved product from the market if we believe that it may pose an unacceptable safety risk to patients, or if the product candidate or approved product no longer meets our business objectives. The ability to develop or market a pharmaceutical product outside of the U.S. is contingent upon receiving appropriate authorization from the respective foreign regulatory authorities. Foreign regulatory approval processes typically include many, if not all, of the risks and requirements associated with the FDA regulatory process for drug development and may include additional risks.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited experience in the development of therapeutic product candidates and therefore may encounter difficulties developing our product candidate or managing our operations in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have limited experience in the discovery, development and manufacturing of therapeutic compounds. In order to successfully develop our product candidate, we must continuously supplement our research, clinical development, regulatory, medicinal chemistry, virology and manufacturing capabilities through the addition of key employees, consultants or third-party contractors to provide certain capabilities and skill sets that we do not possess.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we have adopted an operating model that largely relies on the outsourcing of a number of responsibilities and key activities to third-party consultants, and contract research and manufacturing organizations in order to advance the development of our product candidate. Therefore, our success depends in part on our ability to retain highly qualified key management, personnel, and directors to develop, implement and execute our business strategy, operate the company and oversee the activities of our consultants and contractors, as well as academic and corporate advisors or consultants to assist us in this regard. We are currently highly dependent upon the efforts of our management team. In order to develop our product candidate, we need to retain or attract certain personnel, consultants or advisors with experience in drug development activities that include a number of disciplines, including research and development, clinical trials, medical matters, government regulation of pharmaceuticals, manufacturing, formulation and chemistry, business development, accounting, finance, regulatory affairs, human resources and information systems. We are highly dependent upon our senior management and scientific staff, particularly Mark Erlander, our Chief Executive Officer (&#8220;CEO&#8221;). The loss of services of Dr. Erlander or one or more of our other members of senior management could delay or prevent the successful completion of our planned clinical trials or the commercialization of our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends in part on our continued ability to attract, retain and motivate highly qualified management, clinical and scientific personnel and on our ability to develop and maintain important relationships with leading academic institutions, clinicians and scientists. The competition for qualified personnel in the biotechnology and pharmaceuticals field is intense. We will need to hire additional personnel as we expand our clinical development and commercial activities. While we have not had difficulties recruiting qualified individuals, to date, we may not be able to attract and retain quality personnel on acceptable terms given the competition for such personnel among biotechnology, pharmaceutical and other companies. Although we have not experienced material difficulties in retaining key personnel in the past, we may not be able to continue to do so in the future on acceptable terms, if at all. If we lose any key managers or employees, or are unable to attract and retain </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">qualified key personnel, directors, advisors or consultants, the development of our product candidate could be delayed or terminated and our business may be harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate may not prove to be safe and efficacious in clinical trials and may not meet all the applicable regulatory requirements needed to receive regulatory approval. In order to receive regulatory approval for the commercialization of our product candidate, we must conduct, at our own expense, extensive preclinical testing and clinical trials to demonstrate safety and efficacy of our product candidate for the intended indication of use. Clinical testing is expensive, can take many years to complete, if at all, and its outcome is uncertain. Failure can occur at any time during the clinical trial process.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies and early clinical trials of new drugs do not necessarily predict the results of later-stage clinical trials</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The design of our clinical trials is based on many assumptions about the expected effects of our product candidate, and if those assumptions are incorrect it may not produce statistically significant results. Preliminary results may not be confirmed on full analysis of the detailed results of an early clinical trial. Product candidates in later stages of clinical trials may fail to show safety and efficacy sufficient to support intended use claims despite having progressed through initial clinical testing. The data collected from clinical trials of our product candidate may not be sufficient to support the filing of an NDA or to obtain regulatory approval in the United States or elsewhere. Because of the uncertainties associated with drug development and regulatory approval, we cannot determine if or when we will have an approved product for commercialization or achieve sales or profits.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delays in clinical testing could result in increased costs to us and delay our ability to generate revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience delays in clinical testing of our product candidate. We do not know whether planned clinical trials will begin on time, will need to be redesigned or will be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays in obtaining regulatory approval to commence a clinical trial, in securing clinical trial agreements with prospective sites with acceptable terms, in obtaining institutional review board approval to conduct a clinical trial at a prospective site, in recruiting patients to participate in a clinical trial or in obtaining sufficient supplies of clinical trial materials. Many factors affect patient enrollment, including the size of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the clinical trial, competing clinical trials and new drugs approved for the conditions we are investigating. Clinical investigators will need to decide whether to offer their patients enrollment in clinical trials of our product candidate versus treating these patients with commercially available drugs that have established safety and efficacy profiles. Any delays in completing our clinical trials will increase our costs, slow down our product development, timeliness and approval process and delay our ability to generate revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidate, our business will be substantially harmed.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that our existing product candidate or any product candidate we may seek to develop in the future will ever obtain regulatory approval.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate could fail to receive regulatory approval for many reasons, including the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or comparable foreign regulatory authorities may fail to approve the companion diagnostics we contemplate developing with partners; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidate, which would significantly harm our business, results of operations and prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve our product candidate for fewer or more limited indications than we request, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not previously submitted a BLA, or a NDA, to the FDA, or similar drug approval filings to comparable foreign authorities, for our product candidate, and we cannot be certain that our product candidate will be successful in clinical trials or receive regulatory approval. Further, our product candidate may not receive regulatory approval even if it is successful in clinical trials. If we do not receive regulatory approvals for our product candidate, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenues will be dependent, in part, upon our collaborators&#8217; ability to obtain regulatory approval of the companion diagnostics to be used with our product candidates, as well as the size of the markets in the territories for which we gain regulatory approval and have commercial rights. If the markets for patients that we are targeting for our product candidate are not as significant as we estimate, we may not generate significant revenues from sales of such products, if approved.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to seek regulatory approval and to commercialize our product candidate, directly or with a collaborator, worldwide including the United States, the European Union and other additional foreign countries which we have not yet identified. While the scope of regulatory approval is similar in other countries, to obtain separate regulatory approval in many other countries we must comply with numerous and varying regulatory requirements of such countries regarding safety and efficacy and governing, among other things, clinical trials and commercial sales, pricing and distribution of our product candidates, and we cannot predict success in these jurisdictions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be required to suspend or discontinue clinical trials due to unexpected side effects or other safety risks that could preclude approval of our product candidate.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our clinical trials may be suspended at any time for a number of reasons. For example, we may voluntarily suspend or terminate our clinical trials if at any time we believe that they present an unacceptable risk to the clinical trial patients. In addition, the FDA or other regulatory agencies may order the temporary or permanent discontinuation of our clinical trials at any time if they believe that the clinical trials are not being conducted in accordance with applicable regulatory requirements or that they present an unacceptable safety risk to the clinical trial patients.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Administering our product candidate to humans may produce undesirable side effects. These side effects could interrupt, delay or halt clinical trials of our product candidates and could result in the FDA or other regulatory authorities denying further development or approval of our product candidate for any or all targeted indications. Ultimately, our product candidate may prove to be unsafe for human use. Moreover, we could be subject to significant liability if any volunteer or patient suffers, or appears to suffer, adverse health effects as a result of participating in our clinical trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with healthcare regulations, we could face substantial enforcement actions, including civil and criminal penalties and our business, operations and financial condition could be adversely affected.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a developer of pharmaceuticals, even though we do not intend to make referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, certain federal and state healthcare laws and regulations pertaining to fraud and abuse, false claims and patients&#8217; privacy rights are and will be applicable to our business. We could be subject to healthcare fraud and abuse laws and patient privacy laws of both the federal government and the states in which we conduct our business. The laws include:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal healthcare program anti-kickback law, which prohibits, among other things, persons from soliciting, receiving or providing remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent, and which may apply to entities like us which provide coding and billing information to customers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, which prohibits executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters and which also imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Federal Food, Drug, and Cosmetic Act, which among other things, strictly regulates drug manufacturing and product marketing, prohibits manufacturers from marketing drug products for&#160;off-label&#160;use and regulates the distribution of drug samples; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws which may apply to items or services reimbursed by any third-party payor, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by federal laws, thus complicating compliance efforts.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or any governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, damages, fines and the curtailment or restructuring of our operations. Any penalties, damages, fines, curtailment or restructuring of our operations could adversely affect our ability to operate our business and our financial results. Although compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, the risks cannot be entirely eliminated. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert management&#8217;s attention from the operation of our business. Moreover, achieving and sustaining compliance with applicable federal and state privacy, security and fraud laws may prove costly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to satisfy regulatory requirements, we may not be able to commercialize our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We need FDA approval prior to marketing our product candidate in the United States. If we fail to obtain FDA approval to market our product candidate, we will be unable to sell our product candidate in the United States and we will not generate any revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s review and approval process, including among other things, evaluation of preclinical studies and clinical trials of a product candidate as well as the manufacturing process and facility, is lengthy, expensive and uncertain. To receive approval, we must, among other things, demonstrate with substantial evidence from well-designed and well-controlled&#160;pre-clinical testing and clinical trials that the product candidate is both safe and effective for each indication for which approval is sought. Satisfaction of these requirements typically takes several years and the time needed to satisfy them may vary substantially, based on the type, complexity and novelty of the pharmaceutical product. We cannot predict if or when we will submit an NDA for approval for our product candidate currently under development. Any approvals we may obtain may not cover all of the clinical indications for which we are seeking approval or may contain significant limitations on the conditions of use.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the NDA review process and may either refuse to file our NDA for substantive review or may decide that our data is insufficient to support approval of our product candidate for the claimed intended uses. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following any regulatory approval of our product candidate, we will be subject to continuing regulatory obligations such as safety reporting, required and additional post marketing obligations, and regulatory oversight of promotion and marketing. Even if we receive regulatory approvals, the FDA may subsequently seek to withdraw approval of our NDA if we determine that new data or a reevaluation of existing data show the product is unsafe for use under the conditions of use upon the basis of which the NDA was approved, or based on new evidence of adverse effects or adverse clinical experience, or upon other new information. If the FDA does not file or approve our NDA or withdraws approval of our NDA, the FDA may require that we conduct additional clinical trials, preclinical or manufacturing studies and submit that data before it will reconsider our application. Depending on the extent of these or any other requested studies, approval of any applications that we submit may be delayed by several years, may require us to expend more resources than we have available, or may never be obtained at all.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will also be subject to a wide variety of foreign regulations governing the development, manufacture and marketing of our products to the extent we seek regulatory approval to develop and market our product candidate in a foreign jurisdiction. As of the date hereof we have not identified any foreign jurisdictions which we intend to seek approval from. Whether or not FDA approval has been obtained, approval of a product by the comparable regulatory authorities of foreign countries must still be obtained prior to marketing the product in those countries. The approval process varies and the time needed to secure approval in any region such as the European Union or in a country with an independent review procedure may be longer or shorter than that required for FDA approval. We cannot assure you that clinical trials conducted in one country will be accepted by other countries or that an approval in one country or region will result in approval elsewhere.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our product candidate is unable to compete effectively with marketed drugs targeting similar indications as our product candidate, our commercial opportunity will be reduced or eliminated.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition generally from established pharmaceutical and biotechnology companies, as well as from academic institutions, government agencies and private and public research institutions. Many of our competitors have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. Small or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize any drugs that are safer, more effective, have fewer side effects or are less expensive than our product candidate. These potential competitors compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient enrollment for clinical trials, as well as in acquiring technologies and technology licenses complementary to our programs or advantageous to our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If approved and commercialized,&#160;onvansertib&#160;would compete with the prescription therapies already approved for treatment within the targeted therapeutic area.</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To our knowledge, other potential competitors are in earlier stages of development. If potential competitors are successful in completing drug development for their product candidates and obtain approval from the FDA, they could limit the demand for&#160;onvansertib.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our ability to compete effectively will depend upon our ability to:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully identify and develop key points of product differentiations from currently available therapies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully and rapidly complete clinical trials and submit for and obtain all requisite regulatory approvals in a cost-effective manner;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain a proprietary position for our products and manufacturing processes and other related product technology;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">attract and retain key personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">develop relationships with physicians prescribing these products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">build an adequate sales and marketing infrastructure for our product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we will be competing against significantly larger companies with established track records, we will have to demonstrate that, based on experience, clinical data, side-effect profiles and other factors, our products, if approved, are competitive with other products. If we are unable to compete effectively and differentiate our products from other marketed drugs, we may never generate meaningful revenue.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the manufacturers upon whom we rely fail to produce our product candidate, in the volumes that we require on a timely basis, or fail to comply with stringent regulations applicable to pharmaceutical drug manufacturers, we may face delays in the development and commercialization of our product candidate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently possess internal manufacturing capacity. We plan to utilize the services of GMP, FDA validated contract manufacturers to manufacture our clinical supplies. Any curtailment in the availability of&#160;onvansertib,&#160;however, could result in production or other delays with consequent adverse effects on us. In addition, because regulatory authorities must generally approve raw material sources for pharmaceutical products, changes in raw material suppliers may result in production delays or higher raw material costs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to pursue API and drug product supply agreements with other manufacturers. We may be required to agree to minimum volume requirements, exclusivity arrangements or other restrictions with the contract manufacturers. We may not be able to enter into long-term agreements on commercially reasonable terms, or at all. If we change or add manufacturers, the FDA and comparable foreign regulators may require approval of the changes. Approval of these changes could require new testing by the manufacturer and compliance inspections to ensure the manufacturer is conforming to all applicable laws and regulations and GMP. In addition, the new manufacturers would have to be educated in or independently develop the processes necessary for the production of our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacture of pharmaceutical products requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products may encounter difficulties in production, particularly in scaling up production. These problems include difficulties with production costs and yields, quality control, including stability of the product and quality assurance testing, shortages of qualified personnel, as well as compliance with federal, state and foreign regulations. In addition, any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with conducting our clinical trials and, depending upon the period of delay, require us to commence new clinical trials at significant additional expense or to terminate a clinical trial.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will be responsible for ensuring that each of our future contract manufacturers comply with the GMP requirements of the FDA and other regulatory authorities from which we seek to obtain product approval. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. The approval process for NDAs includes a review of the manufacturer&#8217;s compliance with GMP requirements. We will be responsible for regularly assessing a contract manufacturer&#8217;s compliance with GMP requirements through record reviews and periodic audits and for ensuring that the contract manufacturer takes responsibility and corrective action for any identified deviations. Manufacturers of our product candidates may be unable to comply with these GMP requirements and with other FDA and foreign regulatory requirements, if any.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we will oversee compliance by our contract manufacturers, ultimately, we will not have control over our manufacturers&#8217; compliance with these regulations and standards. A failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, or withdrawal of product approval. If the safety of our product candidate is compromised due to a manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our product candidates, and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical trials, regulatory submissions, approvals or commercialization of&#160;onvansertib&#160;or other product candidates, entail higher costs or result in us being unable to effectively commercialize our product candidates. Furthermore, if our manufacturers fail to deliver the required commercial quantities on a timely basis and at commercially reasonable prices, we may be unable to meet demand for any approved products and would lose potential revenues.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to manufacture our product candidate in commercial quantities, which would prevent us from commercializing our product candidate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, our product candidate has been manufactured in small quantities for preclinical studies and clinical trials. If our product candidate is approved by the FDA or comparable regulatory authorities in other countries for commercial sale, we will need to manufacture such product candidate in larger quantities. We may not be able to increase successfully the manufacturing capacity for our product candidate in a timely or economic manner, or at all. Significant&#160;scale-up&#160;of manufacturing may require additional validation studies, which the FDA must review and approve. If we are unable to increase successfully the manufacturing capacity for a product candidate, the clinical trials as well as the regulatory approval or commercial launch of that product candidate may be delayed or there may be a shortage in supply. Our product candidate requires precise, high-quality manufacturing. Our failure to achieve and maintain these high-quality manufacturing standards in collaboration with our third-party manufacturers, including the incidence of manufacturing errors, could result in patient injury </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or death, product recalls or withdrawals, delays or failures in product testing or delivery, cost overruns or other problems that could harm our business, financial condition, and results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Materials necessary to manufacture our product candidate may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our product candidate. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third party manufacturers to purchase from third-party suppliers the materials necessary to produce bulk APIs, and product candidates for our clinical trials, and we will rely on such manufacturers and any additional similar manufacturers to purchase such materials to produce the APIs and finished products for any commercial distribution of our products if we obtain marketing approval. Suppliers may not sell these materials to our manufacturers at the time they need them in order to meet our required delivery schedule or on commercially reasonable terms, if at all. We do not have any control over the process or timing of the acquisition of these materials by our manufacturers. If our manufacturers are unable to obtain these materials for our clinical trials, testing of the affected product candidate would be delayed, which may significantly impact our ability to develop the product candidate. If we or our manufacturers are unable to purchase these materials after regulatory approval has been obtained for one of our products, the commercial launch of such product would be delayed or there would be a shortage in supply of such product, which would harm our ability to generate revenues from such product and achieve or sustain profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidate, if approved for sale, may not gain acceptance among physicians, patients, and the medical community, thereby limiting our potential to generate revenues.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our product candidate is approved for commercial sale by the FDA or other regulatory authorities, the degree of market acceptance of any approved product by physicians, healthcare professionals and third-party payors and our profitability and growth will depend on a number of factors, including:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">demonstration of safety and efficacy;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the practice guidelines and the standard of care for the targeted indication;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relative convenience and ease of administration;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any adverse side effects;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">budget impact of adoption of our product on relevant drug formularies and the availability, cost and potential advantages of alternative treatments, including less expensive generic drugs;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">pricing, reimbursement and cost effectiveness, which may be subject to regulatory control;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectiveness of our or any of our partners&#8217; sales and marketing strategies;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the product labeling or product insert required by the FDA or regulatory authority in other countries; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate third-party insurance coverage or reimbursement.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidate that we develop does not provide a treatment regimen that is as beneficial as, or is perceived as being as beneficial as, the current standard of care or otherwise does not provide patient benefit, that product candidate, if approved for commercial sale by the FDA or other regulatory authorities, likely will not achieve market acceptance. Our ability to effectively promote and sell any approved products will also depend on pricing and cost-effectiveness, including our ability to produce a product at a competitive price and our ability to obtain sufficient third-party coverage or reimbursement. If any product candidate is approved but does not achieve an adequate level of acceptance by physicians, patients and third-party payors, our ability to generate revenues from that product would be substantially reduced. In addition, our efforts to educate the medical community and third-party payors on the benefits of our product candidates may require significant resources, may be constrained by FDA rules&#160;and policies on product promotion, and may never be successful.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Guidelines and recommendations published by various organizations can impact the use of our product.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government agencies promulgate regulations and guidelines directly applicable to us and to our product. In addition, professional societies, practice management groups, private health and science foundations and organizations involved in various diseases from time to time may also publish guidelines or recommendations to the healthcare and patient communities. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recommendations of government agencies or these other groups or organizations may relate to such matters as usage, dosage, route of administration and use of concomitant therapies. Recommendations or guidelines suggesting the reduced use of our products or the use of competitive or alternative products that are followed by patients and healthcare providers could result in decreased use of our proposed product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party contract manufacturers upon whom we rely to formulate and manufacture our product candidate do not perform, fail to manufacture according to our specifications or fail to comply with strict regulations, our preclinical studies or clinical trials could be adversely affected and the development of our product candidate could be delayed or terminated or we could incur significant additional expenses.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate any manufacturing facilities. We intend to rely on GMP, FDA validated third-party contractors, at least for the foreseeable future, to formulate and manufacture these preclinical and clinical materials. Our reliance on third-party contract manufacturers exposes us to a number of risks, any of which could delay or prevent the completion of our preclinical studies or clinical trials, or the regulatory approval or commercialization of our product candidate, result in higher costs, or deprive us of potential product revenues. Some of these risks include:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors failing to develop an acceptable formulation to support later-stage clinical trials for, or the commercialization of, our product candidates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers failing to manufacture our product candidate according to their own standards, our specifications, CGMPs, or otherwise manufacturing material that we or the FDA may deem to be unsuitable in our clinical trials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers being unable to increase the scale of, increase the capacity for, or reformulate the form of our product candidate. We may experience a shortage in supply, or the cost to manufacture our products may increase to the point where it adversely affects the cost of our product candidate. We cannot assure you that our contract manufacturers will be able to manufacture our products at a suitable scale, or we will be able to find alternative manufacturers acceptable to us that can do so;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers placing a priority on the manufacture of their own products, or other customers&#8217; products;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers failing to perform as agreed or not remain in the contract manufacturing business; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our contract manufacturers&#8217; plants being closed as a result of regulatory sanctions or a natural disaster.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturers of pharmaceutical products are subject to ongoing periodic inspections by the FDA, the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) and corresponding state and foreign agencies to ensure strict compliance with&#160;FDA-CGMPs, other government regulations and corresponding foreign standards. While we are obligated to audit their performance, we do not have control over our third-party contract manufacturers&#8217; compliance with these regulations and standards. Failure by our third-party manufacturers, or us, to comply with applicable regulations could result in sanctions being imposed on us or the drug manufacturer from the production of other third-party products. These sanctions may include fines, injunctions, civil penalties, failure of the government to grant&#160;pre-market&#160;approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of product, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the event that we need to change our third-party contract manufacturers, our preclinical studies, clinical trials or the commercialization of our product candidate could be delayed, adversely affected or terminated, or such a change may result in significantly higher costs.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to regulatory restrictions inherent in an IND, NDA or BLA, various steps in the manufacture of our product candidate may need to be sole-sourced. In accordance with CGMPs, changing manufacturers may require the&#160;re-validation&#160;of manufacturing processes and procedures, and may require further preclinical studies or clinical trials to show comparability between the materials produced by different manufacturers. Changing our current or future contract manufacturers may be difficult for us and could be costly, which could result in our inability to manufacture our product candidate for an extended period of time and therefore a delay in the development of our product candidate. Further, in order to maintain our development time lines in the event of a change in our third-party contract manufacturer, we may incur significantly higher costs to manufacture our product candidate.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not currently have any internal drug discovery capabilities, and therefore we are dependent on&#160;in-licensing&#160;or acquiring development programs from third parties in order to obtain additional product candidates.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If in the future we decide to further expand our pipeline, we will be dependent on&#160;in-licensing&#160;or acquiring product candidates as we do not have significant internal discovery capabilities at this time. Accordingly, in order to generate and expand our development pipeline, we have relied, and will continue to rely, on obtaining discoveries, new technologies, intellectual property and product candidates from third-parties through sponsored research,&#160;in-licensing&#160;arrangements or acquisitions. We may face substantial competition from other biotechnology and pharmaceutical companies, many of which may have greater resources then we have, in obtaining these&#160;in-licensing,&#160;sponsored research or acquisition opportunities. Additional&#160;in-licensing&#160;or acquisition opportunities may not be available to us on terms we find acceptable, if at all.&#160;In-licensed&#160;compounds that appear promising in research or in preclinical studies may fail to progress into further preclinical studies or clinical trials.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a product liability claim is successfully brought against us for uninsured liabilities, or such claim exceeds our insurance coverage, we could be forced to pay substantial damage awards that could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of any of our existing or future product candidates in clinical trials and the sale of any approved pharmaceutical products may expose us to significant product liability claims. We have product liability insurance coverage for our proposed clinical trials; however, such insurance coverage may not protect us against any or all of the product liability claims that may be brought against us now or in the future. We may not be able to acquire or maintain adequate product liability insurance coverage at a commercially reasonable cost or in sufficient amounts or scope to protect us against potential losses. In the event a product liability claim is brought against us, we may be required to pay legal and other expenses to defend the claim, as well as uncovered damage awards resulting from a claim brought successfully against us. In the event our product candidate is approved for sale by the FDA and commercialized, we may need to substantially increase the amount of our product liability coverage. Defending any product liability claim or claims could require us to expend significant financial and managerial resources, which could have an adverse effect on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we materially breach or default under the Nerviano Licensing Agreement, Nerviano will have the right to terminate the agreement and we could lose critical license rights, which would materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is substantially dependent upon certain intellectual property rights that we license from Nerviano. Therefore, our commercial success will depend to a large extent on our ability to maintain and comply with our obligations under the Nerviano Agreement. The Nerviano Agreement provides the right to terminate for an uncured breach by us, or if we are insolvent or the subject of a bankruptcy proceeding, or potentially other reasons. We expect that other technology in-licenses that we may enter into in the future will contain similar provisions and impose similar obligations on us. If we fail to comply with any such obligations such licensor will likely terminate their out-licenses to us, in which case we would not be able to market products covered by these licenses, including our onvansertib asset. The loss of our license with Nerviano with respect to onvansertib, and potentially other licenses that we enter into in the future, would have a material adverse effect on our business. In addition, our failure to comply with obligations under other material in-licenses we may enter into may cause us to become subject to litigation or other potential disputes under any such license agreements.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Nerviano Agreement requires us to make certain payments, including license fees, milestone payments, royalties, and other such terms typically required under licensing agreements and these types of technology&#160;in-licenses&#160;generally could make it difficult for us to find corporate partners and less profitable for us to develop product candidates utilizing these existing product candidates and technologies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may delay or terminate the development of our product candidate at any time if we believe the perceived market or commercial opportunity does not justify further investment, which could materially harm our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though the results of preclinical studies and clinical trials that have been conducted or may conduct in the future may support further development of our product candidate, we may delay, suspend or terminate the future development of a product candidate at any time for strategic, business, financial or other reasons, including the determination or belief that the emerging profile of the product candidate is such that it may not receive FDA approval, gain meaningful market acceptance, generate a significant return to shareholders, or otherwise provide any competitive advantages in its intended indication or market.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to increase the size of our organization, and we may experience difficulties in managing growth.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a small company with 24 employees as of December&#160;31, 2022. Future growth of our company will impose significant additional responsibilities on members of management, including the need to identify, attract, retain, motivate and integrate highly skilled personnel. We may increase the number of employees in the future depending on the progress of our development of our product candidate. Our future financial performance and our ability to commercialize our product candidate and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to:</span></div><div style="padding-left:54pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">manage our clinical studies effectively;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">integrate additional management, administrative, manufacturing and regulatory personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintain sufficient administrative, accounting and management information systems and controls; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">hire and train additional qualified personnel.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no guarantee that we will be able to accomplish these tasks, and our failure to accomplish any of them could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business disruptions could seriously harm future revenue and financial condition and increase our costs and expenses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Our corporate headquarters are located in San Diego, California, an area prone to wildfires and earthquakes. These and other natural disasters could severely disrupt our operations, and have a material adverse effect on our business, results of operations, financial condition and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. Any disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, we rely on third-party manufacturers to manufacture API for our product candidate. Any disruption in production or inability of our manufacturers to produce or ship adequate quantities to meet our needs, whether as a result of a natural disaster or other causes (such as COVID-19 pandemic), could impair our ability to operate our business on a day-to-day basis and to continue our research and development of our product candidate. In addition, we are exposed to the possibility of product supply disruption and increased costs in the event of changes in the policies in countries our manufactures are located, political unrest or unstable economic conditions in these countries. Any recall of the manufacturing lots or similar action regarding our API used in clinical trials could delay the trials or detract from the integrity of the trial data and its potential use in future regulatory filings. In addition, manufacturing interruptions or failure to comply with regulatory requirements by any of these manufacturers could significantly delay clinical development of potential products and reduce third-party or clinical researcher interest and support of proposed trials. These interruptions or failures could also impede commercialization of our product candidate and impair our competitive position.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security threats to our information technology infrastructure and/or our physical buildings could expose us to liability and damage our reputation and business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It is essential to our business strategy that our technology and network infrastructure and our physical buildings remain secure and are perceived by our customers and corporate partners to be secure. Despite security measures, however, any network infrastructure may be vulnerable to cyber-attacks by hackers and other security threats. We may face cyber-attacks that attempt to penetrate our network security, sabotage or otherwise disable our research, products and services, misappropriate our or our partners&#8217; and third party providers proprietary information, which may include personally identifiable information, or cause interruptions of our internal systems and services. Despite security measures, we also cannot guarantee security of our physical buildings. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development and other programs. For example, the loss of nonclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of any product candidate could be delayed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there are a number of state, federal and international laws protecting the privacy and security of health information and personal data. For example, HIPAA imposes limitations on the use and disclosure of an individual&#8217;s healthcare information by healthcare providers, healthcare clearinghouses, and health insurance plans, or, collectively, covered entities, and also grants individuals rights with respect to their health information. HIPAA also imposes compliance obligations and corresponding penalties for&#160;non-compliance on individuals and entities that provide services to healthcare providers and other covered entities. As part of the American Recovery and Reinvestment Act of 2009 (&#8220;ARRA&#8221;), the privacy and security provisions of HIPAA were amended. ARRA also made significant increases in the penalties for improper use or disclosure of an individual&#8217;s health information under HIPAA and extended enforcement authority to state attorneys general. As amended by ARRA and subsequently by the final omnibus rule adopted in 2013, HIPAA also imposes notification requirements on covered entities in the event that certain health information has been inappropriately accessed or disclosed: notification requirements to individuals, federal regulators, and in some cases, notification to local and national media. Notification is not required under HIPAA if the health information that is improperly used or disclosed is deemed secured in accordance with encryption or other standards developed by the HHS. Most states have laws requiring notification of affected individuals and/or state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms, to ensure ongoing protection of personal information. Activities outside of the U.S. implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for&#160;non-compliance.&#160;We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers or to alleviate problems caused by such breaches.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General economic or business conditions may have a negative impact on our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continuing concerns over U.S. healthcare reform legislation and energy costs, geopolitical issues, the availability and cost of credit and government stimulus programs in the U.S. and other countries have contributed to increased volatility and diminished expectations for the global economy. If the economic climate does not improve, or if it deteriorates, our business, including our access to patient samples and the addressable market for tests that we may successfully develop, as well as the financial condition of our suppliers and our third-party payors, could be negatively impacted, which could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities currently require the controlled use of potentially harmful biological materials and chemicals. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations may become significant and could materially adversely affect our business, prospects and financial condition. Moreover, in the event of an accident or if we otherwise fail to comply with applicable regulations, we could lose our permits or approvals or be held liable for damages or penalized with fines.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare reform measures could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs. In 2010, the Patient Protection and Affordable Care Act ("PPACA") was enacted, which includes measures to significantly change the way healthcare is financed by both governmental and private insurers. Among the provisions of the PPACA of greatest importance to the pharmaceutical and biotechnology industry are the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government healthcare programs;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">implementation of the federal physician payment transparency requirements, sometimes referred to as the &#8220;Physician Payments Sunshine Act&#8221;;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a licensure framework for follow-on biologic products;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of a Center for Medicare Innovation at the Centers for Medicare &amp; Medicaid Services to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drug spending;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">extension of manufacturers&#8217; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#8217; Medicaid rebate liability;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expansion of the entities eligible for discounts under the Public Health program.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the provisions of the PPACA have yet to be implemented, and there have been legal and political challenges to certain aspects of the PPACA. During President Trump's administration, he signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the PPACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the PPACA. While Congress has not passed repeal legislation, the TCJA includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the PPACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Congress may consider other legislation to repeal or replace elements of the PPACA.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of the details regarding the implementation of the PPACA are yet to be determined, and at this time, the full effect that the PPACA would have on our business remains unclear. In particular, there is uncertainty surrounding the applicability of the biosimilars provisions under the PPACA to our product candidates. The FDA has issued several guidance documents, but no implementing regulations, on biosimilars. A number of biosimilar applications have been approved over the past few years. It is not certain that we will receive 12 years of biologics marketing exclusivity for any of our products. The regulations that are ultimately promulgated and their implementation are likely to have considerable impact on the way we conduct our business and may require us to change current strategies. A biosimilar is a biological product that is highly similar to an approved drug notwithstanding minor differences in clinically inactive components, and for which there are no clinically meaningful differences between the biological product and the approved drug in terms of the safety, purity, and potency of the product.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states have become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce ultimate demand for our products or put pressure on our product pricing, which could negatively affect our business, results of operations, financial condition and prospects.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, given recent federal and state government initiatives directed at lowering the total cost of healthcare, Congress and state legislatures will likely continue to focus on healthcare reform, the cost of prescription drugs and biologics </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the reform of the Medicare and Medicaid programs. While we cannot predict the full outcome of any such legislation, it may result in decreased reimbursement for drugs and biologics, which may further exacerbate industry-wide pressure to reduce prescription drug prices. This could harm our ability to generate revenues. Increases in importation or re-importation of pharmaceutical products from foreign countries into the United States could put competitive pressure on our ability to profitably price our products, which, in turn, could adversely affect our business, results of operations, financial condition and prospects. We might elect not to seek approval for or market our products in foreign jurisdictions in order to minimize the risk of re-importation, which could also reduce the revenue we generate from our product sales. It is also possible that other legislative proposals having similar effects will be adopted. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, regulatory authorities&#8217; assessment of the data and results required to demonstrate safety and efficacy can change over time and can be affected by many factors, such as the emergence of new information, including on other products, changing policies and agency funding, staffing and leadership. We cannot be sure whether future changes to the regulatory environment will be favorable or unfavorable to our business prospects. For example, average review times at the FDA for marketing approval applications can be affected by a variety of factors, including budget and funding levels and statutory, regulatory and policy changes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Catastrophic events, including global pandemics such as the COVID-19 pandemic, could materially adversely impact our business, results of operations and financial condition, including our clinical trials.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, and those of our CROs, Contract Manufacturing Organizations ("CMOs"), and other contractors, consultants and third parties could be subject to pandemics (including the COVID-19 pandemic), earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics and other natural or man-made disasters or business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could materially adversely affect our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidate. Our ability to obtain clinical supplies of our product candidate could be disrupted if the operations of these suppliers are affected by a man-made or natural disaster or other business interruption.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of regional epidemics or a global pandemic, such as the COVID-19 pandemic, have had and may continue to have an adverse effect on how we and our CROs, CMOs, and other contractors, consultants and third parties are operating our businesses and our operating results. Our operations have also been and may in the future be negatively affected by a range of external factors related to the pandemic that are not within our control, including the emergence and spread of more transmissible variants. The extent to which global pandemics, such as the COVID-19 pandemic, impact our financial condition or results of operations will depend on factors such as the duration and scope of the pandemic, as well as whether there is a material impact on the businesses of our CROs, CMOs, and other contractors, consultants and third parties. To the extent that the pandemic harms our business and results of operations, many of the other risks described in this Part I, Item 1A of this report may be heightened.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Geopolitical risks associated with Russia&#8217;s invasion of Ukraine could result in increased market volatility and uncertainty, which could negatively impact our business, financial condition, and results of operations.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The uncertain nature, scope, magnitude, and duration of hostilities stemming from Russia&#8217;s military invasion of Ukraine, including the potential effects of such hostilities as well as sanctions, embargoes, asset freezes, cyber-attacks and other actions taken in response to such hostilities on the world economy and markets, have disrupted global markets and contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic and other factors that affect our business and supply chain. There can be no certainty regarding the impacts stemming from the invasion, including the imposition of additional sanctions, embargoes, asset freezes or other economic or military measures resulting from the invasion. The impact of these developments, and additional events that may occur as a result, is currently unknown and could adversely affect our business, supply chain, suppliers and third party providers. It is not possible to predict the broader consequences of this conflict, which could include further sanctions, embargoes, regional instability, geopolitical shifts and adverse effects on macroeconomic conditions, the availability and cost of materials, supplies, labor, currency exchange rates and financial markets, all of which could negatively impact our business, financial condition and results of operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Volatile and significantly weakened global economic conditions have in the past and may in the future adversely affect our industry, business, and results of operations.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our overall performance depends in part on worldwide economic and geopolitical conditions. The United States and other key international economies have experienced significant economic and market downturns in the past, and are likely to experience additional cyclical downturns from time to time in which economic activity is impacted by falling demand for a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">variety of goods and services, restricted credit, poor liquidity, reduced corporate profitability, volatility in credit, equity, and foreign exchange markets, inflation, bankruptcies, and overall uncertainty with respect to the economy. These economic conditions can arise suddenly, as did the conditions associated with the COVID-19 pandemic, and the full impact of such conditions can be difficult to predict. In addition, geopolitical and domestic political developments, such as existing and potential trade wars and other events beyond our control, such as Russia's invasion of Ukraine, can increase levels of political and economic unpredictability globally and increase the volatility of global financial markets. All of these risks and conditions could materially adversely affect our future sales and operating results.</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_61"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect our intellectual property effectively, we may be unable to prevent third parties from using our technologies, which would impair our competitive advantage.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on patent protection as well as a combination of trademark, copyright and trade secret protection, and other contractual restrictions, to protect our proprietary technologies, all of which provide limited protection and may not adequately protect our rights or permit us to gain or keep any competitive advantage. We may not be successful in defending challenges made in connection with our patents and patent applications. If we fail to protect our intellectual property, we will be unable to prevent third parties from using our technologies and they will be able to compete more effectively against us.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our patents, we rely on contractual restrictions to protect our proprietary technology. We require our employees and third parties to sign confidentiality agreements and our employees are also required to sign agreements assigning to us all intellectual property arising from their work for us. Nevertheless, we cannot guarantee that these measures will be effective in protecting our intellectual property rights. Any failure to protect our intellectual property rights could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our currently pending or future patent applications may not result in issued patents and any patents issued to us may be challenged, invalidated or held unenforceable. Furthermore, we cannot be certain that we were the first to make the invention claimed in our issued patents or pending patent applications in the U.S., or that we were the first to file for protection of the inventions claimed in our foreign issued patents or pending patent applications. In addition, there are numerous recent changes to the patent laws and proposed changes to the rules of the U.S. Patent and Trademark Office ("USPTO"), which may have a significant impact on our ability to protect our technology and enforce our intellectual property rights. For example, in September 2011, the U.S. enacted sweeping changes to the U.S. patent system under the Leahy-Smith America Invents Act, including changes that transitioned the U.S. from a&#160;&#8220;first-to-invent&#8221;&#160;system to a&#160;&#8220;first-to-file&#8221;&#160;system and alter the processes for challenging issued patents. These changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. In addition, we may become subject to interference proceedings conducted in the patent and trademark offices of various countries to determine our entitlement to patents, and these proceedings may conclude that other patents or patent applications have priority over our patents or patent applications. It is also possible that a competitor may successfully challenge our patents through various proceedings and those challenges may result in the elimination or narrowing of our patents, and therefore reduce our patent protection. Accordingly, rights under any of our issued patents, patent applications or future patents may not provide us with commercially meaningful protection for our products or afford us a commercial advantage against our competitors or their competitive products or processes.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The patents issued to us may not be broad enough to provide any meaningful protection, one or more of our competitors may develop more effective technologies, designs or methods without infringing our intellectual property rights and one or more of our competitors may design around our proprietary technologies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are not able to protect our proprietary technology, trade secrets and&#160;know-how,&#160;our competitors may use our inventions to develop competing products. Our patents may not protect us against our competitors, and patent litigation is very expensive. We may not have sufficient cash available to pursue any patent litigation to its conclusion because we currently do not generate revenues other than licensing, milestone and royalty income.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot rely solely on our current patents to be successful. The standards that the USPTO and foreign patent offices use to grant patents, and the standards that U.S. and foreign courts use to interpret patents, are not the same, are not always applied predictably or uniformly and can change, particularly as new technologies develop. As such, the degree of patent protection obtained in the U.S. may differ substantially from that obtained in various foreign countries. In some instances, patents have been issued in the U.S. while substantially less or no protection has been obtained in Europe or other countries.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain of the level of protection, if any, that will be provided by our patents if they are challenged in court, where our competitors may raise defenses such as invalidity, unenforceability or possession of a valid license. In </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">addition, the type and extent of any patent claims that may be issued to us in the future are uncertain. Any patents that are issued may not contain claims that will permit us to stop competitors from using similar technology.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may challenge the validity of our patents and other intellectual property rights, resulting in costly litigation or other time-consuming and expensive proceedings, which could deprive us of valuable rights. If we become involved in any intellectual property litigation, interference or other judicial or administrative proceedings, we will incur substantial expenses and the attention of our technical and management personnel will be diverted. An adverse determination may subject us to significant liabilities or require us to seek licenses that may not be available from third parties on commercially favorable terms, if at all. Further, if such claims are proven valid, through litigation or otherwise, we may be required to pay substantial monetary damages, which can be tripled if the infringement is deemed willful, or be required to discontinue or significantly delay development, marketing, selling and licensing of the affected products and intellectual property rights.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors may have filed, and may in the future file, patent applications covering technology similar to ours. Any such patent application may have priority over our patent applications and could further require us to obtain rights to issued patents covering such technologies. There may be third-party patents, patent applications and other intellectual property relevant to our potential products that may block or compete with our potential products or processes. If another party has filed a U.S. patent application on inventions similar to ours, we may have to participate in an interference proceeding declared by the USPTO to determine priority of invention in the U.S. The costs of these proceedings could be substantial, and it is possible that such efforts would be unsuccessful, resulting in a loss of our U.S. patent position with respect to such inventions. In addition, we cannot assure you that we would prevail in any of these suits or that the damages or other remedies that we are ordered to pay, if any, would not be substantial. Claims of intellectual property infringement may require us to enter into royalty or license agreements with third parties that may not be available on acceptable terms, if at all. We may also be subject to injunctions against the further development and use of our technology, which could materially adversely affect our business, prospects and financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could materially adversely affect our ability to raise the funds necessary to continue our operations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain rights that we in-license from third-parties are not within our control, and we may be negatively impacted if we lose those rights.  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We license some of the technology that is necessary for our products and services from third parties. In connection with such&#160;in-licenses,&#160;we may agree to pay the licensor royalties based on sales of our products, which become a cost of product revenues and impact the margins on our products and services. We may need to&#160;in-license&#160;other technologies in the future to commercialize on our products and services. We may also need to negotiate licenses after launching our products and services. Our business may suffer if any such licenses terminate, if the licensors fail to abide by the terms of the license, if the licensed patents or other rights are found to be invalid, or if we are unable to enter into necessary licenses on acceptable terms.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_64"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Common Stock</span></div><div style="text-indent:4.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to use our net operating loss carryforwards and certain other tax attributes is limited by Sections 382 and 383 of the Internal Revenue Code. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net operating loss carryforwards allow companies to use past year net operating losses to offset against future years&#8217; profits, if any, to reduce future tax liabilities. Sections 382 and 383 of the Internal Revenue Code of 1986 limit a corporation&#8217;s ability to utilize its net operating loss carryforwards and certain other tax attributes (including research credits) to offset any future taxable income or tax if the corporation experiences a cumulative ownership change of more than 50% over any rolling three year period. State net operating loss carryforwards (and certain other tax attributes) may be similarly limited. An ownership change can therefore result in significantly greater tax liabilities than a corporation would incur in the absence of such a change and any increased liabilities could adversely affect the corporation&#8217;s business, results of operations, financial condition and cash flow.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. federal income tax reform could adversely affect us.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2017, President Trump signed into law the TCJA that significantly reforms the Internal Revenue Code of 1986, as amended. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest, allows for the expensing of capital expenditures, and puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system. We do not expect tax reform to have a material impact to our projection of minimal cash taxes or to our net operating losses. Further, any eligibility we may have or may someday have for tax credits associated with the qualified clinical testing expenses arising out of the development of orphan drugs will be reduced to 25% as a result of the TCJA; thus, our net future taxable income may be affected. We continue to examine the impact this tax reform legislation may have on our business. The impact of this tax reform on holders of our common stock is uncertain and could be adverse. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The rights of the holders of our common stock may be impaired by the potential issuance of preferred stock.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation gives our board of directors the right to create one or more new series of preferred stock. As a result, the board of directors may, without stockholder approval, issue preferred stock with voting, dividend, conversion, liquidation or other rights that could adversely affect the voting power and equity interests of the holders of our common stock. Preferred stock, which could be issued with the right to more than one vote per share, could be used to discourage, delay or prevent a change of control of our company, which could materially adversely affect the price of our common stock. Without the consent of the holders of the outstanding shares of our Series A Convertible Preferred Stock, we may not adversely alter or change the rights of the holders of the Series A Convertible Preferred Stock or increase the number of authorized shares of Series A Convertible Preferred Stock, create a class of stock that is senior to or on parity with the Series A Convertible Preferred Stock, amend our certificate of incorporation in breach of these provisions or agree to any of the foregoing.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock price may be volatile and could fluctuate widely in price, which could result in substantial losses for investors.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market price of our common stock historically has been, and we expect will continue to be, subject to significant fluctuations over short periods of time. For example, during the year ended December&#160;31, 2022, the closing price of our common stock ranged from a low of $1.17 to a high of $7.25. These fluctuations may be due to various factors, many of which are beyond our control, including:</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">technological innovations or new products and services introduced by us or our competitors;</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trial results relating to our tests or those of our competitors;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements or press releases relating to the industry or to our own business or prospects;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">coverage and reimbursement decisions by third party payors, such as Medicare and other managed care organizations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulation and oversight of our product candidates and services, including by the FDA, Centers for Medicare &amp; Medicaid Services and comparable foreign agencies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intellectual property disputes;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">additions or departures of key personnel;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">sales of our common stock;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to integrate operations, technology, products and services;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to execute our business plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">operating results below expectations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of any strategic relationship;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">industry developments;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">economic and other external factors; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">catastrophic weather and/or global disease outbreaks, such as the recent COVID-19 pandemic; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">period-to-period fluctuations in our financial results.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, market fluctuations, as well as general political and economic conditions, could materially adversely affect the market price of our securities. Because we are a development stage company with no revenue from operations to date, other than licensing, milestone and royalty income, you should consider any one of these factors to be material. Our stock price may fluctuate widely as a result of any of the foregoing.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have not paid dividends on our common stock in the past and do not expect to pay dividends on our common stock for the foreseeable future. Any return on investment may be limited to the value of our common stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never paid any cash dividends on our common stock. We expect that any income received from operations will be devoted to our future operations and growth. We do not expect to pay cash dividends on our common stock in the near future. Payment of dividends would depend upon our profitability at the time, cash available for those dividends, and other factors that our board of directors may consider relevant. If we do not pay dividends, our common stock may be less valuable because a return on an investor&#8217;s investment will only occur if our stock price appreciates. In addition, the terms of the Series A Convertible Preferred Stock prohibit us from paying dividends to the holders of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid. Investors in our common stock should not rely on an investment in our company if they require dividend income.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they adversely change their recommendations regarding our stock, our stock price and trading volume could decline.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delaware law and our corporate charter and bylaws contain anti-takeover provisions that could delay or discourage takeover attempts that stockholders may consider favorable.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and bylaws may have the effect of delaying or preventing a change of control of our company or changes in our management. For example, our board of directors has the authority to issue up to 20,000,000 shares of preferred stock in one or more series and to fix the powers, preferences and rights of each series without stockholder approval. The ability to issue preferred stock could discourage unsolicited acquisition proposals or make it more difficult for a third party to gain control of our company, or otherwise could materially adversely affect the market price of our common stock.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware. This provision may prohibit or restrict large stockholders, in particular those owning 15% or more of our outstanding voting stock, from merging or combining with us, which could discourage potential takeover attempts, reduce the price that investors may be willing to pay for shares of our common stock in the future and result in our market price being lower than it would without these provisions.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A sale of a substantial number of shares of our common stock may cause the price of our common stock to decline and may impair our ability to raise capital in the future.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finance transactions resulting in a large amount of newly issued shares that become readily tradable, or other events that cause current stockholders to sell shares, could place downward pressure on the trading price of our common stock. In addition, the lack of a robust resale market may require a stockholder who desires to sell a large number of shares of common stock to sell the shares in increments over time to mitigate any adverse impact of the sales on the market price of our stock.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our stockholders sell, or the market perceives that our stockholders may sell for various reasons, including the ending of restriction on resale, substantial amounts of our common stock in the public market, including shares issued upon the exercise of outstanding options or warrants, the market price of our common stock could fall. Sales of a substantial number of shares of our common stock may make it more difficult for us to sell equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to stockholder litigation, thereby diverting our resources, which could materially adversely affect our profitability and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The market for our common stock is characterized by significant price volatility, and we expect that our share price will continue to be at least as volatile for the indefinite future. In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price for its securities. In addition, stockholders may bring actions against companies relating to past transactions or other matters. Any such actions could give rise to substantial damages and thereby materially adversely affect our financial position, liquidity or results of operations. Even if an action is not resolved against us, the uncertainty and expense associated with stockholder actions could materially adversely affect our business, prospects and financial condition. Litigation can be costly, time-consuming and disruptive to business operations. The defense of lawsuits could also result in diversion of our management&#8217;s time and attention away from business operations, which could harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the continued minimum closing bid requirements of the Nasdaq or other requirements for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not maintain compliance with The Nasdaq Capital Market ("Nasdaq") requirements for continued listing or fail to comply with other requirements for continued listing, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. A delisting of our common stock from Nasdaq could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, employees and fewer business development opportunities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_67"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we discover material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with the rules under the Sarbanes-Oxley Act, related to disclosure controls and procedures, or if we discover additional material weaknesses and other deficiencies in our internal control and accounting procedures, our stock price could decline significantly and raising capital could be more difficult. Moreover, effective internal controls are necessary for us to produce reliable financial reports and are important in helping prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock could drop significantly. We previously identified a material weakness in our internal control over financial reporting, which was subsequently remedied. We cannot be certain that additional material weaknesses or significant deficiencies in our internal controls will not be discovered in the future.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We incur significant costs as a result of operating as a public company and our management expects to continue to devote substantial time to public company compliance programs.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses due to our compliance with regulations and disclosure obligations applicable to us, including compliance with the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, as well as rules implemented by the SEC, and the Nasdaq. The SEC and other regulators have continued to adopt new rules and regulations and make additional changes to existing regulations that require our compliance. For example, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (&#8220;Dodd-Frank Act&#8221;) was enacted. There is significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that have required the SEC to adopt additional rules and regulations in these areas. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact (in ways we cannot currently anticipate) the manner in which we operate our business. Our management and other personnel devote a substantial amount of time to these compliance programs and monitoring of public company reporting obligations and, as a result of the new corporate governance and executive </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compensation related rules, regulations and guidelines prompted by the Dodd-Frank Act and further regulations and disclosure obligations expected in the future, we will likely need to devote additional time and costs to comply with such compliance programs and rules. These rules and regulations will continue to cause us to incur significant legal and financial compliance costs and will make some activities more time-consuming and costly.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_70"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.  UNRESOLVED STAFF COMMENTS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_73"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.  PROPERTIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently lease laboratory and office space for our headquarters in San Diego, California under a lease agreement, as amended from time to time, that expires in February 2027. We believe that our facilities are adequate for our current and near-term needs.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_76"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.  LEGAL PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm our business. As of the date of this report, management believes that there are no claims against us, which it believes will result in a material adverse effect on our business or financial condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.  MINE SAFETY DISCLOSURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_82"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_85"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.  MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock has traded on The Nasdaq Capital Market under the symbol &#8220;CRDF&#8221; since May 8, 2020, and was previously traded as &#8220;TROV&#8221; from May 30, 2012 to May 7, 2020.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_88"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number of Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;23, 2023, we had approximately 58 stockholders of record of our common stock.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_91"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividend Policy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Historically, we have not paid any dividends to the holders of shares of our common stock and we do not expect to pay any such dividends in the foreseeable future as we expect to retain our future earnings for use in the operation and expansion of our business. Pursuant to the terms of our outstanding shares of Series A Convertible Preferred Stock, dividends cannot be paid to the holders of shares of our common stock so long as any dividends due on the Series A Convertible Preferred Stock remain unpaid.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities Authorized for Issuance under Equity Compensation Plans</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 12 of Part III of this Annual Report on Form 10-K for information about our equity compensation plans which is incorporated by reference herein.</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_97"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.  [Reserved]</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_100"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.  MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company Overview</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company, headquartered in San Diego, CA, leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard of care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard of care alone. Our common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Company Updates</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 2, 2023 we announced the appointment of Fairooz Kabbinavar, M.D., FACP, as Chief Medical Officer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 11, 2022 we announced the appointment of Tod Smeal, Ph.D., as Chief Scientific Officer and Charles Monahan, R.Ph., as Senior Vice President, Regulatory Affairs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accumulated deficit through December&#160;31, 2022 is $298.1 million.&#160;To date, we have generated minimal revenues and expect to incur additional losses to perform further research and development activities.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our drug development efforts are in their early stages, and we cannot make estimates of the costs or the time that our development efforts will take to complete, or the timing and amount of revenues related to the sale of our drugs.&#160;The risk of completion of any program is high because of the many uncertainties involved in developing new drug candidates to market, including the long duration of clinical testing, the specific performance of proposed products under stringent clinical trial protocols, extended regulatory approval and review cycles, our ability to raise additional capital, the nature and timing of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">research and development expenses, and competing technologies being developed by organizations with significantly greater resources.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:29.25pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_106"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Estimate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our accounting policies are described in Part II, Item 8. Financial Statements&#8212;Note 2 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation and Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. We believe that the following discussion represents our critical accounting estimates.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We accrue and expense research and development expenditures as incurred, which include costs related to clinical trial activities. We accrue costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations ("CROs"), professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). We accrue costs based on estimated work completed in accordance with agreements established with our service providers. We determine the estimated costs through discussions with internal personnel and external service providers as to the progress or stage of completion of the services and the agreed-upon fee to be paid for such services. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time. Due to the nature of estimates, we cannot assure you that we will not make changes to our estimates in the future as we become aware of additional information about the status or conduct of our clinical trial activities.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_115"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_118"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Years Ended December 31, 2022 and 2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our total revenues were $386,000 and $359,000 for the years ended December&#160;31, 2022 and 2021, respectively. Revenues are from our annual minimum or sales-based royalties on other intellectual property licenses, unrelated to onvansertib. Revenue recognition of the royalty depends on the timing and overall sales activities of the licensees.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials, outside services, and lab supplies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,556&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,382&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,485&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">519&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,107&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,376&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,731&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased by $9.7 million to $27.1 million for the year ended December&#160;31, 2022 from $17.4 million for the year ended December&#160;31, 2021. The overall increase in expenses was primarily related to CMC, clinical pharmacology and for studies to support the development of our lead drug candidate, onvansertib. Salaries and staff costs increased primarily due to additional hires in senior management and our clinical operations team (research and development average headcount grew by 93% over the comparative period). The increase in stock-based compensation is primarily due to additional stock option grants to employees granted subsequent to the prior period.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Salaries and staff costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside services and professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Facilities and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,165&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">469&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total selling, general and administrative</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,181&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,838&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,343&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Selling, general and administrative expenses increased by $1.3 million to $13.2 million for the year ended December&#160;31, 2022, from $11.8 million for the year ended December&#160;31, 2021. Salaries and staff costs increased due to merit increases and higher headcount (average headcount grew by 30% over the comparative period). The increase in stock-based compensation is primarily due to additional stock option grants to employees granted subsequent to the prior period. Facilities and other costs increased due to higher insurance costs and the amending of our operating lease. The decrease in outside services is primarily related to strategic valuation consulting related to our lead drug candidate, onvansertib performed during the prior period.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss and per share amounts were as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:47.651%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.493%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase/(Decrease)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,704)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,291)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,728)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,315)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.89)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,030&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,570&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $10.4 million in net loss attributable to common shareholders was primarily the result of an increase in operating expenses for the year ended December&#160;31, 2022 compared to the same period in the prior year. The $0.16 increase in basic and diluted net loss per share was impacted by the increase in net loss attributable to shareholders and was partially offset by the increase in weighted average shares outstanding resulting primarily from the issuance of approximately 2.7 million shares of common stock primarily from the conversion of Series E Convertible Preferred Stock during the twelve months ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had $16.3 million in cash and cash equivalents and $88.9 million in short-term investments. Net cash used in operating activities for the year ended December&#160;31, 2022 was $33.8 million, compared to $23.0 million for the year ended December&#160;31, 2021. Our use of cash was primarily a result of the net loss of $38.7 million for the year ended December&#160;31, 2022, adjusted for non-cash items mainly related to stock-based compensation of $4.3 million, and amortization of premiums on short-term investments of $0.6 million. The net change in our operating assets and liabilities was $0.4 million increasing cash used in operations.&#160;At our current and anticipated level of operating loss, we expect to continue to incur an operating cash outflow for the next several years.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities was $38.1 million primarily related to sales and maturities in excess of purchases of marketable securities, partially offset by purchases of capital equipment during the year ended December&#160;31, 2022, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to net cash used in investing activities of $131.4 million for net purchases of marketable securities during the same period in 2021. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities was $0.1 million from the exercise of stock options during the year ended December&#160;31, 2022, compared to $35.5 million of proceeds from the sale of common stock and proceeds from warrant exercises for the same period in 2021. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022 and 2021, we had working capital of $103.5 million and $139.6 million, respectively. The decrease in working capital is primarily due to the net loss partially offset by the increase in cash and cash equivalents from financing activities during the year ended December&#160;31, 2022.&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and have negative operating cash flows. As of December&#160;31, 2022, we had $105.3 million in cash, cash equivalents and short-term investments and we believe we have sufficient cash to meet our funding requirements for at least the next 12 months following the issuance date of these financial statements. Based on our current projections we expect that our capital resources are sufficient to fund our operations into 2025.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, we expect to continue to incur losses and require additional capital to further advance our clinical trial programs and support our other operations. We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we can raise additional funds by issuing equity securities, our stockholders may experience additional dilution. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our working capital requirements will depend upon numerous factors including but not limited to the nature, cost and timing of our research and development programs.&#160;To date, our sources of cash have been primarily limited to the sale of equity securities.&#160;We cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that we raise additional funds by issuing equity securities, our stockholders may experience significant dilution. If we are unable to raise additional capital when required or on acceptable terms, we may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more product candidates, all of which may have a material adverse impact on our operations. We may also be required to (i)&#160;seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; or (ii)&#160;relinquish or otherwise dispose of rights to technologies, product candidates or products that we would otherwise seek to develop or commercialize ourselves on unfavorable terms. We are evaluating all options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen our liquidity position, which may include the following: (1) Raising capital through public and private equity offerings; (2) Introducing operation and business development initiatives to bring in new revenue streams; (3) Reducing operating costs by identifying internal synergies; and (4) Engaging in strategic partnerships. We continually assess our spending plans to effectively and efficiently address our liquidity needs.</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_127"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.  FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial information required by this Item is attached hereto at the end of this report beginning on page F-1 and is hereby incorporated by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_133"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_136"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.  CONTROLS AND PROCEDURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disclosure Controls and Procedures</span></div><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive officer and principal financial officer evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2022.&#160;The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules&#160;13a-15(e)&#160;and 15d-15(e)&#160;under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities and Exchange Commission&#8217;s rules&#160;and forms.&#160;Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.&#160;Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Based on that evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="text-indent:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting as such term is defined in Exchange Act Rule&#160;13a-15(f).&#160;Internal control over financial reporting is a process designed under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, our management concluded that, as of December&#160;31, 2022, our internal control over financial reporting was effective based on those criteria.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in our internal control over financial reporting during the quarter ended&#160;December&#160;31, 2022,&#160;that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_139"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.  OTHER INFORMATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:45pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_2442"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_142"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div style="text-align:center"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_145"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.&#160; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in our Definitive Proxy Statement to be filed with the Securities and Exchange Commission in connection with the Annual Meeting of Stockholders to be held in 2023 (the &#8220;2023 Proxy Statement&#8221;), under the heading &#8220;Election of Directors.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_148"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.  EXECUTIVE COMPENSATION</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement under the heading &#8220;Executive Compensation.&#8221;</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_151"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.   SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement under the headings &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.   CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement under the headings &#8220;Family Relationships and other Arrangements.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_157"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.  PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is incorporated by reference from the information contained in the 2023 Proxy Statement under the heading &#8220;Proposal 2: Ratification of the Appointment of Our Independent Registered Public Accounting Firm for Fiscal Year Ending December 31, 2023.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_238"></div><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.&#160; EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description&#160;of&#160;Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(a)(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Financial Statements</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The financial statements required by this item are submitted in a separate section beginning on page&#160;F-1 of this Annual Report on Form 10-K.</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(b) Exhibits</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d1.htm">3.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Certificate of Incorporation of Trovagene,&#160;Inc. (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Form&#160;10-12G filed on November&#160;25, 2011).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912019409/a12-6668_1def14a.htm">3.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Trovagene,&#160;Inc. (incorporated by reference to Appendix B to the Company&#8217;s Proxy Statement on Schedule 14A filed on March&#160;20, 2012).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex3d2.htm">3.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By-Laws of Trovagene,&#160;Inc. (incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s Form&#160;10-12G filed on November&#160;25, 2011).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518181824/d598311dex31.htm">3.4</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment of Amended and Restated Certificate of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on June 1, 2018).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex31.htm">3.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 12, 2018).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519021144/d692543dex31.htm">3.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 29, 2019).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519024055/d647432dex31.htm">3.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendment to Certificate of Designation of Preferences, Rights and Limitations of Series C Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on January 31, 2019).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312519044909/d711195dex31.htm">3.8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on February 20, 2019).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020006555/trov050620ex31.htm">3.9</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Trovagene, Inc. (incorporated by reference to Exhibit 3.1 to the Company&#8217;s Form 8-K filed on May 6, 2020).    </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/ex31crdf051320.htm">3.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series D Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 13, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/a31crdf061620.htm">3.11</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Designation of Preferences, Rights and Limitations of Series E Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465911066179/a11-28276_1ex4d1.htm">4.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Common Stock Certificate of Trovagene,&#160;Inc. (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Form&#160;10-12G filed on November&#160;25, 2011).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000103883804000631/ex43form8k070204.txt">4.2</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2004 Stock Option Plan (incorporated by reference to Exhibit&#160;4.3 to the Company&#8217;s Current Report on Form&#160;8-K filed on July&#160;19, 2004)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465914049723/a14-16399_1ex4d2.htm">4.3</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit&#160;4.2 to the Company&#8217;s Current Report on Form 8-K filed on July 1, 2014).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465914052781/a14-17541_1def14a.htm">4.4</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trovagene, Inc. 2014 Equity Incentive Plan (incorporated by reference to Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed on July 23, 2014).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465916134373/a16-15453_1ex4d1.htm">4.5</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to Form 8-K filed on July 26, 2016).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000119312518190679/d601889dex41.htm">4.6</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Warrant to Purchase Common Stock (Incorporated by reference to Exhibit 4.1 to Form 8-K filed on June 12, 2018).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020002424/exhibit416q42019.htm">4.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Incorporated by reference to Exhibit 4.16 to Form 10-K filed on February 27, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021007919/a2021proxy.htm">4.8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cardiff Oncology, Inc. 2021 Omnibus Equity Incentive Plan (incorporated by reference to Appendix A to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed on April 28, 2021).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912009881/a11-28276_4ex10d3.htm">10.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Summary of Terms of Lease Agreement dated as of October&#160;28, 2009 between Trovagene,&#160;Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Form&#160;10-12G/A filed on February&#160;15, 2012).</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912009881/a11-28276_4ex10d4.htm">10.2</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of First Amendment to Standard Industrial Net Lease dated September&#160;28, 2011 between Trovagene,&#160;Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Form&#160;10-12G/A filed on February&#160;15, 2012).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465912009881/a11-28276_4ex10d5.htm">10.3</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Second Amendment to Standard Industrial Net Lease dated October&#160;2011 between Trovagene,&#160;Inc. and BMR-Sorrento West LLC (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Form&#160;10-12G/A filed on February&#160;15, 2012).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915019213/a15-1864_1ex10d6.htm">10.4</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Third Amendment to Standard Industrial Net Lease dated October&#160;22, 2012 between Trovagene,&#160;Inc. and BMR-Sorrento West, LP. (incorporated by reference to Exhibit 10.6 to the Company&#8217;s Annual Report on Form 10-K filed on March 12, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915019213/a15-1864_1ex10d7.htm">10.5</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Fourth Amendment to Standard Industrial Net Lease dated December&#160;2, 2013 between Trovagene,&#160;Inc. and BMR-Coast 9 LP. (incorporated by reference to Exhibit 10.7 to the Company&#8217;s Annual Report on Form 10-K filed on March 12, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915019213/a15-1864_1ex10d8.htm">10.6</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Fifth Amendment to Standard Industrial Net Lease dated May&#160;14, 2014 between Trovagene,&#160;Inc. and BMR-Coast 9 LP. (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Annual Report on Form 10-K filed on March 12, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915058213/a15-12061_1ex10d1.htm">10.7</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sixth Amendment to Standard Industrial Net Lease dated June 11, 2015 between Trovagene,&#160;Inc. and BMR-Coast 9 LP (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed on August 10, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000110465915084905/a15-25019_1ex10d1.htm">10.8</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Indemnification Agreement to be entered into between the Company and its directors and executive officers (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Current Report on Form 8-K filed on December 15, 2015).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/a109ex022521.htm">10.9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Amended and Restated Employment Agreement, dated February 22, 2021, by and between the Company and Mark Erlander (incorporated by reference to Exhibit 10.9 to Form 10-K filed on February 25, 2021).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828016018502/trov-0630x16exhibit102.htm">10.10</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form&#160;of Seventh Amendment to Standard Industrial Net Lease dated April 4, 2016 between Trovagene,&#160;Inc. and BMR-Coast 9 LP (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed on August 4, 2016). </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828017002601/exhibit1034q42016.htm">10.11</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License Agreement dated as of March 13, 2017 between Nerviano Medical Sciences S.r.l. and Trovagene, Inc. (incorporated by reference to Exhibit 10.34 to the Company&#8217;s Annual Report on Form 10-K filed on March 15, 2017).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/ex101crdf053220.htm">10.12</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock and Warrant Subscription Agreement entered into as of May 8, 2020 by and between Cardiff Oncology, Inc. and POC Capital, LLC. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 13, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020007644/ex102crdf051320.htm">10.13</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.2 to Form 8-K filed on May 13, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020008004/a101crdf51920.htm">10.14</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on May 19, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828020009534/a101crdf061620.htm">10.15</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Securities Purchase Agreement (incorporated by reference to Exhibit 10.1 to Form 8-K filed on June 16, 2020).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021003277/a1016ex022521.htm">10.16</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Employment Agreement, dated February 22, 2021 by and between the Company and Vicki Kelemen (incorporated by reference to Exhibit 10.16 to Form 10-K filed on February 25, 2021).</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021013733/a101ex071221.htm">10.17</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated July 12, 2021 by and between James Levine and Cardiff Oncology, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on July 12,2021).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021023776/a101ex111821.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828021023776/a101ex111821.htm">8</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Securities Purchase Agreement, dated November 17, 2021 (incorporated by reference to Exhibit 10.1 to Form 8-K filed on November 18, 2021).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/a101ex020223.htm">10.1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1213037/000162828023002037/a101ex020223.htm">9</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">+</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employment Agreement, dated January 30, 2023 by and between Dr. Fairooz Kabbinavar and Cardiff Oncology, Inc. (incorporated by reference to Exhibit 10.1 to Form 8-K filed on February 2,2023).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a231exq42022.htm">23.1</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of BDO USA, LLP.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_244">24</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Power of Attorney (included on signature page hereto).</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a311exq42022.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer required under Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a312exq42022.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer required under Rule&#160;13a-14(a)/15d-14(a)&#160;under the Exchange Act.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a321exq42022.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Executive Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a322exq42022.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Schema.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Calculation Linkbase.</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div style="-sec-extract:summary"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:89.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Labels Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Presentation Linkbase.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Taxonomy Extension Definition Linkbase.</span></td></tr></table></div><div style="margin-bottom:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:237.00pt"><tr><td style="width:1.0pt"></td><td style="width:235.00pt"></td><td style="width:1.0pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Indicates a management contract or compensatory plan or arrangement.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;The SEC has granted confidential treatment with respect to certain portions of this exhibit. Omitted portions have been filed separately with the SEC.</span></div><div style="text-align:center"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_241"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.&#160; FORM 10-K SUMMARY</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_244"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARDIFF ONCOLOGY, INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</span></div></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Mark Erlander as his or her attorney-in-fact, with full power of substitution and resubstitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:26.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.853%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.983%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">SIGNATURE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">TITLE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">DATE</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark Erlander</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James Levine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Rodney S. Markin</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rodney S. Markin</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ James O. Armitage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James O. Armitage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mani Mohindru</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mani Mohindru</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gary W. Pace</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gary W. Pace</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Renee Tannenbaum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Renee Tannenbaum</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ L&#226;le White</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3/2/2023</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">L&#226;le White</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_250"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CARDIFF ONCOLOGY, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:90.847%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.953%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_253">Report of Independent Registered Public Accounting Firm (BDO USA, LLP; San Diego, CA; PCAOB ID#</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTAvZnJhZzo5MTQzMjI4M2I0MzI0ODBlOWMwMTE5ODBlZDkxZTg5ZC90YWJsZTo5MDUzMjBlMmE2YWM0OWJlOGYxY2M3NGM1MjkzNDExOS90YWJsZXJhbmdlOjkwNTMyMGUyYTZhYzQ5YmU4ZjFjYzc0YzUyOTM0MTE5XzAtMC0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo5YWY5MGE1OTAxZDg0ZjFlODZjYmJlOTQ4ZGE3MDcwOF85OQ_dbd71f31-cf66-4907-a76f-c4516108583d">243</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_253">)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_253">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_256">Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_256">4</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_259">Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_259">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_262">Statements of Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_262">6</a></span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_265">Statements of Stockholders&#8217; Equity </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_265">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_268">Statements of Cash Flows </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_268">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_271">Notes to Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">F-<a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_271">9</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-1</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_253"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Report of Independent Registered Public Accounting Firm&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board of Directors and Stockholders</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">San Diego, California&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements </span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying balance sheets of Cardiff Oncology, Inc. (the &#8220;Company&#8221;) as of December 31, 2022 and 2021, the related statements of operations, comprehensive loss, stockholders&#8217; equity, and cash flows for the years then ended, and related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that was communicated or required to be communicated to the audit committee of the Company&#8217;s board of directors and that: (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued clinical trial expenses</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As disclosed in Note 2 to the financial statements, the Company expenses research and development expenditures as incurred, which include costs relating to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services performed and costs incurred that have not been invoiced by the service providers. The Company&#8217;s clinical trial accrual balance at December 31, 2022 is $2.3 million, and the Company&#8217;s related 2022 clinical trial expenses are included in research and development expense of $27.1 million for the year ended December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We identified accrued clinical trial expenses as a critical audit matter. When estimating clinical trial expenses, the Company considers several factors including clinical trial budgets, contract amendments and the progress toward completion. These </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">factors are our principal considerations due to the level of management estimation involved. Auditing these elements involves especially challenging auditor judgment due to the nature and extent of audit effort required to address these matters.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The primary procedures we performed to address the critical audit matter included:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Testing management&#8217;s estimation of accrued clinical trial expenses by (i) obtaining and inspecting significant agreements, clinical trial budgets, and contract amendments, (ii) evaluating the Company&#8217;s documentation of trial progress and status (including consideration of patient enrollment and milestones achieved), (iii) confirming clinical trial expenses incurred, cash paid by the Company, and any unbilled  amounts directly with third party service providers, and (iv) agreeing clinical trial accruals to the terms within the clinical trial agreements, budgets, and amendments.  </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Testing the completeness of the Company&#8217;s clinical trial accruals by (i) inspecting board of directors&#8217; minutes to identify clinical trials, (ii) evaluating publicly available information (such as press releases, investor presentations and public databases that track clinical trials) which identify and discuss the status of clinical trials, (iii) inquiring of clinical staff outside of finance to gain an understanding of the status of significant on-going clinical trials, and (iv) testing a sample of  payments subsequent to  year end to evaluate the completeness of clinical trial accruals. </span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTMvZnJhZzplYmYwNjUzNDBiMjQ0NTBjYjRiYjZiZTgxZmI5NjhhOS90ZXh0cmVnaW9uOmViZjA2NTM0MGIyNDQ1MGNiNGJiNmJlODFmYjk2OGE5XzU2MDQ_92e0c84f-83f1-4c74-b2dc-541b0d0c9763">BDO USA, LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2007.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTMvZnJhZzplYmYwNjUzNDBiMjQ0NTBjYjRiYjZiZTgxZmI5NjhhOS90ZXh0cmVnaW9uOmViZjA2NTM0MGIyNDQ1MGNiNGJiNmJlODFmYjk2OGE5XzU2MDY_9ad06207-34a0-4f9b-86c7-eeaea379aa29">San Diego, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;2, 2023 </span></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-3</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_256"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except par value)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMtMS0xLTEtNDAzNjg_2aefec70-0bd2-4b08-9bee-430da5f308e0">16,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMtMy0xLTEtNDAzNjg_5dcb1884-fc42-41c4-ab9a-3dc6a1ec0425">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzQtMS0xLTEtNDAzNjg_36c356d4-b9da-4e70-9ddf-4f5a605b1acb">88,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzQtMy0xLTEtNDAzNjg_444c07f0-1878-4fff-b964-470a20dce3df">128,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzUtMS0xLTEtNDAzNjg_4e9fce90-700b-4484-888b-7085c6802d26">771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzUtMy0xLTEtNDAzNjg_7bc28ac9-27bf-4d06-841c-73c483c1b88f">535</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzYtMS0xLTEtNDAzNjg_1fb9dda4-9f15-47ce-8280-ce1b0d679f81">5,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzYtMy0xLTEtNDAzNjg_8b017ffa-b589-40c6-8760-3adced7564df">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzctMS0xLTEtNDAzNjg_a9a3d366-d265-43fa-ab53-f6b3328649d8">111,284</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzctMy0xLTEtNDAzNjg_b35c15c5-452e-4ed1-aa50-89b03cccb23e">146,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzgtMS0xLTEtNDAzNjg_6f0d3584-a17c-402e-9b7a-d9cedc0e3519">1,269</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzgtMy0xLTEtNDAzNjg_bd618e72-8863-4a00-b166-efe774e9d9ad">382</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzktMS0xLTEtNDAzNjg_4635cfff-9832-4618-a260-1b039c2341ae">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzktMy0xLTEtNDAzNjg_7847c475-231d-4869-bec4-bae06dcb7f12">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzEwLTEtMS0xLTQwMzY4_0824752e-5d78-44de-8cc5-c8ba59459b75">1,387</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzEwLTMtMS0xLTQwMzY4_2b8b9c04-ee88-4b9f-b758-dee3c0c67a54">239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzExLTEtMS0xLTQwMzY4_a18132a5-1acf-496a-a50f-3ebec99d258c">116,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzExLTMtMS0xLTQwMzY4_67a45c91-de80-4bd3-9600-7b0b6074adad">149,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities and Stockholders&#8217; Equity</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE1LTEtMS0xLTQwMzY4_06183b43-d1e4-4290-8445-89217c16b58e">1,956</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE1LTMtMS0xLTQwMzY4_2c86c5a5-6dac-4875-9c8f-1f0d26f4495b">1,439</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE2LTEtMS0xLTQwMzY4_65e31125-8f5a-4c96-b2d6-5dfba20b1f06">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE2LTMtMS0xLTQwMzY4_17179d24-a78d-4f88-b406-2207b8de24e2">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE4LTEtMS0xLTQwMzY4_d5c270c8-ab44-4d14-8682-6c382b675260">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE4LTMtMS0xLTQwMzY4_6574778d-6dcb-4ddd-a7b6-c7a744cea5d7">551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE5LTEtMS0xLTQwMzY4_277e0029-f10c-4fa7-8896-5ba6e167e4d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE5LTMtMS0xLTQwMzY4_c37213c1-adc6-4987-912c-3e9ceb6f8466">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzIxLTEtMS0xLTQwMzY4_1d8a2f49-9bcf-4173-9331-56c5dee760c5">7,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzIxLTMtMS0xLTQwMzY4_badc4fcc-1286-4ec9-aaf7-769d226553fe">6,559</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI0LTEtMS0xLTQwMzY4_f43bdd90-6b87-4cf2-8c74-ac1fd98ad4f1">2,040</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI0LTMtMS0xLTQwMzY4_3f1a858d-b8b7-40ae-a5a9-ae64e2296380">2,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI3LTEtMS0xLTQwMzY4_557eec44-53da-4959-8071-ad679193bdc1">9,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI3LTMtMS0xLTQwMzY4_c47ae41a-d563-4856-b2a3-ac4b3b5d43d7">9,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 10)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI5LTEtMS0xLTQwMzY4_0ab2ddd8-5af8-4900-8435-7ea384126019"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI5LTMtMS0xLTQwMzY4_af275501-d2c5-4af3-b4ae-0e6f5e1d7598"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfNTQ5NzU1ODE0MTcx_3b100c2d-6d5e-49a7-b35b-d9c8bc1da035"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfNTQ5NzU1ODE0MTcx_f984be61-4d73-4f3e-aad7-93f83a7901ea">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyODA1MA_8a3469dc-094a-4d8c-96eb-d8feea3d248a"><ix:nonFraction unitRef="shares" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyODA1MA_94cc66e9-cb71-4200-a253-c58e218e9e4e">20,000</ix:nonFraction></ix:nonFraction> shares authorized; Series A Convertible Preferred Stock liquidation preference $<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyNzk2Mg_43456bb7-6072-4f9c-8e3d-53251f8a1456">1,044</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyODAzOA_32b710a1-c113-4aff-b5c9-33be2c5ae657">1,020</ix:nonFraction> at  December&#160;31, 2022 and December&#160;31, 2021, respectively; (Note 5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTEtMS0xLTQwMzY4_95b05527-e002-4b4b-a7e1-c0255dc4ef94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTMtMS0xLTQwMzY4_3abf2312-dfc2-4ba5-ab1c-1593f750acff">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMTg_3b999295-67ac-4864-b7ca-f7f7c9f6f022"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMTg_c91df306-41da-4272-b308-a64677019d3f">0.0001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMzI_06a1ac55-84e7-4020-b58b-3d754a17ed9a"><ix:nonFraction unitRef="shares" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMzI_bcd5f9dd-24c7-4a13-b35f-deec529258ac">150,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNTQ_83143ea7-119e-427e-aacc-31bc4e3532a8"><ix:nonFraction unitRef="shares" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNTQ_a93a5f30-acb1-4c9e-a9ab-285c811861a6">44,677</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNjE_b9409abb-562f-43ba-a53a-22e45f4b331e"><ix:nonFraction unitRef="shares" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNjE_f5390a30-0ad6-4e3f-bf6c-09ef63fba823">41,964</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTEtMS0xLTQwMzY4_4266d5b5-c6e9-4371-8de5-c4f7ff5c07d1">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTMtMS0xLTQwMzY4_62936613-d729-4992-b33e-60894e89e3a0">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM0LTEtMS0xLTQwMzY4_744ce507-b252-4b09-90ee-d4ed35949783">404,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM0LTMtMS0xLTQwMzY4_0717f582-cf00-4a18-8ff4-710d94e9e402">400,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:Servicereceivable" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM1LTEtMS0xLTQwMzY4_e807c077-fb38-4ddf-94bd-f345fdd7fe68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:Servicereceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM1LTMtMS0xLTQwMzY4_defd1170-a402-4aee-a712-9d7aebc0b444">139</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM2LTEtMS0xLTQwMzY4_f35ad827-ff7b-4370-b4dd-735b961c0d59">395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM2LTMtMS0xLTQwMzY4_b769a813-c1e6-454b-a304-0d918d9dc6b6">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM3LTEtMS0xLTQwMzY4_5879b5d7-ba4a-4d07-a18f-04f391849e74">298,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM3LTMtMS0xLTQwMzY4_9ec48b4e-7a1c-4bb5-854b-cc1feccbb427">259,810</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM4LTEtMS0xLTQwMzY4_2953e4cb-cc4a-4a3e-bdcf-ae4a1839ed6a">106,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM4LTMtMS0xLTQwMzY4_62aa2b89-a25e-445f-87d2-b86fd7da34f1">140,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Liabilities and Stockholders&#8217; Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM5LTEtMS0xLTQwMzY4_a2250f14-3b8f-4114-b312-43aa5f1bd421">116,191</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM5LTMtMS0xLTQwMzY4_5c3d2f13-55a8-4741-afea-d0ce3169dbaa">149,544</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-4</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_259"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology,&#160;Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Operations </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year&#160;Ended&#160;December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzItMS0xLTEtNDAzNjg_f191628a-0918-45d8-a059-9685d5bf4bbd">386</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzItMy0xLTEtNDAzNjg_e50fed9a-1fa4-48bd-87f8-6f13bce431da">359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Costs and expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzEwLTEtMS0xLTQwMzY4_41826e92-4e25-453a-90fe-d15f24e5f61b">27,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzEwLTMtMS0xLTQwMzY4_28e7376e-a5b2-4725-895d-d6608351f0b5">17,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzExLTEtMS0xLTQwMzY4_30904b72-7685-40a6-9436-45a2634cb2b3">13,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzExLTMtMS0xLTQwMzY4_90c654ad-6bca-441d-9f50-6aad9eef9d30">11,838</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE0LTEtMS0xLTQwMzY4_d45527ad-f8a2-4ca7-8634-62f5fca0e99c">40,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE0LTMtMS0xLTQwMzY4_24bfb0d5-9c59-420f-a784-860876fec3c1">29,214</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE2LTEtMS0xLTQwMzY4_2ba41159-6d39-4e18-85a3-9d2585c14054">39,902</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE2LTMtMS0xLTQwMzY4_ffaecbdf-0703-4749-9908-fa5e0bd519c4">28,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE5LTEtMS0xLTQwMzY4_6104ea7b-c0f7-4986-b55d-c48e736b059b">1,581</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:InvestmentIncomeInterest" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE5LTMtMS0xLTQwMzY4_d6391449-129d-45b3-b968-60b372b3cb99">264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIxLTEtMS0xLTQwMzY4_a6c81b04-5175-4af2-84a2-4c70119983eb">383</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:OtherNonoperatingGainsLosses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIxLTMtMS0xLTQwMzY4_4e86753a-7729-4252-befd-04bc48217cc0">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gain from changes in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIzLTEtMS0xLTQwMzY4_d8841955-16c3-4756-b459-5fd62571a47f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIzLTMtMS0xLTQwMzY4_06a03fef-b621-4718-a1d2-e26b8bb11d3f">285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income, net</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI0LTEtMS0xLTQwMzY4_6f6e6af6-6e4e-4f61-b81b-f4dd1586232a">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI0LTMtMS0xLTQwMzY4_fd66f0a0-09d8-43ed-9a67-7a7f0c05cc93">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI2LTEtMS0xLTQwMzY4_816e5567-cb82-45fb-b14b-10c4069002b5">38,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI2LTMtMS0xLTQwMzY4_844d1dca-53c9-41a6-b76a-13b0c4baff18">28,291</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI4LTEtMS0xLTQwMzY4_4e1a4f8b-8a66-4638-a3b6-4ad8252d779d">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI4LTMtMS0xLTQwMzY4_c5722a2a-9ba9-4b5a-8c86-c3c7040582f3">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss attributable&#160;to&#160;common stockholders</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzMzLTEtMS0xLTQwMzY4_3cbb3661-1449-41cd-8275-3b3e73e4973d">38,728</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzMzLTMtMS0xLTQwMzY4_0278c4c0-396a-4fe0-ab5d-d7ff751279af">28,315</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per common share &#8212; basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTEtMS0xLTQwMzY4_c7bffebe-ca19-4620-a614-78bb13389085"><ix:nonFraction unitRef="usdPerShare" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTEtMS0xLTQwMzY4_fa79cad9-fe21-43ff-8ef8-2f1f9a1c80af">0.89</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTMtMS0xLTQwMzY4_d2ed7a9c-b6c6-4ef3-a0a9-abfb1847b709"><ix:nonFraction unitRef="usdPerShare" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTMtMS0xLTQwMzY4_f279e532-aa18-4f15-ada2-5df69a2a07e2">0.73</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares outstanding &#8212; basic and diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTEtMS0xLTQwMzY4_57d0ec5c-2c2d-4eae-897a-5a38edd76477"><ix:nonFraction unitRef="shares" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTEtMS0xLTQwMzY4_8398ce43-f8a4-49f4-b920-2b76965b529d">43,600</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTMtMS0xLTQwMzY4_7a5ec287-1f68-43ee-91ce-57de78f95fe5"><ix:nonFraction unitRef="shares" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTMtMS0xLTQwMzY4_f5cc62e0-a708-49a7-a886-16f04300270d">39,030</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-5</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_262"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology,&#160;Inc. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzItMS0xLTEtNDAzNjg_816e5567-cb82-45fb-b14b-10c4069002b5">38,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzItMy0xLTEtNDAzNjg_844d1dca-53c9-41a6-b76a-13b0c4baff18">28,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Unrealized loss on securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzUtMS0xLTEtNDAzNjg_a36a43db-8972-45fa-b580-79075c1b08bd">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzUtMy0xLTEtNDAzNjg_83f5ac94-9eef-42a3-a779-973b7f025029">142</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzgtMS0xLTEtNDAzNjg_e4f143a5-602b-4ffa-b236-a80eac165524">38,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzgtMy0xLTEtNDAzNjg_a96fd7c7-38ea-4419-8d7b-f029e4e07e35">28,433</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzEwLTEtMS0xLTQwMzY4_4e1a4f8b-8a66-4638-a3b6-4ad8252d779d">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzEwLTMtMS0xLTQwMzY4_c5722a2a-9ba9-4b5a-8c86-c3c7040582f3">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive loss attributable to common stockholders</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="crdf:ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzE0LTEtMS0xLTQwMzY4_645aa0f2-1e2d-4c2e-86d7-866d5fecabd1">38,981</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="crdf:ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzE0LTMtMS0xLTQwMzY4_5a3e5311-8aec-48e5-8c5d-4bce9c391731">28,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-6</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_265"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Stockholders&#8217; Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:27.904%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.016%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.698%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred Stock Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional <br/>Paid-In Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Service Receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated other <br/>comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217; Equity</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTEtMS0xLTQwMzY4_1a8873b3-c89a-42a8-a07d-b220dd405326">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTMtMS0xLTQwMzY4_e45d093d-923f-4c3a-90fa-698a60b91971">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8163d9f52ab94b4aafd5fb22fd53dadf_I20201231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTUtMS0xLTQwMzY4_74c0fc35-9751-4d6f-8df1-e7aef9f5b3b9">36,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8163d9f52ab94b4aafd5fb22fd53dadf_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTctMS0xLTQwMzY4_9ad68a36-3844-4b32-b461-a8f80ec7097d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bdcccd341047f39901c6c37adf4d01_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTktMS0xLTQwMzY4_13c72312-b674-4358-8bb2-c03f4038ae5a">361,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i388253962d4b4b3ab93b1e08702adfdd_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTExLTEtMS00MDM2OA_05a2775d-6ef6-4f06-bc8f-e80bcf37734e">2,171</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b4884c1cff544f0bb9f898e5ddbf8e0_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTEzLTEtMS00MDM2OA_f9caa09e-5a58-4446-90f4-d54d4d45f4e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i08542de1deb8454493ed1ff8baf6b427_I20201231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTE1LTEtMS00MDM2OA_562bbe43-4e5f-4df5-9c61-6c0242ed6c16">231,495</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTE3LTEtMS00MDM2OA_385fa3d6-9062-4986-adec-6e63f76db914">128,158</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc1LTktMS0xLTQwMzY4_4c0700b6-77c8-4ace-a248-96e367def4a0">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc1LTE3LTEtMS00MDM2OA_b68c933e-661e-42b1-9634-710b54430b96">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb897010af224abc95b5952441ea70a0_D20210101-20211231" decimals="-3" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc2LTUtMS0xLTQwMzY4_03651bcd-2de8-43e9-b14a-e3c7b3539f5b">771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc2LTktMS0xLTQwMzY4_8b18eeb0-f9f6-4288-8573-c4f0b544cbd8">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc2LTE3LTEtMS00MDM2OA_8b28dafe-98da-4750-a088-571c95e5e215">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of common stock, net of expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifb897010af224abc95b5952441ea70a0_D20210101-20211231" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTUtMS0xLTQwMzY4_73b7005e-a7c8-4b80-a4e8-2315e826eb30">4,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTktMS0xLTQwMzY4_7028abee-aacd-49fc-8cbf-ce760a5e3489">34,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTE3LTEtMS00MDM2OA_b44d00aa-a7de-4a0f-b422-af1a4d75627b">34,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9c669ee81da4204bcdcb71cf65565a1_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc4LTEzLTEtMS00MDM2OA_8a4778f0-ca86-4134-ab23-f427c9d0cc53">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc4LTE3LTEtMS00MDM2OA_5256cf4d-1a42-413a-bdbb-5544e4d39a2a">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Preferred stock dividend payable on Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc5LTE1LTEtMS00MDM2OA_4b51c186-5eff-47dc-a1cc-c7a5a8fe965f">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:DividendsPreferredStock" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc5LTE3LTEtMS00MDM2OA_cb8499c0-e12f-41a2-ad84-f0795c2d0342">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7978fbf15d3f41dcbf8154394977cca6_D20210101-20211231" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgwLTExLTEtMS00MDM2OA_bef951bd-cdae-4ef4-a452-e49d74104f58">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgwLTE3LTEtMS00MDM2OA_7c56f95a-1d62-4b06-8b19-ea9563962dd9">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgxLTE1LTEtMS00MDM2OA_d88f6340-c7fc-4f2c-98ad-f58e6d5024ed">28,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgxLTE3LTEtMS00MDM2OA_83118ae6-1d76-40e9-9cfd-8ea40a16ca55">28,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief4483220d7c41bea4914cd482792617_I20211231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTEtMS0xLTQwMzY4_bd050bb2-90d0-484a-932a-8479614f11c4">716</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief4483220d7c41bea4914cd482792617_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTMtMS0xLTQwMzY4_9d866c6b-effe-4855-be35-99104acb90e6">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib920a1f02b184e238f9c206b9a064d82_I20211231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTUtMS0xLTQwMzY4_079ff000-ab2d-4a28-8786-88fc73d30791">41,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib920a1f02b184e238f9c206b9a064d82_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTctMS0xLTQwMzY4_c444fb86-3957-459c-aeae-ebee4c7bd119">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a8cbdcbd3ba44fbad8ef0797734695d_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTktMS0xLTQwMzY4_511edd1e-100e-4765-86d9-b2f54b2e021d">400,503</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic0f3d29f09ee44a4bf376bf33507e1fc_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTExLTEtMS00MDM2OA_a29c2312-a860-4e6e-a566-4e6579e8ec80">139</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0614bca5466e47cebcb947482e4d0305_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTEzLTEtMS00MDM2OA_3150a513-8a9a-4bb6-8715-3e333c261502">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5e71be265fa4fa7a538e7d7379fab1d_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTE1LTEtMS00MDM2OA_90a2f2f3-2926-49fc-9cb1-d63a32501d85">259,810</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTE3LTEtMS00MDM2OA_4c8ff311-697d-4a1d-82fe-e9dc5ad3bf9b">140,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f6bc6df8014431a77c99ab2c34a707_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgzLTktMS0xLTQxMzc1_1d191b90-e28a-487c-bc1f-a8e7a2ec5e62">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgzLTE3LTEtMS00MTM3NQ_5ce19e0a-0b89-4a00-9f39-fc059577afcd">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon exercise of stock options    </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4cde148671c44d794a76ed6b416a19d_D20220101-20221231" decimals="-3" name="crdf:StockIssuedDuringPeriodSharesWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg0LTUtMS0xLTQxMzc1_66ee7796-8dce-4322-a9d0-4c5d11d7c448">29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia0f6bc6df8014431a77c99ab2c34a707_D20220101-20221231" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg0LTktMS0xLTQxMzc1_cdc1d1aa-4114-49cc-a5be-c56f790f9c9b">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:StockIssuedDuringPeriodValueWarrantsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg0LTE3LTEtMS00MTM3NQ_c4bc19c8-b11f-4cab-9512-aa9c4cd9178b">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock upon conversion of Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i57d61ca588534e27a11812dffb0c09f4_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTEtMS0xLTQxMzc1_cf486a0a-2792-4f11-8c70-a73fd14a69c9">655</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57d61ca588534e27a11812dffb0c09f4_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTMtMS0xLTQxMzc1_cb1cee1f-e55b-4297-96b1-46e7339aff53">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib4cde148671c44d794a76ed6b416a19d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTUtMS0xLTQxMzc1_16dba0fe-14bd-4c3b-8461-90a6721055bb">2,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTE3LTEtMS00MTM3NQ_d5f06a20-612b-4fd1-a37d-48cf847e05a9">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fa0fcea09ba4d2384358db55c650345_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg2LTEzLTEtMS00MTM3NQ_136a6060-9076-47f1-ac5d-6d0c3b98c4fc">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg2LTE3LTEtMS00MTM3NQ_1b04456c-ddf3-491f-9acd-1d4146ed8500">253</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1460f61dda948aabd2999ef5dc73481_D20220101-20221231" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg4LTExLTEtMS00MTM3NQ_cb564e41-22bd-4a24-a7ed-aa8c29ae2848">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:ReleaseOfClinicalTrialFundingCommitment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg4LTE3LTEtMS00MTM3NQ_7e3cae89-b712-41ab-8d67-581f57cd13cb">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cumulative preferred stock dividend adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i689740219e214ef58af97e73397e9639_D20220101-20221231" decimals="-3" name="crdf:PreferredStockCumulativeDividendAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00NDAzMA_adfa9e98-dd45-4169-8fb4-e22092848d17">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:PreferredStockCumulativeDividendAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00NDAzMA_5a23862e-0f2b-48c4-8d1b-d8a37e2de710">414</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i689740219e214ef58af97e73397e9639_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00MTM3NQ_4ec8dd02-6c79-46db-a8f8-617d5eb8c66c">38,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00MTM3NQ_b864ed47-5fbe-47c4-9285-420871e47935">38,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5c4b1dd7a85546b99de632aa3cd6850d_I20221231" decimals="-3" name="us-gaap:SharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTEtMS0xLTQxMzc1_3adce2c5-5157-48c5-84fe-26c753720325">61</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c4b1dd7a85546b99de632aa3cd6850d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTMtMS0xLTQxMzc1_3b96a271-3664-48cb-96ed-4bc22652eebb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i99b6a1cd1dcc4ce799987fb33f9e4c9d_I20221231" decimals="-3" name="us-gaap:SharesIssued" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTUtMS0xLTQxMzc1_51e2fafd-4a8b-4087-adb7-923b254b1f34">44,677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i99b6a1cd1dcc4ce799987fb33f9e4c9d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTctMS0xLTQxMzc1_f99c7f3b-c611-4235-85cb-67498d3f9ab2">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a6e8d2aa5e54a42941fae9f78ca955b_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTktMS0xLTQxMzc1_aa4d3f75-cc86-4e27-a01a-a68f8cb14d00">404,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5d69223477441e6ba07ac77a66de571_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTExLTEtMS00MTM3NQ_6bf68bb3-e582-402a-a0af-768bd6e33e06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief601a71b15a453791b8b9ef7994a50b_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTEzLTEtMS00MTM3NQ_2f421636-222e-4b4b-82bc-7f4a20a1435b">395</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3e300c60978432fa06883530ae83613_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTE1LTEtMS00MTM3NQ_1e0b25e6-23fa-4e52-99cb-37ecc9802115">298,100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTE3LTEtMS00MTM3NQ_63c55492-84bb-455f-96a9-784d2a042cb4">106,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816" footnoteRole="http://www.xbrl.org/2003/role/footnote">Net of expenses of $<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzE0OA_25007032-26ab-45c9-9f12-7f17cca11ab1">0.8</ix:nonFraction>&#160;million.</ix:footnote> </span></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzU0OTc1NTgxNDI5MQ_1a318d9b-4802-4289-89e7-651eed85f6ed" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 2 to the financial statements.</ix:footnote> </span></div><div style="margin-top:5pt;padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-18pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-7</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_268"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMtMS0xLTEtNDAzNjg_f2d63847-747a-4f99-9a0a-7eb20c4b247b">38,704</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMtMy0xLTEtNDAzNjg_3bc3f7c2-ce0c-44a6-9757-90e07c5615dc">28,291</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss on disposal of assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUtMS0xLTEtNDAzNjg_8cdce1a1-cfe5-49f3-8897-ad42379005bb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUtMy0xLTEtNDAzNjg_68be895f-ad19-4410-a724-34aff394c57b">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzctMS0xLTEtNDAzNjg_466b8b15-a9df-4930-8706-9006701fc81a">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzctMy0xLTEtNDAzNjg_96b6c3a3-86ec-4e00-85fa-eff49407b65e">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzgtMS0xLTEtNDAzNjg_657f29ef-aef7-477f-8332-5eed15143c06">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzgtMy0xLTEtNDAzNjg_223cf8d8-d7a0-43ed-9ee1-1a77b9cc2981">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of premiums on short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzEzLTEtMS0xLTQwMzY4_ad7afb86-27d3-4caa-ad51-87af216434b8">632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzEzLTMtMS0xLTQwMzY4_9ebe6d34-efdd-47c4-9ced-f1679564da18">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments&#8212;warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE2LTEtMS0xLTQwMzY4_d7c7eeee-be32-4584-afca-2144653497b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE2LTMtMS0xLTQwMzY4_482ab216-6cba-4ea0-9d64-d2b2ce84fe97">285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Release of clinical trial funding commitment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE3LTEtMS0xLTQwMzY4_54161a0f-b577-49e4-b2dd-fa9c91b01392">139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE3LTMtMS0xLTQwMzY4_05775123-ae89-4582-9b4c-ce1454f9d544">2,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIwLTEtMS0xLTQwMzY4_e6997cd0-1b4c-4856-b569-a26e2ee651de">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIwLTMtMS0xLTQwMzY4_b7b5a369-befd-4e14-a836-22ce60b0f005">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable and unbilled receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIxLTEtMS0xLTQwMzY4_0df89af9-3214-4481-b2be-adfc0a43e43d">236</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIxLTMtMS0xLTQwMzY4_afe5baef-f0cd-49b0-9bb3-0f44f6c50b9e">215</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIyLTEtMS0xLTQwMzY4_984dad82-2eba-445b-9fe0-18240fdfb387">443</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIyLTMtMS0xLTQwMzY4_dc78143a-8c9e-4416-a9c8-43da4d2032c4">2,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIzLTEtMS0xLTQwMzY4_f8b242a8-a43d-4643-aa5d-b8f667ec761b">545</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIzLTMtMS0xLTQwMzY4_032d7bee-7137-4110-a5e8-c5c760fa30f2">607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI0LTEtMS0xLTQwMzY4_3dd397cf-d675-4086-a7bb-c93106137c25">1,348</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI0LTMtMS0xLTQwMzY4_282414fc-cf09-4c91-985c-232d2e34b482">719</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI1LTEtMS0xLTQwMzY4_02e89187-8a6b-460b-b38f-fc330c7905d5">404</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI1LTMtMS0xLTQwMzY4_97f058ea-5666-4eb9-964e-61d98062a244">811</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI2LTEtMS0xLTQwMzY4_b0627ead-7876-4363-bd38-0978c3d37917">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI2LTMtMS0xLTQwMzY4_0e9efbcf-c607-4c5b-bbca-5c3122d4d5d2">156</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI3LTEtMS0xLTQwMzY4_fa1e568e-4523-416c-bc8b-cea6bd6026a7">33,820</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI3LTMtMS0xLTQwMzY4_e51ee93b-46b3-4726-bb88-3e31c310cd59">23,040</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capital expenditures</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMwLTEtMS0xLTQwMzY4_aa17b2d8-23ef-4ffd-a11f-c836ba74653d">1,006</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMwLTMtMS0xLTQwMzY4_1eaf2470-21c4-4743-a7ae-d50bc3186925">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance proceeds from casualty loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTEtMS0xLTQyNTA4_9554abde-ca25-4395-b28a-759ae7dfeb9e">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromInsuranceSettlementInvestingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTMtMS0xLTQyNTA4_83f273d3-f16e-4129-972d-8a7b957b9230">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTEtMS0xLTQwMzY4_709a0bb4-4e7f-4ea7-8604-3b16f92f250e">76,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTMtMS0xLTQwMzY4_76c2df5e-6282-4203-be49-396179e3a59a">28,391</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMzLTEtMS0xLTQwMzY4_1f7e6098-3c66-4165-af20-7fbf6fded715">91,233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMzLTMtMS0xLTQwMzY4_741c5e42-c623-429d-a4eb-35c3f275ad8f">174,385</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM0LTEtMS0xLTQwMzY4_cf005297-5cc5-4540-b768-98c77b553c8a">53,829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM0LTMtMS0xLTQwMzY4_7596cc8e-b4e0-49a6-a91d-49a17f22f55a">14,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM1LTEtMS0xLTQwMzY4_1f0fb50f-a962-4b16-b98e-78fe02b558a5">38,149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM1LTMtMS0xLTQwMzY4_4fe138c2-7507-4218-bcd3-732484bdd704">131,448</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $<ix:nonFraction unitRef="usd" contextRef="id9cf7788e55c4739b94fc0cf078e531e_D20220101-20221231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTM2NmQ4ZGZhODBhNDM0NDg5MzVmOTE5YTNlZDYyOGFfOTA_a01c5c8b-d124-4631-ba9f-d53947141da3">0</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i866498a356ac40ad9fc5fc95f6654ec4_D20210101-20211231" decimals="-3" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTM2NmQ4ZGZhODBhNDM0NDg5MzVmOTE5YTNlZDYyOGFfOTg_df952ddb-412f-4a49-9cd5-1a9f0d28d862">813</ix:nonFraction> respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTEtMS0xLTQwMzY4_c4edee37-f2e5-4896-a899-9e96abab479c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTMtMS0xLTQwMzY4_02b8d835-e528-4ed4-b3d7-b0bce1d506a3">34,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQyLTEtMS0xLTQwMzY4_91cc8ccb-4492-4819-b747-f183ffd28ac4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromWarrantExercises" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQyLTMtMS0xLTQwMzY4_309487dd-d4bf-4a43-bc4a-85b08c3ebb13">1,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from exercise of options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQzLTEtMS0xLTQwMzY4_00a34bf5-270d-46d0-b1ca-89725a69afd8">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQzLTMtMS0xLTQwMzY4_6ce11dc7-b0f3-4844-a2e4-6ee4cf0a5fa1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQ5LTEtMS0xLTQwMzY4_19b59666-0b22-442f-b8b8-545d197a6b5d">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQ5LTMtMS0xLTQwMzY4_c4695902-2344-43d6-b99b-b880d03ac4ee">35,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUxLTEtMS0xLTQwMzY4_7c3f9d68-53bd-46a3-be27-0ef60b5fbb6d">4,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUxLTMtMS0xLTQwMzY4_1e2b8d46-8706-41c7-b428-6ed9076082a1">119,038</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;Beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUyLTEtMS0xLTQwMzY4_0081ecb1-dfa5-47b8-af64-0a9c34a615d8">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUyLTMtMS0xLTQwMzY4_ff53940e-3eeb-4f1a-b652-bbb1308a11c6">130,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents&#8212;End of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUzLTEtMS0xLTQwMzY4_de338c57-2ac3-403f-bfaa-8bf002be9c78">16,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUzLTMtMS0xLTQwMzY4_64c0bf60-1475-4276-b36a-86d55da3e20e">11,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplementary disclosure of cash flow activity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU1LTEtMS0xLTQwMzY4_01fb5e36-ba47-4907-b77f-7fe394791e45">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxesPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU1LTMtMS0xLTQwMzY4_3fb372c8-7d9a-452f-b56a-c4af77b64daa">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition of property and equipment included in accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU2LTEtMS0xLTQwMzY4_98022a36-339c-46e8-bad5-34a160e5a991">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU2LTMtMS0xLTQwMzY4_c53a7279-7e95-41a0-a44d-65a9754ef342">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accretion of Series A Convertible Preferred Stock dividend</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:PreferredStockDividendAccrued" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzYyLTEtMS0xLTQwMzY4_da8311fb-5cf1-4f2d-acb0-55fedcf94b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:PreferredStockDividendAccrued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzYyLTMtMS0xLTQwMzY4_b56fc7f0-dc7c-4490-a102-0652fbc28f15">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative preferred stock dividend adjustment</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="crdf:NonCashCumulativePreferredStockDividendAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTEtMS0xLTQ0MDUw_f2e0fb40-bbae-4a9e-8106-5f0d6024c12d">414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:NonCashCumulativePreferredStockDividendAdjustment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTMtMS0xLTQ0MDUw_9e89a259-fea7-4ee7-a671-d7f9833e7bd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90ZXh0cmVnaW9uOjM3NTdiYzExYjJhNjRkMzZhY2RjZThiMjAxYjQ2N2MzXzU0OTc1NTgxNDEyOQ_14e5891d-ac53-44b8-98bd-d418bf65976e" footnoteRole="http://www.xbrl.org/2003/role/footnote">See Note 2 to the financial statements.</ix:footnote> </span></div><div style="margin-top:5pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-8</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_271"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cardiff Oncology, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Financial Statements</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_274"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzQvZnJhZzowOGJiMTBlMTY0ZDg0NGNiOWJiNDQ5MzFmNGJjODNkNC90ZXh0cmVnaW9uOjA4YmIxMGUxNjRkODQ0Y2I5YmI0NDkzMWY0YmM4M2Q0XzE1Nzc_9f55f9f9-523b-4333-a83e-46656528ef92" continuedAt="i7b947bc1bf4c4d3580c4664fe3b7abd4" escape="true">Business Overview and Liquidity</ix:nonNumeric></span></div><ix:continuation id="i7b947bc1bf4c4d3580c4664fe3b7abd4"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard of care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company&#8217;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard of care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of December&#160;31, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzQvZnJhZzowOGJiMTBlMTY0ZDg0NGNiOWJiNDQ5MzFmNGJjODNkNC90ZXh0cmVnaW9uOjA4YmIxMGUxNjRkODQ0Y2I5YmI0NDkzMWY0YmM4M2Q0XzcyOQ_89e6a77a-1a6a-4a66-acdb-cb54fc8cd1fe">105.3</ix:nonFraction> million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-9</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_277"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDk4_e4c8f69e-5d66-4000-a79a-ea57e0ba28e3" continuedAt="i6dc89cbf893b417bad6acd783abdb65f" escape="true">Basis of Presentation and Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i6dc89cbf893b417bad6acd783abdb65f" continuedAt="id539cd04ba784cbc9c40800ecdef7ab2"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDg0_6177d7a1-6300-4b5c-aa21-ebee8327763d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, <ix:nonFraction unitRef="segment" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzYxMQ_16f29152-58ff-4171-904f-a754bc74430b">one</ix:nonFraction> operating segment in the United States.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NTAy_41c41cf3-b746-4018-a882-576b524d67a8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="crdf:AccruedClinicalTrialExpensesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDkz_23b51696-aa41-4235-b1c0-e7d3684398a8" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations ("CROs"), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December&#160;31, 2022 the Company&#8217;s clinical trial accrual balance of $<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-5" name="crdf:AccruedClinicalTrialExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE3MTI_199ee3c1-ac90-43d2-a313-4ad3553eed78">2.3</ix:nonFraction> million is included in accrued liabilities. The Company&#8217;s related 2022 clinical trial expenses are included in research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NTQ_45ab5869-fae8-4deb-baad-31b7f9ad46d4">27.1</ix:nonFraction>&#160;million. Certain clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDI0_eea416a7-c1ae-47b3-937e-63e5245d2b54" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash in readily available checking and money market accounts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive loss. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDQ5_6b5d9939-9f8d-450d-a585-12978482f0ee" continuedAt="i72ae6dca890243aa9a8fbfdfaf9fa27a" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i72ae6dca890243aa9a8fbfdfaf9fa27a">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="id539cd04ba784cbc9c40800ecdef7ab2" continuedAt="if9a95418068144db948d2af467e9a417"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDcy_65cde42b-2368-4d24-b8a2-7d50443364f9" continuedAt="i9f4b2bec019c41b282fa6677cfdcba70" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and License Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These patents are from the Company's legacy portfolio and unrelated to onvansertib.&#160;Agreements may involve multiple elements such as license fees, minimum royalties, usage-based royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#8217;s use. The Company estimates and records licensee&#8217;s sales based on historical usage rate and collectability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f4b2bec019c41b282fa6677cfdcba70"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDcz_eb9dc966-8079-4208-a6e0-2ca69c73b615">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.</ix:nonNumeric> Royalties are generally due quarterly or annually.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDg2_7d0eeac2-58f0-457c-950a-781a72415e15" continuedAt="i49c3eb3cc33b490eb351df53ef592fee" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period as they do not meet the criteria for equity classification. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;Change in fair value of derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><ix:continuation id="i49c3eb3cc33b490eb351df53ef592fee" continuedAt="iddd8e96c46e24d4c8f35a6f7981f316a"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments" </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iddd8e96c46e24d4c8f35a6f7981f316a">below).</ix:continuation>&#160;At December&#160;31, 2022 and 2021, the fair value of these warrants was $<ix:nonFraction unitRef="usd" contextRef="ic357b095a944414684981c1dc8b89fb7_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzgzODI_bcf90ab4-c529-4f92-96a6-0343c2ee7335"><ix:nonFraction unitRef="usd" contextRef="i7db42fc039fd45aeaea7b5bc0553089e_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzgzODI_df896022-7887-4986-881a-ef95cf07d64b">0</ix:nonFraction></ix:nonFraction>, for both periods. These warrants expire in the first quarter of 2023. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDc5_b9fa7704-5cbc-438b-b136-a75b6fb905c5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDk2_94c5405c-e251-4f77-944f-629c6734f733" continuedAt="i95f8b765559342f6a67063fadef65d75" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="if9a95418068144db948d2af467e9a417" continuedAt="idd9b1a2da78741a38d2b07b7add46377"><ix:continuation id="i95f8b765559342f6a67063fadef65d75"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted prices for identical instruments in active markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Instruments where significant value drivers are unobservable to third parties.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDgy_cfd4852d-7a60-4ab9-8d09-df2f3169e79d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property, equipment and lease right-of-use assets. The Company records property and equipment at cost. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of the asset. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDg5_8da1bf09-ccbf-42d3-b2f6-3cee40cb02e5" continuedAt="ifaf1f21e78cf4360ad7f75812cacc4ec" escape="true">The estimated useful lives of the major classes of property and equipment are as follows:</ix:nonNumeric></span></div><div style="text-indent:36pt"><span><br/></span></div><div><ix:continuation id="ifaf1f21e78cf4360ad7f75812cacc4ec" continuedAt="ibf77806a658448dc9bb6aa603c8c568c"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.506%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id6e8c265de294538a1036e72f7c48ee4_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzEtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo3YWQyZmM1N2EwMmM0N2Y2OWQ4ODI4YjQyZDJmMzEyNl80_b45be0b8-0521-42b0-ae35-3b353cf8e860">3</ix:nonNumeric> to <ix:nonNumeric contextRef="i3d722eb9049649258eed2c0dc7b7f489_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzEtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo3YWQyZmM1N2EwMmM0N2Y2OWQ4ODI4YjQyZDJmMzEyNl8xMA_e2ccda84-a449-431f-8f49-2d4ddde07e35">5</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6db19d7e4c5b45118fb2b4e6b4642581_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjpiZWY4ZDRhZmY1YmE0NTE3YTNlZjc1ZWJiMmFkZTc0ZF80_7fb06256-8f4f-405c-8abf-3da5ca1c86ff">4</ix:nonNumeric> to <ix:nonNumeric contextRef="ifa12187761644b8fb660f20d8935e788_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjpiZWY4ZDRhZmY1YmE0NTE3YTNlZjc1ZWJiMmFkZTc0ZF8xMA_ebab4131-ec2a-4173-8ed3-00750e54a199">6</ix:nonNumeric> years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i04fc18d316ba46f4b37af84f0a656dae_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzMtMS0xLTEtNDAzNjg_8a565dd8-c547-4917-b97c-2bdc40f0caae">5</ix:nonNumeric> years</span></td></tr></table></ix:continuation></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NTEx_cf781e65-644d-40c6-ac8f-858983e9bf2c" escape="true">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</ix:nonNumeric> </span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDc0_452004cd-57cf-45de-8bac-d41214cd42a7" continuedAt="ia03265e52aca42eaa7bf8cfbfbd16e04" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease Right-of-Use (&#8220;ROU&#8221;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#8217;s balance sheets.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. None of the Company&#8217;s operating leases provide an implicit rate, therefore the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. </span></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia03265e52aca42eaa7bf8cfbfbd16e04">Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="idd9b1a2da78741a38d2b07b7add46377" continuedAt="i6228e61be3064805843324092c50602c"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDMz_50d3cc1a-ddb0-4d45-9294-dcef5e3a5d64" continuedAt="i85afbc1cc77e4b3393411f6e1b90ab73" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revision of Previously Disclosed Amounts</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i85afbc1cc77e4b3393411f6e1b90ab73">During the course of preparing the Company&#8217;s financial statements as of and for the year ended December 31 2022, the Company completed an Internal Revenue Code Section 382 and 383 analysis of its historical net operating loss and tax credit carryforward amounts. As a result, a portion of the prior year net operating loss and tax credit carryforwards were determined to be limited. See Note 9 - Income Taxes, for further details.</ix:continuation> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDQ3_8f3466a5-6c37-4ee6-a1e7-24cb43713742" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDM5_90efce6e-e76f-4821-8e98-42f9299e9d23" continuedAt="i98634f9d751f451eb7784c8f39f67559" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and patent maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i98634f9d751f451eb7784c8f39f67559">Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.</ix:continuation> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront and milestone payments to acquire contractual rights to licensed technology are expensed when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Certain contractual rights may require the Company to make additional milestone payments based on development and commercial milestones, and royalties based on sales volume. See Note 10 - Commitments and Contingencies, for further details.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These potential development milestones include: dosing of the first subject in the first Phase III Clinical Trial for the first Product or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and upon filing of the first NDA or equivalent for the first product</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDMx_24cdfe82-43ed-4f09-b21e-93506858285d" continuedAt="i0da2f2f2f6564981a7061417d7525cc9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0da2f2f2f6564981a7061417d7525cc9">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. The accretion of Series A Convertible Preferred Stock dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</ix:continuation> For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDkx_aa82745e-1b55-4aaf-92fd-d6c42c1e67c5" continuedAt="i8e5f7b53206d40caa6bf0a57e7e21f93" escape="true">Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:</ix:nonNumeric></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8e5f7b53206d40caa6bf0a57e7e21f93" continuedAt="ieead7cef83ec42728c1a6c68ac0cc9ef"> </ix:continuation></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i6228e61be3064805843324092c50602c" continuedAt="i36c16700e1b04d6f815864e02e4d577d"><div style="margin-top:5pt"><ix:continuation id="ieead7cef83ec42728c1a6c68ac0cc9ef"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfc3ebfa98e941b5bc6b10599b18ba6f_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzItMS0xLTEtNDAzNjg_cbadbe2b-d665-4141-8193-c72494d1db4f">5,069,458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9a80f0906358478ab1f82fee730acdf1_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzItMy0xLTEtNDAzNjg_76b296d6-c7a3-4c2c-b9f1-fadbe14df955">3,771,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaabac25eea454ee4a957bcb868f30e54_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzMtMS0xLTEtNDAzNjg_7f16069f-e687-4314-8b57-7edf18ee658e">4,360,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7de3c2329b134630bba5604f67f427b2_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzMtMy0xLTEtNDAzNjg_0abb1605-4dfa-4f09-9fa3-f6132f0c8948">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idbac0ee763c14b4691866040faab8881_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzYtMS0xLTEtNDAzNjg_979f83a1-419e-4df9-9316-71a4ad4217e4">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9cfa801a2fb64cd2a7453b02850a5da8_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzYtMy0xLTEtNDAzNjg_08d2b102-cb9c-4f39-8030-ddb201fb8fe5">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5d7ee18907d4487f8a1215d75d135ee7_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzctMS0xLTEtNDAzNjg_feb02f0b-80e6-45b4-857f-c9a0936d84bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idb4e0e354837488d92217bd45d8de5d9_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzctMy0xLTEtNDAzNjg_e129341a-67bf-426e-9755-b49848070789">2,684,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzgtMS0xLTEtNDAzNjg_17e948cf-3ed7-4649-a536-aec8bc59e8fb">9,431,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzgtMy0xLTEtNDAzNjg_4d62ec28-f10e-4799-85a7-a7569ad5c4ea">10,947,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="crdf:CorrectionPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzU0OTc1NTg0MjgwMQ_84adbb62-099d-4b50-aaaa-ee8b0b54814a" continuedAt="iaa82a50f79574937906cb41b806231d6" escape="true">Correction of Series A Convertible Preferred Stock cumulative dividend liability</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iaa82a50f79574937906cb41b806231d6">During the fourth quarter of 2022, the Company identified an immaterial error related to the accrual of a liability for the accretion of cumulative preferred dividends on the Company's Series A Convertible Preferred Stock. These cumulative preferred dividends do not meet the definition of a liability, as they have not been declared by the Company's Board of Directors. The Company has recorded an adjustment of $<ix:nonFraction unitRef="usd" contextRef="ib79309171dc9429497e5fe33bfa88be7_I20221231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzEwOTk1MTE2NTQwMjU_106e1d9e-246c-4aa4-84df-0d08e463f62c"><ix:nonFraction unitRef="usd" contextRef="ib79309171dc9429497e5fe33bfa88be7_I20221231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzEwOTk1MTE2NTQwMjU_f6aa1d7d-ca99-4a0e-9341-fdeff2178180">0.4</ix:nonFraction></ix:nonFraction>&#160;million within accumulated deficit and accrued liabilities for the year ended December 31, 2022 to correct this immaterial error.</ix:continuation> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDk3_c0e3c6b1-9c92-443a-8e4b-d053fd60ac79" continuedAt="i4b939d0a89a442c29ca3130c242fd1da" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i36c16700e1b04d6f815864e02e4d577d"><ix:continuation id="i4b939d0a89a442c29ca3130c242fd1da">In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for the Company on January 1, 2024. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</ix:continuation></ix:continuation> </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-14</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_280"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEyNDk_091ca679-34df-4cd8-bec2-4d56a0c4c0aa" continuedAt="idccda0ea40c74dbea893b69f91c99707" escape="true">Supplementary Balance Sheet Information</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="idccda0ea40c74dbea893b69f91c99707" continuedAt="i311e9258afb548a68f41635c0ddbdcc4"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEyNDM_53b42de3-a942-4d27-af52-b612bea08c7f" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments available-for-sale securities consist of the following: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtMS0xLTEtNDU5NTQ_8eb5e54d-07d3-4bb6-a254-d80227a24e0b">16,101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtMy0xLTEtNDU5NTQ_59821b06-dd2d-4527-88ee-b241d16868e8">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtNS0xLTEtNDU5NTQ_7451663a-d07f-4bd9-8679-ad5aebf49717">81</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtNy0xLTEtNDU5NTQ_a4698f37-5711-44ac-b6dd-fd689d23f045">16,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtMS0xLTEtNDU5NTQ_0a453960-642d-42ac-9197-7bf191c211a3">44,806</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtMy0xLTEtNDU5NTQ_23fc3aac-66e6-4d1b-a275-abd93a649581">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtNS0xLTEtNDU5NTQ_4c60d1ac-de6a-4eb0-8c76-d40e74374b32">275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtNy0xLTEtNDU5NTQ_e72a40be-6099-4972-9a4f-90ef06cc7e6d">44,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtMS0xLTEtNDU5NTQ_35f9a768-812a-41b5-bef2-355f7b6ecec6">13,203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtMy0xLTEtNDU5NTQ_e9c22004-cb0e-4101-b640-53b2d1ff81b9">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtNS0xLTEtNDU5NTQ_24cf5062-382a-4530-9b8e-4aad38ff4424">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtNy0xLTEtNDU5NTQ_45ee91b8-e0c5-4b73-ad6e-5fb483df93ca">13,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctMS0xLTEtNDU5NTY_1444b377-ae24-4215-b44a-55df11bc92a9">2,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctMy0xLTEtNDU5NTY_301d8fe7-6832-45c9-9072-5e8c6d8e54eb">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctNS0xLTEtNDU5NTY_aa3f82ed-1190-41e3-ab0c-a9d85454aa33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctNy0xLTEtNDU5NTY_bb2f7440-9d90-43c7-85f8-a0bca28add72">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtMS0xLTEtNDU5NTY_10af99a8-59ee-487b-a235-5adfc8625902">7,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtMy0xLTEtNDU5NTY_bd484770-285f-40d9-aaf6-a99bbbca682c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtNS0xLTEtNDU5NTY_d67ff0d4-7f88-492b-a724-b200b07cc239">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtNy0xLTEtNDU5NTY_f859a571-e6d0-44d8-b101-edc48e6bbe1b">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktMS0xLTEtNDU5NTY_60d4cbfe-be27-4dd5-aae5-411ac9c2a4ae">84,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktMy0xLTEtNDU5NTY_16a7a1e0-d69d-4c54-83d7-52a1ff154aca">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktNS0xLTEtNDU5NTY_c886c5e0-1ba7-4c89-b378-4d9f70120b82">394</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktNy0xLTEtNDU5NTY_9286a31c-f7b2-48c9-961e-40b70f3404ee">83,924</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTEtMS0xLTQ1OTU4_06d9cffe-6760-4844-b06a-8bb39cede229">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTMtMS0xLTQ1OTU4_6af5d982-3ac1-4ef9-a10f-c50add4b9f76">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTUtMS0xLTQ1OTU4_ff694d26-a48e-4c90-b475-a7384a63a351">21</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTctMS0xLTQ1OTU4_f2d5c96e-88b3-4eab-9b7c-1d7802934aa9">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTEtMS0xLTQ1OTYw_836ac516-e64a-4cd8-9acc-41047aa9963d">5,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTMtMS0xLTQ1OTYw_988dee63-6814-4912-ae43-b7239ed4df83">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTUtMS0xLTQ1OTYw_235f45e5-ebab-479c-b488-682a70d47838">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTctMS0xLTQ1OTYw_c8d8932b-68f2-48f6-878a-243a9f13cf95">4,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTEtMS0xLTQ1OTYw_0f0f7ac5-378a-40f3-ae4b-1e1799eb237c">89,315</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTMtMS0xLTQ1OTYw_636712a5-4517-4550-b028-4486fe17107b">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTUtMS0xLTQ1OTYw_d1109a67-8be5-487b-ac41-cdb46313ff57">415</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTctMS0xLTQ1OTYw_3992c365-d14b-4335-813b-de71d6074e6c">88,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtMS0xLTEtNDAzNjg_6e05b55a-c077-4ac8-9415-4978b2a9f2da">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtMy0xLTEtNDAzNjg_ae32a5d8-386e-4ee8-90bd-1672180c3e04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtNS0xLTEtNDAzNjg_ce2a92b2-5d7b-4f47-a752-aef5ae822e3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtNy0xLTEtNDAzNjg_1cc48ec8-b92f-415e-b0b1-aee88e15ca4c">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtMS0xLTEtNDAzNjg_628efea2-9d25-4860-b308-3c63d80c4a3d">58,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtMy0xLTEtNDAzNjg_b542736e-220b-4667-8d18-3269eb217c93">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtNS0xLTEtNDAzNjg_68254236-a272-4769-ba4d-b374409c136d">38</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtNy0xLTEtNDAzNjg_622d60ec-8bd1-4a14-8f2d-b223ef1ad756">58,786</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtMS0xLTEtNDAzNjg_d1172e0a-c655-4ad5-bbe2-9a45ba60772d">14,453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtMy0xLTEtNDAzNjg_1e5b7abb-0bc5-4f9d-a147-25757079b61c">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtNS0xLTEtNDAzNjg_a0eeeb05-26b6-4a12-803e-eecc3ff24021">3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtNy0xLTEtNDAzNjg_686e9eb6-fcaa-42ba-b590-1aa30799a530">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtMS0xLTEtNDAzNjg_8ff53ff2-2a60-49a1-86c9-3c626f5ff5a0">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtMy0xLTEtNDAzNjg_67f9d9c9-c6cf-4e8a-9a2c-09a1303c4b99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtNS0xLTEtNDAzNjg_8e120f5a-3184-40b1-9a2d-bea8dcd013eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtNy0xLTEtNDAzNjg_fe087c6e-53bc-48e4-8694-b06df5c63f9a">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctMS0xLTEtNDAzNjg_018b0e39-f1dc-49f7-9d12-410ac46ade79">20,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctMy0xLTEtNDAzNjg_6737fe48-3e5e-4ed3-b4d2-8d4e94899c5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctNS0xLTEtNDAzNjg_51539c75-45d8-4c6d-ba6f-3b62d8e2024d">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctNy0xLTEtNDAzNjg_428eb1ce-bfc8-4f8d-a1ed-2bf32c79c178">20,356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtMS0xLTEtNDAzNjg_8b8637f4-b274-439e-8648-1f49225bf803">95,643</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtMy0xLTEtNDAzNjg_f3ac7479-3b07-4a7f-bda3-af978e654fb5">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtNS0xLTEtNDAzNjg_48fdfeb3-6b71-47d2-8c2b-64a4e30f7728">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtNy0xLTEtNDAzNjg_40359c5e-f06a-49a2-8b65-0b1db8488fdb">95,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTEtMS0xLTQwMzY4_20a34732-4d3c-4618-839e-693113217ee9">29,676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTMtMS0xLTQwMzY4_92dbad2f-7951-41a7-bdd6-6e27653d6c20">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTUtMS0xLTQwMzY4_c65ea1c8-2203-44e3-b1ff-ff5f43aacf72">73</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTctMS0xLTQwMzY4_d4700d42-43ae-46c6-a125-72ef5c65bcf8">29,604</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTEtMS0xLTQwMzY4_2386f4bc-1879-4018-8f77-61b6a824b3dc">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTMtMS0xLTQwMzY4_83f2c739-6473-4764-81f2-a10320e9764c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTUtMS0xLTQwMzY4_8b9aefe4-38c9-49d7-82a0-bd1d84424758">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTctMS0xLTQwMzY4_54497eea-2ae6-43a8-8c3c-c51879f75738">3,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTEtMS0xLTQwMzY4_2ab4df5f-b79a-4b61-a724-585be3ba8abb">33,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTMtMS0xLTQwMzY4_2d0f3780-9538-42ae-8b44-b6f9ff738cd4">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTUtMS0xLTQwMzY4_28aeeb58-200f-49db-851c-e52f754d9ff2">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTctMS0xLTQwMzY4_8deb22c1-db91-479c-9074-9531066b509c">33,294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTEtMS0xLTQwMzY4_9bd6e173-e02c-44bc-8b6d-7463b6a42f75">129,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTMtMS0xLTQwMzY4_e493fde6-a2b4-4853-88e0-97a5fd8291da">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTUtMS0xLTQwMzY4_60fa6d58-05f6-4e55-9072-464d619301da">149</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTctMS0xLTQwMzY4_36d474e6-5593-410e-802a-0c4753bcbee2">128,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022 the net realized loss recorded within the Company's statement of operations from the sale of short-term investments was $<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzIxNg_1c19e486-ebbb-453b-bc95-dccdb97653bd">0.2</ix:nonFraction> million. The amount of gains and losses reclassified out of other comprehensive income for the period related to the sales of short-term investments was not material for the year ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses in investments available for sale debt securities at December&#160;31, 2022, were primarily due to increases in interest rates, not due to increased credit risks associated with specific securities. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzU0OTc1NTgxOTI5MQ_60f36146-299e-45ae-94d6-3d64c69ce11d" continuedAt="i43c606beaa85445087a56c500eb28a40" escape="true">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:</ix:nonNumeric></span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i311e9258afb548a68f41635c0ddbdcc4" continuedAt="ied7ee4f8beb94e57afe4c0292359efad"><div><ix:continuation id="i43c606beaa85445087a56c500eb28a40"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.876%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzMtMS0xLTEtNDU5Njc_db8e26b2-4115-49ab-94fc-2215555da12e">17,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzMtMy0xLTEtNDU5Njc_78af3e91-6f5f-4fde-bdfa-826e92f6e5cd">161</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzUtMS0xLTEtNDU5Njc_e6fde587-d81e-4fa3-8bd4-2e3867d5224b">3,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzUtMy0xLTEtNDU5Njc_0c4a3cf7-24fc-4803-978e-6796365cf6ff">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzYtMS0xLTEtNDU5Njc_a2c184a3-7fd4-4fe1-842e-3b4314a1a05c">20,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzYtMy0xLTEtNDU5Njc_bd19786f-b522-427c-b990-8acc68c08184">175</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Property and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEwOTE_8aff62b1-14b0-4b47-8110-dc667f218e92">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEwOTg_39a0da4f-8f71-41dc-9fba-094fd5a32d33">0.5</ix:nonFraction> million, respectively. <ix:continuation id="ibf77806a658448dc9bb6aa603c8c568c" continuedAt="ib314481c6e2146edaf5047992986f8de">Property and equipment consisted of the following:</ix:continuation></span></div><ix:continuation id="ib314481c6e2146edaf5047992986f8de"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e22fef9a7a4228a7799fa9e0bb1735_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzItMS0xLTEtNDAzNjg_5ac9a58f-9f9e-42ef-bfae-954371233e6a">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i007c30ebe4ca4d128452e15ece8e01d0_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzItMy0xLTEtNDAzNjg_15350c5d-899b-4f84-aa52-0542a7752edb">955</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9081e23b06e6448d9830510d151ca033_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzMtMS0xLTEtNDAzNjg_13d491cf-5b20-4cfe-a5c4-58d55850b1c1">2,560</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14c3caa3006c4f6ebf14421f944e494e_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzMtMy0xLTEtNDAzNjg_bb47dc11-58e0-444f-a853-f53b90df828f">1,962</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd60c6be701446a9bbe35fdcd554faf1_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzQtMS0xLTEtNDAzNjg_fc7e4308-39d1-4441-a8a0-baba627dbb82">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9982ed59fd6427f808ced5af06dbdd1_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzQtMy0xLTEtNDAzNjg_8d8ff310-3bd9-413c-b1c5-34d60f5226e6">906</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzUtMS0xLTEtNDAzNjg_0c736d40-9c68-46af-9c04-166fd1ddf7d3">4,682</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzUtMy0xLTEtNDAzNjg_df546a17-91d8-4d12-a70f-1afea4441fb3">3,823</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzYtMS0xLTEtNDAzNjg_24efb3cb-4617-44fe-82e2-06e5ee1ce24a">3,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzYtMy0xLTEtNDAzNjg_23c1da3a-f792-434f-9eb3-68df707629d6">3,441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzctMS0xLTEtNDAzNjg_80c2cf51-4928-4827-878a-8e2bcb76d7df">1,269</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzctMy0xLTEtNDAzNjg_58628246-9ffb-4f7a-b84c-8f75c08985d7">382</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEyNDc_78a951aa-5554-483a-858a-85cb767d173f" continuedAt="if0f0698262a94a0a94be7d4879aec9d3" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:64.149%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzItMS0xLTEtNDAzNjg_201d9fd5-989a-4179-a1d2-da8a0ea9bbde">1,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzItMy0xLTEtNDAzNjg_99ce45a3-536c-4ba9-b84b-81301e9bf2f5">1,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:AccruedPreferredStockDividend" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzMtMS0xLTEtNDAzNjg_b567fad0-45ac-46f8-b840-217daffae126">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:AccruedPreferredStockDividend" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzMtMy0xLTEtNDAzNjg_b72cb360-6d9c-4ca0-acdc-f312a643b3a8">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:AccruedClinicalTrial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzQtMS0xLTEtNDAzNjg_bfdc8799-7821-4891-8c9a-cf8de6e71b46">2,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:AccruedClinicalTrial" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzQtMy0xLTEtNDAzNjg_00c0f60c-63d4-41df-8d63-024f75c78dae">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:Accruedresearchagreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzUtMS0xLTEtNDAzNjg_2dd6474c-6f6f-454f-ada5-0fdcce87c9e0">509</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:Accruedresearchagreements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzUtMy0xLTEtNDAzNjg_937dbbdb-6b5c-4aeb-982e-ed10f3297a0b">726</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:Accrueddirectorfees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzYtMS0xLTEtNDAzNjg_552e5c20-3b48-4e14-adbc-2954658b9b2b">125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:Accrueddirectorfees" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzYtMy0xLTEtNDAzNjg_137cc530-7a03-4373-a236-dd18a6ef62e6">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:Patentlicenseandotherfeespayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzgtMS0xLTEtNDAzNjg_d29db414-c669-4601-bf40-05e5c23664a2">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:Patentlicenseandotherfeespayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzgtMy0xLTEtNDAzNjg_0cbdea70-959d-4a0d-a512-35d44027e0cd">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzEwLTEtMS0xLTQwMzY4_360d7072-c52f-4b94-b427-5af8e7dc74e1">337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzEwLTMtMS0xLTQwMzY4_90b671b8-6916-44c5-a292-1b9a1c7b2f46">129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzExLTEtMS0xLTQwMzY4_7ebcde65-53b3-4504-b5a7-ecf366c771c9">5,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzExLTMtMS0xLTQwMzY4_478265e9-b5b6-4bc0-b0a0-2020d74707f5">4,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ied7ee4f8beb94e57afe4c0292359efad" continuedAt="i10c9c4c0ced242a5ab64150f3c46a28e"><ix:continuation id="if0f0698262a94a0a94be7d4879aec9d3" continuedAt="ibcd2afdb22584090a7c309916e5a4d60">(1)</ix:continuation></ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt"><ix:continuation id="i10c9c4c0ced242a5ab64150f3c46a28e"><ix:continuation id="ibcd2afdb22584090a7c309916e5a4d60">See Note 2 to the financial statements.</ix:continuation></ix:continuation> </span></div><div style="margin-top:5pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_283"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:OperatingLeasesOfLessorDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTU_83ff6732-15d0-4c8f-94ba-0d3a0fbc378f" continuedAt="i405eb679ccd94cc1bc7cf9bc31e18f1e" escape="true"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTY_c4539787-fb2b-4861-b689-8e87a774e930" continuedAt="id8566280e1e64a659d6e3f7070daaef1" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:continuation id="i405eb679ccd94cc1bc7cf9bc31e18f1e" continuedAt="i3369b819663f4cb881d3f0d71b3c6bb3"><ix:continuation id="id8566280e1e64a659d6e3f7070daaef1" continuedAt="ia3d8f1336ba145bdafcc1df0c8a2ecbf"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July 2021, the Company entered into an amended lease agreement to increase its occupied space, which commenced on January 1, 2022 and expires on February 28, 2027. Under the Company's prior master facility lease which expired on December 31, 2021, the Company was leasing additional suites in which it was not occupying and subleasing to third parties. The amended lease agreement retained the space that the Company was occupying, and a portion of office and lab space that was previously subleased to a third party. The remaining additional suites subleased to third parties were not included in the Company's amended sublease. The Company currently leases office and lab space in San Diego which expires on February 28, 2027. The lease currently required payments of approximately $<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:LesseeOperatingLeaseMonthlyRentPayment" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzEwMTM_cef83284-8f0d-4c91-bf75-7068a2677b6d">61,000</ix:nonFraction> per month with <ix:nonFraction unitRef="number" contextRef="i1fc787def7f7467b8134e270f125cecc_D20220101-20270228" decimals="INF" name="crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzEwNTA_eb44562a-6b4b-4d99-bf78-042bd2d31979">3</ix:nonFraction>% annual escalation. </span></div></ix:continuation></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i3369b819663f4cb881d3f0d71b3c6bb3" continuedAt="i1f6b17bef39d471b83d4cd4d12a127ee"><ix:continuation id="ia3d8f1336ba145bdafcc1df0c8a2ecbf" continuedAt="i6233232d9d9d4bcda3506091277d1259"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under <ix:nonFraction unitRef="lease" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="crdf:LessorNumberOfSubleases" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzEzNDM_b0f649f3-9a06-4793-9839-cb21e094a97e">three</ix:nonFraction> separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing its vacated space to third parties.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTA_e912cc8e-49a4-46d9-b631-663fae21c18a" continuedAt="i8c1a682ac9b146b5bf24f605e4f31415" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzEtNC0xLTEtNDAzNjg_cb64a0d9-075e-459c-bb64-f73bc9c2250b">754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzEtNi0xLTEtNDAzNjg_51eddcd1-8c57-4e80-bb9b-597389ea7398">745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:SubleaseIncome" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzItNC0xLTEtNDAzNjg_a3a40a66-2252-482b-8ca7-34c7a90ccbc9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzItNi0xLTEtNDAzNjg_a862fb66-c302-4ed5-8922-dcb8584e0276">403</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzMtNC0xLTEtNDAzNjg_f5dd61ad-dc49-483f-bf95-59c5ba8bcda5">754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzMtNi0xLTEtNDAzNjg_3bae1eab-3c94-4248-bfd5-a43d6d58bc71">342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-indent:33.75pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="crdf:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTE_12a05e89-50ee-4e8b-9238-8f469088ff33" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzEtMS0xLTEtNDAzNjg_3a0a1761-86bb-4c85-854f-e7814763cfaf">2,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzEtMy0xLTEtNDAzNjg_3dfa13c6-1db4-4dfe-bce0-bd229f1aab8b">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzMtMS0xLTEtNDAzNjg_1ae952c6-608f-491d-a28e-21e001af09fa">675</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzMtMy0xLTEtNDAzNjg_4d7a93b4-6c77-4ce2-8a04-9607fc9bbf61">551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzQtMS0xLTEtNDAzNjg_3ca745ae-ad1c-47be-b00e-7eec21836106">2,040</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzQtMy0xLTEtNDAzNjg_046279c1-17dc-415f-87ba-b4f3a62feaf4">2,568</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzUtMS0xLTEtNDAzNjg_8b4885f0-41ed-47d2-92c2-ab9648aba648">2,715</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzUtMy0xLTEtNDAzNjg_7119380d-c649-43e1-863e-fe3e33df669c">3,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzctMS0xLTEtNDAzNjg_e73469f5-26f5-4062-ac33-4019c1d80896">4.2</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzctMy0xLTEtNDAzNjg_b1cd248e-1f69-4a3b-a904-73df3371fbd1">5.2</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzgtMS0xLTEtNDAzNjg_87465180-8b4c-4fce-ad96-134308d46a4a">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzgtMy0xLTEtNDAzNjg_7f11d447-2648-4195-95b4-079f79b8f7d4">7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><ix:continuation id="i8c1a682ac9b146b5bf24f605e4f31415"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.104%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid included in operating cash flows</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzItMS0xLTEtNDAzNjg_acef30f4-e158-4251-a369-1f4ed25d5d1b">612</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:OperatingLeasePayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzItMy0xLTEtNDAzNjg_211ea335-5aa6-4728-8f73-9245ce5c2f19">949</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzQtMS0xLTEtNDAzNjg_dc17db0b-4f44-47da-8311-5deb7e705369">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzQtMy0xLTEtNDAzNjg_a44db07d-07dc-4849-bf06-5a41c456910c">3,061</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTQ_96d9d60e-71ef-473a-b528-aacdb193436d" continuedAt="ie3f61b5bec3942179105101492e6e54d" escape="true">Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:</ix:nonNumeric></span></div></ix:continuation></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-align:center"><ix:continuation id="i1f6b17bef39d471b83d4cd4d12a127ee"><ix:continuation id="i6233232d9d9d4bcda3506091277d1259"><ix:continuation id="ie3f61b5bec3942179105101492e6e54d"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.133%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzUtMi0xLTEtNDAzNjg_9635af4f-8292-4502-a298-83920431be5a">676</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzYtMi0xLTEtNDAzNjg_bbe79006-290b-437b-ba19-9faa86d71ee7">754</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzctMi0xLTEtNDAzNjg_d4d52100-9d2f-4bfe-ab89-e415fbde5890">775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzgtMi0xLTEtNDAzNjg_0a713f80-53cc-42f1-8c1c-6d9f4e73b01d">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzktMi0xLTEtNDAzNjg_cba8aca3-1235-4889-83fa-ddade479c830">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzEwLTItMS0xLTQwMzY4_ef07175f-5e61-4676-9755-fb11cae74a93">3,137</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzExLTItMS0xLTQwMzY4_b0a5ba2a-c66d-446f-9e2c-6a9b5c286fa0">422</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzEyLTItMS0xLTQwMzY4_23b05005-574b-49b4-a713-2f27ce31ca31">2,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></ix:continuation></ix:continuation></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-18</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjU2_775cedd9-7088-46e6-8dbf-fe584cfddef3" continuedAt="i65ede077e38c44a68a1a3c660678cb46" escape="true">Stockholders&#8217; Equity</ix:nonNumeric></span></div><ix:continuation id="i65ede077e38c44a68a1a3c660678cb46" continuedAt="i6e92799c8e5543c191f4c7a11c29a9d9"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjYw_f49d0fc9-2cc9-4cfb-90e8-c2a62d72d7f1" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.427%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.565%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzktMS0xLTEtNDAzNjg_d2d2ddfd-10cf-4e16-9338-699cc56306f3">5,260,992</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzktMy0xLTEtNDAzNjg_e2f88056-037b-4027-8b73-9bfee8333313">5.19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i437c6b27648f43149169d43e9d00f190_D20200101-20201231" name="crdf:WarrantsWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzktNS0xLTEtNDAzNjg_37010d58-5366-4d61-973e-bc833876dfc4">4.1</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="INF" name="crdf:ClassOfWarrantOrRightNumberExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzExLTEtMS0xLTQwMzY4_2d607165-96fd-4b7b-915a-958ced570da6">770,833</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzExLTMtMS0xLTQwMzY4_43ed2021-3c28-4837-96c9-5c5cd074f779">1.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzEzLTEtMS0xLTQwMzY4_e9e821fb-2e32-4d0b-b631-b79e48941b73">4,490,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzEzLTMtMS0xLTQwMzY4_e6007e74-5272-456f-9c30-4e4f5b1c2dcc">5.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" name="crdf:WarrantsWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzEzLTUtMS0xLTQwMzY4_c2b61681-6502-45d3-a4d4-ed4931e3aeaa">3.0</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="crdf:ClassOfWarrantOrRightNumberExpired" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE2LTEtMS0xLTQxNzI2_be9a7811-fe46-4975-90ef-c0a11752459a">129,191</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE2LTMtMS0xLTQxNzI2_fd9db044-b623-412a-8c5e-83cb25e5e178">21.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE3LTEtMS0xLTQxNzM1_59289ccc-05e7-436e-bcc4-6a939bc429e2">4,360,968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="2" name="crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE3LTMtMS0xLTQxNzM1_8cab51b6-c6bf-4d93-b1d6-ff8faea11d16">5.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="crdf:WarrantsWeightedAverageContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE3LTUtMS0xLTQxNzM1_64cb1fa1-ff4d-4213-a1d9-fdd6b746fc8c">2.1</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfStockByClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjU1_d3f2d960-69e7-46df-a23d-47179d8ddcc0" continuedAt="i0fef9e2b665347aeb9541fc16ddf19eb" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.652%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.369%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.146%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares issued and outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItMi0xLTEtNDAzNjg_8fe20694-a3e8-4e5e-8137-8748dc6fd1bc">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItNC0xLTEtNDAzNjg_58a66396-abb9-4c07-90f8-58aab8d4d03f">277,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItOC0xLTEtNDAzNjg_56f7e4d3-87cf-4357-996a-fa6eeb370c99">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i967e88231f6e41158f5760ef3badc44a_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItMTAtMS0xLTQwMzY4_03645d63-1e15-4d52-9bea-4e4c1d75420c">60,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i15da6dbca1f446fabca739e995d15020_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtMi0xLTEtNDAzNjg_6cc1bfc6-1e59-4ff1-a04e-3f1471e3601d">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15da6dbca1f446fabca739e995d15020_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtNC0xLTEtNDAzNjg_dc9075bf-97c0-4b0d-9b89-7db5c2b14f48">8,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i15da6dbca1f446fabca739e995d15020_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtOC0xLTEtNDAzNjg_20d329e3-1922-4100-b8b9-bd9efa8647d9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaf1325a8adbb464aa4a9459b6c1ebf24_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtMTAtMS0xLTQwMzY4_24b88151-6c87-487c-a10e-2f9c12116329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie1c031a24f5041998bc94baf5d5e7878_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtMi0xLTEtNDAzNjg_006737e7-0eb1-4331-b86e-2557a60fb090">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1c031a24f5041998bc94baf5d5e7878_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtNC0xLTEtNDAzNjg_a52f75b7-b88a-4550-979b-6a5a99e3112c">200,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie1c031a24f5041998bc94baf5d5e7878_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtOC0xLTEtNDAzNjg_49be7418-6fac-47d5-b63c-e076eb158f27">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib2bbcf65ab5b4c44852255c9f2d94146_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtMTAtMS0xLTQwMzY4_828b0163-2597-4ff8-9fad-4c1ff2d503cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6a7c515d9ae6485d9e93a24cb7826442_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtMi0xLTEtNDAzNjg_37db4788-e678-440f-8f38-b8b3f26dee58">0.0001</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a7c515d9ae6485d9e93a24cb7826442_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtNC0xLTEtNDAzNjg_80239350-8fc3-493d-9765-0d1b1a76770c">154,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6a7c515d9ae6485d9e93a24cb7826442_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtOC0xLTEtNDAzNjg_124bd47b-31c8-4201-9c88-9af91ebf8c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iad1bd806a546460c98ffb5ac6f3ac8c5_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtMTAtMS0xLTQwMzY4_7fb0373a-88df-48a3-9f90-df3ffe27bfd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtMi0xLTEtNDAzNjg_e6cf5293-4621-4634-8807-d509e13f26c4">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtNC0xLTEtNDAzNjg_7ed3cd2a-f11d-4d86-bc3d-9804987dc462">865,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtOC0xLTEtNDAzNjg_0b8dc22e-9b35-414c-ac84-166f3722c7fc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icf86537bddcb4f599b70afe570a83e20_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtMTAtMS0xLTQwMzY4_e10e17a9-7de3-4edd-9d11-fda450864252">655,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material terms of the Series A Convertible Preferred Stock consist of:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Dividends. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Company&#8217;s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of <ix:nonFraction unitRef="number" contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231" decimals="INF" name="us-gaap:PreferredStockDividendRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzg4OQ_950012f0-6ee8-4375-9678-006a0bc54deb">4</ix:nonFraction>% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company&#8217;s sole election, in cash or shares of common stock. As of December&#160;31, 2022 and 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="-3" name="crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzExMzE_abbedd51-bad6-4e5a-a57a-f297213edb79">438,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i967e88231f6e41158f5760ef3badc44a_I20211231" decimals="-3" name="crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzExMzg_69e9b49c-43da-4119-85c1-f3cd04ff6353">414,000</ix:nonFraction>, respectively in cumulative unpaid preferred stock dividends, included in the liquidation preference of the Series A Convertible Preferred Stock, and $<ix:nonFraction unitRef="usd" contextRef="i689740219e214ef58af97e73397e9639_D20220101-20221231" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEyODA_06ebc8fe-8411-4418-b6d6-bf420cb0c689">24,000</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231" decimals="-3" name="us-gaap:DividendsPreferredStock" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEyODc_99dce64f-b7a1-4349-aeb0-fa9cae11bc5a">24,000</ix:nonFraction> of cumulative dividends were added to the liquidation preference of the Series A Convertible Preferred Stock during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Voting Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Liquidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $<ix:nonFraction unitRef="usdPerShare" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="INF" name="crdf:ConvertiblePreferredStockStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzIzNzY_89ab1490-3e80-477a-938f-4a76b3d7afdf">10</ix:nonFraction> per share plus any accrued and unpaid dividends.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i6e92799c8e5543c191f4c7a11c29a9d9" continuedAt="ib8c4e1355e8d46d6baa4c5e4e4122201"><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Conversion Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $<ix:nonFraction unitRef="usdPerShare" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="INF" name="crdf:ConvertiblePreferredStockStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI2Mzc_e6bc9eeb-9aca-4ee9-88f7-23c7276d343c">10</ix:nonFraction> per share, by the conversion price, which at the time of issuance was $<ix:nonFraction unitRef="usdPerShare" contextRef="id0c78aec3b59415da597680943386c88_D20070701-20070930" decimals="2" name="crdf:PreferredStockConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI3MTA_07c83c97-d6ff-4678-893f-2f458132a7fb">928.80</ix:nonFraction> per share, and subsequently adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231" decimals="2" name="crdf:PreferredStockConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI3NTM_bc599314-a636-48a5-98f2-2e7f3332fbf2">691.20</ix:nonFraction> per share.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Subsequent Equity Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion price is subject to adjustment for dilutive issuances for a period of <ix:nonNumeric contextRef="i6e2742890db242d6bf741c1ee3352f61_D20060317-20060317" name="crdf:PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI4Nzk_a3823b7d-4d90-4f16-8bba-97183cf0a769">12</ix:nonNumeric> months beginning March 17, 2006 and the conversion price was adjusted to $<ix:nonFraction unitRef="usdPerShare" contextRef="i6e2742890db242d6bf741c1ee3352f61_D20060317-20060317" decimals="2" name="crdf:PreferredStockConversionPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI5NDg_8d223feb-7b3b-4ef8-9c71-e68a7024efee">691.20</ix:nonFraction> per share.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"> Automatic Conversion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the price of the Company&#8217;s common stock equals $<ix:nonFraction unitRef="usdPerShare" contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231" decimals="2" name="crdf:SharePriceForAutomaticConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMwMzk_d74ec215-9bbd-4ef9-a776-d892c87e150c">1,857.60</ix:nonFraction> per share for <ix:nonNumeric contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231" name="crdf:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMwNTY_d11511cb-761f-4b29-b416-b3d1900ef646">20</ix:nonNumeric> consecutive trading days, and an average of <ix:nonFraction unitRef="shares" contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231" decimals="INF" name="crdf:PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMxMDM_e05f9017-2ca8-4c5b-a7db-f42e8e771aaf">116</ix:nonFraction> shares of common stock per day are traded during the <ix:nonNumeric contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231" name="crdf:PreferredStockConversionObligationNumberOfTradingDays" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMxNTk_f7a52afc-c77c-4b0a-b558-381fe0ad23ca">20</ix:nonNumeric> trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met.</span></div><div style="text-indent:58.5pt"><span><br/></span></div><ix:continuation id="i0fef9e2b665347aeb9541fc16ddf19eb"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the liquidation preference for the Series A Convertible Preferred Stock were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.424%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated Value per share liquidation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:PreferredStockLiquidationPreferenceStatedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzItMS0xLTEtNDYwMTg_702894bc-7d90-47c8-917a-b1477c91bf25">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:PreferredStockLiquidationPreferenceStatedValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzItMy0xLTEtNDYwMjA_0632cb4c-d577-4011-ac52-7c7eef0d8f13">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative unpaid preferred stock dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2513f13b8a974c7daed93b812f580722_I20221231" decimals="-3" name="crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzMtMS0xLTEtNDM5NjE_abbedd51-bad6-4e5a-a57a-f297213edb79">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i967e88231f6e41158f5760ef3badc44a_I20211231" decimals="-3" name="crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzMtMy0xLTEtNDM5NjE_69e9b49c-43da-4119-85c1-f3cd04ff6353">414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation preference - Series A Convertible Preferred Stock</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzQtMS0xLTEtNDYwMTM_b6b72b94-de11-412b-b891-7db7b7ac69d3">1,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:PreferredStockLiquidationPreferenceValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzQtMy0xLTEtNDYwMTU_2904e258-74d3-4b00-b8ca-35a0ef37139c">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series E Convertible Preferred Stock</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020 the Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of <ix:nonFraction unitRef="shares" contextRef="icfbfb8b01efa4a1299b3d55a92ac99c6_D20200615-20200615" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU3NzU_ad967666-2865-4b1a-a14d-6801fbbc2304">1,984,328</ix:nonFraction> shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of <ix:nonFraction unitRef="shares" contextRef="i945e201b0a974dac9a79bbce7e560aac_D20200615-20200615" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU4NjU_3302526e-7005-457a-b5c4-ce546a9d5d52">865,824</ix:nonFraction> shares of Series E Preferred Stock (&#8220;Series E Preferred Stock&#8221;) and (b) Series N warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="i6fbb0b602b174b52b951641f74a93e02_I20200615" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU5NzY_4b573814-45b2-4670-a8ff-0b947668f96d">2,213,115</ix:nonFraction> shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4060629a24449e582b7b1c954cde009_I20200615" decimals="INF" name="crdf:ConvertiblePreferredStockStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYwODY_9105eb1a-b35d-4b50-8d60-8b19c8cd55e2">10</ix:nonFraction> stated value per share of the Series E Preferred Stock by a conversion price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ia4060629a24449e582b7b1c954cde009_I20200615" decimals="INF" name="us-gaap:PreferredStockConvertibleConversionPrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYxNjk_e612e965-e41d-4540-9ab4-35f348ccb5a7">2.44</ix:nonFraction> per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable <ix:nonNumeric contextRef="i01b6d2c9f16c4851800bc4d351b41c95_D20200615-20200615" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYyOTg_673b24a6-cec5-45ec-abae-d7c277425a6f">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i34bf0c72c7264502a3fd19a93c17fc34_I20200615" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYzNTY_56360534-01b1-4fcd-be12-a5a820c0277f">2.39</ix:nonFraction> per share and will expire on December 16, 2025. Certain investors converted <ix:nonFraction unitRef="shares" contextRef="i1ac45431f2954aeea968270d5152763f_D20201201-20201231" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzY0MzU_305fc83d-80cd-4bf8-95da-8ca1c6c74493">210,780</ix:nonFraction> shares of Series E Convertible Preferred stock to <ix:nonFraction unitRef="shares" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="INF" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzY0ODg_3039607a-e358-4987-b117-553ca85cf777">863,852</ix:nonFraction> shares of Common Stock during December 2020. Certain investors converted <ix:nonFraction unitRef="shares" contextRef="iba4fe2a0ab954fd996d5aeadefcf0d29_D20220101-20220131" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTE3OQ_4eda180a-ba54-4684-a278-d41c3a6e3e6a">327,535</ix:nonFraction> shares of Series E Convertible Preferred stock to <ix:nonFraction unitRef="shares" contextRef="i537f6a2ef9cb45469a00fe1de5bbadbd_D20220101-20220131" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTE4OA_edc50b92-4ec8-4ffd-87fc-698ac2bcaf33">1,342,357</ix:nonFraction> shares of Common Stock during January 2022. Certain investors converted <ix:nonFraction unitRef="shares" contextRef="i05f68406df2c440b8b525d03472d93a8_D20221001-20221031" decimals="INF" name="us-gaap:ConversionOfStockSharesConverted1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTE5OQ_0e3c9638-6db3-47ec-be39-ac7b88dd4773">327,509</ix:nonFraction> shares of Series E Convertible Preferred stock to <ix:nonFraction unitRef="shares" contextRef="i5c69ebdd813b43cf9b9e7435a5b93db8_D20221001-20221031" decimals="INF" name="us-gaap:ConversionOfStockSharesIssued1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTIwOA_ba11877f-0584-42bd-b0ab-4b4cc73d0736">1,342,250</ix:nonFraction> shares of Common Stock during October 2022. As of December 31, 2022 <ix:nonFraction unitRef="shares" contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTIxOA_32d0623b-4b7a-4abc-9ba3-eff0f1eaa254">no</ix:nonFraction> shares of Series E Convertible Preferred stock were outstanding. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In conjunction with the June 15, 2020 offering, we issued <ix:nonFraction unitRef="shares" contextRef="i6fbb0b602b174b52b951641f74a93e02_I20200615" decimals="INF" name="crdf:ClassOfWarrantOrRightIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzcyMzQ_8f88f840-43c5-4cf1-98f2-abbfba3acc31">184,426</ix:nonFraction> warrants as an advisory fee. These warrants are exercisable <ix:nonNumeric contextRef="i121f9fb27a22487c9da80cbd21f3696c_D20200615-20200615" name="crdf:ClassOfWarrantOrRightMonthsUntilExercisable" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzcyOTc_2379a10e-2176-4e2a-831c-9880f5317dbe">six months</ix:nonNumeric> following the date of issuance at an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6fbb0b602b174b52b951641f74a93e02_I20200615" decimals="2" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzczNTU_0eb9fb62-815a-4732-bb60-8ed736662644">3.05</ix:nonFraction> per share and will expire <ix:nonNumeric contextRef="i121f9fb27a22487c9da80cbd21f3696c_D20200615-20200615" name="crdf:ClassOfWarrantOrRightExpirationTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzczODQ_fc0c0523-4f2f-4155-ac18-a8324245338d">5.5</ix:nonNumeric> years following the date of issuance. These warrants were classified as equity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Agreement with Jefferies LLC</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i108dcc73776440a2bb02b0906b8fb804_D20210501-20210531" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzk5OTc_08f63875-fcdf-4380-af17-9e3c26836de3">2.0</ix:nonFraction>&#160;million shares of its common stock under the Sales Agreement with Jefferies LLC., for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i108dcc73776440a2bb02b0906b8fb804_D20210501-20210531" decimals="-5" name="crdf:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwMTEw_a2af44e1-40fb-40f5-8f4e-5d37b0283723">20.0</ix:nonFraction>&#160;million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Breakthrough Growth Initiative</span></div></ix:continuation><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib8c4e1355e8d46d6baa4c5e4e4122201">During November 2021, the Company sold <ix:nonFraction unitRef="shares" contextRef="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwMTk1_101e6f1a-0134-42af-bc32-39855a521d3e">2.4</ix:nonFraction>&#160;million shares of its common stock under a Securities Purchase Agreement with Pfizer Inc. ("Pfizer"), in a registered direct offering for gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130" decimals="-5" name="crdf:SaleOfStockConsiderationReceivedOnTransactionGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwMzYw_5a61e508-b1ec-4cfd-9197-8874b370a199">15.0</ix:nonFraction>&#160;million. The investment is part of the Pfizer Breakthrough Growth Initiative, which includes an information rights agreement and Pfizer's participation on a Scientific Advisory Board for the Company. Pfizer agreed to not sell or transfer any shares for <ix:nonNumeric contextRef="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130" name="crdf:SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjEy_bee8c8b7-94f8-48ef-bfa5-dc3cdd7a1947">180</ix:nonNumeric> days from the closing date of the agreement, which expired during May 2022.</ix:continuation> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-20</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjc_3e34ca7a-b9ba-425a-95dd-efab1d5354b9" continuedAt="ife6481d4f2e54f509a4ddd623c1fc6b9" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="ife6481d4f2e54f509a4ddd623c1fc6b9" continuedAt="i86b9ffb2967e4a9a9fa966f06084398e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 plan is equal to the sum of (i) <ix:nonFraction unitRef="shares" contextRef="i7370af0295e247098c3f37e012a4710d_I20210630" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzI0Mg_b31016da-2f08-4f3c-9984-bcb9ffe517e9">3,150,000</ix:nonFraction> shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022 the shareholders approved an increase of shares authorized in the 2021 Plan to <ix:nonFraction unitRef="shares" contextRef="ib2ae2c2e51104727ab30997d35b6e45b_I20220609" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzEwOTk1MTE2MzIyMTg_363e71f3-acda-4fa2-b5cf-c738404370dd">5,150,000</ix:nonFraction>. As of December&#160;31, 2022, there were <ix:nonFraction unitRef="shares" contextRef="i9738a5e163944c6ea598de6c5bd1a81c_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQ2MQ_f1ab1374-b4e2-437d-b422-72fdf744acb6">3,087,075</ix:nonFraction> shares available for issuance under the 2021 Plan.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of December&#160;31, 2022, an aggregate of <ix:nonFraction unitRef="shares" contextRef="ia3450ae440464e099c7b194d9e93da51_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzgzNw_8c7d044d-aa37-4b09-b0b1-8960329a87f6">920,208</ix:nonFraction> shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of Stock Options</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 one of the Company's directors did not seek another term on the Board of Directors. At the time of departure, the Compensation Committee passed a resolution to extend the expiration date of the vested stock options, and to immediately accelerate the vesting of the unvested options. The Company recorded incremental reduction to stock compensation expense of $<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzEwOTk1MTE2MzM1Mzg_90f34b2e-609c-4886-bed7-0bc17f56c577">0.1</ix:nonFraction>&#160;million during the year ended December 31, 2022, related to the modifications.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 two of the Company's directors' terms ended. At the conclusion of their term, the Compensation Committee passed a resolution to extend the expiration date of the departing directors vested stock options, and to immediately accelerate the vesting of one of the directors unvested options. The Company recorded incremental stock compensation expenses of $<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzEzMzU_efaa986a-4976-44e8-a5ce-67b5d4121468">0.6</ix:nonFraction>&#160;million during the year ended December 31, 2021, related to the modifications. </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjg_7ea886e0-dfa8-4945-afa8-b6b7d8bd5530" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation has been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4075c1548dc7491f83a6970912aca8fa_D20220101-20221231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzMtMS0xLTEtNDAzNjg_796f62f2-9287-4378-a814-39a8751aec7a">1,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88d9796297a64fb8928bef8b221160e5_D20210101-20211231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzMtMy0xLTEtNDAzNjg_02e4529c-b81b-4883-b054-fafc981b7def">491</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7653394ffa3343d58c6ca060d5bfc38e_D20220101-20221231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzUtMS0xLTEtNDAzNjg_975b6453-89b6-42f4-99fe-9bcc77f5b6a2">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f1151fb051c43a3a54f391052603412_D20210101-20211231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzUtMy0xLTEtNDAzNjg_7002f245-9719-42df-a19c-1060e0659967">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzctMS0xLTEtNDAzNjg_db6ff5f0-db4e-4274-b4de-50b93ac965a3">4,256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="0" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzctMy0xLTEtNDAzNjg_a23d944a-5411-42c7-a5e3-e7473e9060d6">3,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjA_dccbd3f8-6f9b-4fd8-ab62-215e415a6ed5" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.360%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12ca60f5c6f2431eb4b26a3b8e10d21f_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo1YWZmM2VmZmUxMTY0NTE2OGQ5MmNlMzg1NzI4NWJmMF80_a7a26753-800a-49d3-bc70-cc7ea2d9a6b5">1.62</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i54f3b30b34ae4b56b912ae1b787704d5_D20220101-20221231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo1YWZmM2VmZmUxMTY0NTE2OGQ5MmNlMzg1NzI4NWJmMF85_57a6b05f-aca6-4bab-8a2e-1f868b99259e">3.75</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d91a06d3c074593b7c7a0c70ea5c098_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjphNzhhOGY5MjkwZWM0OGZiYWQ5MjY0NTlhNTY0YWY3MV80_1ac66263-987e-4052-8c20-072f6354d98e">0.83</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia6c27981ae474b778f9da78071df3c6c_D20210101-20211231" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjphNzhhOGY5MjkwZWM0OGZiYWQ5MjY0NTlhNTY0YWY3MV85_a466f87d-aff2-4171-a81a-86a5062dea37">1.3</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzMtMS0xLTEtNDAzNjg_83a138f9-5c71-4393-be9f-f3ce6a327637">0</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzMtMy0xLTEtNDAzNjg_4b8f8e5a-d453-4472-85e8-7aef54799f09">0</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (range)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12ca60f5c6f2431eb4b26a3b8e10d21f_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjoxNzk2MDhlZjVkNTQ0MWY2ODc5NTAxMmEyNjFkZTUxOF80_00337b98-a3ba-49c8-871e-65f2ff33237b">98</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i54f3b30b34ae4b56b912ae1b787704d5_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjoxNzk2MDhlZjVkNTQ0MWY2ODc5NTAxMmEyNjFkZTUxOF85_09af661b-c633-4c02-9603-d12ba4f8a0f1">110</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d91a06d3c074593b7c7a0c70ea5c098_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo0ZGU3NGM5NGI5ZDg0Y2MwOThjZWJlMzhiYWYwZmJiY180_1f78c537-1481-4dc9-8883-a23ca612d6c1">107</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="ia6c27981ae474b778f9da78071df3c6c_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo0ZGU3NGM5NGI5ZDg0Y2MwOThjZWJlMzhiYWYwZmJiY185_599280e9-136c-4626-a6f9-455f13a9599a">110</ix:nonFraction>%</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (weighted-average)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzUtMS0xLTEtNDAzNjg_3043ecad-d599-4e4c-bfc9-31f8420cccb0">106</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzUtMy0xLTEtNDAzNjg_ad9a1584-36b0-46c8-b60e-222d94e1f439">108</ix:nonFraction>%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzYtMS0xLTEtNDAzNjg_610dfbcc-49dd-4d09-b2b4-dbb97ce35a6e">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzYtMy0xLTEtNDAzNjg_daf33f37-dba5-4ccc-bf8e-161836df8085">6.0</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i86b9ffb2967e4a9a9fa966f06084398e"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#8217;s stock options.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Cardiff Oncology has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the historical volatility of Cardiff Oncology&#8217;s common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method, which represents the Company's best estimate following the Company's restructuring in 2018. This method averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain vanilla&#8221; share options. Options are considered to be &#8220;plain vanilla&#8221; if they have the following basic characteristics: (1) are granted &#8220;at-the-money&#8221;; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates forfeitures based on its historical experience.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value per share of all options granted during the years ended December&#160;31, 2022 and 2021, estimated as of the grant date using the Black-Scholes option valuation model, was $<ix:nonFraction unitRef="usdPerShare" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMwOTQ_407bcd01-9d95-496a-bc41-a1ca6e63f0e4">2.55</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMxMDE_aea0904e-da3b-4325-bb07-bd73465110cb">5.96</ix:nonFraction> per share, respectively.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at December&#160;31, 2022 was $<ix:nonFraction unitRef="usd" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMyMjQ_72aef9c8-07fd-4ade-a9c6-1878af6e68e3">8.8</ix:nonFraction> million. The weighted-average remaining amortization period at December&#160;31, 2022 for non-vested stock options was <ix:nonNumeric contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMzMTg_df5ab49d-592b-4a01-95c7-02cf6cbd3d8a">2.6</ix:nonNumeric> years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested during the years ended December&#160;31, 2022 and 2021 was $<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMzOTk_8abd1a05-0bcd-4315-9ab4-c13c44103ac2">4.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzM0MDY_4f7b5186-ff81-4092-8838-abf8f80667a7">1.2</ix:nonFraction> million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjM_fe51af1a-45ab-4ffe-a971-8a929670d7f5" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and of changes in stock options outstanding is presented below:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:45.752%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2095721442fd459a96884e78016c08c6_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTEtMS0xLTQwMzY4_e4f064a1-42c0-477a-8237-708743f53b4e">3,771,984</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2095721442fd459a96884e78016c08c6_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTMtMS0xLTQwMzY4_36cf2a4b-d1e5-4af5-a73e-d5ca91681ec1">7.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2095721442fd459a96884e78016c08c6_I20211231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTUtMS0xLTQwMzY4_9e615d21-8f9c-47d4-b01b-bc75b30bd11a">6,405,258</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTctMS0xLTQwMzY4_8780db61-2dc0-439d-bde9-97cbed232f4e">8.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTEtMS0xLTQyMDA2_c670d149-eead-4066-a0b5-d40654c37f8a">1,737,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTMtMS0xLTQyMDA2_7fefd6d4-c55d-4d0c-b00c-1e732700a9ab">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTEtMS0xLTQyMDA2_eb7a6d72-d43a-4a5a-8d21-b70d701fec41">28,858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTMtMS0xLTQyMDA2_44643e63-7f20-4291-87cb-2a6a10de36c8">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTUtMS0xLTQyMDA2_8a7ddd45-10ab-43ef-a142-406c043ed432">1,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE4LTEtMS0xLTQyMDA2_a2425bfe-8108-4f4b-8328-909ad9522453">398,156</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE4LTMtMS0xLTQyMDA2_33605c7b-e8bf-4b09-a279-f773b0b8dabf">4.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="INF" name="crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE5LTEtMS0xLTQyMDA2_70b5157d-d29d-4edd-8583-2ee96b7b3467">13,272</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" decimals="2" name="crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE5LTMtMS0xLTQyMDA2_6c298747-346e-4fa0-953d-ce0fcbf650a6">32.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTEtMS0xLTQyMDA2_f4b9f531-9e6e-4e04-850c-cc7ac10760f6">5,069,458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTMtMS0xLTQyMDA2_08d3d58b-3bf4-440f-bce8-312e065a092a">5.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTUtMS0xLTQyMDA2_02540513-43b0-4f80-8844-b013216083e6">19,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTctMS0xLTQyMDA2_4199eaf1-c812-456f-9e56-d6d56e0021c9">7.4</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTEtMS0xLTQwMzY4_49b93f86-22a9-4da7-939f-fd709ad21c8d">2,300,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTMtMS0xLTQwMzY4_8a52f785-ae9b-4d1a-aabb-8051b748b0f8">7.38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTUtMS0xLTQwMzY4_84789b0c-a185-4f6a-822f-fbde49e86971">12,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTctMS0xLTQwMzY4_60604375-7ed5-4fd9-bef2-554b0c46873f">5.7</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTEtMS0xLTQwMzY4_ff10d8f8-8da4-4397-ad0b-eaf7b0df4f5e">4,990,351</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTMtMS0xLTQwMzY4_a5799b71-2159-4e0a-af94-d86d0e2c1e76">5.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c1532e9351741698480572142e9d643_I20221231" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTUtMS0xLTQwMzY4_c264909b-aa24-49ce-9934-f4c33e6d4bf6">18,752</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTctMS0xLTQwMzY4_93f1770d-1495-440e-b3e6-bf77a038a7d3">7.4</ix:nonNumeric> years</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_292"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90ZXh0cmVnaW9uOjk4MGE5MTIyNWUzYTRmYWRiY2M4ZjFhMzA4YWU0MjBkXzEyMjk_f35057b6-2310-4818-a91b-13981c0914e5" continuedAt="i624dad4e54b14915b7ff0f0fe67f5acd" escape="true">Derivative Financial Instruments &#8212; Warrants</ix:nonNumeric></span></div><ix:continuation id="i624dad4e54b14915b7ff0f0fe67f5acd" continuedAt="i12b188934b314aa09fbe1ceca5c92946"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain warrants issued in connection with the Company&#8217;s equity financings are accounted for as derivative liabilities. Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model. Changes in fair value are recorded within Company&#8217;s statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90ZXh0cmVnaW9uOjk4MGE5MTIyNWUzYTRmYWRiY2M4ZjFhMzA4YWU0MjBkXzEyMTk_925515d8-a526-4131-a495-b58697666d20" continuedAt="i372544a88b7a4842b998c0bbcdfc1f4e" escape="true"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i12b188934b314aa09fbe1ceca5c92946"><div style="margin-top:5pt"><ix:continuation id="i372544a88b7a4842b998c0bbcdfc1f4e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:62.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.495%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.496%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i742d83ea624f49ce83073c6574708721_D20220101-20221231" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzMtMS0xLTEtNDAzNjg_86be0c76-1626-4a58-aba0-c876ff072868">1.40</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i0303b15e3f184176afecec0057db48a9_D20210101-20211231" decimals="2" name="crdf:EstimatedFairValueOfWarrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzMtMy0xLTEtNDAzNjg_03e6b621-0a61-4ec8-bb5a-a0d46f19ecd2">6.01</ix:nonFraction></span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3aa54b0f02c246f49fa614c49650a57b_I20221231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzQtMS0xLTEtNDAzNjg_30c3e920-b51a-490e-af81-05166c6bb8dc">0.1</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i271b9a9812a34766a92109b7e9619679_I20211231" name="us-gaap:WarrantsAndRightsOutstandingTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzQtMy0xLTEtNDAzNjg_3c4cd69c-0c06-4c1b-8f96-df69a86b3690">1.1</ix:nonNumeric> years</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad6ba7c42c22486fbe96bea3b5c38401_I20221231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzUtMS0xLTEtNDAzNjg_92637dc5-558e-46e7-a450-2a6ea034bd72">4.12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92fafe950c8f4417b2b04359b916f56c_I20211231" decimals="4" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzUtMy0xLTEtNDAzNjg_3d214e19-7fbc-4f65-97a6-83e526bb9124">0.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id0914d051b344922b3bc650fe526e585_I20221231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzYtMS0xLTEtNDAzNjg_257de21b-e815-459c-adff-91146c07f82c">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iff69cbb07e994ae88562ba51fc89f559_I20211231" decimals="3" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzYtMy0xLTEtNDAzNjg_58b1eef0-57c3-4b82-8949-ba2d31899155">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a07aa7c69da44d09083212536411b77_I20221231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzctMS0xLTEtNDAzNjg_9dade6b1-8dbd-4b31-98ed-38d65f83fd5f">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2569ead797594df6944309ee7f73c65a_I20211231" decimals="INF" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzctMy0xLTEtNDAzNjg_eedc72a4-294f-425b-a9f4-273727d44ce2">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on the historical volatility of Cardiff Oncology&#8217;s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231" name="crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90ZXh0cmVnaW9uOjk4MGE5MTIyNWUzYTRmYWRiY2M4ZjFhMzA4YWU0MjBkXzEyMTY_736ab2fd-b7bc-4f0c-84ba-afa32cf3480e" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for number of warrants)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i39321e212ba6459991b552dacbff98c5_I20201231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzItNC0xLTEtNDAzNjg_266f7c6d-5c43-4b75-ab5c-bdcb10a76f7e">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39321e212ba6459991b552dacbff98c5_I20201231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzItNi0xLTEtNDAzNjg_c1cbfdc9-0a5d-4d57-a458-e64458dccbf3">285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the year recognized as a gain in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26cfa5a3c7f344f38855d2fe383ea8ca_D20210101-20211231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzQtNi0xLTEtNDAzNjg_c51fb1ea-6fbc-49f1-9f5e-5f5a422fc764">285</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic357b095a944414684981c1dc8b89fb7_I20211231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzUtNC0xLTEtNDAzNjg_106262ea-fbeb-4432-b01a-02b8f7115e01">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic357b095a944414684981c1dc8b89fb7_I20211231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzUtNi0xLTEtNDAzNjg_1e7b9803-ef2c-4c20-a558-84f5257c0d29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants  during the year recognized as a loss in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5a580a4d19d4faaa1dc83d296793561_D20220101-20221231" decimals="-3" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzctNi0xLTEtNDAzNjg_cceea88a-a2bf-481f-b097-3c943aabeb50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7db42fc039fd45aeaea7b5bc0553089e_I20221231" decimals="INF" name="us-gaap:ClassOfWarrantOrRightOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzgtNC0xLTEtNDAzNjg_7a6a8a1c-1cbd-4454-b716-86f765588488">64,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db42fc039fd45aeaea7b5bc0553089e_I20221231" decimals="-3" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzgtNi0xLTEtNDAzNjg_8e409c7a-bb32-4403-bf77-fee5a8d9a59d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-23</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_295"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90ZXh0cmVnaW9uOmZjZmY2NjcwZDBkNDQ1MmQ5NDY1OTc1YmQzZDRkNzMwXzEwNjY_2890fa81-5c1d-4e46-9960-28825c2cc7b8" continuedAt="ib32d9565308144c49929e5d20b9c3469" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="ib32d9565308144c49929e5d20b9c3469"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90ZXh0cmVnaW9uOmZjZmY2NjcwZDBkNDQ1MmQ5NDY1OTc1YmQzZDRkNzMwXzEwNjk_3786dbe0-68cb-41d3-abf3-6f6f1b2ccfe6" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2022 and 2021:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91378a5db9e4460aa7fd228629188cda_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtMS0xLTEtNDYwMzI_ed3b647b-d860-4ddd-bc23-935b4804b3bd">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i559bf50fb42d497ebedd77cbd829099a_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtMy0xLTEtNDYwMzI_af9e92ec-93f2-419d-bc05-c7f4f430abe5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fda4d776d4441dbbfb4413a40f5e88c_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtNS0xLTEtNDYwMzI_a71bdc61-7de9-45cd-a8d0-8725ebb9f781">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15b0c01e3be148e2b5d184d7b0a95541_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtNy0xLTEtNDYwMzI_b5535259-9eb5-4679-9e15-2d2cd1ebd037">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4fe76ae8674e07a30a62a4550a8659_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtMS0xLTEtNDYwMzc_2fe3b16d-bde5-42b4-865d-902ef0ea19f8">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtMy0xLTEtNDYwMzc_17284a30-c0d1-4d2f-9915-1664732ec8e0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a535f0f5474b53930803ca83868183_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtNS0xLTEtNDYwMzc_9da2b118-05a4-4337-897f-e1de7e999d83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fe2e4f93f04be6b765339abdde93a3_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtNy0xLTEtNDYwMzc_966efac7-96f7-4f9f-b3d7-1691a84fe19d">15,722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccb84b1da2524dcca88a14bcd81ef349_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtMS0xLTEtNDYwMzc_76729e13-5bcc-4203-91fb-3ee71f5e192b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05871e6ded54574ac496cd98d0e4696_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtMy0xLTEtNDYwMzc_d4082f25-4ce3-40db-9334-f312bdade83b">16,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie85454a3cb3a449e989750c88baec3c3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtNS0xLTEtNDYwMzc_8ea4b8ed-c4b5-473b-b0de-5a6ff9022d5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b5d8a47de34c9eb00dd9153e2778de_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtNy0xLTEtNDYwMzc_8b5a2700-30f8-44c5-a7a6-1d4668a85faa">16,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if98e0631384e478d878a491576d94a8a_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktMS0xLTEtNDYwMzc_99ed35f5-804e-4c1a-bcc2-5c1be1a80ab5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide57bacb5fcd4817820479a301609b87_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktMy0xLTEtNDYwMzc_1ba66bb1-dbb6-4bdd-81b5-bc5f6a1dcf24">49,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18b7ac7b497e43c5a2626cc79179be2c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktNS0xLTEtNDYwMzc_62f40c71-4450-4468-9811-bdf9c105c0a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb973974a4fc444080d9042fa7203123_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktNy0xLTEtNDYwMzc_6c92e250-d8ec-4034-bb29-e21dad01a6b1">49,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6514853ca989457f9d06c6c616a89977_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTEtMS0xLTQ2MDM3_980117d2-2377-4f17-8f6f-50ad5955b223">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce1d5e58a8f4ea4b1a87da480e31782_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTMtMS0xLTQ2MDM3_0e4d4436-a5cf-4a7b-bfc4-f7419449a406">13,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0acf1c3b475f4b8a81a25aee9941f99b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTUtMS0xLTQ2MDM3_5c21199b-13b7-4275-a1d2-5b0cda66f9f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id799229c6920407f97f22581a8fa94e6_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTctMS0xLTQ2MDM3_84b865ee-4725-47a6-940c-28feb326431f">13,187</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee9cd5b6263248798f95445a96022bad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTEtMS0xLTQ2MDM5_2fbe10c1-e81a-4034-960f-b576e31580f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6eeede3e492747df92a9120df4d9cc8e_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTMtMS0xLTQ2MDM5_a296a904-132a-49fd-9858-e6ffa51c4bd3">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i101cb968b2e848d79fffd76c16210cef_I20221231" xsi:nil="true" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTUtMS0xLTQ2MDM5_40418d33-5932-4310-9847-bff2062e3715"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82958f514bb0410cacf6fa01b1a48f5d_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTctMS0xLTQ2MDM5_f55df3e7-25ca-47a8-b08a-a8d227aca388">2,288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida5f1f7b2ea54929968874ffdbd66397_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTEtMS0xLTQ2MDM5_dd705091-ac99-4734-a11e-975f92411089">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef0de49d2b147eca762ee3c00cc7304_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTMtMS0xLTQ2MDM5_a8cf4f70-8433-4af4-ada2-5c254f5d01a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae038c8a23044d3ebf1fcfa5f900eb65_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTUtMS0xLTQ2MDM5_d9c3f34e-2491-49a8-882c-8109861f8332">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d6e1e6167d64ccaa6c44f9ba201432f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTctMS0xLTQ2MDM5_0b64b8fe-3d66-460f-b3b3-09192cf95459">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4fe76ae8674e07a30a62a4550a8659_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTEtMS0xLTQ2MDM5_11b00d25-fa39-44b2-9e77-f3426b6d27de">7,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTMtMS0xLTQ2MDM5_1325edec-75eb-4e52-970e-d7cd9815d3bd">81,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a535f0f5474b53930803ca83868183_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTUtMS0xLTQ2MDM5_03f0334b-17da-4983-a5be-92607c7ebb70">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fe2e4f93f04be6b765339abdde93a3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTctMS0xLTQ2MDM5_03730a49-27e5-48c1-af3b-a32288d1fcc8">88,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d4fe76ae8674e07a30a62a4550a8659_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTEtMS0xLTQ2MDM5_c663f383-292b-4018-9973-04192b33e3ec">23,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTMtMS0xLTQ2MDM5_8064b368-a3c0-4b96-847d-d818ab68ba9d">81,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31a535f0f5474b53930803ca83868183_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTUtMS0xLTQ2MDM5_5820ea3c-dd86-4ba5-80c2-8d631f62fa6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19fe2e4f93f04be6b765339abdde93a3_I20221231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTctMS0xLTQ2MDM5_9e289132-2644-413d-890f-cb28c999428b">104,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.190%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.293%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.512%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ef75d470db04581b85f0f68742c2606_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtMS0xLTEtNDAzNjg_9a190437-b038-40c0-a009-ba9d7b8669b6">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2ee687a6f34deb8370b027572ae45d_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtMy0xLTEtNDAzNjg_f90ea235-d974-414f-8828-853b7addf8d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i291d4bc8966f478cb947f0421e4b1625_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtNS0xLTEtNDAzNjg_6e068f2a-a93d-4f57-b3da-09c758164f87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2e4c7108fe54d94a35daa0010043cdb_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtNy0xLTEtNDAzNjg_cbc1c2fd-7d36-4546-bffb-a2f449394439">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic637b3f96e40484683e069e269081b5a_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtMS0xLTEtNDAzNjg_122f8d01-ddc6-490e-a008-e5a3878eff23">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtMy0xLTEtNDAzNjg_d34aa999-3bb9-4a48-8c66-a31c6641ea87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id928b4407f1f45369fc9e7339ca8dc19_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtNS0xLTEtNDAzNjg_bf50a425-1a2a-4b4f-a019-3fa63c8a2a6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtNy0xLTEtNDAzNjg_63750681-10f1-44b9-af41-5963673aec71">10,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cf29fe2ae264154a0c772eac0487121_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtMS0xLTEtNDAzNjg_d6dd2c6f-4604-4537-a86e-94aeaa2269f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d295ad0fab4be1ab0b93436cbf5e45_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtMy0xLTEtNDAzNjg_5aa7399a-85cb-484e-a168-6a329a34781a">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96c3d5ecadf6458bb42cbcca79de87c5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtNS0xLTEtNDAzNjg_8e519961-e442-43f9-a961-d8f3de913ae1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58cd328823a74a059647630be8c9bd53_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtNy0xLTEtNDAzNjg_48df6c11-8fe9-45f4-80dd-6ce081afdc61">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d946c3997c8417998d8519879aed8e5_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktMS0xLTEtNDAzNjg_22e44213-14b1-41a9-b716-8978e701ad98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519eaf766bb74f9d94fda2c533facecd_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktMy0xLTEtNDAzNjg_fd27c031-b035-4607-8c8f-7f4d88b80135">88,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57286981e17d447682811b77a9794aaa_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktNS0xLTEtNDAzNjg_2f2d90a6-0884-4512-9445-71d2537fbc40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f92ad9ff9224a48ac42201d146a3949_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktNy0xLTEtNDAzNjg_2925bbc6-da71-4a07-926d-1389984298f6">88,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39404762c230459fbd8d949512073537_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTEtMS0xLTQwMzY4_c1ef975b-fd25-4045-a4fb-7256e6b9f89a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdda4c739f784510827447c73dcf98f8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTMtMS0xLTQwMzY4_566bcde0-4227-453e-92ab-c56dc60959f3">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i371c8b26e2e74115ab24d25d9f222d61_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTUtMS0xLTQwMzY4_7e225c73-0f96-4763-8a4a-8e8925e2593b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40877594c7984b29870c62f1c8d1bdc8_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTctMS0xLTQwMzY4_851da7ad-f945-4ff7-9a3e-b0bb95b376fb">14,454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac4c76631b14de28b082ab760f8c24d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTEtMS0xLTQwMzY4_1e84a5de-43a7-4e44-ab3e-cbd8d5c35f6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59de1a0bb89f47af947b9f576e513d78_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTMtMS0xLTQwMzY4_f71a11ec-17b7-41bb-a36f-9a19fc767ee1">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b28a9f7521d4d68bf4be2df75a35b05_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTUtMS0xLTQwMzY4_f483fdd9-b573-4864-a15e-8c897a55bb5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41d8e41740a749a489f23559bd330d4e_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTctMS0xLTQwMzY4_1718ccfd-f76d-4077-b3bc-dc7c78484d5a">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95814041224f4377a9cb681bea4771a2_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTEtMS0xLTQwMzY4_e63aacce-cfca-4ca2-a887-a4d4a9a4ed8c">24,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iede7ddb493894499ac185e6508bb0bec_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTMtMS0xLTQwMzY4_9018c971-9e63-4db3-abba-46aab70d322c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5863e8943b44c3aae93910dab768c3d_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTUtMS0xLTQwMzY4_a7f8acae-7742-41cb-8799-8ba359427e0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db2823712cb403fb76468ee499dba28_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTctMS0xLTQwMzY4_53a2163e-a11e-4d08-ac2e-0c834ef83fac">24,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic637b3f96e40484683e069e269081b5a_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTEtMS0xLTQwMzY4_4437da49-7218-446d-b801-2e29a440a478">24,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTMtMS0xLTQwMzY4_c6d01328-d089-4091-a41d-e267d82bc56c">104,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id928b4407f1f45369fc9e7339ca8dc19_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTUtMS0xLTQwMzY4_dfa58ee0-b8e7-4f32-91ed-7293e7c0ea59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTctMS0xLTQwMzY4_2ad7a861-4f08-46ad-98ee-9891497b31f4">128,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic637b3f96e40484683e069e269081b5a_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTEtMS0xLTQwMzY4_32a71fd1-0bee-4e59-aa8e-a92fec390fa1">35,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTMtMS0xLTQwMzY4_51c79b50-9d3c-4f8a-98b3-a0e93f107d14">104,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id928b4407f1f45369fc9e7339ca8dc19_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTUtMS0xLTQwMzY4_6f405513-0bd7-45d1-83c2-fc1617298fb6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTctMS0xLTQwMzY4_1ae9e18d-1f08-4a0f-a918-30e1de41f103">139,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the years ended December&#160;31, 2022 and 2021.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-24</span></div></div></div><div id="i0116a601b82b4da2824bf8e7269bebaf_298"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MTU_eeebb6d6-19f6-43dd-8072-e899c22da2bd" continuedAt="i642034860cf74c91b80e0e619bd43893" escape="true">Income Taxes</ix:nonNumeric></span></div><ix:continuation id="i642034860cf74c91b80e0e619bd43893" continuedAt="i54398322c41b44c8b68a8545bc5bc45a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, Cardiff Oncology had federal net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $<ix:nonFraction unitRef="usd" contextRef="i8eb9fb7597594e409dd14b7de369e07d_I20221231" decimals="-5" name="crdf:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzExOA_e2757211-cf5f-492f-9c77-1631a3aa558a">5.1</ix:nonFraction> million which, if not used, will continue to expire through 2037, and federal net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i8eb9fb7597594e409dd14b7de369e07d_I20221231" decimals="-5" name="crdf:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI0MQ_fb5fc3bb-9ffe-4ddc-86db-4b2104c3ba02">85.8</ix:nonFraction> million, which do not expire. Cardiff Oncology also has California NOLs of approximately $<ix:nonFraction unitRef="usd" contextRef="i75170cbe292740eb8905b33cefbb47e2_I20221231" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzMyNQ_9983ace2-6392-406e-b54d-67a73bc52270">17.3</ix:nonFraction> million which, if not used, will begin to expire in 2029. Cardiff Oncology also has research and development tax credits available for federal and California purposes of approximately $<ix:nonFraction unitRef="usd" contextRef="ia539fce54f0549ee98e69a7feb86123b_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzUwNA_2ba4c822-2796-4009-aefe-1e2d00ede7f3">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icf0a0c7937904a32bf6356ddaa1dff71_I20221231" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzUxMQ_9d8a6b77-1bf0-4230-b179-aaf6b0a367fd">2.3</ix:nonFraction> million, respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits do not expire.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) Sections 382 and 383, annual use of a company&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Company has established a valuation allowance as the realization of such deferred tax assets has not met the more likely than not threshold requirement. Due to the existence of the valuation allowance, further changes in the Company&#8217;s unrecognized tax benefits will not impact the Company&#8217;s effective tax rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2022, the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section 382 and 383 and determined that the Company underwent two ownership changes during the period from 2014 to 2022. As a result, net operating loss and tax credit carryforwards attributable to the pre-ownership changes are subject to substantial annual limitations under Section 382 and 383 of Code due to the ownership changes. The Company has adjusted their net operating loss and tax credit carryforwards to address the impact of the ownership changes. This resulted in a reduction of available gross federal and state net operating loss carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="ib7e5322a521b4cd3abc87556084fd935_D20210101-20211231" decimals="-5" sign="-" name="crdf:OperatingLossCarryforwardsIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyMTg_51a63700-324c-4e88-a400-c3ebc2c48ca2">123.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i67adec9130714636a68f59baafa0faeb_D20210101-20211231" decimals="-5" sign="-" name="crdf:OperatingLossCarryforwardsIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyMzQ_5f24b080-1cb5-4596-a93a-a1cf03a4df18">62.8</ix:nonFraction>&#160;million, respectively which related to the year ended December 31, 2021 and prior. The tax effected federal and state NOL amounts were $<ix:nonFraction unitRef="usd" contextRef="i45c1454942fd4f6cb115a433327d89b6_D20210101-20211231" decimals="-5" sign="-" name="crdf:OperatingLossCarryforwardsIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyNDk_c9da4dc8-5bcd-41f9-b26b-63f073236078">26.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ifab578dbdeed4bdaaf35f05006bb4d2a_D20210101-20211231" decimals="-5" sign="-" name="crdf:OperatingLossCarryforwardsIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyNjQ_d65ff2d6-7552-4a21-999b-a0f433546d48">4.4</ix:nonFraction>&#160;million respectively. This also resulted in a reduction of federal tax credit carryforwards of approximately $<ix:nonFraction unitRef="usd" contextRef="i45c1454942fd4f6cb115a433327d89b6_D20210101-20211231" decimals="-5" sign="-" name="crdf:TaxCreditCarryforwardIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUzMjI_ec5986ae-77d1-4825-a9c2-c6b104f53957">1.8</ix:nonFraction>&#160;million related to the years ended December 31, 2021 and prior. Accordingly, the net operating loss and tax credit carryforwards presented below for the year ending December 31, 2021 were reduced by $<ix:nonFraction unitRef="usd" contextRef="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231" decimals="-5" sign="-" name="crdf:OperatingLossCarryforwardsIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyNzg_8518bed1-88bd-4810-9f50-d64514b47906">30.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231" decimals="-5" sign="-" name="crdf:TaxCreditCarryforwardIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyOTM_ea1de854-0fe5-49d0-b6a0-6c7cc6431f66">1.8</ix:nonFraction>&#160;million, respectively, with a corresponding reduction to the valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUzMDc_52d06b2b-72c1-4314-aa16-04e144af8465">32.2</ix:nonFraction>&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MTY_2f5b7a26-318f-4229-bfbe-f39e940cd9c5" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes based on losses from continuing operations consists of the following at December 31:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzQtMS0xLTEtNDAzNjg_1b91036f-ed1d-4a33-ab12-516f0fd549c6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzQtMy0xLTEtNDAzNjg_1538a584-0495-4212-ad29-c6e99b707b24">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzUtMS0xLTEtNDAzNjg_dc3dd013-d3f4-49e5-a6df-e802ff227ea2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzUtMy0xLTEtNDAzNjg_c695e3fa-269d-4c75-96e7-9c975c19889d">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzctMS0xLTEtNDAzNjg_70853f98-fd4f-49a9-9ecd-7f90565e3594">19,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzctMy0xLTEtNDAzNjg_5f6f9fb0-e637-4025-9db8-c1ff49e88f86">5,551</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzgtMS0xLTEtNDAzNjg_7fff7e19-1a61-4946-b303-107049350513">4,902</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzgtMy0xLTEtNDAzNjg_1e7b11b0-3cca-4092-98ef-bbd8429e7965">531</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEwLTEtMS0xLTQwMzY4_ec982bfd-a656-41e6-ad9f-40692bfa0916">23,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEwLTMtMS0xLTQwMzY4_d6df22ab-505d-449a-8b28-31dca0c61f36">6,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" sign="-" name="crdf:ValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzExLTEtMS0xLTQwMzY4_dbd66442-0147-4d6c-bbec-e4d9de8800fa">23,956</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:ValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzExLTMtMS0xLTQwMzY4_69a09695-3bf7-42e6-b6f0-883da88b61bc">6,081</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEyLTEtMS0xLTQwMzY4_8e751eb8-d6c9-4cab-8c8e-d191d0132773">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEyLTMtMS0xLTQwMzY4_2b45be10-fac1-45b3-9edb-82b253d0808f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><ix:continuation id="i54398322c41b44c8b68a8545bc5bc45a"><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MjE_b2343fd3-f394-4336-b0a4-7d76b8d968cc" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s taxes and the rates as of December 31 are shown below: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.287%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.123%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.126%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax computed at the federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItMS0xLTEtNDAzNjg_922ad707-f3f4-4bc0-ada1-87c7c6773272">8,128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItMy0xLTEtNDAzNjg_67facdbb-f598-4d18-956b-db4481284e0f">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItNS0xLTEtNDAzNjg_65ec7565-211c-4d62-b017-68bcacd1ad84">5,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItNy0xLTEtNDAzNjg_64685b8d-da70-4756-be36-ebde69890ec7">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtMS0xLTEtNDAzNjg_390a7bb4-e9f3-43ad-a04b-6b2d25c31982">518</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtMy0xLTEtNDAzNjg_2555271c-155a-443c-a191-d4da2ae22516">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtNS0xLTEtNDAzNjg_9fe65b5a-3ad1-4c07-b09e-6d1c3467e7a7">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtNy0xLTEtNDAzNjg_bbaddba7-19d4-4858-b3c2-5292b23749f1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:IncomeTaxReconciliationPermanentItems" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtMS0xLTEtNDAzNjg_aaaf2837-c924-43cd-830a-97e95b4e5c96">32,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" sign="-" name="crdf:EffectiveIncomeTaxRateReconciliationPermanentItems" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtMy0xLTEtNDAzNjg_39466de8-62da-429d-b05c-dd46ee3f8b80">84</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:IncomeTaxReconciliationPermanentItems" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtNS0xLTEtNDAzNjg_8cf7d662-5657-43df-82af-410eaa328ed4">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" name="crdf:EffectiveIncomeTaxRateReconciliationPermanentItems" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtNy0xLTEtNDAzNjg_b555a770-f318-4cc6-aabb-af786c8baa39">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtMS0xLTEtNDAzNjg_3040c9d9-2aad-4642-b7fa-27c6a5edbdda">553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtMy0xLTEtNDAzNjg_4e1f9997-f4fd-440b-91bb-1c3ef412267d">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtNS0xLTEtNDAzNjg_71738067-69b5-49ba-bbf1-d001581141ba">325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtNy0xLTEtNDAzNjg_013ff0ac-5e0f-4cdf-9bd0-d95a9891fe26">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctMS0xLTEtNDAzNjg_8a4bebf9-13c2-4bca-a51c-6720be599b8d">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctMy0xLTEtNDAzNjg_12ac96ee-7270-4db5-8f67-df120a8e99b0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCredits" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctNS0xLTEtNDAzNjg_9bb82e27-61ab-4f4c-8d2c-9ce8f7389995">366</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctNy0xLTEtNDAzNjg_07e7bfaf-fdfe-4ca3-be5e-6de32964d342">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision and true ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMS0xLTEtNDM3NzM_9657ad86-2897-4dc2-be5d-e4e2dcf85e51">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" name="crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMy0xLTEtNDM3NzM_6f106e4c-9c21-4154-a235-8820fd6f2306">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNS0xLTEtNDM3NzM_b6ac5d66-ac3f-45af-aa9e-ee38c7f156b1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" name="crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNy0xLTEtNDM3NzM_f22c0c46-6595-4fda-9f9f-9887800356f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMS0xLTEtNDAzNjg_5a71c155-e33d-4e38-839c-cd8472a4114b">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMy0xLTEtNDAzNjg_9b12e861-467b-47cb-854c-5adc0b89ed36">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNS0xLTEtNDAzNjg_d5f7a2c0-1252-4acf-8016-4fceb1a4a036">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNy0xLTEtNDAzNjg_7b6a2bb9-46b9-4e72-839b-c14f95cd1df7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance increase (decrease)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktMS0xLTEtNDAzNjg_1cb9477c-ca2f-4b6e-9996-7a2279e284b9">23,956</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktMy0xLTEtNDAzNjg_774d1c88-8cdf-4a9e-9d65-c8646a1952cd">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktNS0xLTEtNDAzNjg_4e9e5a7d-46f4-4699-8c93-fddac0c546cd">6,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="2" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktNy0xLTEtNDAzNjg_931a5851-d4a5-4ff7-be6d-e119b8326be4">22</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTEtMS0xLTQwMzY4_8858638b-b843-4ab7-a2c6-5179496ab6ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTMtMS0xLTQwMzY4_2c515c61-8fd1-43b0-b2f9-f358baaf3c69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTUtMS0xLTQwMzY4_45251a81-f46b-4bfb-9b5e-599988950ac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTctMS0xLTQwMzY4_d70bd76a-c257-436a-a444-acf68f941580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MTI_06a54260-8733-4731-ba47-6e20a08a6847" escape="true"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzMtMS0xLTEtNDAzNjg_5a2833dd-2080-458f-9a2c-081b4dcc605e">20,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzMtMy0xLTEtNDAzNjg_b9953da1-b814-4dfa-b836-00972678f968">17,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzQtMS0xLTEtNDAzNjg_0a71bfe8-4fce-444e-96da-63aac843e7a8">2,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzQtMy0xLTEtNDAzNjg_2b8dca5b-2520-4c1f-911a-7dd0b7824e9a">2,226</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzUtMS0xLTEtNDAzNjg_7d855dab-9ec6-43a6-96d9-fe84c1d46ced">1,317</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzUtMy0xLTEtNDAzNjg_d73a1c8b-8f57-4978-9ae2-f14551f46e52">962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMS0xLTEtNDM3NDQ_0fdc9bdf-e1e2-4506-b04d-c66b895c381a">4,794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMy0xLTEtNDM3NDQ_b0ba59fb-cf06-4635-a1af-7ebf2276bd94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMS0xLTEtNDAzNjg_62f4991f-af0e-4362-8589-a699b9b79d3f">1,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMy0xLTEtNDAzNjg_87c9faea-4488-45bb-9978-ca1e2a1c25ce">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzctMS0xLTEtNDAzNjg_07f0b0c4-36ab-45f6-9047-556c868e17d7">30,574</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzctMy0xLTEtNDAzNjg_43349654-8964-4566-89ca-08b126b20d55">22,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzktMS0xLTEtNDAzNjg_a953fa24-dda9-492d-9ad7-7f545b9ebd2c">492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzktMy0xLTEtNDAzNjg_c841b080-c554-428b-b1db-23c3f11ebd2f">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEwLTEtMS0xLTQwMzY4_938408f2-7816-4799-8890-afde5e31a8be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesOther" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEwLTMtMS0xLTQwMzY4_3ced65ce-7282-49fe-ba1d-d11879e50ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzExLTEtMS0xLTQwMzY4_70526578-2f3c-472b-bcb8-90233976319e">492</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzExLTMtMS0xLTQwMzY4_cbfcc24b-fffa-4146-9464-ec471ed04804">611</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="crdf:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEyLTEtMS0xLTQwMzY4_206086c7-1662-4916-a269-492f7100c3fb">30,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="crdf:DeferredTaxAssetsNetBeforeValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEyLTMtMS0xLTQwMzY4_522d388a-02df-436e-bd27-5d4fc798ad47">21,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEzLTEtMS0xLTQwMzY4_b8838c4b-b389-4158-86a5-21141e59b3f4">30,082</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEzLTMtMS0xLTQwMzY4_ab422c40-922e-465f-bd14-169b5cf268c2">21,833</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzE0LTEtMS0xLTQwMzY4_628c8ade-a583-4d4c-9aeb-c140425d9007">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231" decimals="-3" name="us-gaap:DeferredTaxAssetsNet" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzE0LTMtMS0xLTQwMzY4_eb54aeef-d3af-4796-be91-1ea113a4e78a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception the Company has incurred continuing losses and expects to continue to incur losses for the foreseeable future. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more likely than not they will not be realized. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not have any unrecognized tax benefits. Cardiff Oncology&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and <ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="INF" name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI2MTg_8be08654-b855-4917-aebb-a13bf43993a8">none</ix:nonFraction> have been incurred to date. The Company does not anticipate a significant change in unrecognized tax benefits over the next 12 months. The Company is subject to taxation in the U.S. and California. Due to net operating losses all tax years since inception remain open to examination.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_301"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDEvZnJhZzo3ODNkMjM1Yzg4NWE0YWVjODY5MTExZDRkNGM4MGEyZS90ZXh0cmVnaW9uOjc4M2QyMzVjODg1YTRhZWM4NjkxMTFkNGQ0YzgwYTJlXzE5MDU_71aef653-07a2-45a2-a4ef-4f862a8234ea" continuedAt="i575cdfd408c5440f823b6f7cb19ce27d" escape="true">Commitments and Contingencies</ix:nonNumeric></span></div><ix:continuation id="i575cdfd408c5440f823b6f7cb19ce27d" continuedAt="i45aaf8d6c9e04af28b412f31c7d2f9f8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span><br/></span></div><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i0116a601b82b4da2824bf8e7269bebaf_7">Table of Contents</a></span></div></div><div><span><br/></span></div><ix:continuation id="i45aaf8d6c9e04af28b412f31c7d2f9f8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Terms of the agreement also provide for the Company to pay development and commercial milestones, and royalties based on sales volume. These potential development milestones include: dosing of the first subject in the first Phase III Clinical Trial for the first Product or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and upon filing of the first NDA or equivalent for the first product. During the years ended December&#160;31, 2022 and 2021, <ix:nonFraction unitRef="usd" contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231" decimals="-3" name="crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDEvZnJhZzo3ODNkMjM1Yzg4NWE0YWVjODY5MTExZDRkNGM4MGEyZS90ZXh0cmVnaW9uOjc4M2QyMzVjODg1YTRhZWM4NjkxMTFkNGQ0YzgwYTJlXzEwOTk1MTE2MzA1NDE_53c765a4-2dc8-4f02-a36f-351fe47c6ab8"><ix:nonFraction unitRef="usd" contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" decimals="-3" name="crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDEvZnJhZzo3ODNkMjM1Yzg4NWE0YWVjODY5MTExZDRkNGM4MGEyZS90ZXh0cmVnaW9uOjc4M2QyMzVjODg1YTRhZWM4NjkxMTFkNGQ0YzgwYTJlXzEwOTk1MTE2MzA1NDE_78f48aad-d987-48c4-81de-6362c5d16ed8">no</ix:nonFraction></ix:nonFraction> milestone or royalty payments were made.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party of various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. During the years ended December&#160;31, 2022 and 2021 payments have not been material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div></ix:continuation><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div id="i0116a601b82b4da2824bf8e7269bebaf_304"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDQvZnJhZzo4ZGNjN2U5NmY1MTU0YmNjOTUxMWRkMzU3ZDU5YzUxNS90ZXh0cmVnaW9uOjhkY2M3ZTk2ZjUxNTRiY2M5NTExZGQzNTdkNTljNTE1XzM5MA_a78e2001-35ca-42df-97da-6f73be9450b0" continuedAt="ib75987740e3f4b58ae5396da76039790" escape="true">Employee Benefit Plan</ix:nonNumeric></span></div><ix:continuation id="ib75987740e3f4b58ae5396da76039790"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution retirement plan under Section 401(k) of the Internal Revenue Service ("IRS") Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income through contributions to the plan as allowed by IRS Code. The Company does not currently make matching contributions.</span></div></ix:continuation><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F-27</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>a231exq42022.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ifd412674fab14ad89ed9dc812ed3c772_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 23.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Consent of Independent Registered Public Accounting Firm</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">San Diego, California </font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-1 (Nos. 333-239464, 333-238623, 333-234442, and 333-233568), Form S-3 (Nos. 333-254217, 333-232321, 333-229693, and 333-264148) and Form S-8 (Nos. 333-239725, 333-232363, 333-256978, and 333-266103) of Cardiff Oncology, Inc. (the &#8220;Company&#8221;) of our report dated March&#160;2, 2023, relating to the financial statements which appears in this Annual Report form 10-K.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">&#47;s&#47; BDO USA, LLP</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">San Diego, California</font></div><div><font style="color:#000000;font-family:'Trebuchet',sans-serif;font-size:10.5pt;font-weight:400;line-height:120%">March&#160;2, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a311exq42022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ibd2e29a091c8458db72cd46960890369_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark Erlander, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form&#160;10-K of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;2&#47;2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)<br></font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a312exq42022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="id8414ae23e57481489cea84725b5b482_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;31.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, James Levine, certify that&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this annual report on Form&#160;10-K of Cardiff Oncology,&#160;Inc. (the &#8220;Registrant&#8221;)&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this annual report&#59;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e)&#160;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f)&#160;and 15d-15(f)) for the registrant and have&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt"> Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this annual report is being prepared&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="text-indent:29.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.82pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial&#59; and</font></div><div style="text-indent:29.25pt"><font><br></font></div><div style="padding-left:36pt;text-indent:11.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:17.25pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:49.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.949%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 79.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;2&#47;2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)<br></font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a321exq42022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9aa65d7c13814fcf893ee5bf5a68455b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;2&#47;2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark Erlander</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer (Principal Executive Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a322exq42022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9449d62cd08e42348dba9b5f3d3a290c_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.2</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO 18 U.S.C. SECTION&#160;1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF&#160;2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Cardiff Oncology,&#160;Inc. (the &#8220;Company&#8221;) on Form&#160;10-K for the year ended December&#160;31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;),&#160;I, James Levine, Principal Financial and Accounting Officer of the Company, certify, pursuant to 18 U.S.C. &#167;&#160;1350, as adopted pursuant to &#167;&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="text-indent:24.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 61.75pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#47;2&#47;2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Levine</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-style:italic;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>crdf-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:43395891-7664-4c15-a02f-d7b4811c3213,g:94da96fa-a6f9-430a-8c03-f421ae94b6bc-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:crdf="http://www.cardiffoncology.com/20221231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.cardiffoncology.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="crdf-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="DocumentandEntityInformation" roleURI="http://www.cardiffoncology.com/role/DocumentandEntityInformation">
        <link:definition>0000001 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.cardiffoncology.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheets" roleURI="http://www.cardiffoncology.com/role/BalanceSheets">
        <link:definition>0000003 - Statement - Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BalanceSheetsParenthetical" roleURI="http://www.cardiffoncology.com/role/BalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofOperations" roleURI="http://www.cardiffoncology.com/role/StatementsofOperations">
        <link:definition>0000005 - Statement - Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofStockholdersEquity" roleURI="http://www.cardiffoncology.com/role/StatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementofShareholdersEquityParenthetical" roleURI="http://www.cardiffoncology.com/role/StatementofShareholdersEquityParenthetical">
        <link:definition>0000008 - Statement - Statement of Shareholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlows" roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlows">
        <link:definition>0000009 - Statement - Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StatementsofCashFlowsParenthetical" roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical">
        <link:definition>0000010 - Statement - Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandLiquidity" roleURI="http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity">
        <link:definition>0000011 - Disclosure - Business Overview and Liquidity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPolicies" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies">
        <link:definition>0000012 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformation" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation">
        <link:definition>0000013 - Disclosure - Supplementary Balance Sheet Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.cardiffoncology.com/role/Leases">
        <link:definition>0000014 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.cardiffoncology.com/role/StockholdersEquity">
        <link:definition>0000015 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.cardiffoncology.com/role/StockBasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrants" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants">
        <link:definition>0000017 - Disclosure - Derivative Financial Instruments - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements">
        <link:definition>0000018 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.cardiffoncology.com/role/IncomeTaxes">
        <link:definition>0000019 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies">
        <link:definition>0000020 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlan" roleURI="http://www.cardiffoncology.com/role/EmployeeBenefitPlan">
        <link:definition>0000021 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationTables" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables">
        <link:definition>0000024 - Disclosure - Supplementary Balance Sheet Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.cardiffoncology.com/role/LeasesTables">
        <link:definition>0000025 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables">
        <link:definition>0000026 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationTables">
        <link:definition>0000027 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsTables" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables">
        <link:definition>0000028 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables">
        <link:definition>0000029 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.cardiffoncology.com/role/IncomeTaxesTables">
        <link:definition>0000030 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessOverviewandLiquidityDetails" roleURI="http://www.cardiffoncology.com/role/BusinessOverviewandLiquidityDetails">
        <link:definition>0000031 - Disclosure - Business Overview and Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails">
        <link:definition>0000033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails">
        <link:definition>0000034 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails">
        <link:definition>0000035 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails">
        <link:definition>0000036 - Disclosure - Supplementary Balance Sheet Information - Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1">
        <link:definition>0000036 - Disclosure - Supplementary Balance Sheet Information - Short-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails">
        <link:definition>0000037 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
        <link:definition>0000038 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SupplementaryBalanceSheetInformationAccruedExpensesDetails" roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails">
        <link:definition>0000039 - Disclosure - Supplementary Balance Sheet Information - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails">
        <link:definition>0000040 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseExpenseDetails" roleURI="http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails">
        <link:definition>0000041 - Disclosure - Leases - Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000042 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowInformationDetails" roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails">
        <link:definition>0000043 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails">
        <link:definition>0000044 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesFutureMinimumLeasePaymentsDetails_1" roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1">
        <link:definition>0000044 - Disclosure - Leases - Future Minimum Lease Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityScheduleofWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails">
        <link:definition>0000045 - Disclosure - Stockholders' Equity - Schedule of Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySummaryofPreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails">
        <link:definition>0000046 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesAConvertiblePreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails">
        <link:definition>0000047 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySeriesEConvertiblePreferredStockDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails">
        <link:definition>0000048 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquitySecuritiesPurchaseAgreementsDetails" roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails">
        <link:definition>0000049 - Disclosure - Stockholders' Equity - Securities Purchase Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationDetails" roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails">
        <link:definition>0000051 - Disclosure - Stock-Based Compensation - Stock-Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofStockOptionsActivityDetails" roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails">
        <link:definition>0000053 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeFinancialInstrumentsWarrantsDetails" roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails">
        <link:definition>0000054 - Disclosure - Derivative Financial Instruments - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails">
        <link:definition>0000055 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000056 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>0000057 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofCompanysTaxesDetails" roleURI="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails">
        <link:definition>0000058 - Disclosure - Income Taxes - Significant Components of Company's Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000059 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails">
        <link:definition>0000060 - Disclosure - Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" abstract="true" name="CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_Accrueddirectorfees" abstract="false" name="Accrueddirectorfees" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LessorNumberOfSubleases" abstract="false" name="LessorNumberOfSubleases" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" abstract="false" name="IncreaseDecreaseInOperatingLeaseRightOfUseAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodSharesWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodSharesWarrantsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_SeriesDConvertiblePreferredStockMember" abstract="true" name="SeriesDConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_WarrantsAndRightsRollForward" abstract="true" name="WarrantsAndRightsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_AccruedPreferredStockDividend" abstract="false" name="AccruedPreferredStockDividend" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DeferredTaxAssetsNetBeforeValuationAllowance" abstract="false" name="DeferredTaxAssetsNetBeforeValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" abstract="false" name="PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_NonCashCumulativePreferredStockDividendAdjustment" abstract="false" name="NonCashCumulativePreferredStockDividendAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_IncomeTaxReconciliationPermanentItems" abstract="false" name="IncomeTaxReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" abstract="false" name="LesseeOperatingLeaseAnnualRentIncreasePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="crdf_Accruedresearchagreements" abstract="false" name="Accruedresearchagreements" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" abstract="true" name="ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_Servicereceivable" abstract="false" name="Servicereceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesAConvertiblePreferredStockMember" abstract="true" name="SeriesAConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ValuationAllowance" abstract="false" name="ValuationAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ReleaseOfClinicalTrialFundingCommitment" abstract="false" name="ReleaseOfClinicalTrialFundingCommitment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PreferredStockCumulativeDividendAdjustment" abstract="false" name="PreferredStockCumulativeDividendAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" abstract="false" name="PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" abstract="false" name="PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_SharePriceForAutomaticConversion" abstract="false" name="SharePriceForAutomaticConversion" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" abstract="false" name="PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_ServiceReceivableMember" abstract="true" name="ServiceReceivableMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_OperatingLossCarryforwardsIncreaseDecrease" abstract="false" name="OperatingLossCarryforwardsIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" abstract="false" name="SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" abstract="false" name="ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="crdf_PreferredStockConversionObligationNumberOfTradingDays" abstract="false" name="PreferredStockConversionObligationNumberOfTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_PreferredStockDividendAccrued" abstract="false" name="PreferredStockDividendAccrued" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesEConvertiblePreferredStockMember" abstract="true" name="SeriesEConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_Patentlicenseandotherfeespayable" abstract="false" name="Patentlicenseandotherfeespayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_WarrantsWeightedAverageContractualTerm" abstract="false" name="WarrantsWeightedAverageContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_AccruedClinicalTrialExpensesPolicyTextBlock" abstract="false" name="AccruedClinicalTrialExpensesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="crdf_ConvertiblePreferredStockStatedValuePerShare" abstract="false" name="ConvertiblePreferredStockStatedValuePerShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_StockIssuedDuringPeriodValueWarrantsExercised" abstract="false" name="StockIssuedDuringPeriodValueWarrantsExercised" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_PreferredStockConversionPricePerShare" abstract="false" name="PreferredStockConversionPricePerShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" abstract="false" name="EffectiveIncomeTaxRateReconciliationPermanentItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="crdf_AccruedClinicalTrialExpenses" abstract="false" name="AccruedClinicalTrialExpenses" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_EquityIncentivePlan2014Member" abstract="true" name="EquityIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" abstract="false" name="ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_SaleOfStockConsiderationReceivedOnTransactionGross" abstract="false" name="SaleOfStockConsiderationReceivedOnTransactionGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_TaxYear2021AndPriorMember" abstract="true" name="TaxYear2021AndPriorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_DocumentAndEntityInformationAbstract" abstract="true" name="DocumentAndEntityInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_SeriesBConvertiblePreferredStockMember" abstract="true" name="SeriesBConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="crdf_AccruedClinicalTrial" abstract="false" name="AccruedClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_CorrectionPolicyPolicyTextBlock" abstract="false" name="CorrectionPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="crdf_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_SeriesCConvertiblePreferredStockMember" abstract="true" name="SeriesCConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightExpirationTerm" abstract="false" name="ClassOfWarrantOrRightExpirationTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="crdf_TaxCreditCarryforwardIncreaseDecrease" abstract="false" name="TaxCreditCarryforwardIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" abstract="false" name="Releaseofclinicaltrialfundingcommitmentforservicesreceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_SeriesNWarrantMember" abstract="true" name="SeriesNWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_LesseeOperatingLeaseMonthlyRentPayment" abstract="false" name="LesseeOperatingLeaseMonthlyRentPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightIssued" abstract="false" name="ClassOfWarrantOrRightIssued" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightNumberExercised" abstract="false" name="ClassOfWarrantOrRightNumberExercised" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="crdf_PreferredStockLiquidationPreferenceStatedValue" abstract="false" name="PreferredStockLiquidationPreferenceStatedValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_InducementGrantStockOptionsMember" abstract="true" name="InducementGrantStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_RegisteredDirectOfferingMember" abstract="true" name="RegisteredDirectOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_DerivativeFinancialInstrumentsLiabilityRollForward" abstract="true" name="DerivativeFinancialInstrumentsLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" abstract="false" name="ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="crdf_EstimatedFairValueOfWarrant" abstract="false" name="EstimatedFairValueOfWarrant" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="crdf_CommonStockAndWarrantsMember" abstract="true" name="CommonStockAndWarrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_FurnitureAndOfficeEquipmentMember" abstract="true" name="FurnitureAndOfficeEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightNumberExpired" abstract="false" name="ClassOfWarrantOrRightNumberExpired" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="crdf_BlackScholesOptionPricingMethodMember" abstract="true" name="BlackScholesOptionPricingMethodMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="crdf_ClassOfWarrantOrRightMonthsUntilExercisable" abstract="false" name="ClassOfWarrantOrRightMonthsUntilExercisable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>crdf-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:43395891-7664-4c15-a02f-d7b4811c3213,g:94da96fa-a6f9-430a-8c03-f421ae94b6bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BalanceSheets" xlink:type="simple" xlink:href="crdf-20221231.xsd#BalanceSheets"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_1a6602fc-08fc-40fb-8c79-c40546bb20e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:to="loc_us-gaap_PreferredStockValue_1a6602fc-08fc-40fb-8c79-c40546bb20e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_75355765-4a69-4122-9453-a6e24a0c58f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:to="loc_us-gaap_CommonStockValue_75355765-4a69-4122-9453-a6e24a0c58f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_1cd2e160-aa41-4006-8bba-a2567a962367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_1cd2e160-aa41-4006-8bba-a2567a962367" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d74b67c3-95cd-4354-b4b0-7c0ce5bada9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d74b67c3-95cd-4354-b4b0-7c0ce5bada9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_6f638b3f-4a64-499e-9339-df40c6c1b1c0" xlink:href="crdf-20221231.xsd#crdf_Servicereceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:to="loc_crdf_Servicereceivable_6f638b3f-4a64-499e-9339-df40c6c1b1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8e74664-9664-44a9-bb98-98735d491712" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_756c06fa-28fb-4248-8452-930f6b87754a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e8e74664-9664-44a9-bb98-98735d491712" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_7ea36525-b4be-4a75-9b19-c5c42a52a30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44059d20-8867-49d8-b0bf-92d604486827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ea36525-b4be-4a75-9b19-c5c42a52a30f" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_44059d20-8867-49d8-b0bf-92d604486827" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_4a846a2f-0998-41b8-b947-e737639b095d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ea36525-b4be-4a75-9b19-c5c42a52a30f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_4a846a2f-0998-41b8-b947-e737639b095d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_c4c5ee63-c1ea-41d1-90e5-8443f720a0ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ea36525-b4be-4a75-9b19-c5c42a52a30f" xlink:to="loc_us-gaap_ShortTermInvestments_c4c5ee63-c1ea-41d1-90e5-8443f720a0ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554fc63e-ba3e-4435-a266-618a1f55659c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_7ea36525-b4be-4a75-9b19-c5c42a52a30f" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_554fc63e-ba3e-4435-a266-618a1f55659c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_92ebfaa8-e39e-47ae-9e97-d75f2b71c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_c8cba348-fe51-4464-957f-49b2ae434540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_92ebfaa8-e39e-47ae-9e97-d75f2b71c2e8" xlink:to="loc_us-gaap_AssetsCurrent_c8cba348-fe51-4464-957f-49b2ae434540" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_2215dfc7-5013-41ac-bfcd-b0f4aacae692" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_92ebfaa8-e39e-47ae-9e97-d75f2b71c2e8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_2215dfc7-5013-41ac-bfcd-b0f4aacae692" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_c78bc2cd-15c9-41e9-84fd-79c3aa7e43e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_92ebfaa8-e39e-47ae-9e97-d75f2b71c2e8" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_c78bc2cd-15c9-41e9-84fd-79c3aa7e43e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_94a31e14-434d-43b7-9918-0a1b112b591a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_92ebfaa8-e39e-47ae-9e97-d75f2b71c2e8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_94a31e14-434d-43b7-9918-0a1b112b591a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5d79a3de-d785-4325-b251-1551b5d14ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_25e03855-aaec-4e55-ae46-34e0f5a4dc19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d79a3de-d785-4325-b251-1551b5d14ca5" xlink:to="loc_us-gaap_AccountsPayableCurrent_25e03855-aaec-4e55-ae46-34e0f5a4dc19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_117814af-230e-4de0-abf2-4d6c78939945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d79a3de-d785-4325-b251-1551b5d14ca5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_117814af-230e-4de0-abf2-4d6c78939945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_c0ce2ec0-f7e0-46bd-910e-d0af2d861870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d79a3de-d785-4325-b251-1551b5d14ca5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_c0ce2ec0-f7e0-46bd-910e-d0af2d861870" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_65680f77-750f-4762-81da-520955592bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_5d79a3de-d785-4325-b251-1551b5d14ca5" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_65680f77-750f-4762-81da-520955592bd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8cc7ddd0-181e-42c3-aeb3-258d0a50ea69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_a54f0865-95ab-427f-bc0c-3a797ec2d195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cc7ddd0-181e-42c3-aeb3-258d0a50ea69" xlink:to="loc_us-gaap_LiabilitiesCurrent_a54f0865-95ab-427f-bc0c-3a797ec2d195" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7a4aa6d5-c608-426e-983c-6a461967e4ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cc7ddd0-181e-42c3-aeb3-258d0a50ea69" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_7a4aa6d5-c608-426e-983c-6a461967e4ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26eee5d7-a174-4b61-94b8-235927d734e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_8cc7ddd0-181e-42c3-aeb3-258d0a50ea69" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_26eee5d7-a174-4b61-94b8-235927d734e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_41c8a4ca-51a9-4022-91ac-534e258fc48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_db74b093-5320-43fe-a545-f945814eadf9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_41c8a4ca-51a9-4022-91ac-534e258fc48c" xlink:to="loc_us-gaap_Liabilities_db74b093-5320-43fe-a545-f945814eadf9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_b9cbb392-935b-4175-8924-45779bbea667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_41c8a4ca-51a9-4022-91ac-534e258fc48c" xlink:to="loc_us-gaap_CommitmentsAndContingencies_b9cbb392-935b-4175-8924-45779bbea667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_39c0e9df-03f6-4e57-acd5-aec5cde21429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_41c8a4ca-51a9-4022-91ac-534e258fc48c" xlink:to="loc_us-gaap_StockholdersEquity_39c0e9df-03f6-4e57-acd5-aec5cde21429" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofOperations" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofOperations"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_703f46da-df9f-4de3-a2aa-ce7f1b6adfd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bdad8bb9-724f-45ce-a524-30ef76d39ebd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_703f46da-df9f-4de3-a2aa-ce7f1b6adfd6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_bdad8bb9-724f-45ce-a524-30ef76d39ebd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0176daff-9e5d-4807-a682-c2bf4520285f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_703f46da-df9f-4de3-a2aa-ce7f1b6adfd6" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_0176daff-9e5d-4807-a682-c2bf4520285f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_a77a7a6e-2ce3-4846-80d5-8cd36f2df362" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_637d8975-f5dd-4a81-bb29-96d50afa647c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a77a7a6e-2ce3-4846-80d5-8cd36f2df362" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_637d8975-f5dd-4a81-bb29-96d50afa647c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_f501aa10-5649-435d-b021-77708a585955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a77a7a6e-2ce3-4846-80d5-8cd36f2df362" xlink:to="loc_us-gaap_InvestmentIncomeInterest_f501aa10-5649-435d-b021-77708a585955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_6b19319f-2b8d-4bf4-b1cb-fd01f0fde032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_a77a7a6e-2ce3-4846-80d5-8cd36f2df362" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_6b19319f-2b8d-4bf4-b1cb-fd01f0fde032" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fca9b295-05ce-4c17-aa6d-6aad2b622571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_41dc03dc-2bdc-43a8-a4b6-253e13679491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fca9b295-05ce-4c17-aa6d-6aad2b622571" xlink:to="loc_us-gaap_OperatingIncomeLoss_41dc03dc-2bdc-43a8-a4b6-253e13679491" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_613e8ff2-ff47-456a-9ef5-ea20e977e290" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_fca9b295-05ce-4c17-aa6d-6aad2b622571" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_613e8ff2-ff47-456a-9ef5-ea20e977e290" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_4ca4185e-cf55-4825-9f48-c18cdea75b74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_fe0d33a8-8e16-464d-8252-37627e37e72f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4ca4185e-cf55-4825-9f48-c18cdea75b74" xlink:to="loc_us-gaap_OperatingExpenses_fe0d33a8-8e16-464d-8252-37627e37e72f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09198576-4942-40b9-bfc6-ba08b444bdcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_4ca4185e-cf55-4825-9f48-c18cdea75b74" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_09198576-4942-40b9-bfc6-ba08b444bdcf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6ac51cc8-ca1e-4fa9-a58d-2251d28e1ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_edcaaa07-cd5d-4071-9a24-ee1beb43987f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6ac51cc8-ca1e-4fa9-a58d-2251d28e1ecc" xlink:to="loc_us-gaap_NetIncomeLoss_edcaaa07-cd5d-4071-9a24-ee1beb43987f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_d887483c-8074-4da2-aa98-4e7222afae5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_6ac51cc8-ca1e-4fa9-a58d-2251d28e1ecc" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_d887483c-8074-4da2-aa98-4e7222afae5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="crdf-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae527ea-439e-4cc6-88be-e3f8e4894a57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7e4fb6ec-1206-41ac-9e91-3bae78e91054" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae527ea-439e-4cc6-88be-e3f8e4894a57" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_7e4fb6ec-1206-41ac-9e91-3bae78e91054" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9b77e4d3-2f21-4697-9260-a29ab6ee29f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_9ae527ea-439e-4cc6-88be-e3f8e4894a57" xlink:to="loc_us-gaap_NetIncomeLoss_9b77e4d3-2f21-4697-9260-a29ab6ee29f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_7b31c2e4-d198-4e68-a4ff-de86932e9dd9" xlink:href="crdf-20221231.xsd#crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_28fdce65-0d85-4309-8174-5f1b8e3de352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_7b31c2e4-d198-4e68-a4ff-de86932e9dd9" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_28fdce65-0d85-4309-8174-5f1b8e3de352" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d9caa80-7520-4473-b55d-b40ef9fbb8e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_7b31c2e4-d198-4e68-a4ff-de86932e9dd9" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2d9caa80-7520-4473-b55d-b40ef9fbb8e8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0ce1f30-1ff9-40f5-8389-741288aa256d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_904d960c-119c-45ff-8c3f-a8310278b96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0ce1f30-1ff9-40f5-8389-741288aa256d" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_904d960c-119c-45ff-8c3f-a8310278b96a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_17996cf6-dc72-438f-8f42-f8ef33ddb4d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0ce1f30-1ff9-40f5-8389-741288aa256d" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_17996cf6-dc72-438f-8f42-f8ef33ddb4d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_51c631fe-5b0c-44da-bdfe-0017d7459a99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_b0ce1f30-1ff9-40f5-8389-741288aa256d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_51c631fe-5b0c-44da-bdfe-0017d7459a99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_04070991-0b4c-40f9-9382-e53ba455c291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_NetIncomeLoss_04070991-0b4c-40f9-9382-e53ba455c291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_4afb1065-4703-4c0b-835a-4a452d280292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_4afb1065-4703-4c0b-835a-4a452d280292" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_92513e3c-60f2-4c73-a2a1-b9f19a04cd26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_ShareBasedCompensation_92513e3c-60f2-4c73-a2a1-b9f19a04cd26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_2a9251f4-53e8-4238-a588-9b7a5ef17c16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_2a9251f4-53e8-4238-a588-9b7a5ef17c16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_e36dea4b-29f6-4fad-9af8-eea29f375fa6" xlink:href="crdf-20221231.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_e36dea4b-29f6-4fad-9af8-eea29f375fa6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_eb1b9272-cc9a-4997-8a9d-7a2c062a6c99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_eb1b9272-cc9a-4997-8a9d-7a2c062a6c99" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8bc30875-cb99-4d65-b48a-2bdaf7aa5628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8bc30875-cb99-4d65-b48a-2bdaf7aa5628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5826486b-b6b7-4073-b835-4b43ef51dbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_5826486b-b6b7-4073-b835-4b43ef51dbdf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_34ce3371-4785-4b43-92de-63c3e9f04c38" xlink:href="crdf-20221231.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_34ce3371-4785-4b43-92de-63c3e9f04c38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_66e323ca-0815-4deb-95c7-2a707524928d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_66e323ca-0815-4deb-95c7-2a707524928d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_47be7792-f29c-4ff8-88ba-dba5040445c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_47be7792-f29c-4ff8-88ba-dba5040445c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8d1cbf62-1c72-4d2f-a5a6-4edceb7dec54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_8d1cbf62-1c72-4d2f-a5a6-4edceb7dec54" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_b9255a56-9b42-451c-8d5e-7fed219f6c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_b9255a56-9b42-451c-8d5e-7fed219f6c0a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c119bbc9-a090-4eb0-b5f5-474dd747d249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d8c5ccff-c7a3-4c3d-ba88-f2656670b846" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_c119bbc9-a090-4eb0-b5f5-474dd747d249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_095a7282-47ee-44e1-a114-acdf53016bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f64b3744-6b50-445c-8620-a7eb96783506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_095a7282-47ee-44e1-a114-acdf53016bf7" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_f64b3744-6b50-445c-8620-a7eb96783506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f1c394bf-f86b-4262-8184-0341d0d16632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_095a7282-47ee-44e1-a114-acdf53016bf7" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_f1c394bf-f86b-4262-8184-0341d0d16632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3ce134d6-0efe-4e3b-aa93-583d5c851759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_095a7282-47ee-44e1-a114-acdf53016bf7" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_3ce134d6-0efe-4e3b-aa93-583d5c851759" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e2e2bbcf-2c75-4a4e-aed1-e9e062cfa2f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_095a7282-47ee-44e1-a114-acdf53016bf7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e2e2bbcf-2c75-4a4e-aed1-e9e062cfa2f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_5424d63e-5b17-45ec-835e-b22e097e42d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_095a7282-47ee-44e1-a114-acdf53016bf7" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_5424d63e-5b17-45ec-835e-b22e097e42d0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dbe4aecc-0bbe-4a93-9ee2-1e2d67517b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76c218f8-d01a-429a-961e-3e44b44b5e0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dbe4aecc-0bbe-4a93-9ee2-1e2d67517b0d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_76c218f8-d01a-429a-961e-3e44b44b5e0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_406a7ace-0ecd-475b-bd50-821c2814e679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dbe4aecc-0bbe-4a93-9ee2-1e2d67517b0d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_406a7ace-0ecd-475b-bd50-821c2814e679" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7da6411e-00b1-4e13-b872-7a90cd74f53c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_dbe4aecc-0bbe-4a93-9ee2-1e2d67517b0d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7da6411e-00b1-4e13-b872-7a90cd74f53c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d354e684-8542-4aed-bc8f-eb7449a2f361" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_b15805b5-9ad2-404f-a033-d1698bf1aaff" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d354e684-8542-4aed-bc8f-eb7449a2f361" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_b15805b5-9ad2-404f-a033-d1698bf1aaff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_a6136c02-6435-4d2d-af83-de719700d082" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_d354e684-8542-4aed-bc8f-eb7449a2f361" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_a6136c02-6435-4d2d-af83-de719700d082" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4112937d-4be5-4cfc-bb95-56d07a65fa72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_07a107e6-b442-40bc-8584-cde55d1bfc27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4112937d-4be5-4cfc-bb95-56d07a65fa72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_07a107e6-b442-40bc-8584-cde55d1bfc27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_895fffa2-f378-4854-938a-ef30a6079496" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4112937d-4be5-4cfc-bb95-56d07a65fa72" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_895fffa2-f378-4854-938a-ef30a6079496" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_c9ae59c7-6b5d-45ec-9342-833ad14850c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_c42e75bd-6510-4746-9467-0762e1db5404" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_c9ae59c7-6b5d-45ec-9342-833ad14850c8" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_c42e75bd-6510-4746-9467-0762e1db5404" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_fde6c906-69b5-4b82-b88d-bf1482315cd1" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_c9ae59c7-6b5d-45ec-9342-833ad14850c8" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_fde6c906-69b5-4b82-b88d-bf1482315cd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dfef337d-cbe0-4860-828c-4897b234cc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_c9ae59c7-6b5d-45ec-9342-833ad14850c8" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_dfef337d-cbe0-4860-828c-4897b234cc7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63d9e0c3-28cc-459c-b2da-df2ed2dcbafb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_c2228c03-7cf4-4701-8642-33fa0b7120ed" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63d9e0c3-28cc-459c-b2da-df2ed2dcbafb" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_c2228c03-7cf4-4701-8642-33fa0b7120ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ffb201cd-87d0-4dac-9d1c-9dae230b0b2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63d9e0c3-28cc-459c-b2da-df2ed2dcbafb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_ffb201cd-87d0-4dac-9d1c-9dae230b0b2d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_1dc2ee90-334a-45d9-b35d-567e3049506c" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_63d9e0c3-28cc-459c-b2da-df2ed2dcbafb" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_1dc2ee90-334a-45d9-b35d-567e3049506c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2a8362d-bb88-409c-b7e7-cc3c45d792fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eaa5dab3-7328-4bdb-bc5b-f9eb09657716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2a8362d-bb88-409c-b7e7-cc3c45d792fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_eaa5dab3-7328-4bdb-bc5b-f9eb09657716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a67702a0-e4ec-4f76-8333-47c84f4d28a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b2a8362d-bb88-409c-b7e7-cc3c45d792fb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_a67702a0-e4ec-4f76-8333-47c84f4d28a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_739e68b8-2a45-4048-bf23-e94a016bcb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_732e2a14-0801-42e1-bf55-94b3e6e68f6c" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_739e68b8-2a45-4048-bf23-e94a016bcb9e" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_732e2a14-0801-42e1-bf55-94b3e6e68f6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_0c79b470-1e13-4684-8af7-61699005ade7" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_739e68b8-2a45-4048-bf23-e94a016bcb9e" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_0c79b470-1e13-4684-8af7-61699005ade7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aab1f716-df58-4d6e-9d4a-f1d1c4265858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b873fa5d-2ea0-4f58-9392-c51e633ea99c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aab1f716-df58-4d6e-9d4a-f1d1c4265858" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b873fa5d-2ea0-4f58-9392-c51e633ea99c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dd7c1c70-c438-435b-90ab-430480cf8d83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aab1f716-df58-4d6e-9d4a-f1d1c4265858" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_dd7c1c70-c438-435b-90ab-430480cf8d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58bf02b3-2f58-493b-a2d7-789145ffc39c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_aab1f716-df58-4d6e-9d4a-f1d1c4265858" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_58bf02b3-2f58-493b-a2d7-789145ffc39c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5d886075-3b89-46fa-8097-84db427eeae6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_3597bc8b-c97f-4522-bedb-f468577212b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5d886075-3b89-46fa-8097-84db427eeae6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_3597bc8b-c97f-4522-bedb-f468577212b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_914d71cf-36e0-4af5-99a7-d73aec447dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5d886075-3b89-46fa-8097-84db427eeae6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_914d71cf-36e0-4af5-99a7-d73aec447dc5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff6b9774-6051-4db6-8c1a-198151ce0ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ff6b9774-6051-4db6-8c1a-198151ce0ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedPreferredStockDividend_ee25e58f-1471-4175-8bc4-e09d4dfc76e7" xlink:href="crdf-20221231.xsd#crdf_AccruedPreferredStockDividend"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_crdf_AccruedPreferredStockDividend_ee25e58f-1471-4175-8bc4-e09d4dfc76e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Accruedresearchagreements_787b16b1-7b1b-4942-ac04-996683226325" xlink:href="crdf-20221231.xsd#crdf_Accruedresearchagreements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_crdf_Accruedresearchagreements_787b16b1-7b1b-4942-ac04-996683226325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Accrueddirectorfees_030dc432-6d22-4a79-8ae1-77206d047aac" xlink:href="crdf-20221231.xsd#crdf_Accrueddirectorfees"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_crdf_Accrueddirectorfees_030dc432-6d22-4a79-8ae1-77206d047aac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Patentlicenseandotherfeespayable_0241fa35-68d4-4f26-af48-2363bab76ec8" xlink:href="crdf-20221231.xsd#crdf_Patentlicenseandotherfeespayable"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_crdf_Patentlicenseandotherfeespayable_0241fa35-68d4-4f26-af48-2363bab76ec8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0e174549-1406-4a36-a6db-b902f650c0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_0e174549-1406-4a36-a6db-b902f650c0e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial_8abe11aa-46cc-48c8-9dfd-04b980b8ca0f" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrial"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_11e90ab6-8ede-49e8-8ca9-dcf96261ab38" xlink:to="loc_crdf_AccruedClinicalTrial_8abe11aa-46cc-48c8-9dfd-04b980b8ca0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_524e544c-c9a2-493d-ada1-e026dcf9ae37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_54e34b1d-b785-4382-b9c8-ba6c20484ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_524e544c-c9a2-493d-ada1-e026dcf9ae37" xlink:to="loc_us-gaap_OperatingLeaseCost_54e34b1d-b785-4382-b9c8-ba6c20484ed7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_282504fd-4276-4e34-a6d8-d247a0560d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_524e544c-c9a2-493d-ada1-e026dcf9ae37" xlink:to="loc_us-gaap_SubleaseIncome_282504fd-4276-4e34-a6d8-d247a0560d3a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2b2aa339-6d3e-40a1-bab1-83821f81edf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_5c27b081-af14-432a-b9fb-57fdfe17d434" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2b2aa339-6d3e-40a1-bab1-83821f81edf6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_5c27b081-af14-432a-b9fb-57fdfe17d434" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4de4f9e5-141b-42ac-9fc3-51d2048e0c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_2b2aa339-6d3e-40a1-bab1-83821f81edf6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_4de4f9e5-141b-42ac-9fc3-51d2048e0c2b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_866c8714-252e-40e5-865e-e74f8499f779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b8d8fc2-ca4d-4628-9832-013df3150ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_866c8714-252e-40e5-865e-e74f8499f779" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_4b8d8fc2-ca4d-4628-9832-013df3150ccb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29ce6bc5-d12a-4152-bbb9-5b4493fea9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_866c8714-252e-40e5-865e-e74f8499f779" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_29ce6bc5-d12a-4152-bbb9-5b4493fea9e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0cb892d5-9aa9-46f7-a7c5-38dff9fdf4ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_866c8714-252e-40e5-865e-e74f8499f779" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0cb892d5-9aa9-46f7-a7c5-38dff9fdf4ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d974212f-5bf6-426e-8beb-9c318ec1e801" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_866c8714-252e-40e5-865e-e74f8499f779" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_d974212f-5bf6-426e-8beb-9c318ec1e801" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_78b637ca-b7dc-4395-8317-985919aee15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_866c8714-252e-40e5-865e-e74f8499f779" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_78b637ca-b7dc-4395-8317-985919aee15c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_258f3eda-e937-4e64-98c5-7bdd86d02e85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d6d8ffd3-f53c-4e60-a71a-aca7cd2d258f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_258f3eda-e937-4e64-98c5-7bdd86d02e85" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d6d8ffd3-f53c-4e60-a71a-aca7cd2d258f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_a85d3443-e79a-43ec-8376-86d19f0b6df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_258f3eda-e937-4e64-98c5-7bdd86d02e85" xlink:to="loc_us-gaap_OperatingLeaseLiability_a85d3443-e79a-43ec-8376-86d19f0b6df3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_78ac7874-f5e6-465d-b5bf-1f168181b21f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceStatedValue_b7e646ed-5359-4d93-b6fb-0a72729f174d" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceStatedValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_78ac7874-f5e6-465d-b5bf-1f168181b21f" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceStatedValue_b7e646ed-5359-4d93-b6fb-0a72729f174d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_4446f0ad-052d-44e7-9e38-b103b319a84f" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue_78ac7874-f5e6-465d-b5bf-1f168181b21f" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_4446f0ad-052d-44e7-9e38-b103b319a84f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_d1091b82-b494-43e7-96bc-1750dbcf3d17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cf86f9d1-0f7e-4bc9-8657-7c676efefb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d1091b82-b494-43e7-96bc-1750dbcf3d17" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_cf86f9d1-0f7e-4bc9-8657-7c676efefb7f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c9efaa29-fc2b-43a5-8ffa-db2d13aa910e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_d1091b82-b494-43e7-96bc-1750dbcf3d17" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c9efaa29-fc2b-43a5-8ffa-db2d13aa910e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c5d307d-d915-4e47-a634-d832453630f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ca05a3ff-719e-485d-bc10-4b799893220d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c5d307d-d915-4e47-a634-d832453630f7" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ca05a3ff-719e-485d-bc10-4b799893220d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_addba4aa-b12a-44ea-a6f0-bc0485a4256a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9c5d307d-d915-4e47-a634-d832453630f7" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_addba4aa-b12a-44ea-a6f0-bc0485a4256a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_949ec32a-ec0a-44df-a3af-cd97a47f856e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5d14a7af-add4-4508-93f0-3d1f3ed9db66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_949ec32a-ec0a-44df-a3af-cd97a47f856e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5d14a7af-add4-4508-93f0-3d1f3ed9db66" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesSignificantComponentsofCompanysTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b9d73e99-1167-4bf8-96b6-a46c2bc5f2b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_b9d73e99-1167-4bf8-96b6-a46c2bc5f2b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_d5b085bd-bc85-4af0-a47a-91ca16df7c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_d5b085bd-bc85-4af0-a47a-91ca16df7c4a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_68002986-a114-4b37-95ec-49ea311be741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_68002986-a114-4b37-95ec-49ea311be741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncomeTaxReconciliationPermanentItems_31625bae-c227-497f-904e-8b9e7939eb25" xlink:href="crdf-20221231.xsd#crdf_IncomeTaxReconciliationPermanentItems"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_crdf_IncomeTaxReconciliationPermanentItems_31625bae-c227-497f-904e-8b9e7939eb25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b933ea44-c5bc-440e-a6e6-4a07d264396f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b933ea44-c5bc-440e-a6e6-4a07d264396f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_de914a50-35f6-4485-a867-a0badd18f8d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_de914a50-35f6-4485-a867-a0badd18f8d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c0c0d7b7-6a94-47d9-9a96-971968ed7ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_c0c0d7b7-6a94-47d9-9a96-971968ed7ac7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_5aa7fc03-8732-4a91-914d-46b89bf89e57" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_1ac71410-f231-407c-8154-af22cb009daf" xlink:to="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_5aa7fc03-8732-4a91-914d-46b89bf89e57" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_05102da1-7fe7-4687-9fc5-8afa4342d278" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_05102da1-7fe7-4687-9fc5-8afa4342d278" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c65ffdd7-ee30-4154-bdce-71883e5155ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_c65ffdd7-ee30-4154-bdce-71883e5155ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_001e0a46-6b86-46a1-8d78-06b6318f434a" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_001e0a46-6b86-46a1-8d78-06b6318f434a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_3c51abac-b80a-48fa-a2e4-d5606e767669" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_3c51abac-b80a-48fa-a2e4-d5606e767669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8eae43ca-ab20-4d2a-8ae2-ab8b0cbe1011" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_8eae43ca-ab20-4d2a-8ae2-ab8b0cbe1011" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_76580dd5-5984-4a68-bde7-6a51c678e807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_76580dd5-5984-4a68-bde7-6a51c678e807" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1d6ec932-26a0-41d4-9a20-305f107706d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1d6ec932-26a0-41d4-9a20-305f107706d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_58a95710-efb6-4ff3-ad57-75007d23f628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_bd6c98fa-3392-4903-a4cd-d099559801e9" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_58a95710-efb6-4ff3-ad57-75007d23f628" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_d5ed7772-0170-4a19-ab32-5c7ac9df20d4" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_bdefca02-728b-494e-8336-0886f52b791c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_d5ed7772-0170-4a19-ab32-5c7ac9df20d4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_bdefca02-728b-494e-8336-0886f52b791c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_223be8be-6cbe-469c-b563-baa3798a6912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_d5ed7772-0170-4a19-ab32-5c7ac9df20d4" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_223be8be-6cbe-469c-b563-baa3798a6912" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b1eb7efd-8c48-4e2f-8fec-e185aa9dfd61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_58baaeb2-3c42-4c14-bcd5-9cdbbbae97af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1eb7efd-8c48-4e2f-8fec-e185aa9dfd61" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_58baaeb2-3c42-4c14-bcd5-9cdbbbae97af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_39cd0836-d5e5-4669-a62b-b46f7a7f5338" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1eb7efd-8c48-4e2f-8fec-e185aa9dfd61" xlink:to="loc_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_39cd0836-d5e5-4669-a62b-b46f7a7f5338" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_235abd39-138a-4d8a-b2f6-1fc4a5c2a57c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1eb7efd-8c48-4e2f-8fec-e185aa9dfd61" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_235abd39-138a-4d8a-b2f6-1fc4a5c2a57c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_12ec5046-71e2-4ee7-8a2b-35684b0bd02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1eb7efd-8c48-4e2f-8fec-e185aa9dfd61" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_12ec5046-71e2-4ee7-8a2b-35684b0bd02f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_91477e06-68fc-4eb7-9202-7c837c7dd630" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_b1eb7efd-8c48-4e2f-8fec-e185aa9dfd61" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_91477e06-68fc-4eb7-9202-7c837c7dd630" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_38929c6e-a7aa-4c9c-9fc1-dc16b1922624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_154edf0e-4c87-4a4c-9ea7-87b5abc50f98" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_38929c6e-a7aa-4c9c-9fc1-dc16b1922624" xlink:to="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_154edf0e-4c87-4a4c-9ea7-87b5abc50f98" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32fd0099-03f1-4e67-b477-d9b280a9baae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_38929c6e-a7aa-4c9c-9fc1-dc16b1922624" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_32fd0099-03f1-4e67-b477-d9b280a9baae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_49d9c887-79d5-41fa-9104-b60d1bdb4055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_15fd0475-fdf8-4149-9ca2-f1eec7a8f031" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_49d9c887-79d5-41fa-9104-b60d1bdb4055" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_15fd0475-fdf8-4149-9ca2-f1eec7a8f031" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ad9dfa3e-673f-4fb2-8cb8-ec612c20f87f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_49d9c887-79d5-41fa-9104-b60d1bdb4055" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ad9dfa3e-673f-4fb2-8cb8-ec612c20f87f" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>crdf-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:43395891-7664-4c15-a02f-d7b4811c3213,g:94da96fa-a6f9-430a-8c03-f421ae94b6bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofOperations" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofOperations"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StatementsofOperations" xlink:type="extended" id="i67e94dc768f4476ea2d8bd146629bfe3_StatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_61c9e2e9-d242-4942-acea-a4ddb9f6b168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_61c9e2e9-d242-4942-acea-a4ddb9f6b168" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_56d96f09-fbe4-402c-91d2-54aae5519024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_56d96f09-fbe4-402c-91d2-54aae5519024" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f6843ff3-0cb1-44db-9c73-d08d1ce154ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f6843ff3-0cb1-44db-9c73-d08d1ce154ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9fc0bf48-fa97-4598-8d5e-3816b3351d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:to="loc_us-gaap_OperatingExpenses_9fc0bf48-fa97-4598-8d5e-3816b3351d01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9ccbcf50-f709-43dc-9ec8-5b214585acb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_OperatingIncomeLoss_9ccbcf50-f709-43dc-9ec8-5b214585acb4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5501d495-7c6a-4af9-acae-6cc3b1eac48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5501d495-7c6a-4af9-acae-6cc3b1eac48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_f6955a18-f55b-4403-b04f-c796b379967c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_f6955a18-f55b-4403-b04f-c796b379967c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_fed605cb-54b0-4197-a151-88a5304d676b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_fed605cb-54b0-4197-a151-88a5304d676b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61592310-4857-477b-875c-ca6b0c20bc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61592310-4857-477b-875c-ca6b0c20bc20" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d697609-63c9-4165-9d07-cb44232b5efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_NetIncomeLoss_6d697609-63c9-4165-9d07-cb44232b5efb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_dab1e11c-b799-4784-9a0c-b17622c7c717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_dab1e11c-b799-4784-9a0c-b17622c7c717" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_542131c6-ee0a-4f82-addb-68ec38581bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_542131c6-ee0a-4f82-addb-68ec38581bf7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c211b0ab-4e74-4cd3-9230-fd9900dcf989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_EarningsPerShareBasic_c211b0ab-4e74-4cd3-9230-fd9900dcf989" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_39aad66a-fecb-49cf-a2fd-b7e5c8a70c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_39aad66a-fecb-49cf-a2fd-b7e5c8a70c3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6e12ff9-48cc-479e-a3a5-3b0403424076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6e12ff9-48cc-479e-a3a5-3b0403424076" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7a31738-b655-46cc-a333-d0913921ba4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7a31738-b655-46cc-a333-d0913921ba4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_7f5898ee-386f-4611-a40b-639db27a6992_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:to="loc_us-gaap_ClassOfStockDomain_7f5898ee-386f-4611-a40b-639db27a6992_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:to="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_7a67d25e-a5e3-473e-8c66-5f8af9b83c8b" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_7a67d25e-a5e3-473e-8c66-5f8af9b83c8b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_81812879-4cea-4fed-82dd-7491922b899d" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_81812879-4cea-4fed-82dd-7491922b899d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="crdf-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended" id="i9ab6c2f40de34d9dbb6e60c6f8f45d14_ConsolidatedStatementsofComprehensiveLoss">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23d1e5a7-cabf-49e3-9d3f-002e206c911b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_NetIncomeLoss_23d1e5a7-cabf-49e3-9d3f-002e206c911b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_91eae102-6aba-493e-b5b6-c156cedd7723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_91eae102-6aba-493e-b5b6-c156cedd7723" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a625e2-4868-40da-a6f6-3ef7268039e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a625e2-4868-40da-a6f6-3ef7268039e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9c2ad9d7-9000-4e2e-a7f9-73c6aa0cc5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9c2ad9d7-9000-4e2e-a7f9-73c6aa0cc5e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_bf03324a-a9e6-4c26-84e9-1cbbe7a8d596" xlink:href="crdf-20221231.xsd#crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_bf03324a-a9e6-4c26-84e9-1cbbe7a8d596" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_facf1024-6dfc-46c7-8edd-5d4af47b03c6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:to="loc_us-gaap_ClassOfStockDomain_facf1024-6dfc-46c7-8edd-5d4af47b03c6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:to="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ae33db6c-9fe4-4ae3-8e22-9ee8fe2bfa76" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ae33db6c-9fe4-4ae3-8e22-9ee8fe2bfa76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_b65d9ede-a893-44b7-a1c9-616b7d8db10f" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_b65d9ede-a893-44b7-a1c9-616b7d8db10f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StatementsofStockholdersEquity" xlink:type="extended" id="i2822e6b773ea43dab4da945f7aeb8b73_StatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5719a9d5-1163-4350-b1e9-7168405703f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5719a9d5-1163-4350-b1e9-7168405703f9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_03437dbf-8dae-4b9e-aa37-7389c75b8d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SharesIssued_03437dbf-8dae-4b9e-aa37-7389c75b8d82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e20e3dd4-9022-4d05-96a3-b6630cd338dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockholdersEquity_e20e3dd4-9022-4d05-96a3-b6630cd338dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e2e0fd30-dcab-49a4-8271-ea84fd7a224d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e2e0fd30-dcab-49a4-8271-ea84fd7a224d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_b0173796-5306-4c07-bcbf-4dcd9d240d79" xlink:href="crdf-20221231.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_b0173796-5306-4c07-bcbf-4dcd9d240d79" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_223fbc87-80ca-48b1-a857-2e3e8c989ca4" xlink:href="crdf-20221231.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_223fbc87-80ca-48b1-a857-2e3e8c989ca4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68cc9b56-1edc-435e-bcef-42089ad9b721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68cc9b56-1edc-435e-bcef-42089ad9b721" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_be09022e-e3f3-4c8a-928b-847f04ca8975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_be09022e-e3f3-4c8a-928b-847f04ca8975" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_121712fe-a15f-4fd7-a80c-e9d3c6af69aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_121712fe-a15f-4fd7-a80c-e9d3c6af69aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40ab5df0-ab35-47a3-84d0-affc8910c884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40ab5df0-ab35-47a3-84d0-affc8910c884" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_c7515515-9026-47fe-9178-e11ca2562455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_DividendsPreferredStock_c7515515-9026-47fe-9178-e11ca2562455" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a0d45f7-87f5-4e6a-8bd7-6c988996dffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a0d45f7-87f5-4e6a-8bd7-6c988996dffa" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_14b0e5b3-df57-4e5e-a530-ae003b836627" xlink:href="crdf-20221231.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_14b0e5b3-df57-4e5e-a530-ae003b836627" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockCumulativeDividendAdjustment_a3fab2c6-7886-4f33-be3b-f5076da87580" xlink:href="crdf-20221231.xsd#crdf_PreferredStockCumulativeDividendAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_PreferredStockCumulativeDividendAdjustment_a3fab2c6-7886-4f33-be3b-f5076da87580" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3e2c762-357d-49f2-a949-5ddddec162b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_NetIncomeLoss_a3e2c762-357d-49f2-a949-5ddddec162b7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c11cbebd-b89e-4431-9206-6137b2830494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc62d972-1b08-480a-a031-b7434b715a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5719a9d5-1163-4350-b1e9-7168405703f9" xlink:to="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8650400c-eacf-4808-bee5-9e249201fd63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:to="loc_us-gaap_EquityComponentDomain_8650400c-eacf-4808-bee5-9e249201fd63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:to="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d453057b-4588-4104-9014-daf06632a396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_PreferredStockMember_d453057b-4588-4104-9014-daf06632a396" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d732ed51-ead7-454d-9dcc-8554b4826461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_CommonStockMember_d732ed51-ead7-454d-9dcc-8554b4826461" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_58837541-299b-4966-9d00-10bfb5f6f44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_58837541-299b-4966-9d00-10bfb5f6f44e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_7e15e10d-f215-40e6-b503-3aadaad5d5be" xlink:href="crdf-20221231.xsd#crdf_ServiceReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_crdf_ServiceReceivableMember_7e15e10d-f215-40e6-b503-3aadaad5d5be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40bc8140-6137-427f-9927-ea2adcedd073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40bc8140-6137-427f-9927-ea2adcedd073" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f14b7b42-78f7-4a31-8af4-2fa0f3789ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_RetainedEarningsMember_f14b7b42-78f7-4a31-8af4-2fa0f3789ed8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:to="loc_us-gaap_ClassOfStockDomain_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:to="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_33a41bd3-ce1b-497d-95de-c0af40ef1feb" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_33a41bd3-ce1b-497d-95de-c0af40ef1feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_14dc026d-7a2c-4eff-bede-4c7707b5bf4e" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_14dc026d-7a2c-4eff-bede-4c7707b5bf4e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StatementsofCashFlows" xlink:type="extended" id="ifd584694dfff42358327fa0aaa991b1b_StatementsofCashFlows">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a371c96-95c0-47b1-8fdc-1e4b19650d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:to="loc_us-gaap_NetIncomeLoss_6a371c96-95c0-47b1-8fdc-1e4b19650d52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_25fdfbe5-9e45-42dd-8893-7f60d80fa137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_25fdfbe5-9e45-42dd-8893-7f60d80fa137" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92d8aa61-31a4-4329-a720-85edcfc851ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92d8aa61-31a4-4329-a720-85edcfc851ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3660beca-9bdf-4dcf-b02f-74b181face97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_ShareBasedCompensation_3660beca-9bdf-4dcf-b02f-74b181face97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d350e212-130e-4094-9536-6ceecf07ab9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d350e212-130e-4094-9536-6ceecf07ab9c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_c7e42637-d82f-4dea-97fa-da145c2360dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_c7e42637-d82f-4dea-97fa-da145c2360dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_cbc08c7d-3f52-4782-8a8d-235465eba8fc" xlink:href="crdf-20221231.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_cbc08c7d-3f52-4782-8a8d-235465eba8fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9bdb017d-42b0-4018-b7f5-3dcbd9681b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9bdb017d-42b0-4018-b7f5-3dcbd9681b18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_db25a032-7b66-4809-b93f-f4b6d719ca20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_db25a032-7b66-4809-b93f-f4b6d719ca20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_515862f1-ed37-4626-8217-6c1912131e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_515862f1-ed37-4626-8217-6c1912131e0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_14fe497d-a146-43b5-889a-47733730904b" xlink:href="crdf-20221231.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_14fe497d-a146-43b5-889a-47733730904b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8605e595-be55-4fe6-93cf-257a12158761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8605e595-be55-4fe6-93cf-257a12158761" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e75bba9e-d4f7-4a90-bb08-57713e0d1afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e75bba9e-d4f7-4a90-bb08-57713e0d1afb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0f1484bb-7aba-4e7c-bd84-da321be0dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0f1484bb-7aba-4e7c-bd84-da321be0dbbc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f569dbc-b0c2-4445-a309-0a5b6590e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f569dbc-b0c2-4445-a309-0a5b6590e67d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c11cbea3-e0ae-4442-9d5a-5780f5cc5080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c11cbea3-e0ae-4442-9d5a-5780f5cc5080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_39af9d74-d77b-4ce1-a87d-3f3d1c92ce4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_39af9d74-d77b-4ce1-a87d-3f3d1c92ce4f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b6be9a5f-4522-482c-9f9f-5a033b2a3316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b6be9a5f-4522-482c-9f9f-5a033b2a3316" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c16ad2c5-aa2c-48f6-857c-af4f70a34f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c16ad2c5-aa2c-48f6-857c-af4f70a34f98" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b990f040-76d0-4adc-a362-d5e2d41c8062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b990f040-76d0-4adc-a362-d5e2d41c8062" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b65611d-b325-4095-ae93-e96648af6925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b65611d-b325-4095-ae93-e96648af6925" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c223a20b-459d-4017-aba8-7e92cbde905a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c223a20b-459d-4017-aba8-7e92cbde905a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e64a84cc-40e0-4bd4-9acb-86c6dd8e40ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e64a84cc-40e0-4bd4-9acb-86c6dd8e40ec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c495945a-123c-45e7-88e1-822e2b704634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c495945a-123c-45e7-88e1-822e2b704634" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c0b10ba-c821-409b-8738-ed1e82db6063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c0b10ba-c821-409b-8738-ed1e82db6063" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9366d553-aeba-4aa1-bb7e-2de6ce61af30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9366d553-aeba-4aa1-bb7e-2de6ce61af30" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ec9e997-e169-4a99-94a4-71ae83ca244b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ec9e997-e169-4a99-94a4-71ae83ca244b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b13a693a-068e-4687-8766-bddc379bbc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_43020f57-3cd6-4b47-93aa-6c18eab9526a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:to="loc_us-gaap_IncomeTaxesPaid_43020f57-3cd6-4b47-93aa-6c18eab9526a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_565ad045-0b81-4dc9-a715-3501a16f700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_565ad045-0b81-4dc9-a715-3501a16f700e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_2e9920e4-3b23-4bae-9ea3-8d53ed5de709" xlink:href="crdf-20221231.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:to="loc_crdf_PreferredStockDividendAccrued_2e9920e4-3b23-4bae-9ea3-8d53ed5de709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NonCashCumulativePreferredStockDividendAdjustment_3f88b652-4de2-45c9-93b4-5de991492b6f" xlink:href="crdf-20221231.xsd#crdf_NonCashCumulativePreferredStockDividendAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:to="loc_crdf_NonCashCumulativePreferredStockDividendAdjustment_3f88b652-4de2-45c9-93b4-5de991492b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:to="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_16cc12bb-1b1f-4088-9bb8-4b67e987896c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:to="loc_us-gaap_ClassOfStockDomain_16cc12bb-1b1f-4088-9bb8-4b67e987896c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:to="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_e6550545-a3da-4837-9cf1-9822c9debc11" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_e6550545-a3da-4837-9cf1-9822c9debc11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_6195298d-0c51-45b9-b292-62983e1a7382" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_6195298d-0c51-45b9-b292-62983e1a7382" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofCashFlowsParenthetical"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical" xlink:type="extended" id="i54286bf68e51475aa854fc12c3202db3_StatementsofCashFlowsParenthetical">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ffd97e2-ae7f-4b90-b080-b6c062b8fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_606a36fa-b796-473a-a793-a7710d928e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2ffd97e2-ae7f-4b90-b080-b6c062b8fffb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_606a36fa-b796-473a-a793-a7710d928e4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2ffd97e2-ae7f-4b90-b080-b6c062b8fffb" xlink:to="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_800311ac-a7a6-4646-951f-a3da4104f343_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:to="loc_us-gaap_ClassOfStockDomain_800311ac-a7a6-4646-951f-a3da4104f343_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:to="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CommonStockAndWarrantsMember_718290ee-5b1a-45c1-a4ea-c5db5e41a03c" xlink:href="crdf-20221231.xsd#crdf_CommonStockAndWarrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:to="loc_crdf_CommonStockAndWarrantsMember_718290ee-5b1a-45c1-a4ea-c5db5e41a03c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ebda9b12-632c-4e72-b68f-d3511d7ef223" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ebda9b12-632c-4e72-b68f-d3511d7ef223" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended" id="i31ca961acb424ce988269f99caee1107_DerivativeFinancialInstrumentsWarrantsTables">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0025cc02-0f1f-4b37-86ab-9d44a7aab7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0025cc02-0f1f-4b37-86ab-9d44a7aab7b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_76e01546-197a-44af-b3e0-1ae5a99c47e6" xlink:href="crdf-20221231.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:to="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_76e01546-197a-44af-b3e0-1ae5a99c47e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:to="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:to="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_97a499b6-b1a7-4525-9f01-79fe05a072e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_97a499b6-b1a7-4525-9f01-79fe05a072e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9875e812-6f5e-489e-ab72-ffd5b0617d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9875e812-6f5e-489e-ab72-ffd5b0617d30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_3f0f3810-7bb3-4002-a1c8-e8041369942c" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9875e812-6f5e-489e-ab72-ffd5b0617d30" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_3f0f3810-7bb3-4002-a1c8-e8041369942c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i0570d6b911454be582e3403ff94a727c_BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2173cfe-d8cb-4621-a57b-44c2d06149d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2173cfe-d8cb-4621-a57b-44c2d06149d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_98ff5347-b588-438e-9f94-793c61159902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_98ff5347-b588-438e-9f94-793c61159902" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_f449fbc5-98d8-46a7-b9b0-be1de2cc0957_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_f449fbc5-98d8-46a7-b9b0-be1de2cc0957_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3ce3b8db-077d-4396-b324-16a469450f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3ce3b8db-077d-4396-b324-16a469450f7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_942fda3e-4fc4-4911-a5f1-ec2f000dd80a" xlink:href="crdf-20221231.xsd#crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3ce3b8db-077d-4396-b324-16a469450f7e" xlink:to="loc_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_942fda3e-4fc4-4911-a5f1-ec2f000dd80a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="extended" id="i8e36ff786aa740b1a7bbbbae3397f29c_BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7df9df63-8c2e-42c2-ba83-916e228c4514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ec9cb00a-755c-45d6-8e79-0a8a100c87b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7df9df63-8c2e-42c2-ba83-916e228c4514" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ec9cb00a-755c-45d6-8e79-0a8a100c87b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7df9df63-8c2e-42c2-ba83-916e228c4514" xlink:to="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_d5341ba0-8282-43ec-b583-b2871e18c750_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_d5341ba0-8282-43ec-b583-b2871e18c750_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3d95dd3f-6a8a-4f8f-b351-a57e1b8af950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3d95dd3f-6a8a-4f8f-b351-a57e1b8af950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4e9315cf-f1ba-477d-a782-37e153a95f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3d95dd3f-6a8a-4f8f-b351-a57e1b8af950" xlink:to="loc_us-gaap_WarrantMember_4e9315cf-f1ba-477d-a782-37e153a95f38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_66ecf197-aeaf-4d8d-ba3a-f960bd12262a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:to="loc_us-gaap_ValuationTechniqueDomain_66ecf197-aeaf-4d8d-ba3a-f960bd12262a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_802116a0-a4bc-4661-a1a8-b0a6fac6e497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:to="loc_us-gaap_ValuationTechniqueDomain_802116a0-a4bc-4661-a1a8-b0a6fac6e497" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_d38c33e2-0008-4501-b7e9-904c92492751" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_802116a0-a4bc-4661-a1a8-b0a6fac6e497" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_d38c33e2-0008-4501-b7e9-904c92492751" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="extended" id="i156dd68a5f4f4bbab7576421d50d44ae_BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3621b5-7bb6-4591-b517-e16576c562cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50b33f1f-f1bc-4efb-a29f-3f687a077ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3621b5-7bb6-4591-b517-e16576c562cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50b33f1f-f1bc-4efb-a29f-3f687a077ad6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3621b5-7bb6-4591-b517-e16576c562cd" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56298e00-a23c-4ceb-a155-05513891ceb2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_56298e00-a23c-4ceb-a155-05513891ceb2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_575cecdf-1536-4204-a69e-27a92bbc9160" xlink:href="crdf-20221231.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_575cecdf-1536-4204-a69e-27a92bbc9160" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cc654a13-dab5-4e4a-9c6d-837410506a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cc654a13-dab5-4e4a-9c6d-837410506a53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f412d261-98a4-44f0-9298-766fb115fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:to="loc_us-gaap_EquipmentMember_f412d261-98a4-44f0-9298-766fb115fc2e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:to="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_879492e7-b6ea-40d7-91a2-0ca4469bf1a8_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:to="loc_srt_RangeMember_879492e7-b6ea-40d7-91a2-0ca4469bf1a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:to="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8859a70d-3f76-488e-9802-2534e0bebeec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:to="loc_srt_MinimumMember_8859a70d-3f76-488e-9802-2534e0bebeec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70e1c891-a956-4372-b565-5fbd9879fcd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:to="loc_srt_MaximumMember_70e1c891-a956-4372-b565-5fbd9879fcd9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="extended" id="i903ad34efec740babe517bea7bd2c167_BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8eed9c25-0e2b-4344-a112-c70414016100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e8034f7-6ea8-4054-9db3-f0f809e4fdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8eed9c25-0e2b-4344-a112-c70414016100" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e8034f7-6ea8-4054-9db3-f0f809e4fdd1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8eed9c25-0e2b-4344-a112-c70414016100" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cc008b1c-0783-4167-a04c-7eda0f8b90e2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_cc008b1c-0783-4167-a04c-7eda0f8b90e2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0661658a-fd77-4498-9bd2-7dbe500345ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0661658a-fd77-4498-9bd2-7dbe500345ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b16b5a20-f87a-4818-9d9a-04eaf4c10f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_us-gaap_WarrantMember_b16b5a20-f87a-4818-9d9a-04eaf4c10f7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_977031bf-6502-4a81-8f4b-e98524fe2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_977031bf-6502-4a81-8f4b-e98524fe2be0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_d579bd1b-657c-4367-bbb4-34f22ee6bdb1" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_d579bd1b-657c-4367-bbb4-34f22ee6bdb1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" xlink:type="extended" id="i8c3dc05e6dad471e863fbd90bdb8b49c_SupplementaryBalanceSheetInformationShorttermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1524784f-fc3b-45a7-aa2d-c51b3688587e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1524784f-fc3b-45a7-aa2d-c51b3688587e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_95cb5b20-a8ca-433b-964a-0f08b93acf24" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_95cb5b20-a8ca-433b-964a-0f08b93acf24" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8500140c-1b8b-43e2-af24-2bce2ef030f0" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8500140c-1b8b-43e2-af24-2bce2ef030f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af16c582-b9ee-411f-b8e4-56e68fe4b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af16c582-b9ee-411f-b8e4-56e68fe4b41f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_aa62176a-d904-40c3-b067-2908ebc9a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_aa62176a-d904-40c3-b067-2908ebc9a9c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_01d07476-e792-497a-aedc-adefec6cf883" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_01d07476-e792-497a-aedc-adefec6cf883" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_4362e4b4-4b8b-48ec-94e6-fce262340df8" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_4362e4b4-4b8b-48ec-94e6-fce262340df8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_76bd87a2-3d65-4e29-8b73-4838049683a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_76bd87a2-3d65-4e29-8b73-4838049683a1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11c36c2f-95a5-4fcb-b6d8-cb8a74be15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11c36c2f-95a5-4fcb-b6d8-cb8a74be15d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfee9e96-f1d9-4d36-8fac-0b5ba9f29ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfee9e96-f1d9-4d36-8fac-0b5ba9f29ecc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ca16451-2aff-43b0-9bd1-164f0ebfde23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ca16451-2aff-43b0-9bd1-164f0ebfde23" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b0bf743-b6b1-4f12-9b0b-97a65080216f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b0bf743-b6b1-4f12-9b0b-97a65080216f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a24db85-28a6-4b86-95c1-fcf691ca754b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a24db85-28a6-4b86-95c1-fcf691ca754b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a642416-94e0-4a00-8857-8323eee31e3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_6a642416-94e0-4a00-8857-8323eee31e3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0100ebbc-93bd-4f78-b640-d4fa0bfaf1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0100ebbc-93bd-4f78-b640-d4fa0bfaf1bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fd471990-2389-4698-850a-125a93b06d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fd471990-2389-4698-850a-125a93b06d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7297572b-fd34-47cf-a605-da372bd17de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_CommercialPaperMember_7297572b-fd34-47cf-a605-da372bd17de2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f8b53c7-480a-4ea4-85cf-886a7211f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f8b53c7-480a-4ea4-85cf-886a7211f6a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a47304fb-f28f-4c4f-adca-7350adeddc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a47304fb-f28f-4c4f-adca-7350adeddc75" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4b156588-4735-48a1-814a-c46b8ee33ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4b156588-4735-48a1-814a-c46b8ee33ee4" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="extended" id="id676f15dd2874c129f553d60ea5bbf9f_SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12b49268-c1a8-4087-8033-0a7c50d252bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12b49268-c1a8-4087-8033-0a7c50d252bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9d9dcab7-8493-4b69-8d34-22161c89bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9d9dcab7-8493-4b69-8d34-22161c89bc1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c8f2601-5824-4d3b-bbbe-af96255084a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8c8f2601-5824-4d3b-bbbe-af96255084a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_04b39db4-621c-4a9d-87c1-6279d6325319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_04b39db4-621c-4a9d-87c1-6279d6325319" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1daa252a-e748-42bc-8783-bd77fd473e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1daa252a-e748-42bc-8783-bd77fd473e45" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended" id="i27f0e5f887af49fa8e45b7b8ee9fce3f_SupplementaryBalanceSheetInformationPropertyandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d3d9440c-9d06-41c7-b3bb-c8ee48005651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_Depreciation_d3d9440c-9d06-41c7-b3bb-c8ee48005651" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_acf2fccf-cdae-4408-a85c-a2861a96f107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_acf2fccf-cdae-4408-a85c-a2861a96f107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_177eb68c-b495-42b6-a7df-62ec3f29bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_177eb68c-b495-42b6-a7df-62ec3f29bd0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e2bc7b17-7980-41c5-a72f-014949f8299f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e2bc7b17-7980-41c5-a72f-014949f8299f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6440390-e2e5-4430-a836-a787065bdf65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f6440390-e2e5-4430-a836-a787065bdf65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_df5cf7ae-fedd-4e6d-9152-b2d8ce1dc212" xlink:href="crdf-20221231.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_df5cf7ae-fedd-4e6d-9152-b2d8ce1dc212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6382df76-cc0c-446d-a341-f398460de1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6382df76-cc0c-446d-a341-f398460de1f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_76b63787-4f07-49c5-bd28-b7e2de7505d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:to="loc_us-gaap_EquipmentMember_76b63787-4f07-49c5-bd28-b7e2de7505d5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended" id="i56af1eff174a47e5a6dff7db68f89dbf_LeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_5a6011f1-ccef-4c1e-b827-829b81813207" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_5a6011f1-ccef-4c1e-b827-829b81813207" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_a6326ee4-472c-4096-aac2-617fdb26c2c8" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_a6326ee4-472c-4096-aac2-617fdb26c2c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_fb8d0a8a-03b1-44d9-848b-a63c83fe3bc0" xlink:href="crdf-20221231.xsd#crdf_LessorNumberOfSubleases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_crdf_LessorNumberOfSubleases_fb8d0a8a-03b1-44d9-848b-a63c83fe3bc0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:to="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d1f976ce-217c-4767-b5a6-6aa461204449_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d1f976ce-217c-4767-b5a6-6aa461204449_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0180f849-02ca-443f-9484-a081e847509c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0180f849-02ca-443f-9484-a081e847509c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d90db22e-fe75-400b-8be5-d3c0815d2a36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0180f849-02ca-443f-9484-a081e847509c" xlink:to="loc_srt_ScenarioForecastMember_d90db22e-fe75-400b-8be5-d3c0815d2a36" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended" id="i5d85a8690e594b81915d663ee88821eb_StockholdersEquitySummaryofPreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e77a33c9-209e-4ea0-afd5-5ea8b2112cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e77a33c9-209e-4ea0-afd5-5ea8b2112cbf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a7c10d50-8fc6-48a2-9d33-d70cf7ca28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a7c10d50-8fc6-48a2-9d33-d70cf7ca28ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e9d9241a-a7b3-46cf-bcbc-ea4e4b01c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e9d9241a-a7b3-46cf-bcbc-ea4e4b01c2b4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceStatedValue_b7d6510b-1123-476e-81c9-19bdf09b025a" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceStatedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceStatedValue_b7d6510b-1123-476e-81c9-19bdf09b025a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_bb676ae5-4bda-4b59-bfe8-ce1f62cd76bb" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_bb676ae5-4bda-4b59-bfe8-ce1f62cd76bb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_61f98c36-d327-455b-91ec-44ff8bc53094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_61f98c36-d327-455b-91ec-44ff8bc53094" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_ea0777c4-0e27-4046-8104-fdc508251f16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:to="loc_us-gaap_ClassOfStockDomain_ea0777c4-0e27-4046-8104-fdc508251f16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:to="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_44d85dd0-aad7-44e1-a1bf-969df6eba8bc" xlink:href="crdf-20221231.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_44d85dd0-aad7-44e1-a1bf-969df6eba8bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_2d146a40-fb83-4074-abd8-aba9ba676140" xlink:href="crdf-20221231.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_2d146a40-fb83-4074-abd8-aba9ba676140" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_af30b3bf-2a44-4d17-858b-ce12e84ebe77" xlink:href="crdf-20221231.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_af30b3bf-2a44-4d17-858b-ce12e84ebe77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_d75d8194-6289-4b2a-b45f-1ad276fcd23a" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_d75d8194-6289-4b2a-b45f-1ad276fcd23a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_10817bc5-2a21-4a67-ae30-f14a2e80ea43" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_10817bc5-2a21-4a67-ae30-f14a2e80ea43" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySeriesAConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="extended" id="i4b2453fcacb142bfb9fd0f6b496f863f_StockholdersEquitySeriesAConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_95b54cda-84ac-46f9-8e9c-28d326ba58a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_95b54cda-84ac-46f9-8e9c-28d326ba58a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_d406806b-c493-4184-859c-0768a945e8d6" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_d406806b-c493-4184-859c-0768a945e8d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_701bf4ba-16a1-4b9c-a6ef-b72ae52c00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_us-gaap_DividendsPreferredStock_701bf4ba-16a1-4b9c-a6ef-b72ae52c00d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_70d03ce3-0c9b-4a0d-af85-1138693dfff7" xlink:href="crdf-20221231.xsd#crdf_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_70d03ce3-0c9b-4a0d-af85-1138693dfff7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionPricePerShare_c20ddaae-533a-4e00-98ae-b18914118866" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionPricePerShare_c20ddaae-533a-4e00-98ae-b18914118866" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_dfd04736-08e3-455c-a43c-f75335da3757" xlink:href="crdf-20221231.xsd#crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_dfd04736-08e3-455c-a43c-f75335da3757" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SharePriceForAutomaticConversion_57f140e6-5cc7-4343-a3fa-191434fa64d5" xlink:href="crdf-20221231.xsd#crdf_SharePriceForAutomaticConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_SharePriceForAutomaticConversion_57f140e6-5cc7-4343-a3fa-191434fa64d5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_793ab418-efe3-468d-8856-2a23371e79f5" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_793ab418-efe3-468d-8856-2a23371e79f5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_ec28cdf7-39d2-483e-abb5-53b6a8393582" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_ec28cdf7-39d2-483e-abb5-53b6a8393582" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationNumberOfTradingDays_d9c8e432-fe49-4f62-b30c-a8f994a44696" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationNumberOfTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionObligationNumberOfTradingDays_d9c8e432-fe49-4f62-b30c-a8f994a44696" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:to="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_191497fa-81bc-460b-98cf-5a76b5cd4032_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:to="loc_us-gaap_ClassOfStockDomain_191497fa-81bc-460b-98cf-5a76b5cd4032_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_27e2f3dc-ac63-4f35-a567-6a8ca949eba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:to="loc_us-gaap_ClassOfStockDomain_27e2f3dc-ac63-4f35-a567-6a8ca949eba2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_160da444-c002-4abe-a2ee-8e2bbb08b2a0" xlink:href="crdf-20221231.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_27e2f3dc-ac63-4f35-a567-6a8ca949eba2" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_160da444-c002-4abe-a2ee-8e2bbb08b2a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:to="loc_us-gaap_EquityComponentDomain_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4eae0c0b-650d-438e-8f45-38d6167d4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:to="loc_us-gaap_EquityComponentDomain_4eae0c0b-650d-438e-8f45-38d6167d4ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_524bb7b9-ba4f-463a-8726-a3ba94382b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4eae0c0b-650d-438e-8f45-38d6167d4ee8" xlink:to="loc_us-gaap_RetainedEarningsMember_524bb7b9-ba4f-463a-8726-a3ba94382b5c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended" id="i272413a8b6ed44a28c7603f07692675c_StockholdersEquitySeriesEConvertiblePreferredStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73c57744-f39c-4e9e-8300-313784d23e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73c57744-f39c-4e9e-8300-313784d23e01" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ee274c2e-1762-416b-bd17-bfb9456cd0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ee274c2e-1762-416b-bd17-bfb9456cd0a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_8e7f6698-18d4-4c11-8007-0f421f0aa8a4" xlink:href="crdf-20221231.xsd#crdf_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_8e7f6698-18d4-4c11-8007-0f421f0aa8a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_e4940c29-e953-4dcb-8865-3055ecc20514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_e4940c29-e953-4dcb-8865-3055ecc20514" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_87ca9f5f-66b0-4ec6-b968-d1bab79b8231" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_87ca9f5f-66b0-4ec6-b968-d1bab79b8231" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bd16f15-7b22-4e3b-a99f-177f7c2c239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bd16f15-7b22-4e3b-a99f-177f7c2c239c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_41575edf-d376-4b48-828c-282e321355d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_41575edf-d376-4b48-828c-282e321355d9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_26b9eaa8-be21-47c7-b639-35fcff15ac5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_26b9eaa8-be21-47c7-b639-35fcff15ac5b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_48d3bbbe-2490-4516-a6a5-258a36f23ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_48d3bbbe-2490-4516-a6a5-258a36f23ee9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_51cac829-817a-4e97-9072-2bfcaf80b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_51cac829-817a-4e97-9072-2bfcaf80b34c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightIssued_c7742caa-6c7a-4a4f-bcaa-fce8fbff1971" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ClassOfWarrantOrRightIssued_c7742caa-6c7a-4a4f-bcaa-fce8fbff1971" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm_85a5cfd1-2360-49fa-badf-8b9226f2cb09" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ClassOfWarrantOrRightExpirationTerm_85a5cfd1-2360-49fa-badf-8b9226f2cb09" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_75e495ac-88f5-4281-a062-d0ef0475f8ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_75e495ac-88f5-4281-a062-d0ef0475f8ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_RegisteredDirectOfferingMember_c6a4e99e-4feb-4ac3-a936-112e8fc08dbc" xlink:href="crdf-20221231.xsd#crdf_RegisteredDirectOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:to="loc_crdf_RegisteredDirectOfferingMember_c6a4e99e-4feb-4ac3-a936-112e8fc08dbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_dc0d17f8-c9fc-422b-ad3e-9be31569a4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:to="loc_us-gaap_PrivatePlacementMember_dc0d17f8-c9fc-422b-ad3e-9be31569a4b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_aa4d8722-86b1-42d5-b614-072ce15b88de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:to="loc_us-gaap_ClassOfStockDomain_aa4d8722-86b1-42d5-b614-072ce15b88de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_11f6a5e0-3759-4b35-b174-aae3101c3850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:to="loc_us-gaap_ClassOfStockDomain_11f6a5e0-3759-4b35-b174-aae3101c3850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_4d03f336-cfc5-4882-9fce-500d265b5294" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_11f6a5e0-3759-4b35-b174-aae3101c3850" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_4d03f336-cfc5-4882-9fce-500d265b5294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_cc8014ce-9d6e-4a59-8a54-98d603ae8e62_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_cc8014ce-9d6e-4a59-8a54-98d603ae8e62_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f9339233-f85d-4dce-b561-2dac99fbb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f9339233-f85d-4dce-b561-2dac99fbb8ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesNWarrantMember_788e4d98-03de-4000-be3c-1110a90c3f24" xlink:href="crdf-20221231.xsd#crdf_SeriesNWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f9339233-f85d-4dce-b561-2dac99fbb8ee" xlink:to="loc_crdf_SeriesNWarrantMember_788e4d98-03de-4000-be3c-1110a90c3f24" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i0e6ce60d42954e369fc5d188759a430f_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9181f4b2-ce4a-467b-95b7-e49f677205f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9181f4b2-ce4a-467b-95b7-e49f677205f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58fee3cb-24f6-4c85-8496-2986de6b6231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58fee3cb-24f6-4c85-8496-2986de6b6231" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96bf3442-3edb-4eaa-8dfd-a6893d4a76c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96bf3442-3edb-4eaa-8dfd-a6893d4a76c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_a4372e24-b27d-4509-a35b-83c94cdc39d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_a4372e24-b27d-4509-a35b-83c94cdc39d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cedced38-d9ed-4db3-b4a1-7a0fe3c0cd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cedced38-d9ed-4db3-b4a1-7a0fe3c0cd10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c99ca45-7be6-4f65-9845-c6f2c659add2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c99ca45-7be6-4f65-9845-c6f2c659add2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9cc6dd93-5179-4800-84b4-8216ad13ae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9cc6dd93-5179-4800-84b4-8216ad13ae0b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7d549303-4975-4902-9f11-b1e33a9817e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7d549303-4975-4902-9f11-b1e33a9817e8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_18c0f582-9a2d-4e40-8a0d-c457271c30a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_18c0f582-9a2d-4e40-8a0d-c457271c30a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:to="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7427a28e-5432-47ea-87c5-9c2b3113b21b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:to="loc_us-gaap_PlanNameDomain_7427a28e-5432-47ea-87c5-9c2b3113b21b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_38151987-f67e-4009-a48d-1b0e57a8900a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:to="loc_us-gaap_PlanNameDomain_38151987-f67e-4009-a48d-1b0e57a8900a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2014Member_e7c191dc-80f9-4b14-8b4d-31f7c9c57a87" xlink:href="crdf-20221231.xsd#crdf_EquityIncentivePlan2014Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_38151987-f67e-4009-a48d-1b0e57a8900a" xlink:to="loc_crdf_EquityIncentivePlan2014Member_e7c191dc-80f9-4b14-8b4d-31f7c9c57a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:to="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a1b6fb-44c6-4c78-a514-20fbb691c8d8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_21a1b6fb-44c6-4c78-a514-20fbb691c8d8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_940f6ca0-3146-4263-a852-dca6dc2cd489" xlink:href="crdf-20221231.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:to="loc_crdf_InducementGrantStockOptionsMember_940f6ca0-3146-4263-a852-dca6dc2cd489" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_39818d08-7626-4553-81a6-80e3393bbef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:to="loc_us-gaap_EmployeeStockOptionMember_39818d08-7626-4553-81a6-80e3393bbef6" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationStockBasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="extended" id="i6ffa43812dbf483ca509ea7e10b3f59c_StockBasedCompensationStockBasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87c81bd-1aae-482a-9102-5b311c07b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8675deae-920d-4e90-808a-91c5f00666c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87c81bd-1aae-482a-9102-5b311c07b7b1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8675deae-920d-4e90-808a-91c5f00666c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87c81bd-1aae-482a-9102-5b311c07b7b1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_76ba760b-da8a-4173-b4a7-a1e0d3ca972f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_76ba760b-da8a-4173-b4a7-a1e0d3ca972f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ff823ea-973b-4e55-aa22-b6c97f01633b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ff823ea-973b-4e55-aa22-b6c97f01633b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6b78a86-14d6-4428-ab68-3d434dee59f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6b78a86-14d6-4428-ab68-3d434dee59f0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="extended" id="i378e876a715c4a7bb40826fea8662d40_StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07208df0-36d9-418a-a1eb-2c344e9561d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07208df0-36d9-418a-a1eb-2c344e9561d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6a3f8182-5a5d-42c8-a3d2-f3cc83dcd6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6a3f8182-5a5d-42c8-a3d2-f3cc83dcd6a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5443662a-3883-485b-8958-85e48f4765c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5443662a-3883-485b-8958-85e48f4765c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0342fe0-1e30-48af-9748-009240ceac0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0342fe0-1e30-48af-9748-009240ceac0f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_778e015f-28c5-4446-a20a-9520abac74b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_778e015f-28c5-4446-a20a-9520abac74b9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:to="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b5d94734-1201-4ae5-ba98-9fec0f4d4939_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:to="loc_srt_RangeMember_b5d94734-1201-4ae5-ba98-9fec0f4d4939_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:to="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a349363f-9ce7-4abb-b19d-7881545ecbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:to="loc_srt_MinimumMember_a349363f-9ce7-4abb-b19d-7881545ecbdd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73bd82c6-3aee-454a-bace-f9bbd99c1b4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:to="loc_srt_MaximumMember_73bd82c6-3aee-454a-bace-f9bbd99c1b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:to="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_750df88b-8811-46c6-abe5-3e4056e381b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_750df88b-8811-46c6-abe5-3e4056e381b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b337fdb4-2502-498c-91cc-d4a2f05b1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b337fdb4-2502-498c-91cc-d4a2f05b1f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d4fbbed5-3ff1-4ef0-928a-66b9c9ae4983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b337fdb4-2502-498c-91cc-d4a2f05b1f06" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d4fbbed5-3ff1-4ef0-928a-66b9c9ae4983" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationSummaryofStockOptionsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="extended" id="idc6bca3c270f4a29bacdd8c79b4c65de_StockBasedCompensationSummaryofStockOptionsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f34163ad-3232-43b1-adc4-4231db7a9d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f34163ad-3232-43b1-adc4-4231db7a9d7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_00f0837a-c10b-4ed8-ad00-b9672a70d651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_00f0837a-c10b-4ed8-ad00-b9672a70d651" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a4af169-f920-43e4-8ec8-82194ed74d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a4af169-f920-43e4-8ec8-82194ed74d59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cfcfa06e-82d1-44aa-966a-0b51c1c48dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cfcfa06e-82d1-44aa-966a-0b51c1c48dac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_514b322c-32a2-4cdd-a3dc-b5f242dd545e" xlink:href="crdf-20221231.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_514b322c-32a2-4cdd-a3dc-b5f242dd545e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1cdef795-bab5-4969-8434-71472001f921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d9f45513-e9e5-40aa-be7b-504b5de3d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d9f45513-e9e5-40aa-be7b-504b5de3d88b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1892136-bcdc-4f09-8a06-2f15e353a5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1892136-bcdc-4f09-8a06-2f15e353a5d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e93d8e6-98cf-4547-869f-b8cca1820ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e93d8e6-98cf-4547-869f-b8cca1820ddf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_481bbb40-50b6-43e5-9b6d-3a1f5b18cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_481bbb40-50b6-43e5-9b6d-3a1f5b18cb0e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47825c28-b9b8-426c-80c5-3af86fb2902a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47825c28-b9b8-426c-80c5-3af86fb2902a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9ed3db7-7245-42ca-a724-d2a7e54ee819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9ed3db7-7245-42ca-a724-d2a7e54ee819" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_180d4956-4c7e-4dab-b245-24e42cac0bb8" xlink:href="crdf-20221231.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_180d4956-4c7e-4dab-b245-24e42cac0bb8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_201b9e09-b4ce-405b-8faf-83179258d262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e528867e-3d80-49a9-900e-7fe0429b29e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e528867e-3d80-49a9-900e-7fe0429b29e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d6a409f9-f6a9-4955-9f3e-a3e8aac43b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d6a409f9-f6a9-4955-9f3e-a3e8aac43b91" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3cafbfdd-9ab8-4783-a318-a86a776343ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3cafbfdd-9ab8-4783-a318-a86a776343ac" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_232e05ea-e38e-4898-8adf-3f4ca833ca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_232e05ea-e38e-4898-8adf-3f4ca833ca7f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_343d16bf-5048-4a48-b251-f316292c07aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_343d16bf-5048-4a48-b251-f316292c07aa" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5bb88ab5-d11e-4e13-98fd-57bdbfc7ceec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5bb88ab5-d11e-4e13-98fd-57bdbfc7ceec" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74d2db21-89a7-4276-9208-1711d9a617fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74d2db21-89a7-4276-9208-1711d9a617fb" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90915f9b-053c-4979-99d9-97e96d87cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90915f9b-053c-4979-99d9-97e96d87cf2a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_cc355660-15e3-413a-a51a-0af8539ab8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_cc355660-15e3-413a-a51a-0af8539ab8b9" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:to="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2b90cb2-8cd2-405a-abb4-26e741318389_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c2b90cb2-8cd2-405a-abb4-26e741318389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3e87b0e-9f43-4843-8225-77e2571a0f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3e87b0e-9f43-4843-8225-77e2571a0f8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28b2b6d9-1ece-4643-9ac4-85978c3c9076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3e87b0e-9f43-4843-8225-77e2571a0f8e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28b2b6d9-1ece-4643-9ac4-85978c3c9076" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended" id="iebf9d301b6824e668aef3d0285c56a6e_DerivativeFinancialInstrumentsWarrantsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant_552ebc6d-8b89-477e-b3fc-10d2b3a1fe07" xlink:href="crdf-20221231.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:to="loc_crdf_EstimatedFairValueOfWarrant_552ebc6d-8b89-477e-b3fc-10d2b3a1fe07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2f6fe181-db29-4c55-a27f-a5eed00dee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2f6fe181-db29-4c55-a27f-a5eed00dee0d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_85f9c95c-cc8e-4d4e-884d-b9a7ae1836e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_85f9c95c-cc8e-4d4e-884d-b9a7ae1836e6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:href="crdf-20221231.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:to="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7c8f9c1-1fdb-47c4-92c4-fc6aa2359bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7c8f9c1-1fdb-47c4-92c4-fc6aa2359bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e376286c-c349-484d-890d-c47317281f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ba276fa7-b216-4112-89f2-412eddd3af43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ba276fa7-b216-4112-89f2-412eddd3af43" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_5f09eb85-d266-4f92-9508-9345940dd3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_5f09eb85-d266-4f92-9508-9345940dd3ad" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5859ff95-4e4a-4d67-863c-8e2a6fc4c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:to="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_807c6529-0b83-43ea-84ce-624b711710eb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_807c6529-0b83-43ea-84ce-624b711710eb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_007ed8f9-f248-4b06-8bce-d7b9ff3e229f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_007ed8f9-f248-4b06-8bce-d7b9ff3e229f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_5a4a3a89-fcd7-46cf-ad4d-06bdec2ecfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_5a4a3a89-fcd7-46cf-ad4d-06bdec2ecfd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_37b0b3aa-d9e3-47a0-8842-6c6167572f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_37b0b3aa-d9e3-47a0-8842-6c6167572f56" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f25d8fe-8b5f-498e-8b5e-859b21a2f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f25d8fe-8b5f-498e-8b5e-859b21a2f66f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8c7c8475-1fa0-4825-9d1c-ac57d407f89b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8c7c8475-1fa0-4825-9d1c-ac57d407f89b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e1efc1bc-f751-484e-af8c-c8f4bc0e1eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e1efc1bc-f751-484e-af8c-c8f4bc0e1eb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c3b3f9d0-42af-4146-95c5-6c5bdf033a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e1efc1bc-f751-484e-af8c-c8f4bc0e1eb3" xlink:to="loc_us-gaap_WarrantMember_c3b3f9d0-42af-4146-95c5-6c5bdf033a18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_3e418216-b05f-4efb-a7a3-d1824076fa35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:to="loc_us-gaap_ValuationTechniqueDomain_3e418216-b05f-4efb-a7a3-d1824076fa35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_68be1951-9ce3-453d-8887-fdbb2a46984d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:to="loc_us-gaap_ValuationTechniqueDomain_68be1951-9ce3-453d-8887-fdbb2a46984d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_dad67ffa-a7f7-4679-bcef-1287a87b790c" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_68be1951-9ce3-453d-8887-fdbb2a46984d" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_dad67ffa-a7f7-4679-bcef-1287a87b790c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ief4d95c1799f437491d33ac2250ed9fb_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d8b5c81-e378-42a2-ae92-03fba4f7cd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d8b5c81-e378-42a2-ae92-03fba4f7cd5b" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09693474-04c3-4709-989c-b05cc9a09dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09693474-04c3-4709-989c-b05cc9a09dab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5c3309f-4cf6-4d84-a803-1b61e7f3ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5c3309f-4cf6-4d84-a803-1b61e7f3ceb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_69bb310a-9fdf-4af7-a58d-9b65f2258dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_69bb310a-9fdf-4af7-a58d-9b65f2258dc3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d8b5c81-e378-42a2-ae92-03fba4f7cd5b" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_782a11fd-320c-461d-a91c-953832bfc676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_782a11fd-320c-461d-a91c-953832bfc676" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd98185-aaf6-4446-91be-0920b2e608d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_782a11fd-320c-461d-a91c-953832bfc676" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd98185-aaf6-4446-91be-0920b2e608d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159b0a30-e52b-4888-96d4-e98f6a98ae93_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_159b0a30-e52b-4888-96d4-e98f6a98ae93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0951fcf9-12e5-404f-9d6f-e7c8b60c1308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0951fcf9-12e5-404f-9d6f-e7c8b60c1308" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_53ce9a81-30d2-4972-893d-6374113fcc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_53ce9a81-30d2-4972-893d-6374113fcc0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f80c7d82-f9e9-4504-ad0f-9b3c77c89218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f80c7d82-f9e9-4504-ad0f-9b3c77c89218" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_485ac89c-8f64-4123-b4aa-b15820f521cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_485ac89c-8f64-4123-b4aa-b15820f521cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_74d088a3-fe09-4718-ac3f-3eacf8cae0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_485ac89c-8f64-4123-b4aa-b15820f521cd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_74d088a3-fe09-4718-ac3f-3eacf8cae0d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6e216c61-044c-4098-9db7-29b05fc7e688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6e216c61-044c-4098-9db7-29b05fc7e688" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b499c144-15a6-4290-87a6-14e601fd14bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b499c144-15a6-4290-87a6-14e601fd14bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a6f1e989-330c-4315-a067-f666f971f938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_CommercialPaperMember_a6f1e989-330c-4315-a067-f666f971f938" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c0e5a621-11eb-406b-be1d-ae7c6cb78486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c0e5a621-11eb-406b-be1d-ae7c6cb78486" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_99af24bf-929d-4375-a561-a3b4ae318efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_99af24bf-929d-4375-a561-a3b4ae318efe" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d9a192ea-f8c5-4bc1-9530-e597973d8ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d9a192ea-f8c5-4bc1-9530-e597973d8ab6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="if7c09b02925d4c89bf59f8c46ba4fee4_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsSubjectToExpiration_04adf3bd-240e-4a59-a2aa-ea667d1cc5b2" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_OperatingLossCarryforwardsSubjectToExpiration_04adf3bd-240e-4a59-a2aa-ea667d1cc5b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_e7e0a54d-2b59-480c-8873-b8b7cad088a0" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_e7e0a54d-2b59-480c-8873-b8b7cad088a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b09713bd-23e2-4d86-a724-49d629c810fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b09713bd-23e2-4d86-a724-49d629c810fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_70156b36-5415-4981-bf84-bfecbfb90081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_70156b36-5415-4981-bf84-bfecbfb90081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsIncreaseDecrease_8f6eacac-59cb-4595-8edb-30f8d226ad18" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_OperatingLossCarryforwardsIncreaseDecrease_8f6eacac-59cb-4595-8edb-30f8d226ad18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_TaxCreditCarryforwardIncreaseDecrease_ac4fed6e-93a4-4611-9450-15937cfb1558" xlink:href="crdf-20221231.xsd#crdf_TaxCreditCarryforwardIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_TaxCreditCarryforwardIncreaseDecrease_ac4fed6e-93a4-4611-9450-15937cfb1558" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ab989fab-f0b5-4a44-8c4c-56391b73b571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ab989fab-f0b5-4a44-8c4c-56391b73b571" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_6b40733f-11ff-4255-b7f3-513bb2b16da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_6b40733f-11ff-4255-b7f3-513bb2b16da9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_df9970a0-dffb-426f-a414-f36ea85ea004_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_df9970a0-dffb-426f-a414-f36ea85ea004_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b90d5f24-637b-4ac4-8908-8df15fbbc06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b90d5f24-637b-4ac4-8908-8df15fbbc06d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_65c396d7-b2c2-402d-862e-182359a48981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_b90d5f24-637b-4ac4-8908-8df15fbbc06d" xlink:to="loc_us-gaap_ResearchMember_65c396d7-b2c2-402d-862e-182359a48981" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_d60db481-eca6-455b-954f-4e4c5de06281_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_d60db481-eca6-455b-954f-4e4c5de06281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_fd4c950c-a058-4714-a44d-a6060977082e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_fd4c950c-a058-4714-a44d-a6060977082e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_84563fec-529a-4b9e-8211-51e6796e23e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_84563fec-529a-4b9e-8211-51e6796e23e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_7aa89133-3c79-44e1-8dbd-59b298c3c273_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:to="loc_us-gaap_TaxPeriodDomain_7aa89133-3c79-44e1-8dbd-59b298c3c273_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:to="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_TaxYear2021AndPriorMember_96502bcf-edae-4538-b87b-df5a755a7219" xlink:href="crdf-20221231.xsd#crdf_TaxYear2021AndPriorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:to="loc_crdf_TaxYear2021AndPriorMember_96502bcf-edae-4538-b87b-df5a755a7219" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2021Member_79945d0e-57e5-4fa3-9f97-28b14019b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:to="loc_us-gaap_TaxYear2021Member_79945d0e-57e5-4fa3-9f97-28b14019b7c2" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>crdf-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:43395891-7664-4c15-a02f-d7b4811c3213,g:94da96fa-a6f9-430a-8c03-f421ae94b6bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_83cad4fd-0b25-434c-8738-4889cbb3b1aa_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1506ed01-d92c-4c5b-921e-7b9656c2bdca_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AuditInformationAbstract_label_en-US" xlink:label="lab_crdf_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_crdf_AuditInformationAbstract_documentation_en-US" xlink:label="lab_crdf_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AuditInformationAbstract" xlink:href="crdf-20221231.xsd#crdf_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AuditInformationAbstract" xlink:to="lab_crdf_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_1eb7f28e-2d6a-4ebf-90cc-306e308d6523_totalLabel_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss attributable to common stockholders</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_label_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label id="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_documentation_en-US" xlink:label="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" xlink:href="crdf-20221231.xsd#crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" xlink:to="lab_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_9e3c7cfd-9790-47af-a00a-531962fc7a90_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3ec06d73-f240-40fe-941f-e17ac88fa663_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_0abd4202-8744-4197-9042-693b8621642e_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Patentlicenseandotherfeespayable_673580c5-33d3-4711-ba29-0d4c449b07aa_terseLabel_en-US" xlink:label="lab_crdf_Patentlicenseandotherfeespayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees</link:label>
    <link:label id="lab_crdf_Patentlicenseandotherfeespayable_label_en-US" xlink:label="lab_crdf_Patentlicenseandotherfeespayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:label id="lab_crdf_Patentlicenseandotherfeespayable_documentation_en-US" xlink:label="lab_crdf_Patentlicenseandotherfeespayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patent, license and other fees payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Patentlicenseandotherfeespayable" xlink:href="crdf-20221231.xsd#crdf_Patentlicenseandotherfeespayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Patentlicenseandotherfeespayable" xlink:to="lab_crdf_Patentlicenseandotherfeespayable" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_dabdc958-e2a0-48b6-88db-ef835914e3e3_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Value Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The equity impact during the period due to the cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:href="crdf-20221231.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodValueWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ConvertiblePreferredStockStatedValuePerShare_88694933-9e96-42ff-bb99-23b7a27fa5f7_terseLabel_en-US" xlink:label="lab_crdf_ConvertiblePreferredStockStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated value (in dollars per share)</link:label>
    <link:label id="lab_crdf_ConvertiblePreferredStockStatedValuePerShare_label_en-US" xlink:label="lab_crdf_ConvertiblePreferredStockStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Stated Value Per Share</link:label>
    <link:label id="lab_crdf_ConvertiblePreferredStockStatedValuePerShare_documentation_en-US" xlink:label="lab_crdf_ConvertiblePreferredStockStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ConvertiblePreferredStockStatedValuePerShare" xlink:href="crdf-20221231.xsd#crdf_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ConvertiblePreferredStockStatedValuePerShare" xlink:to="lab_crdf_ConvertiblePreferredStockStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_3b0441c2-4e2c-4529-8647-3623bf7fa957_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative dividend rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_379acd68-2678-4506-8754-955266e01831_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_b465a355-de4b-4510-aeb2-74bb166badca_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_59b4d877-bd13-45e3-b171-fad42c7c790a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment terms</link:label>
    <link:label id="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_label_en-US" xlink:label="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Performance Obligation, Description of Payment Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:to="lab_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_04fcb9ba-b526-4d74-8fa9-15a683f68ea8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_cc062da6-df1b-4569-b5d5-345a6ff916d7_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_638d8d43-95e4-4c4c-987f-c7d9dfeeaa5a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3975ef35-d312-40cb-ab7a-b33e372456c8_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_cf23fb08-eede-47a1-9150-1e13a4950286_totalLabel_en-US" xlink:label="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets before valuation allowance</link:label>
    <link:label id="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_label_en-US" xlink:label="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:label id="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_documentation_en-US" xlink:label="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net, Before Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:to="lab_crdf_DeferredTaxAssetsNetBeforeValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_7ad18723-01f6-4606-b57f-cc6c15d93057_terseLabel_en-US" xlink:label="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_label_en-US" xlink:label="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment for services received</link:label>
    <link:label id="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_documentation_en-US" xlink:label="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment for services received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:href="crdf-20221231.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:to="lab_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_319331dd-5cdf-4986-90c9-9fb9ba49202e_terseLabel_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs, not subject to expiration</link:label>
    <link:label id="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_crdf_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_aadb73bb-5de8-4f6b-9379-048b438cb6fb_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_5fbc599c-c292-465a-bf5f-3371901757a2_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d01bce60-4d01-4dd5-bf99-95cedfacf72c_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Accruedresearchagreements_0b8d5d80-f53c-4fc5-b6ad-fd6c1c9a931e_terseLabel_en-US" xlink:label="lab_crdf_Accruedresearchagreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_crdf_Accruedresearchagreements_label_en-US" xlink:label="lab_crdf_Accruedresearchagreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:label id="lab_crdf_Accruedresearchagreements_documentation_en-US" xlink:label="lab_crdf_Accruedresearchagreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued research agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Accruedresearchagreements" xlink:href="crdf-20221231.xsd#crdf_Accruedresearchagreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Accruedresearchagreements" xlink:to="lab_crdf_Accruedresearchagreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a413f8db-6878-4a16-b2be-ffc33396f385_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_01ddd7fd-6a92-4d01-8adc-1ce4a311d838_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3efdd7ad-a23a-462c-9778-6e8a4fa583e6_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease_fada66f1-b1fc-4e06-afea-b40953bae679_negatedTerseLabel_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to net operating loss carryforwards</link:label>
    <link:label id="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease_label_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Increase (Decrease)</link:label>
    <link:label id="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease_documentation_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsIncreaseDecrease" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_OperatingLossCarryforwardsIncreaseDecrease" xlink:to="lab_crdf_OperatingLossCarryforwardsIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_9f92bfef-bf4f-4d22-8a2a-16db4882428b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedClinicalTrial_90f6c2a2-ed44-4253-b342-1806230ce69f_terseLabel_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Clinical trials</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrial_label_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrial_documentation_en-US" xlink:label="lab_crdf_AccruedClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedClinicalTrial" xlink:to="lab_crdf_AccruedClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_5bcd76a8-92e8-43cb-8088-cf9eab86d5d8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedClinicalTrialExpenses_4dee70ff-2595-497f-91a3-1c7ce08a7e4b_terseLabel_en-US" xlink:label="lab_crdf_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrialExpenses_label_en-US" xlink:label="lab_crdf_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrialExpenses_documentation_en-US" xlink:label="lab_crdf_AccruedClinicalTrialExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrialExpenses" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrialExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedClinicalTrialExpenses" xlink:to="lab_crdf_AccruedClinicalTrialExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPreferredStock_6c8c0217-206b-48a4-b557-488086447764_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_0fde65f3-6c08-467b-b0c3-1781016cbc85_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued dividend during the period</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStock_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStock" xlink:to="lab_us-gaap_DividendsPreferredStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_92f57f84-0c03-4f80-a1fc-eb8bfa107b79_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_a11e8cec-63c6-4062-bcf0-6cd5c29a6713_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_d2946f50-25d2-4010-84e1-40430bcba1ed_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_9fc2a47c-9680-4e2b-ab6f-418fc005b478_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d5ab2c76-d7b8-40c6-8a34-03f1e05fddeb_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a1e54312-491b-41d0-911c-9a420a8b12a1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_73825d9f-2b80-494f-bcf4-b96a2c91de8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (weighted-average)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_1b2fbc77-090b-421b-bef7-28a987e06961_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_f18f9451-a53a-449a-b726-582e6c651fda_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive securities excluded from computation of earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0c42f619-8423-4fb4-8f73-8c5d224316b5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_30ba9b09-1b49-4999-8ecd-91665b051731_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodDomain_86ebe561-9113-4550-98c0-306e4c35f7cd_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodDomain_label_en-US" xlink:label="lab_us-gaap_TaxPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodDomain" xlink:to="lab_us-gaap_TaxPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b813e330-da72-478f-9af6-2152ff61d0fd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_f5bf33dc-2f5d-4634-ba18-4ce2c0da3bba_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_2112d57c-e054-4b7f-8dac-b720eaa74786_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_5bd1e2d1-30c8-40a3-a0c3-6ac5cc99b994_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets measured at fair value on a recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_89de9412-44e1-44e1-811b-ea9006ffd2cf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_fcc866c1-2472-4344-b528-0ec993e4caa2_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e206f484-baeb-4b21-8dab-a19be1ed982b_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_f30b763f-5fd1-45e2-b7e7-f411bc19295b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_c4351c1f-0d7e-48bf-a6b9-673c16231b39_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9362d322-57af-45b0-9652-f6f92473ba15_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_f0af8699-0ca8-4cb2-b488-1284e59614b2_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total available for sale investments</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_1faef921-6960-4d32-9165-14ff935e2d64_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_9f457873-3875-4c7b-b909-db606cddb573_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_fe450179-cba3-4efc-8b1e-da23879840e8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosure of cash flow activity:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_7e2755ab-e310-447c-b104-c42da3cbac8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_88e29dc8-b47b-4c11-9340-3bc9f795892c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightIssued_c459c4c2-d9e7-4c05-9f18-6c4f827701e5_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightIssued_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightIssued_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightIssued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightIssued" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightIssued" xlink:to="lab_crdf_ClassOfWarrantOrRightIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_ab7afc34-8927-446a-b09f-6a7e71955e52_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_780c840b-8435-4e04-acfe-edb6be14e351_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5fe035b7-80e0-4946-859d-78a52ce00449_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_8992a6fa-31dc-4a46-9e0d-18ab36b6a6a0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_61f5cb46-a690-41e3-862d-29f536997a83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedPreferredStockDividend_74607767-32d8-4548-93c1-1aca4842a084_terseLabel_en-US" xlink:label="lab_crdf_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend(1)</link:label>
    <link:label id="lab_crdf_AccruedPreferredStockDividend_label_en-US" xlink:label="lab_crdf_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preferred Stock Dividend</link:label>
    <link:label id="lab_crdf_AccruedPreferredStockDividend_documentation_en-US" xlink:label="lab_crdf_AccruedPreferredStockDividend" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Preferred Stock Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedPreferredStockDividend" xlink:href="crdf-20221231.xsd#crdf_AccruedPreferredStockDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedPreferredStockDividend" xlink:to="lab_crdf_AccruedPreferredStockDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_8d74659d-b340-4feb-9871-2079035376ef_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contract term, outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_07d33a94-ded5-4e77-9ddf-18b3bc72ddba_terseLabel_en-US" xlink:label="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in the Company's derivative financial instruments liability balance</link:label>
    <link:label id="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_label_en-US" xlink:label="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:href="crdf-20221231.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:to="lab_crdf_DerivativeFinancialInstrumentsLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares_98c400fe-65b6-4ff1-a916-bedd577cbd05_terseLabel_en-US" xlink:label="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of days counterparty cannot sell or transfer shares</link:label>
    <link:label id="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares_label_en-US" xlink:label="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement, Number Of Days Counterparty Cannot Sell Or Transfer Shares</link:label>
    <link:label id="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares_documentation_en-US" xlink:label="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities Purchase Agreement, Number Of Days Counterparty Cannot Sell Or Transfer Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" xlink:href="crdf-20221231.xsd#crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" xlink:to="lab_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_01471aab-a5d8-45e2-be15-5c852714dc51_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_dfcce818-fc94-4d1a-be7b-6c0d3ed1d102_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_1b698a03-3d9e-4afd-8b71-d4d4a46b5640_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0b223c24-f085-4301-9f44-ed4f6dff4188_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_d9fc2974-fccd-4fb1-aa08-2d6793e7e026_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_4b053271-1bec-41a3-86ff-d0a0627ba2d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b7e922f2-589e-4032-ab25-bd8416bffbe7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Short-term investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_72f2ce7a-2d00-491f-8e1c-b5f3fea8d18c_terseLabel_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Warrants</link:label>
    <link:label id="lab_crdf_WarrantsAndRightsRollForward_label_en-US" xlink:label="lab_crdf_WarrantsAndRightsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward" xlink:href="crdf-20221231.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsAndRightsRollForward" xlink:to="lab_crdf_WarrantsAndRightsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_ca07af2b-3fde-49e9-89aa-c9f3165af0d4_terseLabel_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release of clinical trial funding commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_label_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:label id="lab_crdf_ReleaseOfClinicalTrialFundingCommitment_documentation_en-US" xlink:label="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Release Of Clinical Trial Funding Commitment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:href="crdf-20221231.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:to="lab_crdf_ReleaseOfClinicalTrialFundingCommitment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_56373594-6c51-46e4-aa78-1e689776f4b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrentAbstract_9540ee94-84c5-4603-bed4-3bcc3d0cb3c6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity 1 to 2 years:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:to="lab_us-gaap_DebtSecuritiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_6699cb83-0041-4caa-adaf-7942b23fe4ae_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeitures (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_e2728020-4307-4b32-9daf-392fc4c8a55c_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_459d75ae-e472-429f-8959-bfe9ee1889bf_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_fde61f66-2740-4e34-a4d7-61c7a1571759_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionPrice_e50af017-9fde-4eb2-a810-de352856a6bd_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockConvertibleConversionPrice_label_en-US" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_816ee745-a2c8-4fe8-9fe5-76a7d763887a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term&#8211;operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_50090f98-13cd-40cc-a124-fa9c26237e11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_84020377-7e12-41ff-a2e5-a7d525a2db66_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual rent increase, percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Annual Rent Increase, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:to="lab_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_f8707e33-f9dd-4ae5-8930-d6ec9c8ddc64_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_4d7306f1-3738-45c8-bf74-19f40a7c1b50_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_fb7e0bfe-2fac-4105-9621-3678d2a1946f_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_77780157-a1ce-45d8-ba5d-e95d7b3a5656_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesConverted1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_us-gaap_ConversionOfStockSharesConverted1" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_4a781880-eb89-4b1f-889d-749d538e73b6_terseLabel_en-US" xlink:label="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability</link:label>
    <link:label id="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_label_en-US" xlink:label="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability [Member]</link:label>
    <link:label id="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_documentation_en-US" xlink:label="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" xlink:href="crdf-20221231.xsd#crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" xlink:to="lab_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ca37c2dd-aac8-4d61-9d3a-79ac37e721cd_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Life of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_1f472e2b-9862-4a6f-8db0-fd6be66a9e9d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_fc6db7cb-ef4e-4072-a1d6-2b84438c5d22_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_7a45c922-53c0-45e8-ba33-e1e564401745_periodStartLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the beginning of the period (in dollars per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_6fc3d3e8-8fd4-43cc-ad28-18c3047fa4e1_periodEndLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average exercise price of warrants at the end of the period (in dollars per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights outstanding.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2a5e6b4f-9e8d-40fd-b062-0fe6a0d2e15c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_0d17fdcd-85ee-43ef-a388-06269f288d90_negatedTerseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Exercised</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExercised_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightNumberExercised" xlink:to="lab_crdf_ClassOfWarrantOrRightNumberExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_f87be680-4563-45f3-84b9-be95ce88ed9b_terseLabel_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_label_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period Shares Warrants Exercised</link:label>
    <link:label id="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_documentation_en-US" xlink:label="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of shares issued during the period upon cash exercise of warrants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:href="crdf-20221231.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:to="lab_crdf_StockIssuedDuringPeriodSharesWarrantsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_6c2f6d12-5628-409c-b601-fde0de7b83ac_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_2608a4ae-1fd7-4489-80da-5931b81aa9ff_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d8a6a379-43f7-44c8-9ef6-08162de2c29b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CorrectionPolicyPolicyTextBlock_f0a31c9b-d440-4043-a6d8-e415b62023a8_terseLabel_en-US" xlink:label="lab_crdf_CorrectionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction of Series A Convertible Preferred Stock cumulative dividend liability</link:label>
    <link:label id="lab_crdf_CorrectionPolicyPolicyTextBlock_label_en-US" xlink:label="lab_crdf_CorrectionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction, Policy [Policy Text Block]</link:label>
    <link:label id="lab_crdf_CorrectionPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_crdf_CorrectionPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Correction, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CorrectionPolicyPolicyTextBlock" xlink:href="crdf-20221231.xsd#crdf_CorrectionPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CorrectionPolicyPolicyTextBlock" xlink:to="lab_crdf_CorrectionPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1a327fcd-30f4-4c4b-966e-449622ba5d45_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_c65ace95-6022-4772-aef7-d7aa7e4561e9_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3533ce84-baa9-4036-8309-abf095d9eee1_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred (benefit) expense</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_b66d37ee-7ea0-4b2d-bc5b-5f63c24aa0de_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period during which the conversion price is subject to adjustment for dilutive issuances</link:label>
    <link:label id="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_label_en-US" xlink:label="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Period of Dilutive Issuance for Conversion Price Adjustments</link:label>
    <link:label id="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_documentation_en-US" xlink:label="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the period during which the conversion price is subject to adjustment for dilutive issuances.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:href="crdf-20221231.xsd#crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:to="lab_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_e4c914e5-2ae4-4aa7-bd6f-daf824c0c171_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_4d61ec72-1030-4cd6-aedb-b8b627ce0028_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_864bf5d0-8e34-4e7d-9056-86417d96f515_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
    <link:label id="lab_us-gaap_ProceedsFromWarrantExercises_label_en-US" xlink:label="lab_us-gaap_ProceedsFromWarrantExercises" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_us-gaap_ProceedsFromWarrantExercises" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6a5a5373-57f9-44a0-8803-2e51bc77b103_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_d4da2325-d857-4800-9179-5d3840fd8ae5_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monthly rent payments</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:to="lab_crdf_LesseeOperatingLeaseMonthlyRentPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_8c163e93-d2ed-4b52-8d42-d7da51cd5a17_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_5930f9d5-9a46-4be6-bf1f-928eb33336fa_terseLabel_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision and true ups</link:label>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_label_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Percent</link:label>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_documentation_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" xlink:to="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_a4bd4f43-5c12-42cd-8ad5-e78246320ea2_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_9d72a65c-886f-4d88-9305-85f8857c7da7_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_67bd1dd9-1d0e-42de-95d9-f5f9365e043c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAbstract_03934c39-d3df-41bd-bf19-1ac3257a6151_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrentAbstract" xlink:to="lab_us-gaap_TaxesPayableCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_0e39e4a8-b2c9-4e3a-93f3-a53c841a5f31_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and/or penalties incurred</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_49edfe28-9dd8-44d7-9349-c7a8571c4755_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ValuationAllowance_27815874-8c06-458b-86bc-f5973a020b5f_terseLabel_en-US" xlink:label="lab_crdf_ValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_crdf_ValuationAllowance_label_en-US" xlink:label="lab_crdf_ValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:label id="lab_crdf_ValuationAllowance_documentation_en-US" xlink:label="lab_crdf_ValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ValuationAllowance" xlink:href="crdf-20221231.xsd#crdf_ValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ValuationAllowance" xlink:to="lab_crdf_ValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_791fc604-d6ad-4b1d-8986-d183968ab4c7_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_ed25ff43-5efa-4dfd-b874-6f28fd6e982d_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_3914979e-e89b-49be-b89d-6ba682219c0c_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_e32beb8e-6e90-44ef-b869-4d88c032f4c3_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bc4cf093-ef5c-4441-a193-26d9e896d463_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d68a528-6ea7-4e72-997e-d9de007c9993_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_04ee3562-64f2-405e-bb2d-df6a949b5e13_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_65e4246d-8b07-47a7-9704-de68cb4f028d_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_14858f13-716b-46b9-8250-537cf910c46a_negatedTerseLabel_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:label id="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_documentation_en-US" xlink:label="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Operating Lease, Right-Of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:href="crdf-20221231.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:to="lab_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_78779248-9b31-473a-9fea-7134cb603788_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_2603d846-4c0d-49f1-a466-60313b3553bb_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_0f08c001-09b2-44e9-bcf4-3e090f859049_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_0ed27ce9-fd19-4613-8def-5432417085d8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a3d33f19-3e7b-4ff5-806d-411efd49ac66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Stock Options - Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_df5e73d1-12ff-44f4-a960-6b894b2955e4_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_0a425539-06a1-4ee6-97da-607abccdb189_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary Balance Sheet Information</link:label>
    <link:label id="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="lab_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_8e56c30c-26cb-4b55-8bf4-ca8daa129653_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_b8faf03e-ba86-4561-8c58-88a09891352e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes Based on Losses from Continuing Operations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_af12c464-5dc8-4809-b1a4-ca6be583fcbf_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_57bdfb60-1c5e-4003-8481-fb701d09a365_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_fc1e44b1-62af-42b6-9dee-5a4617af24e3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance increase (decrease)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_bf617e46-0175-4aab-b137-f7e5a56f1866_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares called by warrants (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_69aa5675-918a-45ec-941b-3ffadf8a5d0a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_c4e3f8dc-5087-49ea-9b6e-1a81c0c778e9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_46ded35f-432b-4137-ab0b-834263e3a272_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_9d57801b-4c37-412a-8197-81c0e41670ac_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_d0287ad5-9ed9-48e1-9cae-34fa2b8dbc1f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c138dbc5-faed-4acf-9fb1-53f0475fdd9a_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired_b0a20cd9-b625-450d-b176-c20022910c4e_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Expired</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights expired during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_f0038be9-2e45-4331-8b83-33b4555cf8b6_terseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:href="crdf-20221231.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:to="lab_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_b5697741-0205-48d4-9f5f-6bd40829a924_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_67777b16-8d3c-49e9-9c76-226f8537b0cf_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_5b5625b2-6c1d-4443-a9fa-7ae04f5035de_negatedTerseLabel_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_label_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period</link:label>
    <link:label id="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_documentation_en-US" xlink:label="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:href="crdf-20221231.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:to="lab_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_3912c24a-3524-4d24-acb2-a28ea547fabc_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plan</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_5d84211d-cd02-448b-952f-dfc3f2c7ff31_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_557addd8-daa8-45e7-a851-012566edd861_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_d6ed04d8-e744-4a86-bc02-48f9513a65fa_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_20094d2f-5298-4975-b36d-464727877f6e_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_814450ef-4745-45c2-9eb4-36ee26fec466_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment_fbc54c99-39e4-43d6-8771-f3a598aeaee8_terseLabel_en-US" xlink:label="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative preferred stock dividend adjustment</link:label>
    <link:label id="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment_label_en-US" xlink:label="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash, Cumulative Preferred Stock Dividend Adjustment</link:label>
    <link:label id="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment_documentation_en-US" xlink:label="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash, Cumulative Preferred Stock Dividend Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NonCashCumulativePreferredStockDividendAdjustment" xlink:href="crdf-20221231.xsd#crdf_NonCashCumulativePreferredStockDividendAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_NonCashCumulativePreferredStockDividendAdjustment" xlink:to="lab_crdf_NonCashCumulativePreferredStockDividendAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_be5405c7-5de3-478e-b743-216e153cfc89_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_302ac2c3-617b-41c8-a29d-487a0c1d137f_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_6f52bbf7-0901-4763-879c-e3ea67ede3c5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_ac1b1f8f-2caf-449b-a652-0eb1f3ba5731_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain from changes in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_92b2f116-bc9c-439e-af4e-22ff6c1fdbce_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_f31bd700-541f-4944-a19d-8cae01006d6f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of derivative financial instruments&#8212;warrants during the year recognized as a loss in the statement of operations</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExpired_3e9ff926-8e2e-4c9f-801a-97fda2b80c7c_negatedTerseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExpired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExpired_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExpired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Number Expired</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightNumberExpired_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightNumberExpired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of warrants or rights expired during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExpired" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightNumberExpired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightNumberExpired" xlink:to="lab_crdf_ClassOfWarrantOrRightNumberExpired" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LessorNumberOfSubleases_70a2c553-3e12-442f-b1eb-74d8bb6ea229_terseLabel_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_label_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:label id="lab_crdf_LessorNumberOfSubleases_documentation_en-US" xlink:label="lab_crdf_LessorNumberOfSubleases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Number Of Subleases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases" xlink:href="crdf-20221231.xsd#crdf_LessorNumberOfSubleases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LessorNumberOfSubleases" xlink:to="lab_crdf_LessorNumberOfSubleases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ee3e6b9d-e3f1-4bd5-a81a-932ec2a6f7c0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_3e3ba4ab-83ed-4a41-ae89-d3ccc4e863a3_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_a9064da3-ecfc-414c-b465-bc40d29b4255_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_cd5f5909-12e2-493c-bdf2-7f6d966b9a49_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_d9d4dd11-6ca9-4916-a3c1-c90f9244c891_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_127742dd-942c-4a61-b1b3-2e9606bb3a0c_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquipmentMember_bf39788f-cc1f-4351-abfb-fdca4ae36d5e_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_label_en-US" xlink:label="lab_us-gaap_EquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember" xlink:to="lab_us-gaap_EquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_183cb10c-fa9a-497a-8632-b0f8dfc452d6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments&#8212;Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_bc33472e-b822-444b-9dd1-572d89309582_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D credits</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0b6997af-2af8-4688-9793-e9f185abe9c3_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_66040b27-51ba-47e9-bf47-2a92cfe5ddb7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_ada7989f-e9c7-45d8-8c33-9ef3f2c0cc36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_90fac35a-53f7-4919-9960-672d2aaa62a3_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_50abbddc-c1e4-435c-856c-9da447e1d969_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total included in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_IncomeTaxReconciliationPermanentItems_c4b6b992-0446-46b4-8ba5-9cf0854d050b_terseLabel_en-US" xlink:label="lab_crdf_IncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_crdf_IncomeTaxReconciliationPermanentItems_label_en-US" xlink:label="lab_crdf_IncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Reconciliation Permanent Items</link:label>
    <link:label id="lab_crdf_IncomeTaxReconciliationPermanentItems_documentation_en-US" xlink:label="lab_crdf_IncomeTaxReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncomeTaxReconciliationPermanentItems" xlink:href="crdf-20221231.xsd#crdf_IncomeTaxReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_IncomeTaxReconciliationPermanentItems" xlink:to="lab_crdf_IncomeTaxReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_d94bd89f-a7c3-446c-a858-a042d1e97181_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Corrections and Prior Period Adjustments Restatement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8d5f300f-510b-49f0-8f87-a4f66dd42730_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_65115b16-2502-4bc4-b3b5-c5dc6eaabe4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0730cc42-090d-4d00-b80a-b7c609f8812f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_af68b88e-c296-4036-9331-6cc09cfae3bf_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_fa0a79d5-688c-41e1-82e6-1af4f502caae_terseLabel_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Return to provision and true ups</link:label>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_label_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Amount</link:label>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_documentation_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" xlink:to="lab_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_a2fcfad7-d3df-4a47-b66c-2a7d2de3a441_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of warrants (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_edd57363-b59d-485c-9967-eb542c98aa27_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5941774a-e306-4bc5-b4f4-64d87da2b917_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_ae8f08f3-ec06-44cc-b069-528acdb3e296_terseLabel_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be paid, After Year Four</link:label>
    <link:label id="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, To Be paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_9dad6d8c-cf1e-409e-9270-560010fd05e6_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_22742fa9-6e32-469e-887b-d9806fa2e1df_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_a2826e8c-437e-44c3-a239-c0b6724f90ea_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_fb84eee9-f51b-4950-b7c8-f0d87cd063fd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Financial Instruments - Warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_bac4f938-b8c8-4417-9698-8802bea03060_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DocumentAndEntityInformationAbstract_3963af42-c34d-4bb2-bd48-6d3325cd2ce7_terseLabel_en-US" xlink:label="lab_crdf_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:label id="lab_crdf_DocumentAndEntityInformationAbstract_label_en-US" xlink:label="lab_crdf_DocumentAndEntityInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document and Entity Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DocumentAndEntityInformationAbstract" xlink:href="crdf-20221231.xsd#crdf_DocumentAndEntityInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract" xlink:to="lab_crdf_DocumentAndEntityInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_58572f8f-35dd-4f24-90e9-65cd47f3c8f3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_07668743-63fd-4d9e-83d0-a00b5e1f1d1d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2aff59ae-3e96-4a7e-9b25-e1dc3f97c7e8_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1cfa33e9-07fc-45f6-859a-912c89143173_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_3a8b532c-5e2e-4397-bb76-f395e359825c_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9224dddc-28ee-4bb7-bd26-afbe5b97a453_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market fund</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_42dd6fa8-11af-4f1a-a356-c920fabb4067_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental stock compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_c052ecdb-205a-4488-baf8-0407f884fc72_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_0116b2ea-560b-4cdc-ab2b-2bd1bab47f28_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_ae4a8cfd-78e4-4cfd-9d34-ff288bba0b16_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation cost for non-vested options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EquityIncentivePlan2014Member_ee5b2d85-c81a-4fe2-ad33-5f1536319852_terseLabel_en-US" xlink:label="lab_crdf_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2014Member_label_en-US" xlink:label="lab_crdf_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan 2014 [Member]</link:label>
    <link:label id="lab_crdf_EquityIncentivePlan2014Member_documentation_en-US" xlink:label="lab_crdf_EquityIncentivePlan2014Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the 2014 Equity Incentive Plan under which common shares will be issued to the members.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2014Member" xlink:href="crdf-20221231.xsd#crdf_EquityIncentivePlan2014Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EquityIncentivePlan2014Member" xlink:to="lab_crdf_EquityIncentivePlan2014Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_1b108730-a34e-4ce1-88a2-443657507e05_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_41af9471-f6c7-49d0-bd2e-e1d6872516d5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_89fc9e1f-38f1-4e5c-a204-73989503b3e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation recognized</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_52eca25c-9da5-4b29-b6b8-999877903faa_terseLabel_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and office equipment</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_label_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture And Office Equipment [Member]</link:label>
    <link:label id="lab_crdf_FurnitureAndOfficeEquipmentMember_documentation_en-US" xlink:label="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to furniture and office equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:href="crdf-20221231.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_FurnitureAndOfficeEquipmentMember" xlink:to="lab_crdf_FurnitureAndOfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c7c7be1b-3d10-4362-9cc7-d32aa4265d18_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Lease Expense and Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_7a24e4b7-cd87-4976-b70b-b9f2686b49e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_e3aca919-2f7f-4e08-bf7d-1f6c7a8d5c81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_6102a912-09bd-4406-a488-7f5a94f35609_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_295bb93e-25ae-43c2-b795-e663523f43cd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_12f73123-bd34-4169-bdea-b06cfadd9c4b_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards (NOLs)</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1ab89d4b-3085-4bd0-bc1d-a174d439398f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_5a0a8074-ad0f-4eba-84f3-997eb84da8a0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_c207706e-c834-4b4e-86d3-799a7d244068_terseLabel_en-US" xlink:label="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits and other tax credits</link:label>
    <link:label id="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_label_en-US" xlink:label="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards Research and Other</link:label>
    <link:label id="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_documentation_en-US" xlink:label="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible research tax credit carryforwards and to other deductible tax credit carryforwards not separately disclosed.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:to="lab_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_a8d8f3c0-4f09-4695-8fb4-c0ef1b724e60_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_201acafe-4b10-44b2-9fe3-0901780cb56e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_8819c787-d8e8-4cda-8445-f712350356ac_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_58a23d45-d5dd-42f0-ac26-f86553fa10e7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Assumptions Used to Determine the Fair Value of Warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_513793f5-a1c3-4257-9363-73dabc7c27d4_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">No definition available</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_81ddc25e-78cd-4f4a-9462-241a6f37d206_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_b4276dc3-af26-4e7d-94e5-a4fe17b3447e_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_52d345b7-4f9c-479a-a55f-f0f856226390_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_bc71f931-4a1b-4c36-a3dd-69241994d8fc_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued upon conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1d7f9869-7f4c-4850-98fd-9b756267355c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_WarrantsWeightedAverageContractualTerm_2b9cb77d-a71e-4d4b-a4a0-6635fbd5f177_terseLabel_en-US" xlink:label="lab_crdf_WarrantsWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_crdf_WarrantsWeightedAverageContractualTerm_label_en-US" xlink:label="lab_crdf_WarrantsWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term</link:label>
    <link:label id="lab_crdf_WarrantsWeightedAverageContractualTerm_documentation_en-US" xlink:label="lab_crdf_WarrantsWeightedAverageContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants, Weighted Average Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsWeightedAverageContractualTerm" xlink:href="crdf-20221231.xsd#crdf_WarrantsWeightedAverageContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_WarrantsWeightedAverageContractualTerm" xlink:to="lab_crdf_WarrantsWeightedAverageContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_eb9ed5a4-739b-48b1-b058-0c2bab1270fa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_ac91afa3-2447-4146-8a8f-ed6be445f6f3_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_45e82108-6270-4825-88b5-279cf88d8453_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_3105d497-2332-47b7-953c-e3c99570bfdf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_626a4051-0519-4ea6-8e48-556344c33827_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration_2932e5f0-3197-4255-a221-386bce8e00ac_terseLabel_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NOLs, subject to expiration</link:label>
    <link:label id="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_crdf_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_356704e4-f725-4195-84d9-bbaeb6db9417_terseLabel_en-US" xlink:label="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross proceeds</link:label>
    <link:label id="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_label_en-US" xlink:label="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:label id="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_documentation_en-US" xlink:label="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Consideration Received On Transaction, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:href="crdf-20221231.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:to="lab_crdf_SaleOfStockConsiderationReceivedOnTransactionGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_db9787c6-1b29-43a8-a107-623679ce6ed0_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_8b9766c4-b2cf-4611-b721-d71166d81f81_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_dec0eeee-3568-4206-9fba-84d44358b7f9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_562630ae-e6a6-44a1-8fe9-7558d3b4b435_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected warrant term</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingTerm_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_9945f006-1b23-4457-9e7c-e41dd27d1362_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_b0d76f04-a78d-4906-a703-ee4626c01ce4_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_d37c0b25-a35f-49b8-aac7-5577f9c04bee_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_daa8d702-5b09-491e-8abc-d3e36ac23b8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_5f72cc90-798e-4918-938e-500c48c118af_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_bc5499b0-9ae9-4711-8314-0ff48497b1ee_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current provision</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_560c1867-94db-4fcf-835c-c44a81e3fbab_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_af1f5698-05f2-4a52-926d-6c9c97f0cb6e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_TaxYear2021AndPriorMember_f11b6058-f71b-46d6-b74e-1beaadec7b95_terseLabel_en-US" xlink:label="lab_crdf_TaxYear2021AndPriorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2021 And Prior</link:label>
    <link:label id="lab_crdf_TaxYear2021AndPriorMember_label_en-US" xlink:label="lab_crdf_TaxYear2021AndPriorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2021 And Prior [Member]</link:label>
    <link:label id="lab_crdf_TaxYear2021AndPriorMember_documentation_en-US" xlink:label="lab_crdf_TaxYear2021AndPriorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2021 And Prior</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_TaxYear2021AndPriorMember" xlink:href="crdf-20221231.xsd#crdf_TaxYear2021AndPriorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_TaxYear2021AndPriorMember" xlink:to="lab_crdf_TaxYear2021AndPriorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_57eac9d5-f368-43ef-bd33-6eb5e1ee5f73_terseLabel_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_label_en-US" xlink:label="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:to="lab_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_12b2c1f6-b5b4-4a8c-8ba5-468605500648_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_f0d9d2a6-c551-4cc6-8594-e83124fae045_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_dcd733f7-fadd-43fe-9df2-e3c64b8821be_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_080aeae0-9303-49ec-a84a-96642746520f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_0ea24607-587a-4e64-9e4d-a8c0b5cf7478_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_cc24be30-5c3e-462b-855a-b86af4c5212b_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Term of Warrants or Rights [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:to="lab_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_35620926-4e92-4bf8-9211-53e55962dc20_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_f5aa2784-e355-4921-aa34-8804c5d7e631_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ffd4f40a-65ce-4cda-929e-5b624d817e07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_ce7ec364-aab4-4584-a702-55d8361e3300_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_137385b4-1474-450c-990b-113cec18a806_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncement Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1a373fe6-816b-4b27-bbfc-a7219b1ff637_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_618a4975-61af-47b0-ba8d-0cef32b50994_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_219d5f22-e4b3-48f3-93d3-5e06e2193b10_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_c668ab01-6c61-4df9-937b-66dd3f0f4f97_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c443d131-afe3-419f-80f5-cc2f4e1e056a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_0c893bf6-b696-4ba3-91e3-f144c1762981_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_a266aafc-eb83-4498-90ef-55a4016d6c93_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidExpense_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9ee1b3fd-2767-43e4-80f5-ffcd5f61b13a_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0e7602d0-7b48-4b35-a50f-35d0c1f34182_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_773cf69d-71ab-42e9-9f76-d80620425921_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_2adeff14-fd8f-4782-a953-8f548a632f82_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_02a7d1ed-d1fb-4ab6-994e-b0468aea6212_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_52a34115-074a-46ef-a0b6-fe03ba2521a8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_60c5f0c2-2fe2-4318-a984-e2ddcf3c97db_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_972e725a-8a1f-494a-a722-5f653af7375b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7f4eb218-2af5-48d9-89e7-a23cb81967b5_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2c420caf-246f-49cb-b032-5cfb437a7722_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_eff72eec-052c-4e2f-8d06-492d637627c2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_a56cc15c-10ad-4933-b111-c3bc03849e3d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_962b938f-9a12-43de-adea-346a4a184c03_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_70ca9702-013b-46f0-acce-76485ccdee8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less&#8212;accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e38ac4f4-1e64-4064-a0d0-6cfcdee54e64_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_a369acf5-51c6-4bda-9f23-49bef6cc565f_negatedTerseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f16df645-ca3d-4c93-b290-3aeb65314847_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_3891b9e1-e23c-4105-b867-97d90f802152_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_54c18f8b-09cd-47ed-af15-bdda7fb8fdf7_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 and 41,964 shares issued and outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_d54f3f0f-58ad-4975-b1fb-e2bb5c831e04_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Months until exercisable</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Months Until Exercisable</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Months Until Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:to="lab_crdf_ClassOfWarrantOrRightMonthsUntilExercisable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_18a246ef-48bd-4f04-ac31-1bebdf5d5648_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_ca7c367d-0e51-4077-90fe-c8bd13cd6f33_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGrossAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsGrossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_dec629e5-dee6-420a-b26e-55d15c68ed28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_1fb37b7c-39a0-4f2b-b656-df7abad807ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7398d109-82db-4ad3-ae6f-45ad28e31ee1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_608363e8-d8d2-4a9a-ac86-44348107501b_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_097f40a5-2f77-4811-bd02-f446045dd5f3_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f503bc83-2e82-4759-b18a-467bb0e2bf9f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;Beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_165763d6-def0-4fa3-8092-576870c056aa_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents&#8212;End of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3f9b534f-dd2d-4fba-a52e-2bd8802eccb6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_046cac19-5388-4519-b66c-a2e3220838da_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="lab_us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_d3453a1e-5d31-4379-bc91-c70129b0c350_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_9133c5bd-28a2-409a-acbd-9105d9b7aa03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from exercise of options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_15d78360-d17d-487e-8985-6008b19b0178_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable&#160;to&#160;common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_2c94dc26-f64a-4022-b51f-58409c304818_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_6faa7480-e8bd-4ff9-b026-5d42c2d36d0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_01558f79-0fa7-437c-b789-ffce9bbe9a8e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining contractual term, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_5750f79c-1beb-4cb1-8cfc-8a3c07e9287c_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_b7e8272b-b6cd-4d2e-8820-082b48ee737b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_300dc051-6ab5-4b48-85d0-39b16b56ac34_terseLabel_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board</link:label>
    <link:label id="lab_us-gaap_CaliforniaFranchiseTaxBoardMember_label_en-US" xlink:label="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California Franchise Tax Board [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:to="lab_us-gaap_CaliforniaFranchiseTaxBoardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_2e52c981-3fa8-4b81-bb64-6316c61fa32f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_7ecbe79d-8313-4c92-a7ce-4dd2bffe958e_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_944aad71-664f-4f3e-b9e5-49676df5a846_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_fce7b59b-457b-4379-8fb5-9c444d3616ac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_bc7f5cfe-3121-44e2-a731-151e3074c82d_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpirationTerm_fa298549-2c58-44f3-88e0-32c78e5a3735_terseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpirationTerm_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Term</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightExpirationTerm_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Warrant Or Right, Expiration Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:to="lab_crdf_ClassOfWarrantOrRightExpirationTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_e02bb75f-562e-4da6-8a57-6a2ad6364f81_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_bea6870e-544f-42cf-b8c9-b2431fd38223_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cde14109-f21a-4908-97c3-4b41ea3662e2_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_f51d8a79-15e2-416c-a5e6-9916802d178c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_a0aec163-8198-46c2-8f11-77d435793860_negatedLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_117cedd8-ea72-4dd1-ac44-591e0f09f689_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock dividend payable on Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_38edd5b3-3e64-4216-9a1c-99d7e3e49fcd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_254e0b71-b439-4f75-82cb-9984ef67a337_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c66096b-6196-435e-9ba4-bd3c2effb8d1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_aa471704-e7d5-440a-ae61-b35b5b07f2f7_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_cefec0ba-3496-443d-bdd2-7962de798c84_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax computed at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_9a6bb898-7761-4641-8dd1-985d66cbaf26_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of Series A Convertible Preferred Stock dividend</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_label_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Dividend Accrued</link:label>
    <link:label id="lab_crdf_PreferredStockDividendAccrued_documentation_en-US" xlink:label="lab_crdf_PreferredStockDividendAccrued" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the value of preferred stock dividend accrued during the reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued" xlink:href="crdf-20221231.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockDividendAccrued" xlink:to="lab_crdf_PreferredStockDividendAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_5293bffc-aedb-4ba1-939f-a1f8b6b34d32_terseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_bf9521e4-96f0-4720-bfc4-2b58f27569dd_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b79cd21a-bd60-4de9-a09b-5eaf921374d4_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d212cc1-97f0-4faa-adf3-b846393ced97_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_08f80647-aa68-4f0b-b70a-2bb5646aefed_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_43a99de1-d2a1-4538-914d-8ea21a2982ba_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_0e026721-77f1-462a-b929-885c53c6bb9b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_94cfc671-fdbe-4f7f-ad32-64f1b41b745d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_f8279f1b-6db9-4a6a-a192-bf30445b5d67_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted</link:label>
    <link:label id="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_label_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Obligation Common Stock Closing Sales Price Number of Trading Days</link:label>
    <link:label id="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_documentation_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of consecutive trading days during which the closing price of the entity's common stock must equal or exceed the applicable price in order for the preferred stock to be automatically converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="lab_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_0c1ebc9e-6b7a-44d8-87f3-384244ddc526_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of deferred tax assets and liabilities from federal and state income taxes</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ceb60c61-3b02-4498-9114-441229d37bde_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ca7b4d11-e5e2-422f-9c8b-1db0032b49e8_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SharePriceForAutomaticConversion_9a9c340a-d1e6-4498-9dff-7678f2cababe_terseLabel_en-US" xlink:label="lab_crdf_SharePriceForAutomaticConversion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share price for 20 consecutive trading days for automatic conversion</link:label>
    <link:label id="lab_crdf_SharePriceForAutomaticConversion_label_en-US" xlink:label="lab_crdf_SharePriceForAutomaticConversion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price for Automatic Conversion</link:label>
    <link:label id="lab_crdf_SharePriceForAutomaticConversion_documentation_en-US" xlink:label="lab_crdf_SharePriceForAutomaticConversion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price target, if reached for the required period of time and if other provisions are achieved, that allows the entity to convert the preferred stock to common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SharePriceForAutomaticConversion" xlink:href="crdf-20221231.xsd#crdf_SharePriceForAutomaticConversion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SharePriceForAutomaticConversion" xlink:to="lab_crdf_SharePriceForAutomaticConversion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_91825aea-2fdf-4d1c-a147-7bec53036f79_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid included in operating cash flows</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Accrueddirectorfees_9c978d65-4b02-4662-8b99-f7f3c63c6930_terseLabel_en-US" xlink:label="lab_crdf_Accrueddirectorfees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Director fees</link:label>
    <link:label id="lab_crdf_Accrueddirectorfees_label_en-US" xlink:label="lab_crdf_Accrueddirectorfees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued director fees</link:label>
    <link:label id="lab_crdf_Accrueddirectorfees_documentation_en-US" xlink:label="lab_crdf_Accrueddirectorfees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued service fees for nonemployee directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Accrueddirectorfees" xlink:href="crdf-20221231.xsd#crdf_Accrueddirectorfees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Accrueddirectorfees" xlink:to="lab_crdf_Accrueddirectorfees" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_TaxCreditCarryforwardIncreaseDecrease_6cf99de4-c626-4b7b-aba9-0d193d989dcc_negatedTerseLabel_en-US" xlink:label="lab_crdf_TaxCreditCarryforwardIncreaseDecrease" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to tax credit carryforwards</link:label>
    <link:label id="lab_crdf_TaxCreditCarryforwardIncreaseDecrease_label_en-US" xlink:label="lab_crdf_TaxCreditCarryforwardIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Increase (Decrease)</link:label>
    <link:label id="lab_crdf_TaxCreditCarryforwardIncreaseDecrease_documentation_en-US" xlink:label="lab_crdf_TaxCreditCarryforwardIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_TaxCreditCarryforwardIncreaseDecrease" xlink:href="crdf-20221231.xsd#crdf_TaxCreditCarryforwardIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_TaxCreditCarryforwardIncreaseDecrease" xlink:to="lab_crdf_TaxCreditCarryforwardIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockLiquidationPreferenceStatedValue_6d9f24cb-57ba-4810-bccb-7677b908a4e3_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockLiquidationPreferenceStatedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated Value per share liquidation</link:label>
    <link:label id="lab_crdf_PreferredStockLiquidationPreferenceStatedValue_label_en-US" xlink:label="lab_crdf_PreferredStockLiquidationPreferenceStatedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Stated Value</link:label>
    <link:label id="lab_crdf_PreferredStockLiquidationPreferenceStatedValue_documentation_en-US" xlink:label="lab_crdf_PreferredStockLiquidationPreferenceStatedValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Stated Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceStatedValue" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceStatedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockLiquidationPreferenceStatedValue" xlink:to="lab_crdf_PreferredStockLiquidationPreferenceStatedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_baad1479-050e-45f1-90ec-c885b3b7c458_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_256b34ae-b24f-4553-b5b4-ba8405645a12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (range)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_d1f1a18e-5577-45de-bf0a-88b8591312db_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized loss on securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_b1a7ca6c-7545-4318-9761-1a50522e4886_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockCumulativeDividendAdjustment_d058d5aa-60ea-46bf-9321-020d9558a31b_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockCumulativeDividendAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative preferred stock dividend adjustment</link:label>
    <link:label id="lab_crdf_PreferredStockCumulativeDividendAdjustment_label_en-US" xlink:label="lab_crdf_PreferredStockCumulativeDividendAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Cumulative Dividend Adjustment</link:label>
    <link:label id="lab_crdf_PreferredStockCumulativeDividendAdjustment_documentation_en-US" xlink:label="lab_crdf_PreferredStockCumulativeDividendAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Cumulative Dividend Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockCumulativeDividendAdjustment" xlink:href="crdf-20221231.xsd#crdf_PreferredStockCumulativeDividendAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockCumulativeDividendAdjustment" xlink:to="lab_crdf_PreferredStockCumulativeDividendAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_cba81bae-59d2-4c28-bce7-48b63814f95e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_738ed588-73f2-4ca6-ac2c-32164cd1c763_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_5353ad83-e21f-43ee-a1d3-81ff93194e81_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8ac17025-84e8-4a15-ae71-8b3de93add9b_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_49c12158-070b-47fe-9750-bff54b597703_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_d28873e6-0cc2-4062-85d1-d6364562e12f_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxYear2021Member_50ae59c6-c6bc-4974-ac4c-053a615ff965_terseLabel_en-US" xlink:label="lab_us-gaap_TaxYear2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2021</link:label>
    <link:label id="lab_us-gaap_TaxYear2021Member_label_en-US" xlink:label="lab_us-gaap_TaxYear2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Year 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2021Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxYear2021Member" xlink:to="lab_us-gaap_TaxYear2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_e5893d7b-5fd2-4163-89eb-63683beb6e44_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_f8bea888-aa9f-40cc-8b2f-17c08d3aba91_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted</link:label>
    <link:label id="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_label_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Obligation Specified Volume of Common Stock Traded Per Day during Trading Days</link:label>
    <link:label id="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_documentation_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the average volume of common stock per day, which must be traded in order for the preferred stock to be automatically converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:to="lab_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_8d117e30-fda3-4434-be77-9384af8316bb_terseLabel_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</link:label>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_label_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]</link:label>
    <link:label id="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_documentation_en-US" xlink:label="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:href="crdf-20221231.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:to="lab_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_f52d43fd-9ef6-43ca-b89b-4a7c4c8eee7d_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_c270d0ae-871b-4186-953c-babff9692c5b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Warrant Activity and Changes in Warrants Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0569aa1c-6b93-415c-bc84-a89373609dab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_e3958cbf-b33a-46cb-890a-f9aad6eef071_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_RegisteredDirectOfferingMember_122463c4-e8cc-48ea-ac78-3cdb7d8b8c89_terseLabel_en-US" xlink:label="lab_crdf_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering</link:label>
    <link:label id="lab_crdf_RegisteredDirectOfferingMember_label_en-US" xlink:label="lab_crdf_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Registered Direct Offering [Member]</link:label>
    <link:label id="lab_crdf_RegisteredDirectOfferingMember_documentation_en-US" xlink:label="lab_crdf_RegisteredDirectOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents information pertaining to registered direct offering</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_RegisteredDirectOfferingMember" xlink:href="crdf-20221231.xsd#crdf_RegisteredDirectOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_RegisteredDirectOfferingMember" xlink:to="lab_crdf_RegisteredDirectOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_a6134650-1bd0-464e-a185-ea76ae50ad80_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_899a872b-0fe0-49dd-99a8-2442559d8d4d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockConversionPricePerShare_d4672d57-c82b-4f83-8e20-cecc6fbd074e_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion price per share (in dollars per share)</link:label>
    <link:label id="lab_crdf_PreferredStockConversionPricePerShare_label_en-US" xlink:label="lab_crdf_PreferredStockConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Price Per Share</link:label>
    <link:label id="lab_crdf_PreferredStockConversionPricePerShare_documentation_en-US" xlink:label="lab_crdf_PreferredStockConversionPricePerShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The price per share of the conversion feature embedded in the convertible preferred stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionPricePerShare" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockConversionPricePerShare" xlink:to="lab_crdf_PreferredStockConversionPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_44b3f6aa-ddcf-4494-952a-d8ae8c59cdfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_c5f38e2b-1258-43c1-ac20-28702d148d84_terseLabel_en-US" xlink:label="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone or royalty payments</link:label>
    <link:label id="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_label_en-US" xlink:label="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made</link:label>
    <link:label id="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_documentation_en-US" xlink:label="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:href="crdf-20221231.xsd#crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:to="lab_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ServiceReceivableMember_01a52469-57d7-47f4-b766-727dc618692b_terseLabel_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_label_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable [Member]</link:label>
    <link:label id="lab_crdf_ServiceReceivableMember_documentation_en-US" xlink:label="lab_crdf_ServiceReceivableMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember" xlink:href="crdf-20221231.xsd#crdf_ServiceReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ServiceReceivableMember" xlink:to="lab_crdf_ServiceReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_35228840-a6a4-42ed-b0d1-323ed61a42fd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_752b5f18-7415-4e22-ac2b-5ad7f650c6ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4cd5df19-fea9-44a9-8e0b-97a4cff9a757_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_e822793a-d2d3-4650-9495-a26204a545c9_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable and unbilled receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_26607e13-866c-4961-b115-6119e2831c61_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_12a9f38c-9331-42fb-92ce-79164f58d3ff_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview and Liquidity</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_e95a899c-ec04-4782-9920-8795e4fbd9ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForErrorCorrectionDomain_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Error Correction, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:to="lab_us-gaap_AdjustmentsForErrorCorrectionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_Servicereceivable_46607fb2-f6e2-4825-ba08-75d3b10a0a5e_negatedTerseLabel_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivable</link:label>
    <link:label id="lab_crdf_Servicereceivable_label_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service receivable</link:label>
    <link:label id="lab_crdf_Servicereceivable_documentation_en-US" xlink:label="lab_crdf_Servicereceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable" xlink:href="crdf-20221231.xsd#crdf_Servicereceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_Servicereceivable" xlink:to="lab_crdf_Servicereceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_ec236834-643e-45a3-8363-833c1c027e75_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_3f2455ec-6cdd-4522-8ef6-a59d78adb99c_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_2ad81a5b-141b-463f-ad42-5b940dc86638_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_cb57b114-eabf-4862-bdb0-0b366bff31bd_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_8d813d46-edfb-4148-92ef-2bfb7bd191f3_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_55580cd1-b8ca-4740-bc5b-401d51d57862_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_90063afb-41f8-44b4-967a-6c29ea138eec_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_5617bcd0-d92d-48f3-b8b5-38aa55bfad70_terseLabel_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Balance Sheet Information</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="crdf-20221231.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_crdf_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_0b0f97e8-7108-434a-bcb1-1d746e9d9cd4_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrentAbstract_76e8d869-77f1-4dc3-8e30-2dbf4db4db00_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity less than 1 year:</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract" xlink:to="lab_us-gaap_DebtSecuritiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_3de3267f-b70d-4d17-a90a-5686b752009c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_0013d93b-1df3-46af-a54e-97f123bb8ce4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of premiums on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_06962572-2aee-47fb-acaa-d26024257ffa_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_82f09131-40e3-425e-bfac-71167d104e78_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_CommonStockAndWarrantsMember_fe82be19-08a9-4650-9644-0888d1b787ae_terseLabel_en-US" xlink:label="lab_crdf_CommonStockAndWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrants</link:label>
    <link:label id="lab_crdf_CommonStockAndWarrantsMember_label_en-US" xlink:label="lab_crdf_CommonStockAndWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrants [Member]</link:label>
    <link:label id="lab_crdf_CommonStockAndWarrantsMember_documentation_en-US" xlink:label="lab_crdf_CommonStockAndWarrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock And Warrants [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CommonStockAndWarrantsMember" xlink:href="crdf-20221231.xsd#crdf_CommonStockAndWarrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_CommonStockAndWarrantsMember" xlink:to="lab_crdf_CommonStockAndWarrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_b4fda239-fd20-427f-87c7-f9224514e236_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20c822e6-fca2-4812-923f-f374e8cadfe0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_38bf8f63-2fca-4c0a-b727-47c42f152528_terseLabel_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of Trovagene common stock (in dollars per share)</link:label>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_label_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value of Warrant</link:label>
    <link:label id="lab_crdf_EstimatedFairValueOfWarrant_documentation_en-US" xlink:label="lab_crdf_EstimatedFairValueOfWarrant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the estimated fair value of warrant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant" xlink:href="crdf-20221231.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EstimatedFairValueOfWarrant" xlink:to="lab_crdf_EstimatedFairValueOfWarrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_786aab39-381c-4dda-875f-7c4725ccd5a3_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_4a7454b8-c37f-41c2-bc8f-6a5f04f15305_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_94b7935d-c00e-4fa8-a27a-86ecfdd6edb7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_66dcacfc-a715-471d-bf41-88603533b71d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_0c5cb598-1283-44f1-b224-59a4a74ad47c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net proceeds</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_3fba55be-4d7b-4074-80dd-5b341a00cc1f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_dcbb377c-4604-4702-8c77-7c405a0c9a54_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_36229d91-a27b-4f57-8bb5-bbf81d5b3766_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_50eb616e-c66b-4656-acd0-7e59583445a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value, vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays_13021d4b-2173-4b8c-a95a-f9921b135baa_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted</link:label>
    <link:label id="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays_label_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock Conversion Obligation Number of Trading Days</link:label>
    <link:label id="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays_documentation_en-US" xlink:label="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the number of trading days during which a specified average volume of common stock must traded in order for the preferred stock to be automatically converted.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationNumberOfTradingDays" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationNumberOfTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockConversionObligationNumberOfTradingDays" xlink:to="lab_crdf_PreferredStockConversionObligationNumberOfTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_93a7ee25-e503-4d48-b40a-860058549f1f_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_efe0a677-9e62-47b5-87e2-22cc5d8699d2_terseLabel_en-US" xlink:label="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative unpaid preferred stock dividends</link:label>
    <link:label id="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_label_en-US" xlink:label="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Cumulative Unpaid Preferred Stock Dividends, Value</link:label>
    <link:label id="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_documentation_en-US" xlink:label="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Cumulative Unpaid Preferred Stock Dividends, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" xlink:to="lab_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WarrantMember_08ee4bc5-ff83-4381-83c1-a17e71d1251f_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_WarrantMember_label_en-US" xlink:label="lab_us-gaap_WarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warrant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantMember" xlink:to="lab_us-gaap_WarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_63428aa9-8e76-409e-86ad-ee30212c92bf_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_34ff2da2-a954-49ea-bccf-40957541ffe0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $0 and $813 respectively</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_778b7888-965d-4d3b-95f4-3536404fdf83_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_93766812-a209-47db-b93a-b2689181112b_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_09f577a1-85a8-438d-b035-10fc7fa65094_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_6e8a9b67-e26a-4095-a003-bb142c0ede5f_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_37cffd97-8f57-43be-8fce-49d65f8c2e19_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4a66deb-383d-499d-9af0-01394bc01538_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_7df1891e-228f-40bd-ab9a-a6af5bd5b64c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_7d33e09c-0586-4831-926f-ab1c2e787773_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on disposal of assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_f1bef243-7d81-478e-867f-06dea643854b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,044 and $1,020 at December&#160;31, 2022 and December&#160;31, 2021, respectively; (Note 5)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_2bfbf191-7384-4308-8b5f-2de98ab7870f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c1bb9248-da1e-4df2-b3fc-172cf0bab261_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3e8b32d5-28dd-46ad-bcad-b33962f10f8b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_ac682917-3b2f-4955-ae16-0cd923b47774_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_2b2aeba3-960c-4355-96c0-17c254b6c26b_terseLabel_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series C Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesCConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock that may be exchanged into common shares at the owner's option.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:href="crdf-20221231.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesCConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesCConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_f0b20ccc-0733-49f6-bf8b-f49ef0c3d241_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3f7dae83-a622-4094-b39e-a1f3a03fa912_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level&#160;3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_a12aa580-2653-4f5b-9e8f-e7ba33b204eb_terseLabel_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_label_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options [Member]</link:label>
    <link:label id="lab_crdf_InducementGrantStockOptionsMember_documentation_en-US" xlink:label="lab_crdf_InducementGrantStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Grant Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember" xlink:href="crdf-20221231.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_InducementGrantStockOptionsMember" xlink:to="lab_crdf_InducementGrantStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_8bca4317-8ccc-4255-8471-894bf46d976c_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_6a4a8281-36b8-4e27-a2da-1f8c38358247_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_e31fcbcd-d41e-4391-82c8-a96ad9b530ee_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ece79622-65c0-4b49-b487-c65885682e8c_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_653b3cc3-4f28-444b-a949-deb8eaaff0bb_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_4e8801fe-f28a-4121-8ede-d69dd193bb61_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_8c096080-6cc6-4f29-960b-f77a835616dc_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_605c9d14-f7fb-4e59-8159-2db5aac3f9ca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_6058e644-c487-4940-9984-851cd142b024_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_ff16d86f-1ae1-4ca4-8f52-989408e9f7ab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7d6f2e5f-e4fb-425a-a0c2-5e8fb2084371_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d7b13c47-e492-42b5-899e-f28ce143d381_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_901c8829-25f8-4ada-a5d9-3aa90975c0b2_terseLabel_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesBConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series B Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:href="crdf-20221231.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesBConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesBConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_b82f5adf-efe9-407d-93c8-ea5b192bcb52_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:to="lab_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_39ba6726-bff1-4cce-a817-618431f2c6a1_verboseLabel_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_label_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised</link:label>
    <link:label id="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_documentation_en-US" xlink:label="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:to="lab_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_bc8beeef-81f3-4efa-9a43-b8880868a4a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level&#160;2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e5281fc2-0604-45ca-9da0-d9be195b2c9f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f67bd128-65e9-4528-befc-7f72f98b49f9_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c061d72d-7df9-4cec-9cfb-66af4c31f5af_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_26a4b0c4-26f5-4e99-bfb8-50d0ac1c3804_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_40eb1779-c76d-47f9-ad9a-c258156729c1_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_bb56cda2-44ba-439b-9f39-d3e5d3aa18dd_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_01a2d0d7-455f-478c-8bb7-785a0d20a710_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_cb4c429a-e549-4973-84c5-19216bf0d11f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_82e33ad8-a8d4-41ea-a8f4-b9265e979726_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_7ac8ac8f-677b-4c49-a189-ab11705aa422_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_235901c8-c8f9-42e1-9f1e-c233610144db_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_5c4c7fc1-8125-4785-87cd-7e19a8875e86_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance proceeds from casualty loss</link:label>
    <link:label id="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Insurance Settlement, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:to="lab_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_4fea4999-0aa1-4b39-9780-8392130ea1a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_dfa65a69-e066-4b81-a2df-a14759742fdf_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingGainsLosses_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingGainsLosses" xlink:to="lab_us-gaap_OtherNonoperatingGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_f088e2cd-4016-40bb-b2cd-eb4272f97c1f_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesNWarrantMember_7687c8ff-65c4-4fe9-a938-38148b3ca6f7_terseLabel_en-US" xlink:label="lab_crdf_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant</link:label>
    <link:label id="lab_crdf_SeriesNWarrantMember_label_en-US" xlink:label="lab_crdf_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant [Member]</link:label>
    <link:label id="lab_crdf_SeriesNWarrantMember_documentation_en-US" xlink:label="lab_crdf_SeriesNWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series N Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesNWarrantMember" xlink:href="crdf-20221231.xsd#crdf_SeriesNWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesNWarrantMember" xlink:to="lab_crdf_SeriesNWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_514bf06d-0e2c-4e2e-b6b0-c3de64b1f3de_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_cc30ed2b-9e20-4563-95f7-549b56f612a4_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_a0701ab8-ce54-4d98-9a95-6a0fee005a0c_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non U.S. government</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_141bf56e-e137-4d6b-adbb-9b6da5dc8f38_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Future Minimum Lease Payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_0e511c98-8e34-4ebb-a813-74739b96a202_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_5e14addb-a5ee-4360-9aac-d07b5cc22675_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of assumptions used to determine the fair value of warrants</link:label>
    <link:label id="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:to="lab_us-gaap_FairValueInputsQuantitativeInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_ebd0ffd4-bbbf-4181-8ffc-824b15d263f2_terseLabel_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesAConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:href="crdf-20221231.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesAConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesAConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_b834960f-3498-4ba7-be4e-d3bde208b0e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_b5060d53-2a50-4e45-b61c-0e3b0307e51a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_59bf71de-c53b-4de5-affa-ad9dea6bfe13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction to the valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_3b3c811d-e897-4358-aa16-1c451749e1af_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_921ba109-04ea-435f-aa74-120b500c683e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_e318e0ef-81dd-4351-8e65-392aff1fbdf8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_7684a990-6002-4cf9-a921-e6ff54a1fc74_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_bc84227c-a0fc-4cbe-b309-331809c4c5c3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_1867aacb-6dc7-47b4-813f-c1444b20d64e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_5e70295c-bd9b-49eb-a43d-ae3da1e77741_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_95ddc3ec-b679-4807-bd59-acfbad87192a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_5007de33-f13f-4842-9562-9bd9cda78167_negatedTerseLabel_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_label_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
    <link:label id="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_documentation_en-US" xlink:label="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:to="lab_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_0b26ba40-84b1-4e38-a915-be652cd2061a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_a2dad298-416e-48b1-88b9-3b8c9b27e82f_terseLabel_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method</link:label>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_label_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Black Scholes Option Pricing Method [Member]</link:label>
    <link:label id="lab_crdf_BlackScholesOptionPricingMethodMember_documentation_en-US" xlink:label="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_BlackScholesOptionPricingMethodMember" xlink:to="lab_crdf_BlackScholesOptionPricingMethodMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5f0bdf29-ac4a-46f7-b7f3-34dcbc92b690_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f19dd717-4234-402c-91db-61b11176724d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Significant Components of the Company&#8217;s Taxes and the Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_a2251738-0b04-4f94-a2c2-049ea5d5fe9e_terseLabel_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesDConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series D Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesDConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesDConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e4e76a14-ade3-4898-99ce-807dfa8b996f_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_5990ac0a-8f2e-4e4f-8092-01f64aa9c6d9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State tax, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_fe911e0f-3d08-43d8-b74e-38b90dcec54e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment Losses on Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_4724b3c4-6b28-4c50-b9f5-942d1dba6310_terseLabel_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent items</link:label>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_label_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Permanent Items</link:label>
    <link:label id="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_documentation_en-US" xlink:label="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Represents the percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:to="lab_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_28f136b1-7970-415c-af6e-97423cc83741_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c63e63d8-5e04-47e0-b484-3c1f93f9d94d_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_988767a2-93ec-4273-9b45-086a5570bac4_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_b9ffc249-74af-4e90-ac91-45c313659056_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_25c19191-c005-4fc4-8411-15ef3032dfd4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_05148020-6b47-471f-bf1b-131e05e31d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_d1e1976f-b8b8-4745-b442-6276a33ac9b9_terseLabel_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_label_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_crdf_SeriesEConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series E Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_SeriesEConvertiblePreferredStockMember" xlink:to="lab_crdf_SeriesEConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_f3c9bc3b-8b0f-4979-a420-7ee7bcf87416_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_ae60724b-c0ea-4253-a35c-8e6dc0173de1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxPeriodAxis_f14a2aba-aa64-45ac-b52b-a44b1a97b16a_terseLabel_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxPeriodAxis_label_en-US" xlink:label="lab_us-gaap_TaxPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxPeriodAxis" xlink:to="lab_us-gaap_TaxPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_b8da8ae0-9a37-4272-9563-6c83a3e0d8a8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_d23c8b65-0324-4b2c-9d19-3a45f1fa1e60_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_ef8fa0e5-06bd-413f-9cce-8a178abb5a9d_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_ccb6cae1-e07c-4fe2-aa48-12318196b0ad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_df33cb89-a8c6-4a8e-8280-ef8243dc99c5_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_337ca98c-d5a3-47c2-a3d3-75857c957b81_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_faaeaea5-6c4a-4269-8e92-2ec37dc4d8a6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_5bc51fc8-f173-4b64-9938-57303a768f75_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax computed at the federal statutory rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_4ce91cd0-61ec-4974-b94c-2b1eea9fb1ab_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_963585a3-ac10-430b-a5f2-dbb83beff6bb_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2c76ec01-4a61-45db-a82b-89b88ad225dd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_9130f993-3ec3-407c-b7eb-7e3c460c6e36_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_ee7bc4b6-80bf-40fe-a170-03e793482b77_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A Convertible Preferred Stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_566c6938-f972-4c2f-bca3-249b9044af60_totalLabel_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liquidation preference - Series A Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockLiquidationPreferenceValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_b02c1308-cbba-4e7b-a2e6-d5cea6f2c06e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_1a89dd2f-1d31-4dcd-be20-11c3b578849b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of warrants outstanding at the end of the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_b817bce2-e602-4561-9760-db79b3abab73_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:to="lab_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock_121032d0-37b6-4de0-8dc3-73b80ce23501_terseLabel_en-US" xlink:label="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock_label_en-US" xlink:label="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses [Policy Text Block]</link:label>
    <link:label id="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock_documentation_en-US" xlink:label="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Trial Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrialExpensesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_crdf_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:to="lab_crdf_AccruedClinicalTrialExpensesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_23628cf6-1719-4091-a5d4-968b1412bc21_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_598c5aca-e471-4309-9a4a-ec35de41ea65_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital expenditures</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_30b0c534-68e3-4e23-b777-ad5b8a03c1ac_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_805a1fe0-253b-47f3-805b-50b047396abf_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_fa98c778-a8ff-4bb4-991b-0947574d6303_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_6ea20f74-0e34-4d71-a79a-940fb97009b1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_7b338d8f-d165-458a-9784-9ffa8dc4b5ff_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative financial instruments&#8212;warrants</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_b9d28997-a55c-45a9-ae3d-d2047ee71aaa_periodStartLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_5a386ae4-b021-4fee-b975-786058b4491a_periodEndLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance of derivative financial instruments liability at the end of the period</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>crdf-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:43395891-7664-4c15-a02f-d7b4811c3213,g:94da96fa-a6f9-430a-8c03-f421ae94b6bc-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DocumentandEntityInformation" xlink:type="simple" xlink:href="crdf-20221231.xsd#DocumentandEntityInformation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DocumentandEntityInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:href="crdf-20221231.xsd#crdf_DocumentAndEntityInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_e8a2b0da-f528-458c-9a1d-6c178901459d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentType_e8a2b0da-f528-458c-9a1d-6c178901459d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_bff05d83-78e0-4d35-8b15-e5f5587808b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentAnnualReport_bff05d83-78e0-4d35-8b15-e5f5587808b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_f2518ed7-c75a-4329-b7af-e85335de4970" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentPeriodEndDate_f2518ed7-c75a-4329-b7af-e85335de4970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_c898309c-5817-4224-a758-7023ae281dd3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_CurrentFiscalYearEndDate_c898309c-5817-4224-a758-7023ae281dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_10c88d61-cfd0-477f-b3b9-df618920068c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentTransitionReport_10c88d61-cfd0-477f-b3b9-df618920068c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_eb286ed1-e676-43cc-a053-f3d2261464b3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityFileNumber_eb286ed1-e676-43cc-a053-f3d2261464b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_1f3fa237-6fa9-4e04-ab15-6af50aac2949" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityRegistrantName_1f3fa237-6fa9-4e04-ab15-6af50aac2949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0097ee4c-17f5-4ea5-8144-8708d070237b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0097ee4c-17f5-4ea5-8144-8708d070237b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c9d987cb-49b6-4d8b-858c-dc80e2580244" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityTaxIdentificationNumber_c9d987cb-49b6-4d8b-858c-dc80e2580244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_16c09dd5-ab08-4d4d-9960-ccf8a81800bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityAddressStateOrProvince_16c09dd5-ab08-4d4d-9960-ccf8a81800bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_3bdb53eb-f32a-4e8d-9241-bd71b330983c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityAddressCityOrTown_3bdb53eb-f32a-4e8d-9241-bd71b330983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_9946c7d3-ef5f-4aa3-86c6-d7a23bb00cb4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityAddressAddressLine1_9946c7d3-ef5f-4aa3-86c6-d7a23bb00cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_32a7bcd3-8d7d-4c72-9b50-c00e5964c1d6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityAddressPostalZipCode_32a7bcd3-8d7d-4c72-9b50-c00e5964c1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_eea44f4e-2ec2-4f73-aab8-2504433ed672" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_CityAreaCode_eea44f4e-2ec2-4f73-aab8-2504433ed672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d4b4dd6f-8e2c-46ec-bb8b-dcf9fe4b780b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_LocalPhoneNumber_d4b4dd6f-8e2c-46ec-bb8b-dcf9fe4b780b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c327cc1c-81d5-4517-aa3a-eb3fdae9161e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_Security12bTitle_c327cc1c-81d5-4517-aa3a-eb3fdae9161e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_848225fe-68f7-4ce5-b0bb-24e048a60ac2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_848225fe-68f7-4ce5-b0bb-24e048a60ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_0b11698c-0e81-4727-9ff5-d671f6ce57ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityVoluntaryFilers_0b11698c-0e81-4727-9ff5-d671f6ce57ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_8aab828d-d9ec-46fa-8bc5-bbcd5aaf264c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityCurrentReportingStatus_8aab828d-d9ec-46fa-8bc5-bbcd5aaf264c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_bf1e148b-7563-4f7e-99a7-31998c53ff22" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityInteractiveDataCurrent_bf1e148b-7563-4f7e-99a7-31998c53ff22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_306db158-4462-46c8-aa6f-53e82cbbdc74" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityFilerCategory_306db158-4462-46c8-aa6f-53e82cbbdc74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c023a4b2-28eb-48c7-866b-f4846dbb42e8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityEmergingGrowthCompany_c023a4b2-28eb-48c7-866b-f4846dbb42e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_7a78e94a-5e72-4a1d-92c4-01a87ec265b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntitySmallBusiness_7a78e94a-5e72-4a1d-92c4-01a87ec265b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_37da1bce-270f-4234-a62a-cbd965c7d820" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_IcfrAuditorAttestationFlag_37da1bce-270f-4234-a62a-cbd965c7d820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_d2ffa94f-0c2c-4ab4-9faa-d022f3edcba6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityShellCompany_d2ffa94f-0c2c-4ab4-9faa-d022f3edcba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_524f017f-b4b0-470f-9596-97950a448b03" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityPublicFloat_524f017f-b4b0-470f-9596-97950a448b03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_0214cc7e-0a35-418a-b932-977fddc39183" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_0214cc7e-0a35-418a-b932-977fddc39183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d8529447-b287-40c6-9bba-f692930ae7ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_d8529447-b287-40c6-9bba-f692930ae7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_fa2aebf6-dc27-4d02-83b0-270c43ef7274" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_EntityCentralIndexKey_fa2aebf6-dc27-4d02-83b0-270c43ef7274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_e9d8493a-b0ad-45a1-94d4-e92306ee8807" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentFiscalYearFocus_e9d8493a-b0ad-45a1-94d4-e92306ee8807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4906cbb2-a1ab-465c-b620-050dfda2c056" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4906cbb2-a1ab-465c-b620-050dfda2c056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_490fc535-002f-4d3f-9b53-402d3b0ffbcf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DocumentAndEntityInformationAbstract_7e80aa07-5d56-4cf8-9b7b-0a0b19cf5609" xlink:to="loc_dei_AmendmentFlag_490fc535-002f-4d3f-9b53-402d3b0ffbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/AuditInformation" xlink:type="simple" xlink:href="crdf-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AuditInformationAbstract_7cdb48b1-6728-40a8-b7f1-12043c45b846" xlink:href="crdf-20221231.xsd#crdf_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_89be5025-b4ad-495d-8055-979b03d3a796" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_AuditInformationAbstract_7cdb48b1-6728-40a8-b7f1-12043c45b846" xlink:to="loc_dei_AuditorFirmId_89be5025-b4ad-495d-8055-979b03d3a796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_3d4b4908-1280-433b-8ffe-feba073a4d59" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_AuditInformationAbstract_7cdb48b1-6728-40a8-b7f1-12043c45b846" xlink:to="loc_dei_AuditorName_3d4b4908-1280-433b-8ffe-feba073a4d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_b1296607-901f-48b4-aaff-7a387c7d80c2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_AuditInformationAbstract_7cdb48b1-6728-40a8-b7f1-12043c45b846" xlink:to="loc_dei_AuditorLocation_b1296607-901f-48b4-aaff-7a387c7d80c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BalanceSheets" xlink:type="simple" xlink:href="crdf-20221231.xsd#BalanceSheets"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ffd8ebba-ceae-4b89-89ec-111662dab0ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ffd8ebba-ceae-4b89-89ec-111662dab0ff" xlink:to="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32a50ce5-6463-4935-8ed7-cc25e5ff2941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_32a50ce5-6463-4935-8ed7-cc25e5ff2941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f654922f-6feb-4f4f-a100-174ff4f8259a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:to="loc_us-gaap_ShortTermInvestments_f654922f-6feb-4f4f-a100-174ff4f8259a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_ad9d0625-4028-4170-a895-9679c3cb5558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_ad9d0625-4028-4170-a895-9679c3cb5558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85c7700d-78aa-49fa-b9e7-7a477061d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85c7700d-78aa-49fa-b9e7-7a477061d182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_bbacfd26-244f-4e22-bba8-d4f647789507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e83cde9a-3b0b-47f5-b344-21e8a27be795" xlink:to="loc_us-gaap_AssetsCurrent_bbacfd26-244f-4e22-bba8-d4f647789507" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_838edd5f-9f10-437b-a2b2-c1482aad55e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_838edd5f-9f10-437b-a2b2-c1482aad55e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_f3082350-837e-4abb-9530-305f65ac5b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_f3082350-837e-4abb-9530-305f65ac5b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3df81d6b-2a24-4858-96dc-48f8b5543b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3df81d6b-2a24-4858-96dc-48f8b5543b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_9665bf95-58a9-4b72-b44b-2ddfd12b7077" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_50ede26b-eafc-4f0a-a0ec-904d7ede2ac7" xlink:to="loc_us-gaap_Assets_9665bf95-58a9-4b72-b44b-2ddfd12b7077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ffd8ebba-ceae-4b89-89ec-111662dab0ff" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_217563f8-7607-461a-8e57-d1f902a59fad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:to="loc_us-gaap_AccountsPayableCurrent_217563f8-7607-461a-8e57-d1f902a59fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d57bf391-c14b-4a31-8a79-40c604e338c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d57bf391-c14b-4a31-8a79-40c604e338c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_05d04b78-ffab-45de-b99a-d81f75e16f1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_05d04b78-ffab-45de-b99a-d81f75e16f1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d33c0f87-80f5-4939-a634-156d68a9e49b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d33c0f87-80f5-4939-a634-156d68a9e49b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e81637ab-0258-4160-b348-a85459ea9813" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f69d9c8a-9b92-46b6-9855-3268b18f55c6" xlink:to="loc_us-gaap_LiabilitiesCurrent_e81637ab-0258-4160-b348-a85459ea9813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_4e1127db-eb38-464a-8221-d36461b0e536" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_4e1127db-eb38-464a-8221-d36461b0e536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc9b4e20-2e14-46ce-b58a-fa78ed28c32c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc9b4e20-2e14-46ce-b58a-fa78ed28c32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_97b662bc-d214-419b-b68d-7a27b323e97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_Liabilities_97b662bc-d214-419b-b68d-7a27b323e97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_657ec9c7-4b9f-43e4-980d-0d67e41dd530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_CommitmentsAndContingencies_657ec9c7-4b9f-43e4-980d-0d67e41dd530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b1ba9789-b615-40a9-9960-f8718e659248" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_us-gaap_PreferredStockValue_b1ba9789-b615-40a9-9960-f8718e659248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_98fca1b9-a68f-4040-b687-c4e5a6f18ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_us-gaap_CommonStockValue_98fca1b9-a68f-4040-b687-c4e5a6f18ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f6a5d3fc-80f1-434b-8e3f-1be1ff98e670" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f6a5d3fc-80f1-434b-8e3f-1be1ff98e670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Servicereceivable_3fa66429-db1e-4c5b-af9c-ae013d390881" xlink:href="crdf-20221231.xsd#crdf_Servicereceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_crdf_Servicereceivable_3fa66429-db1e-4c5b-af9c-ae013d390881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fcd64338-4558-4b07-9f75-1b176cb8bb65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_fcd64338-4558-4b07-9f75-1b176cb8bb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44b33ef8-9448-46d0-ace3-f92794103e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_44b33ef8-9448-46d0-ace3-f92794103e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_2721da5d-b280-4d01-8f22-caf7a3ab298a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ccccb522-c5d2-4104-aee4-7c8d37e03512" xlink:to="loc_us-gaap_StockholdersEquity_2721da5d-b280-4d01-8f22-caf7a3ab298a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d38e6d0-e707-4877-8fb5-2a92a75dcd69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ab7b22b-c7bf-41c7-88e2-0aeb41407bbe" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_1d38e6d0-e707-4877-8fb5-2a92a75dcd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BalanceSheetsParenthetical" xlink:type="simple" xlink:href="crdf-20221231.xsd#BalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b661f8db-4b88-43b7-aa35-649a0e66e2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_b661f8db-4b88-43b7-aa35-649a0e66e2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_88700a54-c0d5-4039-982b-33a4232981dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_88700a54-c0d5-4039-982b-33a4232981dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_8b94a39c-822a-4d40-b76b-69eded473cb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_8b94a39c-822a-4d40-b76b-69eded473cb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3922955-de76-4aed-a5ce-875316a1d707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_b3922955-de76-4aed-a5ce-875316a1d707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_f3c7986d-678c-4163-a51b-7d25ccad8eca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_f3c7986d-678c-4163-a51b-7d25ccad8eca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_3a686a21-936d-469b-9249-bbef41dcd191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_CommonStockSharesIssued_3a686a21-936d-469b-9249-bbef41dcd191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1584b75b-301b-43c8-ad85-3fbae43399bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_49070338-2cf1-4794-bc3b-3bf74abb6592" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1584b75b-301b-43c8-ad85-3fbae43399bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofOperations" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofOperations"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fd64af22-4afd-45db-8b63-28406f97d967" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fd64af22-4afd-45db-8b63-28406f97d967" xlink:to="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:to="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_7f5898ee-386f-4611-a40b-639db27a6992" xlink:to="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_7a67d25e-a5e3-473e-8c66-5f8af9b83c8b" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_7a67d25e-a5e3-473e-8c66-5f8af9b83c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_81812879-4cea-4fed-82dd-7491922b899d" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_0004cc15-e3a2-4e68-96cd-da10ddc56066" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_81812879-4cea-4fed-82dd-7491922b899d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_6fb16300-e3b7-4763-9bec-67e2bcb10007" xlink:to="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_61c9e2e9-d242-4942-acea-a4ddb9f6b168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_61c9e2e9-d242-4942-acea-a4ddb9f6b168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_56d96f09-fbe4-402c-91d2-54aae5519024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_56d96f09-fbe4-402c-91d2-54aae5519024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f6843ff3-0cb1-44db-9c73-d08d1ce154ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f6843ff3-0cb1-44db-9c73-d08d1ce154ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_9fc0bf48-fa97-4598-8d5e-3816b3351d01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_a576018b-f858-4771-9fa3-a446f05fd624" xlink:to="loc_us-gaap_OperatingExpenses_9fc0bf48-fa97-4598-8d5e-3816b3351d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9ccbcf50-f709-43dc-9ec8-5b214585acb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_OperatingIncomeLoss_9ccbcf50-f709-43dc-9ec8-5b214585acb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5501d495-7c6a-4af9-acae-6cc3b1eac48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5501d495-7c6a-4af9-acae-6cc3b1eac48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingGainsLosses_f6955a18-f55b-4403-b04f-c796b379967c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingGainsLosses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_OtherNonoperatingGainsLosses_f6955a18-f55b-4403-b04f-c796b379967c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_fed605cb-54b0-4197-a151-88a5304d676b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_fed605cb-54b0-4197-a151-88a5304d676b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_61592310-4857-477b-875c-ca6b0c20bc20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_daede83c-75b5-40ff-b421-993395ae3c71" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_61592310-4857-477b-875c-ca6b0c20bc20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6d697609-63c9-4165-9d07-cb44232b5efb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_NetIncomeLoss_6d697609-63c9-4165-9d07-cb44232b5efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_dab1e11c-b799-4784-9a0c-b17622c7c717" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_dab1e11c-b799-4784-9a0c-b17622c7c717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_542131c6-ee0a-4f82-addb-68ec38581bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_542131c6-ee0a-4f82-addb-68ec38581bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c211b0ab-4e74-4cd3-9230-fd9900dcf989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_EarningsPerShareBasic_c211b0ab-4e74-4cd3-9230-fd9900dcf989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_39aad66a-fecb-49cf-a2fd-b7e5c8a70c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_EarningsPerShareDiluted_39aad66a-fecb-49cf-a2fd-b7e5c8a70c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6e12ff9-48cc-479e-a3a5-3b0403424076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b6e12ff9-48cc-479e-a3a5-3b0403424076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7a31738-b655-46cc-a333-d0913921ba4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_41893827-2dfc-48f7-a7dd-ba1f710dda3e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f7a31738-b655-46cc-a333-d0913921ba4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="crdf-20221231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2996291-425b-4f2b-8307-372bd666ef23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_f2996291-425b-4f2b-8307-372bd666ef23" xlink:to="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:to="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_facf1024-6dfc-46c7-8edd-5d4af47b03c6" xlink:to="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ae33db6c-9fe4-4ae3-8e22-9ee8fe2bfa76" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ae33db6c-9fe4-4ae3-8e22-9ee8fe2bfa76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_b65d9ede-a893-44b7-a1c9-616b7d8db10f" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_6589a4c4-8185-46a0-bd4b-db022305390f" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_b65d9ede-a893-44b7-a1c9-616b7d8db10f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9465ade7-659f-435c-a715-fb1fc2a3071d" xlink:to="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_23d1e5a7-cabf-49e3-9d3f-002e206c911b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_NetIncomeLoss_23d1e5a7-cabf-49e3-9d3f-002e206c911b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_91eae102-6aba-493e-b5b6-c156cedd7723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_91eae102-6aba-493e-b5b6-c156cedd7723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a625e2-4868-40da-a6f6-3ef7268039e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_30a625e2-4868-40da-a6f6-3ef7268039e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9c2ad9d7-9000-4e2e-a7f9-73c6aa0cc5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_9c2ad9d7-9000-4e2e-a7f9-73c6aa0cc5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_bf03324a-a9e6-4c26-84e9-1cbbe7a8d596" xlink:href="crdf-20221231.xsd#crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_7d34871a-7e9d-45d0-ba43-f7b5f777d985" xlink:to="loc_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic_bf03324a-a9e6-4c26-84e9-1cbbe7a8d596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofStockholdersEquity" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4ee33207-9c4a-4885-8d68-6f88e4a192df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4ee33207-9c4a-4885-8d68-6f88e4a192df" xlink:to="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8650400c-eacf-4808-bee5-9e249201fd63" xlink:to="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_d453057b-4588-4104-9014-daf06632a396" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_PreferredStockMember_d453057b-4588-4104-9014-daf06632a396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_d732ed51-ead7-454d-9dcc-8554b4826461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_CommonStockMember_d732ed51-ead7-454d-9dcc-8554b4826461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_58837541-299b-4966-9d00-10bfb5f6f44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_58837541-299b-4966-9d00-10bfb5f6f44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ServiceReceivableMember_7e15e10d-f215-40e6-b503-3aadaad5d5be" xlink:href="crdf-20221231.xsd#crdf_ServiceReceivableMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_crdf_ServiceReceivableMember_7e15e10d-f215-40e6-b503-3aadaad5d5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40bc8140-6137-427f-9927-ea2adcedd073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_40bc8140-6137-427f-9927-ea2adcedd073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_f14b7b42-78f7-4a31-8af4-2fa0f3789ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2a07ea0d-a5d5-45dc-96ba-53868c584e0c" xlink:to="loc_us-gaap_RetainedEarningsMember_f14b7b42-78f7-4a31-8af4-2fa0f3789ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9b7bf3c3-7ff9-49b7-8f2c-d7363c0ea17c" xlink:to="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_33a41bd3-ce1b-497d-95de-c0af40ef1feb" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_33a41bd3-ce1b-497d-95de-c0af40ef1feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_14dc026d-7a2c-4eff-bede-4c7707b5bf4e" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1d2dbd66-a063-4017-b460-7fae25d318bf" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_14dc026d-7a2c-4eff-bede-4c7707b5bf4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5719a9d5-1163-4350-b1e9-7168405703f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4a4d89b0-b22f-4eaa-8833-24640cadf4f9" xlink:to="loc_us-gaap_StatementLineItems_5719a9d5-1163-4350-b1e9-7168405703f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5719a9d5-1163-4350-b1e9-7168405703f9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_03437dbf-8dae-4b9e-aa37-7389c75b8d82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SharesIssued_03437dbf-8dae-4b9e-aa37-7389c75b8d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_e20e3dd4-9022-4d05-96a3-b6630cd338dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockholdersEquity_e20e3dd4-9022-4d05-96a3-b6630cd338dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e2e0fd30-dcab-49a4-8271-ea84fd7a224d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e2e0fd30-dcab-49a4-8271-ea84fd7a224d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_b0173796-5306-4c07-bcbf-4dcd9d240d79" xlink:href="crdf-20221231.xsd#crdf_StockIssuedDuringPeriodSharesWarrantsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_StockIssuedDuringPeriodSharesWarrantsExercised_b0173796-5306-4c07-bcbf-4dcd9d240d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_223fbc87-80ca-48b1-a857-2e3e8c989ca4" xlink:href="crdf-20221231.xsd#crdf_StockIssuedDuringPeriodValueWarrantsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_StockIssuedDuringPeriodValueWarrantsExercised_223fbc87-80ca-48b1-a857-2e3e8c989ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68cc9b56-1edc-435e-bcef-42089ad9b721" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_68cc9b56-1edc-435e-bcef-42089ad9b721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_be09022e-e3f3-4c8a-928b-847f04ca8975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_be09022e-e3f3-4c8a-928b-847f04ca8975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_121712fe-a15f-4fd7-a80c-e9d3c6af69aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_121712fe-a15f-4fd7-a80c-e9d3c6af69aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40ab5df0-ab35-47a3-84d0-affc8910c884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_40ab5df0-ab35-47a3-84d0-affc8910c884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_c7515515-9026-47fe-9178-e11ca2562455" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_DividendsPreferredStock_c7515515-9026-47fe-9178-e11ca2562455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a0d45f7-87f5-4e6a-8bd7-6c988996dffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5a0d45f7-87f5-4e6a-8bd7-6c988996dffa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_14b0e5b3-df57-4e5e-a530-ae003b836627" xlink:href="crdf-20221231.xsd#crdf_ReleaseOfClinicalTrialFundingCommitment"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_ReleaseOfClinicalTrialFundingCommitment_14b0e5b3-df57-4e5e-a530-ae003b836627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockCumulativeDividendAdjustment_a3fab2c6-7886-4f33-be3b-f5076da87580" xlink:href="crdf-20221231.xsd#crdf_PreferredStockCumulativeDividendAdjustment"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_crdf_PreferredStockCumulativeDividendAdjustment_a3fab2c6-7886-4f33-be3b-f5076da87580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a3e2c762-357d-49f2-a949-5ddddec162b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_NetIncomeLoss_a3e2c762-357d-49f2-a949-5ddddec162b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_c11cbebd-b89e-4431-9206-6137b2830494" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_SharesIssued_c11cbebd-b89e-4431-9206-6137b2830494" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cc62d972-1b08-480a-a031-b7434b715a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_dd1c64f9-6d7c-4655-ab6c-9164f1a1a9a3" xlink:to="loc_us-gaap_StockholdersEquity_cc62d972-1b08-480a-a031-b7434b715a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementofShareholdersEquityParenthetical" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementofShareholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StatementofShareholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_159edbbe-bc8c-4a6c-b305-2592ddefc5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_321f15a2-f0c1-4780-af15-e7be1b4f859e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_159edbbe-bc8c-4a6c-b305-2592ddefc5fe" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_321f15a2-f0c1-4780-af15-e7be1b4f859e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlows" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_da1bcd61-9391-4571-a10d-45c2ea07f1f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_da1bcd61-9391-4571-a10d-45c2ea07f1f7" xlink:to="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:to="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16cc12bb-1b1f-4088-9bb8-4b67e987896c" xlink:to="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_e6550545-a3da-4837-9cf1-9822c9debc11" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_e6550545-a3da-4837-9cf1-9822c9debc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_6195298d-0c51-45b9-b292-62983e1a7382" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_4b3d8ad7-8376-4500-8715-861c45118542" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_6195298d-0c51-45b9-b292-62983e1a7382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_e1d28983-8f16-4708-a086-c7c02ac84161" xlink:to="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a371c96-95c0-47b1-8fdc-1e4b19650d52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:to="loc_us-gaap_NetIncomeLoss_6a371c96-95c0-47b1-8fdc-1e4b19650d52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_25fdfbe5-9e45-42dd-8893-7f60d80fa137" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_25fdfbe5-9e45-42dd-8893-7f60d80fa137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_92d8aa61-31a4-4329-a720-85edcfc851ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_92d8aa61-31a4-4329-a720-85edcfc851ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3660beca-9bdf-4dcf-b02f-74b181face97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_ShareBasedCompensation_3660beca-9bdf-4dcf-b02f-74b181face97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d350e212-130e-4094-9536-6ceecf07ab9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_d350e212-130e-4094-9536-6ceecf07ab9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_c7e42637-d82f-4dea-97fa-da145c2360dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_c7e42637-d82f-4dea-97fa-da145c2360dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_cbc08c7d-3f52-4782-8a8d-235465eba8fc" xlink:href="crdf-20221231.xsd#crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived_cbc08c7d-3f52-4782-8a8d-235465eba8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f6a64531-cca8-4d7a-992d-a350567821bb" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9bdb017d-42b0-4018-b7f5-3dcbd9681b18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_9bdb017d-42b0-4018-b7f5-3dcbd9681b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_db25a032-7b66-4809-b93f-f4b6d719ca20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_db25a032-7b66-4809-b93f-f4b6d719ca20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_515862f1-ed37-4626-8217-6c1912131e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidExpense_515862f1-ed37-4626-8217-6c1912131e0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_14fe497d-a146-43b5-889a-47733730904b" xlink:href="crdf-20221231.xsd#crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset_14fe497d-a146-43b5-889a-47733730904b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8605e595-be55-4fe6-93cf-257a12158761" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_8605e595-be55-4fe6-93cf-257a12158761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e75bba9e-d4f7-4a90-bb08-57713e0d1afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e75bba9e-d4f7-4a90-bb08-57713e0d1afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0f1484bb-7aba-4e7c-bd84-da321be0dbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f472dd5f-5ae9-4c03-b8d3-be7c5ec4d8f1" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0f1484bb-7aba-4e7c-bd84-da321be0dbbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f569dbc-b0c2-4445-a309-0a5b6590e67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_7cae25d5-8de6-4cd4-bc64-504423d3db07" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8f569dbc-b0c2-4445-a309-0a5b6590e67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c11cbea3-e0ae-4442-9d5a-5780f5cc5080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_c11cbea3-e0ae-4442-9d5a-5780f5cc5080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_39af9d74-d77b-4ce1-a87d-3f3d1c92ce4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromInsuranceSettlementInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities_39af9d74-d77b-4ce1-a87d-3f3d1c92ce4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b6be9a5f-4522-482c-9f9f-5a033b2a3316" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_b6be9a5f-4522-482c-9f9f-5a033b2a3316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c16ad2c5-aa2c-48f6-857c-af4f70a34f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_c16ad2c5-aa2c-48f6-857c-af4f70a34f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b990f040-76d0-4adc-a362-d5e2d41c8062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b990f040-76d0-4adc-a362-d5e2d41c8062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b65611d-b325-4095-ae93-e96648af6925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_dcf2ca06-f6de-411a-a84c-a56963165982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4b65611d-b325-4095-ae93-e96648af6925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c223a20b-459d-4017-aba8-7e92cbde905a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_c223a20b-459d-4017-aba8-7e92cbde905a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_e64a84cc-40e0-4bd4-9acb-86c6dd8e40ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_e64a84cc-40e0-4bd4-9acb-86c6dd8e40ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_c495945a-123c-45e7-88e1-822e2b704634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_c495945a-123c-45e7-88e1-822e2b704634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c0b10ba-c821-409b-8738-ed1e82db6063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_ee641eb0-0d68-45a7-b28e-8a532dd7fba6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c0b10ba-c821-409b-8738-ed1e82db6063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9366d553-aeba-4aa1-bb7e-2de6ce61af30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_9366d553-aeba-4aa1-bb7e-2de6ce61af30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ec9e997-e169-4a99-94a4-71ae83ca244b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5ec9e997-e169-4a99-94a4-71ae83ca244b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b13a693a-068e-4687-8766-bddc379bbc49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b13a693a-068e-4687-8766-bddc379bbc49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_43020f57-3cd6-4b47-93aa-6c18eab9526a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:to="loc_us-gaap_IncomeTaxesPaid_43020f57-3cd6-4b47-93aa-6c18eab9526a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_565ad045-0b81-4dc9-a715-3501a16f700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_3dbdd86a-91c6-49ea-97a0-8e94406b07f4" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_565ad045-0b81-4dc9-a715-3501a16f700e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_b809e913-ca2f-4c04-a025-f75bdac45805" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockDividendAccrued_2e9920e4-3b23-4bae-9ea3-8d53ed5de709" xlink:href="crdf-20221231.xsd#crdf_PreferredStockDividendAccrued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:to="loc_crdf_PreferredStockDividendAccrued_2e9920e4-3b23-4bae-9ea3-8d53ed5de709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_NonCashCumulativePreferredStockDividendAdjustment_3f88b652-4de2-45c9-93b4-5de991492b6f" xlink:href="crdf-20221231.xsd#crdf_NonCashCumulativePreferredStockDividendAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_6a3da3dd-66e0-4d42-9f30-148d9b2b32ba" xlink:to="loc_crdf_NonCashCumulativePreferredStockDividendAdjustment_3f88b652-4de2-45c9-93b4-5de991492b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical" xlink:type="simple" xlink:href="crdf-20221231.xsd#StatementsofCashFlowsParenthetical"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_6ac2cd2e-fdd9-4b76-b1b2-f722494477e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_6ac2cd2e-fdd9-4b76-b1b2-f722494477e2" xlink:to="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_800311ac-a7a6-4646-951f-a3da4104f343" xlink:to="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CommonStockAndWarrantsMember_718290ee-5b1a-45c1-a4ea-c5db5e41a03c" xlink:href="crdf-20221231.xsd#crdf_CommonStockAndWarrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:to="loc_crdf_CommonStockAndWarrantsMember_718290ee-5b1a-45c1-a4ea-c5db5e41a03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_ebda9b12-632c-4e72-b68f-d3511d7ef223" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_2dabbf06-9f73-490d-ad68-940a4d98f691" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_ebda9b12-632c-4e72-b68f-d3511d7ef223" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2ffd97e2-ae7f-4b90-b080-b6c062b8fffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f29df5dd-21e2-4ede-ba52-4ab46cde764c" xlink:to="loc_us-gaap_StatementLineItems_2ffd97e2-ae7f-4b90-b080-b6c062b8fffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_606a36fa-b796-473a-a793-a7710d928e4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2ffd97e2-ae7f-4b90-b080-b6c062b8fffb" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_606a36fa-b796-473a-a793-a7710d928e4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity" xlink:type="simple" xlink:href="crdf-20221231.xsd#BusinessOverviewandLiquidity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0be5e793-73cb-4258-a7c2-be56ab9409a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4dc3e670-3534-46fb-a3c3-fefa81781e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0be5e793-73cb-4258-a7c2-be56ab9409a0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_4dc3e670-3534-46fb-a3c3-fefa81781e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_341c0140-0082-4221-894d-feb928ea2bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_87177d22-7cf5-4653-8d66-9348e65d88fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_341c0140-0082-4221-894d-feb928ea2bb1" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_87177d22-7cf5-4653-8d66-9348e65d88fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d584d8c-be7f-4317-8038-b2c8a10beb8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_d5f0f3b7-a554-45ec-b0ec-e73397ac93ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2d584d8c-be7f-4317-8038-b2c8a10beb8d" xlink:to="loc_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_d5f0f3b7-a554-45ec-b0ec-e73397ac93ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/Leases" xlink:type="simple" xlink:href="crdf-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_71a0073a-841f-42de-9d7f-d5353156544d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_046aa864-42ff-44cb-bb57-8ef34b713a85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71a0073a-841f-42de-9d7f-d5353156544d" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_046aa864-42ff-44cb-bb57-8ef34b713a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_311553e0-4da3-45d2-85eb-6d84125838fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesOfLessorDisclosureTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_71a0073a-841f-42de-9d7f-d5353156544d" xlink:to="loc_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock_311553e0-4da3-45d2-85eb-6d84125838fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_00cc4ea4-1da0-4e20-83a3-278f6c3981eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_09a96d0c-0516-4e82-9b18-0fed4f7076dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_00cc4ea4-1da0-4e20-83a3-278f6c3981eb" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_09a96d0c-0516-4e82-9b18-0fed4f7076dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_61f32a42-3ff0-441a-9f44-b8ed52677cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_19fcd6a3-9288-4285-992b-653cb8ef00e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_61f32a42-3ff0-441a-9f44-b8ed52677cc7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_19fcd6a3-9288-4285-992b-653cb8ef00e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="simple" xlink:href="crdf-20221231.xsd#DerivativeFinancialInstrumentsWarrants"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_612f2b47-22fa-4dc1-98dc-57014052a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dc38601f-29a7-47f9-b992-98d86e274e6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_612f2b47-22fa-4dc1-98dc-57014052a78d" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dc38601f-29a7-47f9-b992-98d86e274e6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="crdf-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26bd0db5-28c7-42e5-af69-3e0844a7f7c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_c20a72c5-98ee-4898-a50f-a2ac812724c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26bd0db5-28c7-42e5-af69-3e0844a7f7c9" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_c20a72c5-98ee-4898-a50f-a2ac812724c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxes" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_85f83ca8-cb8a-4af6-b6bb-99570bc51433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_13c017eb-1a31-4b5c-a2ae-9dec85cd5ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_85f83ca8-cb8a-4af6-b6bb-99570bc51433" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_13c017eb-1a31-4b5c-a2ae-9dec85cd5ccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="crdf-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3b6b7ed-fa1b-491f-b186-d6a9a999e7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fada1079-a5e6-4c69-a5d7-302dd78dd017" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c3b6b7ed-fa1b-491f-b186-d6a9a999e7c2" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fada1079-a5e6-4c69-a5d7-302dd78dd017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/EmployeeBenefitPlan" xlink:type="simple" xlink:href="crdf-20221231.xsd#EmployeeBenefitPlan"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/EmployeeBenefitPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5c6ee5a6-0d12-471e-8c27-b055a5e8c3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76d48f77-0710-4ae1-b350-8764671c258d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5c6ee5a6-0d12-471e-8c27-b055a5e8c3b3" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_76d48f77-0710-4ae1-b350-8764671c258d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_125a70f1-f385-4feb-a06f-7f558d175397" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_125a70f1-f385-4feb-a06f-7f558d175397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_2692ae60-19eb-4325-be0d-473978ba3679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_UseOfEstimates_2692ae60-19eb-4325-be0d-473978ba3679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrialExpensesPolicyTextBlock_b8d4c2ce-05db-49c9-b8e5-47b598e837f3" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrialExpensesPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_crdf_AccruedClinicalTrialExpensesPolicyTextBlock_b8d4c2ce-05db-49c9-b8e5-47b598e837f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_513a6366-265e-4ea0-8fbd-8508373fcdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_513a6366-265e-4ea0-8fbd-8508373fcdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_8635b6dc-cd66-40e9-a100-56020d176e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_8635b6dc-cd66-40e9-a100-56020d176e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c97d3d53-6824-4feb-be5a-03d006088348" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_c97d3d53-6824-4feb-be5a-03d006088348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_ea38256b-3f3d-42d1-844c-d1cdccb2d934" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_ea38256b-3f3d-42d1-844c-d1cdccb2d934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f6070372-3b41-4a76-905e-708703dd1a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_f6070372-3b41-4a76-905e-708703dd1a43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_376bb4d4-5d01-4233-a44a-078c78021581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_376bb4d4-5d01-4233-a44a-078c78021581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1bb7d4fd-d573-48a4-874d-6b994e1a49f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_1bb7d4fd-d573-48a4-874d-6b994e1a49f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_dbadd26a-2acc-47dc-8719-dd69f0ea5aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock_dbadd26a-2acc-47dc-8719-dd69f0ea5aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_dd52874f-e01c-4f9e-9ab3-27c24c70ceca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_dd52874f-e01c-4f9e-9ab3-27c24c70ceca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_6fc4901b-7505-498e-93f3-d28a380d4aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_6fc4901b-7505-498e-93f3-d28a380d4aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_c17967c9-c8d6-43bb-85f5-c72faf3e3a81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_c17967c9-c8d6-43bb-85f5-c72faf3e3a81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f9aedce-ea35-4281-b310-631eacdf2a10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_3f9aedce-ea35-4281-b310-631eacdf2a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0a9061f5-162c-4262-b0cf-159b93a621d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0a9061f5-162c-4262-b0cf-159b93a621d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CorrectionPolicyPolicyTextBlock_0f57f6f5-787b-412c-a183-6623ac561ca7" xlink:href="crdf-20221231.xsd#crdf_CorrectionPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_crdf_CorrectionPolicyPolicyTextBlock_0f57f6f5-787b-412c-a183-6623ac561ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bbfa756b-36c1-4a5b-af4f-6bb079fb980a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_b6bc103d-1483-401a-8943-bca82736cad5" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_bbfa756b-36c1-4a5b-af4f-6bb079fb980a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6c6ec3d-d41e-494c-8d6d-f1733d483836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_69c0989a-d731-4a99-b6ee-6554ebfceea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6c6ec3d-d41e-494c-8d6d-f1733d483836" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_69c0989a-d731-4a99-b6ee-6554ebfceea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f27edb4-4edf-49c6-a2e4-04b6d375a438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6c6ec3d-d41e-494c-8d6d-f1733d483836" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_1f27edb4-4edf-49c6-a2e4-04b6d375a438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6669fac1-cf3d-4cd4-bb9b-55da992d7930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1306c247-3fc3-46da-8979-c4efb7bcaacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6669fac1-cf3d-4cd4-bb9b-55da992d7930" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_1306c247-3fc3-46da-8979-c4efb7bcaacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c687cd32-1068-4708-9dc8-4de214e79458" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6669fac1-cf3d-4cd4-bb9b-55da992d7930" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_c687cd32-1068-4708-9dc8-4de214e79458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6af78350-2e37-45fd-83ac-b350a6e0ad31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6669fac1-cf3d-4cd4-bb9b-55da992d7930" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6af78350-2e37-45fd-83ac-b350a6e0ad31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ce30d718-702c-42fb-8a7d-03d3bbdd5adb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6669fac1-cf3d-4cd4-bb9b-55da992d7930" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ce30d718-702c-42fb-8a7d-03d3bbdd5adb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6f3d7fda-847d-43a7-a5f8-cb8eebc82f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_56d5fb7a-dbe0-45cb-9f64-3c677f0b0570" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3d7fda-847d-43a7-a5f8-cb8eebc82f15" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_56d5fb7a-dbe0-45cb-9f64-3c677f0b0570" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_5cf6132c-7914-4cf5-a173-925a03c2c76a" xlink:href="crdf-20221231.xsd#crdf_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3d7fda-847d-43a7-a5f8-cb8eebc82f15" xlink:to="loc_crdf_AssetsAndLiabilitiesLesseeTableTextBlock_5cf6132c-7914-4cf5-a173-925a03c2c76a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e9184817-9bcd-41c0-a530-5fc532dfc559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6f3d7fda-847d-43a7-a5f8-cb8eebc82f15" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e9184817-9bcd-41c0-a530-5fc532dfc559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4471d87f-3e70-42c8-b642-48aaae25e5da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0b0778a0-ea8a-41bc-a49b-805479086b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4471d87f-3e70-42c8-b642-48aaae25e5da" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_0b0778a0-ea8a-41bc-a49b-805479086b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_505adb59-e0d8-413d-8884-316fcf9fee28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4471d87f-3e70-42c8-b642-48aaae25e5da" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_505adb59-e0d8-413d-8884-316fcf9fee28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54d49a20-40d9-430e-bd00-70258c48fd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_06da50c9-9353-494c-8014-f5c61562701a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54d49a20-40d9-430e-bd00-70258c48fd3b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_06da50c9-9353-494c-8014-f5c61562701a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d726e636-33df-44e5-b8c8-ed395ad30bd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54d49a20-40d9-430e-bd00-70258c48fd3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d726e636-33df-44e5-b8c8-ed395ad30bd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8255e331-9bc0-47a2-8fb8-7e923caaf950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_54d49a20-40d9-430e-bd00-70258c48fd3b" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_8255e331-9bc0-47a2-8fb8-7e923caaf950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#DerivativeFinancialInstrumentsWarrantsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6752d8ba-e8ac-4178-9b1b-a9fc6414b509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_6752d8ba-e8ac-4178-9b1b-a9fc6414b509" xlink:to="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:to="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_9875e812-6f5e-489e-ab72-ffd5b0617d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_97a499b6-b1a7-4525-9f01-79fe05a072e8" xlink:to="loc_us-gaap_ValuationTechniqueDomain_9875e812-6f5e-489e-ab72-ffd5b0617d30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_3f0f3810-7bb3-4002-a1c8-e8041369942c" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_9875e812-6f5e-489e-ab72-ffd5b0617d30" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_3f0f3810-7bb3-4002-a1c8-e8041369942c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e4a27eda-ab1d-42a3-9500-e871dd1d4e09" xlink:to="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0025cc02-0f1f-4b37-86ab-9d44a7aab7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_0025cc02-0f1f-4b37-86ab-9d44a7aab7b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_76e01546-197a-44af-b3e0-1ae5a99c47e6" xlink:href="crdf-20221231.xsd#crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_00d85680-7e02-4233-8e06-6c6ac2302e30" xlink:to="loc_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock_76e01546-197a-44af-b3e0-1ae5a99c47e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_257f1219-22e8-4904-92ed-851f6413d59d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1eb1b6dd-5f83-4e4a-8793-98ceee51b553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_257f1219-22e8-4904-92ed-851f6413d59d" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock_1eb1b6dd-5f83-4e4a-8793-98ceee51b553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5b3048e2-22e3-4eab-90c6-60e04782c52e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_56b5398f-38bc-4d9b-b461-ff2de2273ec3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b3048e2-22e3-4eab-90c6-60e04782c52e" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_56b5398f-38bc-4d9b-b461-ff2de2273ec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_aa54f87b-78e5-4f21-9058-22100f2fcf91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b3048e2-22e3-4eab-90c6-60e04782c52e" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_aa54f87b-78e5-4f21-9058-22100f2fcf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_471200cb-5e31-4def-b1b3-228bf74e84b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5b3048e2-22e3-4eab-90c6-60e04782c52e" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_471200cb-5e31-4def-b1b3-228bf74e84b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BusinessOverviewandLiquidityDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BusinessOverviewandLiquidityDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BusinessOverviewandLiquidityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0757049b-18af-4511-9e38-fee90ce41e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_54268ec8-5204-421f-8ec1-338500a3c24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0757049b-18af-4511-9e38-fee90ce41e30" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_54268ec8-5204-421f-8ec1-338500a3c24e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_82bbca6b-db04-4dff-9253-cfc82dbedb1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_886f37e0-cb91-4ad9-aa2f-216b5a9932ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82bbca6b-db04-4dff-9253-cfc82dbedb1d" xlink:to="loc_us-gaap_NumberOfOperatingSegments_886f37e0-cb91-4ad9-aa2f-216b5a9932ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrialExpenses_baa52f51-fb7a-4b4d-985f-ca986fb75abd" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrialExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82bbca6b-db04-4dff-9253-cfc82dbedb1d" xlink:to="loc_crdf_AccruedClinicalTrialExpenses_baa52f51-fb7a-4b4d-985f-ca986fb75abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_f7053287-b5dd-4356-a3fb-cf6c646ed104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82bbca6b-db04-4dff-9253-cfc82dbedb1d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_f7053287-b5dd-4356-a3fb-cf6c646ed104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_e48b78dc-885e-444a-b7d1-ceb5b9d578a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82bbca6b-db04-4dff-9253-cfc82dbedb1d" xlink:to="loc_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms_e48b78dc-885e-444a-b7d1-ceb5b9d578a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_82bbca6b-db04-4dff-9253-cfc82dbedb1d" xlink:to="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3ce3b8db-077d-4396-b324-16a469450f7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForErrorCorrectionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis_f449fbc5-98d8-46a7-b9b0-be1de2cc0957" xlink:to="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3ce3b8db-077d-4396-b324-16a469450f7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_942fda3e-4fc4-4911-a5f1-ec2f000dd80a" xlink:href="crdf-20221231.xsd#crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForErrorCorrectionDomain_3ce3b8db-077d-4396-b324-16a469450f7e" xlink:to="loc_crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember_942fda3e-4fc4-4911-a5f1-ec2f000dd80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable_f92ffb02-7420-445c-a851-5c7331710115" xlink:to="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2173cfe-d8cb-4621-a57b-44c2d06149d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_c2173cfe-d8cb-4621-a57b-44c2d06149d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_98ff5347-b588-438e-9f94-793c61159902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems_e82526e9-6912-42cd-8da7-cf29b717e782" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_98ff5347-b588-438e-9f94-793c61159902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6d77b2ea-3a56-4155-890a-29c072e56dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d77b2ea-3a56-4155-890a-29c072e56dd4" xlink:to="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3d95dd3f-6a8a-4f8f-b351-a57e1b8af950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_d5341ba0-8282-43ec-b583-b2871e18c750" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3d95dd3f-6a8a-4f8f-b351-a57e1b8af950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_4e9315cf-f1ba-477d-a782-37e153a95f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_3d95dd3f-6a8a-4f8f-b351-a57e1b8af950" xlink:to="loc_us-gaap_WarrantMember_4e9315cf-f1ba-477d-a782-37e153a95f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_802116a0-a4bc-4661-a1a8-b0a6fac6e497" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_66ecf197-aeaf-4d8d-ba3a-f960bd12262a" xlink:to="loc_us-gaap_ValuationTechniqueDomain_802116a0-a4bc-4661-a1a8-b0a6fac6e497" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_d38c33e2-0008-4501-b7e9-904c92492751" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_802116a0-a4bc-4661-a1a8-b0a6fac6e497" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_d38c33e2-0008-4501-b7e9-904c92492751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7df9df63-8c2e-42c2-ba83-916e228c4514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_e82df073-c5a0-4d64-9d91-3f01a289472c" xlink:to="loc_us-gaap_DerivativeLineItems_7df9df63-8c2e-42c2-ba83-916e228c4514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ec9cb00a-755c-45d6-8e79-0a8a100c87b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7df9df63-8c2e-42c2-ba83-916e228c4514" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ec9cb00a-755c-45d6-8e79-0a8a100c87b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_23fede47-492f-4fb0-b17a-11cc437cef03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_23fede47-492f-4fb0-b17a-11cc437cef03" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_56298e00-a23c-4ceb-a155-05513891ceb2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_575cecdf-1536-4204-a69e-27a92bbc9160" xlink:href="crdf-20221231.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_575cecdf-1536-4204-a69e-27a92bbc9160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_cc654a13-dab5-4e4a-9c6d-837410506a53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_cc654a13-dab5-4e4a-9c6d-837410506a53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_f412d261-98a4-44f0-9298-766fb115fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b623aa55-d72c-44bc-8215-0bed17a43c95" xlink:to="loc_us-gaap_EquipmentMember_f412d261-98a4-44f0-9298-766fb115fc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:to="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_879492e7-b6ea-40d7-91a2-0ca4469bf1a8" xlink:to="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_8859a70d-3f76-488e-9802-2534e0bebeec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:to="loc_srt_MinimumMember_8859a70d-3f76-488e-9802-2534e0bebeec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70e1c891-a956-4372-b565-5fbd9879fcd9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_db0a8964-1ace-4556-ac89-b2fd12a4de84" xlink:to="loc_srt_MaximumMember_70e1c891-a956-4372-b565-5fbd9879fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3621b5-7bb6-4591-b517-e16576c562cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_873ccc76-d392-4f0f-8176-788f2064983c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3621b5-7bb6-4591-b517-e16576c562cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50b33f1f-f1bc-4efb-a29f-3f687a077ad6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5d3621b5-7bb6-4591-b517-e16576c562cd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_50b33f1f-f1bc-4efb-a29f-3f687a077ad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_e6250749-a2b7-43dd-bcee-cc9901b13fab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_e6250749-a2b7-43dd-bcee-cc9901b13fab" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_cc008b1c-0783-4167-a04c-7eda0f8b90e2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0661658a-fd77-4498-9bd2-7dbe500345ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0661658a-fd77-4498-9bd2-7dbe500345ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_b16b5a20-f87a-4818-9d9a-04eaf4c10f7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_us-gaap_WarrantMember_b16b5a20-f87a-4818-9d9a-04eaf4c10f7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_977031bf-6502-4a81-8f4b-e98524fe2be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_977031bf-6502-4a81-8f4b-e98524fe2be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_d579bd1b-657c-4367-bbb4-34f22ee6bdb1" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_85d5b28e-086f-4e8f-a947-41bfe87e658c" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_d579bd1b-657c-4367-bbb4-34f22ee6bdb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8eed9c25-0e2b-4344-a112-c70414016100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a63e9e02-1cad-493f-8899-4b66ee7a6189" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8eed9c25-0e2b-4344-a112-c70414016100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e8034f7-6ea8-4054-9db3-f0f809e4fdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8eed9c25-0e2b-4344-a112-c70414016100" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9e8034f7-6ea8-4054-9db3-f0f809e4fdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ed71459-66b0-4f93-ac7f-de599f107ee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7ed71459-66b0-4f93-ac7f-de599f107ee0" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:to="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_6a642416-94e0-4a00-8857-8323eee31e3b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_0100ebbc-93bd-4f78-b640-d4fa0bfaf1bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_0100ebbc-93bd-4f78-b640-d4fa0bfaf1bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_fd471990-2389-4698-850a-125a93b06d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_fd471990-2389-4698-850a-125a93b06d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7297572b-fd34-47cf-a605-da372bd17de2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_CommercialPaperMember_7297572b-fd34-47cf-a605-da372bd17de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f8b53c7-480a-4ea4-85cf-886a7211f6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8f8b53c7-480a-4ea4-85cf-886a7211f6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a47304fb-f28f-4c4f-adca-7350adeddc75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_a47304fb-f28f-4c4f-adca-7350adeddc75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_4b156588-4735-48a1-814a-c46b8ee33ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e0da89e4-85b5-4e88-87ef-b718897a56c6" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_4b156588-4735-48a1-814a-c46b8ee33ee4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_c3a2d7e1-ea9d-46b2-82b1-51e040952913" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1524784f-fc3b-45a7-aa2d-c51b3688587e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_1524784f-fc3b-45a7-aa2d-c51b3688587e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_95cb5b20-a8ca-433b-964a-0f08b93acf24" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent_95cb5b20-a8ca-433b-964a-0f08b93acf24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8500140c-1b8b-43e2-af24-2bce2ef030f0" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent_8500140c-1b8b-43e2-af24-2bce2ef030f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af16c582-b9ee-411f-b8e4-56e68fe4b41f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesCurrentAbstract_aa06d104-2270-4d56-b900-c75d4bf28a51" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_af16c582-b9ee-411f-b8e4-56e68fe4b41f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_aa62176a-d904-40c3-b067-2908ebc9a9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent_aa62176a-d904-40c3-b067-2908ebc9a9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_01d07476-e792-497a-aedc-adefec6cf883" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent_01d07476-e792-497a-aedc-adefec6cf883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_4362e4b4-4b8b-48ec-94e6-fce262340df8" xlink:href="crdf-20221231.xsd#crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent_4362e4b4-4b8b-48ec-94e6-fce262340df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_76bd87a2-3d65-4e29-8b73-4838049683a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesNoncurrentAbstract_b7bd2c31-9047-48fe-858c-54d7bee31612" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_76bd87a2-3d65-4e29-8b73-4838049683a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11c36c2f-95a5-4fcb-b6d8-cb8a74be15d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_11c36c2f-95a5-4fcb-b6d8-cb8a74be15d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfee9e96-f1d9-4d36-8fac-0b5ba9f29ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_cfee9e96-f1d9-4d36-8fac-0b5ba9f29ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ca16451-2aff-43b0-9bd1-164f0ebfde23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_1ca16451-2aff-43b0-9bd1-164f0ebfde23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b0bf743-b6b1-4f12-9b0b-97a65080216f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8b0bf743-b6b1-4f12-9b0b-97a65080216f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a24db85-28a6-4b86-95c1-fcf691ca754b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_7a8cb17e-99a0-460d-a7af-3c0d27ac8a18" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_3a24db85-28a6-4b86-95c1-fcf691ca754b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9cec13a-d79e-4013-ac2d-3fc03018c492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9cec13a-d79e-4013-ac2d-3fc03018c492" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8c8f2601-5824-4d3b-bbbe-af96255084a6" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_04b39db4-621c-4a9d-87c1-6279d6325319" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_04b39db4-621c-4a9d-87c1-6279d6325319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_1daa252a-e748-42bc-8783-bd77fd473e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_85496bb6-1945-4ebf-82a8-4cb09b370446" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_1daa252a-e748-42bc-8783-bd77fd473e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_de40cc97-dc18-4be0-9c44-b54a130c13d7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12b49268-c1a8-4087-8033-0a7c50d252bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_12b49268-c1a8-4087-8033-0a7c50d252bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9d9dcab7-8493-4b69-8d34-22161c89bc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4033e011-c024-41d3-86b7-2eee31cbb896" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_9d9dcab7-8493-4b69-8d34-22161c89bc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ea551db-8fbe-40a8-b76d-096ee3d6500d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2ea551db-8fbe-40a8-b76d-096ee3d6500d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f6440390-e2e5-4430-a836-a787065bdf65" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_FurnitureAndOfficeEquipmentMember_df5cf7ae-fedd-4e6d-9152-b2d8ce1dc212" xlink:href="crdf-20221231.xsd#crdf_FurnitureAndOfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:to="loc_crdf_FurnitureAndOfficeEquipmentMember_df5cf7ae-fedd-4e6d-9152-b2d8ce1dc212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_6382df76-cc0c-446d-a341-f398460de1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_6382df76-cc0c-446d-a341-f398460de1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquipmentMember_76b63787-4f07-49c5-bd28-b7e2de7505d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9aab371a-4982-43f6-9e47-fe357cca9f06" xlink:to="loc_us-gaap_EquipmentMember_76b63787-4f07-49c5-bd28-b7e2de7505d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_e40221cc-915f-46fe-96f8-db7bd6dbb871" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d3d9440c-9d06-41c7-b3bb-c8ee48005651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_Depreciation_d3d9440c-9d06-41c7-b3bb-c8ee48005651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_acf2fccf-cdae-4408-a85c-a2861a96f107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_acf2fccf-cdae-4408-a85c-a2861a96f107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_177eb68c-b495-42b6-a7df-62ec3f29bd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_177eb68c-b495-42b6-a7df-62ec3f29bd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_e2bc7b17-7980-41c5-a72f-014949f8299f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_b3a03981-070d-4e77-a52f-f930e77545a7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_e2bc7b17-7980-41c5-a72f-014949f8299f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#SupplementaryBalanceSheetInformationAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_abd74b4a-4b98-4769-8067-5ac88467d3e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_abd74b4a-4b98-4769-8067-5ac88467d3e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedPreferredStockDividend_f6e71ae5-cb81-4ef8-b054-8379fb3e2200" xlink:href="crdf-20221231.xsd#crdf_AccruedPreferredStockDividend"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_crdf_AccruedPreferredStockDividend_f6e71ae5-cb81-4ef8-b054-8379fb3e2200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_AccruedClinicalTrial_9a27e863-df9c-4940-8095-7e28dfb097cc" xlink:href="crdf-20221231.xsd#crdf_AccruedClinicalTrial"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_crdf_AccruedClinicalTrial_9a27e863-df9c-4940-8095-7e28dfb097cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Accruedresearchagreements_a1a70bb3-613b-4d04-9dd1-6c50b41d9c8d" xlink:href="crdf-20221231.xsd#crdf_Accruedresearchagreements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_crdf_Accruedresearchagreements_a1a70bb3-613b-4d04-9dd1-6c50b41d9c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Accrueddirectorfees_8fbaa619-a5b6-44dd-bf9a-2cef3b7baf7f" xlink:href="crdf-20221231.xsd#crdf_Accrueddirectorfees"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_crdf_Accrueddirectorfees_8fbaa619-a5b6-44dd-bf9a-2cef3b7baf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_Patentlicenseandotherfeespayable_9c7536e2-a997-4138-ac2c-968916e1773c" xlink:href="crdf-20221231.xsd#crdf_Patentlicenseandotherfeespayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_crdf_Patentlicenseandotherfeespayable_9c7536e2-a997-4138-ac2c-968916e1773c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a9d311a-41f1-4e85-aecb-38dedc6cb909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_7a9d311a-41f1-4e85-aecb-38dedc6cb909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_176dd2b3-a720-48d6-85a0-70ec557867cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c36f8405-4ed2-404f-849b-31769f433a1f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_176dd2b3-a720-48d6-85a0-70ec557867cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_c84835aa-9a55-4d76-9da7-3856a5c76d73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_c84835aa-9a55-4d76-9da7-3856a5c76d73" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:to="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_0180f849-02ca-443f-9484-a081e847509c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d1f976ce-217c-4767-b5a6-6aa461204449" xlink:to="loc_srt_ScenarioUnspecifiedDomain_0180f849-02ca-443f-9484-a081e847509c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d90db22e-fe75-400b-8be5-d3c0815d2a36" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_0180f849-02ca-443f-9484-a081e847509c" xlink:to="loc_srt_ScenarioForecastMember_d90db22e-fe75-400b-8be5-d3c0815d2a36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_40f14937-d30a-4ef0-8595-831fe61af8f0" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_5a6011f1-ccef-4c1e-b827-829b81813207" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseMonthlyRentPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_crdf_LesseeOperatingLeaseMonthlyRentPayment_5a6011f1-ccef-4c1e-b827-829b81813207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_a6326ee4-472c-4096-aac2-617fdb26c2c8" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage_a6326ee4-472c-4096-aac2-617fdb26c2c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LessorNumberOfSubleases_fb8d0a8a-03b1-44d9-848b-a63c83fe3bc0" xlink:href="crdf-20221231.xsd#crdf_LessorNumberOfSubleases"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_fbba99e7-6007-40ec-ad4e-ba901dcebe77" xlink:to="loc_crdf_LessorNumberOfSubleases_fb8d0a8a-03b1-44d9-848b-a63c83fe3bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5a845761-fd8e-4e34-b731-93ec2974c519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_a2814034-791c-4ff0-a959-7314bce3087a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a845761-fd8e-4e34-b731-93ec2974c519" xlink:to="loc_us-gaap_OperatingLeaseCost_a2814034-791c-4ff0-a959-7314bce3087a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_c187a2e0-6a20-40df-a0d0-5e7f5760a703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a845761-fd8e-4e34-b731-93ec2974c519" xlink:to="loc_us-gaap_SubleaseIncome_c187a2e0-6a20-40df-a0d0-5e7f5760a703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_68466e54-8554-4570-8ebf-135ebd33a680" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5a845761-fd8e-4e34-b731-93ec2974c519" xlink:to="loc_us-gaap_LeaseCost_68466e54-8554-4570-8ebf-135ebd33a680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_6602f8e4-132a-4788-a658-0844c605c76b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_6602f8e4-132a-4788-a658-0844c605c76b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_1226d8f5-f21f-4a8e-80de-b415c2ca514a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_1226d8f5-f21f-4a8e-80de-b415c2ca514a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f5172637-bc3a-4c6d-9b81-c8ce99bae667" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f5172637-bc3a-4c6d-9b81-c8ce99bae667" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_0fdc61b3-4ac9-4cfc-92ba-d2224b9feca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:to="loc_us-gaap_OperatingLeaseLiability_0fdc61b3-4ac9-4cfc-92ba-d2224b9feca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_38034025-36c4-4208-8a39-b02fef251e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_38034025-36c4-4208-8a39-b02fef251e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_757afc8f-922c-4db2-9e4f-88a3d2206e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2964d8e4-a71e-42be-8e4b-ffcfe991a89d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_757afc8f-922c-4db2-9e4f-88a3d2206e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesSupplementalCashFlowInformationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a33fd989-8b39-404f-89b8-ec6ead152f70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_fb294048-c335-4352-839d-8405086aa802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a33fd989-8b39-404f-89b8-ec6ead152f70" xlink:to="loc_us-gaap_OperatingLeasePayments_fb294048-c335-4352-839d-8405086aa802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_76979980-cbc9-4f75-8954-4b7369417b41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a33fd989-8b39-404f-89b8-ec6ead152f70" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_76979980-cbc9-4f75-8954-4b7369417b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesFutureMinimumLeasePaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b78cb226-f9b6-433d-9795-3d1b6b94299a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b78cb226-f9b6-433d-9795-3d1b6b94299a" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74937ecd-4f01-411e-b5aa-34220d261182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74937ecd-4f01-411e-b5aa-34220d261182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5314733d-9e80-44bd-a270-b6a318780424" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_5314733d-9e80-44bd-a270-b6a318780424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5fe2f9a5-d4c1-4042-b3c2-ff2fb20176dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_5fe2f9a5-d4c1-4042-b3c2-ff2fb20176dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d45afba1-a068-471a-87ee-de429b14e5db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d45afba1-a068-471a-87ee-de429b14e5db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b6536bac-fcc8-4b4f-9470-f42ccf950a2a" xlink:href="crdf-20221231.xsd#crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b6536bac-fcc8-4b4f-9470-f42ccf950a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8afb31bb-7c4e-46dc-ba4b-69393277dcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_8afb31bb-7c4e-46dc-ba4b-69393277dcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38ce1b94-abb7-4eef-90c8-0130984611df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_38ce1b94-abb7-4eef-90c8-0130984611df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_74f045f6-f084-4547-bb27-da2061a6a0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_a7734709-99a1-4d7d-b77d-9d90685ce9bc" xlink:to="loc_us-gaap_OperatingLeaseLiability_74f045f6-f084-4547-bb27-da2061a6a0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="simple" xlink:href="crdf-20221231.xsd#LeasesFutureMinimumLeasePaymentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquityScheduleofWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e32999ca-f30d-45a2-b41e-8458e69b17fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsAndRightsRollForward_c0aab0f3-2246-4072-89ec-e9bf949df2c5" xlink:href="crdf-20221231.xsd#crdf_WarrantsAndRightsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e32999ca-f30d-45a2-b41e-8458e69b17fa" xlink:to="loc_crdf_WarrantsAndRightsRollForward_c0aab0f3-2246-4072-89ec-e9bf949df2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8f4b5e4f-6843-496a-b2eb-ee1ba34c6b35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_c0aab0f3-2246-4072-89ec-e9bf949df2c5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_8f4b5e4f-6843-496a-b2eb-ee1ba34c6b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExercised_84af3a01-9f6d-487c-a457-4eaec9f918e8" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightNumberExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_c0aab0f3-2246-4072-89ec-e9bf949df2c5" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExercised_84af3a01-9f6d-487c-a457-4eaec9f918e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightNumberExpired_53d73842-d5a9-45f9-929b-a24d363b61ab" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightNumberExpired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_c0aab0f3-2246-4072-89ec-e9bf949df2c5" xlink:to="loc_crdf_ClassOfWarrantOrRightNumberExpired_53d73842-d5a9-45f9-929b-a24d363b61ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_44c31ca6-30ba-45e9-b756-fddf7c17ac9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_WarrantsAndRightsRollForward_c0aab0f3-2246-4072-89ec-e9bf949df2c5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_44c31ca6-30ba-45e9-b756-fddf7c17ac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_77f2f27c-af2b-4720-ac8d-9391b06d8089" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e32999ca-f30d-45a2-b41e-8458e69b17fa" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_77f2f27c-af2b-4720-ac8d-9391b06d8089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_ac7308b4-9819-4467-8341-fd13fe74d00d" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_77f2f27c-af2b-4720-ac8d-9391b06d8089" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_ac7308b4-9819-4467-8341-fd13fe74d00d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_07a9bb3a-306e-419d-973d-25bfe2838674" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_77f2f27c-af2b-4720-ac8d-9391b06d8089" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised_07a9bb3a-306e-419d-973d-25bfe2838674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired_7bd0f6c0-2d8a-4fb5-9c95-c3d3972f438b" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_77f2f27c-af2b-4720-ac8d-9391b06d8089" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired_7bd0f6c0-2d8a-4fb5-9c95-c3d3972f438b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_96df66c1-a445-4e80-aaa3-3c30a035daa0" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract_77f2f27c-af2b-4720-ac8d-9391b06d8089" xlink:to="loc_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights_96df66c1-a445-4e80-aaa3-3c30a035daa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_35e01d60-4af7-4454-bb4b-6ee4538506db" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e32999ca-f30d-45a2-b41e-8458e69b17fa" xlink:to="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_35e01d60-4af7-4454-bb4b-6ee4538506db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_WarrantsWeightedAverageContractualTerm_25520dc6-2cfe-449e-a9ef-5c780167535e" xlink:href="crdf-20221231.xsd#crdf_WarrantsWeightedAverageContractualTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract_35e01d60-4af7-4454-bb4b-6ee4538506db" xlink:to="loc_crdf_WarrantsWeightedAverageContractualTerm_25520dc6-2cfe-449e-a9ef-5c780167535e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySummaryofPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_39cf9f86-714f-44c2-abcc-a8b177b68cc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_39cf9f86-714f-44c2-abcc-a8b177b68cc1" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_ea0777c4-0e27-4046-8104-fdc508251f16" xlink:to="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_44d85dd0-aad7-44e1-a1bf-969df6eba8bc" xlink:href="crdf-20221231.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_44d85dd0-aad7-44e1-a1bf-969df6eba8bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesBConvertiblePreferredStockMember_2d146a40-fb83-4074-abd8-aba9ba676140" xlink:href="crdf-20221231.xsd#crdf_SeriesBConvertiblePreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesBConvertiblePreferredStockMember_2d146a40-fb83-4074-abd8-aba9ba676140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesCConvertiblePreferredStockMember_af30b3bf-2a44-4d17-858b-ce12e84ebe77" xlink:href="crdf-20221231.xsd#crdf_SeriesCConvertiblePreferredStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesCConvertiblePreferredStockMember_af30b3bf-2a44-4d17-858b-ce12e84ebe77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesDConvertiblePreferredStockMember_d75d8194-6289-4b2a-b45f-1ad276fcd23a" xlink:href="crdf-20221231.xsd#crdf_SeriesDConvertiblePreferredStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesDConvertiblePreferredStockMember_d75d8194-6289-4b2a-b45f-1ad276fcd23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_10817bc5-2a21-4a67-ae30-f14a2e80ea43" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_a642d76a-4ad0-4ba3-924f-2d075b541527" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_10817bc5-2a21-4a67-ae30-f14a2e80ea43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_9b553e4e-85fe-4470-b8af-70c16dd30fd9" xlink:to="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e77a33c9-209e-4ea0-afd5-5ea8b2112cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_e77a33c9-209e-4ea0-afd5-5ea8b2112cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_a7c10d50-8fc6-48a2-9d33-d70cf7ca28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_a7c10d50-8fc6-48a2-9d33-d70cf7ca28ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_e9d9241a-a7b3-46cf-bcbc-ea4e4b01c2b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_e9d9241a-a7b3-46cf-bcbc-ea4e4b01c2b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceStatedValue_b7d6510b-1123-476e-81c9-19bdf09b025a" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceStatedValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceStatedValue_b7d6510b-1123-476e-81c9-19bdf09b025a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_bb676ae5-4bda-4b59-bfe8-ce1f62cd76bb" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_bb676ae5-4bda-4b59-bfe8-ce1f62cd76bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_61f98c36-d327-455b-91ec-44ff8bc53094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_60bc5a32-9401-46f6-aa77-d0569ad60de7" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_61f98c36-d327-455b-91ec-44ff8bc53094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySeriesAConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0e54f497-b96e-49f8-985f-eb2bbdb472e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0e54f497-b96e-49f8-985f-eb2bbdb472e5" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:to="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_27e2f3dc-ac63-4f35-a567-6a8ca949eba2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_191497fa-81bc-460b-98cf-5a76b5cd4032" xlink:to="loc_us-gaap_ClassOfStockDomain_27e2f3dc-ac63-4f35-a567-6a8ca949eba2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesAConvertiblePreferredStockMember_160da444-c002-4abe-a2ee-8e2bbb08b2a0" xlink:href="crdf-20221231.xsd#crdf_SeriesAConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_27e2f3dc-ac63-4f35-a567-6a8ca949eba2" xlink:to="loc_crdf_SeriesAConvertiblePreferredStockMember_160da444-c002-4abe-a2ee-8e2bbb08b2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4eae0c0b-650d-438e-8f45-38d6167d4ee8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1a2fb1a3-9ad8-40e3-b106-66c6e3814fe5" xlink:to="loc_us-gaap_EquityComponentDomain_4eae0c0b-650d-438e-8f45-38d6167d4ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_524bb7b9-ba4f-463a-8726-a3ba94382b5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4eae0c0b-650d-438e-8f45-38d6167d4ee8" xlink:to="loc_us-gaap_RetainedEarningsMember_524bb7b9-ba4f-463a-8726-a3ba94382b5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_abfccc1d-5168-427b-b02a-44a907857256" xlink:to="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_95b54cda-84ac-46f9-8e9c-28d326ba58a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_95b54cda-84ac-46f9-8e9c-28d326ba58a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_d406806b-c493-4184-859c-0768a945e8d6" xlink:href="crdf-20221231.xsd#crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue_d406806b-c493-4184-859c-0768a945e8d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPreferredStock_701bf4ba-16a1-4b9c-a6ef-b72ae52c00d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPreferredStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_us-gaap_DividendsPreferredStock_701bf4ba-16a1-4b9c-a6ef-b72ae52c00d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_70d03ce3-0c9b-4a0d-af85-1138693dfff7" xlink:href="crdf-20221231.xsd#crdf_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_70d03ce3-0c9b-4a0d-af85-1138693dfff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionPricePerShare_c20ddaae-533a-4e00-98ae-b18914118866" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionPricePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionPricePerShare_c20ddaae-533a-4e00-98ae-b18914118866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_dfd04736-08e3-455c-a43c-f75335da3757" xlink:href="crdf-20221231.xsd#crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments_dfd04736-08e3-455c-a43c-f75335da3757" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SharePriceForAutomaticConversion_57f140e6-5cc7-4343-a3fa-191434fa64d5" xlink:href="crdf-20221231.xsd#crdf_SharePriceForAutomaticConversion"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_SharePriceForAutomaticConversion_57f140e6-5cc7-4343-a3fa-191434fa64d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_793ab418-efe3-468d-8856-2a23371e79f5" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_793ab418-efe3-468d-8856-2a23371e79f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_ec28cdf7-39d2-483e-abb5-53b6a8393582" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays_ec28cdf7-39d2-483e-abb5-53b6a8393582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_PreferredStockConversionObligationNumberOfTradingDays_d9c8e432-fe49-4f62-b30c-a8f994a44696" xlink:href="crdf-20221231.xsd#crdf_PreferredStockConversionObligationNumberOfTradingDays"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71ae3c53-fc4f-4172-aaf7-377a54de8107" xlink:to="loc_crdf_PreferredStockConversionObligationNumberOfTradingDays_d9c8e432-fe49-4f62-b30c-a8f994a44696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySeriesEConvertiblePreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b251b3ea-16ad-4df1-90dc-ecb9ce9d7a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b251b3ea-16ad-4df1-90dc-ecb9ce9d7a0e" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_75e495ac-88f5-4281-a062-d0ef0475f8ce" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_RegisteredDirectOfferingMember_c6a4e99e-4feb-4ac3-a936-112e8fc08dbc" xlink:href="crdf-20221231.xsd#crdf_RegisteredDirectOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:to="loc_crdf_RegisteredDirectOfferingMember_c6a4e99e-4feb-4ac3-a936-112e8fc08dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_dc0d17f8-c9fc-422b-ad3e-9be31569a4b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_51f88072-6735-4be4-9325-1c344a81f1f1" xlink:to="loc_us-gaap_PrivatePlacementMember_dc0d17f8-c9fc-422b-ad3e-9be31569a4b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_11f6a5e0-3759-4b35-b174-aae3101c3850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_aa4d8722-86b1-42d5-b614-072ce15b88de" xlink:to="loc_us-gaap_ClassOfStockDomain_11f6a5e0-3759-4b35-b174-aae3101c3850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesEConvertiblePreferredStockMember_4d03f336-cfc5-4882-9fce-500d265b5294" xlink:href="crdf-20221231.xsd#crdf_SeriesEConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_11f6a5e0-3759-4b35-b174-aae3101c3850" xlink:to="loc_crdf_SeriesEConvertiblePreferredStockMember_4d03f336-cfc5-4882-9fce-500d265b5294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_f9339233-f85d-4dce-b561-2dac99fbb8ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_cc8014ce-9d6e-4a59-8a54-98d603ae8e62" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_f9339233-f85d-4dce-b561-2dac99fbb8ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SeriesNWarrantMember_788e4d98-03de-4000-be3c-1110a90c3f24" xlink:href="crdf-20221231.xsd#crdf_SeriesNWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_f9339233-f85d-4dce-b561-2dac99fbb8ee" xlink:to="loc_crdf_SeriesNWarrantMember_788e4d98-03de-4000-be3c-1110a90c3f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2cf70cbb-bfa5-497f-a485-cba9ef6b880c" xlink:to="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73c57744-f39c-4e9e-8300-313784d23e01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_73c57744-f39c-4e9e-8300-313784d23e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ee274c2e-1762-416b-bd17-bfb9456cd0a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_ee274c2e-1762-416b-bd17-bfb9456cd0a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_8e7f6698-18d4-4c11-8007-0f421f0aa8a4" xlink:href="crdf-20221231.xsd#crdf_ConvertiblePreferredStockStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ConvertiblePreferredStockStatedValuePerShare_8e7f6698-18d4-4c11-8007-0f421f0aa8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_e4940c29-e953-4dcb-8865-3055ecc20514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockConvertibleConversionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_e4940c29-e953-4dcb-8865-3055ecc20514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_87ca9f5f-66b0-4ec6-b968-d1bab79b8231" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightMonthsUntilExercisable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ClassOfWarrantOrRightMonthsUntilExercisable_87ca9f5f-66b0-4ec6-b968-d1bab79b8231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bd16f15-7b22-4e3b-a99f-177f7c2c239c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_7bd16f15-7b22-4e3b-a99f-177f7c2c239c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_41575edf-d376-4b48-828c-282e321355d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesConverted1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_41575edf-d376-4b48-828c-282e321355d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_26b9eaa8-be21-47c7-b639-35fcff15ac5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_26b9eaa8-be21-47c7-b639-35fcff15ac5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_48d3bbbe-2490-4516-a6a5-258a36f23ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConversionOfStockSharesIssued1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_48d3bbbe-2490-4516-a6a5-258a36f23ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_51cac829-817a-4e97-9072-2bfcaf80b34c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_51cac829-817a-4e97-9072-2bfcaf80b34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightIssued_c7742caa-6c7a-4a4f-bcaa-fce8fbff1971" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightIssued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ClassOfWarrantOrRightIssued_c7742caa-6c7a-4a4f-bcaa-fce8fbff1971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ClassOfWarrantOrRightExpirationTerm_85a5cfd1-2360-49fa-badf-8b9226f2cb09" xlink:href="crdf-20221231.xsd#crdf_ClassOfWarrantOrRightExpirationTerm"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_75ce8f8a-925d-465a-9e70-4453466fcce7" xlink:to="loc_crdf_ClassOfWarrantOrRightExpirationTerm_85a5cfd1-2360-49fa-badf-8b9226f2cb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockholdersEquitySecuritiesPurchaseAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ab36d812-88ed-4f9a-8be9-03f485d21d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a1f6a571-55a1-44b4-aa0b-e3a39b3f1811" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab36d812-88ed-4f9a-8be9-03f485d21d29" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a1f6a571-55a1-44b4-aa0b-e3a39b3f1811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f29ba13e-7edf-4b64-9792-b31eb9eb0313" xlink:href="crdf-20221231.xsd#crdf_SaleOfStockConsiderationReceivedOnTransactionGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab36d812-88ed-4f9a-8be9-03f485d21d29" xlink:to="loc_crdf_SaleOfStockConsiderationReceivedOnTransactionGross_f29ba13e-7edf-4b64-9792-b31eb9eb0313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares_7efb5cb6-3832-4160-87b8-ec4f6f45d1b5" xlink:href="crdf-20221231.xsd#crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ab36d812-88ed-4f9a-8be9-03f485d21d29" xlink:to="loc_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares_7efb5cb6-3832-4160-87b8-ec4f6f45d1b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58785e61-4ff3-48a7-aa1b-18da1a8eae0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_58785e61-4ff3-48a7-aa1b-18da1a8eae0e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:to="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_38151987-f67e-4009-a48d-1b0e57a8900a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7427a28e-5432-47ea-87c5-9c2b3113b21b" xlink:to="loc_us-gaap_PlanNameDomain_38151987-f67e-4009-a48d-1b0e57a8900a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EquityIncentivePlan2014Member_e7c191dc-80f9-4b14-8b4d-31f7c9c57a87" xlink:href="crdf-20221231.xsd#crdf_EquityIncentivePlan2014Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_38151987-f67e-4009-a48d-1b0e57a8900a" xlink:to="loc_crdf_EquityIncentivePlan2014Member_e7c191dc-80f9-4b14-8b4d-31f7c9c57a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:to="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_21a1b6fb-44c6-4c78-a514-20fbb691c8d8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_InducementGrantStockOptionsMember_940f6ca0-3146-4263-a852-dca6dc2cd489" xlink:href="crdf-20221231.xsd#crdf_InducementGrantStockOptionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:to="loc_crdf_InducementGrantStockOptionsMember_940f6ca0-3146-4263-a852-dca6dc2cd489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_39818d08-7626-4553-81a6-80e3393bbef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72eb4030-e224-42ff-a55b-fc62ba8d0870" xlink:to="loc_us-gaap_EmployeeStockOptionMember_39818d08-7626-4553-81a6-80e3393bbef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_efb4f889-05b6-4450-aca4-66bbe11a2d3b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9181f4b2-ce4a-467b-95b7-e49f677205f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_9181f4b2-ce4a-467b-95b7-e49f677205f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58fee3cb-24f6-4c85-8496-2986de6b6231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_58fee3cb-24f6-4c85-8496-2986de6b6231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96bf3442-3edb-4eaa-8dfd-a6893d4a76c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_96bf3442-3edb-4eaa-8dfd-a6893d4a76c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_a4372e24-b27d-4509-a35b-83c94cdc39d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_a4372e24-b27d-4509-a35b-83c94cdc39d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cedced38-d9ed-4db3-b4a1-7a0fe3c0cd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_cedced38-d9ed-4db3-b4a1-7a0fe3c0cd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c99ca45-7be6-4f65-9845-c6f2c659add2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_1c99ca45-7be6-4f65-9845-c6f2c659add2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9cc6dd93-5179-4800-84b4-8216ad13ae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_9cc6dd93-5179-4800-84b4-8216ad13ae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7d549303-4975-4902-9f11-b1e33a9817e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_7d549303-4975-4902-9f11-b1e33a9817e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_18c0f582-9a2d-4e40-8a0d-c457271c30a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2cd1b76d-1ecb-4401-962b-8632dc68598a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_18c0f582-9a2d-4e40-8a0d-c457271c30a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationStockBasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_302797ed-7ff1-4351-9052-bcc65f25ba90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_302797ed-7ff1-4351-9052-bcc65f25ba90" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_76ba760b-da8a-4173-b4a7-a1e0d3ca972f" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ff823ea-973b-4e55-aa22-b6c97f01633b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7ff823ea-973b-4e55-aa22-b6c97f01633b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6b78a86-14d6-4428-ab68-3d434dee59f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_22679b88-7741-4f71-8504-f69e1e003335" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f6b78a86-14d6-4428-ab68-3d434dee59f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87c81bd-1aae-482a-9102-5b311c07b7b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_43fdeb90-ffe2-467f-817f-f7dbc0c0ae48" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87c81bd-1aae-482a-9102-5b311c07b7b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_8675deae-920d-4e90-808a-91c5f00666c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a87c81bd-1aae-482a-9102-5b311c07b7b1" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_8675deae-920d-4e90-808a-91c5f00666c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0ad0575-139e-4205-8297-2590b4c30647" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d0ad0575-139e-4205-8297-2590b4c30647" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:to="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b5d94734-1201-4ae5-ba98-9fec0f4d4939" xlink:to="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a349363f-9ce7-4abb-b19d-7881545ecbdd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:to="loc_srt_MinimumMember_a349363f-9ce7-4abb-b19d-7881545ecbdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_73bd82c6-3aee-454a-bace-f9bbd99c1b4a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_79193a71-a1ea-4c68-943d-5baa873808c5" xlink:to="loc_srt_MaximumMember_73bd82c6-3aee-454a-bace-f9bbd99c1b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:to="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b337fdb4-2502-498c-91cc-d4a2f05b1f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_750df88b-8811-46c6-abe5-3e4056e381b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b337fdb4-2502-498c-91cc-d4a2f05b1f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_d4fbbed5-3ff1-4ef0-928a-66b9c9ae4983" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_b337fdb4-2502-498c-91cc-d4a2f05b1f06" xlink:to="loc_us-gaap_EmployeeStockOptionMember_d4fbbed5-3ff1-4ef0-928a-66b9c9ae4983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_5cf07420-e85a-4b71-bc99-7037f515c79f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07208df0-36d9-418a-a1eb-2c344e9561d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_07208df0-36d9-418a-a1eb-2c344e9561d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6a3f8182-5a5d-42c8-a3d2-f3cc83dcd6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6a3f8182-5a5d-42c8-a3d2-f3cc83dcd6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5443662a-3883-485b-8958-85e48f4765c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_5443662a-3883-485b-8958-85e48f4765c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0342fe0-1e30-48af-9748-009240ceac0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_a0342fe0-1e30-48af-9748-009240ceac0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_778e015f-28c5-4446-a20a-9520abac74b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_8d664127-e1b3-40c2-a333-9b03d1cf0d55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_778e015f-28c5-4446-a20a-9520abac74b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#StockBasedCompensationSummaryofStockOptionsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3dd07f1e-53da-4403-99a0-9bf5a1626b24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3dd07f1e-53da-4403-99a0-9bf5a1626b24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:to="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3e87b0e-9f43-4843-8225-77e2571a0f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_c2b90cb2-8cd2-405a-abb4-26e741318389" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3e87b0e-9f43-4843-8225-77e2571a0f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_28b2b6d9-1ece-4643-9ac4-85978c3c9076" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d3e87b0e-9f43-4843-8225-77e2571a0f8e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_28b2b6d9-1ece-4643-9ac4-85978c3c9076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_e192bbc3-f926-4ef7-b6aa-cc5ea915a10a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f34163ad-3232-43b1-adc4-4231db7a9d7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_f34163ad-3232-43b1-adc4-4231db7a9d7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_00f0837a-c10b-4ed8-ad00-b9672a70d651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_00f0837a-c10b-4ed8-ad00-b9672a70d651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a4af169-f920-43e4-8ec8-82194ed74d59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8a4af169-f920-43e4-8ec8-82194ed74d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cfcfa06e-82d1-44aa-966a-0b51c1c48dac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cfcfa06e-82d1-44aa-966a-0b51c1c48dac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_514b322c-32a2-4cdd-a3dc-b5f242dd545e" xlink:href="crdf-20221231.xsd#crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod_514b322c-32a2-4cdd-a3dc-b5f242dd545e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1cdef795-bab5-4969-8434-71472001f921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_92f73e73-4c7d-4960-94e0-9519c87a93a4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_1cdef795-bab5-4969-8434-71472001f921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d9f45513-e9e5-40aa-be7b-504b5de3d88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_d9f45513-e9e5-40aa-be7b-504b5de3d88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1892136-bcdc-4f09-8a06-2f15e353a5d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_f1892136-bcdc-4f09-8a06-2f15e353a5d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e93d8e6-98cf-4547-869f-b8cca1820ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_8e93d8e6-98cf-4547-869f-b8cca1820ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_481bbb40-50b6-43e5-9b6d-3a1f5b18cb0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_481bbb40-50b6-43e5-9b6d-3a1f5b18cb0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47825c28-b9b8-426c-80c5-3af86fb2902a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_47825c28-b9b8-426c-80c5-3af86fb2902a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9ed3db7-7245-42ca-a724-d2a7e54ee819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_d9ed3db7-7245-42ca-a724-d2a7e54ee819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_180d4956-4c7e-4dab-b245-24e42cac0bb8" xlink:href="crdf-20221231.xsd#crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice_180d4956-4c7e-4dab-b245-24e42cac0bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_201b9e09-b4ce-405b-8faf-83179258d262" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_0a07a794-05d0-4561-b2ea-e9282ec9790b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_201b9e09-b4ce-405b-8faf-83179258d262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e528867e-3d80-49a9-900e-7fe0429b29e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_e528867e-3d80-49a9-900e-7fe0429b29e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d6a409f9-f6a9-4955-9f3e-a3e8aac43b91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_d6a409f9-f6a9-4955-9f3e-a3e8aac43b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3cafbfdd-9ab8-4783-a318-a86a776343ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3cafbfdd-9ab8-4783-a318-a86a776343ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_232e05ea-e38e-4898-8adf-3f4ca833ca7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_232e05ea-e38e-4898-8adf-3f4ca833ca7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_343d16bf-5048-4a48-b251-f316292c07aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_343d16bf-5048-4a48-b251-f316292c07aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5bb88ab5-d11e-4e13-98fd-57bdbfc7ceec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_5bb88ab5-d11e-4e13-98fd-57bdbfc7ceec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74d2db21-89a7-4276-9208-1711d9a617fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_74d2db21-89a7-4276-9208-1711d9a617fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90915f9b-053c-4979-99d9-97e96d87cf2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_90915f9b-053c-4979-99d9-97e96d87cf2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_cc355660-15e3-413a-a51a-0af8539ab8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_276084cc-317d-455b-aadb-a8252c862d3a" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_cc355660-15e3-413a-a51a-0af8539ab8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#DerivativeFinancialInstrumentsWarrantsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f40b3aeb-ea9f-4e2d-94a0-16bc05c9901a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f40b3aeb-ea9f-4e2d-94a0-16bc05c9901a" xlink:to="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_807c6529-0b83-43ea-84ce-624b711710eb" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_007ed8f9-f248-4b06-8bce-d7b9ff3e229f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_007ed8f9-f248-4b06-8bce-d7b9ff3e229f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_5a4a3a89-fcd7-46cf-ad4d-06bdec2ecfd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_5a4a3a89-fcd7-46cf-ad4d-06bdec2ecfd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_37b0b3aa-d9e3-47a0-8842-6c6167572f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_37b0b3aa-d9e3-47a0-8842-6c6167572f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f25d8fe-8b5f-498e-8b5e-859b21a2f66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_332e2cb2-32ff-4041-892a-ccbe4f8ba925" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_0f25d8fe-8b5f-498e-8b5e-859b21a2f66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e1efc1bc-f751-484e-af8c-c8f4bc0e1eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_8c7c8475-1fa0-4825-9d1c-ac57d407f89b" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e1efc1bc-f751-484e-af8c-c8f4bc0e1eb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantMember_c3b3f9d0-42af-4146-95c5-6c5bdf033a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_e1efc1bc-f751-484e-af8c-c8f4bc0e1eb3" xlink:to="loc_us-gaap_WarrantMember_c3b3f9d0-42af-4146-95c5-6c5bdf033a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_68be1951-9ce3-453d-8887-fdbb2a46984d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_3e418216-b05f-4efb-a7a3-d1824076fa35" xlink:to="loc_us-gaap_ValuationTechniqueDomain_68be1951-9ce3-453d-8887-fdbb2a46984d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_BlackScholesOptionPricingMethodMember_dad67ffa-a7f7-4679-bcef-1287a87b790c" xlink:href="crdf-20221231.xsd#crdf_BlackScholesOptionPricingMethodMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_68be1951-9ce3-453d-8887-fdbb2a46984d" xlink:to="loc_crdf_BlackScholesOptionPricingMethodMember_dad67ffa-a7f7-4679-bcef-1287a87b790c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_14b661a4-84fc-4f5a-be37-4373cfb0655e" xlink:to="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsQuantitativeInformationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:to="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EstimatedFairValueOfWarrant_552ebc6d-8b89-477e-b3fc-10d2b3a1fe07" xlink:href="crdf-20221231.xsd#crdf_EstimatedFairValueOfWarrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:to="loc_crdf_EstimatedFairValueOfWarrant_552ebc6d-8b89-477e-b3fc-10d2b3a1fe07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2f6fe181-db29-4c55-a27f-a5eed00dee0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingTerm_2f6fe181-db29-4c55-a27f-a5eed00dee0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_85f9c95c-cc8e-4d4e-884d-b9a7ae1836e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueInputsQuantitativeInformationAbstract_3f7a3b3a-b765-4981-b530-b5718d2e8a87" xlink:to="loc_us-gaap_WarrantsAndRightsOutstandingMeasurementInput_85f9c95c-cc8e-4d4e-884d-b9a7ae1836e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:href="crdf-20221231.xsd#crdf_DerivativeFinancialInstrumentsLiabilityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_1472d302-1ae5-4f9f-a979-e1458d58fd8e" xlink:to="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7c8f9c1-1fdb-47c4-92c4-fc6aa2359bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_d7c8f9c1-1fdb-47c4-92c4-fc6aa2359bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e376286c-c349-484d-890d-c47317281f82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_e376286c-c349-484d-890d-c47317281f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ba276fa7-b216-4112-89f2-412eddd3af43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_ba276fa7-b216-4112-89f2-412eddd3af43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_5f09eb85-d266-4f92-9508-9345940dd3ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_5f09eb85-d266-4f92-9508-9345940dd3ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5859ff95-4e4a-4d67-863c-8e2a6fc4c93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_crdf_DerivativeFinancialInstrumentsLiabilityRollForward_485c7df2-5021-4a6d-afda-6be0b96514a1" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_5859ff95-4e4a-4d67-863c-8e2a6fc4c93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_37cce27f-b93b-4cf1-ba5b-b096ee8226e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_37cce27f-b93b-4cf1-ba5b-b096ee8226e8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_782a11fd-320c-461d-a91c-953832bfc676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_f1705d59-41c7-43ff-bce2-c7b4ac2c0d9e" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_782a11fd-320c-461d-a91c-953832bfc676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd98185-aaf6-4446-91be-0920b2e608d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_782a11fd-320c-461d-a91c-953832bfc676" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9dd98185-aaf6-4446-91be-0920b2e608d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_159b0a30-e52b-4888-96d4-e98f6a98ae93" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_0951fcf9-12e5-404f-9d6f-e7c8b60c1308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_0951fcf9-12e5-404f-9d6f-e7c8b60c1308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_53ce9a81-30d2-4972-893d-6374113fcc0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_53ce9a81-30d2-4972-893d-6374113fcc0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f80c7d82-f9e9-4504-ad0f-9b3c77c89218" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_50e52178-ed68-46f6-909a-1b6aa49e1421" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f80c7d82-f9e9-4504-ad0f-9b3c77c89218" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_485ac89c-8f64-4123-b4aa-b15820f521cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_2b47d5b1-e24a-4d57-aa5c-36bf8050a8c2" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_485ac89c-8f64-4123-b4aa-b15820f521cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_74d088a3-fe09-4718-ac3f-3eacf8cae0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_485ac89c-8f64-4123-b4aa-b15820f521cd" xlink:to="loc_us-gaap_MoneyMarketFundsMember_74d088a3-fe09-4718-ac3f-3eacf8cae0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_3295d308-87f0-4cfe-8ff8-b1f8d24d4eee" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_6e216c61-044c-4098-9db7-29b05fc7e688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_CertificatesOfDepositMember_6e216c61-044c-4098-9db7-29b05fc7e688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b499c144-15a6-4290-87a6-14e601fd14bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b499c144-15a6-4290-87a6-14e601fd14bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_a6f1e989-330c-4315-a067-f666f971f938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_CommercialPaperMember_a6f1e989-330c-4315-a067-f666f971f938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c0e5a621-11eb-406b-be1d-ae7c6cb78486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_c0e5a621-11eb-406b-be1d-ae7c6cb78486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_99af24bf-929d-4375-a561-a3b4ae318efe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_99af24bf-929d-4375-a561-a3b4ae318efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_d9a192ea-f8c5-4bc1-9530-e597973d8ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4a89340e-300e-44a3-bafb-90e69664b6ca" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_d9a192ea-f8c5-4bc1-9530-e597973d8ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d8b5c81-e378-42a2-ae92-03fba4f7cd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3c4c6dfb-2d52-4766-b64b-47e21ce4e947" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d8b5c81-e378-42a2-ae92-03fba4f7cd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_5d8b5c81-e378-42a2-ae92-03fba4f7cd5b" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09693474-04c3-4709-989c-b05cc9a09dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_09693474-04c3-4709-989c-b05cc9a09dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5c3309f-4cf6-4d84-a803-1b61e7f3ceb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b5c3309f-4cf6-4d84-a803-1b61e7f3ceb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_69bb310a-9fdf-4af7-a58d-9b65f2258dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_b0c3fa9d-422a-494f-9c01-3c93c1c3193d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_69bb310a-9fdf-4af7-a58d-9b65f2258dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_db9729f7-3315-42ab-890b-af4bb134c239" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_db9729f7-3315-42ab-890b-af4bb134c239" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_b90d5f24-637b-4ac4-8908-8df15fbbc06d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_df9970a0-dffb-426f-a414-f36ea85ea004" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_b90d5f24-637b-4ac4-8908-8df15fbbc06d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_65c396d7-b2c2-402d-862e-182359a48981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_b90d5f24-637b-4ac4-8908-8df15fbbc06d" xlink:to="loc_us-gaap_ResearchMember_65c396d7-b2c2-402d-862e-182359a48981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_d60db481-eca6-455b-954f-4e4c5de06281" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_fd4c950c-a058-4714-a44d-a6060977082e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_fd4c950c-a058-4714-a44d-a6060977082e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_84563fec-529a-4b9e-8211-51e6796e23e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CaliforniaFranchiseTaxBoardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_01aea20a-957d-4f97-a861-585a631a119c" xlink:to="loc_us-gaap_CaliforniaFranchiseTaxBoardMember_84563fec-529a-4b9e-8211-51e6796e23e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodAxis_7aa89133-3c79-44e1-8dbd-59b298c3c273" xlink:to="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_TaxYear2021AndPriorMember_96502bcf-edae-4538-b87b-df5a755a7219" xlink:href="crdf-20221231.xsd#crdf_TaxYear2021AndPriorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:to="loc_crdf_TaxYear2021AndPriorMember_96502bcf-edae-4538-b87b-df5a755a7219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxYear2021Member_79945d0e-57e5-4fa3-9f97-28b14019b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxYear2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxPeriodDomain_6a46f485-6cba-4a45-aae6-8551d8c528a8" xlink:to="loc_us-gaap_TaxYear2021Member_79945d0e-57e5-4fa3-9f97-28b14019b7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_ae92f5da-3b1e-4a58-a24f-1324efaf5973" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsSubjectToExpiration_04adf3bd-240e-4a59-a2aa-ea667d1cc5b2" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_OperatingLossCarryforwardsSubjectToExpiration_04adf3bd-240e-4a59-a2aa-ea667d1cc5b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_e7e0a54d-2b59-480c-8873-b8b7cad088a0" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_OperatingLossCarryforwardsNotSubjectToExpiration_e7e0a54d-2b59-480c-8873-b8b7cad088a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_b09713bd-23e2-4d86-a724-49d629c810fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_OperatingLossCarryforwards_b09713bd-23e2-4d86-a724-49d629c810fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_70156b36-5415-4981-bf84-bfecbfb90081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_70156b36-5415-4981-bf84-bfecbfb90081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_OperatingLossCarryforwardsIncreaseDecrease_8f6eacac-59cb-4595-8edb-30f8d226ad18" xlink:href="crdf-20221231.xsd#crdf_OperatingLossCarryforwardsIncreaseDecrease"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_OperatingLossCarryforwardsIncreaseDecrease_8f6eacac-59cb-4595-8edb-30f8d226ad18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_TaxCreditCarryforwardIncreaseDecrease_ac4fed6e-93a4-4611-9450-15937cfb1558" xlink:href="crdf-20221231.xsd#crdf_TaxCreditCarryforwardIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_crdf_TaxCreditCarryforwardIncreaseDecrease_ac4fed6e-93a4-4611-9450-15937cfb1558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ab989fab-f0b5-4a44-8c4c-56391b73b571" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ab989fab-f0b5-4a44-8c4c-56391b73b571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_6b40733f-11ff-4255-b7f3-513bb2b16da9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_094e8a55-9cf6-445e-bc22-37636eb9ca8e" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_6b40733f-11ff-4255-b7f3-513bb2b16da9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_883269ee-d8b9-481a-a906-d5ec9db82063" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrentAbstract_6289a7a7-82a3-4007-a7af-978cba4ad9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxesPayableCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_883269ee-d8b9-481a-a906-d5ec9db82063" xlink:to="loc_us-gaap_TaxesPayableCurrentAbstract_6289a7a7-82a3-4007-a7af-978cba4ad9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_774dfdc6-63cf-4633-8734-4a38cd98bbf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxesPayableCurrentAbstract_6289a7a7-82a3-4007-a7af-978cba4ad9d3" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_774dfdc6-63cf-4633-8734-4a38cd98bbf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b1c527b-5bc4-432f-b350-61cc89de1a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxesPayableCurrentAbstract_6289a7a7-82a3-4007-a7af-978cba4ad9d3" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2b1c527b-5bc4-432f-b350-61cc89de1a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_73b76acb-9533-428a-843e-92f776ecb88a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_883269ee-d8b9-481a-a906-d5ec9db82063" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_73b76acb-9533-428a-843e-92f776ecb88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_26f67459-4db9-4d2a-a91b-77d1891bf88d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_73b76acb-9533-428a-843e-92f776ecb88a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_26f67459-4db9-4d2a-a91b-77d1891bf88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ddce5cff-ce06-43f4-aafe-d955bdd986b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_73b76acb-9533-428a-843e-92f776ecb88a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ddce5cff-ce06-43f4-aafe-d955bdd986b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1d6dd15c-d379-4101-ae53-1736e3e0c24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract_73b76acb-9533-428a-843e-92f776ecb88a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1d6dd15c-d379-4101-ae53-1736e3e0c24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_ValuationAllowance_f205cd2c-ec76-484d-80cf-135f383790fb" xlink:href="crdf-20221231.xsd#crdf_ValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_883269ee-d8b9-481a-a906-d5ec9db82063" xlink:to="loc_crdf_ValuationAllowance_f205cd2c-ec76-484d-80cf-135f383790fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_8ba4382f-f546-4ff1-a278-088c3fafa2b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_883269ee-d8b9-481a-a906-d5ec9db82063" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_8ba4382f-f546-4ff1-a278-088c3fafa2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesSignificantComponentsofCompanysTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f88d14ab-c62f-4e03-b235-505695837542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f88d14ab-c62f-4e03-b235-505695837542" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a33630cc-b260-468c-85e9-febacd842169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a33630cc-b260-468c-85e9-febacd842169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_60b2ff27-a075-4f00-85bf-66cddeaeaa95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_60b2ff27-a075-4f00-85bf-66cddeaeaa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_IncomeTaxReconciliationPermanentItems_d98402f3-58b5-4ea6-85c0-aa04223c744d" xlink:href="crdf-20221231.xsd#crdf_IncomeTaxReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_crdf_IncomeTaxReconciliationPermanentItems_d98402f3-58b5-4ea6-85c0-aa04223c744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_724739a0-0692-41f3-801e-88d816bbe553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount_724739a0-0692-41f3-801e-88d816bbe553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_d9990cc5-1a41-49cb-b7c6-b1d6b7a13498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_d9990cc5-1a41-49cb-b7c6-b1d6b7a13498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_87a7c0f0-2d7e-41db-b57c-df8a8cff0db8" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount_87a7c0f0-2d7e-41db-b57c-df8a8cff0db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_86f3e71c-7de1-4c12-a2d0-16f0d99f6d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_86f3e71c-7de1-4c12-a2d0-16f0d99f6d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_06cd6e9b-0004-40a5-ac56-afb58ec9bc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_06cd6e9b-0004-40a5-ac56-afb58ec9bc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_349f3800-72e3-4e20-baff-62568e3affb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4e7b5797-e659-4a20-a919-dbb382dc1642" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_349f3800-72e3-4e20-baff-62568e3affb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f88d14ab-c62f-4e03-b235-505695837542" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_66d3bf0b-1c75-4c5a-a034-589d158998ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_66d3bf0b-1c75-4c5a-a034-589d158998ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_13a59eee-425c-4b23-95b2-191659e1cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_13a59eee-425c-4b23-95b2-191659e1cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_faf82517-721d-4a7e-8189-c8ab300b2856" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationPermanentItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems_faf82517-721d-4a7e-8189-c8ab300b2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_3a203bd1-a554-4003-8a46-3bd391a33133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_3a203bd1-a554-4003-8a46-3bd391a33133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_47b3a52b-b8e5-436d-a172-b2cd010593ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_47b3a52b-b8e5-436d-a172-b2cd010593ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_5a99d976-6750-42f3-b460-cdd9eaecb7dc" xlink:href="crdf-20221231.xsd#crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent_5a99d976-6750-42f3-b460-cdd9eaecb7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_61423592-0d70-4b0c-a017-7c261aba01ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_61423592-0d70-4b0c-a017-7c261aba01ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_064238c8-652d-4da5-875f-3437ecafd0f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_064238c8-652d-4da5-875f-3437ecafd0f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c0ea561-87e9-49e7-ab80-d20cecd4bd44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_8bcb05fa-e223-4b65-9448-6fc7ddbad7d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c0ea561-87e9-49e7-ab80-d20cecd4bd44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f118a8c4-b9a9-4ec5-bde3-0f4314bcb5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f118a8c4-b9a9-4ec5-bde3-0f4314bcb5f0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGrossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:to="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_eba5e05c-9111-4b73-a2f3-c8d3ca85a359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_eba5e05c-9111-4b73-a2f3-c8d3ca85a359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_d1717348-711b-42dd-9f93-b05d6aac3910" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:to="loc_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther_d1717348-711b-42dd-9f93-b05d6aac3910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6f9ade2b-fcf4-431d-8bbe-18dd029907d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_6f9ade2b-fcf4-431d-8bbe-18dd029907d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4acc99ef-6802-43e3-869b-9f0f5aa63577" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4acc99ef-6802-43e3-869b-9f0f5aa63577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_032bd9bc-748b-4734-984e-85331b9addb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_032bd9bc-748b-4734-984e-85331b9addb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_0169f98c-4c39-4533-88eb-95ce75ead8cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsGrossAbstract_55d1ee89-b0e5-4945-9d01-18cf799d9046" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_0169f98c-4c39-4533-88eb-95ce75ead8cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b349771d-f343-4055-9bbc-12e9bbfa96a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b349771d-f343-4055-9bbc-12e9bbfa96a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_da0858ca-b128-42ac-8ae7-305048e84989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b349771d-f343-4055-9bbc-12e9bbfa96a3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_da0858ca-b128-42ac-8ae7-305048e84989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_d62b726c-c592-44fc-9300-8840e1d92af2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b349771d-f343-4055-9bbc-12e9bbfa96a3" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_d62b726c-c592-44fc-9300-8840e1d92af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_13382a26-1bb5-4cd1-b8e8-175b2eeaeb85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesAbstract_b349771d-f343-4055-9bbc-12e9bbfa96a3" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_13382a26-1bb5-4cd1-b8e8-175b2eeaeb85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_7c06c716-46cc-46fa-bfd6-2f75a74693e0" xlink:href="crdf-20221231.xsd#crdf_DeferredTaxAssetsNetBeforeValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:to="loc_crdf_DeferredTaxAssetsNetBeforeValuationAllowance_7c06c716-46cc-46fa-bfd6-2f75a74693e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c4b0980-9d4d-40bd-9306-5d6719d62bef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_2c4b0980-9d4d-40bd-9306-5d6719d62bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_dd2f8025-a4cf-4d9e-b544-50bec5ab7e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_087c9ee8-3372-4ad0-ad3f-d1e9faf13d5c" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_dd2f8025-a4cf-4d9e-b544-50bec5ab7e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.cardiffoncology.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="simple" xlink:href="crdf-20221231.xsd#CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"/>
  <link:presentationLink xlink:role="http://www.cardiffoncology.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f6b2e9d-3aea-464b-bf77-3efa56ab1ab5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_208b5404-3c2d-4f04-97a0-dae312fc45cb" xlink:href="crdf-20221231.xsd#crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2f6b2e9d-3aea-464b-bf77-3efa56ab1ab5" xlink:to="loc_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade_208b5404-3c2d-4f04-97a0-dae312fc45cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098085040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">CARDIFF ONCOLOGY, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-2004382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11055 Flintkote Avenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">952-7570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 93,819,519<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,677,169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="text-align:center;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Specified portions of the registrant's proxy statement, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14 A in connection with the registrant's 2023 Annual Meeting of Stockholders (the "Proxy Statement"), are incorporated by reference into Part III of this Annual Report on Form 10-K.  Except with respect to information specifically incorporated by reference in this Annual Report, the Proxy Statement is not deemed to be filed as part hereof.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001213037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094917568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">BDO USA, LLP<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Diego, California<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098177872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 16,347<span></span>
</td>
<td class="nump">$ 11,943<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">88,920<span></span>
</td>
<td class="nump">128,878<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable and unbilled receivable</a></td>
<td class="nump">771<span></span>
</td>
<td class="nump">535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">5,246<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">111,284<span></span>
</td>
<td class="nump">146,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">2,251<span></span>
</td>
<td class="nump">2,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">1,387<span></span>
</td>
<td class="nump">239<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">116,191<span></span>
</td>
<td class="nump">149,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,956<span></span>
</td>
<td class="nump">1,439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">7,808<span></span>
</td>
<td class="nump">6,559<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,848<span></span>
</td>
<td class="nump">9,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,044 and $1,020 at December&#160;31, 2022 and December&#160;31, 2021, respectively; (Note 5)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 and 41,964 shares issued and outstanding at December&#160;31, 2022 and December&#160;31, 2021, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">404,834<span></span>
</td>
<td class="nump">400,503<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_Servicereceivable', window );">Service receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(139)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(395)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(298,100)<span></span>
</td>
<td class="num">(259,810)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">106,343<span></span>
</td>
<td class="nump">140,417<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Equity</a></td>
<td class="nump">$ 116,191<span></span>
</td>
<td class="nump">$ 149,544<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Servicereceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Servicereceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098044256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheets (Parenthetical) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">20,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Series A Convertible Preferred Stock, liquidation preference</a></td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,677<span></span>
</td>
<td class="nump">41,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,677<span></span>
</td>
<td class="nump">41,964<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623190088000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues</a></td>
<td class="nump">$ 386<span></span>
</td>
<td class="nump">$ 359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">27,107<span></span>
</td>
<td class="nump">17,376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">13,181<span></span>
</td>
<td class="nump">11,838<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">40,288<span></span>
</td>
<td class="nump">29,214<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(39,902)<span></span>
</td>
<td class="num">(28,855)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">1,581<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingGainsLosses', window );">Other income (expense), net</a></td>
<td class="num">(383)<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Gain from changes in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">285<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income, net</a></td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(38,704)<span></span>
</td>
<td class="num">(28,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable&#160;to&#160;common stockholders</a></td>
<td class="num">$ (38,728)<span></span>
</td>
<td class="num">$ (28,315)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.89)<span></span>
</td>
<td class="num">$ (0.73)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding - basic (in shares)</a></td>
<td class="nump">43,600<span></span>
</td>
<td class="nump">39,030<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding - diluted (in shares)</a></td>
<td class="nump">43,600<span></span>
</td>
<td class="nump">39,030<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7,9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098089712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (38,704)<span></span>
</td>
<td class="num">$ (28,291)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on securities available-for-sale</a></td>
<td class="num">(253)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">(38,957)<span></span>
</td>
<td class="num">(28,433)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic', window );">Comprehensive loss attributable to common stockholders</a></td>
<td class="num">$ (38,981)<span></span>
</td>
<td class="num">$ (28,457)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comprehensive Income (Loss) Available to Common Stockholders, Basic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093222256">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Service Receivable</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">36,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 128,158<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 361,819<span></span>
</td>
<td class="num">$ (2,171)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (231,495)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,234<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">34,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,187<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on securities available-for-sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(28,291)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(28,291)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">716<span></span>
</td>
<td class="nump">41,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">140,417<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">400,503<span></span>
</td>
<td class="num">(139)<span></span>
</td>
<td class="num">(142)<span></span>
</td>
<td class="num">(259,810)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,256<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(655)<span></span>
</td>
<td class="nump">2,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon conversion of Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Preferred stock dividend payable on Series A Convertible Preferred Stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized loss on securities available-for-sale</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ReleaseOfClinicalTrialFundingCommitment', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockCumulativeDividendAdjustment', window );">Cumulative preferred stock dividend adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(38,704)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38,704)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">44,677<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2022</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 106,343<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 404,834<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (395)<span></span>
</td>
<td class="num">$ (298,100)<span></span>
</td>
</tr>
<tr><td colspan="8"></td></tr>
<tr><td colspan="8"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Net of expenses of $0.8&#160;million.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">See Note 2 to the financial statements.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockCumulativeDividendAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Cumulative Dividend Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockCumulativeDividendAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ReleaseOfClinicalTrialFundingCommitment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release Of Clinical Trial Funding Commitment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ReleaseOfClinicalTrialFundingCommitment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodSharesWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of shares issued during the period upon cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodSharesWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_StockIssuedDuringPeriodValueWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The equity impact during the period due to the cash exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_StockIssuedDuringPeriodValueWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095974992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statement of Shareholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093138784">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">$ (38,704)<span></span>
</td>
<td class="num">$ (28,291)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">236<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,256<span></span>
</td>
<td class="nump">3,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">632<span></span>
</td>
<td class="nump">1,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived', window );">Release of clinical trial funding commitment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">139<span></span>
</td>
<td class="nump">2,032<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,148)<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable and unbilled receivable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(236)<span></span>
</td>
<td class="num">(215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(443)<span></span>
</td>
<td class="num">(2,099)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">545<span></span>
</td>
<td class="nump">607<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued expenses</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,348<span></span>
</td>
<td class="nump">719<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(404)<span></span>
</td>
<td class="num">(811)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(156)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(33,820)<span></span>
</td>
<td class="num">(23,040)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Capital expenditures</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(1,006)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities', window );">Insurance proceeds from casualty loss</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">114<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Maturities of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">76,445<span></span>
</td>
<td class="nump">28,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(91,233)<span></span>
</td>
<td class="num">(174,385)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Sales of short-term investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">53,829<span></span>
</td>
<td class="nump">14,751<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">38,149<span></span>
</td>
<td class="num">(131,448)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing activities</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $0 and $813 respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">34,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">75<span></span>
</td>
<td class="nump">35,450<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,404<span></span>
</td>
<td class="num">(119,038)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;Beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">11,943<span></span>
</td>
<td class="nump">130,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents&#8212;End of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">16,347<span></span>
</td>
<td class="nump">11,943<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosure of cash flow activity:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Acquisition of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">232<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockDividendAccrued', window );">Accretion of Series A Convertible Preferred Stock dividend</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_NonCashCumulativePreferredStockDividendAdjustment', window );">Cumulative preferred stock dividend adjustment</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">$ (414)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">See Note 2 to the financial statements.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Operating Lease, Right-Of-Use Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_NonCashCumulativePreferredStockDividendAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash, Cumulative Preferred Stock Dividend Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_NonCashCumulativePreferredStockDividendAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockDividendAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the value of preferred stock dividend accrued during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockDividendAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Release of clinical trial funding commitment for services received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInsuranceSettlementInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21B<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=SL94080549-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInsuranceSettlementInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099697456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Cash Flows (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_CommonStockAndWarrantsMember', window );">Common Stock And Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_CommonStockAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_CommonStockAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095900656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Overview and Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business Overview and Liquidity</a></td>
<td class="text">Business Overview and Liquidity<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Organization and Overview</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology, Inc. (&#8220;Cardiff Oncology&#8221; or the &#8220;Company&#8221;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#8220;PLK1&#8221;) inhibition to develop novel therapies across a range of cancers. The Company&#8217;s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard of care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company&#8217;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard of care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Liquidity</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred net losses since its inception and has negative operating cash flows. As of December&#160;31, 2022, the Company had $105.3 million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#8217;s stockholders may experience additional dilution.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623189859072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Summary of Significant Accounting Policies</a></td>
<td class="text">Basis of Presentation and Summary of Significant Accounting Policies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;). </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment in the United States.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations ("CROs"), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December&#160;31, 2022 the Company&#8217;s clinical trial accrual balance of $2.3 million is included in accrued liabilities. The Company&#8217;s related 2022 clinical trial expenses are included in research and development expense of $27.1&#160;million. Certain clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash in readily available checking and money market accounts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive loss. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and License Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These patents are from the Company's legacy portfolio and unrelated to onvansertib.&#160;Agreements may involve multiple elements such as license fees, minimum royalties, usage-based royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#8217;s use. The Company estimates and records licensee&#8217;s sales based on historical usage rate and collectability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Royalties are generally due quarterly or annually. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period as they do not meet the criteria for equity classification. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;Change in fair value of derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments" </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">below).&#160;At December&#160;31, 2022 and 2021, the fair value of these warrants was $0, for both periods. These warrants expire in the first quarter of 2023. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted prices for identical instruments in active markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Instruments where significant value drivers are unobservable to third parties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property, equipment and lease right-of-use assets. The Company records property and equipment at cost. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of the asset. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. The estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease Right-of-Use (&#8220;ROU&#8221;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#8217;s balance sheets.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. None of the Company&#8217;s operating leases provide an implicit rate, therefore the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revision of Previously Disclosed Amounts</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the course of preparing the Company&#8217;s financial statements as of and for the year ended December 31 2022, the Company completed an Internal Revenue Code Section 382 and 383 analysis of its historical net operating loss and tax credit carryforward amounts. As a result, a portion of the prior year net operating loss and tax credit carryforwards were determined to be limited. See Note 9 - Income Taxes, for further details. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and patent maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upfront and milestone payments to acquire contractual rights to licensed technology are expensed when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Certain contractual rights may require the Company to make additional milestone payments based on development and commercial milestones, and royalties based on sales volume. See Note 10 - Commitments and Contingencies, for further details.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These potential development milestones include: dosing of the first subject in the first Phase III Clinical Trial for the first Product or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and upon filing of the first NDA or equivalent for the first product</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. The accretion of Series A Convertible Preferred Stock dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,431,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,947,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Correction of Series A Convertible Preferred Stock cumulative dividend liability</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2022, the Company identified an immaterial error related to the accrual of a liability for the accretion of cumulative preferred dividends on the Company's Series A Convertible Preferred Stock. These cumulative preferred dividends do not meet the definition of a liability, as they have not been declared by the Company's Board of Directors. The Company has recorded an adjustment of $0.4&#160;million within accumulated deficit and accrued liabilities for the year ended December 31, 2022 to correct this immaterial error. </span></div><div><span><br/></span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div>In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for the Company on January 1, 2024. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095900656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Supplementary Balance Sheet Information</a></td>
<td class="text">Supplementary Balance Sheet Information<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments available-for-sale securities consist of the following: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2022 the net realized loss recorded within the Company's statement of operations from the sale of short-term investments was $0.2 million. The amount of gains and losses reclassified out of other comprehensive income for the period related to the sales of short-term investments was not material for the year ended December&#160;31, 2022.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrealized losses in investments available for sale debt securities at December&#160;31, 2022, were primarily due to increases in interest rates, not due to increased credit risks associated with specific securities. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Property and Equipment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December&#160;31, 2022 and 2021 was $0.2 million and $0.5 million, respectively. Property and equipment consisted of the following:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Liabilities</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)See Note 2 to the financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI https://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095797456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July 2021, the Company entered into an amended lease agreement to increase its occupied space, which commenced on January 1, 2022 and expires on February 28, 2027. Under the Company's prior master facility lease which expired on December 31, 2021, the Company was leasing additional suites in which it was not occupying and subleasing to third parties. The amended lease agreement retained the space that the Company was occupying, and a portion of office and lab space that was previously subleased to a third party. The remaining additional suites subleased to third parties were not included in the Company's amended sublease. The Company currently leases office and lab space in San Diego which expires on February 28, 2027. The lease currently required payments of approximately $61,000 per month with 3% annual escalation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing its vacated space to third parties.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid included in operating cash flows</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;As a lessee, the Company&#8217;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Master Facility Lease </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During July 2021, the Company entered into an amended lease agreement to increase its occupied space, which commenced on January 1, 2022 and expires on February 28, 2027. Under the Company's prior master facility lease which expired on December 31, 2021, the Company was leasing additional suites in which it was not occupying and subleasing to third parties. The amended lease agreement retained the space that the Company was occupying, and a portion of office and lab space that was previously subleased to a third party. The remaining additional suites subleased to third parties were not included in the Company's amended sublease. The Company currently leases office and lab space in San Diego which expires on February 28, 2027. The lease currently required payments of approximately $61,000 per month with 3% annual escalation. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Facility Subleases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing its vacated space to third parties.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid included in operating cash flows</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesOfLessorDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for lessor's operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888252<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesOfLessorDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099094992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders&#8217; Equity<div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Warrants</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Preferred Stock</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares issued and outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series A Convertible Preferred Stock</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The material terms of the Series A Convertible Preferred Stock consist of:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Dividends. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of the Company&#8217;s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company&#8217;s sole election, in cash or shares of common stock. As of December&#160;31, 2022 and 2021, the Company had $438,000 and $414,000, respectively in cumulative unpaid preferred stock dividends, included in the liquidation preference of the Series A Convertible Preferred Stock, and $24,000 and $24,000 of cumulative dividends were added to the liquidation preference of the Series A Convertible Preferred Stock during the years ended December&#160;31, 2022 and 2021, respectively.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Voting Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Liquidation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $10 per share plus any accrued and unpaid dividends.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Conversion Rights. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, which at the time of issuance was $928.80 per share, and subsequently adjusted to $691.20 per share.</span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt">Subsequent Equity Sales. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning March 17, 2006 and the conversion price was adjusted to $691.20 per share.   </span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:40.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"> Automatic Conversion. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the price of the Company&#8217;s common stock equals $1,857.60 per share for 20 consecutive trading days, and an average of 116 shares of common stock per day are traded during the 20 trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met.</span></div><div style="text-indent:58.5pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the liquidation preference for the Series A Convertible Preferred Stock were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated Value per share liquidation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative unpaid preferred stock dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation preference - Series A Convertible Preferred Stock</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Series E Convertible Preferred Stock</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 15, 2020 the Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of 1,984,328 shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of 865,824 shares of Series E Preferred Stock (&#8220;Series E Preferred Stock&#8221;) and (b) Series N warrants to purchase up to 2,213,115 shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $10 stated value per share of the Series E Preferred Stock by a conversion price of $2.44 per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable six months following the date of issuance at an exercise price of $2.39 per share and will expire on December 16, 2025. Certain investors converted 210,780 shares of Series E Convertible Preferred stock to 863,852 shares of Common Stock during December 2020. Certain investors converted 327,535 shares of Series E Convertible Preferred stock to 1,342,357 shares of Common Stock during January 2022. Certain investors converted 327,509 shares of Series E Convertible Preferred stock to 1,342,250 shares of Common Stock during October 2022. As of December 31, 2022 no shares of Series E Convertible Preferred stock were outstanding. </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In conjunction with the June 15, 2020 offering, we issued 184,426 warrants as an advisory fee. These warrants are exercisable six months following the date of issuance at an exercise price of $3.05 per share and will expire 5.5 years following the date of issuance. These warrants were classified as equity. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sales Agreement with Jefferies LLC</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During May 2021, the Company sold 2.0&#160;million shares of its common stock under the Sales Agreement with Jefferies LLC., for gross proceeds of approximately $20.0&#160;million. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pfizer Breakthrough Growth Initiative</span></div>During November 2021, the Company sold 2.4&#160;million shares of its common stock under a Securities Purchase Agreement with Pfizer Inc. ("Pfizer"), in a registered direct offering for gross proceeds of approximately $15.0&#160;million. The investment is part of the Pfizer Breakthrough Growth Initiative, which includes an information rights agreement and Pfizer's participation on a Scientific Advisory Board for the Company. Pfizer agreed to not sell or transfer any shares for 180 days from the closing date of the agreement, which expired during May 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095907952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2021 Equity Incentive Plan</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022 the shareholders approved an increase of shares authorized in the 2021 Plan to 5,150,000. As of December&#160;31, 2022, there were 3,087,075 shares available for issuance under the 2021 Plan.  </span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2014 Equity Incentive Plan</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inducement Grants</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of December&#160;31, 2022, an aggregate of 920,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Modification of Stock Options</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 one of the Company's directors did not seek another term on the Board of Directors. At the time of departure, the Compensation Committee passed a resolution to extend the expiration date of the vested stock options, and to immediately accelerate the vesting of the unvested options. The Company recorded incremental reduction to stock compensation expense of $0.1&#160;million during the year ended December 31, 2022, related to the modifications.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 two of the Company's directors' terms ended. At the conclusion of their term, the Compensation Committee passed a resolution to extend the expiration date of the departing directors vested stock options, and to immediately accelerate the vesting of one of the directors unvested options. The Company recorded incremental stock compensation expenses of $0.6&#160;million during the year ended December 31, 2021, related to the modifications. </span></div><div style="text-indent:38.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation has been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62% - 3.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83% - 1.3%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (range)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98% - 110%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107% - 110%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (weighted-average)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#8217;s stock options.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Cardiff Oncology has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; Based on the historical volatility of Cardiff Oncology&#8217;s common stock.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method, which represents the Company's best estimate following the Company's restructuring in 2018. This method averages an award&#8217;s weighted-average vesting period and expected term for &#8220;plain vanilla&#8221; share options. Options are considered to be &#8220;plain vanilla&#8221; if they have the following basic characteristics: (1) are granted &#8220;at-the-money&#8221;; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forfeitures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#8212; The Company estimates forfeitures based on its historical experience.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average fair value per share of all options granted during the years ended December&#160;31, 2022 and 2021, estimated as of the grant date using the Black-Scholes option valuation model, was $2.55 and $5.96 per share, respectively.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The unrecognized compensation cost related to non-vested stock options outstanding at December&#160;31, 2022 was $8.8 million. The weighted-average remaining amortization period at December&#160;31, 2022 for non-vested stock options was 2.6 years. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total fair value of shares vested during the years ended December&#160;31, 2022 and 2021 was $4.7 million and $1.2 million, respectively.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and of changes in stock options outstanding is presented below:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300,619&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,990,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095809520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Financial Instruments - Warrants</a></td>
<td class="text">Derivative Financial Instruments &#8212; Warrants<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Certain warrants issued in connection with the Company&#8217;s equity financings are accounted for as derivative liabilities. Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model. Changes in fair value are recorded within Company&#8217;s statements of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility is based on the historical volatility of Cardiff Oncology&#8217;s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for number of warrants)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the year recognized as a gain in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants  during the year recognized as a loss in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095871696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2022 and 2021:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the years ended December&#160;31, 2022 and 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095779984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, Cardiff Oncology had federal net operating loss carryforwards (&#8220;NOLs&#8221;) of approximately $5.1 million which, if not used, will continue to expire through 2037, and federal net operating loss carryforwards of approximately $85.8 million, which do not expire. Cardiff Oncology also has California NOLs of approximately $17.3 million which, if not used, will begin to expire in 2029. Cardiff Oncology also has research and development tax credits available for federal and California purposes of approximately $1.0 million and $2.3 million, respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits do not expire.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) Sections 382 and 383, annual use of a company&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Company has established a valuation allowance as the realization of such deferred tax assets has not met the more likely than not threshold requirement. Due to the existence of the valuation allowance, further changes in the Company&#8217;s unrecognized tax benefits will not impact the Company&#8217;s effective tax rate.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During 2022, the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section 382 and 383 and determined that the Company underwent two ownership changes during the period from 2014 to 2022. As a result, net operating loss and tax credit carryforwards attributable to the pre-ownership changes are subject to substantial annual limitations under Section 382 and 383 of Code due to the ownership changes. The Company has adjusted their net operating loss and tax credit carryforwards to address the impact of the ownership changes. This resulted in a reduction of available gross federal and state net operating loss carryforwards of approximately $123.9&#160;million and $62.8&#160;million, respectively which related to the year ended December 31, 2021 and prior. The tax effected federal and state NOL amounts were $26.0&#160;million and $4.4&#160;million respectively. This also resulted in a reduction of federal tax credit carryforwards of approximately $1.8&#160;million related to the years ended December 31, 2021 and prior. Accordingly, the net operating loss and tax credit carryforwards presented below for the year ending December 31, 2021 were reduced by $30.4&#160;million and $1.8&#160;million, respectively, with a corresponding reduction to the valuation allowance of $32.2&#160;million.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes based on losses from continuing operations consists of the following at December 31:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,082)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s taxes and the rates as of December 31 are shown below: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax computed at the federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,941)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision and true ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance increase (decrease)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception the Company has incurred continuing losses and expects to continue to incur losses for the foreseeable future. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more likely than not they will not be realized. </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not have any unrecognized tax benefits. Cardiff Oncology&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and none have been incurred to date. The Company does not anticipate a significant change in unrecognized tax benefits over the next 12 months. The Company is subject to taxation in the U.S. and California. Due to net operating losses all tax years since inception remain open to examination.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094857456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Agreements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development and Clinical Trial Agreements</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Terms of the agreement also provide for the Company to pay development and commercial milestones, and royalties based on sales volume. These potential development milestones include: dosing of the first subject in the first Phase III Clinical Trial for the first Product or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and upon filing of the first NDA or equivalent for the first product. During the years ended December&#160;31, 2022 and 2021, no milestone or royalty payments were made.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is a party of various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. During the years ended December&#160;31, 2022 and 2021 payments have not been material.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#8217;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#8217;s business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623096753024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text">Employee Benefit Plan<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined contribution retirement plan under Section 401(k) of the Internal Revenue Service ("IRS") Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income through contributions to the plan as allowed by IRS Code. The Company does not currently make matching contributions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094874112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment in the United States.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedClinicalTrialExpensesPolicyTextBlock', window );">Accrued Clinical Trial Expenses</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accrued Clinical Trial Expenses</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations ("CROs"), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#8220;service providers&#8221;). As of December&#160;31, 2022 the Company&#8217;s clinical trial accrual balance of $2.3 million is included in accrued liabilities. The Company&#8217;s related 2022 clinical trial expenses are included in research and development expense of $27.1&#160;million. Certain clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cash and Cash Equivalents</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash in readily available checking and money market accounts. </span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investment Securities</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All investments have been classified as &#8220;available-for-sale&#8221; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#8217;s ability to liquidate the investment for use in operations within the next 12 months.</span></div><div><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#8217;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive loss. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Concentration of Credit Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenues</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and License Revenues</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These patents are from the Company's legacy portfolio and unrelated to onvansertib.&#160;Agreements may involve multiple elements such as license fees, minimum royalties, usage-based royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#8217;s use. The Company estimates and records licensee&#8217;s sales based on historical usage rate and collectability.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div>Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Royalties are generally due quarterly or annually.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments&#8212;Warrants</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Financial Instruments&#8212;Warrants</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period as they do not meet the criteria for equity classification. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#8220;Change in fair value of derivative instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants.&#8221;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#8217;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments" </span>below).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-Based Compensation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#8217;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 &#8212; Quoted prices for identical instruments in active markets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 &#8212; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 &#8212; Instruments where significant value drivers are unobservable to third parties.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Long-Lived Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist of property, equipment and lease right-of-use assets. The Company records property and equipment at cost. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of the asset. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. The estimated useful lives of the major classes of property and equipment are as follows:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock', window );">Impairment Losses on Long-Lived Assets</a></td>
<td class="text">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease Right-of-Use (&#8220;ROU&#8221;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#8217;s balance sheets.</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. None of the Company&#8217;s operating leases provide an implicit rate, therefore the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#8217;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. </span></div>Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#8217;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revision of Previously Disclosed Amounts</span></div>During the course of preparing the Company&#8217;s financial statements as of and for the year ended December 31 2022, the Company completed an Internal Revenue Code Section 382 and 383 analysis of its historical net operating loss and tax credit carryforward amounts. As a result, a portion of the prior year net operating loss and tax credit carryforwards were determined to be limited. See Note 9 - Income Taxes, for further details.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and patent maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.</span></div>Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div>Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. The accretion of Series A Convertible Preferred Stock dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_CorrectionPolicyPolicyTextBlock', window );">Correction of Series A Convertible Preferred Stock cumulative dividend liability</a></td>
<td class="text">Correction of Series A Convertible Preferred Stock cumulative dividend liabilityDuring the fourth quarter of 2022, the Company identified an immaterial error related to the accrual of a liability for the accretion of cumulative preferred dividends on the Company's Series A Convertible Preferred Stock. These cumulative preferred dividends do not meet the definition of a liability, as they have not been declared by the Company's Board of Directors. The Company has recorded an adjustment of $0.4&#160;million within accumulated deficit and accrued liabilities for the year ended December 31, 2022 to correct this immaterial error.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncement Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Pronouncement</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#8212;Modifications and Extinguishments (Subtopic 470-50), Compensation&#8212;Stock Compensation (Topic 718), and Derivatives and Hedging&#8212;Contracts in Entity&#8217;s Own Equity (Subtopic 815-40): Issuer&#8217;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recent Accounting Pronouncement Not Yet Adopted</span></div>In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt &#8211; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#8211; Contracts in Entity&#8217;s Own Equity (Subtopic 815-40) (&#8220;ASU 2020-06&#8221;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#8217;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for the Company on January 1, 2024. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedClinicalTrialExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedClinicalTrialExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_CorrectionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Correction, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_CorrectionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126907703&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094729984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Useful Life of Property and Equipment</a></td>
<td class="text">The estimated useful lives of the major classes of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table>Property and equipment consisted of the following:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share</a></td>
<td class="text">Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options to purchase Common Stock</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069,458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Warrants to purchase Common Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,684,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,431,303&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,947,627&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623190071728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Components of Short-term investments</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Short-term investments available-for-sale securities consist of the following: </span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,806&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84,299&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(394)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83,924&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,016&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,996&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,315&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(415)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="text-indent:33.75pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity less than 1 year:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,822&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,786&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,453&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity less than 1 year</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,643&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturity 1 to 2 years:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,676&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total maturity 1 to 2 years</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,377&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,294&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(149)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value</a></td>
<td class="text">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.621%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Market Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Unrealized Loss</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,084&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(161)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,666&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total short-term investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,750&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of Property and Equipment</a></td>
<td class="text">The estimated useful lives of the major classes of property and equipment are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.294%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Useful Lives</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 to 5 years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4 to 6 years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5 years</span></td></tr></table>Property and equipment consisted of the following:<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and office equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,560&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,962&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Laboratory equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">906&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,682&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,823&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less&#8212;accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,413)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,269&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">382&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Liabilities</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued liabilities consisted of the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:64.149%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,849&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,435&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock dividend</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trials</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research agreements and services</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">509&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">726&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patent, license and other fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,527&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>(1)See Note 2 to the financial statements.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099620976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Expense and Supplemental Cash Flow Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="text-indent:33.75pt"><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">745&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating sublease income</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(403)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net operating lease cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">342&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve Months Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid included in operating cash flows</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">612&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">949&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,061&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental Balance Sheet Information</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to leases was as follows:</span></div><div><span><br/></span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.107%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease ROU assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,251&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,040&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,568&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,119&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term&#8211;operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2 years</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate&#8211;operating leases</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Future Minimum Lease Payments</a></td>
<td class="text">Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;Operating Leases </span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">676&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">754&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">775&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total future minimum lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,137&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(422)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,715&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099625520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrant Activity and Changes in Warrants Outstanding</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.182%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.427%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.565%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Exercise Price <br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining Contractual Term</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,260,992&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770,833)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,490,159&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0 years</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(129,191)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,360,968&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 years</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Preferred Stock</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our Company's classes of preferred stock is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:35.652%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.369%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.146%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares issued and outstanding</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares designated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">277,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series B Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series C Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series D Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0001&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series E Convertible Preferred Stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">865,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the liquidation preference for the Series A Convertible Preferred Stock were as follows: </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.424%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.425%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stated Value per share liquidation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">606&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cumulative unpaid preferred stock dividends</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">414&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liquidation preference - Series A Convertible Preferred Stock</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,044&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=65888546&amp;loc=d3e21300-112643<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21553-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=122040564&amp;loc=d3e177068-122764<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21488-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21484-112644<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623264750528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-based compensation recognized</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation has been recognized in operating results as follows:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">491&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,256&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,234&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Estimated Fair Value of Stock Options - Assumptions</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.360%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.62% - 3.75%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83% - 1.3%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (range)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98% - 110%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107% - 110%</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility (weighted-average)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of stock option activity and of changes in stock options outstanding is presented below:</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:45.752%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price Per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Intrinsic<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining<br/>Contractual Life</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance outstanding, December 31, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,771,984&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,405,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,737,760&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28,858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,443&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cancelled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(398,156)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,272)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance Outstanding, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,069,458&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable, December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,300,619&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and expected to vest, December 31, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,990,351&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,752&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4 years</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093087808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Schedule of Assumptions Used to Determine the Fair Value of Warrants</a></td>
<td class="text"><div style="text-indent:33.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:62.976%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.495%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.496%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value of Cardiff Oncology common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1.40</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.01</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected warrant term</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 years</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility of Cardiff Oncology common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock', window );">Schedule of Components of Changes in the Company&#8217;s Derivative Financial Instruments Liability Balance</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the components of changes in the Company&#8217;s derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except for number of warrants)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Warrants</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivative<br/>Instrument<br/>Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants during the year recognized as a gain in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants  during the year recognized as a loss in the statement of operations</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance of derivative financial instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">warrants liability</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,496&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095795072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock', window );">Schedule of Company&#8217;s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2022 and 2021:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,722&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,187&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. government agencies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,887&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,920&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,609&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,033&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,642&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.190%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.293%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.512%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair&#160;Value&#160;Measurements&#160;at<br/>December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities<br/>(Level&#160;1)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Other Observable Inputs<br/>(Level&#160;2)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant Unobservable Inputs<br/>(Level&#160;3)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market fund</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total included in cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Available for sale investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of deposit</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,454&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non U.S. government</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total available for sale investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets measured at fair value on a recurring basis</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104,832&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">139,868&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099246464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes Based on Losses from Continuing Operations</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes based on losses from continuing operations consists of the following at December 31:</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current provision</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;Federal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,054&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,551)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;State</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,902&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred (benefit) expense </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,956&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,082)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,956)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total income tax provision</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Significant Components of the Company&#8217;s Taxes and the Rates</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s taxes and the rates as of December 31 are shown below: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.287%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.123%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.126%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except percentages)</span></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax computed at the federal statutory rate</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,128)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,941)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State tax, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(518)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Permanent items</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(366)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Return to provision and true ups</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance increase (decrease)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Significant Components of the Company&#8217;s Deferred Tax Assets</a></td>
<td class="text"><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant components of the Company&#8217;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development credits and other tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,226&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,317&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,574&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,444&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(492)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(611)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax assets before valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,082&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,833&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30,082)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,833)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net deferred tax asset</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623095907952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Overview and Liquidity (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and short-term investments</a></td>
<td class="nump">$ 105.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094877808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedClinicalTrialExpenses', window );">Accrued Clinical Trial Expenses</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="nump">$ 27,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms', window );">Payment terms</a></td>
<td class="text">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (298,100)<span></span>
</td>
<td class="num">$ (259,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">5,177<span></span>
</td>
<td class="nump">$ 4,527<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember', window );">Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems', window );"><strong>Error Corrections and Prior Period Adjustments Restatement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedClinicalTrialExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial Expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedClinicalTrialExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis=crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099600144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative financial instruments&#8212;warrants</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094096288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098052768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">9,431,303<span></span>
</td>
<td class="nump">10,947,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">5,069,458<span></span>
</td>
<td class="nump">3,771,984<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">4,360,968<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">877<span></span>
</td>
<td class="nump">877<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Net Loss Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,684,607<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093601296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Short-term Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">$ 84,299,000<span></span>
</td>
<td class="nump">$ 95,643,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">19,000<span></span>
</td>
<td class="nump">6,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(394,000)<span></span>
</td>
<td class="num">(65,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">83,924,000<span></span>
</td>
<td class="nump">95,584,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">5,016,000<span></span>
</td>
<td class="nump">33,377,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="num">(84,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">4,996,000<span></span>
</td>
<td class="nump">33,294,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">89,315,000<span></span>
</td>
<td class="nump">129,020,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">20,000<span></span>
</td>
<td class="nump">7,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(415,000)<span></span>
</td>
<td class="num">(149,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Market Value</a></td>
<td class="nump">88,920,000<span></span>
</td>
<td class="nump">128,878,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized loss</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">16,101,000<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(81,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">16,023,000<span></span>
</td>
<td class="nump">1,260,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">44,806,000<span></span>
</td>
<td class="nump">58,822,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">8,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(275,000)<span></span>
</td>
<td class="num">(38,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">44,539,000<span></span>
</td>
<td class="nump">58,786,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="nump">5,016,000<span></span>
</td>
<td class="nump">29,676,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(21,000)<span></span>
</td>
<td class="num">(73,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="nump">4,996,000<span></span>
</td>
<td class="nump">29,604,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">13,203,000<span></span>
</td>
<td class="nump">14,453,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(20,000)<span></span>
</td>
<td class="num">(3,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">13,187,000<span></span>
</td>
<td class="nump">14,454,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">2,284,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">2,288,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesCurrentAbstract', window );"><strong>Maturity less than 1 year:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Amortized Cost</a></td>
<td class="nump">7,905,000<span></span>
</td>
<td class="nump">20,380,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent', window );">Gross Unrealized Losses</a></td>
<td class="num">(18,000)<span></span>
</td>
<td class="num">(24,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Fair Market Value</a></td>
<td class="nump">$ 7,887,000<span></span>
</td>
<td class="nump">20,356,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesNoncurrentAbstract', window );"><strong>Maturity 1 to 2 years:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,701,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Fair Market Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,690,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094753760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Market Value</a></td>
<td class="nump">$ 20,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(175)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Market Value</a></td>
<td class="nump">17,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">(161)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember', window );">U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Fair Market Value</a></td>
<td class="nump">3,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">Gross Unrealized Loss</a></td>
<td class="num">$ (14)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094100816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">4,682<span></span>
</td>
<td class="nump">3,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less&#8212;accumulated depreciation</a></td>
<td class="num">(3,413)<span></span>
</td>
<td class="num">(3,441)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,269<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember', window );">Furniture and office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,560<span></span>
</td>
<td class="nump">1,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">$ 906<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=crdf_FurnitureAndOfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094075376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Supplementary Balance Sheet Information - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 1,849<span></span>
</td>
<td class="nump">$ 1,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedPreferredStockDividend', window );">Preferred stock dividend(1)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_AccruedClinicalTrial', window );">Clinical trials</a></td>
<td class="nump">2,333<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_Accruedresearchagreements', window );">Clinical trials</a></td>
<td class="nump">509<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_Accrueddirectorfees', window );">Director fees</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_Patentlicenseandotherfeespayable', window );">Patent, license and other fees</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 5,177<span></span>
</td>
<td class="nump">$ 4,527<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_AccruedPreferredStockDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Preferred Stock Dividend</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_AccruedPreferredStockDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Accrueddirectorfees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued service fees for nonemployee directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Accrueddirectorfees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Accruedresearchagreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Accruedresearchagreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_Patentlicenseandotherfeespayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Patent, license and other fees payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_Patentlicenseandotherfeespayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623097201328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">62 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>lease</div>
</th>
<th class="th"><div>Feb. 28, 2027</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseMonthlyRentPayment', window );">Monthly rent payments | $</a></td>
<td class="nump">$ 61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LessorNumberOfSubleases', window );">Number of subleases | lease</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage', window );">Annual rent increase, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Annual Rent Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseMonthlyRentPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Monthly Rent Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseMonthlyRentPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LessorNumberOfSubleases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessor, Number Of Subleases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LessorNumberOfSubleases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623190071984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 754<span></span>
</td>
<td class="nump">$ 745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Operating sublease income</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net operating lease cost</a></td>
<td class="nump">$ 754<span></span>
</td>
<td class="nump">$ 342<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094965712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 2,251<span></span>
</td>
<td class="nump">$ 2,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">675<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Non-current operating lease liabilities</a></td>
<td class="nump">2,040<span></span>
</td>
<td class="nump">2,568<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 2,715<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term&#8211;operating leases</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
<td class="text">5 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate&#8211;operating leases</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099350096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid included in operating cash flows</a></td>
<td class="nump">$ 612<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for lease obligations</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098053264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Future Minimum Lease Payments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 676<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">754<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">3,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(422)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 2,715<span></span>
</td>
<td class="nump">$ 3,119<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, To Be paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093348528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_WarrantsAndRightsRollForward', window );"><strong>Number of Warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="nump">5,260,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(770,833)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightNumberExpired', window );">Expired (in shares)</a></td>
<td class="num">(129,191)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares)</a></td>
<td class="nump">4,360,968<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
<td class="nump">5,260,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired', window );">Expired (in dollars per share)</a></td>
<td class="nump">21.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights', window );">Weighted average exercise price of warrants at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 5.33<span></span>
</td>
<td class="nump">$ 5.80<span></span>
</td>
<td class="nump">$ 5.19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract', window );"><strong>Weighted-Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_WarrantsWeightedAverageContractualTerm', window );">Weighted-Average Remaining Contractual Term</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">4 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightNumberExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightNumberExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>No definition available</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights exercised during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average exercise price of each class of warrants or rights expired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsAndRightsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsAndRightsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_WarrantsWeightedAverageContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Warrants, Weighted Average Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_WarrantsWeightedAverageContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623096893440">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockLiquidationPreferenceStatedValue', window );">Stated Value per share liquidation</a></td>
<td class="nump">$ 606<span></span>
</td>
<td class="nump">$ 606<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation preference - Series A Convertible Preferred Stock</a></td>
<td class="nump">$ 1,044<span></span>
</td>
<td class="nump">$ 1,020<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">277,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">60,600<span></span>
</td>
<td class="nump">60,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue', window );">Cumulative unpaid preferred stock dividends</a></td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember', window );">Series B Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">8,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember', window );">Series C Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember', window );">Series D Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">154,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">655,044<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Cumulative Unpaid Preferred Stock Dividends, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockLiquidationPreferenceStatedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Stated Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockLiquidationPreferenceStatedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesBConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesCConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesDConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093587280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series A Convertible Preferred Stock (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 17, 2006</div></th>
<th class="th"><div>Sep. 30, 2007</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Accrued dividend during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember', window );">Accumulated Deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPreferredStock', window );">Accrued dividend during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember', window );">Series A Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Cumulative dividend rate (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue', window );">Cumulative unpaid preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 438<span></span>
</td>
<td class="nump">$ 414<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ConvertiblePreferredStockStatedValuePerShare', window );">Stated value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockConversionPricePerShare', window );">Conversion price per share (in dollars per share)</a></td>
<td class="nump">$ 691.20<span></span>
</td>
<td class="nump">$ 928.80<span></span>
</td>
<td class="nump">691.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments', window );">Period during which the conversion price is subject to adjustment for dilutive issuances</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_SharePriceForAutomaticConversion', window );">Share price for 20 consecutive trading days for automatic conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,857.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays', window );">Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays', window );">Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_PreferredStockConversionObligationNumberOfTradingDays', window );">Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ConvertiblePreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ConvertiblePreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of consecutive trading days during which the closing price of the entity's common stock must equal or exceed the applicable price in order for the preferred stock to be automatically converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockConversionObligationNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days during which a specified average volume of common stock must traded in order for the preferred stock to be automatically converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockConversionObligationNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the average volume of common stock per day, which must be traded in order for the preferred stock to be automatically converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Liquidation Preference, Cumulative Unpaid Preferred Stock Dividends, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period during which the conversion price is subject to adjustment for dilutive issuances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SharePriceForAutomaticConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price target, if reached for the required period of time and if other provisions are achieved, that allows the entity to convert the preferred stock to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SharePriceForAutomaticConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093690544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Series E Convertible Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 15, 2020</div></th>
<th class="th"><div>Oct. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2022</div></th>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,400,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of shares called by warrants (in shares)</a></td>
<td class="nump">2,213,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 3.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Shares issued upon conversion (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">863,852<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Conversion of stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,342,250<span></span>
</td>
<td class="nump">1,342,357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightIssued', window );">Class Of Warrant Or Right, Issued</a></td>
<td class="nump">184,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightExpirationTerm', window );">Expiration term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesNWarrantMember', window );">Series N Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable', window );">Months until exercisable</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price of warrants (in dollars per share)</a></td>
<td class="nump">$ 2.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember', window );">Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ConvertiblePreferredStockStatedValuePerShare', window );">Stated value (in dollars per share)</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price (in dollars per share)</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Shares converted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,509<span></span>
</td>
<td class="nump">327,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">655,044<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=crdf_RegisteredDirectOfferingMember', window );">Registered Direct Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">1,984,328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement | Series E Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">865,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Expiration Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Issued</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ClassOfWarrantOrRightMonthsUntilExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Right, Months Until Exercisable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ClassOfWarrantOrRightMonthsUntilExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ConvertiblePreferredStockStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Stated Value Per Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ConvertiblePreferredStockStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesNWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=crdf_SeriesNWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=crdf_SeriesEConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=crdf_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=crdf_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094866976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Securities Purchase Agreements (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, shares issued (in shares)</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_SaleOfStockConsiderationReceivedOnTransactionGross', window );">Gross proceeds</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares', window );">Number of days counterparty cannot sell or transfer shares</a></td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SaleOfStockConsiderationReceivedOnTransactionGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Consideration Received On Transaction, Gross</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SaleOfStockConsiderationReceivedOnTransactionGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities Purchase Agreement, Number Of Days Counterparty Cannot Sell Or Transfer Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093150592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 09, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,150,000<span></span>
</td>
<td class="nump">3,150,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Incremental stock compensation</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Fair value of shares vested</a></td>
<td class="nump">$ 4,700,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember', window );">Inducement Grant Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">920,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,737,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in dollars per share)</a></td>
<td class="nump">$ 2.55<span></span>
</td>
<td class="nump">$ 5.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation cost for non-vested options</a></td>
<td class="nump">$ 8,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Period for recognition</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="nump">$ 1,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2014Member', window );">Equity Incentive Plan 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="nump">3,087,075<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=crdf_InducementGrantStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=crdf_EquityIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093588864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 4,256,000<span></span>
</td>
<td class="nump">$ 3,234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">1,035,000<span></span>
</td>
<td class="nump">491,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 3,221,000<span></span>
</td>
<td class="nump">$ 2,743,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623094894256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details) - Options to purchase Common Stock<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility (weighted-average)</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">108.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.62%<span></span>
</td>
<td class="nump">0.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (range)</a></td>
<td class="nump">98.00%<span></span>
</td>
<td class="nump">107.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (range)</a></td>
<td class="nump">110.00%<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093467504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Options Activity (Details) - Options to purchase Common Stock - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">3,771,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,737,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(28,858)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares)</a></td>
<td class="num">(398,156)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod', window );">Expired (in shares)</a></td>
<td class="num">(13,272)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">5,069,458<span></span>
</td>
<td class="nump">3,771,984<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable (in shares)</a></td>
<td class="nump">2,300,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">4,990,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">$ 7.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">2.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">32.52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share)</a></td>
<td class="nump">5.92<span></span>
</td>
<td class="nump">$ 7.13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">7.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 5.94<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Intrinsic value, outstanding</a></td>
<td class="nump">$ 19,322<span></span>
</td>
<td class="nump">$ 6,405,258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value, exercised</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Intrinsic value, vested and exercisable</a></td>
<td class="nump">12,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Intrinsic value, vested and expected to vest</a></td>
<td class="nump">$ 18,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted average remaining contract term, outstanding</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">8 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, exercisable</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted average remaining contractual term, vested and expected to vest</a></td>
<td class="text">7 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093166000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Financial Instruments - Warrants (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="nump">4,490,159<span></span>
</td>
<td class="nump">5,260,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">4,360,968<span></span>
</td>
<td class="nump">4,490,159<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the year recognized as a loss in the statement of operations | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (285)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_EstimatedFairValueOfWarrant', window );">Estimated fair value of Trovagene common stock (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="nump">$ 6.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember', window );">Warrants to purchase Common Stock | Black Scholes Option Pricing Method</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward', window );"><strong>Changes in the Company's derivative financial instruments liability balance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the beginning of the period (in shares) | shares</a></td>
<td class="nump">64,496<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Balance of warrants outstanding at the end of the period (in shares) | shares</a></td>
<td class="nump">64,496<span></span>
</td>
<td class="nump">64,496<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the beginning of the period | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Change in fair value of derivative financial instruments&#8212;warrants during the year recognized as a loss in the statement of operations | $</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Balance of derivative financial instruments liability at the end of the period | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Expected warrant term</a></td>
<td class="text">1 month 6 days<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.0412<span></span>
</td>
<td class="nump">0.0041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected volatility | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.54<span></span>
</td>
<td class="nump">0.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Dividend yield | Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueInputsQuantitativeInformationAbstract', window );"><strong>Range of assumptions used to determine the fair value of warrants</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DerivativeFinancialInstrumentsLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DerivativeFinancialInstrumentsLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_EstimatedFairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the estimated fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_EstimatedFairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsQuantitativeInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsQuantitativeInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=crdf_BlackScholesOptionPricingMethodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623089910224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">$ 88,920<span></span>
</td>
<td class="nump">$ 128,878<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,722<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">88,920<span></span>
</td>
<td class="nump">128,878<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">104,642<span></span>
</td>
<td class="nump">139,868<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">16,023<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">49,535<span></span>
</td>
<td class="nump">88,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">13,187<span></span>
</td>
<td class="nump">14,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">2,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">7,887<span></span>
</td>
<td class="nump">24,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,722<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,722<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">7,887<span></span>
</td>
<td class="nump">24,046<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">23,609<span></span>
</td>
<td class="nump">35,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">7,887<span></span>
</td>
<td class="nump">24,046<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities (Level&#160;1) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">15,722<span></span>
</td>
<td class="nump">10,990<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">81,033<span></span>
</td>
<td class="nump">104,832<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">81,033<span></span>
</td>
<td class="nump">104,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">16,023<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">49,535<span></span>
</td>
<td class="nump">88,390<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">13,187<span></span>
</td>
<td class="nump">14,454<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">2,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">728<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Other Observable Inputs (Level&#160;2) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets measured at fair value on a recurring basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Certificate of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | U.S. government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Non U.S. government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | U.S. treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total available for sale investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring basis | Significant Unobservable Inputs (Level&#160;3) | Money market fund</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total included in cash and cash equivalents</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093262368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Interest and/or penalties incurred</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2021Member', window );">Tax Year 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsIncreaseDecrease', window );">Reduction to net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_TaxCreditCarryforwardIncreaseDecrease', window );">Reduction to tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Reduction to the valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsSubjectToExpiration', window );">NOLs, subject to expiration</a></td>
<td class="nump">5,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsNotSubjectToExpiration', window );">NOLs, not subject to expiration</a></td>
<td class="nump">85,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Tax Year 2021 And Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsIncreaseDecrease', window );">Reduction to net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">123,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal | Tax Year 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsIncreaseDecrease', window );">Reduction to net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_TaxCreditCarryforwardIncreaseDecrease', window );">Reduction to tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOLs</a></td>
<td class="nump">17,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board | Tax Year 2021 And Prior</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsIncreaseDecrease', window );">Reduction to net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember', window );">California Franchise Tax Board | Tax Year 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_OperatingLossCarryforwardsIncreaseDecrease', window );">Reduction to net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credits | Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">R&amp;D credits | California Franchise Tax Board</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating loss carryforwards (NOLs)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credits</a></td>
<td class="nump">$ 2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_OperatingLossCarryforwardsIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_OperatingLossCarryforwardsIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_TaxCreditCarryforwardIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Credit Carryforward, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_TaxCreditCarryforwardIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_TaxYear2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_TaxYear2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=crdf_TaxYear2021AndPriorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=crdf_TaxYear2021AndPriorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_CaliforniaFranchiseTaxBoardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623099440704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrentAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current provision</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">19,054<span></span>
</td>
<td class="num">(5,551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">4,902<span></span>
</td>
<td class="num">(531)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred (benefit) expense</a></td>
<td class="nump">23,956<span></span>
</td>
<td class="num">(6,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_ValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(23,956)<span></span>
</td>
<td class="nump">6,081<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Total income tax provision</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_ValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_ValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093225536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Company's Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax computed at the federal statutory rate</a></td>
<td class="num">$ (8,128)<span></span>
</td>
<td class="num">$ (5,941)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="num">(518)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_IncomeTaxReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="nump">32,369<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount', window );">Stock based compensation</a></td>
<td class="nump">553<span></span>
</td>
<td class="nump">325<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">Research and development credits</a></td>
<td class="num">(319)<span></span>
</td>
<td class="num">(366)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount', window );">Return to provision and true ups</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance increase (decrease)</a></td>
<td class="num">(23,956)<span></span>
</td>
<td class="nump">6,081<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Percent [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax computed at the federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of federal tax benefit</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems', window );">Permanent items</a></td>
<td class="num">(84.00%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Research and development credits</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent', window );">Return to provision and true ups</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance increase (decrease)</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="num">(22.00%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_EffectiveIncomeTaxRateReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_EffectiveIncomeTaxRateReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_IncomeTaxReconciliationPermanentItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_IncomeTaxReconciliationPermanentItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126970579&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623093376544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGrossAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Tax loss carryforwards</a></td>
<td class="nump">$ 20,289<span></span>
</td>
<td class="nump">$ 17,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther', window );">Research and development credits and other tax credits</a></td>
<td class="nump">2,743<span></span>
</td>
<td class="nump">2,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,317<span></span>
</td>
<td class="nump">962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">4,794<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">30,574<span></span>
</td>
<td class="nump">22,444<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease right-of-use assets</a></td>
<td class="num">(492)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred tax liabilities</a></td>
<td class="num">(492)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_DeferredTaxAssetsNetBeforeValuationAllowance', window );">Net deferred tax assets before valuation allowance</a></td>
<td class="nump">30,082<span></span>
</td>
<td class="nump">21,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(30,082)<span></span>
</td>
<td class="num">(21,833)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeferredTaxAssetsNetBeforeValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, Before Valuation Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeferredTaxAssetsNetBeforeValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible research tax credit carryforwards and to other deductible tax credit carryforwards not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGrossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGrossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139623098086832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade', window );">Milestone or royalty payments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>crdf_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>crdf-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crdf="http://www.cardiffoncology.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crdf-20221231.xsd" xlink:type="simple"/>
    <context id="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6f11541efb704082a265f9324c80eedc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i06ea67f0d3b64fe49af654a24cca7b41_I20230223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2023-02-23</instant>
        </period>
    </context>
    <context id="i8e8826dc39c04031b505d8c4ed59725d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7f96c19e96104c05b51cc23d98344c24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8163d9f52ab94b4aafd5fb22fd53dadf_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie1bdcccd341047f39901c6c37adf4d01_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i388253962d4b4b3ab93b1e08702adfdd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8b4884c1cff544f0bb9f898e5ddbf8e0_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i08542de1deb8454493ed1ff8baf6b427_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ia11a41c8cea2407c8bdeb44938a52270_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifb897010af224abc95b5952441ea70a0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie9c669ee81da4204bcdcb71cf65565a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7978fbf15d3f41dcbf8154394977cca6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ief4483220d7c41bea4914cd482792617_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib920a1f02b184e238f9c206b9a064d82_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9a8cbdcbd3ba44fbad8ef0797734695d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic0f3d29f09ee44a4bf376bf33507e1fc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0614bca5466e47cebcb947482e4d0305_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5e71be265fa4fa7a538e7d7379fab1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia0f6bc6df8014431a77c99ab2c34a707_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib4cde148671c44d794a76ed6b416a19d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i57d61ca588534e27a11812dffb0c09f4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9fa0fcea09ba4d2384358db55c650345_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib1460f61dda948aabd2999ef5dc73481_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i689740219e214ef58af97e73397e9639_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5c4b1dd7a85546b99de632aa3cd6850d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i99b6a1cd1dcc4ce799987fb33f9e4c9d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9a6e8d2aa5e54a42941fae9f78ca955b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5d69223477441e6ba07ac77a66de571_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">crdf:ServiceReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ief601a71b15a453791b8b9ef7994a50b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic3e300c60978432fa06883530ae83613_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id9cf7788e55c4739b94fc0cf078e531e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i866498a356ac40ad9fc5fc95f6654ec4_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:CommonStockAndWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic357b095a944414684981c1dc8b89fb7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7db42fc039fd45aeaea7b5bc0553089e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id6e8c265de294538a1036e72f7c48ee4_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3d722eb9049649258eed2c0dc7b7f489_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6db19d7e4c5b45118fb2b4e6b4642581_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ifa12187761644b8fb660f20d8935e788_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i04fc18d316ba46f4b37af84f0a656dae_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icfc3ebfa98e941b5bc6b10599b18ba6f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a80f0906358478ab1f82fee730acdf1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iaabac25eea454ee4a957bcb868f30e54_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7de3c2329b134630bba5604f67f427b2_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="idbac0ee763c14b4691866040faab8881_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9cfa801a2fb64cd2a7453b02850a5da8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d7ee18907d4487f8a1215d75d135ee7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idb4e0e354837488d92217bd45d8de5d9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ib79309171dc9429497e5fe33bfa88be7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis">crdf:CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9dc25c72ae12437eaaac485fab890f66_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id39a83cf8e894d87a841a0c710893a25_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibcb3367ce4cc4990a02e061fdb54b181_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i148a84869fe740b3a3078739ed04eb1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3de22f800dcc41fe9ec79feeab414c28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idb08599bdf3f4cd491334a0f7a14e458_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id1e22fef9a7a4228a7799fa9e0bb1735_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i007c30ebe4ca4d128452e15ece8e01d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crdf:FurnitureAndOfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9081e23b06e6448d9830510d151ca033_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i14c3caa3006c4f6ebf14421f944e494e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd60c6be701446a9bbe35fdcd554faf1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9982ed59fd6427f808ced5af06dbdd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1fc787def7f7467b8134e270f125cecc_D20220101-20270228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2027-02-28</endDate>
        </period>
    </context>
    <context id="i437c6b27648f43149169d43e9d00f190_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2513f13b8a974c7daed93b812f580722_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i967e88231f6e41158f5760ef3badc44a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15da6dbca1f446fabca739e995d15020_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf1325a8adbb464aa4a9459b6c1ebf24_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesBConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1c031a24f5041998bc94baf5d5e7878_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib2bbcf65ab5b4c44852255c9f2d94146_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesCConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6a7c515d9ae6485d9e93a24cb7826442_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iad1bd806a546460c98ffb5ac6f3ac8c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesDConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf86537bddcb4f599b70afe570a83e20_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i492ca89c37204a0da71301af85c79a73_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0c78aec3b59415da597680943386c88_D20070701-20070930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2007-07-01</startDate>
            <endDate>2007-09-30</endDate>
        </period>
    </context>
    <context id="i6e2742890db242d6bf741c1ee3352f61_D20060317-20060317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2006-03-17</startDate>
            <endDate>2006-03-17</endDate>
        </period>
    </context>
    <context id="icfbfb8b01efa4a1299b3d55a92ac99c6_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">crdf:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i945e201b0a974dac9a79bbce7e560aac_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i6fbb0b602b174b52b951641f74a93e02_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="ia4060629a24449e582b7b1c954cde009_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i01b6d2c9f16c4851800bc4d351b41c95_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i34bf0c72c7264502a3fd19a93c17fc34_I20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crdf:SeriesNWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-15</instant>
        </period>
    </context>
    <context id="i1ac45431f2954aeea968270d5152763f_D20201201-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iba4fe2a0ab954fd996d5aeadefcf0d29_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i537f6a2ef9cb45469a00fe1de5bbadbd_D20220101-20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-31</endDate>
        </period>
    </context>
    <context id="i05f68406df2c440b8b525d03472d93a8_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">crdf:SeriesEConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i5c69ebdd813b43cf9b9e7435a5b93db8_D20221001-20221031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-31</endDate>
        </period>
    </context>
    <context id="i121f9fb27a22487c9da80cbd21f3696c_D20200615-20200615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2020-06-15</startDate>
            <endDate>2020-06-15</endDate>
        </period>
    </context>
    <context id="i108dcc73776440a2bb02b0906b8fb804_D20210501-20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <startDate>2021-11-01</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="i7370af0295e247098c3f37e012a4710d_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib2ae2c2e51104727ab30997d35b6e45b_I20220609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
        </entity>
        <period>
            <instant>2022-06-09</instant>
        </period>
    </context>
    <context id="i9738a5e163944c6ea598de6c5bd1a81c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">crdf:EquityIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia3450ae440464e099c7b194d9e93da51_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">crdf:InducementGrantStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4075c1548dc7491f83a6970912aca8fa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i88d9796297a64fb8928bef8b221160e5_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i7653394ffa3343d58c6ca060d5bfc38e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5f1151fb051c43a3a54f391052603412_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i12ca60f5c6f2431eb4b26a3b8e10d21f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i54f3b30b34ae4b56b912ae1b787704d5_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2d91a06d3c074593b7c7a0c70ea5c098_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ia6c27981ae474b778f9da78071df3c6c_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9c1532e9351741698480572142e9d643_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2095721442fd459a96884e78016c08c6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i742d83ea624f49ce83073c6574708721_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0303b15e3f184176afecec0057db48a9_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3aa54b0f02c246f49fa614c49650a57b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i271b9a9812a34766a92109b7e9619679_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iad6ba7c42c22486fbe96bea3b5c38401_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i92fafe950c8f4417b2b04359b916f56c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0914d051b344922b3bc650fe526e585_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iff69cbb07e994ae88562ba51fc89f559_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a07aa7c69da44d09083212536411b77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2569ead797594df6944309ee7f73c65a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39321e212ba6459991b552dacbff98c5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i26cfa5a3c7f344f38855d2fe383ea8ca_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if5a580a4d19d4faaa1dc83d296793561_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">crdf:BlackScholesOptionPricingMethodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i91378a5db9e4460aa7fd228629188cda_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i559bf50fb42d497ebedd77cbd829099a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5fda4d776d4441dbbfb4413a40f5e88c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15b0c01e3be148e2b5d184d7b0a95541_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d4fe76ae8674e07a30a62a4550a8659_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i31a535f0f5474b53930803ca83868183_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i19fe2e4f93f04be6b765339abdde93a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iccb84b1da2524dcca88a14bcd81ef349_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id05871e6ded54574ac496cd98d0e4696_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie85454a3cb3a449e989750c88baec3c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i80b5d8a47de34c9eb00dd9153e2778de_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if98e0631384e478d878a491576d94a8a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ide57bacb5fcd4817820479a301609b87_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i18b7ac7b497e43c5a2626cc79179be2c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb973974a4fc444080d9042fa7203123_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6514853ca989457f9d06c6c616a89977_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifce1d5e58a8f4ea4b1a87da480e31782_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0acf1c3b475f4b8a81a25aee9941f99b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id799229c6920407f97f22581a8fa94e6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iee9cd5b6263248798f95445a96022bad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6eeede3e492747df92a9120df4d9cc8e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i101cb968b2e848d79fffd76c16210cef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i82958f514bb0410cacf6fa01b1a48f5d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ida5f1f7b2ea54929968874ffdbd66397_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieef0de49d2b147eca762ee3c00cc7304_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae038c8a23044d3ebf1fcfa5f900eb65_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4d6e1e6167d64ccaa6c44f9ba201432f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ef75d470db04581b85f0f68742c2606_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea2ee687a6f34deb8370b027572ae45d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i291d4bc8966f478cb947f0421e4b1625_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie2e4c7108fe54d94a35daa0010043cdb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic637b3f96e40484683e069e269081b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id928b4407f1f45369fc9e7339ca8dc19_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9cf29fe2ae264154a0c772eac0487121_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8d295ad0fab4be1ab0b93436cbf5e45_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i96c3d5ecadf6458bb42cbcca79de87c5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58cd328823a74a059647630be8c9bd53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1d946c3997c8417998d8519879aed8e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i519eaf766bb74f9d94fda2c533facecd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i57286981e17d447682811b77a9794aaa_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3f92ad9ff9224a48ac42201d146a3949_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i39404762c230459fbd8d949512073537_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibdda4c739f784510827447c73dcf98f8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i371c8b26e2e74115ab24d25d9f222d61_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i40877594c7984b29870c62f1c8d1bdc8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3ac4c76631b14de28b082ab760f8c24d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59de1a0bb89f47af947b9f576e513d78_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b28a9f7521d4d68bf4be2df75a35b05_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i41d8e41740a749a489f23559bd330d4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95814041224f4377a9cb681bea4771a2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iede7ddb493894499ac185e6508bb0bec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia5863e8943b44c3aae93910dab768c3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7db2823712cb403fb76468ee499dba28_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8eb9fb7597594e409dd14b7de369e07d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i75170cbe292740eb8905b33cefbb47e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia539fce54f0549ee98e69a7feb86123b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icf0a0c7937904a32bf6356ddaa1dff71_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib7e5322a521b4cd3abc87556084fd935_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">crdf:TaxYear2021AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i67adec9130714636a68f59baafa0faeb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">crdf:TaxYear2021AndPriorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i45c1454942fd4f6cb115a433327d89b6_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ifab578dbdeed4bdaaf35f05006bb4d2a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:CaliforniaFranchiseTaxBoardMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001213037</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:TaxYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>crdf:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="lease">
        <measure>crdf:lease</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF80LTEtMS0xLTQwMzY4_5273c1d5-1945-4f47-9cb1-cc04e8a6f232">0001213037</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF85LTEtMS0xLTQwMzY4_b026c205-8993-4cc9-aefb-bd782d4f9330">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF8xMC0xLTEtMS00MDM2OA_413bea19-7b73-4754-8245-da380010722f">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl80L2ZyYWc6YTk1OWRjOWVjN2M2NDM4MWE4NGIxZWRlNmE0ZDM1NzcvdGFibGU6MDU3ZjJlMzBmMGIzNDAyMTg1ODRhZTlmMmJiODYyMmQvdGFibGVyYW5nZTowNTdmMmUzMGYwYjM0MDIxODU4NGFlOWYyYmI4NjIyZF8xMS0xLTEtMS00MDM2OA_c5079820-da30-4657-9ea5-b5cfd38ba2ab">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI2_1fd90097-e270-4445-8abf-cff4196e7a88">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MzlkNTIxNmIxMGM4NDUxYTgzMGEzNGExYTc2OTkxOTkvdGFibGVyYW5nZTozOWQ1MjE2YjEwYzg0NTFhODMwYTM0YTFhNzY5OTE5OV8wLTAtMS0xLTQwMzY4_a0e58ebd-ae7d-40e7-9844-64be4545577a">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18xMjg_cba57136-1fdc-47fb-b3b0-fa70fc1cb6ee">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18xMjg_627b0a46-9255-42e0-9597-6071251b4d39">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGMwNjZlZWMwOWMyNGQwZThjMTc5N2QwYmU0MWYyZWQvdGFibGVyYW5nZTowYzA2NmVlYzA5YzI0ZDBlOGMxNzk3ZDBiZTQxZjJlZF8wLTAtMS0xLTQwMzY4_981a6def-06be-443b-8526-058f8a1d0326">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTMw_a849504f-adc5-4516-856a-e7d26d706f8c">001-35558</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTMz_fbf60868-0f2b-4b73-9ea0-2ca4526f26a4">CARDIFF ONCOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8wLTAtMS0xLTQwMzY4_a85a8a38-0aa1-403f-a769-ed42cd4d73ee">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8wLTItMS0xLTQwMzY4_1d0a94bd-2cd4-404a-8dd1-54f9001c9799">27-2004382</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTQ0MjczOWMyNDNkNDk4ZGIyNzI5MTU1YmJjYmUxZjZfNA_50046be0-c994-4df7-966e-f86cf2bdfede">11055 Flintkote Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTQ0MjczOWMyNDNkNDk4ZGIyNzI5MTU1YmJjYmUxZjZfOA_01e38c64-2ed9-4fbb-9c55-bc9254469b9d">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTQ0MjczOWMyNDNkNDk4ZGIyNzI5MTU1YmJjYmUxZjZfMTI_0426a01f-100f-4e3e-a485-ee548d094994">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF8yLTItMS0xLTQwMzY4_d2b10e3a-aef7-445b-830d-ccb4a0a151ae">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF80LTAtMS0xLTQwMzY4L3RleHRyZWdpb246ZmM3NmYwNjY5NDI2NDIzN2IzYWJhNDY4NzQ5MTc4OWJfNQ_46aa6fad-e2ae-43d9-af39-673cbc5a3982">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF80LTAtMS0xLTQwMzY4L3RleHRyZWdpb246ZmM3NmYwNjY5NDI2NDIzN2IzYWJhNDY4NzQ5MTc4OWJfOQ_03718b12-94f9-4a7e-987d-1bfb7c665c67">952-7570</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6NDA4ODk2YjE2NDMyNDFjN2E1OGI3Mjg0OTI5ZDlhMjQvdGFibGVyYW5nZTo0MDg4OTZiMTY0MzI0MWM3YTU4YjcyODQ5MjlkOWEyNF84LTAtMS0xLTQwMzY4_ca3ab3ac-7124-454d-8ea5-4a166b249a9e">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTM0_326a24a9-c5e2-4a45-8782-cfcab2499a30">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI3_4dea4d52-ab03-4b5e-badb-45eee5359cd4">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTM1_d3ddb8ee-a42f-496a-9b96-3862ca09a81e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTM2_3e40dfc8-ba2c-4d8a-a398-7d97c317def3">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGJmMjE5ODZmNjc1NGU1MTg3YTJmMjMxNTk2OGJjNDgvdGFibGVyYW5nZTowYmYyMTk4NmY2NzU0ZTUxODdhMmYyMzE1OTY4YmM0OF8wLTQtMS0xLTQwMzY4L3RleHRyZWdpb246ZTMwYzE2MmYxM2FjNDRkZDkxNjVkNTRlMGQ4M2RkYmFfNA_c5b37331-d404-482d-93c0-3d0dce00af81">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGJmMjE5ODZmNjc1NGU1MTg3YTJmMjMxNTk2OGJjNDgvdGFibGVyYW5nZTowYmYyMTk4NmY2NzU0ZTUxODdhMmYyMzE1OTY4YmM0OF8wLTYtMS0xLTQwMzY4L3RleHRyZWdpb246ZTE2ODY5YzhjOTY4NDA2MWE3NWMzY2U3M2IxYmI1ODJfMzA_8e683b59-a5a6-49dc-a3ab-b8ff2429a43f">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGFibGU6MGJmMjE5ODZmNjc1NGU1MTg3YTJmMjMxNTk2OGJjNDgvdGFibGVyYW5nZTowYmYyMTk4NmY2NzU0ZTUxODdhMmYyMzE1OTY4YmM0OF8wLTgtMS0xLTQwMzY4L3RleHRyZWdpb246MDg4MzljYjZmMmEwNDE1NWE1ZDdhYjA2M2JlZTljNmRfMjg_25052abd-4307-4975-b601-80119501cc4d">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI4_6e3737de-3441-403d-8ca4-7731d8606ff2">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMTI5_fe0e7853-4523-429f-89d3-0306c3dbb55e">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i6f11541efb704082a265f9324c80eedc_I20220630"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMDA5_e786c1f4-bc2b-4fb5-960d-5e5e13dc6764"
      unitRef="usd">93819519</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i06ea67f0d3b64fe49af654a24cca7b41_I20230223"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN18zMDI0_2ab35688-ca02-4f94-ae99-b451f55cbdb3"
      unitRef="shares">44677169</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8xL2ZyYWc6MTAyODdiMzAxMTM3NDk5ZmE4NjgyNzFhNGUwZDY3ZDcvdGV4dHJlZ2lvbjoxMDI4N2IzMDExMzc0OTlmYTg2ODI3MWE0ZTBkNjdkN181NDk3NTU4MjUyMjk_f3e07583-21eb-408c-acac-348b0ef5fd24">&lt;div style="text-align:center;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Specified portions of the registrant's proxy statement, which will be filed with the Securities and Exchange Commission pursuant to Regulation 14 A in connection with the registrant's 2023 Annual Meeting of Stockholders (the "Proxy Statement"), are incorporated by reference into Part III of this Annual Report on Form 10-K.  Except with respect to information specifically incorporated by reference in this Annual Report, the Proxy Statement is not deemed to be filed as part hereof.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTAvZnJhZzo5MTQzMjI4M2I0MzI0ODBlOWMwMTE5ODBlZDkxZTg5ZC90YWJsZTo5MDUzMjBlMmE2YWM0OWJlOGYxY2M3NGM1MjkzNDExOS90YWJsZXJhbmdlOjkwNTMyMGUyYTZhYzQ5YmU4ZjFjYzc0YzUyOTM0MTE5XzAtMC0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo5YWY5MGE1OTAxZDg0ZjFlODZjYmJlOTQ4ZGE3MDcwOF85OQ_dbd71f31-cf66-4907-a76f-c4516108583d">243</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTMvZnJhZzplYmYwNjUzNDBiMjQ0NTBjYjRiYjZiZTgxZmI5NjhhOS90ZXh0cmVnaW9uOmViZjA2NTM0MGIyNDQ1MGNiNGJiNmJlODFmYjk2OGE5XzU2MDQ_92e0c84f-83f1-4c74-b2dc-541b0d0c9763">BDO USA, LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTMvZnJhZzplYmYwNjUzNDBiMjQ0NTBjYjRiYjZiZTgxZmI5NjhhOS90ZXh0cmVnaW9uOmViZjA2NTM0MGIyNDQ1MGNiNGJiNmJlODFmYjk2OGE5XzU2MDY_9ad06207-34a0-4f9b-86c7-eeaea379aa29">San Diego, California</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMtMS0xLTEtNDAzNjg_2aefec70-0bd2-4b08-9bee-430da5f308e0"
      unitRef="usd">16347000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMtMy0xLTEtNDAzNjg_5dcb1884-fc42-41c4-ab9a-3dc6a1ec0425"
      unitRef="usd">11943000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzQtMS0xLTEtNDAzNjg_36c356d4-b9da-4e70-9ddf-4f5a605b1acb"
      unitRef="usd">88920000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzQtMy0xLTEtNDAzNjg_444c07f0-1878-4fff-b964-470a20dce3df"
      unitRef="usd">128878000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzUtMS0xLTEtNDAzNjg_4e9fce90-700b-4484-888b-7085c6802d26"
      unitRef="usd">771000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzUtMy0xLTEtNDAzNjg_7bc28ac9-27bf-4d06-841c-73c483c1b88f"
      unitRef="usd">535000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzYtMS0xLTEtNDAzNjg_1fb9dda4-9f15-47ce-8280-ce1b0d679f81"
      unitRef="usd">5246000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzYtMy0xLTEtNDAzNjg_8b017ffa-b589-40c6-8760-3adced7564df"
      unitRef="usd">4771000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzctMS0xLTEtNDAzNjg_a9a3d366-d265-43fa-ab53-f6b3328649d8"
      unitRef="usd">111284000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzctMy0xLTEtNDAzNjg_b35c15c5-452e-4ed1-aa50-89b03cccb23e"
      unitRef="usd">146127000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzgtMS0xLTEtNDAzNjg_6f0d3584-a17c-402e-9b7a-d9cedc0e3519"
      unitRef="usd">1269000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzgtMy0xLTEtNDAzNjg_bd618e72-8863-4a00-b166-efe774e9d9ad"
      unitRef="usd">382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzktMS0xLTEtNDAzNjg_4635cfff-9832-4618-a260-1b039c2341ae"
      unitRef="usd">2251000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzktMy0xLTEtNDAzNjg_7847c475-231d-4869-bec4-bae06dcb7f12"
      unitRef="usd">2796000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzEwLTEtMS0xLTQwMzY4_0824752e-5d78-44de-8cc5-c8ba59459b75"
      unitRef="usd">1387000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzEwLTMtMS0xLTQwMzY4_2b8b9c04-ee88-4b9f-b758-dee3c0c67a54"
      unitRef="usd">239000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzExLTEtMS0xLTQwMzY4_a18132a5-1acf-496a-a50f-3ebec99d258c"
      unitRef="usd">116191000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzExLTMtMS0xLTQwMzY4_67a45c91-de80-4bd3-9600-7b0b6074adad"
      unitRef="usd">149544000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE1LTEtMS0xLTQwMzY4_06183b43-d1e4-4290-8445-89217c16b58e"
      unitRef="usd">1956000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE1LTMtMS0xLTQwMzY4_2c86c5a5-6dac-4875-9c8f-1f0d26f4495b"
      unitRef="usd">1439000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE2LTEtMS0xLTQwMzY4_65e31125-8f5a-4c96-b2d6-5dfba20b1f06"
      unitRef="usd">5177000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE2LTMtMS0xLTQwMzY4_17179d24-a78d-4f88-b406-2207b8de24e2"
      unitRef="usd">4527000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE4LTEtMS0xLTQwMzY4_d5c270c8-ab44-4d14-8682-6c382b675260"
      unitRef="usd">675000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE4LTMtMS0xLTQwMzY4_6574778d-6dcb-4ddd-a7b6-c7a744cea5d7"
      unitRef="usd">551000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE5LTEtMS0xLTQwMzY4_277e0029-f10c-4fa7-8896-5ba6e167e4d6"
      unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzE5LTMtMS0xLTQwMzY4_c37213c1-adc6-4987-912c-3e9ceb6f8466"
      unitRef="usd">42000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzIxLTEtMS0xLTQwMzY4_1d8a2f49-9bcf-4173-9331-56c5dee760c5"
      unitRef="usd">7808000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzIxLTMtMS0xLTQwMzY4_badc4fcc-1286-4ec9-aaf7-769d226553fe"
      unitRef="usd">6559000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI0LTEtMS0xLTQwMzY4_f43bdd90-6b87-4cf2-8c74-ac1fd98ad4f1"
      unitRef="usd">2040000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI0LTMtMS0xLTQwMzY4_3f1a858d-b8b7-40ae-a5a9-ae64e2296380"
      unitRef="usd">2568000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI3LTEtMS0xLTQwMzY4_557eec44-53da-4959-8071-ad679193bdc1"
      unitRef="usd">9848000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI3LTMtMS0xLTQwMzY4_c47ae41a-d563-4856-b2a3-ac4b3b5d43d7"
      unitRef="usd">9127000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI5LTEtMS0xLTQwMzY4_0ab2ddd8-5af8-4900-8435-7ea384126019"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzI5LTMtMS0xLTQwMzY4_af275501-d2c5-4af3-b4ae-0e6f5e1d7598"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfNTQ5NzU1ODE0MTcx_3b100c2d-6d5e-49a7-b35b-d9c8bc1da035"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfNTQ5NzU1ODE0MTcx_f984be61-4d73-4f3e-aad7-93f83a7901ea"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyODA1MA_8a3469dc-094a-4d8c-96eb-d8feea3d248a"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyODA1MA_94cc66e9-cb71-4200-a253-c58e218e9e4e"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyNzk2Mg_43456bb7-6072-4f9c-8e3d-53251f8a1456"
      unitRef="usd">1044000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MzVkNjM1MWYxZWNiNDU2ZGI5Y2Y4ZmNjMWEyNzRhMmNfMTA5OTUxMTYyODAzOA_32b710a1-c113-4aff-b5c9-33be2c5ae657"
      unitRef="usd">1020000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockValue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTEtMS0xLTQwMzY4_95b05527-e002-4b4b-a7e1-c0255dc4ef94"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMyLTMtMS0xLTQwMzY4_3abf2312-dfc2-4ba5-ab1c-1593f750acff"
      unitRef="usd">1000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMTg_3b999295-67ac-4864-b7ca-f7f7c9f6f022"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMTg_c91df306-41da-4272-b308-a64677019d3f"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMzI_06a1ac55-84e7-4020-b58b-3d754a17ed9a"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfMzI_bcd5f9dd-24c7-4a13-b35f-deec529258ac"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNTQ_83143ea7-119e-427e-aacc-31bc4e3532a8"
      unitRef="shares">44677000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNTQ_a93a5f30-acb1-4c9e-a9ab-285c811861a6"
      unitRef="shares">44677000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNjE_b9409abb-562f-43ba-a53a-22e45f4b331e"
      unitRef="shares">41964000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTAtMS0xLTQwMzY4L3RleHRyZWdpb246MDViNzgwZTZhMjI1NGUzNGExZjMyOTA4ODY1NDIxOTJfNjE_f5390a30-0ad6-4e3f-bf6c-09ef63fba823"
      unitRef="shares">41964000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTEtMS0xLTQwMzY4_4266d5b5-c6e9-4371-8de5-c4f7ff5c07d1"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzMzLTMtMS0xLTQwMzY4_62936613-d729-4992-b33e-60894e89e3a0"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM0LTEtMS0xLTQwMzY4_744ce507-b252-4b09-90ee-d4ed35949783"
      unitRef="usd">404834000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM0LTMtMS0xLTQwMzY4_0717f582-cf00-4a18-8ff4-710d94e9e402"
      unitRef="usd">400503000</us-gaap:AdditionalPaidInCapital>
    <crdf:Servicereceivable
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM1LTEtMS0xLTQwMzY4_e807c077-fb38-4ddf-94bd-f345fdd7fe68"
      unitRef="usd">0</crdf:Servicereceivable>
    <crdf:Servicereceivable
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM1LTMtMS0xLTQwMzY4_defd1170-a402-4aee-a712-9d7aebc0b444"
      unitRef="usd">139000</crdf:Servicereceivable>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM2LTEtMS0xLTQwMzY4_f35ad827-ff7b-4370-b4dd-735b961c0d59"
      unitRef="usd">-395000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM2LTMtMS0xLTQwMzY4_b769a813-c1e6-454b-a304-0d918d9dc6b6"
      unitRef="usd">-142000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM3LTEtMS0xLTQwMzY4_5879b5d7-ba4a-4d07-a18f-04f391849e74"
      unitRef="usd">-298100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM3LTMtMS0xLTQwMzY4_9ec48b4e-7a1c-4bb5-854b-cc1feccbb427"
      unitRef="usd">-259810000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM4LTEtMS0xLTQwMzY4_2953e4cb-cc4a-4a3e-bdcf-ae4a1839ed6a"
      unitRef="usd">106343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM4LTMtMS0xLTQwMzY4_62aa2b89-a25e-445f-87d2-b86fd7da34f1"
      unitRef="usd">140417000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM5LTEtMS0xLTQwMzY4_a2250f14-3b8f-4114-b312-43aa5f1bd421"
      unitRef="usd">116191000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTYvZnJhZzpmMWJhODMyNWEwOTY0NzIxYjg5ZTdlNWU0YjYzMGNmNS90YWJsZToyZDhkYzM1MzEzMmE0ODg5YWMxNDVmOGE0YTRhYzQ0NC90YWJsZXJhbmdlOjJkOGRjMzUzMTMyYTQ4ODlhYzE0NWY4YTRhNGFjNDQ0XzM5LTMtMS0xLTQwMzY4_5c3d2f13-55a8-4741-afea-d0ce3169dbaa"
      unitRef="usd">149544000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzItMS0xLTEtNDAzNjg_f191628a-0918-45d8-a059-9685d5bf4bbd"
      unitRef="usd">386000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzItMy0xLTEtNDAzNjg_e50fed9a-1fa4-48bd-87f8-6f13bce431da"
      unitRef="usd">359000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzEwLTEtMS0xLTQwMzY4_41826e92-4e25-453a-90fe-d15f24e5f61b"
      unitRef="usd">27107000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzEwLTMtMS0xLTQwMzY4_28e7376e-a5b2-4725-895d-d6608351f0b5"
      unitRef="usd">17376000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzExLTEtMS0xLTQwMzY4_30904b72-7685-40a6-9436-45a2634cb2b3"
      unitRef="usd">13181000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzExLTMtMS0xLTQwMzY4_90c654ad-6bca-441d-9f50-6aad9eef9d30"
      unitRef="usd">11838000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE0LTEtMS0xLTQwMzY4_d45527ad-f8a2-4ca7-8634-62f5fca0e99c"
      unitRef="usd">40288000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE0LTMtMS0xLTQwMzY4_24bfb0d5-9c59-420f-a784-860876fec3c1"
      unitRef="usd">29214000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE2LTEtMS0xLTQwMzY4_2ba41159-6d39-4e18-85a3-9d2585c14054"
      unitRef="usd">-39902000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE2LTMtMS0xLTQwMzY4_ffaecbdf-0703-4749-9908-fa5e0bd519c4"
      unitRef="usd">-28855000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE5LTEtMS0xLTQwMzY4_6104ea7b-c0f7-4986-b55d-c48e736b059b"
      unitRef="usd">1581000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzE5LTMtMS0xLTQwMzY4_d6391449-129d-45b3-b968-60b372b3cb99"
      unitRef="usd">264000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIxLTEtMS0xLTQwMzY4_a6c81b04-5175-4af2-84a2-4c70119983eb"
      unitRef="usd">-383000</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:OtherNonoperatingGainsLosses
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIxLTMtMS0xLTQwMzY4_4e86753a-7729-4252-befd-04bc48217cc0"
      unitRef="usd">15000</us-gaap:OtherNonoperatingGainsLosses>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIzLTEtMS0xLTQwMzY4_d8841955-16c3-4756-b459-5fd62571a47f"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzIzLTMtMS0xLTQwMzY4_06a03fef-b621-4718-a1d2-e26b8bb11d3f"
      unitRef="usd">285000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI0LTEtMS0xLTQwMzY4_6f6e6af6-6e4e-4f61-b81b-f4dd1586232a"
      unitRef="usd">1198000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI0LTMtMS0xLTQwMzY4_fd66f0a0-09d8-43ed-9a67-7a7f0c05cc93"
      unitRef="usd">564000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI2LTEtMS0xLTQwMzY4_816e5567-cb82-45fb-b14b-10c4069002b5"
      unitRef="usd">-38704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI2LTMtMS0xLTQwMzY4_844d1dca-53c9-41a6-b76a-13b0c4baff18"
      unitRef="usd">-28291000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI4LTEtMS0xLTQwMzY4_4e1a4f8b-8a66-4638-a3b6-4ad8252d779d"
      unitRef="usd">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzI4LTMtMS0xLTQwMzY4_c5722a2a-9ba9-4b5a-8c86-c3c7040582f3"
      unitRef="usd">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzMzLTEtMS0xLTQwMzY4_3cbb3661-1449-41cd-8275-3b3e73e4973d"
      unitRef="usd">-38728000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzMzLTMtMS0xLTQwMzY4_0278c4c0-396a-4fe0-ab5d-d7ff751279af"
      unitRef="usd">-28315000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTEtMS0xLTQwMzY4_c7bffebe-ca19-4620-a614-78bb13389085"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTEtMS0xLTQwMzY4_fa79cad9-fe21-43ff-8ef8-2f1f9a1c80af"
      unitRef="usdPerShare">-0.89</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTMtMS0xLTQwMzY4_d2ed7a9c-b6c6-4ef3-a0a9-abfb1847b709"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM1LTMtMS0xLTQwMzY4_f279e532-aa18-4f15-ada2-5df69a2a07e2"
      unitRef="usdPerShare">-0.73</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTEtMS0xLTQwMzY4_57d0ec5c-2c2d-4eae-897a-5a38edd76477"
      unitRef="shares">43600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTEtMS0xLTQwMzY4_8398ce43-f8a4-49f4-b920-2b76965b529d"
      unitRef="shares">43600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTMtMS0xLTQwMzY4_7a5ec287-1f68-43ee-91ce-57de78f95fe5"
      unitRef="shares">39030000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNTkvZnJhZzo1OWY3NTNkODAyMjM0ZjQ3ODJiOGM1NjI0YjgzNjdmOS90YWJsZTpjZGMyZTUwMzEyYzI0ZmVkYjcyMmQ5YmJiYWM0NzNkNS90YWJsZXJhbmdlOmNkYzJlNTAzMTJjMjRmZWRiNzIyZDliYmJhYzQ3M2Q1XzM4LTMtMS0xLTQwMzY4_f5cc62e0-a708-49a7-a886-16f04300270d"
      unitRef="shares">39030000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzItMS0xLTEtNDAzNjg_816e5567-cb82-45fb-b14b-10c4069002b5"
      unitRef="usd">-38704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzItMy0xLTEtNDAzNjg_844d1dca-53c9-41a6-b76a-13b0c4baff18"
      unitRef="usd">-28291000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzUtMS0xLTEtNDAzNjg_a36a43db-8972-45fa-b580-79075c1b08bd"
      unitRef="usd">-253000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzUtMy0xLTEtNDAzNjg_83f5ac94-9eef-42a3-a779-973b7f025029"
      unitRef="usd">-142000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzgtMS0xLTEtNDAzNjg_e4f143a5-602b-4ffa-b236-a80eac165524"
      unitRef="usd">-38957000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzgtMy0xLTEtNDAzNjg_a96fd7c7-38ea-4419-8d7b-f029e4e07e35"
      unitRef="usd">-28433000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzEwLTEtMS0xLTQwMzY4_4e1a4f8b-8a66-4638-a3b6-4ad8252d779d"
      unitRef="usd">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzEwLTMtMS0xLTQwMzY4_c5722a2a-9ba9-4b5a-8c86-c3c7040582f3"
      unitRef="usd">24000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <crdf:ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzE0LTEtMS0xLTQwMzY4_645aa0f2-1e2d-4c2e-86d7-866d5fecabd1"
      unitRef="usd">-38981000</crdf:ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic>
    <crdf:ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjIvZnJhZzo2YTU4NDk2N2U3NjU0NTcwYmM5Mzc4OTVkOTM1ZWNmNC90YWJsZTpkMjZhMmRjZWU0ZGE0NjhkYjZmN2UzYjA0YWQ3ZjUzMy90YWJsZXJhbmdlOmQyNmEyZGNlZTRkYTQ2OGRiNmY3ZTNiMDRhZDdmNTMzXzE0LTMtMS0xLTQwMzY4_5a3e5311-8aec-48e5-8c5d-4bce9c391731"
      unitRef="usd">-28457000</crdf:ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic>
    <us-gaap:SharesIssued
      contextRef="i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTEtMS0xLTQwMzY4_1a8873b3-c89a-42a8-a07d-b220dd405326"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTMtMS0xLTQwMzY4_e45d093d-923f-4c3a-90fa-698a60b91971"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i8163d9f52ab94b4aafd5fb22fd53dadf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTUtMS0xLTQwMzY4_74c0fc35-9751-4d6f-8df1-e7aef9f5b3b9"
      unitRef="shares">36781000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i8163d9f52ab94b4aafd5fb22fd53dadf_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTctMS0xLTQwMzY4_9ad68a36-3844-4b32-b461-a8f80ec7097d"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1bdcccd341047f39901c6c37adf4d01_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTktMS0xLTQwMzY4_13c72312-b674-4358-8bb2-c03f4038ae5a"
      unitRef="usd">361819000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i388253962d4b4b3ab93b1e08702adfdd_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTExLTEtMS00MDM2OA_05a2775d-6ef6-4f06-bc8f-e80bcf37734e"
      unitRef="usd">-2171000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8b4884c1cff544f0bb9f898e5ddbf8e0_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTEzLTEtMS00MDM2OA_f9caa09e-5a58-4446-90f4-d54d4d45f4e5"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i08542de1deb8454493ed1ff8baf6b427_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTE1LTEtMS00MDM2OA_562bbe43-4e5f-4df5-9c61-6c0242ed6c16"
      unitRef="usd">-231495000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc0LTE3LTEtMS00MDM2OA_385fa3d6-9062-4986-adec-6e63f76db914"
      unitRef="usd">128158000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc1LTktMS0xLTQwMzY4_4c0700b6-77c8-4ace-a248-96e367def4a0"
      unitRef="usd">3234000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc1LTE3LTEtMS00MDM2OA_b68c933e-661e-42b1-9634-710b54430b96"
      unitRef="usd">3234000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ifb897010af224abc95b5952441ea70a0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc2LTUtMS0xLTQwMzY4_03651bcd-2de8-43e9-b14a-e3c7b3539f5b"
      unitRef="shares">771000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc2LTktMS0xLTQwMzY4_8b18eeb0-f9f6-4288-8573-c4f0b544cbd8"
      unitRef="usd">1263000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc2LTE3LTEtMS00MDM2OA_8b28dafe-98da-4750-a088-571c95e5e215"
      unitRef="usd">1263000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ifb897010af224abc95b5952441ea70a0_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTUtMS0xLTQwMzY4_73b7005e-a7c8-4b80-a4e8-2315e826eb30"
      unitRef="shares">4412000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="ifb8c80c376624c18a1940767d15afb02_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTktMS0xLTQwMzY4_7028abee-aacd-49fc-8cbf-ce760a5e3489"
      unitRef="usd">34187000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTE3LTEtMS00MDM2OA_b44d00aa-a7de-4a0f-b422-af1a4d75627b"
      unitRef="usd">34187000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie9c669ee81da4204bcdcb71cf65565a1_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc4LTEzLTEtMS00MDM2OA_8a4778f0-ca86-4134-ab23-f427c9d0cc53"
      unitRef="usd">-142000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc4LTE3LTEtMS00MDM2OA_5256cf4d-1a42-413a-bdbb-5544e4d39a2a"
      unitRef="usd">-142000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:DividendsPreferredStock
      contextRef="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc5LTE1LTEtMS00MDM2OA_4b51c186-5eff-47dc-a1cc-c7a5a8fe965f"
      unitRef="usd">24000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc5LTE3LTEtMS00MDM2OA_cb8499c0-e12f-41a2-ad84-f0795c2d0342"
      unitRef="usd">24000</us-gaap:DividendsPreferredStock>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i7978fbf15d3f41dcbf8154394977cca6_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgwLTExLTEtMS00MDM2OA_bef951bd-cdae-4ef4-a452-e49d74104f58"
      unitRef="usd">2032000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgwLTE3LTEtMS00MDM2OA_7c56f95a-1d62-4b06-8b19-ea9563962dd9"
      unitRef="usd">2032000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <us-gaap:NetIncomeLoss
      contextRef="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgxLTE1LTEtMS00MDM2OA_d88f6340-c7fc-4f2c-98ad-f58e6d5024ed"
      unitRef="usd">-28291000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgxLTE3LTEtMS00MDM2OA_83118ae6-1d76-40e9-9cfd-8ea40a16ca55"
      unitRef="usd">-28291000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="ief4483220d7c41bea4914cd482792617_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTEtMS0xLTQwMzY4_bd050bb2-90d0-484a-932a-8479614f11c4"
      unitRef="shares">716000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ief4483220d7c41bea4914cd482792617_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTMtMS0xLTQwMzY4_9d866c6b-effe-4855-be35-99104acb90e6"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="ib920a1f02b184e238f9c206b9a064d82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTUtMS0xLTQwMzY4_079ff000-ab2d-4a28-8786-88fc73d30791"
      unitRef="shares">41964000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="ib920a1f02b184e238f9c206b9a064d82_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTctMS0xLTQwMzY4_c444fb86-3957-459c-aeae-ebee4c7bd119"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a8cbdcbd3ba44fbad8ef0797734695d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTktMS0xLTQwMzY4_511edd1e-100e-4765-86d9-b2f54b2e021d"
      unitRef="usd">400503000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic0f3d29f09ee44a4bf376bf33507e1fc_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTExLTEtMS00MDM2OA_a29c2312-a860-4e6e-a566-4e6579e8ec80"
      unitRef="usd">-139000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0614bca5466e47cebcb947482e4d0305_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTEzLTEtMS00MDM2OA_3150a513-8a9a-4bb6-8715-3e333c261502"
      unitRef="usd">-142000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia5e71be265fa4fa7a538e7d7379fab1d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTE1LTEtMS00MDM2OA_90a2f2f3-2926-49fc-9cb1-d63a32501d85"
      unitRef="usd">-259810000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgyLTE3LTEtMS00MDM2OA_4c8ff311-697d-4a1d-82fe-e9dc5ad3bf9b"
      unitRef="usd">140417000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ia0f6bc6df8014431a77c99ab2c34a707_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgzLTktMS0xLTQxMzc1_1d191b90-e28a-487c-bc1f-a8e7a2ec5e62"
      unitRef="usd">4256000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzgzLTE3LTEtMS00MTM3NQ_5ce19e0a-0b89-4a00-9f39-fc059577afcd"
      unitRef="usd">4256000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <crdf:StockIssuedDuringPeriodSharesWarrantsExercised
      contextRef="ib4cde148671c44d794a76ed6b416a19d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg0LTUtMS0xLTQxMzc1_66ee7796-8dce-4322-a9d0-4c5d11d7c448"
      unitRef="shares">29000</crdf:StockIssuedDuringPeriodSharesWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ia0f6bc6df8014431a77c99ab2c34a707_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg0LTktMS0xLTQxMzc1_cdc1d1aa-4114-49cc-a5be-c56f790f9c9b"
      unitRef="usd">75000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <crdf:StockIssuedDuringPeriodValueWarrantsExercised
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg0LTE3LTEtMS00MTM3NQ_c4bc19c8-b11f-4cab-9512-aa9c4cd9178b"
      unitRef="usd">75000</crdf:StockIssuedDuringPeriodValueWarrantsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="i57d61ca588534e27a11812dffb0c09f4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTEtMS0xLTQxMzc1_cf486a0a-2792-4f11-8c70-a73fd14a69c9"
      unitRef="shares">-655000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="i57d61ca588534e27a11812dffb0c09f4_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTMtMS0xLTQxMzc1_cb1cee1f-e55b-4297-96b1-46e7339aff53"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib4cde148671c44d794a76ed6b416a19d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTUtMS0xLTQxMzc1_16dba0fe-14bd-4c3b-8461-90a6721055bb"
      unitRef="shares">2684000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg1LTE3LTEtMS00MTM3NQ_d5f06a20-612b-4fd1-a37d-48cf847e05a9"
      unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i9fa0fcea09ba4d2384358db55c650345_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg2LTEzLTEtMS00MTM3NQ_136a6060-9076-47f1-ac5d-6d0c3b98c4fc"
      unitRef="usd">-253000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg2LTE3LTEtMS00MTM3NQ_1b04456c-ddf3-491f-9acd-1d4146ed8500"
      unitRef="usd">-253000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ib1460f61dda948aabd2999ef5dc73481_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg4LTExLTEtMS00MTM3NQ_cb564e41-22bd-4a24-a7ed-aa8c29ae2848"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:ReleaseOfClinicalTrialFundingCommitment
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg4LTE3LTEtMS00MTM3NQ_7e3cae89-b712-41ab-8d67-581f57cd13cb"
      unitRef="usd">139000</crdf:ReleaseOfClinicalTrialFundingCommitment>
    <crdf:PreferredStockCumulativeDividendAdjustment
      contextRef="i689740219e214ef58af97e73397e9639_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00NDAzMA_adfa9e98-dd45-4169-8fb4-e22092848d17"
      unitRef="usd">414000</crdf:PreferredStockCumulativeDividendAdjustment>
    <crdf:PreferredStockCumulativeDividendAdjustment
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00NDAzMA_5a23862e-0f2b-48c4-8d1b-d8a37e2de710"
      unitRef="usd">414000</crdf:PreferredStockCumulativeDividendAdjustment>
    <us-gaap:NetIncomeLoss
      contextRef="i689740219e214ef58af97e73397e9639_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00MTM3NQ_4ec8dd02-6c79-46db-a8f8-617d5eb8c66c"
      unitRef="usd">-38704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00MTM3NQ_b864ed47-5fbe-47c4-9285-420871e47935"
      unitRef="usd">-38704000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesIssued
      contextRef="i5c4b1dd7a85546b99de632aa3cd6850d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTEtMS0xLTQxMzc1_3adce2c5-5157-48c5-84fe-26c753720325"
      unitRef="shares">61000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i5c4b1dd7a85546b99de632aa3cd6850d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTMtMS0xLTQxMzc1_3b96a271-3664-48cb-96ed-4bc22652eebb"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="i99b6a1cd1dcc4ce799987fb33f9e4c9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTUtMS0xLTQxMzc1_51e2fafd-4a8b-4087-adb7-923b254b1f34"
      unitRef="shares">44677000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquity
      contextRef="i99b6a1cd1dcc4ce799987fb33f9e4c9d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTctMS0xLTQxMzc1_f99c7f3b-c611-4235-85cb-67498d3f9ab2"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9a6e8d2aa5e54a42941fae9f78ca955b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTktMS0xLTQxMzc1_aa4d3f75-cc86-4e27-a01a-a68f8cb14d00"
      unitRef="usd">404834000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib5d69223477441e6ba07ac77a66de571_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTExLTEtMS00MTM3NQ_6bf68bb3-e582-402a-a0af-768bd6e33e06"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ief601a71b15a453791b8b9ef7994a50b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTEzLTEtMS00MTM3NQ_2f421636-222e-4b4b-82bc-7f4a20a1435b"
      unitRef="usd">-395000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic3e300c60978432fa06883530ae83613_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTE1LTEtMS00MTM3NQ_1e0b25e6-23fa-4e52-99cb-37ecc9802115"
      unitRef="usd">-298100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzkwLTE3LTEtMS00MTM3NQ_63c55492-84bb-455f-96a9-784d2a042cb4"
      unitRef="usd">106343000</us-gaap:StockholdersEquity>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzE0OA_25007032-26ab-45c9-9f12-7f17cca11ab1"
      unitRef="usd">800000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NetIncomeLoss
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMtMS0xLTEtNDAzNjg_f2d63847-747a-4f99-9a0a-7eb20c4b247b"
      unitRef="usd">-38704000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMtMy0xLTEtNDAzNjg_3bc3f7c2-ce0c-44a6-9757-90e07c5615dc"
      unitRef="usd">-28291000</us-gaap:NetIncomeLoss>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUtMS0xLTEtNDAzNjg_8cdce1a1-cfe5-49f3-8897-ad42379005bb"
      unitRef="usd">-1000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUtMy0xLTEtNDAzNjg_68be895f-ad19-4410-a724-34aff394c57b"
      unitRef="usd">-1000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzctMS0xLTEtNDAzNjg_466b8b15-a9df-4930-8706-9006701fc81a"
      unitRef="usd">236000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzctMy0xLTEtNDAzNjg_96b6c3a3-86ec-4e00-85fa-eff49407b65e"
      unitRef="usd">451000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzgtMS0xLTEtNDAzNjg_657f29ef-aef7-477f-8332-5eed15143c06"
      unitRef="usd">4256000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzgtMy0xLTEtNDAzNjg_223cf8d8-d7a0-43ed-9ee1-1a77b9cc2981"
      unitRef="usd">3234000</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzEzLTEtMS0xLTQwMzY4_ad7afb86-27d3-4caa-ad51-87af216434b8"
      unitRef="usd">-632000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzEzLTMtMS0xLTQwMzY4_9ebe6d34-efdd-47c4-9ced-f1679564da18"
      unitRef="usd">-1607000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE2LTEtMS0xLTQwMzY4_d7c7eeee-be32-4584-afca-2144653497b7"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE2LTMtMS0xLTQwMzY4_482ab216-6cba-4ea0-9d64-d2b2ce84fe97"
      unitRef="usd">285000</us-gaap:UnrealizedGainLossOnDerivatives>
    <crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE3LTEtMS0xLTQwMzY4_54161a0f-b577-49e4-b2dd-fa9c91b01392"
      unitRef="usd">139000</crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived>
    <crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzE3LTMtMS0xLTQwMzY4_05775123-ae89-4582-9b4c-ce1454f9d544"
      unitRef="usd">2032000</crdf:Releaseofclinicaltrialfundingcommitmentforservicesreceived>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIwLTEtMS0xLTQwMzY4_e6997cd0-1b4c-4856-b569-a26e2ee651de"
      unitRef="usd">1148000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIwLTMtMS0xLTQwMzY4_b7b5a369-befd-4e14-a836-22ce60b0f005"
      unitRef="usd">-166000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIxLTEtMS0xLTQwMzY4_0df89af9-3214-4481-b2be-adfc0a43e43d"
      unitRef="usd">236000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIxLTMtMS0xLTQwMzY4_afe5baef-f0cd-49b0-9bb3-0f44f6c50b9e"
      unitRef="usd">215000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIyLTEtMS0xLTQwMzY4_984dad82-2eba-445b-9fe0-18240fdfb387"
      unitRef="usd">443000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIyLTMtMS0xLTQwMzY4_dc78143a-8c9e-4416-a9c8-43da4d2032c4"
      unitRef="usd">2099000</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIzLTEtMS0xLTQwMzY4_f8b242a8-a43d-4643-aa5d-b8f667ec761b"
      unitRef="usd">-545000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzIzLTMtMS0xLTQwMzY4_032d7bee-7137-4110-a5e8-c5c760fa30f2"
      unitRef="usd">-607000</crdf:IncreaseDecreaseInOperatingLeaseRightOfUseAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI0LTEtMS0xLTQwMzY4_3dd397cf-d675-4086-a7bb-c93106137c25"
      unitRef="usd">1348000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI0LTMtMS0xLTQwMzY4_282414fc-cf09-4c91-985c-232d2e34b482"
      unitRef="usd">719000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI1LTEtMS0xLTQwMzY4_02e89187-8a6b-460b-b38f-fc330c7905d5"
      unitRef="usd">-404000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI1LTMtMS0xLTQwMzY4_97f058ea-5666-4eb9-964e-61d98062a244"
      unitRef="usd">-811000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI2LTEtMS0xLTQwMzY4_b0627ead-7876-4363-bd38-0978c3d37917"
      unitRef="usd">-42000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI2LTMtMS0xLTQwMzY4_0e9efbcf-c607-4c5b-bbca-5c3122d4d5d2"
      unitRef="usd">-156000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI3LTEtMS0xLTQwMzY4_fa1e568e-4523-416c-bc8b-cea6bd6026a7"
      unitRef="usd">-33820000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzI3LTMtMS0xLTQwMzY4_e51ee93b-46b3-4726-bb88-3e31c310cd59"
      unitRef="usd">-23040000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMwLTEtMS0xLTQwMzY4_aa17b2d8-23ef-4ffd-a11f-c836ba74653d"
      unitRef="usd">1006000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMwLTMtMS0xLTQwMzY4_1eaf2470-21c4-4743-a7ae-d50bc3186925"
      unitRef="usd">205000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTEtMS0xLTQyNTA4_9554abde-ca25-4395-b28a-759ae7dfeb9e"
      unitRef="usd">114000</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromInsuranceSettlementInvestingActivities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTMtMS0xLTQyNTA4_83f273d3-f16e-4129-972d-8a7b957b9230"
      unitRef="usd">0</us-gaap:ProceedsFromInsuranceSettlementInvestingActivities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTEtMS0xLTQwMzY4_709a0bb4-4e7f-4ea7-8604-3b16f92f250e"
      unitRef="usd">76445000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMyLTMtMS0xLTQwMzY4_76c2df5e-6282-4203-be49-396179e3a59a"
      unitRef="usd">28391000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMzLTEtMS0xLTQwMzY4_1f7e6098-3c66-4165-af20-7fbf6fded715"
      unitRef="usd">91233000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzMzLTMtMS0xLTQwMzY4_741c5e42-c623-429d-a4eb-35c3f275ad8f"
      unitRef="usd">174385000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM0LTEtMS0xLTQwMzY4_cf005297-5cc5-4540-b768-98c77b553c8a"
      unitRef="usd">53829000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM0LTMtMS0xLTQwMzY4_7596cc8e-b4e0-49a6-a91d-49a17f22f55a"
      unitRef="usd">14751000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM1LTEtMS0xLTQwMzY4_1f0fb50f-a962-4b16-b98e-78fe02b558a5"
      unitRef="usd">38149000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM1LTMtMS0xLTQwMzY4_4fe138c2-7507-4218-bcd3-732484bdd704"
      unitRef="usd">-131448000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="id9cf7788e55c4739b94fc0cf078e531e_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTM2NmQ4ZGZhODBhNDM0NDg5MzVmOTE5YTNlZDYyOGFfOTA_a01c5c8b-d124-4631-ba9f-d53947141da3"
      unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="i866498a356ac40ad9fc5fc95f6654ec4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTAtMS0xLTQwMzY4L3RleHRyZWdpb246YTM2NmQ4ZGZhODBhNDM0NDg5MzVmOTE5YTNlZDYyOGFfOTg_df952ddb-412f-4a49-9cd5-1a9f0d28d862"
      unitRef="usd">813000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTEtMS0xLTQwMzY4_c4edee37-f2e5-4896-a899-9e96abab479c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzM4LTMtMS0xLTQwMzY4_02b8d835-e528-4ed4-b3d7-b0bce1d506a3"
      unitRef="usd">34187000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQyLTEtMS0xLTQwMzY4_91cc8ccb-4492-4819-b747-f183ffd28ac4"
      unitRef="usd">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQyLTMtMS0xLTQwMzY4_309487dd-d4bf-4a43-bc4a-85b08c3ebb13"
      unitRef="usd">1263000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQzLTEtMS0xLTQwMzY4_00a34bf5-270d-46d0-b1ca-89725a69afd8"
      unitRef="usd">75000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQzLTMtMS0xLTQwMzY4_6ce11dc7-b0f3-4844-a2e4-6ee4cf0a5fa1"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQ5LTEtMS0xLTQwMzY4_19b59666-0b22-442f-b8b8-545d197a6b5d"
      unitRef="usd">75000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzQ5LTMtMS0xLTQwMzY4_c4695902-2344-43d6-b99b-b880d03ac4ee"
      unitRef="usd">35450000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUxLTEtMS0xLTQwMzY4_7c3f9d68-53bd-46a3-be27-0ef60b5fbb6d"
      unitRef="usd">4404000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUxLTMtMS0xLTQwMzY4_1e2b8d46-8706-41c7-b428-6ed9076082a1"
      unitRef="usd">-119038000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUyLTEtMS0xLTQwMzY4_0081ecb1-dfa5-47b8-af64-0a9c34a615d8"
      unitRef="usd">11943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUyLTMtMS0xLTQwMzY4_ff53940e-3eeb-4f1a-b652-bbb1308a11c6"
      unitRef="usd">130981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUzLTEtMS0xLTQwMzY4_de338c57-2ac3-403f-bfaa-8bf002be9c78"
      unitRef="usd">16347000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzUzLTMtMS0xLTQwMzY4_64c0bf60-1475-4276-b36a-86d55da3e20e"
      unitRef="usd">11943000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU1LTEtMS0xLTQwMzY4_01fb5e36-ba47-4907-b77f-7fe394791e45"
      unitRef="usd">2000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU1LTMtMS0xLTQwMzY4_3fb372c8-7d9a-452f-b56a-c4af77b64daa"
      unitRef="usd">1000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU2LTEtMS0xLTQwMzY4_98022a36-339c-46e8-bad5-34a160e5a991"
      unitRef="usd">232000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzU2LTMtMS0xLTQwMzY4_c53a7279-7e95-41a0-a44d-65a9754ef342"
      unitRef="usd">6000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <crdf:PreferredStockDividendAccrued
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzYyLTEtMS0xLTQwMzY4_da8311fb-5cf1-4f2d-acb0-55fedcf94b97"
      unitRef="usd">0</crdf:PreferredStockDividendAccrued>
    <crdf:PreferredStockDividendAccrued
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzYyLTMtMS0xLTQwMzY4_b56fc7f0-dc7c-4490-a102-0652fbc28f15"
      unitRef="usd">24000</crdf:PreferredStockDividendAccrued>
    <crdf:NonCashCumulativePreferredStockDividendAdjustment
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTEtMS0xLTQ0MDUw_f2e0fb40-bbae-4a9e-8106-5f0d6024c12d"
      unitRef="usd">-414000</crdf:NonCashCumulativePreferredStockDividendAdjustment>
    <crdf:NonCashCumulativePreferredStockDividendAdjustment
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTMtMS0xLTQ0MDUw_9e89a259-fea7-4ee7-a671-d7f9833e7bd7"
      unitRef="usd">0</crdf:NonCashCumulativePreferredStockDividendAdjustment>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzQvZnJhZzowOGJiMTBlMTY0ZDg0NGNiOWJiNDQ5MzFmNGJjODNkNC90ZXh0cmVnaW9uOjA4YmIxMGUxNjRkODQ0Y2I5YmI0NDkzMWY0YmM4M2Q0XzE1Nzc_9f55f9f9-523b-4333-a83e-46656528ef92">Business Overview and Liquidity&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Business Organization and Overview&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology, Inc. (&#x201c;Cardiff Oncology&#x201d; or the &#x201c;Company&#x201d;) headquartered in San Diego, California, is a clinical-stage biotechnology company leveraging Polo-like Kinase 1 (&#x201c;PLK1&#x201d;) inhibition to develop novel therapies across a range of cancers. The Company&#x2019;s lead asset is onvansertib, a PLK1 inhibitor that is being evaluated in combination with standard of care therapies in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer, metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer. These programs and the Company&#x2019;s broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the standard of care alone. The Company's common stock is listed on the Nasdaq Capital Market under the ticker symbol "CRDF".&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has incurred net losses since its inception and has negative operating cash flows. As of December&#160;31, 2022, the Company had $105.3 million in cash, cash equivalents and short-term investments and believes it has sufficient cash to meet its funding requirements for at least the next 12 months following the issuance date of these financial statements.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the foreseeable future, the Company expects to continue to incur losses and require additional capital to further advance its clinical trial programs and support its other operations. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company&#x2019;s stockholders may experience additional dilution.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzQvZnJhZzowOGJiMTBlMTY0ZDg0NGNiOWJiNDQ5MzFmNGJjODNkNC90ZXh0cmVnaW9uOjA4YmIxMGUxNjRkODQ0Y2I5YmI0NDkzMWY0YmM4M2Q0XzcyOQ_89e6a77a-1a6a-4a66-acdb-cb54fc8cd1fe"
      unitRef="usd">105300000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDk4_e4c8f69e-5d66-4000-a79a-ea57e0ba28e3">Basis of Presentation and Summary of Significant Accounting Policies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying financial statements of Cardiff Oncology have been prepared in accordance with accounting principles generally accepted in the United States of America (&#x201c;U.S. GAAP&#x201d;). &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Clinical Trial Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations ("CROs"), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#x201c;service providers&#x201d;). As of December&#160;31, 2022 the Company&#x2019;s clinical trial accrual balance of $2.3 million is included in accrued liabilities. The Company&#x2019;s related 2022 clinical trial expenses are included in research and development expense of $27.1&#160;million. Certain clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash in readily available checking and money market accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#x2019;s ability to liquidate the investment for use in operations within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#x2019;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive loss. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and License Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These patents are from the Company's legacy portfolio and unrelated to onvansertib.&#160;Agreements may involve multiple elements such as license fees, minimum royalties, usage-based royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#x2019;s use. The Company estimates and records licensee&#x2019;s sales based on historical usage rate and collectability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Royalties are generally due quarterly or annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Financial Instruments&#x2014;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period as they do not meet the criteria for equity classification. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#x201c;Change in fair value of derivative instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#x2019;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments" &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;below).&#160;At December&#160;31, 2022 and 2021, the fair value of these warrants was $0, for both periods. These warrants expire in the first quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Instruments where significant value drivers are unobservable to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property, equipment and lease right-of-use assets. The Company records property and equipment at cost. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of the asset. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. The estimated useful lives of the major classes of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 to 6 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease Right-of-Use (&#x201c;ROU&#x201d;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. None of the Company&#x2019;s operating leases provide an implicit rate, therefore the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revision of Previously Disclosed Amounts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the course of preparing the Company&#x2019;s financial statements as of and for the year ended December 31 2022, the Company completed an Internal Revenue Code Section 382 and 383 analysis of its historical net operating loss and tax credit carryforward amounts. As a result, a portion of the prior year net operating loss and tax credit carryforwards were determined to be limited. See Note 9 - Income Taxes, for further details. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and patent maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upfront and milestone payments to acquire contractual rights to licensed technology are expensed when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. Certain contractual rights may require the Company to make additional milestone payments based on development and commercial milestones, and royalties based on sales volume. See Note 10 - Commitments and Contingencies, for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These potential development milestones include: dosing of the first subject in the first Phase III Clinical Trial for the first Product or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and upon filing of the first NDA or equivalent for the first product&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. The accretion of Series A Convertible Preferred Stock dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share. For all periods presented, there is no difference in the number of shares used to calculate basic and diluted shares outstanding as inclusion of the potentially dilutive securities would be antidilutive. Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,360,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,431,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,947,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Correction of Series A Convertible Preferred Stock cumulative dividend liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2022, the Company identified an immaterial error related to the accrual of a liability for the accretion of cumulative preferred dividends on the Company's Series A Convertible Preferred Stock. These cumulative preferred dividends do not meet the definition of a liability, as they have not been declared by the Company's Board of Directors. The Company has recorded an adjustment of $0.4&#160;million within accumulated deficit and accrued liabilities for the year ended December 31, 2022 to correct this immaterial error. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for the Company on January 1, 2024. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDg0_6177d7a1-6300-4b5c-aa21-ebee8327763d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker in making decisions regarding resource allocation and assessing performance. The Company views its operations as, and manages its business in, one operating segment in the United States.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzYxMQ_16f29152-58ff-4171-904f-a754bc74430b"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NTAy_41c41cf3-b746-4018-a882-576b524d67a8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. GAAP requires management to make significant estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The most significant estimate involves accrued clinical trial expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <crdf:AccruedClinicalTrialExpensesPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDkz_23b51696-aa41-4235-b1c0-e7d3684398a8">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Clinical Trial Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses research and development expenditures as incurred, which include costs related to clinical trial activities. The Company accrues costs for clinical trial activities based upon estimates of the services received and related expenses incurred that have yet to be invoiced by the Clinical Research Organizations ("CROs"), investigators, professional service providers, and other vendors providing clinical trial services (collectively, the &#x201c;service providers&#x201d;). As of December&#160;31, 2022 the Company&#x2019;s clinical trial accrual balance of $2.3 million is included in accrued liabilities. The Company&#x2019;s related 2022 clinical trial expenses are included in research and development expense of $27.1&#160;million. Certain clinical trial expenses are released from service receivables classified within equity (see Note 5) as clinical trial services are performed.&lt;/span&gt;&lt;/div&gt;</crdf:AccruedClinicalTrialExpensesPolicyTextBlock>
    <crdf:AccruedClinicalTrialExpenses
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE3MTI_199ee3c1-ac90-43d2-a313-4ad3553eed78"
      unitRef="usd">2300000</crdf:AccruedClinicalTrialExpenses>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NTQ_45ab5869-fae8-4deb-baad-31b7f9ad46d4"
      unitRef="usd">27100000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDI0_eea416a7-c1ae-47b3-937e-63e5245d2b54">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all highly liquid investments with original maturities of three months or less from the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash in readily available checking and money market accounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investment Securities&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All investments have been classified as &#x201c;available-for-sale&#x201d; and are carried at fair value as determined based upon quoted market prices or pricing models for similar securities at period end. Investments with contractual maturities less than 12 months at the balance sheet date are considered short-term investments. Investments with contractual maturities beyond one year are also classified as short-term due to the Company&#x2019;s ability to liquidate the investment for use in operations within the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on investment securities are included in earnings and are derived using the specific identification method for determining the cost of securities sold. The Company has not realized any significant gains or losses on sales of available-for-sale investment securities during any of the periods presented. As all the Company&#x2019;s investment holdings are in the form of debt securities or certificates of deposit, unrealized gains and losses that are determined to be temporary in nature are reported as a component of accumulated other comprehensive loss. A decline in the fair value of any security below cost that is deemed other than temporary results in a charge to earnings and the establishment of a new cost basis for the security. Interest income is recognized when earned and is included in investment income, as are the amortization of purchase premiums and accretion of purchase discounts on investment securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDQ5_6b5d9939-9f8d-450d-a585-12978482f0ee">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposit accounts at financial institutions that are in excess of federally insured limits. The Company has not experienced any losses in such accounts and believes it is not exposed to significant risk on its cash due to the financial position of the depository institution in which those deposits are held. The Company limits its exposure to credit loss by generally placing its cash in high credit quality financial institutions and investment in non FDIC insured money market funds denominated and payable in U.S. dollars.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDcy_65cde42b-2368-4d24-b8a2-7d50443364f9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue when control of its products and services are transferred to its customers in an amount that reflects the consideration it expects to receive from its customers in exchange for those products and services. This process involves identifying the contract with a customer, determining the performance obligations in the contract, determining the contract price, allocating the contract price to the distinct performance obligations in the contract, and recognizing revenue when the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. The Company considers a performance obligation satisfied once it has transferred control of goods or service to the customer, meaning the customer has the ability to use and obtain the benefit of goods or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. For sales-based royalties, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and License Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company licenses and sublicenses its patent rights to healthcare companies, medical laboratories and biotechnology partners. These patents are from the Company's legacy portfolio and unrelated to onvansertib.&#160;Agreements may involve multiple elements such as license fees, minimum royalties, usage-based royalties and milestone payments.&#160;Revenue is recognized when the criteria described above have been met as well as the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Up-front nonrefundable license fees pursuant to agreements under which the Company has no continuing performance obligations are recognized as revenues on the effective date of the agreement and when collection is probable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Minimum royalties are recognized as earned, and royalties are earned based on the licensee&#x2019;s use. The Company estimates and records licensee&#x2019;s sales based on historical usage rate and collectability.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;For sales-based royalties, we recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/span&gt;&lt;/div&gt;Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice. Royalties are generally due quarterly or annually.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDcz_eb9dc966-8079-4208-a6e0-2ca69c73b615">Payment terms and conditions vary by contracts, although terms generally include a requirement of payment within 30 to 45 days after invoice.</us-gaap:RevenuePerformanceObligationDescriptionOfPaymentTerms>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDg2_7d0eeac2-58f0-457c-950a-781a72415e15">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Financial Instruments&#x2014;Warrants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has issued common stock warrants in connection with the execution of certain equity financings. Such warrants are classified as derivative liabilities and are recorded at their fair market value as of each reporting period as they do not meet the criteria for equity classification. Changes in fair value of derivative liabilities are recorded in the statement of operations under the caption &#x201c;Change in fair value of derivative instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of warrants is determined using the Black-Scholes option-pricing model using assumptions regarding the historical volatility of Cardiff Oncology&#x2019;s common stock price, the remaining life of the warrants, and the risk-free interest rates at each period end. The Company thus uses model-derived valuations where inputs are observable in active markets to determine the fair value. The use of the Black-Scholes model classifies such warrants as Level 3 (See "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments" &lt;/span&gt;below).</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic357b095a944414684981c1dc8b89fb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzgzODI_bcf90ab4-c529-4f92-96a6-0343c2ee7335"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7db42fc039fd45aeaea7b5bc0553089e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzgzODI_df896022-7887-4986-881a-ef95cf07d64b"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDc5_b9fa7704-5cbc-438b-b136-a75b6fb905c5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense is measured at the grant date based on the estimated fair value of the award and is recognized straight-line over the requisite service period of the individual grants, which typically equals the vesting period.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDk2_94c5405c-e251-4f77-944f-629c6734f733">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Financial instruments consist of cash equivalents, accounts receivable, accounts payable and derivative liabilities. The Company applies ASC 820 for financial assets and liabilities that are required to be measured at fair value and non-financial assets and liabilities that are not required to be measured at fair value on a recurring basis. These financial instruments are stated at their &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;respective historical carrying amounts, which approximate fair value due to their short-term nature as they reflect current market interest rates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;The authoritative guidance establishes a fair value hierarchy that is based on the extent and level of judgment used to estimate the fair value of assets and liabilities. In general, the authoritative guidance requires us to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. An asset or liability&#x2019;s categorization within the fair value hierarchy is based upon the lowest level of input that is significant to the measurement of its fair value. The three levels of input defined by the authoritative guidance are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis using the three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value. The three tiers include:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 &#x2014; Quoted prices for identical instruments in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 &#x2014; Quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in markets that are not active; and model-derived valuations where inputs are observable or where significant value drivers are observable.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 &#x2014; Instruments where significant value drivers are unobservable to third parties.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDgy_cfd4852d-7a60-4ab9-8d09-df2f3169e79d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist of property, equipment and lease right-of-use assets. The Company records property and equipment at cost. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful life of the asset. Depreciation of leasehold improvements is computed based on the shorter of the life of the asset or the term of the lease. The estimated useful lives of the major classes of property and equipment are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 to 6 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDg5_8da1bf09-ccbf-42d3-b2f6-3cee40cb02e5">The estimated useful lives of the major classes of property and equipment are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.506%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.294%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 to 5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4 to 6 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;Property and equipment consisted of the following:&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="id6e8c265de294538a1036e72f7c48ee4_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzEtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo3YWQyZmM1N2EwMmM0N2Y2OWQ4ODI4YjQyZDJmMzEyNl80_b45be0b8-0521-42b0-ae35-3b353cf8e860">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3d722eb9049649258eed2c0dc7b7f489_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzEtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo3YWQyZmM1N2EwMmM0N2Y2OWQ4ODI4YjQyZDJmMzEyNl8xMA_e2ccda84-a449-431f-8f49-2d4ddde07e35">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6db19d7e4c5b45118fb2b4e6b4642581_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjpiZWY4ZDRhZmY1YmE0NTE3YTNlZjc1ZWJiMmFkZTc0ZF80_7fb06256-8f4f-405c-8abf-3da5ca1c86ff">P4Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ifa12187761644b8fb660f20d8935e788_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjpiZWY4ZDRhZmY1YmE0NTE3YTNlZjc1ZWJiMmFkZTc0ZF8xMA_ebab4131-ec2a-4173-8ed3-00750e54a199">P6Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i04fc18d316ba46f4b37af84f0a656dae_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTo3NjEyNjM4MzdhNWY0NDQ0ODBmODFlZGZmYTE0ZTYzNi90YWJsZXJhbmdlOjc2MTI2MzgzN2E1ZjQ0NDQ4MGY4MWVkZmZhMTRlNjM2XzMtMS0xLTEtNDAzNjg_8a565dd8-c547-4917-b97c-2bdc40f0caae">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NTEx_cf781e65-644d-40c6-ac8f-858983e9bf2c">Impairment losses on long-lived assets used in operations are recorded when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets carrying amount. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the estimated fair value of the assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDc0_452004cd-57cf-45de-8bac-d41214cd42a7">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease Right-of-Use (&#x201c;ROU&#x201d;) assets, current operating lease liabilities and non-current operating lease liabilities in the Company&#x2019;s balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. None of the Company&#x2019;s operating leases provide an implicit rate, therefore the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The incremental borrowing rate is the rate of interest that the Company would expect to pay to borrow on a collateralized and fully amortizing basis over a similar term an amount equal to the lease payments in a similar economic environment. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company&#x2019;s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. Our facilities lease agreement contains lease and non-lease components, such as common area maintenance. We have elected to account for these lease and non-lease components of this agreement as a single lease component. &lt;/span&gt;&lt;/div&gt;Leases with an initial term of 12 months or less are not recorded on the Company's balance sheets. These short-term leases are expensed on a straight-line basis over the lease term.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDMz_50d3cc1a-ddb0-4d45-9294-dcef5e3a5d64">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income taxes are determined using the asset and liability approach of accounting for income taxes. Under this approach, deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid. Deferred taxes result from differences between the financial statement and tax bases of Cardiff Oncology&#x2019;s assets and liabilities and are adjusted for changes in tax rates and tax laws when changes are enacted. Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not that a tax benefit will not be realized. The assessment of whether or not a valuation allowance is required often requires significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revision of Previously Disclosed Amounts&lt;/span&gt;&lt;/div&gt;During the course of preparing the Company&#x2019;s financial statements as of and for the year ended December 31 2022, the Company completed an Internal Revenue Code Section 382 and 383 analysis of its historical net operating loss and tax credit carryforward amounts. As a result, a portion of the prior year net operating loss and tax credit carryforwards were determined to be limited. See Note 9 - Income Taxes, for further details.</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDQ3_8f3466a5-6c37-4ee6-a1e7-24cb43713742">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the normal course of business, Cardiff Oncology is subject to loss contingencies, such as legal proceedings and claims arising out of its business, that cover a wide range of matters, including, among others, government investigations, stockholder lawsuits, product and environmental liability, and tax matters. In accordance with FASB ASC Topic 450, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingencies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, Cardiff Oncology records such loss contingencies when it is probable that a liability has been incurred and the amount of loss can be reasonably estimated. Cardiff Oncology, in accordance with this guidance, does not recognize gain contingencies until realized.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDM5_90efce6e-e76f-4821-8e98-42f9299e9d23">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include expenditures in connection with an in-house research and development laboratory, salaries and staff costs, clinical trials, purchased in-process research and development and regulatory and scientific consulting fees, as well as contract research and insurance. Also, patent filing and patent maintenance expenses are considered legal in nature and therefore classified as general and administrative expense, if any.&lt;/span&gt;&lt;/div&gt;Non-refundable advance payments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. As the related goods are delivered or the services are performed, or when the goods or services are no longer expected to be provided, the deferred amounts are recognized as an expense.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDMx_24cdfe82-43ed-4f09-b21e-93506858285d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;Basic and diluted net loss per common share is determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. The accretion of Series A Convertible Preferred Stock dividends and deemed dividends recognized in connection with certain preferred share issuances are included in net loss attributable to common stockholders in the computation of basic and diluted earnings per share.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDkx_aa82745e-1b55-4aaf-92fd-d6c42c1e67c5">Shares used in calculating diluted net loss per common share exclude as anti-dilutive the following share equivalents: &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.293%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Warrants to purchase Common Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,360,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,684,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,431,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,947,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="icfc3ebfa98e941b5bc6b10599b18ba6f_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzItMS0xLTEtNDAzNjg_cbadbe2b-d665-4141-8193-c72494d1db4f"
      unitRef="shares">5069458</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9a80f0906358478ab1f82fee730acdf1_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzItMy0xLTEtNDAzNjg_76b296d6-c7a3-4c2c-b9f1-fadbe14df955"
      unitRef="shares">3771984</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="iaabac25eea454ee4a957bcb868f30e54_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzMtMS0xLTEtNDAzNjg_7f16069f-e687-4314-8b57-7edf18ee658e"
      unitRef="shares">4360968</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7de3c2329b134630bba5604f67f427b2_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzMtMy0xLTEtNDAzNjg_0abb1605-4dfa-4f09-9fa3-f6132f0c8948"
      unitRef="shares">4490159</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idbac0ee763c14b4691866040faab8881_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzYtMS0xLTEtNDAzNjg_979f83a1-419e-4df9-9316-71a4ad4217e4"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9cfa801a2fb64cd2a7453b02850a5da8_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzYtMy0xLTEtNDAzNjg_08d2b102-cb9c-4f39-8030-ddb201fb8fe5"
      unitRef="shares">877</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i5d7ee18907d4487f8a1215d75d135ee7_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzctMS0xLTEtNDAzNjg_feb02f0b-80e6-45b4-857f-c9a0936d84bb"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="idb4e0e354837488d92217bd45d8de5d9_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzctMy0xLTEtNDAzNjg_e129341a-67bf-426e-9755-b49848070789"
      unitRef="shares">2684607</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzgtMS0xLTEtNDAzNjg_17e948cf-3ed7-4649-a536-aec8bc59e8fb"
      unitRef="shares">9431303</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90YWJsZTpkMTNmNWNjYWQxMzI0ZjJjOWQ1ZjFkMjA1MGYyMTUzNC90YWJsZXJhbmdlOmQxM2Y1Y2NhZDEzMjRmMmM5ZDVmMWQyMDUwZjIxNTM0XzgtMy0xLTEtNDAzNjg_4d62ec28-f10e-4799-85a7-a7569ad5c4ea"
      unitRef="shares">10947627</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <crdf:CorrectionPolicyPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzU0OTc1NTg0MjgwMQ_84adbb62-099d-4b50-aaaa-ee8b0b54814a">Correction of Series A Convertible Preferred Stock cumulative dividend liabilityDuring the fourth quarter of 2022, the Company identified an immaterial error related to the accrual of a liability for the accretion of cumulative preferred dividends on the Company's Series A Convertible Preferred Stock. These cumulative preferred dividends do not meet the definition of a liability, as they have not been declared by the Company's Board of Directors. The Company has recorded an adjustment of $0.4&#160;million within accumulated deficit and accrued liabilities for the year ended December 31, 2022 to correct this immaterial error.</crdf:CorrectionPolicyPolicyTextBlock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ib79309171dc9429497e5fe33bfa88be7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzEwOTk1MTE2NTQwMjU_106e1d9e-246c-4aa4-84df-0d08e463f62c"
      unitRef="usd">400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ib79309171dc9429497e5fe33bfa88be7_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzEwOTk1MTE2NTQwMjU_f6aa1d7d-ca99-4a0e-9341-fdeff2178180"
      unitRef="usd">400000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNzcvZnJhZzphNTc5YTVmMGYyOGQ0MWNiYTRlODRjNDljYmE5ODdhMi90ZXh0cmVnaW9uOmE1NzlhNWYwZjI4ZDQxY2JhNGU4NGM0OWNiYTk4N2EyXzE4NDk3_c0e3c6b1-9c92-443a-8e4b-d053fd60ac79">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recently Adopted Accounting Pronouncement&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2021-04 ("ASU 2021-04"), Earnings Per Share (Topic 260), Debt&#x2014;Modifications and Extinguishments (Subtopic 470-50), Compensation&#x2014;Stock Compensation (Topic 718), and Derivatives and Hedging&#x2014;Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40): Issuer&#x2019;s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (a consensus of the FASB Emerging Issues Task Force). The amendments in this update are effective for all entities for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. The Company has prospectively adopted this standard as of January 1, 2022 for periods presented after the adoption. The adoption of ASU 2021-04 did not have a material impact on the Company's financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Recent Accounting Pronouncement Not Yet Adopted&lt;/span&gt;&lt;/div&gt;In August 2020, the FASB issued ASU No. 2020-06 ("ASU 2020-06"), Debt &#x2013; Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging &#x2013; Contracts in Entity&#x2019;s Own Equity (Subtopic 815-40) (&#x201c;ASU 2020-06&#x201d;). ASU 2020-06 eliminates the beneficial conversion and cash conversion accounting models for convertible instruments. It also amends the accounting for certain contracts in an entity&#x2019;s own equity that are currently accounted for as derivatives because of specific settlement provisions. In addition, ASU 2020-06 modifies how particular convertible instruments and certain contracts that may be settled in cash or shares impact the diluted EPS computation. The amendments in this update are effective for the Company on January 1, 2024. The amendment is to be adopted through either a fully retrospective or modified retrospective method of transition. Early adoption is permitted. The Company is currently evaluating the impact of this standard on its financial statements and related disclosures.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEyNDk_091ca679-34df-4cd8-bec2-4d56a0c4c0aa">Supplementary Balance Sheet Information&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments available-for-sale securities consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2022 the net realized loss recorded within the Company's statement of operations from the sale of short-term investments was $0.2 million. The amount of gains and losses reclassified out of other comprehensive income for the period related to the sales of short-term investments was not material for the year ended December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrealized losses in investments available for sale debt securities at December&#160;31, 2022, were primarily due to increases in interest rates, not due to increased credit risks associated with specific securities. It is not more likely than not that we will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fixed assets consist of furniture and office equipment, leasehold improvements and laboratory equipment. Depreciation expense for property and equipment for the years ended December&#160;31, 2022 and 2021 was $0.2 million and $0.5 million, respectively. Property and equipment consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and office equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,560&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;906&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,682&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,823&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less&#x2014;accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,413)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)See Note 2 to the financial statements.</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEyNDM_53b42de3-a942-4d27-af52-b612bea08c7f">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Short-term investments available-for-sale securities consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,806&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;84,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;89,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(415)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity less than 1 year:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,786&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity less than 1 year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturity 1 to 2 years:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total maturity 1 to 2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(149)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtMS0xLTEtNDU5NTQ_8eb5e54d-07d3-4bb6-a254-d80227a24e0b"
      unitRef="usd">16101000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtMy0xLTEtNDU5NTQ_59821b06-dd2d-4527-88ee-b241d16868e8"
      unitRef="usd">3000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtNS0xLTEtNDU5NTQ_7451663a-d07f-4bd9-8679-ad5aebf49717"
      unitRef="usd">81000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i9dc25c72ae12437eaaac485fab890f66_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzMtNy0xLTEtNDU5NTQ_a4698f37-5711-44ac-b6dd-fd689d23f045"
      unitRef="usd">16023000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtMS0xLTEtNDU5NTQ_0a453960-642d-42ac-9197-7bf191c211a3"
      unitRef="usd">44806000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtMy0xLTEtNDU5NTQ_23fc3aac-66e6-4d1b-a275-abd93a649581"
      unitRef="usd">8000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtNS0xLTEtNDU5NTQ_4c60d1ac-de6a-4eb0-8c76-d40e74374b32"
      unitRef="usd">275000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzQtNy0xLTEtNDU5NTQ_e72a40be-6099-4972-9a4f-90ef06cc7e6d"
      unitRef="usd">44539000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtMS0xLTEtNDU5NTQ_35f9a768-812a-41b5-bef2-355f7b6ecec6"
      unitRef="usd">13203000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtMy0xLTEtNDU5NTQ_e9c22004-cb0e-4101-b640-53b2d1ff81b9"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtNS0xLTEtNDU5NTQ_24cf5062-382a-4530-9b8e-4aad38ff4424"
      unitRef="usd">20000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ib1431504fbab4e16bdc6ba6ef4c78b7d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzUtNy0xLTEtNDU5NTQ_45ee91b8-e0c5-4b73-ad6e-5fb483df93ca"
      unitRef="usd">13187000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctMS0xLTEtNDU5NTY_1444b377-ae24-4215-b44a-55df11bc92a9"
      unitRef="usd">2284000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctMy0xLTEtNDU5NTY_301d8fe7-6832-45c9-9072-5e8c6d8e54eb"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctNS0xLTEtNDU5NTY_aa3f82ed-1190-41e3-ab0c-a9d85454aa33"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id39a83cf8e894d87a841a0c710893a25_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzctNy0xLTEtNDU5NTY_bb2f7440-9d90-43c7-85f8-a0bca28add72"
      unitRef="usd">2288000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtMS0xLTEtNDU5NTY_10af99a8-59ee-487b-a235-5adfc8625902"
      unitRef="usd">7905000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtMy0xLTEtNDU5NTY_bd484770-285f-40d9-aaf6-a99bbbca682c"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtNS0xLTEtNDU5NTY_d67ff0d4-7f88-492b-a724-b200b07cc239"
      unitRef="usd">18000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzgtNy0xLTEtNDU5NTY_f859a571-e6d0-44d8-b101-edc48e6bbe1b"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktMS0xLTEtNDU5NTY_60d4cbfe-be27-4dd5-aae5-411ac9c2a4ae"
      unitRef="usd">84299000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktMy0xLTEtNDU5NTY_16a7a1e0-d69d-4c54-83d7-52a1ff154aca"
      unitRef="usd">19000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktNS0xLTEtNDU5NTY_c886c5e0-1ba7-4c89-b378-4d9f70120b82"
      unitRef="usd">394000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzktNy0xLTEtNDU5NTY_9286a31c-f7b2-48c9-961e-40b70f3404ee"
      unitRef="usd">83924000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTEtMS0xLTQ1OTU4_06d9cffe-6760-4844-b06a-8bb39cede229"
      unitRef="usd">5016000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTMtMS0xLTQ1OTU4_6af5d982-3ac1-4ef9-a10f-c50add4b9f76"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTUtMS0xLTQ1OTU4_ff694d26-a48e-4c90-b475-a7384a63a351"
      unitRef="usd">21000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzExLTctMS0xLTQ1OTU4_f2d5c96e-88b3-4eab-9b7c-1d7802934aa9"
      unitRef="usd">4996000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTEtMS0xLTQ1OTYw_836ac516-e64a-4cd8-9acc-41047aa9963d"
      unitRef="usd">5016000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTMtMS0xLTQ1OTYw_988dee63-6814-4912-ae43-b7239ed4df83"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTUtMS0xLTQ1OTYw_235f45e5-ebab-479c-b488-682a70d47838"
      unitRef="usd">21000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzEzLTctMS0xLTQ1OTYw_c8d8932b-68f2-48f6-878a-243a9f13cf95"
      unitRef="usd">4996000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTEtMS0xLTQ1OTYw_0f0f7ac5-378a-40f3-ae4b-1e1799eb237c"
      unitRef="usd">89315000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTMtMS0xLTQ1OTYw_636712a5-4517-4550-b028-4486fe17107b"
      unitRef="usd">20000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTUtMS0xLTQ1OTYw_d1109a67-8be5-487b-ac41-cdb46313ff57"
      unitRef="usd">415000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTpmOGZkMzFmNjhmNTc0YTlkYjY4M2I2NDkxMjdhNWVmZi90YWJsZXJhbmdlOmY4ZmQzMWY2OGY1NzRhOWRiNjgzYjY0OTEyN2E1ZWZmXzE1LTctMS0xLTQ1OTYw_3992c365-d14b-4335-813b-de71d6074e6c"
      unitRef="usd">88920000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtMS0xLTEtNDAzNjg_6e05b55a-c077-4ac8-9415-4978b2a9f2da"
      unitRef="usd">1260000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtMy0xLTEtNDAzNjg_ae32a5d8-386e-4ee8-90bd-1672180c3e04"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtNS0xLTEtNDAzNjg_ce2a92b2-5d7b-4f47-a752-aef5ae822e3e"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="ibcb3367ce4cc4990a02e061fdb54b181_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzMtNy0xLTEtNDAzNjg_1cc48ec8-b92f-415e-b0b1-aee88e15ca4c"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtMS0xLTEtNDAzNjg_628efea2-9d25-4860-b308-3c63d80c4a3d"
      unitRef="usd">58822000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtMy0xLTEtNDAzNjg_b542736e-220b-4667-8d18-3269eb217c93"
      unitRef="usd">2000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtNS0xLTEtNDAzNjg_68254236-a272-4769-ba4d-b374409c136d"
      unitRef="usd">38000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzQtNy0xLTEtNDAzNjg_622d60ec-8bd1-4a14-8f2d-b223ef1ad756"
      unitRef="usd">58786000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtMS0xLTEtNDAzNjg_d1172e0a-c655-4ad5-bbe2-9a45ba60772d"
      unitRef="usd">14453000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtMy0xLTEtNDAzNjg_1e5b7abb-0bc5-4f9d-a147-25757079b61c"
      unitRef="usd">4000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtNS0xLTEtNDAzNjg_a0eeeb05-26b6-4a12-803e-eecc3ff24021"
      unitRef="usd">3000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i3de22f800dcc41fe9ec79feeab414c28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzUtNy0xLTEtNDAzNjg_686e9eb6-fcaa-42ba-b590-1aa30799a530"
      unitRef="usd">14454000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtMS0xLTEtNDAzNjg_8ff53ff2-2a60-49a1-86c9-3c626f5ff5a0"
      unitRef="usd">728000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtMy0xLTEtNDAzNjg_67f9d9c9-c6cf-4e8a-9a2c-09a1303c4b99"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtNS0xLTEtNDAzNjg_8e120f5a-3184-40b1-9a2d-bea8dcd013eb"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i8aaa14970b63477fb4435dd4e7e58d9a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzYtNy0xLTEtNDAzNjg_fe087c6e-53bc-48e4-8694-b06df5c63f9a"
      unitRef="usd">728000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctMS0xLTEtNDAzNjg_018b0e39-f1dc-49f7-9d12-410ac46ade79"
      unitRef="usd">20380000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctMy0xLTEtNDAzNjg_6737fe48-3e5e-4ed3-b4d2-8d4e94899c5a"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctNS0xLTEtNDAzNjg_51539c75-45d8-4c6d-ba6f-3b62d8e2024d"
      unitRef="usd">24000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzctNy0xLTEtNDAzNjg_428eb1ce-bfc8-4f8d-a1ed-2bf32c79c178"
      unitRef="usd">20356000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtMS0xLTEtNDAzNjg_8b8637f4-b274-439e-8648-1f49225bf803"
      unitRef="usd">95643000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtMy0xLTEtNDAzNjg_f3ac7479-3b07-4a7f-bda3-af978e654fb5"
      unitRef="usd">6000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtNS0xLTEtNDAzNjg_48fdfeb3-6b71-47d2-8c2b-64a4e30f7728"
      unitRef="usd">65000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzgtNy0xLTEtNDAzNjg_40359c5e-f06a-49a2-8b65-0b1db8488fdb"
      unitRef="usd">95584000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTEtMS0xLTQwMzY4_20a34732-4d3c-4618-839e-693113217ee9"
      unitRef="usd">29676000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTMtMS0xLTQwMzY4_92dbad2f-7951-41a7-bdd6-6e27653d6c20"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTUtMS0xLTQwMzY4_c65ea1c8-2203-44e3-b1ff-ff5f43aacf72"
      unitRef="usd">73000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i148a84869fe740b3a3078739ed04eb1c_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEwLTctMS0xLTQwMzY4_d4700d42-43ae-46c6-a125-72ef5c65bcf8"
      unitRef="usd">29604000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTEtMS0xLTQwMzY4_2386f4bc-1879-4018-8f77-61b6a824b3dc"
      unitRef="usd">3701000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTMtMS0xLTQwMzY4_83f2c739-6473-4764-81f2-a10320e9764c"
      unitRef="usd">0</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTUtMS0xLTQwMzY4_8b9aefe4-38c9-49d7-82a0-bd1d84424758"
      unitRef="usd">11000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="idb08599bdf3f4cd491334a0f7a14e458_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzExLTctMS0xLTQwMzY4_54497eea-2ae6-43a8-8c3c-c51879f75738"
      unitRef="usd">3690000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTEtMS0xLTQwMzY4_2ab4df5f-b79a-4b61-a724-585be3ba8abb"
      unitRef="usd">33377000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTMtMS0xLTQwMzY4_2d0f3780-9538-42ae-8b44-b6f9ff738cd4"
      unitRef="usd">1000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent>
    <crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTUtMS0xLTQwMzY4_28aeeb58-200f-49db-851c-e52f754d9ff2"
      unitRef="usd">84000</crdf:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzEyLTctMS0xLTQwMzY4_8deb22c1-db91-479c-9074-9531066b509c"
      unitRef="usd">33294000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTEtMS0xLTQwMzY4_9bd6e173-e02c-44bc-8b6d-7463b6a42f75"
      unitRef="usd">129020000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTMtMS0xLTQwMzY4_e493fde6-a2b4-4853-88e0-97a5fd8291da"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTUtMS0xLTQwMzY4_60fa6d58-05f6-4e55-9072-464d619301da"
      unitRef="usd">149000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozMzA1Y2E1NzI1ZTc0ODc2ODBhOWExY2YyNWUyY2Y4NS90YWJsZXJhbmdlOjMzMDVjYTU3MjVlNzQ4NzY4MGE5YTFjZjI1ZTJjZjg1XzE0LTctMS0xLTQwMzY4_36d474e6-5593-410e-802a-0c4753bcbee2"
      unitRef="usd">128878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzIxNg_1c19e486-ebbb-453b-bc95-dccdb97653bd"
      unitRef="usd">200000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzU0OTc1NTgxOTI5MQ_60f36146-299e-45ae-94d6-3d64c69ce11d">Investments available for sale that have been in a continuous unrealized loss position for greater than one-year consist of the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.876%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Market Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,084&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(161)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total short-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(175)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzMtMS0xLTEtNDU5Njc_db8e26b2-4115-49ab-94fc-2215555da12e"
      unitRef="usd">17084000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ibd9a28d0a3004e4594b1a617ff6a14fb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzMtMy0xLTEtNDU5Njc_78af3e91-6f5f-4fde-bdfa-826e92f6e5cd"
      unitRef="usd">161000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzUtMS0xLTEtNDU5Njc_e6fde587-d81e-4fa3-8bd4-2e3867d5224b"
      unitRef="usd">3666000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="if4c2a9f74cfe468ea1c9fddd789c75f7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzUtMy0xLTEtNDU5Njc_0c4a3cf7-24fc-4803-978e-6796365cf6ff"
      unitRef="usd">14000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzYtMS0xLTEtNDU5Njc_a2c184a3-7fd4-4fe1-842e-3b4314a1a05c"
      unitRef="usd">20750000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozZDBmY2FkNzNhNDg0MzY0ODgxZmNiZDFlYTg5YTgwZS90YWJsZXJhbmdlOjNkMGZjYWQ3M2E0ODQzNjQ4ODFmY2JkMWVhODlhODBlXzYtMy0xLTEtNDU5Njc_bd19786f-b522-427c-b990-8acc68c08184"
      unitRef="usd">175000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:Depreciation
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEwOTE_8aff62b1-14b0-4b47-8110-dc667f218e92"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEwOTg_39a0da4f-8f71-41dc-9fba-094fd5a32d33"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id1e22fef9a7a4228a7799fa9e0bb1735_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzItMS0xLTEtNDAzNjg_5ac9a58f-9f9e-42ef-bfae-954371233e6a"
      unitRef="usd">1066000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i007c30ebe4ca4d128452e15ece8e01d0_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzItMy0xLTEtNDAzNjg_15350c5d-899b-4f84-aa52-0542a7752edb"
      unitRef="usd">955000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9081e23b06e6448d9830510d151ca033_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzMtMS0xLTEtNDAzNjg_13d491cf-5b20-4cfe-a5c4-58d55850b1c1"
      unitRef="usd">2560000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i14c3caa3006c4f6ebf14421f944e494e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzMtMy0xLTEtNDAzNjg_bb47dc11-58e0-444f-a853-f53b90df828f"
      unitRef="usd">1962000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibd60c6be701446a9bbe35fdcd554faf1_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzQtMS0xLTEtNDAzNjg_fc7e4308-39d1-4441-a8a0-baba627dbb82"
      unitRef="usd">1056000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic9982ed59fd6427f808ced5af06dbdd1_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzQtMy0xLTEtNDAzNjg_8d8ff310-3bd9-413c-b1c5-34d60f5226e6"
      unitRef="usd">906000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzUtMS0xLTEtNDAzNjg_0c736d40-9c68-46af-9c04-166fd1ddf7d3"
      unitRef="usd">4682000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzUtMy0xLTEtNDAzNjg_df546a17-91d8-4d12-a70f-1afea4441fb3"
      unitRef="usd">3823000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzYtMS0xLTEtNDAzNjg_24efb3cb-4617-44fe-82e2-06e5ee1ce24a"
      unitRef="usd">3413000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzYtMy0xLTEtNDAzNjg_23c1da3a-f792-434f-9eb3-68df707629d6"
      unitRef="usd">3441000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzctMS0xLTEtNDAzNjg_80c2cf51-4928-4827-878a-8e2bcb76d7df"
      unitRef="usd">1269000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTozYjhkMjg0OGE5YzY0OTRiYmE1MTdlMGU4YWNlOGE2Zi90YWJsZXJhbmdlOjNiOGQyODQ4YTljNjQ5NGJiYTUxN2UwZThhY2U4YTZmXzctMy0xLTEtNDAzNjg_58628246-9ffb-4f7a-b84c-8f75c08985d7"
      unitRef="usd">382000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90ZXh0cmVnaW9uOjYzYmYzN2FkNGI1YTQwNjA5OGI5YTA2YWNlMjViNGNiXzEyNDc_78a951aa-5554-483a-858a-85cb767d173f">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued liabilities consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.149%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Preferred stock dividend&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Clinical trials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research agreements and services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Director fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patent, license and other fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;(1)See Note 2 to the financial statements.</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzItMS0xLTEtNDAzNjg_201d9fd5-989a-4179-a1d2-da8a0ea9bbde"
      unitRef="usd">1849000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzItMy0xLTEtNDAzNjg_99ce45a3-536c-4ba9-b84b-81301e9bf2f5"
      unitRef="usd">1435000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <crdf:AccruedPreferredStockDividend
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzMtMS0xLTEtNDAzNjg_b567fad0-45ac-46f8-b840-217daffae126"
      unitRef="usd">0</crdf:AccruedPreferredStockDividend>
    <crdf:AccruedPreferredStockDividend
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzMtMy0xLTEtNDAzNjg_b72cb360-6d9c-4ca0-acdc-f312a643b3a8"
      unitRef="usd">414000</crdf:AccruedPreferredStockDividend>
    <crdf:AccruedClinicalTrial
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzQtMS0xLTEtNDAzNjg_bfdc8799-7821-4891-8c9a-cf8de6e71b46"
      unitRef="usd">2333000</crdf:AccruedClinicalTrial>
    <crdf:AccruedClinicalTrial
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzQtMy0xLTEtNDAzNjg_00c0f60c-63d4-41df-8d63-024f75c78dae"
      unitRef="usd">1639000</crdf:AccruedClinicalTrial>
    <crdf:Accruedresearchagreements
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzUtMS0xLTEtNDAzNjg_2dd6474c-6f6f-454f-ada5-0fdcce87c9e0"
      unitRef="usd">509000</crdf:Accruedresearchagreements>
    <crdf:Accruedresearchagreements
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzUtMy0xLTEtNDAzNjg_937dbbdb-6b5c-4aeb-982e-ed10f3297a0b"
      unitRef="usd">726000</crdf:Accruedresearchagreements>
    <crdf:Accrueddirectorfees
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzYtMS0xLTEtNDAzNjg_552e5c20-3b48-4e14-adbc-2954658b9b2b"
      unitRef="usd">125000</crdf:Accrueddirectorfees>
    <crdf:Accrueddirectorfees
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzYtMy0xLTEtNDAzNjg_137cc530-7a03-4373-a236-dd18a6ef62e6"
      unitRef="usd">141000</crdf:Accrueddirectorfees>
    <crdf:Patentlicenseandotherfeespayable
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzgtMS0xLTEtNDAzNjg_d29db414-c669-4601-bf40-05e5c23664a2"
      unitRef="usd">24000</crdf:Patentlicenseandotherfeespayable>
    <crdf:Patentlicenseandotherfeespayable
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzgtMy0xLTEtNDAzNjg_0cbdea70-959d-4a0d-a512-35d44027e0cd"
      unitRef="usd">43000</crdf:Patentlicenseandotherfeespayable>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzEwLTEtMS0xLTQwMzY4_360d7072-c52f-4b94-b427-5af8e7dc74e1"
      unitRef="usd">337000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzEwLTMtMS0xLTQwMzY4_90b671b8-6916-44c5-a292-1b9a1c7b2f46"
      unitRef="usd">129000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzExLTEtMS0xLTQwMzY4_7ebcde65-53b3-4504-b5a7-ecf366c771c9"
      unitRef="usd">5177000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODAvZnJhZzo2M2JmMzdhZDRiNWE0MDYwOThiOWEwNmFjZTI1YjRjYi90YWJsZTo4NDg0MGFlMWJiNDg0NGI1OGU3YjViYzE4MzgyMGVkOC90YWJsZXJhbmdlOjg0ODQwYWUxYmI0ODQ0YjU4ZTdiNWJjMTgzODIwZWQ4XzExLTMtMS0xLTQwMzY4_478265e9-b5b6-4bc0-b0a0-2020d74707f5"
      unitRef="usd">4527000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeasesOfLessorDisclosureTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTU_83ff6732-15d0-4c8f-94ba-0d3a0fbc378f">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During July 2021, the Company entered into an amended lease agreement to increase its occupied space, which commenced on January 1, 2022 and expires on February 28, 2027. Under the Company's prior master facility lease which expired on December 31, 2021, the Company was leasing additional suites in which it was not occupying and subleasing to third parties. The amended lease agreement retained the space that the Company was occupying, and a portion of office and lab space that was previously subleased to a third party. The remaining additional suites subleased to third parties were not included in the Company's amended sublease. The Company currently leases office and lab space in San Diego which expires on February 28, 2027. The lease currently required payments of approximately $61,000 per month with 3% annual escalation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing its vacated space to third parties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid included in operating cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OperatingLeasesOfLessorDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTY_c4539787-fb2b-4861-b689-8e87a774e930">Leases&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;As a lessee, the Company&#x2019;s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Master Facility Lease &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During July 2021, the Company entered into an amended lease agreement to increase its occupied space, which commenced on January 1, 2022 and expires on February 28, 2027. Under the Company's prior master facility lease which expired on December 31, 2021, the Company was leasing additional suites in which it was not occupying and subleasing to third parties. The amended lease agreement retained the space that the Company was occupying, and a portion of office and lab space that was previously subleased to a third party. The remaining additional suites subleased to third parties were not included in the Company's amended sublease. The Company currently leases office and lab space in San Diego which expires on February 28, 2027. The lease currently required payments of approximately $61,000 per month with 3% annual escalation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Facility Subleases&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, which all expired on December 31, 2021. Prior to the expiration of the sublease agreements, the Company as a sublessor was leasing its vacated space to third parties.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid included in operating cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <crdf:LesseeOperatingLeaseMonthlyRentPayment
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzEwMTM_cef83284-8f0d-4c91-bf75-7068a2677b6d"
      unitRef="usd">61000</crdf:LesseeOperatingLeaseMonthlyRentPayment>
    <crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage
      contextRef="i1fc787def7f7467b8134e270f125cecc_D20220101-20270228"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzEwNTA_eb44562a-6b4b-4d99-bf78-042bd2d31979"
      unitRef="number">0.03</crdf:LesseeOperatingLeaseAnnualRentIncreasePercentage>
    <crdf:LessorNumberOfSubleases
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzEzNDM_b0f649f3-9a06-4793-9839-cb21e094a97e"
      unitRef="lease">3</crdf:LessorNumberOfSubleases>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTA_e912cc8e-49a4-46d9-b631-663fae21c18a">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(403)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Twelve Months Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash paid included in operating cash flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;612&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;949&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,061&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzEtNC0xLTEtNDAzNjg_cb64a0d9-075e-459c-bb64-f73bc9c2250b"
      unitRef="usd">754000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzEtNi0xLTEtNDAzNjg_51eddcd1-8c57-4e80-bb9b-597389ea7398"
      unitRef="usd">745000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzItNC0xLTEtNDAzNjg_a3a40a66-2252-482b-8ca7-34c7a90ccbc9"
      unitRef="usd">0</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzItNi0xLTEtNDAzNjg_a862fb66-c302-4ed5-8922-dcb8584e0276"
      unitRef="usd">403000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzMtNC0xLTEtNDAzNjg_f5dd61ad-dc49-483f-bf95-59c5ba8bcda5"
      unitRef="usd">754000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZToyZDZjM2EyZTY1ZDQ0MDI1ODdjMmI4NDBjNzk5MjU0YS90YWJsZXJhbmdlOjJkNmMzYTJlNjVkNDQwMjU4N2MyYjg0MGM3OTkyNTRhXzMtNi0xLTEtNDAzNjg_3bae1eab-3c94-4248-bfd5-a43d6d58bc71"
      unitRef="usd">342000</us-gaap:LeaseCost>
    <crdf:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTE_12a05e89-50ee-4e8b-9238-8f469088ff33">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.104%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.107%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,040&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.2 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.2 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&#x2013;operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzEtMS0xLTEtNDAzNjg_3a0a1761-86bb-4c85-854f-e7814763cfaf"
      unitRef="usd">2251000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzEtMy0xLTEtNDAzNjg_3dfa13c6-1db4-4dfe-bce0-bd229f1aab8b"
      unitRef="usd">2796000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzMtMS0xLTEtNDAzNjg_1ae952c6-608f-491d-a28e-21e001af09fa"
      unitRef="usd">675000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzMtMy0xLTEtNDAzNjg_4d7a93b4-6c77-4ce2-8a04-9607fc9bbf61"
      unitRef="usd">551000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzQtMS0xLTEtNDAzNjg_3ca745ae-ad1c-47be-b00e-7eec21836106"
      unitRef="usd">2040000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzQtMy0xLTEtNDAzNjg_046279c1-17dc-415f-87ba-b4f3a62feaf4"
      unitRef="usd">2568000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzUtMS0xLTEtNDAzNjg_8b4885f0-41ed-47d2-92c2-ab9648aba648"
      unitRef="usd">2715000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzUtMy0xLTEtNDAzNjg_7119380d-c649-43e1-863e-fe3e33df669c"
      unitRef="usd">3119000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzctMS0xLTEtNDAzNjg_e73469f5-26f5-4062-ac33-4019c1d80896">P4Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzctMy0xLTEtNDAzNjg_b1cd248e-1f69-4a3b-a904-73df3371fbd1">P5Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzgtMS0xLTEtNDAzNjg_87465180-8b4c-4fce-ad96-134308d46a4a"
      unitRef="number">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTo0MTcwMTcwMDVlNWY0ZmZkYWVlMDUwNmE1MTVhNTg3MS90YWJsZXJhbmdlOjQxNzAxNzAwNWU1ZjRmZmRhZWUwNTA2YTUxNWE1ODcxXzgtMy0xLTEtNDAzNjg_7f11d447-2648-4195-95b4-079f79b8f7d4"
      unitRef="number">0.07</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzItMS0xLTEtNDAzNjg_acef30f4-e158-4251-a369-1f4ed25d5d1b"
      unitRef="usd">612000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzItMy0xLTEtNDAzNjg_211ea335-5aa6-4728-8f73-9245ce5c2f19"
      unitRef="usd">949000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzQtMS0xLTEtNDAzNjg_dc17db0b-4f44-47da-8311-5deb7e705369"
      unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTozMGVkYTEyZDc2OTQ0MTY0OWI0YTE1ZDdhODhmNTU2OC90YWJsZXJhbmdlOjMwZWRhMTJkNzY5NDQxNjQ5YjRhMTVkN2E4OGY1NTY4XzQtMy0xLTEtNDAzNjg_a44db07d-07dc-4849-bf06-5a41c456910c"
      unitRef="usd">3061000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90ZXh0cmVnaW9uOjhlYmFhNTQwYmE2ZDRjZGE4OTk1Y2MzZmZhYWI2Njg0XzE5MTQ_96d9d60e-71ef-473a-b528-aacdb193436d">Total remaining annual commitments under non-cancelable operating lease agreements as of  December&#160;31, 2022, are summarized are as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:84.133%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.937%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;Operating Leases &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;676&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(422)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzUtMi0xLTEtNDAzNjg_9635af4f-8292-4502-a298-83920431be5a"
      unitRef="usd">676000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzYtMi0xLTEtNDAzNjg_bbe79006-290b-437b-ba19-9faa86d71ee7"
      unitRef="usd">754000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzctMi0xLTEtNDAzNjg_d4d52100-9d2f-4bfe-ab89-e415fbde5890"
      unitRef="usd">775000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzgtMi0xLTEtNDAzNjg_0a713f80-53cc-42f1-8c1c-6d9f4e73b01d"
      unitRef="usd">796000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzktMi0xLTEtNDAzNjg_cba8aca3-1235-4889-83fa-ddade479c830"
      unitRef="usd">136000</crdf:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzEwLTItMS0xLTQwMzY4_ef07175f-5e61-4676-9755-fb11cae74a93"
      unitRef="usd">3137000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzExLTItMS0xLTQwMzY4_b0a5ba2a-c66d-446f-9e2c-6a9b5c286fa0"
      unitRef="usd">422000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODMvZnJhZzo4ZWJhYTU0MGJhNmQ0Y2RhODk5NWNjM2ZmYWFiNjY4NC90YWJsZTowMjE3NjM3YTUxNmI0NzMxOGJhMDAzMzIwN2EzMjlkMi90YWJsZXJhbmdlOjAyMTc2MzdhNTE2YjQ3MzE4YmEwMDMzMjA3YTMyOWQyXzEyLTItMS0xLTQwMzY4_23b05005-574b-49b4-a713-2f27ce31ca31"
      unitRef="usd">2715000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjU2_775cedd9-7088-46e6-8dbf-fe584cfddef3">Stockholders&#x2019; Equity&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Warrants&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,360,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.146%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The material terms of the Series A Convertible Preferred Stock consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Dividends. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Holders of the Company&#x2019;s Series A Convertible Preferred Stock are entitled to receive cumulative dividends at the rate per share of 4% per annum, payable quarterly on March 31, June 30, September 30 and December 31, beginning with September 30, 2005. Dividends are payable, at the Company&#x2019;s sole election, in cash or shares of common stock. As of December&#160;31, 2022 and 2021, the Company had $438,000 and $414,000, respectively in cumulative unpaid preferred stock dividends, included in the liquidation preference of the Series A Convertible Preferred Stock, and $24,000 and $24,000 of cumulative dividends were added to the liquidation preference of the Series A Convertible Preferred Stock during the years ended December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Voting Rights. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shares of the Series A Convertible Preferred Stock have no voting rights. However, so long as any shares of Series A Convertible Preferred Stock are outstanding, the Company may not, without the affirmative vote of the holders of the shares of Series A Convertible Preferred Stock then outstanding, (a) adversely change the powers, preferences or rights given to the Series A Convertible Preferred Stock, (b) authorize or create any class of stock senior or equal to the Series A Convertible Preferred Stock, (c) amend its certificate of incorporation or other charter documents, so as to affect adversely any rights of the holders of Series A Convertible Preferred Stock or (d) increase the authorized number of shares of Series A Convertible Preferred Stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Liquidation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon any liquidation, dissolution or winding-up of the Company, the holders of the Series A Convertible Preferred Stock are entitled to receive an amount equal to the Stated Value per share, which is currently $10 per share plus any accrued and unpaid dividends.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Conversion Rights. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each share of Series A Convertible Preferred Stock is convertible at the option of the holder into that number of shares of common stock determined by dividing the Stated Value, currently $10 per share, by the conversion price, which at the time of issuance was $928.80 per share, and subsequently adjusted to $691.20 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt;Subsequent Equity Sales. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The conversion price is subject to adjustment for dilutive issuances for a period of 12 months beginning March 17, 2006 and the conversion price was adjusted to $691.20 per share.   &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:40.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:23.17pt"&gt; Automatic Conversion. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the price of the Company&#x2019;s common stock equals $1,857.60 per share for 20 consecutive trading days, and an average of 116 shares of common stock per day are traded during the 20 trading days, the Company will have the right to deliver a notice to the holders of the Series A Convertible Preferred Stock, requesting the holders to convert any portion of the shares of Series A Convertible Preferred Stock into shares of common stock at the applicable conversion price. As of the date of these financial statements, such conditions have not been met.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:58.5pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the liquidation preference for the Series A Convertible Preferred Stock were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stated Value per share liquidation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative unpaid preferred stock dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation preference - Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 15, 2020 the Company entered into a Securities Purchase Agreement with certain accredited investors, pursuant to which the Company agreed to offer, issue and sell to Acorn, CDK and Third Street, (i) in a registered direct offering, an aggregate of 1,984,328 shares of common stock and (ii) in a concurrent private placement, (a) an aggregate of 865,824 shares of Series E Preferred Stock (&#x201c;Series E Preferred Stock&#x201d;) and (b) Series N warrants to purchase up to 2,213,115 shares of Common Stock. The Series E Preferred Stock is convertible at any time determined by dividing the $10 stated value per share of the Series E Preferred Stock by a conversion price of $2.44 per share, subject to adjustment in accordance with the Certificate of Designation. The Series N Warrants will be exercisable six months following the date of issuance at an exercise price of $2.39 per share and will expire on December 16, 2025. Certain investors converted 210,780 shares of Series E Convertible Preferred stock to 863,852 shares of Common Stock during December 2020. Certain investors converted 327,535 shares of Series E Convertible Preferred stock to 1,342,357 shares of Common Stock during January 2022. Certain investors converted 327,509 shares of Series E Convertible Preferred stock to 1,342,250 shares of Common Stock during October 2022. As of December 31, 2022 no shares of Series E Convertible Preferred stock were outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In conjunction with the June 15, 2020 offering, we issued 184,426 warrants as an advisory fee. These warrants are exercisable six months following the date of issuance at an exercise price of $3.05 per share and will expire 5.5 years following the date of issuance. These warrants were classified as equity. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Sales Agreement with Jefferies LLC&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During May 2021, the Company sold 2.0&#160;million shares of its common stock under the Sales Agreement with Jefferies LLC., for gross proceeds of approximately $20.0&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Pfizer Breakthrough Growth Initiative&lt;/span&gt;&lt;/div&gt;During November 2021, the Company sold 2.4&#160;million shares of its common stock under a Securities Purchase Agreement with Pfizer Inc. ("Pfizer"), in a registered direct offering for gross proceeds of approximately $15.0&#160;million. The investment is part of the Pfizer Breakthrough Growth Initiative, which includes an information rights agreement and Pfizer's participation on a Scientific Advisory Board for the Company. Pfizer agreed to not sell or transfer any shares for 180 days from the closing date of the agreement, which expired during May 2022.</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjYw_f49d0fc9-2cc9-4cfb-90e8-c2a62d72d7f1">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications, is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.182%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.427%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.565%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Exercise Price &lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining Contractual Term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,260,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,490,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(129,191)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,360,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzktMS0xLTEtNDAzNjg_d2d2ddfd-10cf-4e16-9338-699cc56306f3"
      unitRef="shares">5260992</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="ia11a41c8cea2407c8bdeb44938a52270_I20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzktMy0xLTEtNDAzNjg_e2f88056-037b-4027-8b73-9bfee8333313"
      unitRef="usdPerShare">5.19</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:WarrantsWeightedAverageContractualTerm
      contextRef="i437c6b27648f43149169d43e9d00f190_D20200101-20201231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzktNS0xLTEtNDAzNjg_37010d58-5366-4d61-973e-bc833876dfc4">P4Y1M6D</crdf:WarrantsWeightedAverageContractualTerm>
    <crdf:ClassOfWarrantOrRightNumberExercised
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzExLTEtMS0xLTQwMzY4_2d607165-96fd-4b7b-915a-958ced570da6"
      unitRef="shares">770833</crdf:ClassOfWarrantOrRightNumberExercised>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzExLTMtMS0xLTQwMzY4_43ed2021-3c28-4837-96c9-5c5cd074f779"
      unitRef="usdPerShare">1.64</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzEzLTEtMS0xLTQwMzY4_e9e821fb-2e32-4d0b-b631-b79e48941b73"
      unitRef="shares">4490159</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzEzLTMtMS0xLTQwMzY4_e6007e74-5272-456f-9c30-4e4f5b1c2dcc"
      unitRef="usdPerShare">5.80</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:WarrantsWeightedAverageContractualTerm
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzEzLTUtMS0xLTQwMzY4_c2b61681-6502-45d3-a4d4-ed4931e3aeaa">P3Y</crdf:WarrantsWeightedAverageContractualTerm>
    <crdf:ClassOfWarrantOrRightNumberExpired
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE2LTEtMS0xLTQxNzI2_be9a7811-fe46-4975-90ef-c0a11752459a"
      unitRef="shares">129191</crdf:ClassOfWarrantOrRightNumberExpired>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE2LTMtMS0xLTQxNzI2_fd9db044-b623-412a-8c5e-83cb25e5e178"
      unitRef="usdPerShare">21.60</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE3LTEtMS0xLTQxNzM1_59289ccc-05e7-436e-bcc4-6a939bc429e2"
      unitRef="shares">4360968</us-gaap:ClassOfWarrantOrRightOutstanding>
    <crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE3LTMtMS0xLTQxNzM1_8cab51b6-c6bf-4d93-b1d6-ff8faea11d16"
      unitRef="usdPerShare">5.33</crdf:ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights>
    <crdf:WarrantsWeightedAverageContractualTerm
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo0ZTE3OTZlZmJjZmI0M2NjODJkNTg3Zjk5OTI2YTVjZi90YWJsZXJhbmdlOjRlMTc5NmVmYmNmYjQzY2M4MmQ1ODdmOTk5MjZhNWNmXzE3LTUtMS0xLTQxNzM1_64cb1fa1-ff4d-4213-a1d9-fdd6b746fc8c">P2Y1M6D</crdf:WarrantsWeightedAverageContractualTerm>
    <us-gaap:ScheduleOfStockByClassTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjU1_d3f2d960-69e7-46df-a23d-47179d8ddcc0">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of our Company's classes of preferred stock is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.652%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.142%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.146%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Class&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares designated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;277,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series B Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series C Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series D Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series E Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;865,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the liquidation preference for the Series A Convertible Preferred Stock were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:65.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.424%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stated Value per share liquidation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;606&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cumulative unpaid preferred stock dividends&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liquidation preference - Series A Convertible Preferred Stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItMi0xLTEtNDAzNjg_8fe20694-a3e8-4e5e-8137-8748dc6fd1bc"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItNC0xLTEtNDAzNjg_58a66396-abb9-4c07-90f8-58aab8d4d03f"
      unitRef="shares">277100</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItOC0xLTEtNDAzNjg_56f7e4d3-87cf-4357-996a-fa6eeb370c99"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i967e88231f6e41158f5760ef3badc44a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzItMTAtMS0xLTQwMzY4_03645d63-1e15-4d52-9bea-4e4c1d75420c"
      unitRef="shares">60600</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i15da6dbca1f446fabca739e995d15020_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtMi0xLTEtNDAzNjg_6cc1bfc6-1e59-4ff1-a04e-3f1471e3601d"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i15da6dbca1f446fabca739e995d15020_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtNC0xLTEtNDAzNjg_dc9075bf-97c0-4b0d-9b89-7db5c2b14f48"
      unitRef="shares">8860</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i15da6dbca1f446fabca739e995d15020_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtOC0xLTEtNDAzNjg_20d329e3-1922-4100-b8b9-bd9efa8647d9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iaf1325a8adbb464aa4a9459b6c1ebf24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzMtMTAtMS0xLTQwMzY4_24b88151-6c87-487c-a10e-2f9c12116329"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ie1c031a24f5041998bc94baf5d5e7878_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtMi0xLTEtNDAzNjg_006737e7-0eb1-4331-b86e-2557a60fb090"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ie1c031a24f5041998bc94baf5d5e7878_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtNC0xLTEtNDAzNjg_a52f75b7-b88a-4550-979b-6a5a99e3112c"
      unitRef="shares">200000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ie1c031a24f5041998bc94baf5d5e7878_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtOC0xLTEtNDAzNjg_49be7418-6fac-47d5-b63c-e076eb158f27"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ib2bbcf65ab5b4c44852255c9f2d94146_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzQtMTAtMS0xLTQwMzY4_828b0163-2597-4ff8-9fad-4c1ff2d503cb"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6a7c515d9ae6485d9e93a24cb7826442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtMi0xLTEtNDAzNjg_37db4788-e678-440f-8f38-b8b3f26dee58"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6a7c515d9ae6485d9e93a24cb7826442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtNC0xLTEtNDAzNjg_80239350-8fc3-493d-9765-0d1b1a76770c"
      unitRef="shares">154670</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6a7c515d9ae6485d9e93a24cb7826442_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtOC0xLTEtNDAzNjg_124bd47b-31c8-4201-9c88-9af91ebf8c7c"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iad1bd806a546460c98ffb5ac6f3ac8c5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzUtMTAtMS0xLTQwMzY4_7fb0373a-88df-48a3-9f90-df3ffe27bfd1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtMi0xLTEtNDAzNjg_e6cf5293-4621-4634-8807-d509e13f26c4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtNC0xLTEtNDAzNjg_7ed3cd2a-f11d-4d86-bc3d-9804987dc462"
      unitRef="shares">865824</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtOC0xLTEtNDAzNjg_0b8dc22e-9b35-414c-ac84-166f3722c7fc"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="icf86537bddcb4f599b70afe570a83e20_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTo2Y2Y3ZGI3MDY3M2I0OTE3YjY1YTY5ZDlhZjIzZjVkMi90YWJsZXJhbmdlOjZjZjdkYjcwNjczYjQ5MTdiNjVhNjlkOWFmMjNmNWQyXzYtMTAtMS0xLTQwMzY4_e10e17a9-7de3-4edd-9d11-fda450864252"
      unitRef="shares">655044</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzg4OQ_950012f0-6ee8-4375-9678-006a0bc54deb"
      unitRef="number">0.04</us-gaap:PreferredStockDividendRatePercentage>
    <crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzExMzE_abbedd51-bad6-4e5a-a57a-f297213edb79"
      unitRef="usd">438000</crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue>
    <crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue
      contextRef="i967e88231f6e41158f5760ef3badc44a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzExMzg_69e9b49c-43da-4119-85c1-f3cd04ff6353"
      unitRef="usd">414000</crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue>
    <us-gaap:DividendsPreferredStock
      contextRef="i689740219e214ef58af97e73397e9639_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEyODA_06ebc8fe-8411-4418-b6d6-bf420cb0c689"
      unitRef="usd">24000</us-gaap:DividendsPreferredStock>
    <us-gaap:DividendsPreferredStock
      contextRef="i996a08b3a2e64d389e548aa5d2d57cb4_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEyODc_99dce64f-b7a1-4349-aeb0-fa9cae11bc5a"
      unitRef="usd">24000</us-gaap:DividendsPreferredStock>
    <crdf:ConvertiblePreferredStockStatedValuePerShare
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzIzNzY_89ab1490-3e80-477a-938f-4a76b3d7afdf"
      unitRef="usdPerShare">10</crdf:ConvertiblePreferredStockStatedValuePerShare>
    <crdf:ConvertiblePreferredStockStatedValuePerShare
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI2Mzc_e6bc9eeb-9aca-4ee9-88f7-23c7276d343c"
      unitRef="usdPerShare">10</crdf:ConvertiblePreferredStockStatedValuePerShare>
    <crdf:PreferredStockConversionPricePerShare
      contextRef="id0c78aec3b59415da597680943386c88_D20070701-20070930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI3MTA_07c83c97-d6ff-4678-893f-2f458132a7fb"
      unitRef="usdPerShare">928.80</crdf:PreferredStockConversionPricePerShare>
    <crdf:PreferredStockConversionPricePerShare
      contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI3NTM_bc599314-a636-48a5-98f2-2e7f3332fbf2"
      unitRef="usdPerShare">691.20</crdf:PreferredStockConversionPricePerShare>
    <crdf:PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments
      contextRef="i6e2742890db242d6bf741c1ee3352f61_D20060317-20060317"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI4Nzk_a3823b7d-4d90-4f16-8bba-97183cf0a769">P12M</crdf:PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments>
    <crdf:PreferredStockConversionPricePerShare
      contextRef="i6e2742890db242d6bf741c1ee3352f61_D20060317-20060317"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzI5NDg_8d223feb-7b3b-4ef8-9c71-e68a7024efee"
      unitRef="usdPerShare">691.20</crdf:PreferredStockConversionPricePerShare>
    <crdf:SharePriceForAutomaticConversion
      contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMwMzk_d74ec215-9bbd-4ef9-a776-d892c87e150c"
      unitRef="usdPerShare">1857.6</crdf:SharePriceForAutomaticConversion>
    <crdf:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays
      contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMwNTY_d11511cb-761f-4b29-b416-b3d1900ef646">P20D</crdf:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
    <crdf:PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays
      contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMxMDM_e05f9017-2ca8-4c5b-a7db-f42e8e771aaf"
      unitRef="shares">116</crdf:PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays>
    <crdf:PreferredStockConversionObligationNumberOfTradingDays
      contextRef="i492ca89c37204a0da71301af85c79a73_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzMxNTk_f7a52afc-c77c-4b0a-b558-381fe0ad23ca">P20D</crdf:PreferredStockConversionObligationNumberOfTradingDays>
    <crdf:PreferredStockLiquidationPreferenceStatedValue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzItMS0xLTEtNDYwMTg_702894bc-7d90-47c8-917a-b1477c91bf25"
      unitRef="usd">606000</crdf:PreferredStockLiquidationPreferenceStatedValue>
    <crdf:PreferredStockLiquidationPreferenceStatedValue
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzItMy0xLTEtNDYwMjA_0632cb4c-d577-4011-ac52-7c7eef0d8f13"
      unitRef="usd">606000</crdf:PreferredStockLiquidationPreferenceStatedValue>
    <crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue
      contextRef="i2513f13b8a974c7daed93b812f580722_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzMtMS0xLTEtNDM5NjE_abbedd51-bad6-4e5a-a57a-f297213edb79"
      unitRef="usd">438000</crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue>
    <crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue
      contextRef="i967e88231f6e41158f5760ef3badc44a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzMtMy0xLTEtNDM5NjE_69e9b49c-43da-4119-85c1-f3cd04ff6353"
      unitRef="usd">414000</crdf:PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzQtMS0xLTEtNDYwMTM_b6b72b94-de11-412b-b891-7db7b7ac69d3"
      unitRef="usd">1044000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90YWJsZTozYzk5ODU1NWQzOWM0YjY4YjIzOTNhNTRjN2I5YWVlYi90YWJsZXJhbmdlOjNjOTk4NTU1ZDM5YzRiNjhiMjM5M2E1NGM3YjlhZWViXzQtMy0xLTEtNDYwMTU_2904e258-74d3-4b00-b8ca-35a0ef37139c"
      unitRef="usd">1020000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="icfbfb8b01efa4a1299b3d55a92ac99c6_D20200615-20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU3NzU_ad967666-2865-4b1a-a14d-6801fbbc2304"
      unitRef="shares">1984328</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i945e201b0a974dac9a79bbce7e560aac_D20200615-20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU4NjU_3302526e-7005-457a-b5c4-ce546a9d5d52"
      unitRef="shares">865824</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i6fbb0b602b174b52b951641f74a93e02_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU5NzY_4b573814-45b2-4670-a8ff-0b947668f96d"
      unitRef="shares">2213115</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <crdf:ConvertiblePreferredStockStatedValuePerShare
      contextRef="ia4060629a24449e582b7b1c954cde009_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYwODY_9105eb1a-b35d-4b50-8d60-8b19c8cd55e2"
      unitRef="usdPerShare">10</crdf:ConvertiblePreferredStockStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="ia4060629a24449e582b7b1c954cde009_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYxNjk_e612e965-e41d-4540-9ab4-35f348ccb5a7"
      unitRef="usdPerShare">2.44</us-gaap:PreferredStockConvertibleConversionPrice>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i01b6d2c9f16c4851800bc4d351b41c95_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYyOTg_673b24a6-cec5-45ec-abae-d7c277425a6f">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i34bf0c72c7264502a3fd19a93c17fc34_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzYzNTY_56360534-01b1-4fcd-be12-a5a820c0277f"
      unitRef="usdPerShare">2.39</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i1ac45431f2954aeea968270d5152763f_D20201201-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzY0MzU_305fc83d-80cd-4bf8-95da-8ca1c6c74493"
      unitRef="shares">210780</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzY0ODg_3039607a-e358-4987-b117-553ca85cf777"
      unitRef="shares">863852</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="iba4fe2a0ab954fd996d5aeadefcf0d29_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTE3OQ_4eda180a-ba54-4684-a278-d41c3a6e3e6a"
      unitRef="shares">327535</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i537f6a2ef9cb45469a00fe1de5bbadbd_D20220101-20220131"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTE4OA_edc50b92-4ec8-4ffd-87fc-698ac2bcaf33"
      unitRef="shares">1342357</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:ConversionOfStockSharesConverted1
      contextRef="i05f68406df2c440b8b525d03472d93a8_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTE5OQ_0e3c9638-6db3-47ec-be39-ac7b88dd4773"
      unitRef="shares">327509</us-gaap:ConversionOfStockSharesConverted1>
    <us-gaap:ConversionOfStockSharesIssued1
      contextRef="i5c69ebdd813b43cf9b9e7435a5b93db8_D20221001-20221031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTIwOA_ba11877f-0584-42bd-b0ab-4b4cc73d0736"
      unitRef="shares">1342250</us-gaap:ConversionOfStockSharesIssued1>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ifa37db5b3ec34f6ea7aeab26dbdc66e5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzU0OTc1NTgzOTIxOA_32d0623b-4b7a-4abc-9ba3-eff0f1eaa254"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <crdf:ClassOfWarrantOrRightIssued
      contextRef="i6fbb0b602b174b52b951641f74a93e02_I20200615"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzcyMzQ_8f88f840-43c5-4cf1-98f2-abbfba3acc31"
      unitRef="shares">184426</crdf:ClassOfWarrantOrRightIssued>
    <crdf:ClassOfWarrantOrRightMonthsUntilExercisable
      contextRef="i121f9fb27a22487c9da80cbd21f3696c_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzcyOTc_2379a10e-2176-4e2a-831c-9880f5317dbe">P6M</crdf:ClassOfWarrantOrRightMonthsUntilExercisable>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i6fbb0b602b174b52b951641f74a93e02_I20200615"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzczNTU_0eb9fb62-815a-4732-bb60-8ed736662644"
      unitRef="usdPerShare">3.05</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crdf:ClassOfWarrantOrRightExpirationTerm
      contextRef="i121f9fb27a22487c9da80cbd21f3696c_D20200615-20200615"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzczODQ_fc0c0523-4f2f-4155-ac18-a8324245338d">P5Y6M</crdf:ClassOfWarrantOrRightExpirationTerm>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i108dcc73776440a2bb02b0906b8fb804_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzk5OTc_08f63875-fcdf-4380-af17-9e3c26836de3"
      unitRef="shares">2000000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <crdf:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i108dcc73776440a2bb02b0906b8fb804_D20210501-20210531"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwMTEw_a2af44e1-40fb-40f5-8f4e-5d37b0283723"
      unitRef="usd">20000000</crdf:SaleOfStockConsiderationReceivedOnTransactionGross>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwMTk1_101e6f1a-0134-42af-bc32-39855a521d3e"
      unitRef="shares">2400000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <crdf:SaleOfStockConsiderationReceivedOnTransactionGross
      contextRef="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwMzYw_5a61e508-b1ec-4cfd-9197-8874b370a199"
      unitRef="usd">15000000</crdf:SaleOfStockConsiderationReceivedOnTransactionGross>
    <crdf:SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares
      contextRef="i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODYvZnJhZzpiYTEyMTBmZTI5ZDE0MTkwYTZjNzNlZGNhODViNzBlMC90ZXh0cmVnaW9uOmJhMTIxMGZlMjlkMTQxOTBhNmM3M2VkY2E4NWI3MGUwXzEwNjEy_bee8c8b7-94f8-48ef-bfa5-dc3cdd7a1947">P180D</crdf:SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjc_3e34ca7a-b9ba-425a-95dd-efab1d5354b9">Stock-Based Compensation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:38.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2021 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 the Company's stockholders approved the 2021 Omnibus Equity Incentive Plan ("2021 Plan"). The number of authorized shares in the 2021 plan is equal to the sum of (i) 3,150,000 shares, plus (ii) the number of shares of Common Stock reserved, but unissued under the 2014 Plan; and (iii) the number of shares of Common Stock underlying forfeited awards under the 2014 Plan. On June 9, 2022 the shareholders approved an increase of shares authorized in the 2021 Plan to 5,150,000. As of December&#160;31, 2022, there were 3,087,075 shares available for issuance under the 2021 Plan.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2014 Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent to the adoption of the 2021 Plan, no additional equity awards can be made under the terms of the 2014 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Inducement Grants&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company began issuing equity awards to certain new employees as inducement grants outside of its 2021 Plan. As of December&#160;31, 2022, an aggregate of 920,208 shares were issuable upon the exercise of inducement grant stock options approved by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Modification of Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022 one of the Company's directors did not seek another term on the Board of Directors. At the time of departure, the Compensation Committee passed a resolution to extend the expiration date of the vested stock options, and to immediately accelerate the vesting of the unvested options. The Company recorded incremental reduction to stock compensation expense of $0.1&#160;million during the year ended December 31, 2022, related to the modifications.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 two of the Company's directors' terms ended. At the conclusion of their term, the Compensation Committee passed a resolution to extend the expiration date of the departing directors vested stock options, and to immediately accelerate the vesting of one of the directors unvested options. The Company recorded incremental stock compensation expenses of $0.6&#160;million during the year ended December 31, 2021, related to the modifications. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:38.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation has been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62% - 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83% - 1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (range)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98% - 110%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107% - 110%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (weighted-average)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Based on the daily yield curve rates for U.S. Treasury obligations with maturities that correspond to the expected term of the Company&#x2019;s stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Cardiff Oncology has not paid any dividends on common stock since its inception and does not anticipate paying dividends on its common stock in the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; Based on the historical volatility of Cardiff Oncology&#x2019;s common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The expected option term represents the period that stock-based awards are expected to be outstanding based on the simplified method, which represents the Company's best estimate following the Company's restructuring in 2018. This method averages an award&#x2019;s weighted-average vesting period and expected term for &#x201c;plain vanilla&#x201d; share options. Options are considered to be &#x201c;plain vanilla&#x201d; if they have the following basic characteristics: (1) are granted &#x201c;at-the-money&#x201d;; (2) exercisability is conditioned upon service through the vesting date; (3) termination of service prior to vesting results in forfeiture; (4) limited exercise period following termination of service; and (5) are non-transferable and non-hedgeable.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forfeitures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &#x2014; The Company estimates forfeitures based on its historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average fair value per share of all options granted during the years ended December&#160;31, 2022 and 2021, estimated as of the grant date using the Black-Scholes option valuation model, was $2.55 and $5.96 per share, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The unrecognized compensation cost related to non-vested stock options outstanding at December&#160;31, 2022 was $8.8 million. The weighted-average remaining amortization period at December&#160;31, 2022 for non-vested stock options was 2.6 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total fair value of shares vested during the years ended December&#160;31, 2022 and 2021 was $4.7 million and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and of changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,737,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,990,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7370af0295e247098c3f37e012a4710d_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzI0Mg_b31016da-2f08-4f3c-9984-bcb9ffe517e9"
      unitRef="shares">3150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="ib2ae2c2e51104727ab30997d35b6e45b_I20220609"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzEwOTk1MTE2MzIyMTg_363e71f3-acda-4fa2-b5cf-c738404370dd"
      unitRef="shares">5150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i9738a5e163944c6ea598de6c5bd1a81c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQ2MQ_f1ab1374-b4e2-437d-b422-72fdf744acb6"
      unitRef="shares">3087075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="ia3450ae440464e099c7b194d9e93da51_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzgzNw_8c7d044d-aa37-4b09-b0b1-8960329a87f6"
      unitRef="shares">920208</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzEwOTk1MTE2MzM1Mzg_90f34b2e-609c-4886-bed7-0bc17f56c577"
      unitRef="usd">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzEzMzU_efaa986a-4976-44e8-a5ce-67b5d4121468"
      unitRef="usd">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjg_7ea886e0-dfa8-4945-afa8-b6b7d8bd5530">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation has been recognized in operating results as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;491&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4075c1548dc7491f83a6970912aca8fa_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzMtMS0xLTEtNDAzNjg_796f62f2-9287-4378-a814-39a8751aec7a"
      unitRef="usd">1035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i88d9796297a64fb8928bef8b221160e5_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzMtMy0xLTEtNDAzNjg_02e4529c-b81b-4883-b054-fafc981b7def"
      unitRef="usd">491000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7653394ffa3343d58c6ca060d5bfc38e_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzUtMS0xLTEtNDAzNjg_975b6453-89b6-42f4-99fe-9bcc77f5b6a2"
      unitRef="usd">3221000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f1151fb051c43a3a54f391052603412_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzUtMy0xLTEtNDAzNjg_7002f245-9719-42df-a19c-1060e0659967"
      unitRef="usd">2743000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzctMS0xLTEtNDAzNjg_db6ff5f0-db4e-4274-b4de-50b93ac965a3"
      unitRef="usd">4256000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTpiYTdjZWVkMGNiNTA0NDZmYTY1MDgxMDlkOGJhZjVjNS90YWJsZXJhbmdlOmJhN2NlZWQwY2I1MDQ0NmZhNjUwODEwOWQ4YmFmNWM1XzctMy0xLTEtNDAzNjg_a23d944a-5411-42c7-a5e3-e7473e9060d6"
      unitRef="usd">3234000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjA_dccbd3f8-6f9b-4fd8-ab62-215e415a6ed5">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following assumptions during the years indicated below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.360%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.62% - 3.75%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83% - 1.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (range)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98% - 110%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107% - 110%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility (weighted-average)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i12ca60f5c6f2431eb4b26a3b8e10d21f_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo1YWZmM2VmZmUxMTY0NTE2OGQ5MmNlMzg1NzI4NWJmMF80_a7a26753-800a-49d3-bc70-cc7ea2d9a6b5"
      unitRef="number">0.0162</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i54f3b30b34ae4b56b912ae1b787704d5_D20220101-20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo1YWZmM2VmZmUxMTY0NTE2OGQ5MmNlMzg1NzI4NWJmMF85_57a6b05f-aca6-4bab-8a2e-1f868b99259e"
      unitRef="number">0.0375</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i2d91a06d3c074593b7c7a0c70ea5c098_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjphNzhhOGY5MjkwZWM0OGZiYWQ5MjY0NTlhNTY0YWY3MV80_1ac66263-987e-4052-8c20-072f6354d98e"
      unitRef="number">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ia6c27981ae474b778f9da78071df3c6c_D20210101-20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzItMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjphNzhhOGY5MjkwZWM0OGZiYWQ5MjY0NTlhNTY0YWY3MV85_a466f87d-aff2-4171-a81a-86a5062dea37"
      unitRef="number">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzMtMS0xLTEtNDAzNjg_83a138f9-5c71-4393-be9f-f3ce6a327637"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzMtMy0xLTEtNDAzNjg_4b8f8e5a-d453-4472-85e8-7aef54799f09"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i12ca60f5c6f2431eb4b26a3b8e10d21f_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjoxNzk2MDhlZjVkNTQ0MWY2ODc5NTAxMmEyNjFkZTUxOF80_00337b98-a3ba-49c8-871e-65f2ff33237b"
      unitRef="number">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i54f3b30b34ae4b56b912ae1b787704d5_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMS0xLTEtNDAzNjgvdGV4dHJlZ2lvbjoxNzk2MDhlZjVkNTQ0MWY2ODc5NTAxMmEyNjFkZTUxOF85_09af661b-c633-4c02-9603-d12ba4f8a0f1"
      unitRef="number">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i2d91a06d3c074593b7c7a0c70ea5c098_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo0ZGU3NGM5NGI5ZDg0Y2MwOThjZWJlMzhiYWYwZmJiY180_1f78c537-1481-4dc9-8883-a23ca612d6c1"
      unitRef="number">1.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ia6c27981ae474b778f9da78071df3c6c_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzQtMy0xLTEtNDAzNjgvdGV4dHJlZ2lvbjo0ZGU3NGM5NGI5ZDg0Y2MwOThjZWJlMzhiYWYwZmJiY185_599280e9-136c-4626-a6f9-455f13a9599a"
      unitRef="number">1.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzUtMS0xLTEtNDAzNjg_3043ecad-d599-4e4c-bfc9-31f8420cccb0"
      unitRef="number">1.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzUtMy0xLTEtNDAzNjg_ad9a1584-36b0-46c8-b60e-222d94e1f439"
      unitRef="number">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzYtMS0xLTEtNDAzNjg_610dfbcc-49dd-4d09-b2b4-dbb97ce35a6e">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo5YzY0MmIwM2QxNDY0YTYwYTFlNWI4MTk3YzcyZjM5NC90YWJsZXJhbmdlOjljNjQyYjAzZDE0NjRhNjBhMWU1YjgxOTdjNzJmMzk0XzYtMy0xLTEtNDAzNjg_daf33f37-dba5-4ccc-bf8e-161836df8085">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMwOTQ_407bcd01-9d95-496a-bc41-a1ca6e63f0e4"
      unitRef="usdPerShare">2.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMxMDE_aea0904e-da3b-4325-bb07-bd73465110cb"
      unitRef="usdPerShare">5.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMyMjQ_72aef9c8-07fd-4ade-a9c6-1878af6e68e3"
      unitRef="usd">8800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMzMTg_df5ab49d-592b-4a01-95c7-02cf6cbd3d8a">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzMzOTk_8abd1a05-0bcd-4315-9ab4-c13c44103ac2"
      unitRef="usd">4700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzM0MDY_4f7b5186-ff81-4092-8838-abf8f80667a7"
      unitRef="usd">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90ZXh0cmVnaW9uOjIzYWVjNGEzNWNiYjQ4NjRiZTBiNjA0ODI5MmRlM2RiXzQxMjM_fe51af1a-45ab-4ffe-a971-8a929670d7f5">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of stock option activity and of changes in stock options outstanding is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.752%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance outstanding, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,771,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,405,258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,737,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28,858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cancelled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(398,156)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,272)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance Outstanding, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,069,458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,300,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and expected to vest, December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,990,351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,752&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2095721442fd459a96884e78016c08c6_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTEtMS0xLTQwMzY4_e4f064a1-42c0-477a-8237-708743f53b4e"
      unitRef="shares">3771984</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2095721442fd459a96884e78016c08c6_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTMtMS0xLTQwMzY4_36cf2a4b-d1e5-4af5-a73e-d5ca91681ec1"
      unitRef="usdPerShare">7.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2095721442fd459a96884e78016c08c6_I20211231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTUtMS0xLTQwMzY4_9e615d21-8f9c-47d4-b01b-bc75b30bd11a"
      unitRef="usd">6405258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i62ecf6748a0d43e4be10ec041c94e28f_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE1LTctMS0xLTQwMzY4_8780db61-2dc0-439d-bde9-97cbed232f4e">P8Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTEtMS0xLTQyMDA2_c670d149-eead-4066-a0b5-d40654c37f8a"
      unitRef="shares">1737760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTMtMS0xLTQyMDA2_7fefd6d4-c55d-4d0c-b00c-1e732700a9ab"
      unitRef="usdPerShare">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTEtMS0xLTQyMDA2_eb7a6d72-d43a-4a5a-8d21-b70d701fec41"
      unitRef="shares">28858</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTMtMS0xLTQyMDA2_44643e63-7f20-4291-87cb-2a6a10de36c8"
      unitRef="usdPerShare">2.60</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTUtMS0xLTQyMDA2_8a7ddd45-10ab-43ef-a142-406c043ed432"
      unitRef="usd">1443</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE4LTEtMS0xLTQyMDA2_a2425bfe-8108-4f4b-8328-909ad9522453"
      unitRef="shares">398156</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE4LTMtMS0xLTQyMDA2_33605c7b-e8bf-4b09-a279-f773b0b8dabf"
      unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE5LTEtMS0xLTQyMDA2_70b5157d-d29d-4edd-8583-2ee96b7b3467"
      unitRef="shares">13272</crdf:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod>
    <crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE5LTMtMS0xLTQyMDA2_6c298747-346e-4fa0-953d-ce0fcbf650a6"
      unitRef="usdPerShare">32.52</crdf:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTEtMS0xLTQyMDA2_f4b9f531-9e6e-4e04-850c-cc7ac10760f6"
      unitRef="shares">5069458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTMtMS0xLTQyMDA2_08d3d58b-3bf4-440f-bce8-312e065a092a"
      unitRef="usdPerShare">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTUtMS0xLTQyMDA2_02540513-43b0-4f80-8844-b013216083e6"
      unitRef="usd">19322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzIwLTctMS0xLTQyMDA2_4199eaf1-c812-456f-9e56-d6d56e0021c9">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTEtMS0xLTQwMzY4_49b93f86-22a9-4da7-939f-fd709ad21c8d"
      unitRef="shares">2300619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTMtMS0xLTQwMzY4_8a52f785-ae9b-4d1a-aabb-8051b748b0f8"
      unitRef="usdPerShare">7.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTUtMS0xLTQwMzY4_84789b0c-a185-4f6a-822f-fbde49e86971"
      unitRef="usd">12210</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE2LTctMS0xLTQwMzY4_60604375-7ed5-4fd9-bef2-554b0c46873f">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTEtMS0xLTQwMzY4_ff10d8f8-8da4-4397-ad0b-eaf7b0df4f5e"
      unitRef="shares">4990351</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTMtMS0xLTQwMzY4_a5799b71-2159-4e0a-af94-d86d0e2c1e76"
      unitRef="usdPerShare">5.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i9c1532e9351741698480572142e9d643_I20221231"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTUtMS0xLTQwMzY4_c264909b-aa24-49ce-9934-f4c33e6d4bf6"
      unitRef="usd">18752</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yODkvZnJhZzoyM2FlYzRhMzVjYmI0ODY0YmUwYjYwNDgyOTJkZTNkYi90YWJsZTo3NWYzYTQyODdkOTg0MjYxOGRjNzZkZTBkMmViYWZkMS90YWJsZXJhbmdlOjc1ZjNhNDI4N2Q5ODQyNjE4ZGM3NmRlMGQyZWJhZmQxXzE3LTctMS0xLTQwMzY4_93f1770d-1495-440e-b3e6-bf77a038a7d3">P7Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90ZXh0cmVnaW9uOjk4MGE5MTIyNWUzYTRmYWRiY2M4ZjFhMzA4YWU0MjBkXzEyMjk_f35057b6-2310-4818-a91b-13981c0914e5">Derivative Financial Instruments &#x2014; Warrants&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Certain warrants issued in connection with the Company&#x2019;s equity financings are accounted for as derivative liabilities. Accordingly, the warrants are remeasured at each balance sheet date based on their estimated fair value using the Black-Scholes option pricing model. Changes in fair value are recorded within Company&#x2019;s statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Expected volatility is based on the historical volatility of Cardiff Oncology&#x2019;s common stock. The warrants have a transferability provision and based on guidance for instruments issued with such a provision, Cardiff Oncology used the remaining contractual term as the expected term of the warrants. The risk-free interest rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except for number of warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the year recognized as a gain in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants  during the year recognized as a loss in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90ZXh0cmVnaW9uOjk4MGE5MTIyNWUzYTRmYWRiY2M4ZjFhMzA4YWU0MjBkXzEyMTk_925515d8-a526-4131-a495-b58697666d20">&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The assumptions used to determine the fair value of the warrants using the Black-Scholes option pricing model were:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:62.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1.40&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.01&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected warrant term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility of Cardiff Oncology common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="i742d83ea624f49ce83073c6574708721_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzMtMS0xLTEtNDAzNjg_86be0c76-1626-4a58-aba0-c876ff072868"
      unitRef="usdPerShare">1.40</crdf:EstimatedFairValueOfWarrant>
    <crdf:EstimatedFairValueOfWarrant
      contextRef="i0303b15e3f184176afecec0057db48a9_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzMtMy0xLTEtNDAzNjg_03e6b621-0a61-4ec8-bb5a-a0d46f19ecd2"
      unitRef="usdPerShare">6.01</crdf:EstimatedFairValueOfWarrant>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i3aa54b0f02c246f49fa614c49650a57b_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzQtMS0xLTEtNDAzNjg_30c3e920-b51a-490e-af81-05166c6bb8dc">P0Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i271b9a9812a34766a92109b7e9619679_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzQtMy0xLTEtNDAzNjg_3c4cd69c-0c06-4c1b-8f96-df69a86b3690">P1Y1M6D</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iad6ba7c42c22486fbe96bea3b5c38401_I20221231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzUtMS0xLTEtNDAzNjg_92637dc5-558e-46e7-a450-2a6ea034bd72"
      unitRef="number">0.0412</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i92fafe950c8f4417b2b04359b916f56c_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzUtMy0xLTEtNDAzNjg_3d214e19-7fbc-4f65-97a6-83e526bb9124"
      unitRef="number">0.0041</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="id0914d051b344922b3bc650fe526e585_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzYtMS0xLTEtNDAzNjg_257de21b-e815-459c-adff-91146c07f82c"
      unitRef="number">0.54</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="iff69cbb07e994ae88562ba51fc89f559_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzYtMy0xLTEtNDAzNjg_58b1eef0-57c3-4b82-8949-ba2d31899155"
      unitRef="number">0.83</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i0a07aa7c69da44d09083212536411b77_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzctMS0xLTEtNDAzNjg_9dade6b1-8dbd-4b31-98ed-38d65f83fd5f"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i2569ead797594df6944309ee7f73c65a_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZTo0Y2I2MDliY2E0MTg0MDE3YjU2OTU4Yjc0N2Y0N2JlOS90YWJsZXJhbmdlOjRjYjYwOWJjYTQxODQwMTdiNTY5NThiNzQ3ZjQ3YmU5XzctMy0xLTEtNDAzNjg_eedc72a4-294f-425b-a9f4-273727d44ce2"
      unitRef="number">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock
      contextRef="i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90ZXh0cmVnaW9uOjk4MGE5MTIyNWUzYTRmYWRiY2M4ZjFhMzA4YWU0MjBkXzEyMTY_736ab2fd-b7bc-4f0c-84ba-afa32cf3480e">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the components of changes in the Company&#x2019;s derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.455%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except for number of warrants)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Warrants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivative&lt;br/&gt;Instrument&lt;br/&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants during the year recognized as a gain in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants  during the year recognized as a loss in the statement of operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance of derivative financial instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;warrants liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</crdf:ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i39321e212ba6459991b552dacbff98c5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzItNC0xLTEtNDAzNjg_266f7c6d-5c43-4b75-ab5c-bdcb10a76f7e"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i39321e212ba6459991b552dacbff98c5_I20201231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzItNi0xLTEtNDAzNjg_c1cbfdc9-0a5d-4d57-a458-e64458dccbf3"
      unitRef="usd">285000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i26cfa5a3c7f344f38855d2fe383ea8ca_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzQtNi0xLTEtNDAzNjg_c51fb1ea-6fbc-49f1-9f5e-5f5a422fc764"
      unitRef="usd">285000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="ic357b095a944414684981c1dc8b89fb7_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzUtNC0xLTEtNDAzNjg_106262ea-fbeb-4432-b01a-02b8f7115e01"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="ic357b095a944414684981c1dc8b89fb7_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzUtNi0xLTEtNDAzNjg_1e7b9803-ef2c-4c20-a558-84f5257c0d29"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="if5a580a4d19d4faaa1dc83d296793561_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzctNi0xLTEtNDAzNjg_cceea88a-a2bf-481f-b097-3c943aabeb50"
      unitRef="usd">0</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i7db42fc039fd45aeaea7b5bc0553089e_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzgtNC0xLTEtNDAzNjg_7a6a8a1c-1cbd-4454-b716-86f765588488"
      unitRef="shares">64496</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="i7db42fc039fd45aeaea7b5bc0553089e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTIvZnJhZzo5ODBhOTEyMjVlM2E0ZmFkYmNjOGYxYTMwOGFlNDIwZC90YWJsZToxMmE3NmY3MjdkYjE0OWZjOGZmMmMyNDgxMDQ5Y2I5OS90YWJsZXJhbmdlOjEyYTc2ZjcyN2RiMTQ5ZmM4ZmYyYzI0ODEwNDljYjk5XzgtNi0xLTEtNDAzNjg_8e409c7a-bb32-4403-bf77-fee5a8d9a59d"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90ZXh0cmVnaW9uOmZjZmY2NjcwZDBkNDQ1MmQ5NDY1OTc1YmQzZDRkNzMwXzEwNjY_2890fa81-5c1d-4e46-9960-28825c2cc7b8">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change in circumstances that caused the transfer. There were no transfers into or out of Level 3 during the years ended December&#160;31, 2022 and 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90ZXh0cmVnaW9uOmZjZmY2NjcwZDBkNDQ1MmQ5NDY1OTc1YmQzZDRkNzMwXzEwNjk_3786dbe0-68cb-41d3-abf3-6f6f1b2ccfe6">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of December&#160;31, 2022 and 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,187&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. government agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.293%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.512%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&#160;Value&#160;Measurements&#160;at&lt;br/&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices in&#160;Active Markets&#160;for Identical&#160;Assets and&#160;Liabilities&lt;br/&gt;(Level&#160;1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Other Observable Inputs&lt;br/&gt;(Level&#160;2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant Unobservable Inputs&lt;br/&gt;(Level&#160;3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market fund&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total included in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Available for sale investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificate of deposit&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,454&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non U.S. government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total available for sale investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total assets measured at fair value on a recurring basis&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;139,868&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i91378a5db9e4460aa7fd228629188cda_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtMS0xLTEtNDYwMzI_ed3b647b-d860-4ddd-bc23-935b4804b3bd"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i559bf50fb42d497ebedd77cbd829099a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtMy0xLTEtNDYwMzI_af9e92ec-93f2-419d-bc05-c7f4f430abe5"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5fda4d776d4441dbbfb4413a40f5e88c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtNS0xLTEtNDYwMzI_a71bdc61-7de9-45cd-a8d0-8725ebb9f781"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i15b0c01e3be148e2b5d184d7b0a95541_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzMtNy0xLTEtNDYwMzI_b5535259-9eb5-4679-9e15-2d2cd1ebd037"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i3d4fe76ae8674e07a30a62a4550a8659_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtMS0xLTEtNDYwMzc_2fe3b16d-bde5-42b4-865d-902ef0ea19f8"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtMy0xLTEtNDYwMzc_17284a30-c0d1-4d2f-9915-1664732ec8e0"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i31a535f0f5474b53930803ca83868183_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtNS0xLTEtNDYwMzc_9da2b118-05a4-4337-897f-e1de7e999d83"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i19fe2e4f93f04be6b765339abdde93a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzUtNy0xLTEtNDYwMzc_966efac7-96f7-4f9f-b3d7-1691a84fe19d"
      unitRef="usd">15722000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iccb84b1da2524dcca88a14bcd81ef349_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtMS0xLTEtNDYwMzc_76729e13-5bcc-4203-91fb-3ee71f5e192b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id05871e6ded54574ac496cd98d0e4696_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtMy0xLTEtNDYwMzc_d4082f25-4ce3-40db-9334-f312bdade83b"
      unitRef="usd">16023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie85454a3cb3a449e989750c88baec3c3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtNS0xLTEtNDYwMzc_8ea4b8ed-c4b5-473b-b0de-5a6ff9022d5f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i80b5d8a47de34c9eb00dd9153e2778de_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzgtNy0xLTEtNDYwMzc_8b5a2700-30f8-44c5-a7a6-1d4668a85faa"
      unitRef="usd">16023000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if98e0631384e478d878a491576d94a8a_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktMS0xLTEtNDYwMzc_99ed35f5-804e-4c1a-bcc2-5c1be1a80ab5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ide57bacb5fcd4817820479a301609b87_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktMy0xLTEtNDYwMzc_1ba66bb1-dbb6-4bdd-81b5-bc5f6a1dcf24"
      unitRef="usd">49535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18b7ac7b497e43c5a2626cc79179be2c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktNS0xLTEtNDYwMzc_62f40c71-4450-4468-9811-bdf9c105c0a9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb973974a4fc444080d9042fa7203123_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzktNy0xLTEtNDYwMzc_6c92e250-d8ec-4034-bb29-e21dad01a6b1"
      unitRef="usd">49535000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6514853ca989457f9d06c6c616a89977_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTEtMS0xLTQ2MDM3_980117d2-2377-4f17-8f6f-50ad5955b223"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ifce1d5e58a8f4ea4b1a87da480e31782_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTMtMS0xLTQ2MDM3_0e4d4436-a5cf-4a7b-bfc4-f7419449a406"
      unitRef="usd">13187000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0acf1c3b475f4b8a81a25aee9941f99b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTUtMS0xLTQ2MDM3_5c21199b-13b7-4275-a1d2-5b0cda66f9f3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id799229c6920407f97f22581a8fa94e6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEwLTctMS0xLTQ2MDM3_84b865ee-4725-47a6-940c-28feb326431f"
      unitRef="usd">13187000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iee9cd5b6263248798f95445a96022bad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTEtMS0xLTQ2MDM5_2fbe10c1-e81a-4034-960f-b576e31580f8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6eeede3e492747df92a9120df4d9cc8e_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTMtMS0xLTQ2MDM5_a296a904-132a-49fd-9858-e6ffa51c4bd3"
      unitRef="usd">2288000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i101cb968b2e848d79fffd76c16210cef_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTUtMS0xLTQ2MDM5_40418d33-5932-4310-9847-bff2062e3715"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i82958f514bb0410cacf6fa01b1a48f5d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEyLTctMS0xLTQ2MDM5_f55df3e7-25ca-47a8-b08a-a8d227aca388"
      unitRef="usd">2288000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ida5f1f7b2ea54929968874ffdbd66397_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTEtMS0xLTQ2MDM5_dd705091-ac99-4734-a11e-975f92411089"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieef0de49d2b147eca762ee3c00cc7304_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTMtMS0xLTQ2MDM5_a8cf4f70-8433-4af4-ada2-5c254f5d01a4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae038c8a23044d3ebf1fcfa5f900eb65_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTUtMS0xLTQ2MDM5_d9c3f34e-2491-49a8-882c-8109861f8332"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4d6e1e6167d64ccaa6c44f9ba201432f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzEzLTctMS0xLTQ2MDM5_0b64b8fe-3d66-460f-b3b3-09192cf95459"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3d4fe76ae8674e07a30a62a4550a8659_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTEtMS0xLTQ2MDM5_11b00d25-fa39-44b2-9e77-f3426b6d27de"
      unitRef="usd">7887000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTMtMS0xLTQ2MDM5_1325edec-75eb-4e52-970e-d7cd9815d3bd"
      unitRef="usd">81033000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31a535f0f5474b53930803ca83868183_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTUtMS0xLTQ2MDM5_03f0334b-17da-4983-a5be-92607c7ebb70"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i19fe2e4f93f04be6b765339abdde93a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE0LTctMS0xLTQ2MDM5_03730a49-27e5-48c1-af3b-a32288d1fcc8"
      unitRef="usd">88920000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d4fe76ae8674e07a30a62a4550a8659_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTEtMS0xLTQ2MDM5_c663f383-292b-4018-9973-04192b33e3ec"
      unitRef="usd">23609000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c5f36c7781f45d3b16f83a9e43c6275_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTMtMS0xLTQ2MDM5_8064b368-a3c0-4b96-847d-d818ab68ba9d"
      unitRef="usd">81033000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i31a535f0f5474b53930803ca83868183_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTUtMS0xLTQ2MDM5_5820ea3c-dd86-4ba5-80c2-8d631f62fa6e"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i19fe2e4f93f04be6b765339abdde93a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTpmNjYyMmU5MWFkNDk0ZWFmYWU0MjFhYjA5MzA0YjZmZC90YWJsZXJhbmdlOmY2NjIyZTkxYWQ0OTRlYWZhZTQyMWFiMDkzMDRiNmZkXzE2LTctMS0xLTQ2MDM5_9e289132-2644-413d-890f-cb28c999428b"
      unitRef="usd">104642000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4ef75d470db04581b85f0f68742c2606_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtMS0xLTEtNDAzNjg_9a190437-b038-40c0-a009-ba9d7b8669b6"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iea2ee687a6f34deb8370b027572ae45d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtMy0xLTEtNDAzNjg_f90ea235-d974-414f-8828-853b7addf8d6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i291d4bc8966f478cb947f0421e4b1625_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtNS0xLTEtNDAzNjg_6e068f2a-a93d-4f57-b3da-09c758164f87"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ie2e4c7108fe54d94a35daa0010043cdb_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzMtNy0xLTEtNDAzNjg_cbc1c2fd-7d36-4546-bffb-a2f449394439"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic637b3f96e40484683e069e269081b5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtMS0xLTEtNDAzNjg_122f8d01-ddc6-490e-a008-e5a3878eff23"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtMy0xLTEtNDAzNjg_d34aa999-3bb9-4a48-8c66-a31c6641ea87"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id928b4407f1f45369fc9e7339ca8dc19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtNS0xLTEtNDAzNjg_bf50a425-1a2a-4b4f-a019-3fa63c8a2a6e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzUtNy0xLTEtNDAzNjg_63750681-10f1-44b9-af41-5963673aec71"
      unitRef="usd">10990000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9cf29fe2ae264154a0c772eac0487121_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtMS0xLTEtNDAzNjg_d6dd2c6f-4604-4537-a86e-94aeaa2269f4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id8d295ad0fab4be1ab0b93436cbf5e45_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtMy0xLTEtNDAzNjg_5aa7399a-85cb-484e-a168-6a329a34781a"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i96c3d5ecadf6458bb42cbcca79de87c5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtNS0xLTEtNDAzNjg_8e519961-e442-43f9-a961-d8f3de913ae1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58cd328823a74a059647630be8c9bd53_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzgtNy0xLTEtNDAzNjg_48df6c11-8fe9-45f4-80dd-6ce081afdc61"
      unitRef="usd">1260000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i1d946c3997c8417998d8519879aed8e5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktMS0xLTEtNDAzNjg_22e44213-14b1-41a9-b716-8978e701ad98"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i519eaf766bb74f9d94fda2c533facecd_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktMy0xLTEtNDAzNjg_fd27c031-b035-4607-8c8f-7f4d88b80135"
      unitRef="usd">88390000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i57286981e17d447682811b77a9794aaa_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktNS0xLTEtNDAzNjg_2f2d90a6-0884-4512-9445-71d2537fbc40"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3f92ad9ff9224a48ac42201d146a3949_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzktNy0xLTEtNDAzNjg_2925bbc6-da71-4a07-926d-1389984298f6"
      unitRef="usd">88390000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i39404762c230459fbd8d949512073537_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTEtMS0xLTQwMzY4_c1ef975b-fd25-4045-a4fb-7256e6b9f89a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibdda4c739f784510827447c73dcf98f8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTMtMS0xLTQwMzY4_566bcde0-4227-453e-92ab-c56dc60959f3"
      unitRef="usd">14454000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i371c8b26e2e74115ab24d25d9f222d61_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTUtMS0xLTQwMzY4_7e225c73-0f96-4763-8a4a-8e8925e2593b"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i40877594c7984b29870c62f1c8d1bdc8_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEwLTctMS0xLTQwMzY4_851da7ad-f945-4ff7-9a3e-b0bb95b376fb"
      unitRef="usd">14454000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ac4c76631b14de28b082ab760f8c24d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTEtMS0xLTQwMzY4_1e84a5de-43a7-4e44-ab3e-cbd8d5c35f6c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59de1a0bb89f47af947b9f576e513d78_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTMtMS0xLTQwMzY4_f71a11ec-17b7-41bb-a36f-9a19fc767ee1"
      unitRef="usd">728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7b28a9f7521d4d68bf4be2df75a35b05_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTUtMS0xLTQwMzY4_f483fdd9-b573-4864-a15e-8c897a55bb5a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i41d8e41740a749a489f23559bd330d4e_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzExLTctMS0xLTQwMzY4_1718ccfd-f76d-4077-b3bc-dc7c78484d5a"
      unitRef="usd">728000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i95814041224f4377a9cb681bea4771a2_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTEtMS0xLTQwMzY4_e63aacce-cfca-4ca2-a887-a4d4a9a4ed8c"
      unitRef="usd">24046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iede7ddb493894499ac185e6508bb0bec_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTMtMS0xLTQwMzY4_9018c971-9e63-4db3-abba-46aab70d322c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia5863e8943b44c3aae93910dab768c3d_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTUtMS0xLTQwMzY4_a7f8acae-7742-41cb-8799-8ba359427e0d"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7db2823712cb403fb76468ee499dba28_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEyLTctMS0xLTQwMzY4_53a2163e-a11e-4d08-ac2e-0c834ef83fac"
      unitRef="usd">24046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic637b3f96e40484683e069e269081b5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTEtMS0xLTQwMzY4_4437da49-7218-446d-b801-2e29a440a478"
      unitRef="usd">24046000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTMtMS0xLTQwMzY4_c6d01328-d089-4091-a41d-e267d82bc56c"
      unitRef="usd">104832000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id928b4407f1f45369fc9e7339ca8dc19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTUtMS0xLTQwMzY4_dfa58ee0-b8e7-4f32-91ed-7293e7c0ea59"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzEzLTctMS0xLTQwMzY4_2ad7a861-4f08-46ad-98ee-9891497b31f4"
      unitRef="usd">128878000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic637b3f96e40484683e069e269081b5a_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTEtMS0xLTQwMzY4_32a71fd1-0bee-4e59-aa8e-a92fec390fa1"
      unitRef="usd">35036000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i25ec08fa46bb4ccdb242c330adf1c22f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTMtMS0xLTQwMzY4_51c79b50-9d3c-4f8a-98b3-a0e93f107d14"
      unitRef="usd">104832000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id928b4407f1f45369fc9e7339ca8dc19_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTUtMS0xLTQwMzY4_6f405513-0bd7-45d1-83c2-fc1617298fb6"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i354e93ed24fd46bd9a17fa47d3bba49f_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTUvZnJhZzpmY2ZmNjY3MGQwZDQ0NTJkOTQ2NTk3NWJkM2Q0ZDczMC90YWJsZTo1OTU2MTgxNjgyNDg0MjJlYWMwYTA4NTM5NmVhODcwOC90YWJsZXJhbmdlOjU5NTYxODE2ODI0ODQyMmVhYzBhMDg1Mzk2ZWE4NzA4XzE1LTctMS0xLTQwMzY4_1ae9e18d-1f08-4a0f-a918-30e1de41f103"
      unitRef="usd">139868000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MTU_eeebb6d6-19f6-43dd-8072-e899c22da2bd">Income Taxes&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, Cardiff Oncology had federal net operating loss carryforwards (&#x201c;NOLs&#x201d;) of approximately $5.1 million which, if not used, will continue to expire through 2037, and federal net operating loss carryforwards of approximately $85.8 million, which do not expire. Cardiff Oncology also has California NOLs of approximately $17.3 million which, if not used, will begin to expire in 2029. Cardiff Oncology also has research and development tax credits available for federal and California purposes of approximately $1.0 million and $2.3 million, respectively. The federal research and development tax credits will begin to expire on January 31, 2025. The California research and development tax credits do not expire.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) Sections 382 and 383, annual use of a company&#x2019;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. The Company has established a valuation allowance as the realization of such deferred tax assets has not met the more likely than not threshold requirement. Due to the existence of the valuation allowance, further changes in the Company&#x2019;s unrecognized tax benefits will not impact the Company&#x2019;s effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During 2022, the Company completed an assessment of the available net operating loss and tax credit carryforwards under Section 382 and 383 and determined that the Company underwent two ownership changes during the period from 2014 to 2022. As a result, net operating loss and tax credit carryforwards attributable to the pre-ownership changes are subject to substantial annual limitations under Section 382 and 383 of Code due to the ownership changes. The Company has adjusted their net operating loss and tax credit carryforwards to address the impact of the ownership changes. This resulted in a reduction of available gross federal and state net operating loss carryforwards of approximately $123.9&#160;million and $62.8&#160;million, respectively which related to the year ended December 31, 2021 and prior. The tax effected federal and state NOL amounts were $26.0&#160;million and $4.4&#160;million respectively. This also resulted in a reduction of federal tax credit carryforwards of approximately $1.8&#160;million related to the years ended December 31, 2021 and prior. Accordingly, the net operating loss and tax credit carryforwards presented below for the year ending December 31, 2021 were reduced by $30.4&#160;million and $1.8&#160;million, respectively, with a corresponding reduction to the valuation allowance of $32.2&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes based on losses from continuing operations consists of the following at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s taxes and the rates as of December 31 are shown below: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax computed at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision and true ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since inception the Company has incurred continuing losses and expects to continue to incur losses for the foreseeable future. The Company has recorded a full valuation allowance against its net deferred tax assets as it is more likely than not they will not be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not have any unrecognized tax benefits. Cardiff Oncology&#x2019;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense, and none have been incurred to date. The Company does not anticipate a significant change in unrecognized tax benefits over the next 12 months. The Company is subject to taxation in the U.S. and California. Due to net operating losses all tax years since inception remain open to examination.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <crdf:OperatingLossCarryforwardsSubjectToExpiration
      contextRef="i8eb9fb7597594e409dd14b7de369e07d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzExOA_e2757211-cf5f-492f-9c77-1631a3aa558a"
      unitRef="usd">5100000</crdf:OperatingLossCarryforwardsSubjectToExpiration>
    <crdf:OperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="i8eb9fb7597594e409dd14b7de369e07d_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI0MQ_fb5fc3bb-9ffe-4ddc-86db-4b2104c3ba02"
      unitRef="usd">85800000</crdf:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i75170cbe292740eb8905b33cefbb47e2_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzMyNQ_9983ace2-6392-406e-b54d-67a73bc52270"
      unitRef="usd">17300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="ia539fce54f0549ee98e69a7feb86123b_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzUwNA_2ba4c822-2796-4009-aefe-1e2d00ede7f3"
      unitRef="usd">1000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="icf0a0c7937904a32bf6356ddaa1dff71_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzUxMQ_9d8a6b77-1bf0-4230-b179-aaf6b0a367fd"
      unitRef="usd">2300000</us-gaap:TaxCreditCarryforwardAmount>
    <crdf:OperatingLossCarryforwardsIncreaseDecrease
      contextRef="ib7e5322a521b4cd3abc87556084fd935_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyMTg_51a63700-324c-4e88-a400-c3ebc2c48ca2"
      unitRef="usd">-123900000</crdf:OperatingLossCarryforwardsIncreaseDecrease>
    <crdf:OperatingLossCarryforwardsIncreaseDecrease
      contextRef="i67adec9130714636a68f59baafa0faeb_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyMzQ_5f24b080-1cb5-4596-a93a-a1cf03a4df18"
      unitRef="usd">-62800000</crdf:OperatingLossCarryforwardsIncreaseDecrease>
    <crdf:OperatingLossCarryforwardsIncreaseDecrease
      contextRef="i45c1454942fd4f6cb115a433327d89b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyNDk_c9da4dc8-5bcd-41f9-b26b-63f073236078"
      unitRef="usd">-26000000</crdf:OperatingLossCarryforwardsIncreaseDecrease>
    <crdf:OperatingLossCarryforwardsIncreaseDecrease
      contextRef="ifab578dbdeed4bdaaf35f05006bb4d2a_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyNjQ_d65ff2d6-7552-4a21-999b-a0f433546d48"
      unitRef="usd">-4400000</crdf:OperatingLossCarryforwardsIncreaseDecrease>
    <crdf:TaxCreditCarryforwardIncreaseDecrease
      contextRef="i45c1454942fd4f6cb115a433327d89b6_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUzMjI_ec5986ae-77d1-4825-a9c2-c6b104f53957"
      unitRef="usd">-1800000</crdf:TaxCreditCarryforwardIncreaseDecrease>
    <crdf:OperatingLossCarryforwardsIncreaseDecrease
      contextRef="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyNzg_8518bed1-88bd-4810-9f50-d64514b47906"
      unitRef="usd">-30400000</crdf:OperatingLossCarryforwardsIncreaseDecrease>
    <crdf:TaxCreditCarryforwardIncreaseDecrease
      contextRef="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUyOTM_ea1de854-0fe5-49d0-b6a0-6c7cc6431f66"
      unitRef="usd">-1800000</crdf:TaxCreditCarryforwardIncreaseDecrease>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i9179fbb6d8654b2085fc792aa63633e0_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzEwOTk1MTE2NDUzMDc_52d06b2b-72c1-4314-aa16-04e144af8465"
      unitRef="usd">-32200000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MTY_2f5b7a26-318f-4229-bfbe-f39e940cd9c5">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes based on losses from continuing operations consists of the following at December 31:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total current provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,054&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(531)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred (benefit) expense &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzQtMS0xLTEtNDAzNjg_1b91036f-ed1d-4a33-ab12-516f0fd549c6"
      unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzQtMy0xLTEtNDAzNjg_1538a584-0495-4212-ad29-c6e99b707b24"
      unitRef="usd">1000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzUtMS0xLTEtNDAzNjg_dc3dd013-d3f4-49e5-a6df-e802ff227ea2"
      unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzUtMy0xLTEtNDAzNjg_c695e3fa-269d-4c75-96e7-9c975c19889d"
      unitRef="usd">1000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzctMS0xLTEtNDAzNjg_70853f98-fd4f-49a9-9ecd-7f90565e3594"
      unitRef="usd">19054000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzctMy0xLTEtNDAzNjg_5f6f9fb0-e637-4025-9db8-c1ff49e88f86"
      unitRef="usd">-5551000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzgtMS0xLTEtNDAzNjg_7fff7e19-1a61-4946-b303-107049350513"
      unitRef="usd">4902000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzgtMy0xLTEtNDAzNjg_1e7b11b0-3cca-4092-98ef-bbd8429e7965"
      unitRef="usd">-531000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEwLTEtMS0xLTQwMzY4_ec982bfd-a656-41e6-ad9f-40692bfa0916"
      unitRef="usd">23956000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEwLTMtMS0xLTQwMzY4_d6df22ab-505d-449a-8b28-31dca0c61f36"
      unitRef="usd">-6082000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <crdf:ValuationAllowance
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzExLTEtMS0xLTQwMzY4_dbd66442-0147-4d6c-bbec-e4d9de8800fa"
      unitRef="usd">-23956000</crdf:ValuationAllowance>
    <crdf:ValuationAllowance
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzExLTMtMS0xLTQwMzY4_69a09695-3bf7-42e6-b6f0-883da88b61bc"
      unitRef="usd">6081000</crdf:ValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEyLTEtMS0xLTQwMzY4_8e751eb8-d6c9-4cab-8c8e-d191d0132773"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo5ZWE2ODFiOGJmZTI0MTA4YTI0Y2UzODE1ZDY0Mzc5ZS90YWJsZXJhbmdlOjllYTY4MWI4YmZlMjQxMDhhMjRjZTM4MTVkNjQzNzllXzEyLTMtMS0xLTQwMzY4_2b45be10-fac1-45b3-9edb-82b253d0808f"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MjE_b2343fd3-f394-4336-b0a4-7d76b8d968cc">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s taxes and the rates as of December 31 are shown below: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.287%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.123%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.126%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except percentages)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax computed at the federal statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5,941)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State tax, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(518)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(366)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Return to provision and true ups&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance increase (decrease)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision for income taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItMS0xLTEtNDAzNjg_922ad707-f3f4-4bc0-ada1-87c7c6773272"
      unitRef="usd">-8128000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItMy0xLTEtNDAzNjg_67facdbb-f598-4d18-956b-db4481284e0f"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItNS0xLTEtNDAzNjg_65ec7565-211c-4d62-b017-68bcacd1ad84"
      unitRef="usd">-5941000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzItNy0xLTEtNDAzNjg_64685b8d-da70-4756-be36-ebde69890ec7"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtMS0xLTEtNDAzNjg_390a7bb4-e9f3-43ad-a04b-6b2d25c31982"
      unitRef="usd">-518000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtMy0xLTEtNDAzNjg_2555271c-155a-443c-a191-d4da2ae22516"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtNS0xLTEtNDAzNjg_9fe65b5a-3ad1-4c07-b09e-6d1c3467e7a7"
      unitRef="usd">-233000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzMtNy0xLTEtNDAzNjg_bbaddba7-19d4-4858-b3c2-5292b23749f1"
      unitRef="number">0.01</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <crdf:IncomeTaxReconciliationPermanentItems
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtMS0xLTEtNDAzNjg_aaaf2837-c924-43cd-830a-97e95b4e5c96"
      unitRef="usd">32369000</crdf:IncomeTaxReconciliationPermanentItems>
    <crdf:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtMy0xLTEtNDAzNjg_39466de8-62da-429d-b05c-dd46ee3f8b80"
      unitRef="number">-0.84</crdf:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <crdf:IncomeTaxReconciliationPermanentItems
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtNS0xLTEtNDAzNjg_8cf7d662-5657-43df-82af-410eaa328ed4"
      unitRef="usd">62000</crdf:IncomeTaxReconciliationPermanentItems>
    <crdf:EffectiveIncomeTaxRateReconciliationPermanentItems
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzUtNy0xLTEtNDAzNjg_b555a770-f318-4cc6-aabb-af786c8baa39"
      unitRef="number">0</crdf:EffectiveIncomeTaxRateReconciliationPermanentItems>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtMS0xLTEtNDAzNjg_3040c9d9-2aad-4642-b7fa-27c6a5edbdda"
      unitRef="usd">553000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtMy0xLTEtNDAzNjg_4e1f9997-f4fd-440b-91bb-1c3ef412267d"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtNS0xLTEtNDAzNjg_71738067-69b5-49ba-bbf1-d001581141ba"
      unitRef="usd">325000</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzYtNy0xLTEtNDAzNjg_013ff0ac-5e0f-4cdf-9bd0-d95a9891fe26"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctMS0xLTEtNDAzNjg_8a4bebf9-13c2-4bca-a51c-6720be599b8d"
      unitRef="usd">319000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctMy0xLTEtNDAzNjg_12ac96ee-7270-4db5-8f67-df120a8e99b0"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:IncomeTaxReconciliationTaxCredits
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctNS0xLTEtNDAzNjg_9bb82e27-61ab-4f4c-8d2c-9ce8f7389995"
      unitRef="usd">366000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzctNy0xLTEtNDAzNjg_07e7bfaf-fdfe-4ca3-be5e-6de32964d342"
      unitRef="number">-0.01</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMS0xLTEtNDM3NzM_9657ad86-2897-4dc2-be5d-e4e2dcf85e51"
      unitRef="usd">0</crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount>
    <crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMy0xLTEtNDM3NzM_6f106e4c-9c21-4154-a235-8820fd6f2306"
      unitRef="number">0</crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent>
    <crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNS0xLTEtNDM3NzM_b6ac5d66-ac3f-45af-aa9e-ee38c7f156b1"
      unitRef="usd">0</crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount>
    <crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNy0xLTEtNDM3NzM_f22c0c46-6595-4fda-9f9f-9887800356f7"
      unitRef="number">0</crdf:EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMS0xLTEtNDAzNjg_5a71c155-e33d-4e38-839c-cd8472a4114b"
      unitRef="usd">-1000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtMy0xLTEtNDAzNjg_9b12e861-467b-47cb-854c-5adc0b89ed36"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNS0xLTEtNDAzNjg_d5f7a2c0-1252-4acf-8016-4fceb1a4a036"
      unitRef="usd">72000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzgtNy0xLTEtNDAzNjg_7b6a2bb9-46b9-4e72-839b-c14f95cd1df7"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktMS0xLTEtNDAzNjg_1cb9477c-ca2f-4b6e-9996-7a2279e284b9"
      unitRef="usd">-23956000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktMy0xLTEtNDAzNjg_774d1c88-8cdf-4a9e-9d65-c8646a1952cd"
      unitRef="number">0.62</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktNS0xLTEtNDAzNjg_4e9e5a7d-46f4-4699-8c93-fddac0c546cd"
      unitRef="usd">6081000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzktNy0xLTEtNDAzNjg_931a5851-d4a5-4ff7-be6d-e119b8326be4"
      unitRef="number">-0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTEtMS0xLTQwMzY4_8858638b-b843-4ab7-a2c6-5179496ab6ad"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTMtMS0xLTQwMzY4_2c515c61-8fd1-43b0-b2f9-f358baaf3c69"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTUtMS0xLTQwMzY4_45251a81-f46b-4bfb-9b5e-599988950ac2"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTpjMDQ1YzY5N2QzNzI0YmY4YTAxMjI1MzkxNTU0M2RkZi90YWJsZXJhbmdlOmMwNDVjNjk3ZDM3MjRiZjhhMDEyMjUzOTE1NTQzZGRmXzExLTctMS0xLTQwMzY4_d70bd76a-c257-436a-a444-acf68f941580"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI5MTI_06a54260-8733-4731-ba47-6e20a08a6847">&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Significant components of the Company&#x2019;s deferred tax assets and liabilities from federal and state income taxes as of December 31 are shown below (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development credits and other tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,226&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,317&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,574&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(492)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(611)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets before valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30,082)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,833)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net deferred tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzMtMS0xLTEtNDAzNjg_5a2833dd-2080-458f-9a2c-081b4dcc605e"
      unitRef="usd">20289000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzMtMy0xLTEtNDAzNjg_b9953da1-b814-4dfa-b836-00972678f968"
      unitRef="usd">17506000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <crdf:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzQtMS0xLTEtNDAzNjg_0a71bfe8-4fce-444e-96da-63aac843e7a8"
      unitRef="usd">2743000</crdf:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther>
    <crdf:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzQtMy0xLTEtNDAzNjg_2b8dca5b-2520-4c1f-911a-7dd0b7824e9a"
      unitRef="usd">2226000</crdf:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzUtMS0xLTEtNDAzNjg_7d855dab-9ec6-43a6-96d9-fe84c1d46ced"
      unitRef="usd">1317000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzUtMy0xLTEtNDAzNjg_d73a1c8b-8f57-4978-9ae2-f14551f46e52"
      unitRef="usd">962000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMS0xLTEtNDM3NDQ_0fdc9bdf-e1e2-4506-b04d-c66b895c381a"
      unitRef="usd">4794000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMy0xLTEtNDM3NDQ_b0ba59fb-cf06-4635-a1af-7ebf2276bd94"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMS0xLTEtNDAzNjg_62f4991f-af0e-4362-8589-a699b9b79d3f"
      unitRef="usd">1431000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzYtMy0xLTEtNDAzNjg_87c9faea-4488-45bb-9978-ca1e2a1c25ce"
      unitRef="usd">1750000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzctMS0xLTEtNDAzNjg_07f0b0c4-36ab-45f6-9047-556c868e17d7"
      unitRef="usd">30574000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzctMy0xLTEtNDAzNjg_43349654-8964-4566-89ca-08b126b20d55"
      unitRef="usd">22444000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzktMS0xLTEtNDAzNjg_a953fa24-dda9-492d-9ad7-7f545b9ebd2c"
      unitRef="usd">492000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzktMy0xLTEtNDAzNjg_c841b080-c554-428b-b1db-23c3f11ebd2f"
      unitRef="usd">611000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEwLTEtMS0xLTQwMzY4_938408f2-7816-4799-8890-afde5e31a8be"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEwLTMtMS0xLTQwMzY4_3ced65ce-7282-49fe-ba1d-d11879e50ab6"
      unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzExLTEtMS0xLTQwMzY4_70526578-2f3c-472b-bcb8-90233976319e"
      unitRef="usd">492000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzExLTMtMS0xLTQwMzY4_cbfcc24b-fffa-4146-9464-ec471ed04804"
      unitRef="usd">611000</us-gaap:DeferredIncomeTaxLiabilities>
    <crdf:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEyLTEtMS0xLTQwMzY4_206086c7-1662-4916-a269-492f7100c3fb"
      unitRef="usd">30082000</crdf:DeferredTaxAssetsNetBeforeValuationAllowance>
    <crdf:DeferredTaxAssetsNetBeforeValuationAllowance
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEyLTMtMS0xLTQwMzY4_522d388a-02df-436e-bd27-5d4fc798ad47"
      unitRef="usd">21833000</crdf:DeferredTaxAssetsNetBeforeValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEzLTEtMS0xLTQwMzY4_b8838c4b-b389-4158-86a5-21141e59b3f4"
      unitRef="usd">30082000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzEzLTMtMS0xLTQwMzY4_ab422c40-922e-465f-bd14-169b5cf268c2"
      unitRef="usd">21833000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i8e8826dc39c04031b505d8c4ed59725d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzE0LTEtMS0xLTQwMzY4_628c8ade-a583-4d4c-9aeb-c140425d9007"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i7f96c19e96104c05b51cc23d98344c24_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90YWJsZTo1OTY2NmQxZTI5YzQ0Y2E5YjhlZmRkZGNiMGJmNDRhNC90YWJsZXJhbmdlOjU5NjY2ZDFlMjljNDRjYTliOGVmZGRkY2IwYmY0NGE0XzE0LTMtMS0xLTQwMzY4_eb54aeef-d3af-4796-be91-1ea113a4e78a"
      unitRef="usd">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yOTgvZnJhZzoyNDA0NzU0YzdhMTk0ZjczYWRiNWE2MWU5NjM5YzFhZC90ZXh0cmVnaW9uOjI0MDQ3NTRjN2ExOTRmNzNhZGI1YTYxZTk2MzljMWFkXzI2MTg_8be08654-b855-4917-aebb-a13bf43993a8"
      unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDEvZnJhZzo3ODNkMjM1Yzg4NWE0YWVjODY5MTExZDRkNGM4MGEyZS90ZXh0cmVnaW9uOjc4M2QyMzVjODg1YTRhZWM4NjkxMTFkNGQ0YzgwYTJlXzE5MDU_71aef653-07a2-45a2-a4ef-4f862a8234ea">Commitments and Contingencies&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Executive Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain executive agreements provide for severance payments in case of terminations without cause or certain change of control scenarios. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research and Development and Clinical Trial Agreements&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, the Company entered into a license agreement with Nerviano which granted the Company development and commercialization rights to NMS-1286937, which Cardiff Oncology refers to as onvansertib. Terms of the agreement also provide for the Company to pay development and commercial milestones, and royalties based on sales volume. These potential development milestones include: dosing of the first subject in the first Phase III Clinical Trial for the first Product or after completion of a Phase II Clinical Trial that is used as the basis for an NDA submission; and upon filing of the first NDA or equivalent for the first product. During the years ended December&#160;31, 2022 and 2021, no milestone or royalty payments were made.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is a party of various agreements under which it licenses technology on an exclusive basis in the field of oncology therapeutics. These agreements include License fees, Royalties and Milestone payments. The company also has a legacy license agreement in the field of oncology diagnostics under which royalty payments are due. These royalty payments are calculated as a percent of revenue. During the years ended December&#160;31, 2022 and 2021 payments have not been material.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:33.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cardiff Oncology does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company&#x2019;s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company&#x2019;s business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
      contextRef="i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDEvZnJhZzo3ODNkMjM1Yzg4NWE0YWVjODY5MTExZDRkNGM4MGEyZS90ZXh0cmVnaW9uOjc4M2QyMzVjODg1YTRhZWM4NjkxMTFkNGQ0YzgwYTJlXzEwOTk1MTE2MzA1NDE_53c765a4-2dc8-4f02-a36f-351fe47c6ab8"
      unitRef="usd">0</crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade>
    <crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDEvZnJhZzo3ODNkMjM1Yzg4NWE0YWVjODY5MTExZDRkNGM4MGEyZS90ZXh0cmVnaW9uOjc4M2QyMzVjODg1YTRhZWM4NjkxMTFkNGQ0YzgwYTJlXzEwOTk1MTE2MzA1NDE_78f48aad-d987-48c4-81de-6362c5d16ed8"
      unitRef="usd">0</crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="ib81372bc50644817b94ca49265c1efc6_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8zMDQvZnJhZzo4ZGNjN2U5NmY1MTU0YmNjOTUxMWRkMzU3ZDU5YzUxNS90ZXh0cmVnaW9uOjhkY2M3ZTk2ZjUxNTRiY2M5NTExZGQzNTdkNTljNTE1XzM5MA_a78e2001-35ca-42df-97da-6f73be9450b0">Employee Benefit Plan&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined contribution retirement plan under Section 401(k) of the Internal Revenue Service ("IRS") Code covering its employees. The plan allows employees to defer, up to the maximum allowed, a percentage of their income through contributions to the plan as allowed by IRS Code. The Company does not currently make matching contributions.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00NDAzMA_adfa9e98-dd45-4169-8fb4-e22092848d17"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00NDAzMA_adfa9e98-dd45-4169-8fb4-e22092848d17"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00NDAzMA_5a23862e-0f2b-48c4-8d1b-d8a37e2de710"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00NDAzMA_5a23862e-0f2b-48c4-8d1b-d8a37e2de710"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzU0OTc1NTgxNDI5MQ_1a318d9b-4802-4289-89e7-651eed85f6ed" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzU0OTc1NTgxNDI5MQ_1a318d9b-4802-4289-89e7-651eed85f6ed" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 2 to the financial statements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE1LTEtMS00NDAzMA_adfa9e98-dd45-4169-8fb4-e22092848d17"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzU0OTc1NTgxNDI5MQ_1a318d9b-4802-4289-89e7-651eed85f6ed"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzg5LTE3LTEtMS00NDAzMA_5a23862e-0f2b-48c4-8d1b-d8a37e2de710"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzU0OTc1NTgxNDI5MQ_1a318d9b-4802-4289-89e7-651eed85f6ed"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTUtMS0xLTQwMzY4_73b7005e-a7c8-4b80-a4e8-2315e826eb30"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTUtMS0xLTQwMzY4_73b7005e-a7c8-4b80-a4e8-2315e826eb30"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTktMS0xLTQwMzY4_7028abee-aacd-49fc-8cbf-ce760a5e3489"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTktMS0xLTQwMzY4_7028abee-aacd-49fc-8cbf-ce760a5e3489"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTE3LTEtMS00MDM2OA_b44d00aa-a7de-4a0f-b422-af1a4d75627b"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTE3LTEtMS00MDM2OA_b44d00aa-a7de-4a0f-b422-af1a4d75627b"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Net of expenses of $0.8&#160;million.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTUtMS0xLTQwMzY4_73b7005e-a7c8-4b80-a4e8-2315e826eb30"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTktMS0xLTQwMzY4_7028abee-aacd-49fc-8cbf-ce760a5e3489"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90YWJsZTo2MjIxN2ZlMDdkMjk0ZDFhYjJkYmIxMGI0ODc1MGJmMC90YWJsZXJhbmdlOjYyMjE3ZmUwN2QyOTRkMWFiMmRiYjEwYjQ4NzUwYmYwXzc3LTE3LTEtMS00MDM2OA_b44d00aa-a7de-4a0f-b422-af1a4d75627b"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjUvZnJhZzowMzgwOTc1YTQzMjg0ZTZiYWRjZTA0MGZhMDBlYTFjMy90ZXh0cmVnaW9uOjAzODA5NzVhNDMyODRlNmJhZGNlMDQwZmEwMGVhMWMzXzIyOA_f12c624f-4e5f-4ba7-adfa-eecbaf01c816"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTEtMS0xLTQ0MDUw_f2e0fb40-bbae-4a9e-8106-5f0d6024c12d"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTEtMS0xLTQ0MDUw_f2e0fb40-bbae-4a9e-8106-5f0d6024c12d"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTMtMS0xLTQ0MDUw_9e89a259-fea7-4ee7-a671-d7f9833e7bd7"
          xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTMtMS0xLTQ0MDUw_9e89a259-fea7-4ee7-a671-d7f9833e7bd7"
          xlink:type="locator"/>
        <link:footnote id="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90ZXh0cmVnaW9uOjM3NTdiYzExYjJhNjRkMzZhY2RjZThiMjAxYjQ2N2MzXzU0OTc1NTgxNDEyOQ_14e5891d-ac53-44b8-98bd-d418bf65976e" xlink:label="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90ZXh0cmVnaW9uOjM3NTdiYzExYjJhNjRkMzZhY2RjZThiMjAxYjQ2N2MzXzU0OTc1NTgxNDEyOQ_14e5891d-ac53-44b8-98bd-d418bf65976e" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">See Note 2 to the financial statements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTEtMS0xLTQ0MDUw_f2e0fb40-bbae-4a9e-8106-5f0d6024c12d"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90ZXh0cmVnaW9uOjM3NTdiYzExYjJhNjRkMzZhY2RjZThiMjAxYjQ2N2MzXzU0OTc1NTgxNDEyOQ_14e5891d-ac53-44b8-98bd-d418bf65976e"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90YWJsZTpmMWQzYWYyMGJjYmE0NDJjOGNiYTc2ZmNhNTZhNGY5ZS90YWJsZXJhbmdlOmYxZDNhZjIwYmNiYTQ0MmM4Y2JhNzZmY2E1NmE0ZjllXzY0LTMtMS0xLTQ0MDUw_9e89a259-fea7-4ee7-a671-d7f9833e7bd7"
          xlink:to="id3VybDovL2RvY3MudjEvZG9jOjAxMTZhNjAxYjgyYjRkYTI4MjRiZjhlNzI2OWJlYmFmL3NlYzowMTE2YTYwMWI4MmI0ZGEyODI0YmY4ZTcyNjliZWJhZl8yNjgvZnJhZzozNzU3YmMxMWIyYTY0ZDM2YWNkY2U4YjIwMWI0NjdjMy90ZXh0cmVnaW9uOjM3NTdiYzExYjJhNjRkMzZhY2RjZThiMjAxYjQ2N2MzXzU0OTc1NTgxNDEyOQ_14e5891d-ac53-44b8-98bd-d418bf65976e"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>73
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M#T_CP'L6XDH9GJZFI%(K#1>F,/Y\"*V!ZS<;W=%E5.0T<$TS0LXT(VG*3=9
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M40!O!.#]1@ G'&_,&73]G\/R?U!+ P04    "  B@&)6VB/F& \#  "R"0
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ME!9<M#]"T)H1%*TMH<:*QF8O6LV<!E93%G5J>^SSR!QW!6(L<;5 (&D^*"T
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MS-00LS1OP;4C$R@M *6%H+0(BM96ULEUS&8W^>]<\3*7OGK@ G6D06D^*"T
MI86@M(CTW?+!I3'2&-+$;$A#+(T1G14Z[5Z<9&[(U2H"M:U!:0$H+;QH[T90
M-=LR:DQK8C:M_]^E,=)WDGNVWY.Y#5<K")+F@]*"2W9'"%HR@J*U!=18U\1L
M72\.MPJINXVV0R=&FOQW5PY)Z/%,@2]$>]41T1C3N'MMB!E]M?! +P8'I06@
MM!"4%IWIJK;P&B^?F*\(-ZW(DOXEU&/;FUD]?8!:\* T'Y06@-)"4%ITOK?:
M$FG,=6(VUR]8D25:^4!:QD^D;WJ[O9^"&F/<<6>SKGL V;  E!:"TB(H6ELY
MC<].S#[[P(*L7BU>?Z'5<FVG-X_NQUE=&?1#>@:2)L1RO-YM1.>KA9J0L3V?
M=B>HFBBB%F,'5F.)<I3;]WLV]J!MM@>_X-_5L"XGH^R[6@ICU?WI[ZP;[]"W
M&YZF/,]NY)S@A3'T<RX8(DCD2*P96O%,]IF:NI;'V]MO=&J8G-PXOV'%:_74
MA5).='>9.-R=>OST^&2'Q^H!"-W/R?PV)'/=-[9U&QX>!C%I2AP>)?$?6KSR
MK$0I6\ERULU,[MKB\'2&PQN1;ZM;][_F0N2;ZN6:T805*D!^O\KE=M=O5('C
M,S(>_@=02P,$%     @ (H!B5E=3T4U! @  U00  !@   !X;"]W;W)K<VAE
M971S+W-H965T."YX;6R-5$UOVS ,_2N$5FPM,,0?2;LB<PPT;8?M4"!HT.TP
M[*#83"Q4EER)3II_/TE.O&Q(@UULD>)[?*1)9QMMGFV%2/!:2V4GK")JQE%D
MBPIK;@>Z0>5NEMK4G)QI5I%M#/(R@&H9I7%\%=5<*)9GP3<S>:9;DD+AS(!M
MZYJ;[12EWDQ8PO:.1[&JR#NB/&OX"N=(3\W,."OJ64I1H[)"*S"XG+";9#P=
M^?@0\%W@QAZ<P5>RT/K9&]_*"8N]()18D&?@[K7&6Y32$SD9+SM.UJ?TP,/S
MGOU+J-W5LN 6;[7\(4JJ)NR:08E+WDIZU)NON*OGTO,56MKPA$T7>S5B4+26
M=+T#.P6U4-V;O^[Z< !(TS< Z0Z0!MU=HJ#RCA//,Z,W8'RT8_.'4&I .W%"
M^8\R)^-NA<-1/B=.Z)I,H)<PK[C!2LL2C?T ]R^MH"V<SYQ3484D"BXOX R$
M@@<AI6NJS2)R(CQ55.P23KN$Z1L)DQ0>M*.S<*]*+/\FB)SZOH1T7\(T/<EX
MA\4 ALE'2.,T@:?Y'9R?79S@'?:M&0;>X7^UAG3Q_&]K?MXL+!DW6+^.]:%C
M'QUG]\LVM@TO<,+<-EDT:V3Y^W?)5?SYA/91KWUTBCV?\:U7;KUTZZ6#L+;E
MJD HM*6CWZUC3.) Z9=YG<>#ZRQ:'^J(#D:M1K,*"V4=::NHF[K>V^_L33>J
M?\*[A7_@9B64!8E+!XT'GRX9F&Z).H-T$P9WH<FM03A6[K^#Q@>X^Z76M#=\
M@OY/EO\&4$L#!!0    ( "* 8E;$)M8D!P@  %0C   8    >&PO=V]R:W-H
M965T<R]S:&5E=#DN>&ULK5IM;]LX$OXKA+=8[ )U+9+R6S8QD#I;7(%K-VAN
M[SX<[@,CT;&NDN@EJ:2Y7W]#2I%L\24)D"^)+ U'SW"&\\R0.G\0\KO:<Z[1
MCZJLU<5DK_7A;#93V9Y73'T0!U[#DYV0%=/P4][-U$%REMM!53DC2;*85:RH
M)YMS>^]:;LY%H\NBYM<2J::JF'S\R$OQ<#'!DZ<;WXJ[O38W9IOS [OC-US_
M>;B6\&O6:\F+BM>J$#62?'<QN<1G5RDU ZS$/PO^H(ZND3'E5HCOYL?G_&*2
M&$2\Y)DV*AC\N^=;7I9&$^#XJU,ZZ=]I!AY?/VG_9(T'8VZ9XEM1_JO(]?YB
MLIJ@G.]84^IOXN%OO#-H;O1EHE3V+WKH9),)RAJE1=4-!@154;?_V8]N(HX&
M8!H80+H!9#Q@$1A NP%T/" -#$B[ :F=F=84.P]73+/-N10/2!IIT&8N[&3:
MT6!^41N_WV@)3PL8IS<WFFD.?M0*B1W:,K5'GR 6%)JB/V^NT"_O?D7O4%&C
M?^Q%HUB=J_.9AM>:P;.L>\6V?04)O (3]$74>J_0[W7.\U,%,\#;@R9/H+<D
MJO&*9Q\0Q>\120CQ +IZ^7 <@4/[.:16'PWH^^/ )=-%?==&<:$+[IVF5DOJ
MUV(6^)DZL(Q?3& %*R[O^63S\T]XD?SF,_&-E)T8G/8&IS'MFZ^0CTJAO$:V
M(^=VI$DZ]YLI72V3]'QV?PS?(T969(U[L1-@\Q[8/.J)R_R_L&3:<-8"\E(F
MZJPH.:H[Q.:NN<Y,H#>*YR:VA<=_9S[;YF_IP#=2=C)/BWZ>%E$'_MU,!63=
MO% 'H5AIUCY3BFNO2UM=BR-?X9$W8Q(G )<]P&44X!4'J[."&6[P05HZ+R1T
M,0+ERJ3S *Q5#VL5A76C1?9]:G@F1YFH@'R5A8CX#W/-?5!7+@PR'V-UA2BA
MJ1_LN@>[CH*]K(34Q?]:@.!@F-&J:"KK>+6'9U/-904+X)YW:\8'?^T@6U R
M0N_*0)PN_>AQ,C!3$L6_W;/ZCIL%NF.%1/>L;+BQ(^>RN&>F7$"[HF:PP"&
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MTU<O,O+]Q;1_B:Y-E\'<15PMTZ/L4?:B 'GEL!B'%S$P_G=P\C=02P,$%
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M3@[)CFW .W^L 1PQ;0J$&E#6%!+F,@:+B4D8+,G,8133YGGD<V;@T3Q[RX0
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M-LR#5%89:1^7F;P^M:6D#+%LU4JF0$.%D#\$#2;'0N,BD-HI<,]R,+:AQ-W
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MR4^,[4Z2&I13E3X_?X6)(Y9DTGGV6;/;Q%<=0YTCOI^&5QZZI&7/N Z/&(!
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M(%.7+%WQVZKS,GCE!BTU0HL,H:R4HAO.ZTW>?IMI@E=,Z/Y6M*>1TES4IIJ
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M\8__ W+.O_>WL%UG-_QQ;7(@,'H!SY<6L$7_H 7"#T"^_%]02P,$%     @
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MNL;I!OK6[.RM<O8KVG7:<9AP'NZ??8,?1_MIN]$:?CO8Q3Q#[Z+G,!/N)>>
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M!N@O_E-'OW!ZZ3\O3+5SNO6/"REJ:9@ [V=:N^V"!>R^-UW]%U!+ P04
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M;V*PVP0WQ*G)1807+6*\0?V K<L7SX)1[VP/P$$-<+#/^I[4[]7;C:J,]LJ
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M+C$%\->E0D]M: 'NS[4NFQ]T0/O&]^)_4$L#!!0    ( ". 8E;@:  7N0D
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M8W-LASG^C8 T"BC/!!Y0[<1LL/V_F?X-4$L#!!0    ( ". 8E:J.E[PF D
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MT *\7RIEZQO:H/F)ZN9O4$L#!!0    ( ". 8E9)78S-@@4   \-   9
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MO?)TW*D>J2!5VZP_/D.YY5&]P"V?,S04BDS)OMU.KOCJ94L8#RKLM#$*V*M
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;-T\V6[;R):_4O"]N.,
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M10FM::>6)R^GK;P8ZB"(Q,B 8P-T*7+#1!%?6JW4%\BLT<W&^GXJ=)(]L+W
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M?EQM /-!61L%,EP5.(0\%KHMXK#08GQ8Z )R%Y%"_(4&0P)UCD;IAH8%P9:
MQQ(?3#UR)5<W:&X->\\FC<*&SOM_C,*[>!UZ!?X*5 MR*5]"Q:N5W7G6]-<'
M,+]%4\?7(2&KJ]-KNV0MY>HG706)YM47%#I7+Q(L=^$ 'M\P!1BG..]S=-^>
M_0'L_J01=;X*CYCN^"UIK5+FP2&2J>CFC4XJ<1'+MQ8'&/#J;(%LLW6O,+_1
M+AF8JB1L] '6W\]FC_E'*OQE66D8IE>"$%NL,?C+++W+LX':=/O-X.]]#-WC
MQ2E-DBSV2'W.CFG\(HZF+,;G22X-9L:=GS.!Z,"VOF;Q$Q#TOX )YSGDI?W?
M)1'UN,\.X(<%Q/&](.#X##DWG'[.(AX'))(U5PV056- P9P\/<&HY.2!'\ ;
M>%5=[ZCV<GIR?G4-;_YD9[3+].PQ?^?_POO>[_T=JFBI3CG<63P]@^?OS+*1
M3MAGFX=)-W9C[^]PXU8N7#EU>M4N&XZ5GIU-G^#Z=&I'X+!1Z(SSR);/YL\?
M3,1I^WD.WNE?)E_#5@+A0AP7>>;W</JDP?WEMJ(+P'BS.:#S?/YD^OCLP0OU
M$:E6AY?/NXFGOVG=/2D\>'_G4R,<;X%4W2&M<1EO-;V(CNR7NF@PR[C @=,O
M4DDYU9R*@F\-W1P*+]]O38TG8\P<I-7N.T[19N:!9#Q VCQ4DD@WVEVXIQJ'
MDE<RXHKF,:C="G(6D"=NSRP-;$1E.+U"^QJ4</YD(F(8@G NJQ7;<,LQ# I8
MFC:)8 _-"40L?L0$*VFB!X2Y\R+*\Y?_H:L6[_=Y(X H'URK%&S)7N>^7/0M
M^0LA)5(-=C4GRT@F$FLV8D>PFP'FY<"0#_VN!V:!?\%4L'EZF/Q"$[*9?H>*
M?M2C:OC'FL*WX;>NSOD7GN+K_$-9GS5*">9@*UAZ-GOVY(3KYOX/D'/ZO:>E
M;1J[I8\;HR$&PQ?@^<K:QO^!&X1? 'OSOU!+ P04    "  C@&)6_W^PS@H$
M   X"0  &0   'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6R-5MMNXS80_96!
MME@D@!KK9MG.V@:<RZ(%LJBQWNT^%'V@J9'-AA*U)&4G?]\A92L)X+A]L'F;
M.7.&/$-JNE?ZT6P1+3Q5LC:S8&MM<ST8&+[%BIDKU6!-*Z72%;,TU)N!:32R
MPCM5<I!$43ZHF*B#^=3/+?5\JEHK18U+#::M*J:?;U"J_2R(@^/$5['96C<Q
MF$\;ML$5VN_-4M-HT*,4HL+:"%6#QG(6+.+KFZ&S]P9_"MR;5WUPF:R5>G2#
MWXM9$#E"*)%;A\"HV>$M2NF B,;/ V;0AW2.K_M'],\^=\IES0S>*OE#%'8[
M"\8!%%BR5MJO:O\;'O+Q!+F2QO_#_F ;!<!;8U5U<"8&E:B[ECT=]N'_."0'
MA\3S[@)YEG?,LOE4JSUH9TUHKN-3]=Y$3M3N4%96TZH@/SN_84884"4L-1JL
M+>OVJBY@U1V36UN)32U*P5EM8<&Y:FLKZ@TLE11<H(&+;VPMT5Q.!Y8H.> !
M/X2_Z<(G[X2/$_BB:KLU<%\76+P%&% N?4+),:&;Y"SB'?(K2.,0DBA)SN"E
M_0:E'B]]!^]4OG\MUL9J$M3?IS+N\++3>*[(KDW#.,Z"QFVYWF$P__@ASJ-/
M9]AF/=OL'/K\N\&RE? @2NP.E:I7VV=_H/<_6]%0/=E3I,_"GB;];8N Q@HJ
M#2R@[2)+JC&O)TNK%?M':>"2&=---J_YX)$/,(W #)1*TAUAKN&^1^WS<:B?
M6UT+VSIC<E<E*1)?H:1@%0SA&9DV\(!4JELE"Q 51=VA,S&0.9O\:,/62C.K
M2.0O*$> A2=,:L)JC=HKZD+4E)9J#84WEUY@[B_^+V*_0!Q&>4[M9#A\CUD2
M#O.(#"=Y<IH880QSF$0Y9&$^3B -QTE*:,9\_#!.XN03X[RM6NGWK4 Z)RZZ
M:KY(PRQ.+WV;Q9=O5=$'"*'&CFN23ZA-*<8910Y[10[/*G)%STC12B_'!=51
M(63K+F)8(6^UL*Z>[I^X;*G\H=2J\LJY99*[5!Q]<G2W%/=T[YP[63XH8V!)
M![/:DGI.*?HLK=.*]EC&29D.IP9^)$&U7QSBNCV2+C;M('!55430.#? +@DG
M9+HGQ:]]HBZ?3MH.Z&!,N[YCTIW\]5N1O:CJC\:E;YQBFU;S+<D&;KN(*ZOX
M(PQ)59,P&XY)"Z,126><P0^F-7-Z>M<K"],\(IF-J9=-HC >3N@LM#N'!5G6
M.Y*&H.O<O0@E:DU)=X[CT<C_#L;W9XT/FB19YV/2:S0"8DKYI5$*,87/1F&>
MC$X*;/#J-:M0;_R;;<!?P]W#UL_VGP6+[C5\,>^^*;XPO1&TA1)+<HVN1B0*
MW;W3W<"JQK^-:V7II?7=+7W:H'8&M%XJ98\#%Z#_6)K_"U!+ P04    "  C
M@&)6'35""V0&   ;$0  &0   'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6S-
M6%MSVS86_BMGU$Q'FF$LWB^N[1G;2;J92;>>*.D^[.P#1$(2-B3! J#=]-?O
M!U"2U81BVMV7?;!)@ ?G^IT+=/4DU2>]X]S0;TW=ZNO9SICN<KG4Y8XW3%_(
MCK?XLI&J809+M5WJ3G%6N4--O0Q]/UTV3+2SFRNW]Z!NKF1O:M'R!T6Z;QJF
M/M_Q6CY=SX+98>.]V.Z,W5C>7'5LRU?<?.P>%%;+(Y=*-+S50K:D^.9Z=AM<
MWF66WA'\(OB3/GDG:\E:RD]V\;:ZGOE6(5[STE@.#(]'?L_KVC*"&K_N><Z.
M(NW!T_<#]S?.=MBR9IK?R_H?HC*[ZUD^HXIO6%^;]_+I;WQO3V+YE;+6[C\]
M[6G]&96]-K+9'X8&C6B')_MM[X<_<R#<'PB=WH,@I^4K9MC-E9)/I"PUN-D7
M9ZH[#>5$:X.R,@I?!<Z9FU7?=36'EPU"0G>L9FW):>7P\+8=@FZ]-__ UC77
MBZNE@51[=EGN)=P-$L(S$H*0?I*MV6EZW5:\^B.#)=0]ZAP>=+X+)SF^XN4%
M18%'H1^&$_RBHP\BQR\ZP^]GM66M^-T9ZM&];+6L1378S=J*'A37UD%N0V[H
MC6CA)<%J6F'3.4_3/V_7VBB [%]C+AH4B,<5L(EWJ3M6\NM99V6I1SZ[^?Z[
M(/5_F# O/IH73W&_N9=-)UNG))1?[:0R+PU7#8GVD6OCU!_3>9+KN,[CS(D]
M,E%;_+P$H%YJ5G/2O.R5,()K*N%PH8U5SNPX;62-2B':[27=.HT1;MZLN3J&
MG.:B!:GL-:*C%W3;0*KXG5>('?C\J*36]+%%C:K=[H^H3?KK[7=80_P;)A3]
MQ-0G(/X75O<<"V-U^TP O(8@UE) GSE3EW3/(6DC2H3=JE;Q3FIAZ 4%J1?X
M 5XB_,WS8#'L^6$$I50GE3U1\;4YM3R.O=Q/*:=YF"4+NTRB O1-PY7#5\<Z
MV!U$7NA'%(/,7]A5D&?T\6)U05OYR%5KG4RHH, DF(9>F,<@_OZ[/ S"']PZ
M'\@-;-<]\OQ$A\PK_.1(/ _R!;9R"/@@#31HSOF"\M@+BX*"@N91$2\HC[PB
MC)^=%Y"1%#I:?3GAA,3S@Q34\Q!.B[VB2+\4?<KI/+D>Q]X+R@LO"A*\A+Z-
M31PD-CAY#G7],Q +_B\AYH6IM> 0J].WX=N$DW,O1^(@=2($&*LL3T> %GMQ
MXH 6+89%3']'S?L2:UF8'V4?GG;O+,A"WXMR_QEE(?!B]Y*O8OT5S(K$2^.(
M4IJGB!M62?Y?@"PLO#1SL,E@FEWY\7EU(R]#+C_G!) 6>6GA3P(SBKPHRZR(
M'-9A%1;QMZ 90!/?P3*ST SBPM6-$-'*<IJH_<FQ]B>3M?^5]</J:)E'MW\H
MQ2N48N]+P-*#!9SKA0ZX#K%C#6):]-NQ!H#JCHG0-@#$V-"./7):<]["+\1L
M)S"B[9%UU#_K5%N=NKU.CL$6W^#- 2=H;2\=4O[G/O)UFHXF] 3,$+O,\P%0
M&\P4L)F 6)JF-N*+;V$$>9(EKG(%:!(3F$B/F$C_PCSPH##@*X#93CJO?^U%
M9P6/A7N2Z_@\\ %Q@"D"&0/G]9IO^IIJC.'Z$*6&_1L!+6OF"B4VNU-]^$$?
M8HH3T_N@(M5?'[E^'+B^<US?]*H5R$[NCLL-ZB@_X1+9A$WV"?L.4>$[65<D
M&DA]W ]RL:5)#S1L;2,M$;QG+@<&([#Z E$.9:Z??$,Q6\%] .(%*EQR3K/0
M2U#D Z](PW'%P ,5M<!($7MI'@)D.>:/=RBI^UK&RK)O^MKY#8U%<13_8;R/
MO#A 9;3/&+A]&(V"1RT_=*+"SCJ0,0'([ C(["\ \K8L56]33;"UJ%VVC*%Q
MDN4X&@^<ZV?.AZ+!JS]7-L[&]\"[A"VXL@Y>M9[*X\(]XRBQ%XD-5PIDN->5
MGZ@2CZ+B\/ <+C^TFSB(Z1[V8 *H43K0G6WDHR@"DQ3CX7N8PU2YP\2G^!X9
M-DK62( *O=XOT(U3>B407R"$-AR[09B@I0?T@.#;2-:@;?4>CC!\3X8)#MWV
M9[?!1OP519GM6ONB-4;Q B-:D-E^AG$VS$8!LCRYL&($V;IKN0U&WYKA[GK<
M/=[\;X<+[S/Y\+,!ZO76SEXUW^"H?Y&A*ZGA*CXLC.S<]7<M#2[3[G7'6<65
M)<#WC93FL+ "CK^'W/P'4$L#!!0    ( ". 8E;>D6(]7 0  +,+   9
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MJ-T&>C]7RJYNW 'MG#[Y"5!+ P04    "  C@&)6P44U92D$  "9"@  &0
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MVJRQHL:PL#&<6SZ?-X+"]5#6BN;# 8GQ^Z"UJD*>8K9VTGT)L*[XZA)4&WV
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M!+J_L_4;J];NGK10EFY=;EG3-1<U"]#[I5+VL&$#P\5Y^A]02P,$%     @
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M5TP[E+4;I^LP",VUH[$J+$N:8]%X ?I>:.VZC7?03\:3OP%02P,$%     @
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M&)H3 )[QG#(DR *%(F?$[[I]S/*,V-<47.R,:F.%PO*$EWAVF'P2JE:6L!W
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MMYIH4=A[YEQHO+7:X0K_)H T#FA?".S(>F(V:/YX3/X&4$L#!!0    ( ".
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M905H?R6EV4^L@?:;;?$/4$L#!!0    ( ". 8E:W*!2&0 (  '8$   9
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M0.L#>']E#+T9?EAW3TW^#U!+ P04    "  C@&)6%8P'HS4$  !R#P  &0
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MU'&YSY2:8E1V ?U?2&D>!G:#NLT>_PM02P,$%     @ (X!B5MAC)ZV9 @
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M%GNNGY;XC()V#KA?*&5?#==XAX<Y_0=02P,$%     @ (X!B5K6Q2;DN P
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M,*F7]1NA[FA15/?RA=#FEE\U,_.N FD7F/E$"+WJV W:E]KX+U!+ P04
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MJ@&\OLP )\"U@3I/&9.O"WV#[JM+]!]02P,$%     @ (X!B5NT]G=%@!P
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M<E.J&)AW2-^KV-= 4+=^P@,$&,!I6H56C.$>8S@.XU_J6H @0^/Q)S1A)DS
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M:KTG;KT?$8^ ?2T %4X/+#"UG!.WG(\)23&P*8F ? \RI/8<BF@1)N[-Z+#
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M/C4AQ5(U>=Z*?._?MR>R5R+[M<C^_ZK _CYCL">R5S$8U#$8M";ZC+$*4U>
MA*7"A:($D>H5W=F;Q+<ROE>\(PO#K4((.L%++3A5_E;3*T L[%U HI173+G^
M5Z_6UXTSVV7]%W-W5[G"8D&8U)4YU]"@T]=U)ES_=Q/%2]M"9USIAFR'N;XR
M@3 &^ON<<[69F WJ2UCR#U!+ P04    "  C@&)6)E0.5H<"  #>!@  &0
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M4WM>#WU5#>V],_04YA?(=[\@S_&\%OGDXW+WK=Q6D]#,A-?,A&?\_'?\?A;
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M+F*EY]5%I:I(5IBS_HE)=7,PQ51=[H#K#NK]DC&YK>CK0W-=3/X"4$L#!!0
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MCN>=HBV[0JLJ>Y[0<?N(_G^5;4<GZ UT_F$4Z3,F<I!'WYH.4(L/@.P,J%'
M=L_^%5O(M#-+!_<(^"Z] !'(9?M89J??8K6X9'E(KQ9JZW-]^9)>")QALIN;
M[Y2K?Y@"A;!5D%9OJ"9KGEV&9"^2)>GUP(9)R:+TT0?J =<&ZOLM8_+TH@,4
M5U*S_P!02P,$%     @ (X!B5J88]\+2!   #A\  !D   !X;"]W;W)K<VAE
M971S+W-H965T-#8N>&ULO9GO;^(V',;_%2L[;:W4-8D#@7: =*4W[:2;5!WK
M[<6T%RXQ8#6).=N!N_WULY,T)B08B,SU19L?]M?/\PUY^#09;2E[Y2N,!?B6
MQ"D?.RLAUO>NR^<KG"!^2]<XE6<6E"5(R%VV=/F:813EDY+8A9X7N@DBJ3,9
MY<>>V&1$,Q&3%#\QP+,D0>S[ X[I=NSXSMN!SV2Y$NJ .QFMT1+/L'A>/S&Y
MYU95(I+@E!.: H878^>]?S\-H)J0C_A"\);O; -EY8725[7S,1H[GE*$8SP7
MJ@22?S9XBN-859(ZOI9%G6I--7%W^ZWZ[[EY:>8%<3RE\=\D$JNQ,W1 A!<H
MB\5GNOT#EX;ZJMZ<QCS_#;;E6,\!\XP+FI23I8*$I,5?]*ULQ,X$OW=@ BPG
MP%,G!.6$(#=:*,MM/2*!)B-&MX"IT;*:VLA[D\^6;DBJ+N-,,'F6R'EB,A-T
M_KJB<809_P5\^)H1\1W\"F;%505T 9YD7S%C. +Y6'#UB 4B,;^6PYYGC^#J
MW35X!US 5XAA#D@*GE,B^(T\*+?_6M&,HS3B(U=(N6I1=UY*>RBDP0/2'O'\
M%@3^#8 >A"W3IZ=/]^O37=FDJE.PZA3,ZP4'ZDUCQ+EJ2-&&?S[)\^"CP G_
MM\U;4:S77DS=G/=\C>9X[,B[CV.VP<[DYY_\T/NMS:FE8C7?0>4[,%6?Z.O/
ME?$;L$8,;%"<87 E+W!$XQ@Q#M:8%1^!Z[9N%$L,\B54LFPFWJWGR<NRV;5Y
M;%1-?Z_2WSM/?_E!19E844;^DR>4C^)HJ_BB?K@C2X9D_K.G_X2!-0O]RD+?
M:&$FD) RO^1-KQH-8B)OUPBI.&R37=3L[Z@)O7!/L7E,36Q8B0V-8C]I56"=
M]QZG<ZPR!3,B^_X>3&FZP4R0EQCOITN;C["AT?=ZO3TC;8/@@;8/*B<#<]L[
M"C96/??6MU2LUH!AU8"AS<@;VO1MJ5C-]UWE^^[RD7=W4N09A72TZ7OZR]^[
M<#:6"]0R;S#P&]%H%M+5Z [E^)V,2K#E0N()29='G?H-IS(KFT:/#:L[T/3A
M&[_D)],LR6*DF!=DZ1J1J S7RA.(R(9$^!!JP49 ]H+AOO:607[O@'+-#[X9
M(,H8?3@W1LUES\T36]7J3= 0XO=L1JEO9)JSO5NJ5O>NZ<4WXXN5."W7.):G
M9BE=K6KV\<WP8R%0PT9^#(=A(V6,,KK:U&#DF\G(1IP.&CX;)DU#ZLHUT?A&
M<'@+H^G98605;FQ5JS=!XXU_9S6,+$%*Z?T2R ,U\L SD:=+&)5K' LCLY2N
M5C7TP&[0<WH8P2;,P+9_?,U"NAK=>3)C9B,+<52N8(HCXY"Z<LU&\"0V>CPW
MCLQESWZ\= DV@IJ-H%4V@E;9R%:UNG?-1O 'L%&YQG OCIIY= DX@AJ.X*7A
M"#;AR._WPD'C5KT$'D&-1_#B> 2/XY%Q2%VYQB-X$AY].#N/K.*1K6KU)F@\
M@E;Q"%K%(UO5ZL_Z-1X%/P"/@M/PR"REJU6-1\&E\2AHXM$P[ _A_L-ILY"N
M1C4>!1?'H^ X'K4,"?O]W2?UA7QWYV6E>E/\)V)+DG(0XX6<Z-T.Y)<4*UZ^
M%CN"KO/WER]4")KDFRN,(LS4 'E^0:EXVU&O1*M7X)/_ 5!+ P04    "  C
M@&)6&\!D&'T%  ##'@  &0   'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6RU
M65UOVS84_2N$5ZPMT%FB_)G.,9!8+E9@'8)ZV1Z&/= 2';&51)>D[.;?[Y*2
M)=F1F7A@7VQ]\!Z2Y]Q[J4O.]EQ\E0FE"GW/TEQ>]Q*EMN\]3T8)S8CL\RW-
MX<V&BXPHN!4/GMP*2F)CE*5>X/MC+R,L[\UGYMF=F,]XH5*6TSN!9)%E1#S>
MTI3OKWNX=WCPF3TD2C_PYK,M>: KJNZW=P+NO!HE9AG-)>,Y$G1SW;O![Y=X
MJ@U,B[\8W<O6-=)367/^5=]\C*][OAX136FD- 2!OQU=T#352#".;Q5HK^Y3
M&[:O#^@?S.1A,FLBZ8*G?[-8)=>]:0_%=$.*5'WF^]]H-:&1QHMX*LTOVE=M
M_1Z*"JEX5AG#"#*6E__D>T5$RP /SQ@$E4%P:C Z8S"H# :G!N,S!L/*8/C2
M(8TJ S-UKYR[(2XDBLQG@N^1T*T!35\8]HTU\,5R[2@K)> M SLU7RD>?4UX
M&E,A7Z/EMX*I1_0+6E'!J$0W:,'S'16*K5.*[D!#*@2-D;%";T*J"$OE6S"X
M7X7HS:NWZ!7RD$R( &.6H_N<*?D.'L+UGPDO),EC.?,4#%QW[T75(!?E((,S
M@QR@3SQ7B43+/*9QAWUHM\>!!< #QFK:@@-MMX$5\1,1?80G[Y .R*X)V<U7
M=-M' ]^83[KF8S</:03F6)L'08?Y\N7FV$+&H/:A@<$;G,%;I$1*Q#>56_SS
M.[Q''Q7-Y+\=@[LMP8;=8#HQOI=;$M'K'F0^2<6.]N8__X3'_J]=/+L$"UV"
M+1V!'2DRK!49VM#G-U$D"HC3F.U83'.X* 3+'Y!**-I":/.N(+JU8EXJC$NP
MT"78L@0;&3"]CN[FP7#F[3KH'M5TCYZCN\B*E"B@/*0;%C'5Q:\5Y%)^78*%
M+L&6CL".E!C72HQ=IJ*Q2T5<@H4NP9:.P(X4F=2*3'Y *K)B7BJ,2[!P8LL>
M)=UED_$+$LRT)G%J)?$EGV-=-%I1+Z71)5CH$FSI".Q(FJM:FBN7&>?*I2(N
MP4*78$M'8$>*8+^I:7QKN"S*U1@JT";M"%B=T1LB$=%I)Z*Y>MNECQWY4H&<
MHH45&L:MS.+W_=/TXZK38_);!25^*?E%OB4L1MLZ44D3(P=-NBK!6SOZQ0*X
M1 LKM';R'PZFI_1W-,)G\C\.&E8#^PJ@S-?ECJ0%N#&4TS%/4R*D=N:RX.YV
M9ROJQ6RZ1 LKM#91V#\ETU&/QZPWA2VV5FGS<KDUFV);P2+:L'V)!F4?5ZUY
MCJ]P/SB>ZJ*CV54P[9^X5U@UPX$=;FF?V?]EKBE L;T"O3.?=H>/O7W"HL1\
M\D6GC#*)9+'^0B.%%$<D_E)(E4%V1ALN(%.DA<DD3,J"Y!'M3AGVH>  96;W
MI].EG=:I3M&6KM".)6R*6FRO:E?&STN5M!B!K]63-"HE48+$6MN8/$KSGA2*
M9Y#XHY;(G7(YK8.=HH45FEY"FZ0T'4WZX]/P^A%5+F[*7&RMV>9_%-D:D@Y\
M=IZ5!/)3*^Q2+O6;4DTPTP\ARIAZ?"T!(X,(J5;G# (0T6\%21&(2K]'%-8=
M@N261FS#:'R(VQQ>QS &+;TIYDY6>8CF-6V<@J3I8^48JG,/]]8^Y8O]PFDY
M_HP<$!J:\\X@_A'%-VZJ;VPOO]N.TA*YVJ+7#J,5A18P_G9I#C-Z$N!N5'9:
MVCM%"_'3RAWC)Y'OJ,MC09N= &S?"F@$/1_M3:SN>%ID](G\)L;7]*"_.W&=
M;C@X10N?X=46PD[W%[S685U&Q8,Y)=4YN,A5>0!5/ZU/8F_,^>/)\U"?T)I#
MP :F/-[]1,0#RR5*Z08@_?X$%BM1GIB6-XIOS9'@FBO0UEPF%%Q!Z ;P?L.Y
M.MSH#NISZ_E_4$L#!!0    ( ". 8E9LYK=Y0 <  *9*   9    >&PO=V]R
M:W-H965T<R]S:&5E=#0X+GAM;*V<6V_;-AS%OPKA#=L*=+%$6;YDB8'6N@YK
M$S38^C#L0;'I6*@N+D4[#; //^H2RW04VEY/'QI+YOF1BD^HOW1D7CWF_$NQ
M8DR0;VF2%=>]E1#KRWZ_F*]8&A47^9IE\IUESM-(R$W^T"_6G$6+2I0F?6H8
MPWX:Q5EO>E7MN^73JWPCDCACMYP4FS2-^--[EN2/USVS][SC4_RP$N6._O1J
M'3VP.R;^7-]RN=7?419QRK(BSC/"V?*Z]\Z\#.FH%%0M_HK98['WFI2'<I_G
M7\J-<''=,\H1L83-18F(Y(\MF[$D*4ER'%\;:&_79RG<?_U,]ZJ#EP=S'Q5L
MEB>?XX587??&/;)@RVB3B$_Y8\": [)+WCQ/BNI_\MBT-7IDOBE$GC9B.8(T
MSNJ?T;?F%[$G,$>O"&@CH(<"^Q6!U0BL0\'@%<&@$0Q.%=B-P#X46*\(AHU@
M>&H/HT8P.E4P;@3C4P631C"I[%!_?M6'[T0BFE[Q_)'PLK6DE2\J!U5J^9G'
M66GV.\'EN['4B>F=R.=?5GFR8+SXF;A?-[%X(K^2.\9C5A"7S/)LR[B([Q-&
M;J4/&>=L02H5^<5A(HJ3XHT4_$CZI%A%G!57?2''5=+[\V8,LWH,])4QF.1#
MGHF5["Y;L(6J[\OCV1T4?3ZH]U0+_'V371#3?DNH08VN\>CE-W-Q02RSDM,.
MN7.D]RC3REV]_&.^E7*CDIL=<D\O_Q ]/7?>I?;U:H?-=V/O^LT%I\N[#CT\
M76YJ?&#MS&U5/.L5WBR)BH+DR\:O?_\AWR>A8&GQ3\?@WM>P03>L/.M<%NMH
MSJY[\K12,+YEO>E//YA#X[<NBR%A#A+F(F$>$N8C80$2%H)@BHL'.Q</=/3I
M723G7FGBHC3QVV:6)7%1;.1,_$N<-7O>=%E:2S[7TDB8@X2Y-6Q8P<KR;CNE
M Z/\=]7?[KNUHYW1T<Y'#BY PD(03#&BO3.BK37BQTUZSWAEQ=J#\RA)I ?O
MG\ACQ'F4B>*8'^V7'P U+=.TU0]@IAW(N59#PEPDS$/"?"0L0,)"$$PQ[7!G
MVJ'6M$UIN<E$G!#VC?%Y7$2RFNURIYXT)&G%ZIH:M<IS_8J$N4B8AX3Y2%B
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M\X>QS47K$L,.RY;NBI;<,RU!%WPA&5\S$&01CIH MDB[RMU]R?W.U2+Z..R
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M$<Q /A13CCNS0@F3#'*1L)QP6 R,H7T]MBWEH"U^)+ 6.VNB4IDS]J@VM^'
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M)ZBRF2D'1N:N'WB1!KL+]YA@ PC*&N#[A91F,[ +U"WE]%]02P,$%     @
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M(6'R!G%]32D_'L@ ]1>@^?]02P,$%     @ (X!B5I@3#1:A!0  !AX  !D
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M=K]\\EC4=;'I7JY8NF!E&]#\?5D4]<N;]L=43K^>,_LO4$L#!!0    ( ".
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MH3-AK'4Z<TI:KM2:]BUI$3+$;":.0*K*P1!81BR6D9>QK--DF[WPE':Q%]S
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MFT6Q&FR,EWNMCT9^AW _QB<C.^*X1ASW(M[KJ4]%N$9Z@]-NL=$VF*6FF*&
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M8G26]3F_'FA15D?EI=!X\*XNM_AM!-(8X/.U$/IE8$[?[==6\A]02P,$%
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MSN?FZ^4ORZ^=>+]H+S@G^'?G\2]02P,$%     @ (X!B5G32QF+> 0  6B,
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M\UG_2\WL#5!+ 0(4 Q0    ( "* 8E8'04UB@0   +$    0
M  "  0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ (H!B5GQ.:"+M
M    *P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L!
M A0#%     @ (H!B5IE<G",0!@  G"<  !,              ( !RP$  'AL
M+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    "  B@&)6-G6W"N$'   @+@
M&               @($,"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!
M A0#%     @ (H!B5B9!:D,W @  M04  !@              ("!(Q   'AL
M+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( "* 8E;L</COZ04
M '\8   8              " @9 2  !X;"]W;W)K<VAE971S+W-H965T,RYX
M;6Q02P$"% ,4    "  B@&)6VB/F& \#  "R"0  &               @(&O
M&   >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ (H!B5I/%
M!KG?!   @Q$  !@              ("!]!L  'AL+W=O<FMS:&5E=',O<VAE
M970U+GAM;%!+ 0(4 Q0    ( "* 8E:C?BSRZ0(  +$'   8
M  " @0DA  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  B
M@&)6&.\Z?4T(   O0P  &               @($H)   >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&UL4$L! A0#%     @ (H!B5E=3T4U! @  U00  !@
M         ("!JRP  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0
M   ( "* 8E;$)M8D!P@  %0C   8              " @2(O  !X;"]W;W)K
M<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  B@&)6H'Z*9&\"  "&!@
M&0              @(%?-P  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+
M 0(4 Q0    ( "* 8E8/\8<KC 4  "D,   9              " @04Z  !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ (H!B5E:TWN*Y
M&P  #%(  !D              ("!R#\  'AL+W=O<FMS:&5E=',O<VAE970Q
M,BYX;6Q02P$"% ,4    "  B@&)6-P\*2RT'  ![$@  &0
M@(&X6P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( "*
M8E9)1H7\,@8  %$;   9              " @1QC  !X;"]W;W)K<VAE971S
M+W-H965T,30N>&UL4$L! A0#%     @ (X!B5G^NCTTS"@  _1T  !D
M         ("!A6D  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M    "  C@&)6X&@ %[D)  !_&0  &0              @('O<P  >&PO=V]R
M:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ". 8E9*VZE6[ 0  (T-
M   9              " @=]]  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
M4$L! A0#%     @ (X!B5MLOQ=^3!   ZPP  !D              ("! H,
M 'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  C@&)6JCI>
M\)@)  "N&@  &0              @(',AP  >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;%!+ 0(4 Q0    ( ". 8E9)78S-@@4   \-   9
M  " @9N1  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @
M(X!B5@BWC:VS @  #P8  !D              ("!5)<  'AL+W=O<FMS:&5E
M=',O<VAE970R,2YX;6Q02P$"% ,4    "  C@&)6+]7PA0\8   -3   &0
M            @($^F@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4
M Q0    ( ". 8E;_?[#."@0  #@)   9              " @82R  !X;"]W
M;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ (X!B5ATU0@MD!@
M&Q$  !D              ("!Q;8  'AL+W=O<FMS:&5E=',O<VAE970R-"YX
M;6Q02P$"% ,4    "  C@&)6WI%B/5P$  "S"P  &0              @(%@
MO0  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ". 8E;!
M135E*00  )D*   9              " @?/!  !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&UL4$L! A0#%     @ (X!B5M.EVQ/-!   1 L  !D
M     ("!4\8  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ". 8E85C >C-00  '(/   9              "
M@??;  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ (X!B
M5MAC)ZV9 @  I <  !D              ("!8^   'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6Q02P$"% ,4    "  C@&)6M;%)N2X#  "U#0  &0
M        @($SXP  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0
M   ( ". 8E:>";M!Q@,  ($1   9              " @9CF  !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ (X!B5NT]G=%@!P  [#(
M !D              ("!E>H  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q0
M2P$"% ,4    "  C@&)66_GL[>T"  #""0  &0              @($L\@
M>&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ". 8E83(;,<
MO ,  -@/   9              " @5#U  !X;"]W;W)K<VAE971S+W-H965T
M,S@N>&UL4$L! A0#%     @ (X!B5NBO",T^ P  OPD  !D
M ("!0_D  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  C
M@&)6,$_7]>0"  "0"0  &0              @(&X_   >&PO=V]R:W-H965T
M<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( ". 8E8F5 Y6AP(  -X&   9
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M970T-2YX;6Q02P$"% ,4    "  C@&)6IACWPM($   .'P  &0
M    @('T#P$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    (
M ". 8E8;P&08?04  ,,>   9              " @?T4 0!X;"]W;W)K<VAE
M971S+W-H965T-#<N>&UL4$L! A0#%     @ (X!B5FSFMWE !P  IDH  !D
M             ("!L1H! 'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"
M% ,4    "  C@&)60LH+^=@"  !V!P  &0              @($H(@$ >&PO
M=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( ". 8E;6]AZ<(@4
M /X>   9              " @3<E 0!X;"]W;W)K<VAE971S+W-H965T-3 N
M>&UL4$L! A0#%     @ (X!B5G0-?%L@ P  N L  !D              ("!
MD"H! 'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    "  C@&)6
M!5ZSI[0#  !>#@  &0              @('G+0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4R+GAM;%!+ 0(4 Q0    ( ". 8E9%[V>Z*@4   T:   9
M      " @=(Q 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%
M  @ (X!B5I@3#1:A!0  !AX  !D              ("!,S<! 'AL+W=O<FMS
M:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    "  C@&)6^YOI3%H*  !)9P
M&0              @($+/0$ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+
M 0(4 Q0    ( ". 8E;O@K0@$ 4  !PC   9              " @9Q' 0!X
M;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ (X!B5GO;XW(4
M P  -@H  !D              ("!XTP! 'AL+W=O<FMS:&5E=',O<VAE970U
M-RYX;6Q02P$"% ,4    "  C@&)6'AAR+GT$  "Q$@  &0
M@($N4 $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ".
M8E8V]BV,P@,  'D-   9              " @>)4 0!X;"]W;W)K<VAE971S
M+W-H965T-3DN>&UL4$L! A0#%     @ (X!B5K>%\@)[ @  _P4  !D
M         ("!VU@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
M    "  C@&)6%R57^5X#  "R%@  #0              @ &-6P$ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( ". 8E:7BKL<P    !,"   +
M  "  19? 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( ". 8E8?E[7\U 0   HH
M   /              "  ?]? 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M"  C@&)6F!M:GOL!  #+(P  &@              @ $ 90$ >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    "  C@&)6=-+&8MX!  !:(P
M$P              @ $S9P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..1 !$ ),2  !":0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>194</ContextCount>
  <ElementCount>340</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>53</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DocumentandEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BalanceSheets</Role>
      <ShortName>Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StatementsofOperations</Role>
      <ShortName>Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StatementsofStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Statement of Shareholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StatementofShareholdersEquityParenthetical</Role>
      <ShortName>Statement of Shareholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StatementsofCashFlows</Role>
      <ShortName>Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical</Role>
      <ShortName>Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Business Overview and Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity</Role>
      <ShortName>Business Overview and Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Supplementary Balance Sheet Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</Role>
      <ShortName>Supplementary Balance Sheet Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Derivative Financial Instruments - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants</Role>
      <ShortName>Derivative Financial Instruments - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/EmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Supplementary Balance Sheet Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables</Role>
      <ShortName>Supplementary Balance Sheet Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/Leases</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/StockholdersEquity</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Derivative Financial Instruments - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/IncomeTaxes</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Business Overview and Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BusinessOverviewandLiquidityDetails</Role>
      <ShortName>Business Overview and Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails</Role>
      <ShortName>Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Supplementary Balance Sheet Information - Short-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Short-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Supplementary Balance Sheet Information - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails</Role>
      <ShortName>Supplementary Balance Sheet Information - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Leases - Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails</Role>
      <ShortName>Leases - Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Leases - Supplemental Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Leases - Future Minimum Lease Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails</Role>
      <ShortName>Leases - Future Minimum Lease Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Stockholders' Equity - Schedule of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Summary of Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series A Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails</Role>
      <ShortName>Stockholders' Equity - Series E Convertible Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stockholders' Equity - Securities Purchase Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails</Role>
      <ShortName>Stockholders' Equity - Securities Purchase Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock-Based Compensation - Stock-Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Options Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Derivative Financial Instruments - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails</Role>
      <ShortName>Derivative Financial Instruments - Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cardiffoncology.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Income Taxes - Significant Components of Company's Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Company's Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="crdf-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cardiffoncology.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails</Role>
      <ShortName>Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="crdf-20221231.htm">crdf-20221231.htm</File>
    <File>a231exq42022.htm</File>
    <File>a311exq42022.htm</File>
    <File>a312exq42022.htm</File>
    <File>a321exq42022.htm</File>
    <File>a322exq42022.htm</File>
    <File>crdf-20221231.xsd</File>
    <File>crdf-20221231_cal.xml</File>
    <File>crdf-20221231_def.xml</File>
    <File>crdf-20221231_lab.xml</File>
    <File>crdf-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="626">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="35">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>78
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "crdf-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 22,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 626,
    "http://xbrl.sec.gov/dei/2022": 35
   },
   "contextCount": 194,
   "dts": {
    "calculationLink": {
     "local": [
      "crdf-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "crdf-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "crdf-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "crdf-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "crdf-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "crdf-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 512,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 4
   },
   "keyCustom": 63,
   "keyStandard": 277,
   "memberCustom": 15,
   "memberStandard": 35,
   "nsprefix": "crdf",
   "nsuri": "http://www.cardiffoncology.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.cardiffoncology.com/role/DocumentandEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000010 - Statement - Statements of Cash Flows (Parenthetical)",
     "menuCat": "Statements",
     "order": "10",
     "role": "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical",
     "shortName": "Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "id9cf7788e55c4739b94fc0cf078e531e_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Business Overview and Liquidity",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity",
     "shortName": "Business Overview and Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Supplementary Balance Sheet Information",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation",
     "shortName": "Supplementary Balance Sheet Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.cardiffoncology.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OperatingLeasesOfLessorDisclosureTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.cardiffoncology.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Derivative Financial Instruments - Warrants",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants",
     "shortName": "Derivative Financial Instruments - Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.cardiffoncology.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.cardiffoncology.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorFirmId",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.cardiffoncology.com/role/EmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "22",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Supplementary Balance Sheet Information (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables",
     "shortName": "Supplementary Balance Sheet Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.cardiffoncology.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.cardiffoncology.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Derivative Financial Instruments - Warrants (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables",
     "shortName": "Derivative Financial Instruments - Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i26e876afeb3b441ab6bc9151db73e076_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.cardiffoncology.com/role/BalanceSheets",
     "shortName": "Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.cardiffoncology.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Business Overview and Liquidity (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.cardiffoncology.com/role/BusinessOverviewandLiquidityDetails",
     "shortName": "Business Overview and Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DerivativeLiabilitiesNoncurrent",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i7db42fc039fd45aeaea7b5bc0553089e_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeLiabilitiesNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "id6e8c265de294538a1036e72f7c48ee4_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Long-Lived Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "id6e8c265de294538a1036e72f7c48ee4_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
     "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Anti-dilutive Share Equivalents (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Supplementary Balance Sheet Information - Short-term Investments (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails",
     "shortName": "Supplementary Balance Sheet Information - Short-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
     "shortName": "Supplementary Balance Sheet Information - Investments Available-for-sale in a Continuous Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails",
     "shortName": "Supplementary Balance Sheet Information - Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Supplementary Balance Sheet Information - Accrued Expenses (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails",
     "shortName": "Supplementary Balance Sheet Information - Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical",
     "shortName": "Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LesseeOperatingLeaseMonthlyRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.cardiffoncology.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:LesseeOperatingLeaseMonthlyRentPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Leases - Lease Expense (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails",
     "shortName": "Leases - Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "crdf:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Leases - Supplemental Cash Flow Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails",
     "shortName": "Leases - Supplemental Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Leases - Future Minimum Lease Payments (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
     "shortName": "Leases - Future Minimum Lease Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i7f96c19e96104c05b51cc23d98344c24_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Stockholders' Equity - Schedule of Warrants (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails",
     "shortName": "Stockholders' Equity - Schedule of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "crdf:ClassOfWarrantOrRightNumberExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Stockholders' Equity - Summary of Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails",
     "shortName": "Stockholders' Equity - Summary of Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "crdf:PreferredStockLiquidationPreferenceStatedValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DividendsPreferredStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stockholders' Equity - Series A Convertible Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series A Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i492ca89c37204a0da71301af85c79a73_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:PreferredStockDividendRatePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stockholders' Equity - Series E Convertible Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
     "shortName": "Stockholders' Equity - Series E Convertible Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i6fbb0b602b174b52b951641f74a93e02_I20200615",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stockholders' Equity - Securities Purchase Agreements (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
     "shortName": "Stockholders' Equity - Securities Purchase Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i027d44ba7f284c1cb1bf03b726320f57_D20211101-20211130",
      "decimals": "-5",
      "lang": "en-US",
      "name": "crdf:SaleOfStockConsiderationReceivedOnTransactionGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Statements of Operations",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.cardiffoncology.com/role/StatementsofOperations",
     "shortName": "Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib2ae2c2e51104727ab30997d35b6e45b_I20220609",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib2ae2c2e51104727ab30997d35b6e45b_I20220609",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock-Based Compensation - Stock-Based Compensation (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions Using Black-Scholes for Estimated Fair Value of Stock Options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i2095721442fd459a96884e78016c08c6_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Options Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i54650e319a0b4eb5ac7bd7cc59d6742c_D20220101-20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i7f96c19e96104c05b51cc23d98344c24_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Derivative Financial Instruments - Warrants (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
     "shortName": "Derivative Financial Instruments - Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i742d83ea624f49ce83073c6574708721_D20220101-20221231",
      "decimals": "2",
      "lang": "en-US",
      "name": "crdf:EstimatedFairValueOfWarrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Fair Value Measurements (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i19fe2e4f93f04be6b765339abdde93a3_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Income Taxes - Significant Components of Company's Taxes (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails",
     "shortName": "Income Taxes - Significant Components of Company's Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Significant Components of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i8e8826dc39c04031b505d8c4ed59725d_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Loss",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.cardiffoncology.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails",
     "shortName": "Commitments and Contingencies - Research and Development and Clinical Trial Agreements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "crdf:CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
     "shortName": "Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i66fd5cf3fd2b46a7bf978e72ec63ddfd_I20201231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "link:footnote",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "i176f01c2d46c4436ad7072b85249fb48_D20210101-20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsOfStockIssuanceCosts",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Statement of Shareholders' Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.cardiffoncology.com/role/StatementofShareholdersEquityParenthetical",
     "shortName": "Statement of Shareholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.cardiffoncology.com/role/StatementsofCashFlows",
     "shortName": "Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "crdf-20221231.htm",
      "contextRef": "ib81372bc50644817b94ca49265c1efc6_D20220101-20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfAssets1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 53,
   "tag": {
    "crdf_AccruedClinicalTrial": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial",
        "label": "Accrued Clinical Trial",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "AccruedClinicalTrial",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedClinicalTrialExpenses": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expenses",
        "label": "Accrued Clinical Trial Expenses",
        "terseLabel": "Accrued Clinical Trial Expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpenses",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AccruedClinicalTrialExpensesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Trial Expenses",
        "label": "Accrued Clinical Trial Expenses [Policy Text Block]",
        "terseLabel": "Accrued Clinical Trial Expenses"
       }
      }
     },
     "localname": "AccruedClinicalTrialExpensesPolicyTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_AccruedPreferredStockDividend": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Preferred Stock Dividend",
        "label": "Accrued Preferred Stock Dividend",
        "terseLabel": "Preferred stock dividend(1)"
       }
      }
     },
     "localname": "AccruedPreferredStockDividend",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_Accrueddirectorfees": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued service fees for nonemployee directors",
        "label": "Accrued director fees",
        "terseLabel": "Director fees"
       }
      }
     },
     "localname": "Accrueddirectorfees",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_Accruedresearchagreements": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research agreements",
        "label": "Accrued research agreements",
        "terseLabel": "Clinical trials"
       }
      }
     },
     "localname": "Accruedresearchagreements",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental Balance Sheet Information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information [Abstract]",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "xbrltype": "stringItemType"
    },
    "crdf_BlackScholesOptionPricingMethodMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the Black-Scholes option pricing method which is used for valuation of derivative instruments.",
        "label": "Black Scholes Option Pricing Method [Member]",
        "terseLabel": "Black Scholes Option Pricing Method"
       }
      }
     },
     "localname": "BlackScholesOptionPricingMethodMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ClassOfWarrantOrRightExpirationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Expiration Term",
        "label": "Class Of Warrant Or Right, Expiration Term",
        "terseLabel": "Expiration term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExpirationTerm",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Issued",
        "label": "Class Of Warrant Or Right, Issued",
        "terseLabel": "Class Of Warrant Or Right, Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightMonthsUntilExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Right, Months Until Exercisable",
        "label": "Class Of Warrant Or Right, Months Until Exercisable",
        "terseLabel": "Months until exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightMonthsUntilExercisable",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_ClassOfWarrantOrRightNumberExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Number Exercised",
        "negatedTerseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberExercised",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightNumberExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants or rights expired during the period.",
        "label": "Class of Warrant or Right Number Expired",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberExpired",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Warrant or Right Term of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTermOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights outstanding.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights",
        "periodEndLabel": "Weighted average exercise price of warrants at the end of the period (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price of warrants at the beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsAbstract",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights exercised during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Exercised",
        "verboseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average exercise price of each class of warrants or rights expired during the period.",
        "label": "Class of Warrant or Right Weighted Average Exercise Price of Warrants or Rights Expired",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExpired",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made",
        "label": "Collaborative Arrangement, Rights and Obligations, Milestone And Royalty Payments Made",
        "terseLabel": "Milestone or royalty payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMilestoneAndRoyaltyPaymentsMade",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingenciesResearchandDevelopmentandClinicalTrialAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_CommonStockAndWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock And Warrants [Member]",
        "label": "Common Stock And Warrants [Member]",
        "terseLabel": "Common Stock And Warrants"
       }
      }
     },
     "localname": "CommonStockAndWarrantsMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comprehensive Income (Loss) Available to Common Stockholders, Basic",
        "label": "Comprehensive Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Comprehensive loss attributable to common stockholders"
       }
      }
     },
     "localname": "ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ConvertiblePreferredStockStatedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Preferred Stock, Stated Value Per Share",
        "label": "Convertible Preferred Stock, Stated Value Per Share",
        "terseLabel": "Stated value (in dollars per share)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockStatedValuePerShare",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability",
        "label": "Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability [Member]",
        "terseLabel": "Correction of Series A Convertible Preferred Stock Cumulative Dividend Liability"
       }
      }
     },
     "localname": "CorrectionOfSeriesAConvertiblePreferredStockCumulativeDividendLiabilityMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_CorrectionPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Correction, Policy",
        "label": "Correction, Policy [Policy Text Block]",
        "terseLabel": "Correction of Series A Convertible Preferred Stock cumulative dividend liability"
       }
      }
     },
     "localname": "CorrectionPolicyPolicyTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Current",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxCurrent",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent",
        "label": "Debt Securities, Available-For-Sale, Accumulated Gross Unrealized Gain, Before Tax, Noncurrent",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTaxNoncurrent",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Current",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxCurrent",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax, Noncurrent",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTaxNoncurrent",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DeferredTaxAssetsNetBeforeValuationAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "label": "Deferred Tax Assets, Net, Before Valuation Allowance",
        "totalLabel": "Net deferred tax assets before valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetBeforeValuationAllowance",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible research tax credit carryforwards and to other deductible tax credit carryforwards not separately disclosed.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards Research and Other",
        "terseLabel": "Research and development credits and other tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndOther",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_DerivativeFinancialInstrumentsLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Financial Instruments Liability [Roll Forward]",
        "terseLabel": "Changes in the Company's derivative financial instruments liability balance"
       }
      }
     },
     "localname": "DerivativeFinancialInstrumentsLiabilityRollForward",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information",
        "terseLabel": "Document and Entity Information"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "xbrltype": "stringItemType"
    },
    "crdf_EffectiveIncomeTaxRateReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.",
        "label": "Effective Income Tax Rate Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPermanentItems",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Amount",
        "terseLabel": "Return to provision and true ups"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsAmount",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Return To Provision And True Ups, Percent",
        "terseLabel": "Return to provision and true ups"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationReturnToProvisionAndTrueUpsPercent",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_EquityIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the 2014 Equity Incentive Plan under which common shares will be issued to the members.",
        "label": "Equity Incentive Plan 2014 [Member]",
        "terseLabel": "Equity Incentive Plan 2014"
       }
      }
     },
     "localname": "EquityIncentivePlan2014Member",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_EstimatedFairValueOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the estimated fair value of warrant.",
        "label": "Estimated Fair Value of Warrant",
        "terseLabel": "Estimated fair value of Trovagene common stock (in dollars per share)"
       }
      }
     },
     "localname": "EstimatedFairValueOfWarrant",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_FurnitureAndOfficeEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to furniture and office equipment.",
        "label": "Furniture And Office Equipment [Member]",
        "terseLabel": "Furniture and office equipment"
       }
      }
     },
     "localname": "FurnitureAndOfficeEquipmentMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_IncomeTaxReconciliationPermanentItems": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to permanent items.",
        "label": "Income Tax Reconciliation Permanent Items",
        "terseLabel": "Permanent items"
       }
      }
     },
     "localname": "IncomeTaxReconciliationPermanentItems",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_IncreaseDecreaseInOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "label": "Increase (Decrease) In Operating Lease, Right-Of-Use Asset",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_InducementGrantStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement Grant Stock Options",
        "label": "Inducement Grant Stock Options [Member]",
        "terseLabel": "Inducement Grant Stock Options"
       }
      }
     },
     "localname": "InducementGrantStockOptionsMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_LesseeOperatingLeaseAnnualRentIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "label": "Lessee, Operating Lease, Annual Rent Increase, Percentage",
        "terseLabel": "Annual rent increase, percentage"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualRentIncreasePercentage",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "crdf_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, To Be paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, To Be paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LesseeOperatingLeaseMonthlyRentPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Monthly Rent Payment",
        "label": "Lessee, Operating Lease, Monthly Rent Payment",
        "terseLabel": "Monthly rent payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRentPayment",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_LessorNumberOfSubleases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessor, Number Of Subleases",
        "label": "Lessor, Number Of Subleases",
        "terseLabel": "Number of subleases"
       }
      }
     },
     "localname": "LessorNumberOfSubleases",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "crdf_NonCashCumulativePreferredStockDividendAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Cash, Cumulative Preferred Stock Dividend Adjustment",
        "label": "Non-Cash, Cumulative Preferred Stock Dividend Adjustment",
        "terseLabel": "Cumulative preferred stock dividend adjustment"
       }
      }
     },
     "localname": "NonCashCumulativePreferredStockDividendAdjustment",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_OperatingLossCarryforwardsIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Increase (Decrease)",
        "label": "Operating Loss Carryforwards, Increase (Decrease)",
        "negatedTerseLabel": "Reduction to net operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIncreaseDecrease",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "terseLabel": "NOLs, not subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_OperatingLossCarryforwardsSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Loss Carryforwards, Subject To Expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "terseLabel": "NOLs, subject to expiration"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_Patentlicenseandotherfeespayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patent, license and other fees payable",
        "label": "Patent, license and other fees payable",
        "terseLabel": "Patent, license and other fees"
       }
      }
     },
     "localname": "Patentlicenseandotherfeespayable",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of consecutive trading days during which the closing price of the entity's common stock must equal or exceed the applicable price in order for the preferred stock to be automatically converted.",
        "label": "Preferred Stock Conversion Obligation Common Stock Closing Sales Price Number of Trading Days",
        "terseLabel": "Number of consecutive trading days in which the closing price of the entity's common stock must equal or exceed a specified price in order for the preferred stock to be automatically converted"
       }
      }
     },
     "localname": "PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_PreferredStockConversionObligationNumberOfTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of trading days during which a specified average volume of common stock must traded in order for the preferred stock to be automatically converted.",
        "label": "Preferred Stock Conversion Obligation Number of Trading Days",
        "terseLabel": "Number of trading days in which the specified volume of common stock must be traded for the preferred stock to be automatically converted"
       }
      }
     },
     "localname": "PreferredStockConversionObligationNumberOfTradingDays",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the average volume of common stock per day, which must be traded in order for the preferred stock to be automatically converted.",
        "label": "Preferred Stock Conversion Obligation Specified Volume of Common Stock Traded Per Day during Trading Days",
        "terseLabel": "Number of common stock shares traded per day during the 20 trading days for the preferred stock to be automatically converted"
       }
      }
     },
     "localname": "PreferredStockConversionObligationSpecifiedVolumeOfCommonStockTradedPerDayDuringTradingDays",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_PreferredStockConversionPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The price per share of the conversion feature embedded in the convertible preferred stock.",
        "label": "Preferred Stock Conversion Price Per Share",
        "terseLabel": "Conversion price per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConversionPricePerShare",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_PreferredStockCumulativeDividendAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Cumulative Dividend Adjustment",
        "label": "Preferred Stock, Cumulative Dividend Adjustment",
        "terseLabel": "Cumulative preferred stock dividend adjustment"
       }
      }
     },
     "localname": "PreferredStockCumulativeDividendAdjustment",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PreferredStockDividendAccrued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of preferred stock dividend accrued during the reporting period.",
        "label": "Preferred Stock Dividend Accrued",
        "terseLabel": "Accretion of Series A Convertible Preferred Stock dividend"
       }
      }
     },
     "localname": "PreferredStockDividendAccrued",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PreferredStockLiquidationPreferenceValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Cumulative Unpaid Preferred Stock Dividends, Value",
        "label": "Preferred Stock, Liquidation Preference, Cumulative Unpaid Preferred Stock Dividends, Value",
        "terseLabel": "Cumulative unpaid preferred stock dividends"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceCumulativeUnpaidPreferredStockDividendsValue",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PreferredStockLiquidationPreferenceStatedValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PreferredStockLiquidationPreferenceValue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred Stock, Liquidation Preference, Stated Value",
        "label": "Preferred Stock, Liquidation Preference, Stated Value",
        "terseLabel": "Stated Value per share liquidation"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceStatedValue",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the period during which the conversion price is subject to adjustment for dilutive issuances.",
        "label": "Preferred Stock Period of Dilutive Issuance for Conversion Price Adjustments",
        "terseLabel": "Period during which the conversion price is subject to adjustment for dilutive issuances"
       }
      }
     },
     "localname": "PreferredStockPeriodOfDilutiveIssuanceForConversionPriceAdjustments",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to registered direct offering",
        "label": "Registered Direct Offering [Member]",
        "terseLabel": "Registered Direct Offering"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ReleaseOfClinicalTrialFundingCommitment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release Of Clinical Trial Funding Commitment",
        "label": "Release Of Clinical Trial Funding Commitment",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "ReleaseOfClinicalTrialFundingCommitment",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_Releaseofclinicaltrialfundingcommitmentforservicesreceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Release of clinical trial funding commitment for services received",
        "label": "Release of clinical trial funding commitment for services received",
        "terseLabel": "Release of clinical trial funding commitment"
       }
      }
     },
     "localname": "Releaseofclinicaltrialfundingcommitmentforservicesreceived",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_SaleOfStockConsiderationReceivedOnTransactionGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "label": "Sale Of Stock, Consideration Received On Transaction, Gross",
        "terseLabel": "Gross proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransactionGross",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of a concept from the beginning of a period to the end of the period.",
        "label": "Schedule of Components of Changes in Derivative Financial Liability [Table Text Block]",
        "terseLabel": "Schedule of Components of Changes in the Company\u2019s Derivative Financial Instruments Liability Balance"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfChangesInDerivativeFinancialLiabilityTableTextBlock",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "crdf_SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities Purchase Agreement, Number Of Days Counterparty Cannot Sell Or Transfer Shares",
        "label": "Securities Purchase Agreement, Number Of Days Counterparty Cannot Sell Or Transfer Shares",
        "terseLabel": "Number of days counterparty cannot sell or transfer shares"
       }
      }
     },
     "localname": "SecuritiesPurchaseAgreementNumberOfDaysCounterpartyCannotSellOrTransferShares",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "crdf_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A Convertible Preferred Stock [Member]",
        "label": "Series A Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesBConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B Convertible Preferred Stock [Member]",
        "label": "Series B Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesCConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares at the owner's option.",
        "label": "Series C Convertible Preferred Stock [Member]",
        "terseLabel": "Series C Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesCConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesDConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series D Convertible Preferred Stock",
        "label": "Series D Convertible Preferred Stock [Member]",
        "terseLabel": "Series D Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesDConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesEConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series E Convertible Preferred Stock",
        "label": "Series E Convertible Preferred Stock [Member]",
        "terseLabel": "Series E Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesEConvertiblePreferredStockMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_SeriesNWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series N Warrant",
        "label": "Series N Warrant [Member]",
        "terseLabel": "Series N Warrant"
       }
      }
     },
     "localname": "SeriesNWarrantMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ServiceReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Receivable",
        "label": "Service Receivable [Member]",
        "terseLabel": "Service Receivable"
       }
      }
     },
     "localname": "ServiceReceivableMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_Servicereceivable": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Monetary value of future clinical trial services to be received in connection with issuance of common stock, preferred stock and warrants",
        "label": "Service receivable",
        "negatedTerseLabel": "Service receivable"
       }
      }
     },
     "localname": "Servicereceivable",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that expired during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expired in Period",
        "negatedTerseLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpiredInPeriod",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expired in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpiredInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_SharePriceForAutomaticConversion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price target, if reached for the required period of time and if other provisions are achieved, that allows the entity to convert the preferred stock to common stock.",
        "label": "Share Price for Automatic Conversion",
        "terseLabel": "Share price for 20 consecutive trading days for automatic conversion"
       }
      }
     },
     "localname": "SharePriceForAutomaticConversion",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "crdf_StockIssuedDuringPeriodSharesWarrantsExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of shares issued during the period upon cash exercise of warrants.",
        "label": "Stock Issued During Period Shares Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "crdf_StockIssuedDuringPeriodValueWarrantsExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The equity impact during the period due to the cash exercise of warrants.",
        "label": "Stock Issued During Period Value Warrants Exercised",
        "terseLabel": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercised",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_TaxCreditCarryforwardIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Credit Carryforward, Increase (Decrease)",
        "label": "Tax Credit Carryforward, Increase (Decrease)",
        "negatedTerseLabel": "Reduction to tax credit carryforwards"
       }
      }
     },
     "localname": "TaxCreditCarryforwardIncreaseDecrease",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_TaxYear2021AndPriorMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Year 2021 And Prior",
        "label": "Tax Year 2021 And Prior [Member]",
        "terseLabel": "Tax Year 2021 And Prior"
       }
      }
     },
     "localname": "TaxYear2021AndPriorMember",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "crdf_ValuationAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowance",
        "label": "Valuation Allowance",
        "terseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowance",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "crdf_WarrantsAndRightsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants and Rights [Roll Forward]",
        "terseLabel": "Number of Warrants"
       }
      }
     },
     "localname": "WarrantsAndRightsRollForward",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "crdf_WarrantsWeightedAverageContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants, Weighted Average Contractual Term",
        "label": "Warrants, Weighted Average Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contractual Term"
       }
      }
     },
     "localname": "WarrantsWeightedAverageContractualTerm",
     "nsuri": "http://www.cardiffoncology.com/20221231",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r523",
      "r524",
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DocumentandEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r331",
      "r475",
      "r485",
      "r496",
      "r497",
      "r510",
      "r514",
      "r519",
      "r561",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r331",
      "r475",
      "r485",
      "r496",
      "r497",
      "r510",
      "r514",
      "r519",
      "r561",
      "r609",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r314",
      "r331",
      "r363",
      "r364",
      "r365",
      "r451",
      "r475",
      "r485",
      "r496",
      "r497",
      "r510",
      "r514",
      "r519",
      "r557",
      "r561",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r275",
      "r276",
      "r277",
      "r278",
      "r314",
      "r331",
      "r363",
      "r364",
      "r365",
      "r451",
      "r475",
      "r485",
      "r496",
      "r497",
      "r510",
      "r514",
      "r519",
      "r557",
      "r561",
      "r610",
      "r611",
      "r612",
      "r613",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r332",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r205",
      "r332",
      "r530",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r205",
      "r332",
      "r530",
      "r531",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r11",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r249",
      "r250"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Amortization of premiums on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r68",
      "r160"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less\u2014accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r166",
      "r481",
      "r490",
      "r491"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r18",
      "r21",
      "r109",
      "r444",
      "r486",
      "r487",
      "r535",
      "r536",
      "r537",
      "r544",
      "r545",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r6",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r372",
      "r373",
      "r374",
      "r544",
      "r545",
      "r546",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForErrorCorrectionDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of error correction.",
        "label": "Error Correction, Type [Domain]",
        "terseLabel": "Error Correction, Type [Domain]"
       }
      }
     },
     "localname": "AdjustmentsForErrorCorrectionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r98",
      "r99",
      "r335"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r132",
      "r146",
      "r162",
      "r187",
      "r231",
      "r240",
      "r244",
      "r259",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r405",
      "r407",
      "r422",
      "r518",
      "r559",
      "r560",
      "r607"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r155",
      "r167",
      "r187",
      "r259",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r405",
      "r407",
      "r422",
      "r518",
      "r559",
      "r560",
      "r607"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets measured at fair value on a recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r252",
      "r266"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r57",
      "r251",
      "r266",
      "r477"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "totalLabel": "Fair Market Value",
        "verboseLabel": "Total available for sale investments"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r56",
      "r266"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Current",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r56",
      "r158",
      "r266"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Noncurrent",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CaliforniaFranchiseTaxBoardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government of the state of California.",
        "label": "California Franchise Tax Board [Member]",
        "terseLabel": "California Franchise Tax Board"
       }
      }
     },
     "localname": "CaliforniaFranchiseTaxBoardMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Acquisition of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r157",
      "r499"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Total included in cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r533"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BusinessOverviewandLiquidityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r35",
      "r41",
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents\u2014End of period",
        "periodStartLabel": "Cash and cash equivalents\u2014Beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r35",
      "r131"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r142"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificate of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r187",
      "r209",
      "r210",
      "r213",
      "r215",
      "r219",
      "r220",
      "r259",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r291",
      "r292",
      "r296",
      "r300",
      "r308",
      "r422",
      "r498",
      "r529",
      "r541",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]",
        "terseLabel": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]",
        "terseLabel": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of shares called by warrants (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "periodEndLabel": "Balance of warrants outstanding at the end of the period (in shares)",
        "periodStartLabel": "Balance of warrants outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquityScheduleofWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r15",
      "r137",
      "r150"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r70",
      "r273",
      "r274",
      "r492",
      "r558"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r71",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r544",
      "r545",
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r5",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r5",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, $0.0001 par value, 150,000 shares authorized; 44,677 and 41,964 shares issued and outstanding at December\u00a031, 2022 and December\u00a031, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of deferred tax assets and liabilities from federal and state income taxes"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r22",
      "r173",
      "r175",
      "r180",
      "r478",
      "r482"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r143",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConversionOfStockSharesConverted1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Converted",
        "terseLabel": "Shares converted (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesConverted1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConversionOfStockSharesIssued1": {
     "auth_ref": [
      "r44",
      "r45",
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Shares Issued",
        "terseLabel": "Conversion of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "ConversionOfStockSharesIssued1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "auth_ref": [
      "r291",
      "r292",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option.",
        "label": "Convertible Preferred Stock [Member]",
        "terseLabel": "Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "ConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r3",
      "r4",
      "r78",
      "r81",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Shares issued upon conversion (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r511",
      "r513",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r108",
      "r390",
      "r398",
      "r543"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current provision"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r543",
      "r596",
      "r598"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "auth_ref": [
      "r266",
      "r550"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent": {
     "auth_ref": [
      "r266",
      "r550"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Noncurrent",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r256",
      "r268",
      "r507"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Fair Market Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r256",
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r257"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Realized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Components of Short-term investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r255",
      "r507",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Current [Abstract]",
        "terseLabel": "Maturity less than 1 year:"
       }
      }
     },
     "localname": "DebtSecuritiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Noncurrent [Abstract]",
        "terseLabel": "Maturity 1 to 2 years:"
       }
      }
     },
     "localname": "DebtSecuritiesNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r543",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r39",
      "r108",
      "r391",
      "r397",
      "r398",
      "r543"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred (benefit) expense"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r1",
      "r2",
      "r133",
      "r144",
      "r384"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "crdf_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r543",
      "r597",
      "r598"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "crdf_DeferredTaxAssetsNetBeforeValuationAllowance",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGrossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsGrossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Capitalized research and development"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r594"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Tax loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r386"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Gross [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedTerseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r106",
      "r595"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r39",
      "r229"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r116",
      "r117",
      "r119",
      "r120",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r125",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative Financial Instruments - Warrants"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r168"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "periodEndLabel": "Balance of derivative financial instruments liability at the end of the period",
        "periodStartLabel": "Balance of derivative financial instruments liability at the beginning of the period",
        "verboseLabel": "Derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative financial instruments"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r111",
      "r112",
      "r113",
      "r114",
      "r115",
      "r118",
      "r119",
      "r121",
      "r123",
      "r124",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r111",
      "r112",
      "r114",
      "r115",
      "r122",
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments\u2014Warrants"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r337",
      "r368",
      "r369",
      "r371",
      "r376",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsPreferredStock": {
     "auth_ref": [
      "r85",
      "r141"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK).",
        "label": "Dividends, Preferred Stock",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock",
        "terseLabel": "Accrued dividend during the period"
       }
      }
     },
     "localname": "DividendsPreferredStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r181",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r206",
      "r209",
      "r213",
      "r214",
      "r215",
      "r217",
      "r412",
      "r413",
      "r479",
      "r483",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per common share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r181",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r209",
      "r213",
      "r214",
      "r215",
      "r217",
      "r412",
      "r413",
      "r479",
      "r483",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per common share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r49",
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r188",
      "r380",
      "r399"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Tax computed at the federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r591",
      "r599"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r591",
      "r599"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r590",
      "r591"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Percent",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r591",
      "r599"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State tax, net of federal tax benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r591",
      "r599"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "Research and development credits"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r589"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation cost for non-vested options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options to purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r77",
      "r153",
      "r177",
      "r178",
      "r179",
      "r191",
      "r192",
      "r193",
      "r195",
      "r202",
      "r204",
      "r218",
      "r260",
      "r310",
      "r372",
      "r373",
      "r374",
      "r393",
      "r394",
      "r411",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r444",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of error correction.",
        "label": "Error Correction, Type [Axis]",
        "terseLabel": "Error Correction, Type [Axis]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementByRestatementPeriodAndAmountAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Error Corrections and Prior Period Adjustments Restatement [Line Items]",
        "terseLabel": "Error Corrections and Prior Period Adjustments Restatement [Line Items]"
       }
      }
     },
     "localname": "ErrorCorrectionsAndPriorPeriodAdjustmentsRestatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r414",
      "r415",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used to Determine the Fair Value of Warrants"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r288",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r415",
      "r448",
      "r449",
      "r450",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r414",
      "r415",
      "r417",
      "r418",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r288",
      "r316",
      "r321",
      "r415",
      "r448",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Quoted\u00a0Prices in\u00a0Active Markets\u00a0for Identical\u00a0Assets and\u00a0Liabilities (Level\u00a01)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r288",
      "r316",
      "r321",
      "r415",
      "r449",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Significant Other Observable Inputs (Level\u00a02)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r288",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r415",
      "r450",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Significant Unobservable Inputs (Level\u00a03)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsQuantitativeInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Abstract]",
        "terseLabel": "Range of assumptions used to determine the fair value of warrants"
       }
      }
     },
     "localname": "FairValueInputsQuantitativeInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r126",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). Where the quoted price in an active market for the identical liability is not available, the Level 1 input is the quoted price of an identical liability when traded as an asset.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Company\u2019s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r288",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r448",
      "r449",
      "r450",
      "r508",
      "r509",
      "r511",
      "r512",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring basis"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r129",
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r267",
      "r269",
      "r270",
      "r290",
      "r306",
      "r409",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r507",
      "r552",
      "r553",
      "r554",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r562",
      "r617"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Non U.S. government"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Loss on disposal of assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment Losses on Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r271",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r188",
      "r381",
      "r382",
      "r389",
      "r395",
      "r400",
      "r402",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r592"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.",
        "label": "Income Tax Examination, Penalties and Interest Expense",
        "terseLabel": "Interest and/or penalties incurred"
       }
      }
     },
     "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r189",
      "r203",
      "r204",
      "r230",
      "r379",
      "r396",
      "r401",
      "r484"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Total income tax provision",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Continuing Operations, by Jurisdiction [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsByJurisdictionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r176",
      "r377",
      "r378",
      "r382",
      "r383",
      "r388",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "terseLabel": "Valuation allowance increase (decrease)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r380"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "terseLabel": "Tax computed at the federal statutory rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "terseLabel": "State tax, net of federal tax benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "auth_ref": [
      "r591"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "negatedTerseLabel": "Research and development credits"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesSignificantComponentsofCompanysTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r36",
      "r43"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable and accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable and unbilled receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r539",
      "r604"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidExpense": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.",
        "label": "Increase (Decrease) in Prepaid Expense",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r25",
      "r228"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r440",
      "r517"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Net operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Expense and Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Summary of Future Minimum Lease Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r12",
      "r187",
      "r259",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r406",
      "r407",
      "r408",
      "r422",
      "r505",
      "r559",
      "r607",
      "r608"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r10",
      "r134",
      "r148",
      "r518",
      "r542",
      "r555",
      "r603"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r14",
      "r156",
      "r187",
      "r259",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r406",
      "r407",
      "r408",
      "r422",
      "r518",
      "r559",
      "r607",
      "r608"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market fund"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r184"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]",
        "terseLabel": "Investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r35",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]",
        "terseLabel": "Operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r23",
      "r40",
      "r138",
      "r151",
      "r154",
      "r172",
      "r174",
      "r179",
      "r187",
      "r194",
      "r196",
      "r197",
      "r199",
      "r200",
      "r203",
      "r204",
      "r211",
      "r231",
      "r239",
      "r243",
      "r245",
      "r259",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r413",
      "r422",
      "r506",
      "r559"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r196",
      "r197",
      "r199",
      "r200",
      "r206",
      "r207",
      "r212",
      "r215",
      "r231",
      "r239",
      "r243",
      "r245",
      "r506"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net loss attributable\u00a0to\u00a0common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncement Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r549"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r231",
      "r239",
      "r243",
      "r245",
      "r506"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r434",
      "r517"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesFutureMinimumLeasePaymentsDetails",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities",
        "verboseLabel": "Current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r430"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion",
        "verboseLabel": "Non-current operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r431",
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid included in operating cash flows"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r429"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r439",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r438",
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term\u2013operating leases"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesOfLessorDisclosureTextBlock": {
     "auth_ref": [
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for lessor's operating leases.",
        "label": "Lessor, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "OperatingLeasesOfLessorDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "NOLs"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating loss carryforwards (NOLs)"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business Overview and Liquidity"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BusinessOverviewandLiquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationAccruedExpensesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r161"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r169",
      "r170",
      "r171"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized loss on securities available-for-sale"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingGainsLosses": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Gains (Losses)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Payments of stock issuance costs"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementofShareholdersEquityParenthetical",
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r30",
      "r55",
      "r182"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Capital expenditures"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r314",
      "r315",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/EmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share conversion price of preferred stock.",
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockConvertibleConversionPrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Cumulative dividend rate (as a percent)"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "crdf_ComprehensiveIncomeLossAvailabletoCommonStockholdersBasic",
       "weight": -1.0
      },
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "negatedLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock",
        "negatedTerseLabel": "Preferred stock dividend payable on Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r185",
      "r296"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Series A Convertible Preferred Stock, liquidation preference",
        "totalLabel": "Liquidation preference - Series A Convertible Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r4",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheetsParenthetical",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r4",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, $0.001 par value, 20,000 shares authorized; Series A Convertible Preferred Stock liquidation preference $1,044 and $1,020 at December\u00a031, 2022 and December\u00a031, 2021, respectively; (Note 5)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r533"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromInsuranceSettlementInvestingActivities": {
     "auth_ref": [
      "r29",
      "r34"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow for proceeds from settlement of insurance claim, classified as investing activities. Excludes insurance settlement classified as operating activities.",
        "label": "Proceeds from Insurance Settlement, Investing Activities",
        "terseLabel": "Insurance proceeds from casualty loss"
       }
      }
     },
     "localname": "ProceedsFromInsuranceSettlementInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from sale of common stock, preferred stock and warrants, net of expenses of $0 and $813 respectively"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r55",
      "r182",
      "r183"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r28",
      "r55",
      "r182"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "terseLabel": "Sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r96"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Proceeds from Warrant Exercises",
        "terseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r67",
      "r159"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r69",
      "r149",
      "r480",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r69",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Components of Property and Equipment",
        "verboseLabel": "Useful Life of Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r100",
      "r152",
      "r615"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r100"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]",
        "terseLabel": "R&amp;D credits"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r157"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r7",
      "r85",
      "r147",
      "r489",
      "r491",
      "r518"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r153",
      "r191",
      "r192",
      "r193",
      "r195",
      "r202",
      "r204",
      "r260",
      "r372",
      "r373",
      "r374",
      "r393",
      "r394",
      "r411",
      "r486",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r226",
      "r227",
      "r238",
      "r241",
      "r242",
      "r246",
      "r247",
      "r248",
      "r312",
      "r313",
      "r476"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Royalty revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuePerformanceObligationDescriptionOfPaymentTerms": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of payment terms in contract with customer. Includes, but is not limited to, timing of payment, existence of financing component, variability of consideration and constraint on variable consideration.",
        "label": "Revenue, Performance Obligation, Description of Payment Terms",
        "terseLabel": "Payment terms"
       }
      }
     },
     "localname": "RevenuePerformanceObligationDescriptionOfPaymentTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r437",
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesSupplementalCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySecuritiesPurchaseAgreementsDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Components of Accrued Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from the Calculation of Basic and Diluted Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r60",
      "r61",
      "r62",
      "r63",
      "r64",
      "r65",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-Sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for Income Taxes Based on Losses from Continuing Operations"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Company\u2019s Deferred Tax Assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Significant Components of the Company\u2019s Taxes and the Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r94",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Stock-based compensation recognized"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable": {
     "auth_ref": [
      "r196",
      "r197",
      "r198",
      "r201",
      "r202",
      "r203",
      "r204",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of prior period adjustments to correct an error in previously issued financial statements. The disclosure may include, but is not limited to: (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustment (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. This table can be used to disclose the amounts as previously reported and the effect of the correction or other adjustment on per line item or per share amount basis. This table uses as its line items financial statement line items that are affected by prior period adjustments.",
        "label": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]",
        "terseLabel": "Schedule of Error Corrections and Prior Period Adjustment Restatement [Table]"
       }
      }
     },
     "localname": "ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentRestatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesLongLivedAssetsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationPropertyandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r334",
      "r336",
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r89",
      "r90",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Estimated Fair Value of Stock Options - Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r73",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r82",
      "r83",
      "r84",
      "r85",
      "r163",
      "r164",
      "r165",
      "r219",
      "r291",
      "r292",
      "r294",
      "r296",
      "r300",
      "r306",
      "r308",
      "r510",
      "r529",
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "auth_ref": [
      "r3",
      "r4",
      "r5",
      "r74",
      "r75",
      "r76",
      "r78",
      "r79",
      "r80",
      "r82",
      "r83",
      "r84",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "terseLabel": "Schedule of Preferred Stock"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r86",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Summary of Warrant Activity and Changes in Warrants Outstanding"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r232",
      "r233",
      "r234",
      "r235",
      "r236",
      "r237",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Reporting"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r24"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationStockBasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.",
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Incremental stock compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (range)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility (weighted-average)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for issuance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Intrinsic value, exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Intrinsic value, outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r342",
      "r343"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding (in dollars per share)",
        "periodStartLabel": "Outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r358"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Intrinsic value, vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r338",
      "r339",
      "r340",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r341",
      "r360",
      "r361",
      "r362",
      "r363",
      "r366",
      "r375",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationAssumptionsUsingBlackScholesforEstimatedFairValueofStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Intrinsic value, vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contract term, outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted average remaining contractual term, vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of shares vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r135",
      "r136",
      "r145",
      "r532"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r163",
      "r164",
      "r165",
      "r187",
      "r209",
      "r210",
      "r213",
      "r215",
      "r219",
      "r220",
      "r259",
      "r279",
      "r281",
      "r282",
      "r283",
      "r286",
      "r287",
      "r291",
      "r292",
      "r296",
      "r300",
      "r308",
      "r422",
      "r498",
      "r529",
      "r541",
      "r548"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails",
      "http://www.cardiffoncology.com/role/StockholdersEquitySummaryofPreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r17",
      "r77",
      "r153",
      "r177",
      "r178",
      "r179",
      "r191",
      "r192",
      "r193",
      "r195",
      "r202",
      "r204",
      "r218",
      "r260",
      "r310",
      "r372",
      "r373",
      "r374",
      "r393",
      "r394",
      "r411",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r444",
      "r486",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity",
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesAConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r191",
      "r192",
      "r193",
      "r218",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofCashFlowsParenthetical",
      "http://www.cardiffoncology.com/role/StatementsofOperations",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r16",
      "r77",
      "r78",
      "r85",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Convertible Preferred Stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r4",
      "r5",
      "r77",
      "r85",
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockBasedCompensationSummaryofStockOptionsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r17",
      "r77",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Issuance of common stock upon conversion of Convertible Preferred Stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r5",
      "r8",
      "r9",
      "r54",
      "r518",
      "r542",
      "r555",
      "r603"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets",
      "http://www.cardiffoncology.com/role/StatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r87",
      "r186",
      "r292",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r304",
      "r305",
      "r307",
      "r310",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r435",
      "r517"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedTerseLabel": "Operating sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/LeasesLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StockholdersEquitySeriesEConvertiblePreferredStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Supplementary Balance Sheet Information"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplementary disclosure of cash flow activity:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credits"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]",
        "terseLabel": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]",
        "terseLabel": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxYear2021Member": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax year 2021.",
        "label": "Tax Year 2021 [Member]",
        "terseLabel": "Tax Year 2021"
       }
      }
     },
     "localname": "TaxYear2021Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxesPayableCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Taxes Payable, Current [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "TaxesPayableCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r253",
      "r254",
      "r290",
      "r306",
      "r409",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r552",
      "r553",
      "r554",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r503",
      "r511",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. government agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r503",
      "r511",
      "r513",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/FairValueMeasurementsDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationInvestmentsAvailableforsaleinaContinuousLossPositionDetails",
      "http://www.cardiffoncology.com/role/SupplementaryBalanceSheetInformationShorttermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.cardiffoncology.com/role/StatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.cardiffoncology.com/role/StatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "negatedLabel": "Change in fair value of derivative financial instruments\u2014warrants",
        "negatedTerseLabel": "Change in fair value of derivative financial instruments\u2014warrants during the year recognized as a loss in the statement of operations",
        "terseLabel": "Gain from changes in fair value of derivative financial instruments\u2014warrants"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/StatementsofCashFlows",
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r51",
      "r52",
      "r53",
      "r221",
      "r222",
      "r224",
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r387"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Reduction to the valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]",
        "terseLabel": "Warrants to purchase Common Stock"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesAntidilutiveShareEquivalentsDetails",
      "http://www.cardiffoncology.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesWarrantsDetails",
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "Warrants and Rights Outstanding, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Warrants and Rights Outstanding, Term",
        "terseLabel": "Expected warrant term"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/DerivativeFinancialInstrumentsWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r208",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r206",
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.cardiffoncology.com/role/StatementsofOperations"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3151-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7,9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=SL94080549-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888252",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r524": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r525": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r526": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r527": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r528": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "https://asc.fasb.org/topic&trid=2122208",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126970579&loc=d3e23163-113944",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r621": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r622": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r623": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r624": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>79
<FILENAME>0001628280-23-006037-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-006037-xbrl.zip
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M^=\#IWSK0O$J"SK:TEQUH2&DPL+N[[*/X^V]G5Q^^KO2[M;VY?\ 4$L#!!0
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MX,/%ND.$LC6$4.>Z!K9*FAL^6'P90CW/)9T/1.9&=)V&I:Y06:M25#><(BD
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MJ;4X9 GCSIFI_EPIT6*<TF3GO IH2@IT3;9HSE*<O6H6$ :M()S&Y<""_DT
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M"4FZ)+RJU593[H(VP@6*:0+R>U@+$FXX[,O@/\XBY-^%:YRM"&R?:4J+0KH
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MR,-+#IWW#MXFU\_J;EO?LE_\ U!+ P04    "  C@&)6P"15V/BZ @ A^AL
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MY>V\NE8\LL GSB(848.YIP%+ANL):X&5@$%S!JC*/)T%-TNRG HQH5IS9E!
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M&(;B,=_@T&9.9IP9@B0/0)V)UF#:*/7H9\+0[ LP/WM5^H[NPWM7A_EQ AY
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M[6AW^L,$L%2;CSI[)T2. :U526-LHCN4Q-2UVIG5G9CT!<8CMO_?9)6@:"9
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M&O3T:?R[""^:O+WFJQ&]Z0RO("Y":)S,^J+F5[H#;,> P@/*E'?CH,39,(9
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M\HIW>HD*C?,![P_:IQ'S!&EUBZ\B/<OM/0(/RRGTM*SZ@N)>6?$";V]0]:^
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M>?-I9[.]L;-S+\M,Q \5 M%:64Q)5I^;4)B>A%C3.G$I,3G06WO8@VX<#)N
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MVL)*&,/B5I9TK"R.UVR^K5X:G,D,>$QW7QR=^9NOW(.W5!Q5640:CTND?P_
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M90+>B =\'9"SU!CFRQL/+:>!/.^=3V_VG:/"B;$6.!^JM)Y3<H!SE-9N^H1
M/^:'BH([D&#D11'KG<PG<=VGX"ND0E_M%*00BPV%,H=Q4E>>(/(D?&K;YBHD
M@QUAQ&U.U6<*!M/T[#T/WX5<W]!W$N7E('<FG9^&%0I%>Y^NH]085K<H0ZL"
MZ E96'E*I7EF[X_:O&4ZG(G+TR@1]U E5*,_9)6>'3'Y(]&$%81B'^?%4M.>
M+)80O-BF7\]S,4:1Q^H'.;.FE7$+TD3C>]/H2S-,?O*; \O9SNLR=.EIZQ3
M<H*7@](L<J%"IN.5&\WF"P>$!T'TA.:I<=[/TX$Y?_/I4J\92;Y;MC@'$_>Y
MN;^<7;C ]NFGL9E9%K-:_*0]A\Q7 F(<[X$8>R#&_0%BL$I@\L !>X>^SKKM
MQ/GOA_1H)J>R  HOY$#Y)B*FY\2U)4RE^03:SZ<E+;JW("2U,830<!/M(V-%
MQ9WM2 @8OU1: [EAA9E?,8S#^FK!IY !&UVX+=HPG)M*>&49B3#+FLW"5^F.
M(8^/AD_H"PY!$P=]:M)6T[P96J^KO.PM%,J[T2_(5"@6.O3]_&,%ST%H \75
MMC,W.?F6*<LS D2\>1XYW&"Q<4]@^7W:1(<D2^Z=_11@5!NXZS)GR*U8&I5@
MR7\!_ ^%H(FORQ(?]K!-=781G6FC7+$QD[!RFBJEIC;9^-[%V9 /O2 R0D4G
M7-)XSVE=EO6UA*SQ9:A5E9Q#?@@>'S(H^\&4DC=@L1L8RM)%M)"A9:(@H =E
M?%8\WR0J>?SYXO*A^F/Q%-EH\73)J$4U&S.GLM!5R+^ISZ23#**'?_C&R-;Z
MMT9RZ/(T5E  5_CJ#E$(?@]W<%65.;/H1-MT\><WE]30U2IZ1%$YVR,0^-LT
M5(5IQOD<<R1IT" AO/=U _.2.-DQ(D9?PN2/N"W'+<*;J/''O:$'&;,>VL D
MN!7SOJJ<%_\= V3"LTZ<,GRPH<.YKWQ#AC2#T!KA(>$(^VU!#D%@4_;IVQ5E
M74.@RA \8DH++KZ?RL-_/4S.M_X-<W+PT*UT[W+ ,+8M["$08%3UVM=*K*P9
M<^G+C1'>@UJ^J'*F[#&258':-'SJ1LZIHD^ KSE21L1@&STB=7&B6P>WQX0I
M*7I1K&QQ!EN/4D][-/D!9QHYR5,T/I(QV )_5HL\ZGR^^<%2$\6)JL)V#NQF
M'#:I^9GP6N%I?,>T?4W>L.N:.JV+3^JT<">J5'\5$<;]^79KF$O=O6:G%G)5
M43*[OUORT-L%:B3\#(-UR[ZFQ8U($>45C0%A/T/44?B=N>:DSK7821<WUX8N
M#'Z8T+87[!A3[4PH/QZLJMG4"]G*G1H09;>&8V S6Q5M"ZEO/PP._N&X*49]
M;Y62^?HA4V.0WB9?J?0C5&Y+JX63N$W%Q'T;-K^%R6.Y.U)D5<& P5"*C7?S
M%FG K57EMJ7@:N%JFI"%[&.NIGP@]-%C6$PC; XDSL/Y-8\05( HMW6%&<>2
MCR%B>&B0?L^7#V6P9Y,FNZY0C>M[&()Y@5OAS:T>OL"0DC(4H';'9<%1E>$0
M9C^79:#H(AEZ:'UD;VGCWX4U>V?A$@]3<Y"49=8?0<Y/8J>4D96B&SA;:7K*
M?#(O.IT6RW"8O")7 ,('/+>>\W'I#III^95)W7%W5E 5_8[*CDBB"!D_V 87
M9+W?#SHEI#/HJ0ZZ6CHBH2Q#_Z8[#-/I 9WS<-/4MR0?D,FK40 P##_D3+O'
MT$*/S!XP/!A\G?A/!J8UUU$@>?=0;51H-Q'-Q1M,:>YR[9T-E;V(=)S11!N0
M)E&M#!WTI7)_A5 ]N\!\2 Z9E;RD$\"US$GP70/B1U;A,I&E,MQN<DTJ\)A"
M>VA*)$"*=>I#GRY!@X*';VR>];C[A:F,DD\XI')6B7)!^)FE'B6@=$R-$%Z7
M8B&?@9=WWON>8 @XJ>6#OY"'D"=K>_.UVL))2"90W<QWHCB'8T9M.-&::82#
MUUFU<MC;;)'S@DS0)L3)'L6^5<;=C9^7:,34&>Q_KB6ZFBV$6?H$PO.B,X^\
MLK?^.9G=L/3$>3\T5<FSQBC&/8AL](?M7[2(#80O0 5R+T<1TS\]3*5PKN 2
ML,J$;KU0K/5Q'..T:=8Y/M1&M=C@I&P>&2<7(:SBC(7Q,LGF!%/CR\Q,ZN-D
MC5$-3\-?J-K?RU*ZP$.J_$HA[CO3;G)0%5(C:4=5.*8K9UEFXTA/U544-LI0
M,"8C8X^475_31H?K",&S\44)MJ.A>\J0ZVZM]5R+> X%[:@_>YF-/V8SWU#I
M/6-SIB4U%#@TP/KDX@C\R,DO[@X(V,PW&RPS>H;YZ5U8[L3"4!M)L"=R0'$R
M!NYP1L%]VNMUPRWE,<SF\MS<3CK ;UVOA=Y+X*J"AEFY#9UHTK$0#D2]M)0"
M0J)1M(M\O-V:[3$XOL%TH=/@9 3=M\JX'M\,K#>Q0##]0PK)R]>I)OZ JQ2M
M39.?>JV8^%1?)NQ\NBT/9YQG"4#II7#B-% 9"&4H_4_%AWX_*6E WSP+-&W;
MQ](.Q3BIP*<]#5X;XIL; AHRV<74DJFO*B2I9A5-G(IBI(">CYB^OKJFWA>^
M=R]\G^P+W_O"]^]:^/[,% ,UX;P2<JJ+NFE6R\[T'H%\Y6$Z>G# ;G_Y-,PZ
MOLZM_:4$&/% PRXV2Q$=C0S=^Q:3%4P)8;/R:D:>"?65B($W<7= H)+AH9\\
M"QCW'Q;5M%SEG!L!6A1PK;KY*-?,X(Y,F:5AG#E'B!)VG$!WKEX^8WJ&9;:F
M;$+>R+\H*-"\K+2$K;6]T1DX8LO!S_ N<YUWK%QFLT $IW=/[2^=]9N"BQ]P
M6%#=E#*AE?G[F#]<?F5;$,B?#-ROMZU,H+_\DC5Z8!G#5X8>B7"=R:LF6S'6
M]'P$I_NG[-IS4=W%N7N@ZH3Y\$!ZJ^5O(B.9KUN#,HD9HM>(%EP\11"5IEB@
M=\]YM;[VW<>94-Z.*B!+CYU5_+9GBQCH=6#U)<=HLR$IBKMPH+@O+U03$.)%
M99JMO%^]/_08.IN<F&VH_L@I3P0,TA:B_^SF#57:QBYRJ!>TB.ASPU A5# "
MO\W4RW5&<AU0//.P%4,T=HD?2VSJ(5:G8'Q[16HB:VC:Z<(WJ%I,?>N?5?J_
M;GI]*<5@$5,>0M9C)=VZDYY-V% Z"OQ'N:FUF:>K__1 3Q>,M;9-GV.VTU^+
M\<>1B_=)R6']> ^\34[)4(D10&G-?<D=.ACC83XXI%<HA/5<F],5THUD+26]
ML&;:)F>TQH6/S@ARS8BJ"EF<Q:J2,=A!ROM"#A,IOQ[+SP3;&6?MG#][X*S6
M)&7#[Z0@YSM=HY]4&SU)0[B'4VKMK#)^!VQTJEBCY:H9SS.N)92Y_$#X!WT)
M%G0*_./OY/R-G#[%D GV#.PI<\*WH%*_D($Z[V Q6C5M1FUXQ&U?<^&;.J(:
M=P2X:9T'6@.YSS\57/D+:4K9<V3CZ5 Z(9]'BA8DO)Q,(R8-:;6UNR ]MYY,
MU>L2*F\XA2IPAC#YK^?UX/* 68B@^>OTOI\1US!^L$I#!YG<J!DIU8HK\YPR
M7^=F$R(;H;-@D*Y":QT1(+O D;]/N6[6?NY#A\FY6R/23?@=.ZZ9:4SBER&"
MF4_PLPQ-2\A=  OA'GM4<[*BD[$IZK]J-UYP8\G5-7Q77%[KW2&Z+)Z+:\65
M6[;ZNI1TD*>!T60^4S[8?:7UYQDJ_I 8@$!8N%:/J05$:LG'\OB.&_?4R(!3
M8F^MDPV8^T%&=53A=7B,@'^9AYH0MZIWZ@(:H#ZS8B&Y4*(^0QZ/^/:9 VU-
MILI6IB@)J>S#=(T+O@9%6*RZ&>O01G3*GE--"&ZH>I0C8SMFJ+1SFZYH5I,3
MP'_F53#)_&"_L9^[U3<?7LE_K(JDRQ9W.VU. 2(A>OUB0REP;;4A@$5)!]<H
MUS]RR9[D!GQY[NX=\ICD9L&!6Y4(%$FBA("!PT]I U/!"T$EW2H\PR+[2/>7
MB5[]IUAD\)7D 3BESN%JHR2N"H]A'D3^W-##X<]7-0S4)*?.<P_DRBG<<OYU
MJ147B:TIO;W]37KUCDQN9)BH.F1V@UUMS0@$4K59<N6<Q8CZYF8G"? "HJG
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M(>DX,>"7_H*7?,$V>;]",;#B"6@:H>]JV17SJZ9]T>]L1E60ALV3.4MMIS-
MOE0T*1F,KB-#I1 F+XQ W\_XW59TT3K1Q;PH)VYM?*2Y&3VQ\Y\\YC'I\MCY
M)S#RX,6>,.!5)IE4;&$U^1(-A7@)$JQ.H29R([S47XA5[[U:<.\[_>6]=YRL
M+Z(#0CGGYOUQ"<RPW5-92X:P4%H*'PZ5^<=HEZWB*I!SRV5.*7:/&-GK)3(#
M7</_6M839[?H'VS/7,Q5+P4#S+Y=!S<+.S^OVR6RQ&UJ4<R8H]H0.5M6*:^T
M#-%PZI'XWBGYA#1W'T8 AZA88/\)ND\'28 V#]4W9S1+9D8I.E<CP0%R&\O;
M/O7SQ E$/ (Q@NH"+DD$5OVN./BHZ5&ZJ$W(\(<]3D <<&TQ4?8+C4B9L\IV
M7VK_IJ\)#J5R.1W#,082-"%E1C#ZS1!^,] O<##_Q;9<7'W?+A$G%4,*#JNN
MZM>"PS6)EV[P'_<NI0UV7ALR5V?6K.WE9JL"0725AQ$I3B7E5UE\5WQ,;[]8
ME3/261)<;BER0&TV*IZB4V?%M),GSZLVX(*T=\B41SUU3ZSL!K.N!K&T,6DO
MU>AB<!O,.$L)/<7YY^@39W$@@&1BZI9)4^((K,?2X(O-13->+;AKL]]9V0T&
MJ?9QJ$-,PMZJ[D*1@EZ$+:9YDW%-4Z^I*+!"I@5@^K)N/<?@TL]%#R]XH)8H
MK*"^8Q*-&J&A.G[4.;B.L-B$$B7M)8U;42$4OC=?F"AF_5#Z)C] %I%E2;(7
ME/$-X^P-&8:11^ZW>*B*XX<X@8Z=GW1J&.QT4_R5D0>6VMA"%(3L)%1*2.RI
M9S/$Y $"(54CVY,\1WT"W8_L?EG^)" Q8)'P/(QB:<?U4JAP3+4LMFP>"X;9
M#QY-S/UI>M<F6Q83;;M40B >I^VN?.5\%<7M6CW0H&-SD2:4:BF$]BDIL;*Z
M-B4T$O,H:'H"[)_Y1*MZQLT]3%YM3.NTKS6J)[Y8@FM0XXH0>^?JYGA8!F6I
MG&>DB0N%U@Q6C[8EE-3S!HJG%!??X&*BE#57R;5FQO/LKQ03R5JNZTH_THB6
MQZ*BQ'X\U#++CW ^.&/M3D0X#!;^)+;5^3),"IZWV\85W@;:+%I*&4G6GT95
MA/'!8,0)",YE[K'X#2J;*^8W'M%!B"KFHHDE;0F"&L9=3<1YC+!HYF$C5RT:
MXW(C!G03<V1RA::/&SFO-"0'"1863V4TWY/<G9]&Z&S5K&YFTH-M$('.&W+A
M2BT.AHO9P$ #]A28GNB-IBO*6FXB[8P'K5$D/5U [VDCY(KZLN7)G/.RZI2)
M .N#IZ3WF>?*,L([+A/0<Q[J"'<D6"^3K_90"S&*:-DE)55,XXGHVIG!9 8S
M<DF(^U6K([*U_E<4OK:4)::RLO9.3\E%[_<8!F4L9:P5E'$9("9<%ULI1#.(
M9II$7@ WS JQ?6!JN5&<O%^J-4;T0N@4>T /_8GT?JDG;<;?P\,\--H4@\5_
M1Q9MD/#ZFY[%.3R0F\&>'GP0"+&U_79$:*A@[TKT)G.*O __5#8)\7=EF%V@
MK>A9NW;==EIG$6D.Z'HYUG::WU:Y]J4"(Y_ Z82A$AOO.?":/:M.-&HT!$MP
M'IMCQ$N,,96HAFH7I H(5AIY&*T.&KJ4T1F7(1@@0 $\ZPF9B0M\ X5 36)=
M7IY?&"2!4Z-.C^NHB#<819Z<'!T?^<*?0J 6SB&B_G7 5$-84.HNT2NY&"%R
M/]J F7;!P<AINEC+\\;V$@G).>$:AGE,Z/'QCQF7ZSL96JQ, @-!M'0T=*%8
MJFX1C\'!5FC[\Y^^LI^TA/&H9@=E/N6OO;#7.3C^_LY.+XG LQ=WAP1]$:W-
M\=/#,ZP%^NXH:9O"VDUR:KTG=%B>,\_#6O&ADAL+IU8'AZ% J#')R'F"D[S7
MM40I[;C3!50$U+)!PY7<A^" J1R"BT-+S9DR#8BT%3I@*6GG['+[>QN W8 ?
M\V)WH=G+VF\B:SXW-PA?_;TK-Z*3]V)QUV*!R508_0YW88KAE&C@Y4D/9"8.
MG*QL=,CMM^WNMPU0$_&(#BZHP.^.X=M5ARGKK7/#VYS<&YV32/X"Q6W@,O<3
MOH17G[GHO/O*#:W([4CX:T<QF4%1C=PEM<.>$<QJ8YL2U=*G7FS/RWRAV.Q1
M*+NC4)[N42A[%,I-*)2]#OY,'1P1BS'<FA4QJ3Z?KWM=5?655 XY%N9/M?''
M_I@MEB\"0L3C,>!X4^0GE[D*E"&<$N<68 \L7M23G"FRG/4VZ),H;PCV9M+2
M:2 BYE* +WCW(@C_C;WMOVNYH[YS:8E3GG[?7HPL+^9Y-DX5<-=9G!$'/QQZ
MY4)KE9>)E]CF=_0]Q1U10_S)Z>'Q'TA\CD__X,$>:#&:Y?'5G3<QEM8FC//1
M<)1@LT#(.A=2 %8!7"P%AK&+1;D$Y6[)67YZ$!>6KH2C5$Z C+*AS!(,CC[1
MN3R1)1!T[X$GTG30^1L_T'TOQG<NQN3"NDAR7D\X4S5:>Y@>"V]]S;FT&*:W
MF^A2NLNYK.,5HP2H&4QR%9LID:@>-$CT*O DSGK,LQ+]7D4U7;7\@_.R2_[=
M N![(C4F<'>.=.->VNY:VFC>E[9O1O*DZ6\O3*)Y0B\9-081M:-(#@V0K5I/
MA>"YQZ[G-=/N5 T@+9QFUNLR?014'0U!GF55\4_.MW_]R&@O'Y\M'^Y!5#Z<
M+S4K9/.=%T1]8,9;*R:A,W6T'FY-S)1BM&7X+:)O A[Y2Y!(\4#N> YR$*>,
MQY3Q\[*Z!+TI\XC89P3?L(OC!9$<2:3,;@=^)NMXGHI[,F?*@RWW24"BQEES
M94:*/@##QAZB3H'_O$.TUX!W+>%L;WTX<)DU7?(R2.$L6S*'+=PMT^LJ)GF
M9IB*^$&PSYPKMJP+]VCU]*!U!M)?#O6LJ;O[K.ZX]8C\Q+:':B)O410L.IY(
MODOM@QT7&<EWF+!8-/'#,SDS-Q.:$33:.CY8R:]7G8P,#S<&:[QH^QB_+TM&
MW09[:;Y/^IK8!;1FY06')WVH" :O\7+EHO:QMD HI]5N6W/V],XP&;?LTO&S
MHQ>;_WUO9EULJR]367^==XK9"L,B_."&J/C/[*94S0YTH@JZ;.U8F$RHSNWM
M#I.7?(0O70Q(>>CD0[-:+/^CC3!7 .XBL"UFU"ARK2W[!:'$?*LJ&UWNX22X
MP237KZ"AOP3_*D.9KQ3F7=9UFU?#W;UL7@-27)[XHJX$RPF^+/>O&<:ZR80V
M'E^'82.*[5!^BVMAY5^"L89[UG-9.?<C\?ICF#NU@3==;Y5^F:-U-+H7(9 S
M&G0GES*W9.ZO#]FGY&(EX*[_J4=MZ(L^_L['P1\N_N?<-/<(Z"$+$B+7IP11
MF,GV/TZ% HU_G.)RS_F.7?;I@&>54TEXHC/AU#?QC5$+1K38E46-6_>A[T:#
MZ3WBFQ=:,.KOX:/KU;^0DMB5S)Q$8SH)M2&WPIU&TTRV52P-<D_$0);H,.P"
M (5^8"'+7K3K=;S;M,6Y(E:C_?VFP5!O#(YS H[@LC5SC?';X6HS;SI,:5 W
M.L%>M0WE2-V.\<0"!C.56G@*O#%\*3YAI)IH=LI-8%!WQFELZJJB7O@M&">+
M\7;2V[IC7TM!JYO[ 94BVPIW+VII56JMDC46AX_T!S/9D48I(GW+5#V^747I
M*5IF'*WJ&WH:N32KM\9DGP#!"G^(!T0;#)<.&\$I8@.1.:]NZD0$1\=/S^[Q
MN&+WP(D%>@QF /+M-;95+MI^ AD7'W/NS:)'T%/$/2B+)5&#5!Y7=2-]HU8H
M^5X1[-(.=C'8.47BA]$L6"VS1FC;'!I1J_IC[J3?/;T9>F3'M5""W&EG!%LT
M@8+BHZ(B!P3.,3BR";*NA50*I3)6JRBTUI4@<KCI)XP-$2Y))P?FJXL\ US7
M'8SH^@K0%YGLOXO"4N/'IHGIS2+JQ0"+Q5+8+-C.=P0#Z<^/>9@X^]?!$$CP
M+H>&@N@0 2-S/2.[(/.389NQ\]8D4*OIEA,<.2LZ8F48S]??2T109)VC'D6F
MK=6(QG<\2D=>!>DO2,R\6YQN$$_[D7XJ-6,,+-,62R7" BS3=&FQ;%G$D"(H
MQ86L>1 +66O!,'8>"Z_C-MT#-=I+,EJ5'PV/[F'R$[Q.(B 4%XW?5Y:-'MW7
MQ1;L\I.KL4$ [D'HT9N/Q9(TBQU!X*IV4HNRM7CSP&H=@E'!]K);W&/#P]@B
M!NP'^)R=H!//.0@]SI*2-E+)[$>C8B)RX:<QD4\LYM:I&!"X##.+,],3Z2#I
M=2<B-Y[_J .#I?A4- /5PFU=CY0T$X)?'5I%D%\U*<(S&*7K_5,12R)UX?'4
M^[K:/! 6WU]1/\'59P/\O\;>/E3=:"1V!AR0-)(- +P-(M0"PCE8R\G3HQ*U
M^E9<]R/-$G7)F8C+HL=9QY)<DV2*@V%AZ5/G3)%F&&BYX[Y3OM<M>%G;T4'=
M#6('ATOK0<HYA'.F&RV(:%1T]YD4'J*/@(7Q6MH:Q;V)-J8K.G%IB/03I:M<
MN_5B]3X-9=&XK*7IN[6[8T,G,O_DQ+\9,0Q=9II>.U\LG*N Q-\\V9R[BX[P
M9VA-4U)ASB0:(N[$"+3?KZ6JS1,UC978 \"^ @#L; \ VP/ A@!@=R./E"$Y
ML*=\^Z 3=A.5#"$XBLZ9':*Z8:T$3X%X&SIF#+%>PV<K*YW,3A%O,?8QD"I8
MJI2X;U?IMM;"K^%3G-_<[4H=F3F8%"A5B-XEXH2+AMCZ#@Z_N$7EE_;O+NAK
M)T6@H^,)%$C# 5>D,ZMH *I[_'@#8]^+Z/O$BK#I)"WOU?[$3R\@_PT%HU8G
M:,54R12#]Y)MM)_HD8,#[,(SJK1*<*XS5=5?S2;ULON*8QGO2]?E.Q])*@SL
MQQ68N-VSN?,P9#:_)4\S# LG#PL283J-!<YQ91-4\*:04U+W+%(*%&QMKE$J
M1,$90G23 \P26"OGS]+43W^"?"PEN3"=Y-;CB,Z\6*,(4I9&9<FS]9^BWW\(
MQW21_;UN(FTG7Z/V>TJ2AN<IN#S <"3_O 4/.N%KK(=OKA0:*\&SR-PJ>XVL
MLB'ZMNM(OO,:+9-HVYX6\>CT,/R<O>_%BKK69;IJ^,2$:%^D;#O)[4:8OU-_
MI>_G;J!I:\^+X_3HDNW?YDV<&J61PV&.D!T!'L8J\UP+D^GVK\L#AILL?F1B
MKZ @5"H\UCT/DVZ]-/N1Q>"AJVELK^ST@]-4S-;^SF2^'F9T_$L^J*RJU2)O
MP!H]P/!4UF-EW;;4PA0)+L!9WM"\>V+(T=F*81BXG:' N1X9XY-:TAE67)TR
M+$T+*N?^$[.M)'W&63K VF!1*?RFOPO5M44 A3]@_#'S0_6SE$J=C1@X9T8W
M%% CAB7FH^U-<O;D/!MT)%5]+?.L0G_[ R53HIH]Q_+* <_L\ $D%J56H""1
M63GDDO_;QCF)DL;@W["FRQ,A&0JUEY""[:0T95V^D+&]B?-M K!8O4PZM*AS
MH1,FM:&Q&D5+\3R%]O*4'I C7]3FB=H\MF>%=!IR_-&,AV<>&E^2H-G=9GJ@
M<QA9(FU>_#I#8X0O0=J$!L&&_^:V*7F5]X@#7O[ME2^1HP#L>8Z(10J<8$OD
M43NAPAR[%9KE>B3HN03DQ$YW>+=4:>H[T&0KKR$'%^16R$03&8?!Q"?.LXGW
MW)TO !K8G(6Q,.FM*ZOI,=J[6>-.%?R89)JU9!-YF@$_0_\ZSN)Y 8PE8H#0
MY.8#5TS^Z]'M<>S39X]^QS!UV'1=: 195Y_WCM^2QGE;7;EOYTU7C-21)"U;
M-,XMN?SIKT"\@WBS%D#%G(@TN.74MX8::7F1S.MK5+93#'$>Y661HT+6)1Y%
M@]O@%H3)J)$W=K<Y-O?1><WYX WX,:3G*51G*?;%=^S%Z(STWI M]-I%HO#D
MBC&/:UB,G"H)\QJ\V<:$$'* LZ468CH<]XX;5MROZ1R$"G1>S:F8[_[]GQ1>
M8'"> F.8N4.UI7M+%]^W\;# NBS<E5<+FE\#-(+RJSG#*JW8"\JI0?%);#.-
MUJHC\\OO0?7]DZ,C+0P2<B L!UA16K=?E0 R0)=[X&XC43K-6)H0=(>0E51C
MRIE"0BSRQLHI%%I6[*$60XB49O-T$.VE]#*53-OBC,*,PI%!87Y\B;&)R>F3
M%+)Y59<9;PVH@]QK'<3WD&\RE.J'.I_#\W/+_=K]MW3/MS@<_"WMLWP7YB?<
M)EF63LA_>GE^X6US$$_WS.=O?O+<F1-2#HL\[S34HBG*3KP)^HN/OWWW+GG\
MXU_.@1%[]H11),0'"B$CE(B+%*?95<W8#\)PE>#4;JX*,O%-7DT"22SC$=A&
M<D@W^.0&AR>PK@6C^[(6Y____'?^H^U?$B=6*!%A0S4S11HP\Q@02I2I0L%C
ML(YA;;FA@)B0G/6,?*W%-T[H+^Z'4[=+:V%O:[OX1$)!R1@*47$NC$4\ &<A
MW&/@<<ATA_6)]1X]S)P.\3PKIP<N0J?U/'GJU+6+5),K=U*O[$(=GY[)G^1]
MBI:4-;*:@M7$BC]0/_QME5N?>]- Y5E3K@_X; \>;&1HG+JN]3A+E@=^/8Y@
M=)(OUF/ !<O#Y#)\A;9+#YGNO(ZWH@<2\E\7$6[YB)6XK[5/.[IOS^_>?6-R
M^XN,H!*_B8\&0O,9800/Y*6F]#\O?D\K-*?7'/-K)C5E'BC8NLY#$9SG'60S
M;7'TP#D_B;DC*DF"401+D4HLCJP@OOHQU_&E%:3UK;M2[B+X>IU+>(2.*79"
MN#CC@OJQD/WBMK;SC7$FG#4!1-?'4T"=*/FDO8'V&4%WYS1A*3YRE'!0AQ/?
MY*8[]AGS;$$'JI-AA$T!W%Q2Y7@\'!\$O8IV+M>&SAQ70K"$% 5#"-<;''B3
MAF)L@*#G=8D86J99_^+I<*-ZU :GN([_(G0A;X59^GC=29>4DFH*4Q@SLFT2
M_;:!9) *2( +(H5$L.0O!"#O"^Z[%]R?[0ON^X+[38PK]\3/.2?5_"H?->CN
MX)3AR2EZ//#?:^2*G5,M\"SXB\^"/G:?.N,JC/.8KU$\ Z[I &DZY^ 23LEI
M-^>63 ]TZH 4@R@D.&/ZADC%!W(JS&ZI%T(W>OK]+1_-$J<Q"^Z]R+MYA2 9
M$&SG"QTFR<]$ ]__/ML=;O9#HZV?1 "\KPOQQ>1YNN)4#59H EDUDKA'EIJC
MW^@6'%3/ZGI'-_GDNZ_D?IV=W+W[=2%TT-AP,\OQ<Q?B;KKI[GM\\DO.)\Z)
M^*RHM#U;";C-[&:NJ$@"G&>\X,"[IRPF&=S"<Q=BE$@1G5 J2?J\1!,P/VY.
M8(_/N/Q+=RBN%1S)K1@3.AJ5S%K]@(P^T" IW^AU-::[O\G"G4]2^@IW;[GU
MK<<?*8]1(O(DU0+O]^>LG63_4"\?O+[ MSQ^Q+]_],0\:L?UA':]&-5E\N'=
MV__3>T+='='1'GC6"[0V3:<NG!X354F:T-,2RME]3!X@OKA>!U]_]_(5>\J!
M'_TZ'SE'B"),@K:ZJ/#Z^OIPS'>JY4:'[M7YFTP4*Z3LY,^_ A3U^.C@KREZ
MXQIGZJF_;>/O_TMC%3ZMDS!!-_4=,?W/?W_P5V[#PB1-+N>0&X]Y3/I99$V(
MWF2Z:I13'G,D,^9S?R_DS,>GC[,G^-CQV>/)$R\@/*D&B=0?/PF;LA\"??K4
M#H--N9KJQZG1C'$DT;C8@@[+X16CBFD-M[J5#) @MZ@Z2M<B9XO!4DVM?37N
MQ0A(M/+36LWX<O/@6"#_\!>(6R@4.4S.JW4T$T?F"9.H"J0AZQ1PP9T5E"@D
MK '+NLJ%9):B(S>2_D4*6P!^ V\P-2\5##5QMT?W5*9MD"G#1,Y9=M[Q3",K
M.I2>,UOKR]=AU669VWQ\.*NO!I((7\58G=V]L7K]X<<WR?&Y<Q;>O7[_U^35
M^<6'M^_>W_?"SE8HQA9GKXHGWY',M4&T960O)0G=UUQL/9-3!] ?)%R^#W;/
M.=4H 8'GB>#>*U*0H)WPP;PC=AY?QX.7AHX+U?EOE%RO?+69Q^HF?VAIG.[M
M)]?7?=__>!&JOA_\6^!KH2VTR ?>2R9$A:)6)>D7!-O)N1FKL>6*,E^JY?H8
MII-31881&-Q/GIL"FB8YJ/MGX6>LTQ0\RCHOEEG1Q(F>B.$_FL;B.>'U\6BB
M"%YC[&Z91I<9AJKR^(U-8*O 04>Y':C>1\="U^,Q>&2DN.E&*OD:+DJ#0*=F
M?B,:ND2(&96PIA4H8:XV>^O1F>J%?T=W_.CPY.QK>>3?W[V2>T?;^RX,\81O
M\8/L[)=4N.\>7::HJY"#EY2\"(1692M4I&G4#0,TI\6 #-PS[;X3W.RF%Z?"
M5L'T%4"; 7Z)&NZ8TZ-F[#JG 5[F8YIJRB[X*5$]G)Q(&H#RB?!;5HN5"E!'
M"5@0]'1"Z.-\3>T.__>3Y]\?'KLXO"SI'J^DOC@M6CPN]9DG/+)]^,;T#NZ'
M8Y.(J/*.7H22I,5HU6FQS(8)G()M!Q[I]/O#[_2)Z/+_?O+]X:G^)J:F=#:@
M3IC]3Q<@)(Y#?Z$S@>T\F<(.4.FP#\ 9Y!/D%S5U/\H4TST"1KXL%@1B5O0\
M]\M&4XTH'X&G8K"A(.T,$$G7RV"O@/=O\YR]:IX50X;9#V+17C%%=W&R>['(
M&ZA])Z/#3^_>3LR8[W,C\(,JX-;?+CP4^<6$,KCF6JS;5NGZ)%04]6"DF#0%
MI%)9DNF2FL&JTKWWW6068VA7;>.!:=C8X*VN<^X=P*O 3Y=;M*N6/OWUYSC=
M,[W2F^;H<3#;/)>L;>LQ,WN1XV50!GVY<;_;V(AT<S>'!0@Z3<1'Y-E(#NW8
M5M&!ZO=@5#8$TL]OP'=XV'6],I]1Y"3P=>CNX:$L QZT53VQDSSP :9/V^(V
MVY,;6)72K8M?5.A9X"<A=H>NDPFE5@OU]T$[KH:/<5@ J=WI<]ZD %+OD7M_
MDZ[#ARA<:$>_ZRF5.>[H!&P+<N^%L\.Z*6?WK<F*-A8:.W]6,F(&IGN[(N=?
MZ%Z"ADE:@J4Q1.<[T,'#8^3L7M&8480K@7E+VK^0D"]IMF*71\;02JAGU*2>
ME[+,1IHXWCHZ]UO2J3=[5Z0AG ^1LB=AAZP3P&/N%N  Q U&];3)*"MY-")2
M9K&3<WQT%GP:?S!] X'(Q> 73P_/@L/VDFO;7.6 $TG\)N),Q+Z(;Y)G7\3R
MH(G,VFHYNRERI0C5'^SO* ]-,E[4A\6;F@CR+M_ +6]3?+SDD@3=<,Z"*S8O
MH,4E/]@@YG8*>*GCKJ6)8\F,@M3#Z(M,[L&)/R<D/";YJ-/8N6*R21PFSF+$
MP_<\"'_;2Z?J+:G'UM)-PN?X_@I!I5N;@!J@=.GS2L8PMAT2%<)JY:G-ZLRW
MILG=>B[1!-P&20#S$9-0RIX5^VJ4NC;S,N6FX3G]>O@]CP:*!E0LL'@\']I#
M^Z63U?;#F+5$/TS>4(0C8%R3ND+=D $C0][D5E$CI>>%$BM%\5"^[.S[7QM0
MX<8$0=&-"(!09,1T9^&IU-.Q*<+_63?;I5BE=P_:^ J@C>_VH(T]:./^L"28
M\0-*5]4S%T:5PY@0ZQ6)$/0?$21X] )5^2SVFM358?)JP\<;T'Q9MZ'H/,&I
MDM-D/L<K,[0IRVOH_7J6[KZWN>X6(]R/P.#M;DDF^4WAG2X",7/BL-W:H<#P
M[];8H.3*CT=08DUCM]6Q,B/&74AOTI3.?B.H[?6KI$.MV(9]B4)@SO0PVB$.
M?7MIMPV2CP$W;\CX1S&ODV'R'D+CQ;;Q(%'DJ[Z,J7G@68:P\M]2%",<"I43
M&@I'4AL?#J[;4#_BT/H%A\DJ$5$@0OX*[=4.I&3AE$8W#\#ZR&\B]D!XC"@W
M3=#"C^PQ?\JY-1-*, T(R8=-$+/?Z$F.N5@*TB_ OK<416?<WE^W-,I%,'"$
M.+[IGR)V/ -3I[F6)_^D\8SD@JY]]R_5\,(!-.2#R&+%+(V<[C%,L#?<='L6
MB3 -7.+,/#OKF&IVE63L)*><,7D/\G.>!-@6'&%9JEDMP\LVU@F"L-$<1VU'
M2RXM-\G?5RUA"9D9CIWQR6ZY?%NBI<OZQ*'GWC%=UO1Q9:OYC 6G02&?)SL/
M-$,]:.PXK0I ?>MVL2EF-6>MPP(3-V_63$ABI L,4NSTBQ.,,8KJJ(Q0H1V%
MKJ#[?7Z!K."0B42J-T![^J>,M)8^&A="_,-PO(AGSZL9$:16E$.I/( ?.>!N
MOMY= ?AL7_#8^D01GHJ%DD,CX<+?)$+9*EG)RQP,I+F\CF3ITAO4NSO&^Y'S
M=SPW@V>UF*[ED.Y9$(-E&?I0J'$X_X0.:72K$7^ __3&%K=,3VEZM*7-6=HX
M46L19N)EO11BC\\8"[1U9_<B\G5%9,3]2KDVA!/WC*A)WWJZHXL_8'?W6W[_
MMMS[;F D1V93./3V>W7_]FHD0&CR*)'X<CO&>:S&_9.++_L=O,\[2/0)9O+9
MD(>ZW[?[MV^8#)<M-6?,/?PH+PD6CG&&GI!U(M0H(?G0K@1H\@^T2@1 ,E*K
M41D)W&@OW'G>R\!]E(&=LAFCM4$QU,U#A8K]"#>QH"3J)%_PB)$N-Q5A3=$0
M*FLX>AVDT=!(]GK7!!#.X/!%?#(V/%5>44(M$ U\0=(GGK<4./$D&3T\QZ7W
M6^'?+W3&C 676B CU8S=:K1YAXHQKYND7ELEF0TY?//XMER^?8E2 .0J:8K*
MQO,BOY(LP:)HF2)U<!M!;D0<#<U-N^A6:CRN:3A8N0[\U^3 :&)E\B7B<7,V
M6; *@B6DP8'32&JD3"_)#_=_6*!&;J6/_HJ1L.#>D54J9/ 9&IBE7SBP6>^4
MH)$NFZVSQJ.SE!FY'<I9"8U1JFUK_&X1] X?+20DMP+?KD;: $/PRN1G3@)G
M26!?_JD88]1U<FZ(?!\_^N&G\T=/3,%P*'/4)Y;4?IPT)!&&DJ"SG$C-0@8T
M(B4W)#H6&R1($&;#*<MH3-7#U+S#*5!)/O, -*M!3$47T.^L&<^9\]5H.I_"
M8V4(.A;5@!9@&+I_W)6<_(XUBSA8O%LV1=V$U+6O2BO"?%LRE=VK;>8UMJTW
ME F&SY>D_HT=)_@A"CI:;*$C#G[0'DB1JT"-KK26OB-'#[71,LP(H.>;U'0>
M!:B_I= CTX=W>&>>>=DE98ZA?3I&D ?WW?>R^M>H;#//XB=BXXJB8&* ]R,
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M35,TUA9+A8S!%GT8&4_Z4Y@\M:L.IGZX8&V!K!C*XRA;*H&$6&%IPDJP>5\
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M[2X8UY)7LVXNO5 ZM<:G6QD55&V.HM')M7Z 21BUL3'E;.M0:;$HS"XCUWK
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M86J:,145255":M3QT.)M"O!>1H05Q9,'#4W[NX?+"HDC)"5G!&30%06QK-N
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M*'_L,E ;2-V3,O ]PN5%BAGNNK_7F9IZE7Q)?K;!#":FG5FD0;4U@@+@&3!
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MD3;&A=$?#UO%C!I^T-Q <:(G3V32TEH0H)!9&/!Y'J%BBWC^XD$8X@U5T,,
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M+<TGYFX%NS3II:GNI;76CEX^.@P[WGE6.%SE-<WR+@2L7%J'N"P]I*;YD4*
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M3LN!EY$E=:Z0UO?E0'#AF6-3YD#)TETYA5? ^6 <XLLISRUPV*&%)A[G9Q>
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M2_0E^%#[3_>>LA?^41S,CR&DQLL>8I5U1 ?S"+^*.<DG/WS\>'AT^,-/J/[
MRX^\.VD2J(,(QTBA4UUVNNMU%J6F\UHT%D>; U ]QO67-Z6X=R$FA1@R#F>E
M3\S;O">]%SXJ_L"PRC4YY$CKB7I9&P]CQ%/J^XEPG.&8-/4"<[25DHE.I^4U
MV(O5DZM?5H;<CD+=<10*3591-.@$%"6F@+%AE^R(<^PT+#DQNU1,5]/NR=EL
M:B/0#.V@RIBY!/X^K').?Q$QE<H%^8G$E89A;3:7:0(DOE,YK%U(!O?P(TN@
M1G@HMG/?1+EQ>8'BW#7'+U%$_%)5O'HO58[N7G3>"N1=AV\Q0"=UI>$S*0Q1
MU=R5!%ZA(IGA"%\!SPZ1R["3B 6'<$'/"VZ!JR2G*+&Z%(0^^@M^%&BTY+PI
MZ@D\*RIKJ15M9>=!R$XFX'0$] !GWE&O('K$;'!VL)BK&NB.Y+E?>6^W_3+K
M]\OL;?MEMOTR-_7+;!7EG14E4L=(S+)S1.(-UO&T66 2I4[.=$#II*C!#VL6
MW(5)433RC0@PD+*9<]'>QY+< LG\?10W^MY6#WQ"-:'0F)U-T?/C#$7C.6ZY
M7*:?VMK@!R%:C@:\\GH28!U9OFA'WSM$'03S?%(4Y974NC@DYT_5\<?^5S:;
MOY8?\U%R;CJ(.!B5RUQY:%O;"H]-MSDU!\W*D6-RR2G-1/L;X*?]Y6M!FTJC
M''>H*76"&O^-+;;+YDDBM5))*[MD:C'+TU#N"JN4LV8&VF7 *;.8 IH MI!W
M(\#(>RDA^O S^AZF>S"XI&Z!_8/=O?\B@=H[^"\-7#)/JV*N#FISR)G:&2:[
M-6;V[13@G0J7L[3W<2601QGF<\>URT6YH.XD>A!AQ: &,SX39:5Q]R)![\9W
MSLD36;YU> ]XHCL(\59DOZ%=AJAU4HXX=3982F)0!174%R7WXHG.]<24\F]@
MAS&-NA!R%DV>=',TG7)Z%QI;X!XX#S/)IH[ [L;8[H+_ -]ARK^;8>NK  _G
MQ;^HXVHK;O<M;M0S6DN:)1(H'7CSTB1J)I0OJ8XEQ$(D.ECU(\JY5B,ER&_)
MX^J%U)%!VOQU&4T+]1I1/ 48WOIULI6/>Y</>!"5#W"E+A5> '%=L*!JG+5\
M%#J*!@@92LE<(2F9X/P@NOF<]=<>4HPID+4[7,)7MS%1%QH*V_WE.-Y.S\OZ
MTK=61L^(([EEY=NNK43FU 5*!>-L(3C@Y378[6"X?<81GPB; K$T)*4GN'W+
M040OH\.N?NLAVFK ^Y9P-K@^&OB($P9O@A1>9G-F7&T"LZ\AH6E1QJ//2)P8
M0;"?@]\U+W-XM'*\0SQH>CFLL(VQSZO$VB153"BRP8@I] 20:R@*%IM?2+[Q
M]^ F(EYA1O(]8M (KHY$#\] 1"ECHX2F-.W&LR_@APW*9J'M<O[& ^>U/;L:
MK26[(]+A5IJ_O;ZFSA2MHGG!&<ND (M@<!L_-A"T#Q-NI5!1?Z2$.^>H]P.Q
M0V_%FYH+EFXAPN^K4LK5W&Y!"/R,H4MW.,%F<.V&4$<[D_XB>[O=Y T?X8\0
M\''_T$75S.;_9QVAD>+0PX1[G-#-NL8&>3=L*/U!/-1VA&J45QPYXC2'?J54
M;HYA7@V;V17!V8)(3,NR=J&2&G7YLWD-HR#RQ$=EX3L&4_R)@;EQ'F>(L.,C
MTA:VJ9G[:652?>YX#EO^Q:TE#'0FH'-VW$ON^?L$.3FB>Q%7:4:#/G(I<TON
MS;@X^I_#T%B1A3V7;U#&QZ<FD_\!I8A3X03$OO>*K['(/N\,J.&9RLZC&%U]
MZ;-//#P1KU42L>G%CK'VA'D@6D8@7:(PR+A*Q.[:6IL,9#2K_%@00N&4!75P
MKBIXA@?0C94:YVY85Z&&H3U4MC*[CV6\?[1I;JH377;''J<">1^PE; ;';:P
M-HA3!!756\5F:4"K&32+4M*H8K%L\ZG@#4PU<YYXHAJ^E"&&:XU."( ,\;_B
M:.J*'JJ</L"RN< N]XJ@//0UU!/QH&+XRT%>"MI6;=6GL27T; +;T$T:<)LG
M\N/@^:51!@'4!(FZ;'(>4AN5H)^XCC]H%@A?Z]<4GRYJEN2RKC[4;G)HFK_"
M'R+D"-L]IERU-)Q!1B$#3VX,LH*'"SN]%CJNI\<X M!5RI^]??Z"W):3*-*M
M@L_L/H,*JK'=>NE;A6.H*ED;V]OJ$RS843SCT48D;F^FEZ24Q1CE55OF"(M-
MF!5+/\1!9YI;BOW(C7:24<\I5V\B46+4Z] 6+EB8W(8F-D QD'A6UZXZS^>%
M_G 5"-59RADA'T>%9?:$LNRP\ABRT8P:15EY06X,NMC(S1.1=%- EK$J)][[
M0CJ-N"E27/<PS0Z29;YJ.)KL]0=N<>U<H?+??A<_3A(]-LH)<>G)P:FSL4/(
MHKE %V7*"SE<&G<$+_A(]>9)L#UVBE1:MT,839339(IR 4 % T]H?ZT1J54J
M(?)X9()A19MB>RLQ#".'P)9]<D:EU+"H<OELT%0U#S;BJ2(@<90R[UM3[GY1
M2>.M=0&\T-!$42K'2Y4$M;^;F7"!*0\]3@'+2: EX;=P7-%!D-9,#O%P&*(]
MRL60;--/*()P?G%-=Y-WZ+I.E\'/X_=5$'M\=%];$UIT\F[:XTN6?<V\N4*]
MMKCY_A#<L05.A&WG))'I^=.Y=WUGX_1,RIH&2&O)6AN98\CC03Z272^';J0M
MN-Y,@_Y 2(-8EB)@,58P8>!+0=;% QU),2JO>NJ)P7WOZ6!$XY 'K"=J2U:K
M  \X4PUG#0J);4, S[5,QD9FV8N['2XSTV>]0Q)?O'./5:T9<;S$[@9R"; <
MU^DP-SVJMBV=@S5'[A]5J-4#XR*?SL0$H3 1EVU?9_5(0FNIE6US_!@<*SK4
MG0G45 :^:D'FO+&#MUZ=GM_VMJW?V[:_[6W;]K;U];;=CSRJ(RMS5.*5]G?+
M!+/$:9EK/]\YQ\GSX2)$KR4WEBE,'O-[VS2-X/); $,=,(^=K7%H:XA+U0%G
M4_'YW&<PT-6 9UUX &7G&D$RO"T,TSU=2\SI^,CD>A_&U$ ]_(70=)!W8O!_
MK$M&V9*=Z#?CE9X$^6\ZQ!4\.*)<[TY\\0.BH8\PC5M&WSRWY\M>JGMKG 99
M31YP;*I"!]-OF9W\<H<.T3]0"C&+-%Q0I(UC3SB!Y0$KR;/QPQ^1CY,7_>-N
MA']945JBY(X?Y/*S,\?Q?L1>$"$8>83K0,0"<NYWG;ULXT]AC<=G#.@*GD8B
M$%1$0W4\.8<.*01#5!Q5L@9:X^ _"M#2[FK#^Z"]J+=\;&<E.C<6L33X\AZ&
MMX;356N#H8*02@Z99="BR(!KS"':0F-PQM=  A!$@$$8,<EF< H(V::YV:J@
MA5<8(VZ[(=ABAH.R-"9$'4U,P0CN"FL281693IHB8,3*::.;4\RA,/N4";RD
M>$\:8FE(&YY89JRG#O&.D";!#M8CU#.>=Z5$D*G*UDRF65Q77.55R?ZHRMDX
MNRHY142 _>''-NRU.< 1)I_VO,&!R6$=> 1'\I:8]AO[8TQOHP<\2L_U+'V6
M7&&YDQ.1?@O"P@Z:T:7C7(PV$<L\IWK(U/H7"Y<4;(9^FO6Q#4<?P<D V2_G
MH-EX4CU:-,%CF6?,>U%'(MVAQ5!#T#M/KPG%VVW"JMGZ=L-9BZOA84]JG_8P
M1(%FJSV5SM'9:4UA'=-.O(\((4YM:U3RY(>C]Z?U#S^E$6 /?U& 9 I<]TQ1
MNF*@# ]>$1 BC 0\B=F ^[A1#&>6LDS5$[2BA'6Q0"M>SF9-X8^STC> A471
ML9\>3\L28<<F346(CG2%Y7Q2BO- WX(MQ'(DV-Y,7U;@I%)"UZ/A@GDN;Q 6
M12E@&(!MA[ : Y>7!:B*T,%3DRD6, WT:4L$ Z$9;!#X\0Y/4(\X9R]\6J+_
M(_*-P6K*M]N *6X_,Y+?NIG_#4W$6GP_"NPM_AG!)]U JFPI<0;,GN6Y;CG_
M5;<J'+W0V)ZJ2X /S5O[130 2E7;+OBM+;N,;2$KV;O5CS0EU95(GR8-QX1H
MRUH&(+W- %#&?I*-?%7(YI88UJWH(?*:E-=TD@3\2G3=^]/Z"U48M8NRF(BQ
MT.UU 6(K?$#,$$NM$2]^8'33/9 $4S5([$KN4XS'%8M>Q6[CF/!7B9)!/).$
MLEV&G4E6,!3TT&'#LI: ]$N^O4W&'MQ*ALZ!<T[$<N@G<V%@EDN @>X1+A<K
M)(7B+T6/M2W]K3MM['DOL%FUPK@;ZG/<>5T/>[=14X4B3CV$+_L"F+^]P593
M=];7K TM0US&-$(06]4OEK1>:H-H0S& K[L5TQ71\,ST#DBUA- R1Y2 &&AY
M %Z2.NM.4H@EW2S9.^0OY2A81)XD<)E\["$>[:$6>-B>ZR\6\9 7"0*_<LCM
MDM3#>]: Z&>^<S$OKC)M?_OM$Y;D7-)FQ@C(A9)): $8FG:(E4617D^WUY]=
M*0@/VY=%_>(72A@A4S[(*.&71;YH1HY?WY]UK%^4]4+9/1$,:$:3GIA#:>WD
M##_%U!R=+6UKR,!-IAF34BAA[.V,.H$W5S@D-QMDU65)U530&DCVYMQ_\,>8
ME2AHCDQ22PMP?HGE4!K!R/YU[JK=%66%6&\,>FD*OK78T^ !B9:6/WMDHU[H
MS3L*<-LX!\TYRX95Z2$XP[NJZF:3U4WY"4PX\0M"^)P79'EHQHBB]\)W/1)(
M<JM!*L.MBJ6 _B([WMYFZJSSF)IF.&"-[33DMP:<U@N9QUH*P'V=QV&CJFNF
M7JGA@%&0O_!@'&TK;LY2"8D"365*/7L>=K$I/A7EM<)9K9%PM4N?MB!&>VFJ
M;"M3R$N64<+>0VFC4"/\NW2E+S@17HQ!>R]BR5)F*\V\]^^(]T!S(H$DB6WA
MVM:3?"Q2'[N0=5=,;0BXN D'UX,/^B6"?\$GB8:!/>0E]F9Q!K *"&I>H?O#
M*C24?] LW,4J?(5HA.M\_VIJ'-G_=@9C?>M.!$3_8*TE;FT$< 9!_B=T:&*P
MX)@K5*F1?;M>O^O>>X"T&I2:;?K2+8D6]_6#CADI-*(N3"*PIN0U=6*2*U]S
M'U9%!H/L&=72(JL1G>6P6:PZNQ"%K)$_N66+,D:NJ>UAF,6H<D>H=A;>,[JU
MV,(1Z$^L6-56-D0Q1_V0X:(1T/UR.&7Z4W\=-@18$<! +J<^-5$ X0$81'<I
MS R9AH=C6$I"@0V].=FV;>)KM$T<;-LFMFT3F],V80I3EYC-MB DIA,4YYP)
ME!^3YCAUD_^[R4?D!G&=.:)PE0J]^$G&R\<TJUP&JYS:2JPE<._*>+<E!Z=-
MZI"#K/B$H<;0LTRIRK=S #W44@&R_X(!&GN,,KK]L!*4K1V!.</!H S3WB/I
M+/.?; ?R*U)0VHY"323!]Z8PJW5?RB-C11?C_.#2MII%(PM%T2GB'2T0#L[_
M.O;I/9O+Y[Q>:/4UA)R+"O/.UUDT>B6._\ M2\E$^N2>7H[CW?^S-V>1T@OY
MG+X4,0EYW3ZZWX&FD)=5[Y?])D$,\=?!A312A++*_E7'T=U-#J<&O5MR+P+N
MI&N^5OU"W##JBN %ZJ1D[Y@(R4?__</M6N/GO1^^HU+HSU^=T;*=A30P.E@G
MH,&(^0U[D3\2A]-B^3 IQYEG@493BLP'DLR8HR3%_E7G\JIASDZ ZB6-:2^A
MQ%\=;']NT([XM4F-2:&.8]%^>G>03O 9P2%XV(DW4\>;9Y2/-AQ.)L6%P]ZS
M@:<N&+.>PN.-Z>[YDH#1=+: J/E 2=B+]27+&X(;"JW]:7O'+:=NO$-1X*Q\
M@,362/,&$68V2@0F*."Y_MWX@2=_$V$_+!417\:1D*()?_G)N3F57_MW7YG'
M?;>,TKIPT^&8X;SLZ"X5%M'DED4A3TDFB_G!%YX(2_;#=K$0O<UU /Z_]72D
M?J;LCQT)-9S+T#RF;.VT*H[+1^8L>HZKYD_0I>]G$WG[:-7U6*T2]K5D?2F5
M=IZ3PX\%NI)N#5.0W2-J:DI>(89$8%AK7:9RVID8.MSH,O9K-07*#)K=U'3\
M^M4QNFLVWPFJTX/F@BC XB/\R<1-*4L26GP#<;P6Q)#F0_.H*G5AJ#KW5'LJ
MK_W/PZ<;'!!JLZ.FD?7LBJB%C65'VK#3@+Y(R#P+BB'J3_'8>K29UYNFF,;#
MNU8-$@VZ_"Q_9AD40^\U*R&$78'$\]!963&-25,(:2!JK-TDZ@J]MHV.G5%<
MI^0">54O>*;^D],</IXN/-W3+)]QC95$*7Y^YDOAZ:^>]S=$:2FS#ZVZ\S@7
MJ(V8QC%ZEKK],!J_W>FA6O&-&6MM9JY"KBL916KU@,JE/)W.*OX.I'CU ZS$
MFO%1'@*^=*%.17**D9=+GOSPV_G'BU-L3 O]^,+U%U'D1G1_<5NZ/^>&0(+"
M'1:+-71'U(P*BWONY@M'\^#[$#BDX56$>R.IK\%I$+-O7YX^)"LE["5AROV=
MRR;+G?,9^@+"1@Q[P9'?(59(0OG*7Y94)?9LY$)YX.]"^C=C+DQ!:B!IVEF4
M.RPR M/ 'U$NE7+5=U "^[Y!1W2ZT$%W;O$2B"P]FOC(L1!JT*\OXLL^(;(,
MZ0/U/[@/K0TI@ J7,$L"-U[?6=/(WS*(XN@'>FBA9;+]E-%9\,$%$T.%5D?*
M-LMH-R^!P\>K=?K=CVCZ)U,_F62])%FG0X%Y'SQC83XC&A4ERXT0/#RD+$2$
MH5;(5M,^@314<3G-# Q89="S6G3$!(QYR4WLUCWM_]8-4PJ9]YZI<;)%?^A5
M>'23Q03V^7+BU\2^5NAUC1QK._!#FRV\<-)>5&0@.H07%PE*6#R:4G(ZHV%$
M*:A=9,D5 A$,.,5+X%-L\!=B04I[%[EM'(-!U("F$6@Y;'YUU3!O(PH8:] W
MIYL161#Y:^82(7CQ/KH-;F7P>B'87W;XQTP ZSE_;#U"%Q.WVML01X$*VG .
M23K9QM!NX?;W;@X"BE O*05)(B%VO?'BDB5L!5*ML)=A"&@+&-25!:1L4.3'
MV-B]CC?,4< ZC\1Q .G;&P/R1^K4AHP4Y0]Z<E+]45L:94%HO=EH8C_&SJ2\
M3OG'OD5O:G5)O%]'-H"E0S[-< *"\')JE*;1(/2,>/;[#WEJDPR8!K[T//*$
M<,Z]WOE5G.(@PU W:+$(N6*8U1/ME)#5:2HX-L9MMQ='8TE!54'(-8BSXX@@
ME5QQ'SZ,2KI99Q;2PW^"*# S"PTRP<Y#8(T"357W<@D.R5+P.!^I9(81+<HS
MU.54T@UEB,.")2WCU!37SSU#>VA!)6<[JOW(%JJ+TG!;VB6&ZAWKV;ZB)X V
M4Z=([247(:]I3EE"?R$Y:0QN@WA5_NQ1I97M)[.!<7T"7QJ'RG+L+O"0YCI^
MEQJ$*OQC37-T46)+#A:8=>XH3@6$BV WL432R8KR8$+PZ>@U25T2O@\ZAK@0
M@N4J>1!TO,SWU*?IS..2RUDS>DU-I'C>>; 04V*:[!-<T\QT?/,IC5M4V#=G
M7@!1LN@J]HF.FXJZIJLVQLNC/T F])>PE ID#%D13'A.0S@"4*[Y*#']U)QA
M?5>>.V%^PI"@X*POG &,9EWE>HUNE>74!TAQ2>ARE]0&%6=-2D-*;Q7YVXAO
M)-V,"7U:E*0CJ=KVB7R%/I%GVSZ1;9_(YO2)1(DZG')T,J<G5MNZ890=--W#
MB"!E(YQ6HV-E4C"</@^!N5(T\-?5-R1Z\[R(;D2*,JJK@:,VCY2>*3MYS+Y0
M_WAD\:6XTCE"W5ICK4.6H9>;N)*#Y^P-LTV#L(;FJHQ)+?$';\QI/DZC?A&5
MPRCWY5-+U*TB)K25_UEST5+3SD^6O,98I6^/L*USAZ; 9MKAX\,INX%QU_O(
M(94R97TH%3AMF,9=LM <C'ILPZMR>L4N!9[Q_N<.SY;&24K_I/]J1CDEA3!=
M9)"A.\\I9>2NX.I,<,"L7"RD."*K3*?9=QDQ00>E+^$A:RR"3[T_-4)V+<(D
M.0QS)9K_Y$7F["'G7ILVF[6G0LAY1B-&&"7\%W&)C"(4)S!$L>*S6UFB0JY)
MPAD0"T3D9/<0PY2I+S'1[[BSC!6B0.\AG!L)8NI3G#TR= U>H.UGL=79.2^!
MWX(9A+Z4@1AE,YZ!%['B-C9PX^?3, PMB2+>@APC(#>CMKGI%&+#E-DK8KP3
MQ*"4H5QDT8N:ZPG_V_:XI0&+(\6Y]JF'&-&(W7-9Z>1K!'?X)]1;ISUQ  5[
M6'49*:)G>Q8!_]B?62:$;[(+H>1E\'#A4$I%G,2S>X7P *MJ -WB"NLPG=B)
M#Y[,\DOV$6/_N"3IGY>>)THLR@"8G((8)/2&W/JM&MU!D)=Q"87>RC=@>ED,
MCM*T''Y"P==>E]"NT_U6E!Q'G9T56G'!^V+L39L*=MY6 ^WB8Q(N)/]:^^9U
M FT/*0/,<.1SAB5+J-&SMQR%$&A3@IH7+'G.]D0%IK#=8U/DMFF&"T%T-$@*
M<<4K((&H?F+YS4G9Q&4AVFZ'50J$I=*O-D5(5;5L;I9,R]J/8ML%]+-\[59C
MND=8SVY-3]( &2.;+<LFU.$9!*UR:!G4TAH B7Q1^[(]@T:1^K6XM8@EHK9&
M4LD$(.85>4@L\-U\'YE?OMWDB.T'[4F?,$<:O0NL31$C [UI;I1ZQ<D.VBX?
MZ9R.6HI6&DELKH-=FB]66$'Q= 4+(2Z7_JN1>3Z?G&:UQKK#V!(>0 WU69MB
MMZ[3MC]G78Z2OI23:>>KFUJ:8,PQQ\]/W>>>?'ZGZX]2\]<ZL,NI?<J$2>'
M9B=!\ B[!PXK/-70M<\FGK:X"Z!WG)9!;TL=<R4_Q;>IXC7,\ZXG+:9_A+-Q
M+)TXLU8X5$Q4[2D#4DF,K//88M8C)7$1\RVZ+"]V5(<$AWG'XJFL B3!C0J>
M;6?@E5U5^,"TI+4OZQ $/5*LPM^=U\>U(1,R[INR&P0![%3\[8Q03PQ#IZO=
M=(S6D6N183MKJ4[*%GD&,@P[*#U.'\/HBJP)[C8SV<!%>3"C14*ANEIBU\Q
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M#3.+&AYSQ&.99BIRHJ2E->,.&J0$Q43U[^(9 .#)739+GJR&O2.X7$>XN@0
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M<+%A#^@//EAF;"<GMX+EK77X^4B_W-WS$M./<0+JAZ4-S#P87OHNB)'[#+:
MQ'<.9F%"N#3P US@DQ-L!3>4SZ>]KDGTO:&8&=1X<SP9ULJO<:I7[DN+)7Y>
MUH15\U=ZQ?S*K>2-ET#J:?A*-JA+=.6^%M7\;5_[WK+S;#]^1/O?B4]$S\%K
MW!F :OFTDXWA8?^:3:^S9?W#7V*\C;S8:2W]5UJUE6LS'G^SM>% >>2&):O.
MOT+X[2K\%#QKMC'/DDS 4_[O'_Z/VQW-%Q";T2&%HP>N]@)-T?_UE^S_[A.
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MM$?C,=HVQFMVQ>4"19\ F7VA2U-\J1$P5GM.;+4X4']-GNS]E)S!PUF%NIB
MPKR$N+893*7H"UKJ"MTK.=T05C@,!>K7R9/]GY*38D%+3%I2192^-VC@RB@.
M]N" X8;P!#U66IL!!154'K[65:!W UT*US^ !W3QQ?%9"1,;]0Z:I'R\Y&O
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MY@JO?=Z_K>U^0]7/M;3V^:^TY@JI[7YJG%S\P@>?75&V[[BZ^^VGP 8J3A/
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MK[.L9<T<T-M?I8RQ%M;2U%S8Z27XR9QL'Z:AV^_6/ TAWOP9,Q,RR?\W3,C
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M!)E1)KV2<=WXAJ:O94FH3"<?>AO^L-\^<W@^H(-&; ?#8:1@%($D)MSU2DR
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MO_2Q]ZR>$G(X.'Q4Z/:D^+@'D4)L<D8<2O;"?+T7]P!T,P?0(:NH^"S"FZ'
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M%@D45C=02>.$1*']@S 8&92HR5(_(?CO%?H\XFS#EUPDMN8501A('D) 36B
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MIW?_*0RW9N?6E[=.7I_3<R)@\02(1Z3-!=HHC C%-=&6\H0[81+.0<_9CAZ
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MT-V:HQL'E?Y?=S?_1W- Y#;/66IT+'3$HYBJ) +5 &O@$TPI-?Z N&OG7GM
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M>=&T22ZBFKB=,75OYBJZSVC$XK^/QMZ=*DPKI.%@@=@0Q+Q%5[?W:P[ZC62
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MR0*L#]D=67R#L9C15V"=P)21]9_1P!=+A+US5OIS#W8U_H3;JS<PMAN,MJJ
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MSQKN]0=B^(.ROCQ]<-7Z&;ZHG'^BW9F;NC/C\<Z<\G==B[HS"I;76HK2A(*
MI0B *YT.]]Z^IW$+ORHQ46YX@2&SX5[?($"V1^QOLX /]T\N/FEG>)XP0S(P
ME@F72I#<1((8QS#/0]A,;'3ST7\&P /_>$&WY[6_C=>E-D21]@O7#5UR@MH\
MY=0]J[EFVWMVSWH3"Q+!0GUY,QDXX@$3_,.+8 BEQZH-KPF=R29O&GJ,U)W.
MOCV#6XL:M;&_ZGX$S)!=74/"3D'\SL3@:F#?<2AN$M6#8;I1=R9WSH]Z?@ N
MS \!<SM%#R$VFIYSH>7K:#A?%NB=%2&=(50)SGVA4^._>G=&<Q-^X\Y[RJ^4
M>[^XQ$L^Y492Y4#$::T<X<S$1#&7DEA;RR.M(F87ZAZ<=-0Q:K-<.QZGD329
MRY*<,BVUYE;/2\CCY?OOZZ1754]^]GVN9,"(=BMY9=ZH_UX[^1\V\E=Y.*^<
M]NPR*9=E>93*-,EAWQHME$HEG"NQSG62YAH&,?2JQ3C"4(*62K#459Y5]DGS
MPY^FJ,ZZ\N))T?>"RS_T)^B])T6?U&$)=*=_12@#$ VUZ]S/.5R>>-IWHN!M
M'Y;P/]-\N;Z\XR_],32+U_)T!]AOY>5HAZZ\]KW74KK#!+_6:__P0P[#AI5!
MDOV_K7AK3CE^$G6H)V_SON_<RLZ^X<U_+H0;YE<R+.*Z3Z9\[F#*Y@\F3ZEG
M8[YY%_@&3_?)L7Z-E5%2?SDI!Z.^(?68-?"V<W]^9QU0C5[83X.SGW\X^S5X
M/BK[17!^(QZ1<YA),A8*,VMQPR6H60ZF]@16 /'M"]/!"=UT<<9;9+/B>%&3
MTKSJ;#6IS36<I,8"'R9Q+FD4IS9C+M,\AQ/@-F=KV+#_@!:PV&;<C$IL)_%
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MP/P+YI'!L/#K.O?6R>'SG79G&E)_)UWS$5 ;5KF1WZ5M#K1E:^(31"8=-0)
M6?>BADNRPW%?W+#*/CMBDEXRO>B3[_@F)C.0MSWYI7E# R@/NZ?PZ2%C>/PZ
MV^)H?A=-IK*0+3X'%3WTL$S8LM'OY,7R\6:$XX-K;DSCC)3);'<ZAXB#7Q]R
M\\LWF.>)NML++B6<S"!\BE#MLAVZA,!JVAEX]%'3CP 8*=0;R&X'K-O2 ^('
MC.F9*13]8'OARDYZOBR=.K#!0E^?[R] R WZSE"*H >4-?SZN*#')[A.S^M\
M,.J:NM,1[@#X@M=/_.M"8K]/(1AB64K=G!NTBA&6U=?=D2<I_YXL<IQD6V_"
M1EWQ5?A-X<8<07U+GN8YV"G87%)W;/]K40[Z>$N8\8+D:O9<:"=?"[DJ] &=
M_4)/FEJY"Q>*!OFC*:JULP!>XZTSV6)-0X> 3CNH$<JPU@<+@HS/3/)4;,I^
MPJ--)QJ/=B"K01]VPL6XP&*1(D6WB_"-I2[PNWAY4$MV?_I-PS%,,94GU6SZ
MUA11YGGE:(2U&+IAT/H8&0/TH\+@>[G6%VJ9'GX;=Q:'$Z'I85'#K &CR] )
MUF(9+DB)]W5/"8MU9D$UKNN6&XE5V2N^$G@:C[M) X'*;Y?^2;=Y>'S[?+7:
M=8WHAWE^+$\RNE+#J_6HNK\8VED%XI./D^HHPYZOPU/? ,DSS:1"N[;/!C-G
M]_]=.+7K>NRIVL,I;:3>PC?<M5<",K=%VVLKVF9MT79;M'V]HNTKB[#G[,^4
ML=RF5-DX2GD>)3F/8\8CP= W$#%]G\77/Q5?YV4?3BU[++^USHS#_8/+3TED
M8JVI),:HB'##$R*8X,1HZQ(;R\2D?'XSY8ET2E.ML\QR%<<BYI2ZU%*%:(I9
MO,G.C$#_#FR MEOL=0=8K]D0U\RK$DNAAFN;8,H,O0A("8C8BQ7X007U9BV6
M"$Z]=*?SKL;^1HVS?@;[IS9=9?V79XUU-_*)I7#)>X'!T$$#KZK-JKI1'/:?
MF6Y.@TCH:$X%/(?5N !CZ_FK]RW[;C*%P4*+N1%5HV[=\A2AD.%F/P9EA^?6
M-H"1#3C.!/?<>\]AX$K66?,KH917#:^&@I?F\ZCR+F?,PI]@L^/+RW$7)_RM
M*\]KD('F-J\3]B6NU8X'F:KM9LS0EWUMYV(#OB&O&6D[0Y9F@%/V5@_-^&[Q
M!9NI>I\^JK"AR#-,NNY%ZFTNO.;]\L'0#=:@+R:H&GP!>'7H %N&"M%))>AD
MK,$NJW&,!J 6]2>(#=.E@@UBQ(V;:FY,D.^&XNZ-_5I4=570JQ)^&8PJH,M^
M4>GN (V!O< *5]IO&[8,/V"@77EJ[>X'J(/0\W=4!K .D#EG<OSW>4?%$NZN
MZN8+WF=3.P@Q&(UPY;#@#9IT)Z8>1WJV>2V:U%WK952_\Q*U\3Z\N^DL^71@
M;.=MW78BS@,&=9S'\%_9O? F7,#CF *QZ=L9?_"@FL@$#=P"C.A#7##2 !$9
M]L-.9Z_R^!(HX+:QQ3&ZG<(^"KZR J;FIW6S#V!WR]D3)$3FND6O\)((T= /
M!T/;$1W2F3ZM U2O&Y5>&L +9-&MVH9!5^B[L+%@8?V^W.N;IWZA3N"4*MIP
M'FK K^-/N8MYFLJ$I#K."+<V)9+:C#"N%8\SH !GFZS1SM"T56FOJ])Z,=;'
M<$%W2MHKU&=!^=A>4,D\&-)(?:Y]]E[.Z>FEGSAFL8-Q%Z,=F!R +7]"8[:N
M+'J3T,Y@-$9/FGS4JTFZ=NF?8ZS$QQ[QQIX<@LB$>XHFBV8;A36^"04B7#C!
MY_HA3MGWF+MU]]CMT(H#L]?AQ:@)C@IT),,(0:$+ZNB4VQ\[.C<:_/98EM??
M]XA9J,J7 :W)>S.?[[W]RR-;'@_.0(;Q)-H>[X -9I+[V'A+-E939NZWS^*^
MFM:MFVZ]C3X]L;3&33"+T"3 C%-T)HDKX=TPYZ!Q-U&1<>+*SL+8M@/<RRRU
MO976P'6!E3:PU=A-'5J%GLC0(6MJ$FCY=2=Z?HL!_=T^F95%E"XXL/<1"67@
M4TR?!?_]+XP ?9!\$A&LH4TML5GJ" <MG.16Y(0S)Y@05ABVB "=IS%WPF0)
M=3RA5F59[CO!")=F22(V^7!OMH+GYJG-T)[SU\SUF%X_,UF_)AHV!J\+?S"^
M6GEI@S\?L2.G \P%*5>]M3M.OM_&%LAPUM<N&+ .0:PB7 BF], XO6TV+,%R
MQ(-X!"^3(3F3>+VAJE9_)#3F/D$<$<SR]Z\'&0M;W@5AA#:;=[-9U$HDFES=
M;H@8AT:PL^\NX($R1([WNM4 AB,]UJ:#DP537?JF^<M4E'FR@'-YF$'Y@05L
M8$_#,52G=\PV.JR1-X,[RV J!H8E/;A8_?KMD(0UWSC\,6=I+T'.O4J [1X.
M^@16>-0W(>/%?/4T&B=BH.5\,A@8'UNN6SK4R&O>#:=LR V&JR6Z*<K:I5@[
M65=O181KFWA,QYY!K^_*,R_FO%MOKYII#Q[&$A[!#.7:R>JQ:)K1^73CT"H:
M\WD'4X[<Q:F$4+E/>085=]H'K&R3=U0G!4\&67N!YS.ED&.;_;<._\+#V'KO
MSASH_\,:M+8+2B&F=HUWD,\A\1[5L13!S"*?(N>OPGD6T@N&5I_V@V8[DW90
M)Y?7VFGA@E1 K7;4KQ-SAA=SZ8EUFI 79F$KCO.4&C?R.$6N'IY9,CY0;.O,
MGR5CQ_RBVED\\^DF-0_KGY#P\,22=1GGG\U+:)]R5GK7X/BQNL=A.6Z+/7X:
M#@OX]>N@"Q)MR@=&HP[I3+EP_.,SMLPJK]ACW*(AN^5L@&<1KNOTDD_6> Q'
M"Y9)L+3=5.>NQH2?:>?U"@_?SLN7+SM/FZ/Y&(_FL?^VOJVVE[%AN6]\7GMK
M:[^H'+]G_C4-F+*7L0$'O$ZY<;[Y>>=P?P]'UBLJ=-8'^$L/T%R?P3-3P)OK
M#KVA6<7<,&NS?M.I^5--JF>RQ#S/ZI4M?7>RUO<)YM2W3XQKXVS."(^M(1SA
MQ!2CEH@8UCI/<I8G9MZ<BHQD#O\O35+L2RFS**6<9J">L$3KC3:G#NVP\P]Z
M06 ?=/Q&V$Q#:O,=(LLUU2OWQNY?(/9TT".+KD<BQ/B1]TR=!8GJ6P>?RJ :
M3,6)U 4\ GH<RL/Q,[ZMCFYP7J<;#P=O9]74=H7)P":7H&W*$SOSI0J]L6"B
M]?W+S20,6'<L"U%IK<NQK']KO6FWAX>QKW_&$;PJ&]72MW4+PP5UNJKU9@N*
M[-0?IXO1%NW-)E?Y;/S29E&JT20\/UUB,EF4(1B6:C3\WK+4YU_ @QP#1ZH%
MZMA:<'KJ^!$L4XF?XS$&=D3=0[-)I:]5[D!*4,\G.1+-]_LC'PN%3]>$:%HY
MC)$REXQI"<UD?>Q7TS'*1E'H7H1'T:ZL$#$_6"PA#5^AB3HLFAON'-'RK3ZU
M9M2U1VYOZK-OQ\-Z]BU0]#GHM4\GU#ER\T?8KWUX??GV2<J<93RQA*HD(5Q*
M1P1SAIA4<P;T2#.]@("9V\1E*HE9E!J.M>.I<I%,,IM91IU82%U[.[4KD4GK
M7>G%Q)7RRP92!HMR6)#Q)O2ZFH?"Q!?5-T]ZC]T:'G,S#H.KUWJ6-M9*DVGK
M\M@" 3.6:RI3G>921W!T6.=/R<6R_389_4Z2T>,V&;U-1K]>,OJ5R>5SC!ZG
MFJ99%%FJ(FY2E],D3[F-F.4FR3(SNR5JO%R$^@PU/TO'<+7P^,F8O2+;82+^
M$<C>C.VD@MT%9&\:9S_TVN]? PE_-X,5UWWM$CRCAHQPBMJ;WWE-S.*;0O>M
M5Y1?"X8X-&1;"0 E'B:X\E02Y?9-()4?#^&FD+M602%'WT=#WCRJHLFTK@E?
M T[\42T<O<;"W:E,7!=RWKW"QQU-ZLN;F+P/OX"6X5TZ*Q>9W0*R?'Z[19TE
M2^6#51NU5K6?Y#F&TU -&_6+X"4)[IFM6<^)=CJVRDF16\'!8%<Z531*A% T
M5S)U2STGH-@6/=FM_M]6-.]&N:7S))0]S&#U/>F/>L0,O#J-7P6*PDI;_^T'
MZ6 )R'UG7PZ.#WN'[P\_?WC_^MO!)7SK\]^?C]Z_IA\_/_]R\'F/XKL.CM]=
M'CZ=0^[KP?WL _W #D\_[C^[A/GT#GH'R<=]^/[[UQ<'^^_06?/M\/@@6H+\
M^4DK:91EBI@T30BGG)*<BICHC''!#36*@UJ>;$>IV.9)WC@]F@VUX@1<&YOA
M5<]NUV>SV^!GKCR06M%QA>@0,H]<)*(T!LLRRZ6B+F?.VBR.I#8N($C31G30
M5G0\0-%Q,2LZLE0QD9H49(6,"==,$R4<A=T($H5RXT22;.W&VUE&MT7.'[;H
M^,EJV2WAY^]#7KSW&&S#->ME2Q;B4<I/*6'N++%6\H1;RZ5(,J55GN8N1@CM
M5O5ZX/)S$30Y<R#_4N&(3?,,VWMPDJLD(YF%\S*W-DUR$"!\.TZC;9'>6O5:
M+E+N5+N:^^0/:5>_B@#(C(TUBQG86C%/XT@IF:01=VGF.,L4:Q6HAR\ YA2H
M2"H%+ QFEW$R)'8)!ZJ42VG,7*1SP7,4 %Q$VS01&R\ [E1'NMW+'\J=[2+\
M(D[,Z^2FW<:1^>C/2P-3CZS-TEA3KG@J:)[">1DYT*3S?$7+JKL_+]LC\09'
MXH<%G5ADPN6QI(138?%<A",QIBG)J.32<$8SR[=V\RQ;DS?A@?H:'SUW"^UD
M'E')G$JY-DQF/(E5Q/(DDHF1^3UIPRUWWXR[YQ5>1,"D$2-:"0T*;RQ('L41
MPAJ"I'8J=S9Y&-S=N@.OJ> \6[N"\ZLX!!*364MS$66&\SQS.796A#\FAL8)
M*#X;X!%TQ3=KR*4M!ZUHO)%HU N*C[-PNKE(@4"T*>&)XB1/,D>TD)&(4Y-S
MI3#?* ="_[GQGH#6%7@[TX;;R,8)S^.,Y[D1P-V9,CPQN;&)$:TK\.&S_YQF
M9"E#J$M)TDPYPEEJB<B2A"@N<IY'693E8FN7;:<YWTZC6^M'#]L5N.$.H&M)
MA"LR1Z^?;U*GN\= /C,8H9*%8U\=)G_\XO.'ZO]:\?EPQ.?)@O9$,RMXKAV)
MK<D(3[D@,HE3(JW.82,(FSO0GL0VC^EV',7K346Y%0<^(*=3*W!6"!R:I2ZB
MFAF>:L[C5!HXKYG*$\:%4_R^G%6MP%FCP)G3U[A)F=4L)XY&EO!,"##79$9D
MEJ1"FD1S*[=V:;0M>+:=LG4YM#9/XJQ!T;NJV_<&EMXNPHMM"GC*'0$CZ-*X
M)T\'91G0+]I>X AQ\"XZ.M;T\/@D.OA\<G[P^E/.I5$J9202PA"NDHA(^(=8
MFZM(@3U/N5QH.BQS)I/(92+)N(@S$:5:<:KR*(7U-^D\V,&$"->&.-&CWBA4
MSX^!32:@Q%?"&#PD\+$57?^N6N+IIA)N@#!MG?^,9#D,H">+#2!P"8<U0":V
M245@9H\A!JONT1F[35?U88U)@U!V'GUL @;=X('-0-9,D6J"*3-!HUGH+7@=
M^C<=!Z]XMQEX@.B>M<,&@M%W/VQPTZ;AQCTZVD5H8!FZPU@$U]-=.=6I?3+*
MOP;8M0+>LE_@WAV4U4Q'48^+/>YA@WU1?<><IK?,?ZW4QD:5F;?],A%'@F;4
M:,&9X"*SB;-QK)S,<V6S3R^7F7PD641W1EP?:QK=:D_7JV?-/JR++JZI7Z6_
MG%!\=GYT_(7B& ^/7Y\??'[WB4:II498PD _1@@83G)N'(E,E%N>QB[UK>U^
M/I'WD#&M^6?2L^EIZ,W=TO:ZM'6IE-1DH*=*4(&YC!"6CE/B0'HX1K.<YM'6
M;K2S6/VQ0B.&0Z';P&L%6/N&[[Q PF[4'H@XD&ZFW];W^_AL>SD>D+;\"1H@
M\N>%][6P9%<?B7<+2P6GY-ZX0=NK<M ?C.I^V56KD8U!I^)/.K(QEJX2H04C
M8))+ I)&$1,EL3-I)'4FYO4PKD0L3"1S(3EGF@DM8QI'FG'F##5R&6+B2O23
MS; %WE@TDKH7G3TS.$,.FFR>SLSN>= ZW\M^YT!>('?3H*4]'[?[FIKO6P2A
M\ZVM@C+RVQ;V0]GZW4/US2Y-<VOGW9GO0O_;UM[;=W#GX6#'?X5$//RM^6WK
M]^U.HRA,0"L[OX5&*RR-X/J^5<,Z>GLP,+[57:AB1VGV[!M^>%14IP% ^+>W
M(S4,75JRB"3X/*I*ME_YA^KW!.5^^D+SR8SFOV_7W0C*XJL,W=SQ]_^Q!G;J
M2?T&!!)"\>N1!I_![(>3IFE'Y_"G_XQ04YT,)Z<)X='O3SHO<=7*\<U[LVTC
M&R#GV9G"A6??FL:&H-<]+ZT=8P.&3Y&G$^CY]V4QQ!Z!3Q&SL*GY_TV&1I+]
M:E0U$(*^L<TSD+@XLS"RJG,LJR^(>*CM[S4R)"RM"<OK80T1Z3?0UP.[.8=&
MU5<;P'ZQT3PN1W.LN +/?'^R8 <7^%#? QIZ@.'Q(4.3[7H;CMO_=!"+ORQZ
M8]#%^EP;G@XJ._/:18WXK!Q49V%4P,.RYF$_\JK9HJ&+W=\2SJKRHM,<<CCD
M!93'>K3>Y,!WP7K6*U/_AF^:VM5@&ABOW'LM'[O7U^=D 4-$@.5Y6V19F[U%
MD.L?@PJ[%\FY4EXB[G?G ]A)M6#]/B[L4KR[!R)A*5MI55\#(&SI<U<>M"C1
M]T8G8 'B5HRV)TS>R&K8I+4PCDB43H0Q_K95"]N.%T[TS_"+1VL--K)''T59
M>.31V,>294;FLNCW[\G/\<M_5()V?L/;6/3GU,C]7^B?(*^F_MBQV'2Q[]O$
M>D1RCZCON4S/3D?+ZG3F;Y/-VQL8VPV23$_Y"8I^!;I,X-/.2U"LN]4@R,FJ
M\4Q,2_4&[%9/SQF[,,Q.>P#3MF':H0$6=B,(=A6*L?#.NG6%1/#@R0HKJ^4H
M]'A#R>=;I51V..P&KO,M(G!N=8.S&O-_>V:]>O[,@9>=#LX[9Q(=VF _K)QX
M6+J%F?F18],!9>L1U-"BL,:#L@&WK26A]Y;40*//7KV=QNN]^=DS[6<"*LZ*
M=C[W/H3L#>TS)L=#.1B=G'9LX7>W[+@10NN6=C@Y37 &]3*9N2L]"R>3=]7
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MZ"AVJJS@$WL2.Z5AS*WP1#@C @,06<<CD2YXZ:R,B7NEG0K%3; *"/5ES$W
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M7]PTRRS=(ZK<.9H4YQB9D*6;>86T2!I9[+RE&C:THGV.ODRQEZ\FEJ-R)O1
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M4_$7Z7R,=(YVAV#*>\$P MW.$&>*(4N91"$0;65,DN9:D&1"Q82E=0)<YIK
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M/3TZLAW8DZ'ZSZ&(A9'0C^&LYS'QFBAP]\O4/<(XD =.JVM^.6EWF_GF;ZJ
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M53XRL!Q@W>;3977N,O0J=-U5584I$KXG_&;ZX@JS5&60)7W\*=+']>WIXWG
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MMT4.E@NL):<"]+L48AWS9=+OTS6R68E^-3.5Q[T<_.6PEZ2;26W9![AS$&N
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M'@8+(S_@7K)U$QTWIC*O%2WF]2R#IJM@7G]M]_+V^2-_;\$F]I]7UL/4F__
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M!'>F=((!UV-XEXUNBA*>4>")1L&3P,;R$(*DS!-X5/G]$3S1DPP'W;.81P[
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M:WX9]S4%28Y$BV31?6P202:)B$02EE.:O))\LJ\Y=B+W%!H[IS;=U<ED3\/
M^UST3<OI(U7)ZBI9O>PF=;9DM6=".6R$-9QSPJ7F>9H:"5X[;9)34W<H5,GJ
MIS.UW\:2U01+*BF8VN2B0YPSBAPF%F'J=%*$B(C)*TU65U@PE7?],"!X0 )W
M& 92\U<,Z#)V.Y6S/2L"C#C;)"IG-&8H)@K.MJ<862$TTCP)*I3'@9HA/V U
M(*!*[E;)W2JY6R5WES"*N3>[V^KT>E5VM\KNON+'-(/[F805&EL>B D\66NS
MY\G 9Y'*,"'OF]_R@.1NY8?.P0_UXTE?< VMUA99ZE(>TYX@$C4*,6\XLQ;"
M4X'GYH=6V=^'9W^G&EQ797^K[.]KR/[V.S(9@$?HG.7^SL&6O)J4T,3T<![\
M1)/'S*3 A8WPO\H)Y[$0#&L3IZ:^JM+#3V>4]\?2P\I*JRWQB/A,A<4%1TX1
MB;1,2@JA-==Z,>GA.2C6:A0[+PI!7DPU]#PV:$6A=3S<>1BN5MGV9P/4D2A'
M1XZ-5Q8YQR@ *F;():50BE%8'8P5)BPHV_Z,B'J3E*OTVVX..9I U?4<[GI)
MZ;%(PBY%GXTYY_;;ZK^-TPV5N45..KUF?@9ONK%58,0UI<C?;W("]64*7W_$
M.A"?L]/;/W(;<<LT>[@$?"\?$64C$<C0OWG!!2YB0J25F#A-'0^6:LI=TE%1
M:5QT-NU1(]8&GSJX&C5^8O<C<MUHCY!-<)-O;.O<7O36_G&36:;91B./;$Z[
M?>N>IK2P/2VQ!(Q5I\QNOP$$B]W\+EBK79JUU ZZV0+_[?Y'J]8V"\*Q@N<N
M&^\BKK>;D\3F"4!NK)^_D&.]4;N+K,UIPA1U7F#)N2;*&>XM-U0*3V+R=Y&U
M#5R,J_&]6\V>;W4RU6AO>3C8OO7=AY/C7?H#G 7X]D]?SG]L?<&-G7\=;>]\
MH8V=(];X_J^C.OV"?VSYR_HH!]OQCT,P^[1QZ.%S?QPUMKZ0^O$7T=C:)=L[
MGNP>?[G\L?7UJ'%9/__O);@%A[M[5!N<K"8(MA'BJ<@E,D9B1+6FPE/OE=.E
MQP=V,(9WV0$#1R$8(;-_1W@>AFJHB2)0[(QG7)I1SK9B,GRQ\;4AAM?>N,4=
MEL81ZUL^G7N_^3F-]-2\@_,4Y2%GN;^W8;O]-;,SYC.]/VRO^<I%_&B/*2V#
MBQA)[1WB)#!D76)()IF( Q%/4:XHS> )(%C!*CB)1]#V"A;"S$':NI82>*L]
MK=ENK!WWY:5XQ_"9[^F-H_5VS>972X'*G*#-7LWG'%@S-3.S7K9'Q??;DY-N
MYZ3;S.RAK?@SM@94GT-7.VC&KNWZ@XM\L@PO#U+Y91PQR.<7*\I%6F_FY/>N
M$-4=5QO$+(0ZC1JV")ZW!_+R58M]ML5.QTTX)7?:[4<69#5YI;)I+>&H,+#E
MC\-^2_D76_),W7T6^7+XYVZP$$Y#,_A0;J?E$X@O9YW3&,JG_A]PY@KFWO+7
M=[XX.*W;[E$<"$9F9OR<[5)>?O]M5Y:X_'W(:2N$Z+=_9W-9OD;FMKG3G&B_
MF(?T)RP '!)OVZ>U;7 ZNK5M!U?Z69C]8IC$^%;3:JL?N]7?VIU[MYE5V_R0
M;=[IG-K67-@+5Z:PI\3)-X\IYYF;'#T[[V&UR(4L<IYC\0JQ7EIMJG?:\:)V
M7/@FM01W])ABQ)=VHC_I%E_,F;PA3&DK@C.1<XFM52E0JB4U1&L?[+1G\N]M
M[^!=.^3_?/C?L^9/V\KQSX0T^G0U3\]_1/^P!&1Y1'^2WW]1/_XFZM\_'C6V
MCO"/[Q^/RYDF'P]V#]^)^N4[O'OXX_CJ6']P1%\D+#]?_-@Y^K7[_0O>WOG:
MVOW^X^#'SI<+N%:SOG5T6=_ZVFP<_SCZ[V5]:/P?W-?EY[T8F)-<.12TQ(B'
M$)#SE"'#A.,:<\=<6-LD8EWE\'-IZI#GU%E0H=0+12DAC$L")\=IX$9%%T-0
MRKN@J<'&+!JEEK*&:$4 ZN(F0-EDHJ'1 R(EBC@Q&:"P0%XEGCC#UD6QC)T2
M%4)5"'4G0J5@.6"2#)E)(#B7\IPX9CE.(H(G52'4LB)48\2%LHJXX"5!*D2#
MN/ !61TPTHJ*Z)Q)2I,*H2J$6HI[FP&AB'#88Q*9BX3K2)T(1 -D.6R-$)Q4
MD=YRP]2((^6$8((*@TQT G&I\D]$(!JH#R2Z@)E:PDBO(C=9%AJ4R1G_%4A6
M%J<=M6;;M\Y"#)EMP@,6%85 Q0_Q&I7FQNWSHLW>;#?_8@PB"SQ%)6W44O&(
ME87H4U++A<!62V$J@[C$!O';2.K3[V529$=D0"Y$,(C4<01/,2"#:4PX6F*2
MGI=!G$EC5J.5L\*\UX!YRHO$I%<0PR8N0E:8I)DUD3,OJ1)5FF)IX>[B)MP1
M134'DX4\#@3Q0!,R!OQ_(B57C$:OX_PH9RJ\J_!N>>YZ%A^/6 B3$TZ"*^X$
M,PQKS+S53$M--*OP;EGQKC'BWIE@J2-$(RPL1YPQA;11"442HHK&F*!9A7<5
MWKUNO(,@)]+(DV$)<Q>E4U(P9JP+(1IF%XUW54S[2- ;<?*,E#%9KY"122%X
MK DY%A0X>898S5,D9F[E/$^">?TLY0AW Q$%HCT#I_']=SL/QN1JA2NUPGFF
MTODR9]+?_;3-5M&/D3N1>@#5M6;[9^R=%LUKCRJN7Y:J[^H:4USC]12ZO\\+
MR0U)IWU&TX+[IZIV?R4U$-X[S1V!4%)0'KS/G,V$.Q\TB8GQJ8]\KH#S8Z?[
M)\#FGYGTH&C2W(KN]/JW*ALP%\=X?^RP1TE%320,"><]XA0S9$ARB,6H2!+@
M%U-7%6E5 +44]S8#0 4LM")1AA@$%XI;SXWTP>B (Y=&+A:@JO#]D2@U$KX'
MCC5-5"#N(T,<!X<,8QPE1J@+-D3- *6(7,>9EZ\"J0JD5@*DH@9LXI9YQRSG
M)AIME,!>:V>C9W[J)&/E13TQ/HV>J>AHN=.PFY[G&E+%''(X1"2L3,G ,PPB
M55Y4!5!+<6\S )3&3@1MN0J1<6^BPS@$0P2+5"D=IB8:K[RH9T&I$2]*.V&I
MPA@QG#3BW MDE96(!"ZEMEHD:Y?0BWH]!=GO.]V3S#D<09G<::UWI1>W)I"G
MF%'SDJ;,3)C\9G3$DA&F>>0 25H!7 %"*1D,MWKJAN;*A7I2<#H:2T09$P,3
M22"->80XCUCDO*>9(]E%8C6V;G[]S'<@Q K,&7_9&AVB4'#K3B0?,E.SII@K
M8QF&)VR<5I7/L=1J/5I=ZZR4SA$4G).(NQ"0)A C.2^2S&,Z$^5KF]RL"R8J
MK7ZY6DVT4]8KETE'.//@B$HJO5>&*.,BG;JMO[+33ZS0HZD.21/'7I$\!P[#
M/U(CHPE!+B3C"18>6U/9Z5>@T<X9Q8SBEB?/.<<:!X,Y3591S$"1*SN]U&H]
M8J>E-S12T.B@HT<<,XZ<HP9%2H(-F%CIR!+:Z3D5W"QO2J#<VO%_WW>.CV.W
M&!Q\8D]B]T$9@FG3LRN-4U(0K@7SUFC#A4HF8.GA?XFTVABUX'BB\CP>"%$?
MSC,\E5F"+[2^56=[1F-"5*"(,I6+N(E".LF$!+9!&"$<I?/K7%F^4Y9*I:^2
M?CZ2(*+05B>>C]Z(U2I8KG%D.6%0N1[+K=?UFWJ-(P^<,XFL\ EQJQQRX%.B
MI#@QG!O+L5S;)&R=:%6I]<M5:VQ](IXYKD3B#I2;6"ILC,9PDHQQE:5>6HW^
M=E.CA:>$P!-#A#FPU%0)9 D8[LR<%JR4R:3*4K\&E0[*&$J-EX9BCL'Y5HE2
M 8JMDS4\5F682Z[7_J9>:X!E*6)$7.5BS%P\8#CVB.H4':.2,Y*6T%)77'FK
MP)7'ECD/\VWCSXW:?@?6T\X]?36[']N^JLRXJ[@U&A^$DU0RRK4R.AG!N;!&
M N([&RIO;CE1_V(D[R+V:'*18$]0!,-=YH;A(2;DA)(0< N-,R%<=>3SXE5:
MQAA#9)$;JK@*R5!K",4A\6"\UU4YZ)+K=?VF7EMJI#680Y1&0:]-"LAHH5&4
M*5E!/'<!HC2Z3K5^P5K]@&O,4/: B7=&:D>CYAJB(7!I@Y*>2 J(&M.PQOSJ
M-=^TFZW^./0'JTRE"U/IPK>;NL Q)SHPAH1A%$$<@T$7N$(N)8HEC4P1D:5G
M1 TJ0[.8O@-JA$Z"<.?@N6!O?9+)8N*(Y?#W!?N.E:%YK'+YF\J5A B)186H
M\#:G#31R6-L\#H129;UE6B^?H9DKF<?R![>GW6+>^L5CVPY>1U[3BD22 K-N
M!7C#!DR\5AQLNPM2,E,5*2\S0%V.1;@A*"RP(<AZ8W+_)D>6D(B,$A#D<$*P
M-FN;:ETO55JS.JV8>\HJX0#1;:".<!6]5>#Y1>8Q]EXQS*N4U=(J]&AHJWWB
M26&D.?CTW"90Z&!S-Q$5'!Q(#(YD=0#Y"E3:1LRTUY:"^O+ H@.S[1-8;X-Q
M=')JGOY*I9]<I4<B]& \2XQ'1#D8:FX@B-":>J0)-EJ2I!FCE4J_ I7F0482
M)9$J2.Z]M=)SGHRS%!/.:*I\[^76ZY'D ':2.YTB8A Z(5X<+#''$+CCAOI\
M:"B6T/>>Z\FW6>;D0#DESM[)<%N-AZNH]!<^'J["ZV? :SR6*R$DLP!1 7+%
M#.+<462B4@A\,RJ=#%2%.">\KJ:'5)"W/'?]#-/A*LA['L@;R2811D6$W41*
M1(=X% !Y"D<45&:4)?D!A[5-3=8Q>S1Q5H5Y%>8MSUT_PX2X*M/VY' WDFG#
M+ &0<8>("KDN3#-DA8O(4(F55]$Y54W$K/#NE>/=O";$53[>\X#>:!J2*88M
M-XBJ//5<>X)L8@Y91JG6@23O-?AX>MU0O!*85TV(JU:X]"N<4QI]Z;/GO5X\
M[=6.BPJ[&&KVM)9LLUO[F6> UL#.V%HW WT7[JGF;*_YT(QZ"0%O&&Q]Z)SE
M='VQ]Y5C\MBM>3%NR]RR\85(5X-L%^NGT+'TNY>2)08A&374(8Z)1L8HAC#/
MH[H8BRSZM4W*UB4V\_53'J5 JQ&Y5?!9P><39?8K^'P:^!Q)Y6LLN6-20USG
M,>+.2*2Y"BAHHJV3VEFSH%1^!9\5?+YZ^)S;(<%T\%F="CP".4=.!82F. )J
MHA!T9O*W>52'IT@'R4B2-%D9%W0J4$%G!9VO'CKG=MY0>9Y/@Y\C!PPF4FT(
MHXA*SA$G+"!M<$+>4>V-,9SJ/,,6\W7)Z0O SXIT[7E(UY9OP:ORSFIC%[FQ
M_SC-A]SPW]#\N?G/XI\GMK@T6]S:%88.UC%8P;'M[C?;!1SV#TF+?H<!QI9@
M"<MLV9->?#/XX>W@AIOMXLN*#[WM7ZL/O'"YL1.IC*7ERV_/F^'T(#L$&[AT
M"OHRV/_F_LL;Q4LCR%^^QM4&,;>_C#?(K:_==5E"-JAA#[KLW:\)0JO%KM9B
MQ527O0=![^]M)&/OG1#9^ AN<?=I_'@] BIJHAN?O>G20RM\ZO+'>GG:6S1(
ME7^QI_]TW7]L;D4?CUWLUAA9KX'33FZX=5/NX;-&?-/MRF_-=NWTH',&EPB]
MWV\EDQD*KF]S2"?XI,LM$%_..J<QE$_]/]VFAPLWV^6O[\"A_QEK==L]B@/!
MR#UUGP/<15Y^_VUER0!L7?G[OYO6-5LE+4\6HM_^'7_&_GO)W#9WFM*/%_.0
M_H0%-!,LIGU:VSX] (7<=G"EGX79_]P^.3L=WVI:;?5CM_I;NW/O-K-JFQ^R
MS46UT2S69/4+K$J<?#.-N,Q<A_GHPKHY<I!6BWR^1<Z5"1 OLS;5(6J_J!T7
MODDMP1T]AEOAI1U+3+K%%W.\P&-2(G"%@\-<:.)T/J:56G'JJ<3EI!9R__'"
M>]L[>-<.^3\?_O>L^=.V<OSS2H\;.@0^3^L[^[\:L+;&UCZN'\):OM?/=W?>
M\<9.732._SK8WO+GVZ/'#8??1&-G]]?VU@>:U[:]]>6B#N_=O?SCH+ZU3^J7
M1_3']P^\<?F.__=R4.22Y[F^NX3OVC.6&,R90@XSC3CV&%F,#<KU+<II*8W+
M,]7PNC&/;F=8/K*D"J5>*$I%2V,$4+(R,1ZBTTQAAZD2BMK(^\30BT.I%U=/
M\H0 =7$3H)+!\#"90,&H?!S*4Z9STT@+YA3(;M)!OF ZMPJA7BA"44,"=UX;
M*1-7VCO#5<*<DL@=D514"+6L"-48<:%DQ%(G:I$U+"">!#A3+%B$C5?@($N>
MM*H0JD*HI;BW67PH&KE7!.L4!0^&6R:"A>  +L29#ZZ*])8;ID8<*>\\\30%
MI *3B LN\] :ARQ-G!MF.&=F"2.]JMCF>:J89F,F7>ID9=E;W6S[UEF( 7ZH
M><"B?&1:_A"O4:DB**V87&XUB%XRY5@R,G+,-9>:@>=G(I4&:^*$K0SB$AO$
M;V.I3T)IT@$3%(('@VAPS*E/C:*P3"L-$D[9O QBQ5Y58=[RW/4L:0H1/40
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MJK%&UM.(L->,QZ3SV<P5)-]+#?R;578/U)7<[$^ST#8EW)IT]_=>PJT![$<
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M/?E<'HFKSEY?<OQZM6<Z+^O+ZO BJ4>?T\"1!0;N7N%G61E6'S6)QML16!Q
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MW3OPOSN>JP$?O='4I8"L%!)Q$B6RP:2<<=C WRTV!$Q'RM:,6'(-^":DN<*
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M^(>Y+4/?RCVZ\/I[W+#01)YN$7E25T>>?G7]< +_:0V[G8W_#U!+ P04
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MWMB(L?=IE@=!C:K8Z?C4.5Q0/;,/MXW^8BOPTNA+R#9G5H/9H^:06[,+AB%
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MCV'/.Z*>,X6.*:V.QZCRL@%^0]O_\G2T?=5O<[)MCDM)IJ@XP,TY8KO_RD/
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ME4S)%\K=BY_W@+<3N?Y@B>^AI->-7I<29M/5Y\5JVN;NY[J-1N6$8U%K.52
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MC^?KY'7M2\?M.R%KZ5"$V](KV=TSGQ"U9$F8!@$U *JM_O5OU@&X@00!$'4
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MT1?+71;H@K.-F=Z-PL/OA_MB8^V4R?8::=@!N2MA>#V;#XD<O)KU^JXL%]Y
M:X$QF0PN.@^*-G*(LB3@+(M8:TR1V4V[V*:7''%4;P_*F?0@V1[LHHN=E0[Q
M#S5Z>/U*K 8+!Z*8@IQ8S5$0?4EK",+2"M"(F;&,R+8:/[?#'K&)IB<)E%X4
MTD.E]WWT+>>"U2.[$]3 Z>*3UPE2JLEJ62$XIS)$'VP@)J3!UK;U+O0]6R#M
MI:B&]<W=[GB_Z7<Q=N[;]>:4BNQ&FXL S40=\$G;9R@Y@(G(HC>:J\"W.HYV
M?_?C-4D.(>P>3JB7HS";79Z7[Z8=F*]A>9!M<H1>#KSD2"<HN81>T)>23 A"
M:A]SZR*U330=#B0'4>JD1XT< S$HK1'.T&XGE:_Q";*^/,N0E)7<"L>+:UU8
MNAMB]O-I+^=T_DHN_?ET2B 81+(13 D6HN &%.>"6";U*RXPYRQ#4:T'I&T@
MZ6FOD9;ZZ*&AR._C*8;1\-^8_T*2^V5"V!Q?D3P;Z,(\1J<A"V/J^2+ :^;
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M4CR079F*93I[S<!SQ42T EU1">_>-';XPC00VZF1IXM..D3TMTKAW(88E>#
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M;IVQ6XI!5A_7+Q$6^/>__0]02P,$%     @ (X!B5AR/27K \P  G2H* !4
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M) 'G,-;62!Q@D291;&-V7"?&U(R0'47 0NL :%GF<[8NC1YFM^25)J#HJ.+
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M0G/82XDF*9' &&EN4HJ$J7!R7I^89VIDM!43/&DYX7P)>"VI&P>=@M6.=3R
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M<KYR)L83?-P$B]$7Y" ;8WP)^NV'M\MR+N:+=3E_[N2#O/_.%VLAQ<\:6J/
MN@XXNE/O:;Z<+[\6GV1>R?]QOI0?2OE8S$(6*<:S# 8DT'9WI(UO)E4&(TP)
MSF20DM3)[O8EV-3V,N.BJM)7M:0UK;GM6]X6S&Y7>HUE&'C/Z:K428L#K5+
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MTI00SG ,@P!I(Y53"JF@"F8$12R*E414SI;R*RVEN/?8 =)=5*N7D=0OXX'
MP[V8W?9]IMMCG07KN\5CCY6U-#Q?::'^>-5MCO9I'+$-8_^%&*O38@\)I]5,
ML3_$SOT2KYC*O1;WN\9E=KM<KNGBLWQ:Y>5,1EF$@R@P(;@91"R.(#','Y-(
M<<0Q31*KNZE3$TS-[FQE!+60H);2ON#V41#/DZP/:(:V*]U0<:JJ?4[U7M6T
MCPXX6A7M<^ITJV>?_5P_R^^MS,LJ_:B4Q9UZIX<LYF53A!DE1&0)E5"B+((H
M(@IBDA#(E"12AA@3YE0/\<Q<4WNE.Z)6I4IJ6=U,KW/0VIE0G@ ;^$7O2FG
M:N0<H+:U!1Z>+))S,XUJ65BHO&\AV#S2CRPZE=]G2L@T5&D*H\P42Y4Q@A2)
M#*8ASVB89&&6$)<\P<[83F0P0B+@O9FC?W9'%S6[][XG%@._YQ\M '!^I8^H
MZND5[HX\ZBM[1*7]5_381WJVO]LIOOQVM7PV;S];R/JOA3;YJZX/,YD$5 5A
M!DD5,2)9!"D. RADG$0X26G*A%-C/,N))[>S;\0#3T:^RK4B5HL%S0OPU!8;
M<_2R6*^"W?L_!+8#D\->F?4;T)&Z_4<%>B6XQ[Y\CE#YZMAG.^VXO?P<P3CH
M\N?ZO(\TWE,%;JM?FM*VX0R'J9092B"-.#:%V;%F,9G +*69R-(8X\RJV&Q?
M :;&8:W$\+"J>AU:9&+X_^G/. K#O^TEJ5Z5F6JQ5'8$-^0"#$QT!]FK9\J1
M5Y_P7(B\+W2#I+A:3/^*2:_VX)Q/@W489^3KMX_SI?Q0RL=BE@0!"13!,(Q-
M5G[ .:2A*85 "8_2*,YDZ%0%[WJ1ID::W937RS<V>ZFQ5:VYWXQNH%+.-?+K
M^@4>^-*MU[)-_8[-;L7&NU [ /FU[\^V OTQKLL. /1V.W8X<H_LC8^R**3<
MW3Q:7_VR_+#DN?G))ZG?CV6I=Y(91D$4Q%D&-3U'$(5*:1-7&[;:K$VBA$:"
MI5816[UFGQI!-_=$5>#1O)'VQAS)&WD=\@V<%^(\NPX.[]">NTKT&W!@NVZN
MYC3D'S:0?QH%<H=<CR&A'RGIP_\2N&6 ](7P;"J(\Z#CY83TU7<G.:3W('V;
MFIN$D]6R\K[4E;([C8!F"F=!)N,8*B*TB4_U/H%)'$"12DXX%H*G5CE_=M--
M;7>H)0:UR*V3L9:ZVQX,_. 4)F<)_?GMP3^@ ^\'EECZ[(!N@\P5?=#/#C]R
M-W0;50][HEL]=65G]%\T7:WSR@XN-C_\GW--;SE_>'FW,GZ-&1)9'*0JA'$6
MFWKZ'$.F,@1#HE! ,QZR).C5*]UF]JFQSK9W-]A(6F75_WK[[^"W6F9'7X#;
M:M@=^P?#>& BN@[>_KW176#RW2W=:N[7Z9_N LO)CNI.@PQ1[^GV<967ILJ4
MJ2_5UM!4+),!4Q)&BIHJ@4$"21IIDDLS+"(:$I0JEW 5=Q&F%M6RD1$8(7U6
M>3JZ '9$-BRL [.91<6GJM9>!_8!*I[VAW"4ZD]'!9A0#:AS +E5@CH[4L]H
MW<T]_)WJF(K-3;T4X2S+,AR$209IR*6VWH2VWF@BH"2)R%A,DS1QR@&]../4
M++;F&,-; ?NG3ET&VX[3O$(X,(5U G5,0<"=D^%&8(\!O;;0^ KKO3C?N,&]
MMNH?A/A:/]CC%N/M2E,5K_/8O\C<,%LG%&@O1FC]N%Y4/5O?S4WQ_Z78U(QN
MDPAHAD., R@9)A Q4Z@.$P$S1$028YG%S/Z*PZMH4V.NK7+5NU>I!VZ[@71@
M+\H.;'4$K9+;:NH.SGN_2VYQF?)J"SDX?_I=P\M)%$,OIL,US:LMZDAW.*.]
MH&Y7.X/ ?O;>Q^^,XUT*#8+4SHW1,#/T30TPL9_ERZ>%Z2VV%.__<SU_,J_)
MM@ SIW'&(R$@I2:P5J0A)"*F,".4QYG,HI +MUXNER=U>;''Z>?R]T*J]4*_
METK6??MJ%2I'Y$9^UX2 B]B'"F61C!@D.(T@HJDVC 0+H!(IDVE*B22."1D^
MD1^_^OA(L-N=V?R".;#1T0I[ RIQ=P$<M,:X/4S>\BXN3CARQH4M (>Y%M9/
M]NR2O>>.VCJJ=MU6&P\Y3P7+.(-2(=,7(8L@#44*(X81BC%/1.34;]=Q_JF1
M4W4U]0O-?Y=E?4/EV&G;$7T[6AH0TRGXQKW[PGOBY:O5M^/LXS8#[P?-0;OP
MGL/T\4LM:%'<J:;T^EU>%5[?R\UX_UWF?%[(*DUM\]FB^7 QRRA*.(DBF,0\
M@"B1QCT>QU"&,DD1"L(,);.GJBK.EY+FI8U/ZGJQ7-[3?>&&>V4WB4UMEIEL
MM&@29[7-]FW3:* $Y8,$3'Z=+ZO4)_U+\X-:VJMR;+VM?:IX+&*]XE@)!%%L
M4F1$A&&(>1R@3%$DPV;MW^NSV$17OA5M4NMNW!H37'$;1^2X:SBT^]%HT^F-
MHLFU[O]QF*78*E4G9'?[J6P><NFLXF.Y7%R-XR[;:)T!GNKF\$7U*GV[_")*
MRA\ ;U?]6V<%\[KMRVH;1?@77_Y&?]B?]S)ZF&=$WZ(_5'8]BA['[5_?[UX_
M.HMH(E.&%"02FQQ3)2 +T@@&2J8T$)$,W>OZF8&G=O3;5*XSPKF7\:NP.K_U
M7(/ T <U*^5[5>OK:GI5E;YJH-&K\W7%/U:5;^?WOLXW=;NS]@47LT"$F1)<
M0)Q(J8U8J2"-,8;Z/4R)BC 6)'"HJFP]L=4W=/P:R1OYW,-\[#'O:T;V@?"U
M[<2FO=Y&:-]87FOC78'IZQAQRTV_PB/6F=Q\?<4Z-\?F[0EJ4&OM!(KNYMC^
M0*]L;YW0Z[)!=>K!'C1>W>U^*(JU%.^J1:V++-<16JUIMGTA%,Z83+%Q1J6Q
M_I^*(4:,0"9)PB7&4A!F'1_E-O?4["XC.%W6!QM>YZ85513%^DG_=7/XZ;Y*
M_5C?<8DL^'\XX ?>">HPE5IR4(O>%*!OPSXW;H$^>X(CT@Z[PW"(O_8^47^?
MP;Q>DX.-H7X;."T>CKX2OO:-?OB>W4$<AQQO+^FGZ\ZNTG.(UVG7TDDM/>=)
M^+Q:+%33'#GED4I%&,$DC; ^^Q,.61J$4 D9")DQ'%.KL__KJ3"UW6Y3Q.^$
M1W;3E6[<AB\]OAMV=]?37O&AMUF/[6(Z0!RI/KCW+1JB@]?KK>1KU\OJK\ ?
MH[[6U0ODNUO-%9)X#IJM@T1-C.@L2@-,$94P5"*#"&$"<2 H3$@<,AQ22I13
M7PR+.:>V>;TOROFC<?*!=1T\NY@_N]:6M8':;FOQ#.# >\'9<,T;T(E&'B%0
M\Q"AH2,U.S-.(U3S$ +K6,TCC_8,UBP*V2F7\&Y>\,7*E%'8]!T5F*8TS@A$
ML3*DPS$D4J4PP&$:"1GQR,Y/9#WCU"BG%MBQG>ME7.T8QBM: _-++>L-Z!17
MV<H[B$%HC8ZOP,J+\XT;2FFK_D'PI/6#5Z7Q?EHMYORE_O\V$4(%- XY85 @
MT\ G0#&DJ<!0HC!AJ<8\IKA'8N[1R:;&)3TR^?@VDT^TF7R+JU)MCR^+S66C
M/["'OF?<2*J-G4I*\%OSITT^BCMZO;)5KT9Q]/S3%DWO&:1GH;#,"3T^QFMD
M>9[5YD3>YOEG^EEWO\KR+2T>M!EIB$.\>=%VH_BPW!06O=4S/]=A\JNE_L%:
M_ZSYI3X#;TR5D,91IKB <: 01!PQ2-)4:F.0I%%DRKR@Q,4$]"/6U+A]6V&7
M;N1W,QH]+9>=93G^(@S,^5HA8#0"K4K&K_F#T0K,ES]V"B!O-:L:1#6Z@:UR
M@]BJ?O'V9-!Z$FI4J]<OD/NFL>?1^Q9D_O(@%POCNJ3+EQE/$_V5)PE,]?I!
ME)D,2:D/XR*C-),H24-)W HP=X>?&H\V18(K$4$CHVM1Y1WXSO/A]: ,S&M.
M>/2HD'Q,[2LJ(N\,-W(%Y&.J'%8\/OJIO@5!Z[/:AR5?/<I[^OW]=W/9(-_(
MI53S<A8G<<PE1I!12O19-TXAC@,"*5,!20214H9NU3_/SN?T*H_6P%:T!]H?
M6"WFCT#68KL6_SP/MIW=XQ'"@5_\5E)0BPJTK* 1%OS0B'LZ^JQ'_4XK8+P5
MZSP_V\B5.:U4/RS#:?=8#R?:;L6>.J;G3KV;+];&$]0&+/Z\RO<Z9-Z*_U@7
M954#><;25,29E#"3-("(10(RGC"8J#3F$:(T$-+:T>9!H*D9&DVX81/H]NUA
MSA^J<#>^WZEW7H!BS?Y#G]-!N0)THQ%0JQR(!H(J;LY@X)*]Z&.9+1QW(R_>
MX/>8NQ[29AU7"K0:@4U$KUFA_2; H*/6R&OEX"8<><U>)_CT::!7T%<PJL=%
M..O$]#'/>(Y.CZCL.$-]CMO/GC_6>&E3'*\)$RK>K>6O\GMY_TTNGN4OJV7Y
M4,PDXB1$,H$1E0CJO36#3*0*"JIPA'C P\RI#6I?0::VQYKK/#<KO_<2V)G_
M8P [\/YWLJ7;1H\;0Y),@D]T+F[ _Y$T!W=+CU$]UX+HZ0S16XQ1#Q?7@K5_
MZKAZO)[-G.9+S;YSNOBP+,J\LA5NO\^+F2G>*7D6P3"(]2F#BQ12*1ADF*51
MQF401%;7^1?FF1JQ;<0$6SG!;T92U[9,)W"UHS,/: W,5GV <F^P=!X&7ZV4
M3LPR;M.D\ZH>M$>Z\/'>T<I<2E'\K,5KDHS:N.ABAE/$5"("B&6L;2&9"4B"
M)(7ZYV$F2*J2T.FZ^-QD4Z.%5E9@%NYHGIQSK/)IH.THPA=\@Y_JN\BU]0$V
MDGH-2;Z(A[]8Y--3C1V$?%'I(]''EY_I7]KG4UM6[ATMY2RE"4WB+(9)I@A$
MB&KZP$$,(YF$C&<9T^:%:XV?G1FFQA2;>C>-^TJ+"8R<[G5_=H&\?-MY-3Q#
MWWNX(M.K*-!1[:^J#K0[XNAE@HXJ=*Q>T/$/]KBD.'82J<X:BQ?3I[HYB\P$
M$C2*HP0*G&00X2" ),P(3$2,33$O3*65/> PY]1>]D9"8$K1@J?FC'9ED_LC
M2%M<!?C'[[6\'2VF50?[1F[_D#IX[/U#.Y)3W@_$;IYU-[#..L\MAQK//^ZF
MVXX+W/'1(=K85FT;9IB':2Q)#$4D!40LB2 6*((B$S0)N4AHF+D<XBSFG!II
M7R@=7VBYFR87CBX?&_SMSG:>41W:L+M<B_\BH)[;TNY -$H?VGK&"36>W8'
MK=/L[J,]+,CW2IGLAV>Y":'YK&W2S](H-E_,JWWOLRS7^?)^587DFCN_VZ6X
MS]?R[T^%MF2YV:03$@>*B 02BE)-5C*%3(4*D@A+%NO_4D6M+4P_,DV-S&J)
MS;W04RMSE0!>:JG!^LG%&/6T:!;&ZOA+,3 #;A3JQO09G<"N4C>@6:_[%=@H
M!K1FP*@&M&XWH-%N_(5S,(G'7\"13.8Q%]+-L/8+^5G#V]-4XQGF?K'9,=P]
M#WU-F_8C+1^;GJH4,8$4BF'"PPBBR)1SIGK;E!F.4!I'@:1.K;8NS#>U/= F
MW[I/J_;3@-M9\1YA''C_.I>H?K%C<,\N[1=Q\=JC_?1LK]"A_:+JQ_NS7W[L
MFF(Q,R*RB*8)AQBG"B*!,=3V=P)QHC!.,IX)FKDDM=3#.I'%:+DKM6Q]:K\X
M%7B9T"M^0>.>-5H\OZO-H*]0;>74F[?WVWXO6&T[?-'&:U6C[J,!UY@))AXH
MS9@(A2 P%('4>[>0T&20094H$J>)#%#L5 CUS%Q3V[<;$WLC*VB%[15P=0YD
MNW?6$W0#O\B]47-^Q2WP\/3>GYMI5#*P4'F?(6P>Z4<;^K ABT_TQ7CCFGZ7
MFV(004QBQ&,"1:S/<"ADPKC&-(M0'D=)1M,P<0I,/S/7U&BC$<^Q<MLY,.WH
MP1-$ ]-#)25HQ-RTP!VD](4%()[XX=Q,H_*#A<K[_&#SR#5F196?2A_GRXIV
M/LDE750^_:7XL-2OHRS*)GUU%LB82$0Q9!$G$,F8:@-?Q9 F,<<HI(F*G3C#
M<?ZI\4@KGO&7_[3*P5,K.I@ON5DHR\84?9?#Q2@9!.1Q#)4ZO7TCN_&+MCB;
MBXK-*KR_4#N@I_GBC)Q7D\9^]E<P<YRA.6[ZN _3TTVQ+.=M2NCV[O+]=[Y8
M"RE,-*LI_K&NKPCNU'N:F\[1Q@5;EP1_.3Y G>U"I% RPI (@2%"(M/4B CD
M&<5)%G*4)4ZQ[0/*.C4:[4K:B0+H=88;<HDM_3;36+BAG4']ULS=230\FKX\
M3P-*.JX[:WC(#WQD(TS9(PC%U$"NC^*+Q>J;23&?11D.$YPAB'F00I1@!G'*
M.%0)R6(:1 %+K#HMG!A_:M2\D1#05D2'L((C^)WG4 ^H#,Q[6T!N_0#B$#-Q
M'3 CQ3^X .06OW!:_;.Q"$<>&R^NX+3,.S$"9SYV13^VHN[^-LM(J'@:("A2
M:B)V0P$QP2D4(8Y)BBE#/)O5!5>^E#0O[0S4[A0NW\/]B8;[*KZABZK4CW-+
MSJ,H2A$EJ@J1D(I")$RO>;,1I"K"2J22X$@T*+Y?BC$P;*?YHR!H9S_WQ61@
MXJ_%NFD:DWIN7;:GKL^F8NW0X[?[VE/J:".N_<_T/-=SGNM1VEH7I@1O[2:=
MQ21$)",22DP81(1)_=(2 5-&4ZQW"L(#I[O1DS--S7!K!-TTA' N.7X:4QE'
M3#(LH>:\ "(DE<8T)56\!P_B2"$>.T5Y>,%TM, /.ARRE@X&'W@-[1YH0.H(
MN;E)\N@<N(2$KZ/]R7G&/9A?4O?@6'WQ@8&Z_187FBANJ@5\6-8YQ^=:*<X8
M1UP%)(92)5P3#@HA#?4_HU00S>NI0*E5!8#7$7]J.\.FY7-EU8G58D'SPM1;
MK"V\/@;>>%\%!Q-RD@L\AI%ZH:EO8=O5=P,"T-^3&H:+W7U';.D[R!J.U<[7
MK_#3:N4[R,(XM_$=1@JOW9::"ES=UB$S+%),DPAKXYIFID16! G))!1$R"#(
M."'$R;BVGWIJUK;IVL--UYZG3M<>U<KMNY72L;6PVVR&07C@C>)"2Z2-\)V6
M2(,W/#J#V+!-C8Y-/(7&16< L6Q.=&Z$WJZ6U=JT-_I:-:0SEVR;@%(D99RD
M$4R1BB *$@F9:2T@5$H)(BR1H9.9?GJJJ9G46TE!*ZI-N*0KP-;N 0^P#>\?
MZ(-8'P_!!3#\N0A.332VC^""PD><!)>>Z.DE,.EE#ZN%?J(P_<G+EU]7Y;;-
M=9I(%*%40,P";>EDVMPAF;FDDBGF#*D@PL+I5']VNJE11E?:?P:UO, (W)LX
M+L!M>7+V!N+0)]UK\',_C%K!XNOP>'ZR<0][5HH?',[LGNH1D?-AR7-3^>J=
MK/_L]%^L*F)]-F>X.Z6MGRKM;A8BG& 5QC +4P91R@C$41+ ),ZX(F' 44IG
M2_F5ZH/?O674CJ,,5B\-J5^: TF&>X&V)=T61FB0&ZGA2L&U_@=U2&[MM2[G
MV6@PF$<+6Z\D!C^TLO\(/BP/B^A5&L [!;4.=3[Q@(@[Q!D-B/Q(04@#K(!;
MK%)/",\&,KF..5Z44T]M=T*@^H[1SS9]__BT6+U(^5DN#.$>N8O-<):1"&%(
M6!QJ\]2D.BE)]482(\[2(,ZP4_>*BS-.S4)MKW!YQ[_J9I%>!MG.*/4*W<#<
MW\H*\UK8@6_ K:'Q9)M>GF]4\]1:_7T+U?Y!7V??S4$LTMPAL*E&R ,!$5$A
MI"A-H?YQ&+,X26+&KCOW_A'.O/_T9QR%V=^ K"2^]J1[]2GWCW+"O2W+?,[6
MI4D%-B4;/]'!<K,O@S38>7<J9UWW<ZXGU]FG7#[1N6BR'F^7XJY\D'E=2:;=
M.P,58!X$(0P(BTP8'H&,*P1C&9! X80$B+@UT[DXY]0(I1&Y;1I>IP.OC-B
M-U4+7$ZR+NC;$8UG3 =FG!;.MI6X0;,2N"EV-8#]X@"0M\X[EV<<N0&/-02'
M?7CL'^U;$+XN%7=/OW=LI&J:62"%:>-'H!(A@2@-8XB%5#!!<83"+,")P Z^
M-8LII^I*,[*Y%GH_C:L=M5P+TUB%W9M*D*:&P\Y1Z#QH/8JY7X3#6Q'WTS.-
M7+S]HLJ'1=LO/]+SP,,?I%@OY)TZ'G55F4I-Z-4VVZTHUH_USZJ"\??R>_E&
MJ_C[C,8BCDTUJEAF#"*E$HB#5!^7PE J@0CE:>IT2/(JWM3LH/=%.7^LO T_
MTWD.C )59\&Z_&JC%H"@HY#CB<OOZEJ>TEYMS88^V36*54MT.A!W9_5N0">Q
M=JMCTQ4#&#5!I:?/$^ @"^#KU.A7N'%/FH, >W Z'6:6G@7(:?&@#53SASDI
M/].%B=&M(DY>ML0@5"*S6(0PC)329UI]G*4D#6#*,$$L(DDBD5,9<IM9I\;F
M55RF.7M5?^G([5B!W IQ.RKVCN/ #'L2PILZW.P%_-;\.0AQ.L'EJTBYU9SC
MEBIW@>&@8+G3PSV-UO73TZ+*%J"+)M7]RX.4Y;MYP1>K8JV_DMLW): H2I*8
MP""E(412II!D@L(TR"CC7+ 0._G;7":?&D5U9,]?0%LEH!(??%BJ5?[8X[K0
M:34L3<B!,![:0.R(O8=N1W)M^PUB]?7 S)=-YS+UN!9;#U .[+$^8_2NZWHV
MF*(]_+_,L$Q2'@<<1BEGIINC/F@S;79QB@6E8432Q"EHWWKFJ5':?CQ<[_1^
M>^SM.&P01 <FL&/Q5_.#^*N-0_#T_6^?DJUN:/DKUFHY[]AE6MW@.%*@U7&
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MQF.HMRIN&EIC2 ,4B5"2+,1.!6JODF9J.UBE#.AH4[WME3Z@5JC3(:< '97
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MHQM4JQP:[6[ 5C_0Z:Y35?]J5;P!801J+4VSAEI/GZ0[!/[>:-FK<",3]Q#
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M(YW>^'DB)/?Y1R6KWO#L$UG_@7HV^CTYV?WJC33?IUNEF<),][/^0L^HQ"K
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MIC&<WT#0D:'>>HAN[CMP;] #<XY[?AY^H.?\!T.J9I?5O'=00F2)B@3(G!4
ME3S6"2Y"5T?DN(!9DO/,:;;#H82Q;8%J!>L,?<>1#$?@V3V55T$2^.ELHQ'
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M\:.KJ\D&=SNJ\8QF8+)I33S60.[I&_VA-8Z,RAZIQP$@3^1C(W%0^G& X)"
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M_6VWV=^_UR $<%+]S=-[^I=7=+EY6LSXP_/+<O'=+,)FBA)%L,BYVIH2"7.
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MQ="I>ME*ZMC>.XW2T59KQW>+%=*6;P;?^(7F]4/HAAGGX023+RJUDCDL$;K
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M]IQ9IWK5GOULC^R9MS-258^R:5SUN#2).;I5U?9G5?/#W=&5,8BH2&.0L50
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M@*;CNPX^H>FL8:=&-)W_\&U\T)NA<%M?AZDH>YBOEM-Y-64F+V BI%3G'L%
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MXMCX:F.AKI-IV]B*,D4;*R/]M8I63R)Z2V9,!V:U"UA=^(;HPFCCU&K*FG2
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M\AR $R3,TP6"MT#/22$#AWJZ##T.]G1^VD=0MVZS<K_-BIO$92%13#( 95$
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M6,38]A9;#:.95C%B"]>LF!,PVK'-=> $9I4=+D:[N^AM%S#.O''>=D_\<$+
MH#QPWL##Y[WCDWU#6NK!F9/99_%=S-?BBUA^GS+Q\/E+XQ:EK) 9DP*D"4P
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M:JU\J)&;=I %&<!Y0?0-QW':@=(]G-/R'CUS!G7SLN.^]Y,4*[[+: I2D2.
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M#[KV#F>(!JC[ GI6SQV$YPZ"=W7EB7X352LC<Y+GG!$F&2!%D@%4)!Q0B1*
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MX<9A]O-D1V.#H#\PD[4V1V\/P-V9'=5V#])2P1FM0*1F/^ZHO.8,QS&UN=_
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M^E^J[-1Q*D(7F;H.[QDTS6E5[;HM/:P^FI%>+Q]IN9@50D%,H 1)@DT. 1.
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M=2@MZR$FY6H0%'3 \4*E(7 Z"*@&&2"<B&[2;C,PCIF44@$,50J05!00BE+
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MVK+HO5Q'\V75G&1U^SY&(!*-R3<=>/7!;AF'W@[FP#2VM=!D"C1227=1:V7
MX/ Z#*&"O NCC!NL77?U).CJ^;AGSA0UY_QU#M9[/?</ZO.*Z@"N/NY_O7RD
MY6*&8LE@41# BUP 5.A5%!6$ IYD&&9YD1#NIAO7.^34&,187->I-QF#C9&N
MR4O]0-L115CXAMZ#<D/./8O(&HQ064+] XZ;!60-P$F6C_V5OD4UW>X)QUT6
M]$IGM38[0F8OJ--4A+$LYX(F "%&3;<#!HA*"1"IS$1**<1"N-7<>%CA1$ C
ME.3LS(R,G:YU.#[38,=%@X,[,#U9M7<Y!'^8=B\W 1FL$LC'AI$+A6Z Z;2.
MZ):;^7'B5O6[)=ZW5;6AVO-Z/WP60YJ(6!0 99G2"RW, 6:L  7.:"R2F!8P
M=EEH71ML:DNLK:UFL5#5BX6R-5>';)5K[>%5F.VH+11X S-8%[=FD;6UM&:K
M@-6(-H $8J*K0XU*.#9.'_.*U36W5KC4M_[AN4X#VRM4<88X2G1L)C-$ ")%
M"C#B&8 D@3E3L8#0*=NA9[RID4BWU,&K*-$69\M(+1QZ0X=I73&VFD78<]0D
M'X\C[G45H. %'N='>Z'JC:NN7R[-N'Z99Q_.74%']7GY2HC2Q()T_H&6XNVB
M31"I]Y[8\6'_1_G;IJS*]38EH#GF;X_]S0?J;+$93F2:4H$!Q0(!!"75?U,(
M,)*8<_J"%$GNU+5S8(,G1W!U@Z<F/8M[-W@:?)KMZ'%*DS<PO[[Z\/;^[GQ[
M@6Y"UML%7YD#HDC557JFE\#>IX"]14<"/E0GTJ'-';=OZ4C@GW0Y'6O<FR6\
MV^R164$YUO]7("\*!O3"E@ *L?Z#05C$&:4H23Q%N^^GN<W7*.^T.PW1?&^O
MMQ[WO=-VWFT(#<RA'>/NHOO0&W"770^OL7W_$EMGEQV\HJ-]_,D!\K:VT?+K
MC3298I]_7\Z2-*NE=H!^^'44FT@(B((2\"1-<QA#A(15WSK/\:>VZ--?)10P
M&>L,X);L,!R,0U.'10+6>ADQ&9G7X5V3%:I=&"GUZC)V8R1=G1E].NE6EZ%Q
M2K2Z<AO/??S5DDLIJA^U.V\7U69E=O@^R?5Z7B_EWRZ^R<J8\<H("]=4.LLX
MXH7B$&"89&9W/P.XX (4$A**<9%)[!3[NILP-6+;61T]M;Y$YNL1<5IMZ'S]
M7&=M.6[\N\^+Y7' H&@/?4AP .\>]KW])O9L/8CV+@0\//"&+]21@KL!XQXT
M> -T<OS@?Z=;#R6.SU#WIZN-^A)2DB)""(@IA0"QE !2X!C@E"0PC26%U+,5
M2L_(4V.^[G[[8<I!91*F]M;?*I35-R.N!QD!<1[Q2.,TJ\,%XAN.-2SA"G[
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MHB[GX4<E-E]PCFG/^SXW[N^_+BL^7YIMTFJW0YRRE&,(!9"8% "E&0:4PAQ
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MP,^Z'.B1/KSWJ _Q6;>.']OS'_)[4!_67^7J%>>KC10="?;[ML\*PX)B*F-
M:&JT'(NZ$U(*<HY3FLI88(I=GMSKPTWM4:ZMC6ACKG^?A1Z,[9[Q<,@-_- W
MH+66'C9;N _54<8-E$"TT#/8J#QAY_@Q<5A>Y<<DG0//MXNGS?JSODW]#A-)
MRC'+,Q"GB7[[,R,%*R !*469@HI"'5VX<,BE@:;&'MT#^]K0R%CJM2BXB*T=
M=X1 ;&#6\ /+F3#ZD A$%1>'&94D^IP]IH?>S[O76-R7Z^=7*TGOET+.I,**
MQE(30<X$0*:W(N%&DX[" E/&,FJ7EW!\XZD]^,:VR!@7&>OLZR@.P+K^9-\"
MP=#QOYWW3K42YUSU*I$XN-%HE1'GS.\61)S]O6<=1*T=\(I5.JKGZQGG+.=4
M0B#C@@.D9*)C<(2!.3_#D.0LIDZI0(>WG]J#YR.\<@28W0O5'X:!'[[&,/W:
M;$T+68IPUN=0A0>'-Q^WS."L8R=%!><_Y5UFO-_@-U)[Z[)Y[[XN*SY?FK?P
M[ALI5)IRA@F@F.< 4:Q?F F.@7Z;)B@5G!">.18?VXX]M>=[;VOT0R,>8/55
MOWD*;+?G!P%V8,;PQ-2GHMD5G7!USM8CCUW][ K)F9IHYUMXIHP82;M:RTC5
M>2A?EW-]<65T0?7B9?NDI&G!*<$<B(RF !5<KS=2D8(BPUG!258P['12:#7J
MU&AJ9W2=(] Q^]^CQG!OTK*;!#NZ"@[MP$05!%7W= H7E$*E2EB-.6X:A L,
M)RD.3A=[TM.&5:4HZ>K9-*]N!VH.'RF5^G\9R.OV?DE. )8D 8GD:2$X$IBZ
M9:A=&FER-$3;+*4F+]9CV_$RJ)84$P*JH6G%!25W^NA#(!1E7!QG7)KH<_>$
M&GHO"*H9OOMQ6P?1KGA?K7]L!,8^;?7%#O2F9AGC&50< P4+O:IA.0*$I!AD
M11JGM,BQ*IQ"L*#638UVS*'_3M&-KFLAMU/]-B/:%D1TW'-*[0CLQ29J8-*S
MUE[4\]?Z%.V<.KYF--WRVV ?5M7<T[8I:)[?!JNE(OJ-@_B]!>I>J%)4/VHH
M?M;W;X1 /JSD4Y,\6^F0^9[.Y]6#>O6-EG.31OOC<F5>17O=D!GBDD N8I!#
MHQQ$"@0801PD#$I)B6)0#^G _D&LFAKK[QTQBZGJZW*U!GK<QZC<R2XX;LR'
MF3P[GA]]2@;F]ZT_C?KIWJ.[J.-37=U;>V6F[+5DZP-%HYVC0"U7P+@:CN"#
MXAV(V,/8-"JA!X7QF,C#WMR/P-_0U:)<?#$MA^K*A^,.!R1/,VQV&BF',4!I
MS #-5 ($8SAE4JF<.5%SSWA3(UW3ELYTH#!)MDV-D1O%]L%K1YX!01MZV=M:
MNL=KG&H$2X0"$5G?:*-2E*7KQ^1C>YGG9N'92JM9PHM<\A@"1'.CVB8TF^"$
M 4P8QE0D22;<>M:?'69J)%)ON;0UIKQ;Q-@*M3MN&9Z'UG*_\&; AMXL/%?'
MN2_0NXO>ZZ>B;@C9@YW[1N)5:$+M(IX?9-PMQ*N.GNP?7O]T2'KHS/.E.LR'
MI[JQP$_Z@Z:Q2U.D\7=9?OFZEN+5-QWG?I'U+U_KV':G%34C,(T5(2E()4\!
M,IE:K) ,%#+E*(]Y+E.W$XIQ[9\:H6T-CFAC<?3%F!P)L[VEM-'1-V-U]%VY
MB,1R/J>KRG1^T#&KAN3[$&PWW#?E%AJ=Q/R/R,^7"O*OUN/?12T&=U&#@NGW
MW.!P%^V^6"T4S4<B T9DT(AJ.(;F_,'G<="7R7#63^ M-?C4V+W^AC?#=SNV
M*V3SKOQM4XJFA4O]"]-CJ*&Y6CL&L1S@F"G]0E024%C$($YE05*DU^1%X;;C
M:C?PU-YDK1K3JVMJ3'?1?.^/:8'4.N2ZV6HY-5F>\]R<?2I2) #Q1 '&:0H2
M1!B)$:+*%',MUW3^@E.S&WZXJ7EW%O0(1#9S-M#<V.YUAT=\\.WLHZ]\%_V]
MV7>A7\"N4 7;B;8<=N3-9C<P3O>3':_W3*V?TZIZ4'^GYB6X?EA]-.^TA\VZ
M6M.%:;,Y8W'"=<"% 6>, J1?-8 F,@<BXY+F*N%Q+F=/]0OQTYJNUG8\UC>L
MR]-T//AP#]8/5/^3U_E/OS>65]%R;_0V?8/)+^5B47?/4]LV@4;4P810==A4
M.<9-O9,$*29"Z)<+%"D$2' !F$QB "%/659@K%\W[22]68B7FJ+MT"\^07(A
M1IL:N[=,2+ '?KO4IAKX6F--H^C:7!T,[@T.6 EA"4VH\H>^X<:M>;!T_J30
MP?8Z3QF4IBOHXLL[J4,E/= [657+U;Z*8G\HQC#4T8E,@,QCO0+.<@A(D<=
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M@42>QD[GO/9#3XY.6]NBN3;.C28=\+9CQ6%0')@$+6KK[Z(=RN^NH>S,>.Z
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M(W@?+$CN:6-H68IH<3K=OOINQ7%/-DO;0.1=0&=C+5^$-7Y:++]/)#,Y<NU
M*4-AG$F.'#-RW[5$)U*,.=D6.;<KB^X&E">;G3U<P%W@XY<ON/Q$IO&OR\7O
MZ\\O%E^^AOGW2:H56BH*$ XC*)<L.&,B%.44,1B50-< )[<NOAM>GFQV]GB!
M=X&;#U_";/;\9#6=XVHUL<$Z]"J 1DNPKY7E7B0%C =G,0FC(V^ ERN+[H:3
M)YN1/5S (^/C=2K+9R=Y2K_Q;+W&U58GKV;ATT3:''A,",*R DI(!<&( "EF
M;W2RV8GC2K3O7GLWM#S!-&TC<?=A5#[C;'9F$K,H)7A5@*6:6PQ148 7 F12
M>)&84PPM+GLNK[D;2)Y@XO9(\78!CG<G<39-KV:+L)YHH0KCM4)8Q5HK3/#V
MVAOPUFL6%#GHK$6][:4E=X/&$TS>'B?<+I!!D/Y2*_D6Z1\?/I,X5V]/UO7=
M:WU*/&&"JY0H3F-!:E#<!8A>"N+&EIR3]-RU@,I]-.R&G2>;QVTF_D[>@*PN
M"D0Q/__^OE*"\X0?\8_U<_KE?TRRT\(K92$*9T&Q1)LCQ@#%>.$E"VA#FT<A
M#Y*R&[2>8-)W&&7T8:Z(K668O9YG_.-_X/=)"2)@+ 9R$L0 '<#@)%E>\MJ2
MDEBL:)*4N;;L;LAYNJG?(X3<B1VZ>%#WBKZSFJ#/3GE)!I2%#$H'#EYE!>B%
M9 ;1.6:;6)UK"^_VQ/4)9GI;"+HKK&P?ZVZ94)Z9%*. P$,$1?$>1",8,,UR
MR4$DIH\+G^Y<>C>\/,&$;QMACXR89\1!WG!14P1$>$F:/#-66]^H+$LM\9-T
MC(I,YK&4F(Z[JKZRW&[(>(*IW<.%V@P-__[S#:&^H6\<V8MGDUDZLO_.C<]H
MV7/G?@);]-FYOL(%6%*.% QS,+;V5&'!0;2% Q=,R:1T=,H\))M[5SAJFV]3
M@J^FRR^O\\3YB)H)32%]/=&\SN"8UC6DIV ^RV#]<8?!E>5&[*C31%E7=O;!
M<AS;SF\)WSR1E;5.TS-'W#H&2LH(KA2$@I&,G0PJZ^,>(5]:;,2F.4,I?V\9
M]J'Z-Z>-WB:1"V\,G6J><3J/7%000BE@@W2V7@.P(ZL8KRTX8D^<H2!PD"P[
M/]N?AUGM#?CA,^)Z=<C!?O4#6I[J]Y!VY)%^LH)/(7R=;)Y?5H_M;7DUG=-B
M4_+H%]N&).>@*24[K+FDA %!1>?!U9(QSKDQ(H?JR]VS<4I8Q8UF3Q?=[AZ<
MK5=GW[G81OO0=:AM.%OCV6I%8CWG4C/,*$P$#"6!*BQ 8,2E9RK;^J.0[LLK
M',+E50K&\1<&0\*9^6@@[A$/DJO4G]:_G3.!3J:,/@#%,Q3PUE8)42H%@M=.
M@S:B]??UXSL<,]<(&1<ZQVCV5I <(^8.L/(BK#Y3?%W_]<L_3Z;?PJQF\)^M
M7X3E\OMT_NF_PNQD\ZQ0LUK5;U2MH?2UT^"FIUP2&G4IPJO[BH4.P<Y.A/6
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M[>!,NJ6.0%ON@R??CM>IRTIJ.K4Y>K#<.,6T97*XR\PW>Q50#U\JUM![.4S
M'4"$ KPEAA6^Q.V_7\]O7O*^7\QFKQ;+W\,R3W+FR9!$P&1;WSUI#6'S"(73
M=WG@P8?6D?F>)';B\!R(B!M-:X=33P?HNS+-FTDE;8X%7 YD4F/M3Q&D!2N=
M3U9'EUWSN:/[SE ?<D#M<(J^;K4.E?K!B/E*Q^NB]A58KAL=;-=E,T'!4.9<
M+]_J.-_,-'@3)$1C)$M92I?;OY"_O>YK+(?H43%TG :Z0=+%"X'5Q\4=URZ;
M_1))H)N> SA?;33Z'HGMU72-I]GY=QO*WF-:?)IO/N6_PNP$22K(2I8,<JJ=
MPGQ0X(2MUX!.E4Q^I%"M<3DT3^.Z;X^)\J[0,7H,6L6\/35>GBRG\T];GK:G
MR=_#<AE(3+_\@<LT)6%,(D5?TGH#6K):/LPH%DOU[5A.V6>A6+;7(HV[8M&]
MUAWWXN\QP#FT,CK%V6;#W.1,"%EB<A8<!6N@7.00:B]K@1)=\N3$!'4,S&Y?
M=MQ+P+%1UD 5/00?88:GZ:.KG?.V#+^>?R3^5B%5K4Z,2\E';8!C3C6(0]I
M2!M(,.=#]M&*UD52^] W[EWBHSJ>0VFM+T36?FS3O.G97YV)6OB!^>T5YB*R
MZFDCH"R2;+H+X(6+X)0M3*7@O&W>"V$? L?M)3T2)AOKK0=0WN=I;!/F*V+K
M;;F4/+]X@3WA@ELN"M81);3QR*FE0Z'6:_M<GRX6XT,8(BX_F.)Q&U<_>@S_
M.)KM%\<;7^9A9A4+4>?"2+I2@[)!TG[-]&4IR7G.DG.MYT0>1?"XK;0[0/$
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MBCI5#-=L-B:G4]8I#3 >_$YZQC4FK3!Q9]NE8S70N2FI;\"FFZX&JS#/VW;
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M\.@RXT8QXR&JL0(Z@=)+^LMIQ(N/"Y+4Q*.PV1D)J?@(Y&0PL@5R:VT6+I7
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MHE<^!VR-GN=3]720>I^N>CI$UF.'FGM6Y7#R,U$I!9$Q 8H^!%#D.A61=N?
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M-9O+U=X[C3\XBH*EA)A!2XI+5&8,O*,_!NX\5YP[9XXY!W<LUV-92Z/3K86
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M,G!K!"ANR(3K+(I0@E?:Q,2P=7^H$TGN\N76">@\IP;']K,.>@3BLBW&D.O
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MO*:O :-5H?4X[>&X&;=%6O_&-3Z$GF61ZH>K+U]P\?UN!>6+>$EN\^7W]AT
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MA0G'A=7]#?KK]Z0X#28GAM6O9WUX5ANGLMZ/;X20?%%:<PG99Q("H\,R9!M
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MS$D4BM^R(%:$IHT[TW:M27;>K;[+=3)0$!Q%,>9<I^A#ZL9]@GGFT_1$Y70
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M),\OTW7U-\[2NKKP4YY%DM_U'3+>N4.NOT7+3>O4SL44+UY\6N1U['-"Y=T
M5+2LP1M:2(VJ\6Z1^>(>F5NJJT0QY.3Y!!(STGFL IW'EB+57% ;#!Q#:P_\
M( )/<A-?SB_H1_-:__ MWPK0WT\_?5XM_C9<3#^MRV=_GU[DY25M*O3C]_/O
M>''Y_1U^7U'Y.R8Z/9@CZV8*9*P5X(6^\Q89),R2BQ*5COO-06I(U.BU5 ,!
M[8Y[.982AQ^FL_F+^B7@,O^?__7_ 5!+ 0(4 Q0    ( ". 8E9)J./Q20,
M !@,   0              "  0    !A,C,Q97AQ-#(P,C(N:'1M4$L! A0#
M%     @ (X!B5N0$F?9)"   $"X  !               ( !=P,  &$S,3%E
M>'$T,C R,BYH=&U02P$"% ,4    "  C@&)6MDH G$@(   <+@  $
M        @ 'N"P  83,Q,F5X<30R,#(R+FAT;5!+ 0(4 Q0    ( ". 8E:7
M(2(@!P4  *$7   0              "  604  !A,S(Q97AQ-#(P,C(N:'1M
M4$L! A0#%     @ (X!B5H$J$?H/!0  P!<  !               ( !F1D
M &$S,C)E>'$T,C R,BYH=&U02P$"% ,4    "  C@&)6P"15V/BZ @ A^AL
M$0              @ '6'@  8W)D9BTR,#(R,3(S,2YH=&U02P$"% ,4
M"  C@&)6 MIBX_\1  #<T   $0              @ ']V0( 8W)D9BTR,#(R
M,3(S,2YX<V102P$"% ,4    "  C@&)6MU!DO\<D   >=@$ %0
M    @ $K[ ( 8W)D9BTR,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ (X!B
M5N3T>'VR6P    D$ !4              ( !)1$# &-R9&8M,C R,C$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    ( ". 8E8<CTEZP/,  )TJ"@ 5
M  "  0IM P!C<F1F+3(P,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  C@&)6
M8+RYMX:0  #*H 8 %0              @ ']8 0 8W)D9BTR,#(R,3(S,5]P
<<F4N>&UL4$L%!@     +  L P (  +;Q!     $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
